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The first edition of this book will provide a comprehensive overview of ischemic heart 
disease, including epidemiology, risk factors, pathogenesis, clinical presentation, 
diagnostic tests, differential diagnosis, treatment, complications and prognosis. Also 
discussed are current treatment options, protocols and diagnostic procedures, as 
well as the latest advances in the field. The book will serve as a cutting-edge point of 
reference for the basic or clinical researcher, and any clinician involved in the diagnosis 
and management of ischemic heart disease. This book is essentially designed to fill the 
vital gap existing between these practices, to provide a textbook that is substantial and 
readable, compact and reasonably comprehensive, and to provide an excellent blend of 
“basics to bedside and beyond” in the field of ischemic heart disease. The book also covers 
the future novel treatment strategies, focusing on the basic scientific and clinical aspects 
of the diagnosis and management of ischemic heart disease.
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Preface 
To study the phenomena of disease without books is to sail an uncharted sea, while to study 
books without patients is not to go to sea at all. 
SIR WILLIAM OSLER 
Ischemic heart disease continues to be the leading cause of morbidity and mortality in 
both developed and developing countries, and remains one of the most important 
public health problems. The continuous rise in the prevalence of disorders such as 
obesity, diabetes, dyslipidemia and hypertension is driving the ever-increasing 
number of incidences of ischemic heart disease.  In recent years we have seen 
remarkable advances in the understanding of ischemic heart disease in areas such as 
epidemiology, risk assessment, risk factor reduction, pathophysiology, early detection, 
biochemical markers, imaging and in treatments. Nevertheless, the importance of 
prevention and personal responsibility in controlling the disease has also attracted 
great attention. As we all know, cardiovascular medicine is an ever-growing field; 
ongoing research has led to new discoveries in management, leading to improvements 
in the outcomes of the patients with cardiovascular diseases. 
The first edition of this book will provide a comprehensive overview of ischemic heart 
disease, including epidemiology, risk factors, pathogenesis, clinical presentation, 
diagnostic tests, differential diagnosis, treatment, complications and prognosis. Also 
discussed are current treatment options, protocols and diagnostic procedures, as well 
as the latest advances in the field. The book will serve as a cutting-edge point of 
reference for the basic or clinical researcher, and any clinician involved in the 
diagnosis and management of ischemic heart disease. This book is essentially designed 
to fill the vital gap existing between these practices to provide a textbook that is 
substantial and readable, compact and reasonably comprehensive, and to provide an 
excellent blend of “basics to bedside and beyond” in the field of ischemic heart 
disease. 
With increasing life expectancy and increasing prevalence of the disease, patients with 
ischemic heart disease are being taken care of by various health care providers. I 
sincerely hope that this textbook will meet the needs of nurses, healthcare providers, 
medical students, clinicians, physician scientists and, of course, patients. With this 
X Preface 
 
information easily accessible via the internet, no one is deprived of the pioneering 
technology and ongoing research. I am thrilled to present the various chapters like 
epidemiology, diagnosis of ischemic heart disease and its complications, management 
of ischemic heart disease and its risk factors and complications. Chapters discussing 
translational research and novel treatment strategies will be really exciting for those 
interested in basic science research. 
I gratefully acknowledge the invaluable organisational skills of the publisher InTech, 
the timely and invaluable assistance of publishing process manager Ms Maja 
Bozicevic, designer, technical editors, information technology staff  and finally the 
marketing representatives who are working constantly to promote the book on various 
platforms. I sincerely applaud all the contributing authors for their excellence, hard 
work and commitment in respect of their chapters. They have taken time from their 
personal and professional lives to complete this task and I thank them profusely for it. 
I believe that this book will provide valuable information for all healthcare providers 
who are trying to make a positive difference in our fellow human beings' lives. 
Let's love humanity through love of our profession. 
 
Umashankar Lakshmanadoss MD 
Formerly Director, Inpatient Medicine Consult Service, 
JHBMC, Johns Hopkins University School of Medicine, 
Baltimore, MD,  
USA 
 
Division of Cardiology, Guthrie Clinic, 




This book is dedicated to my mother Mrs Jana, my wife Mrs Priya for constant 
support, encouragement and fond memories without which this textbook would not 
have been possible, and to my nieces Karnika, Rithisha, Deepshika and Trisha for 
making my life more joyous. 
X Preface 
 
information easily accessible via the internet, no one is deprived of the pioneering 
technology and ongoing research. I am thrilled to present the various chapters like 
epidemiology, diagnosis of ischemic heart disease and its complications, management 
of ischemic heart disease and its risk factors and complications. Chapters discussing 
translational research and novel treatment strategies will be really exciting for those 
interested in basic science research. 
I gratefully acknowledge the invaluable organisational skills of the publisher InTech, 
the timely and invaluable assistance of publishing process manager Ms Maja 
Bozicevic, designer, technical editors, information technology staff  and finally the 
marketing representatives who are working constantly to promote the book on various 
platforms. I sincerely applaud all the contributing authors for their excellence, hard 
work and commitment in respect of their chapters. They have taken time from their 
personal and professional lives to complete this task and I thank them profusely for it. 
I believe that this book will provide valuable information for all healthcare providers 
who are trying to make a positive difference in our fellow human beings' lives. 
Let's love humanity through love of our profession. 
 
Umashankar Lakshmanadoss MD 
Formerly Director, Inpatient Medicine Consult Service, 
JHBMC, Johns Hopkins University School of Medicine, 
Baltimore, MD,  
USA 
 
Division of Cardiology, Guthrie Clinic, 




This book is dedicated to my mother Mrs Jana, my wife Mrs Priya for constant 
support, encouragement and fond memories without which this textbook would not 
have been possible, and to my nieces Karnika, Rithisha, Deepshika and Trisha for 







Overview of Coronary Artery Disease 
Umashankar Lakshmanadoss 
Formerly Director, Inpatient Consult Service,  
Johns Hopkins University School of Medicine, Baltimore, MD 
Division of Cardiology, Guthrie Clinic, Sayre, PA 
USA 
1. Introduction 
Coronary artery disease (CAD) is a major cause of death and disability in developed 
countries. Although CAD mortality rates have declined over the past four decades in the 
United States (and elsewhere), CAD remains responsible for about one-third of all deaths in 
individuals over age 35 [1,2]. It has been estimated that nearly one-half of all middle-aged 
men and one-third of middle-aged women in the United States will develop some 
manifestation of CAD. 
2. Prevalence 
The 2010 Heart Disease and Stroke Statistics update of the American Heart Association 
reported that 17.6 million persons in the United States have CAD, including 8.5 million with 
myocardial infarction (MI) and 10.2 million with angina pectoris [2]. The reported 
prevalence increases with age for both women and men. In a 2009 report that used National 
Health and Nutrition Examination Survey (NHANES) data, MI prevalence was compared 
by sex in middle-aged individuals (35 to 54 years) during the 1998 to 1994 and 1999 to 2004 
time periods [3]. Although MI prevalence was significantly greater in men than women in 
both time periods (2.5 versus 0.7 and 2.2 versus 1.0 respectively), there were trends toward a 
decrease in men and an increase in women. Data from NHANES (and other databases) that 
rely on self-reported MI and angina from health interviews probably underestimate the 
actual prevalence of advanced CAD.  
This is likely as advanced occlusive coronary artery disease often exists with few symptoms 
or overt clinical manifestations. Silent ischemia, which is thought to account for 75 percent 
of all ischemic episodes [4], may be brought to light by electrocardiographic changes (ST 
segment depression) on an exercise test, ambulatory 24 hour electrocardiographic recording, 
or periodic routine electrocardiogram (ECG). 
3. Global trends 
Heart disease mortality has been declining in the United States and in regions where 
economies and health care systems are relatively advanced, but the experience is often quite 
different around the world [5]. Coronary artery disease is the number one cause of death in 
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adults from both low- and middle income countries as well as from high-income countries 
[5]. At the turn of the century, it was reported that CAD mortality was expected to increase 
approximately 29 percent in women and 48 percent in men in developed countries between 
1990 and 2020. The corresponding estimated increases in developing countries were 120 
percent in women and 137 percent in men [6]. 
The most dramatic increments in ischemic heart disease events on a percentage basis were 
forecast for the Middle East and Latin America. The experience in Asia is especially 
important because of the large populations involved. In India, CAD may not be largely 
explained by traditional risk factors [7]. In China, risk factor trends complement tracking of 
event rates. For example, the dramatic increase in CAD mortality in Beijing is attributable to 
greater cholesterol levels. The mean cholesterol level was 4.30 mmol/L (166 mg/dL) in 1984 
and 5.33 mmol/L (206 mg/dL) only 15 years later [8]. In Latin America, declines in vascular 
disease rates have been less favorable than in the United States; unfavorable trends in 
physical activity, obesity, and smoking contribute to these differences [9].  
International leaders have called for action plans to avert the projected global epidemic of 
ischemic heart disease in developing countries [10]. 
4. Pathophysiology 
4.1 Cellular level 
Angina is caused by myocardial ischemia, which occurs whenever myocardial oxygen 
demand exceeds oxygen supply (Figure 1). Because oxygen delivery to the heart is closely  
Cellular Mechanism of Ischemia
Consequence(s) of Mechanical Dysfunction
Mechanical Dysfunction
• Abnormal Contraction and Relaxation
•  Diastolic Tension
O2 Consumption
(to maintain tonic contraction)

ATP Hydrolysis




 Blood Flow to Microcirculation
(O2 delivery to Myocytes)
Belardinelli et al. Eur Heart 8 (Suppl. A):A10-A13, 2006  
Fig. 1.  
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coupled to coronary blood flow, a sudden cessation of regional perfusion following a 
thrombotic coronary occlusion quickly leads to the cessation of aerobic metabolism, 
depletion of creatine phosphate, and the onset of anaerobic glycolysis. This is followed by 
the accumulation of tissue lactate, a progressive reduction in tissue ATP levels, and an 
accumulation of catabolites, including those of the adenine nucleotide pool. As ischemia 
continues, tissue acidosis develops and there is an efflux of potassium into the extracellular 
space. Subsequently, ATP levels fall below those required to maintain critical membrane 
function, resulting in the onset of myocyte death. Irreversible myocardial injury begins after 
20 minutes of coronary occlusion in the absence of significant collaterals [11]. 
Irreversible injury begins in the subendocardium and progresses as a wave front over time, 
from the subendocardial layers to the subepicardial layers. This reflects the higher oxygen 
consumption in the subendocardium and the redistribution of collateral flow to the outer 
layers of the heart by the compressive determinants of flow at reduced coronary pressure. 
Factors that increase myocardial oxygen consumption (e.g., tachycardia) or reduce oxygen 
delivery (e.g., anemia, arterial hypotension) accelerate the progression of irreversible injury. 
In contrast, repetitive reversible ischemia or angina prior to an occlusion can reduce 
irreversible injury through preconditioning [12].  
4.2 Anatomical level 
Acute coronary syndrome is usually caused by an unstable atherosclerotic plaque rupture 
with subsequent platelet-rich thrombus overlying the culprit lesion causing severe 
narrowing (Figure. 2). This abrupt decrease in blood supply often results in chest pain and 
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enzyme elevation. Less commonly, non ST elevation myocardial infarction is caused by 
diseases in which myocardial demand exceeds myocardial supply causing a similar clinical 
presentation. These diseases usually cause a hypermetabolic or high cardiac output state 
and include hyperthyroidism, anemia, fever, pheochromocytoma, hypertrophic 
cardiomyopathy, AV fistula and hypertensive urgency/emergency. 
Whatever the mechanism of angina may be, patients usually develop the clinical 
manifestations in a sequence as described in Figure 3. Note that diastolic dysfunction is the 
earliest manifestation of ischemia, next to perfusion abnormalities which are seen in nuclear 
studies.  
5. Clinical features 
Coronary artery disease could be manifesting as a continuum from stable angina to acute 
coronary syndrome. Angina pectoris is a discomfort in the chest or adjacent areas caused by 
myocardial ischemia. It is usually brought on by exertion and is associated with a 
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Heberden's initial description of angina as conveying a sense of “strangling and anxiety” is 
still remarkably pertinent. Other adjectives frequently used to describe this distress include 
viselike, constricting, suffocating, crushing, heavy, and squeezing. In other patients, the 
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quality of the sensation is more vague and described as a mild pressure-like discomfort, an 
uncomfortable numb sensation, or a burning sensation.  
The site of the discomfort is usually retrosternal, but radiation is common and usually 
occurs down the ulnar surface of the left arm; the right arm and the outer surfaces of both 
arms may also be involved. Epigastric discomfort alone or in association with chest pressure 
is not uncommon. Anginal discomfort above the mandible or below the epigastrium is rare. 
Anginal equivalents (i.e., symptoms of myocardial ischemia other than angina), such as 
dyspnea, faintness, fatigue, and eructations, are common, particularly in the elderly. 
A history of abnormal exertional dyspnea may be an early indicator of CAD even when 
angina is absent or no evidence of ischemic heart disease can be found on the 
electrocardiogram (ECG). Dyspnea at rest or with exertion may be a manifestation of severe 
ischemia, leading to increases in left ventricular (LV) filling pressure. Nocturnal angina 
should raise the suspicion of sleep apnea.  
The term acute coronary syndrome (ACS) is applied to patients in whom there is a suspicion 
of myocardial ischemia. There are three types of ACS: ST elevation (formerly Q-wave) MI 
(STEMI), non-ST elevation (formerly non-Q wave) MI (NSTEMI), and unstable angina (UA). 
The first two are characterized by a typical rise and/or fall in biomarkers of myocyte injury.  
For many years, the diagnosis of acute MI relied on the revised criteria established by the 
World Health Organization (WHO) in 1979. These criteria were epidemiological and aimed 
at specificity. A joint European Society of Cardiology (ESC) and American College of 
Cardiology (ACC) committee proposed a more clinically based definition of an acute, 
evolving, or recent MI in 2000 (13). In 2007 the Joint Task Force of the European Society of 
Cardiology, American College of Cardiology Foundation, the American Heart Association, 
and the World Health Federation (ESC/ACCF/AHA/WHF) refined the 2000 criteria and 
defined acute MI as a clinical event consequent to the death of cardiac myocytes (myocardial 
necrosis) that is caused by ischemia (as opposed to other etiologies such as myocarditis or 
trauma) [14]. 
The criteria used to define MI differ somewhat depending upon the particular clinical 
circumstance of the patient: those suspected of acute MI based upon their presentation, 
those undergoing either coronary artery bypass graft surgery or percutaneous intervention, 
or those who have sustained sudden unexpected, cardiac arrest with or without death [14].  
For patients who have undergone recent revascularization or who have sustained cardiac 
arrest or death, the criteria for the diagnosis of MI are given in detail in the Table 1. 
For all other patients in whom there is a suspicion of MI, a typical rise and/or gradual fall 
(troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial 
necrosis, with at least one of the following is required: 
 Ischemic symptoms 
 Development of pathologic Q waves on the ECG 
 ECG changes indicative of ischemia (ST segment elevation or depression) 
 Imaging evidence of new loss of viable myocardium or a new regional wall motion 
abnormality. 
In addition, pathologic findings (generally at autopsy) of an acute MI are accepted criteria. 
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The joint task force [14] further refined the definition of MI by developing a clinical 
classification according to the assumed proximate cause of the myocardial ischemia.  
Patulous aneurysmal dilation involving most of the length of a major epicardial coronary 
artery is present in approximately 1 to 3 percent of patients with obstructive CAD at 
autopsy or angiography. This angiographic lesion does not appear to affect symptoms, 
survival, or incidence of MI. Most coronary artery ectasia and/or aneurysms are caused by 
coronary atherosclerosis (50 percent), and the rest are caused by congenital anomalies and 
inflammatory diseases, such as Kawasaki disease.  
 
Table 1. Types of Myocardial Infarction 
6. Diagnosis 
Evaluation of new onset chest pain in stable individuals should begin with the consideration 
of imminently life-threatening causes (including acute coronary syndrome, pulmonary 
embolus, aortic dissection, pneumothorax, and esophageal rupture). This is usually 
accomplished using clinical judgement, along with ECG testing, and less frequently exercise 
testing, other noninvasive testing, or invasive angiography.  
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coronary atherosclerosis (50 percent), and the rest are caused by congenital anomalies and 
inflammatory diseases, such as Kawasaki disease.  
 
Table 1. Types of Myocardial Infarction 
6. Diagnosis 
Evaluation of new onset chest pain in stable individuals should begin with the consideration 
of imminently life-threatening causes (including acute coronary syndrome, pulmonary 
embolus, aortic dissection, pneumothorax, and esophageal rupture). This is usually 
accomplished using clinical judgement, along with ECG testing, and less frequently exercise 
testing, other noninvasive testing, or invasive angiography.  
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This is being discussed in detail by other authors in various chapters. nce a life-threatening 
etiology has been excluded, attempts should be made to identify the specific cause of 
symptoms and begin treatment. A diagnostic pattern will frequently emerge, based upon 
the patient's risk factors, description of the pain, and associated symptoms. 
Standard clinical characteristics routinely obtained during the initial medical evaluation of 
patients with UA/NSTEMI can be used to construct a simple classification system that is 
predictive of risk for death and cardiac ischemic events. The TIMI (Thrombolysis in 
Myocardial Infarction) risk score (Table 2) includes variables that can be easily ascertained 
when a patient with UA/NSTEMI presents to the medical care system. The variables used to 
construct the score were based on observations from prior studies of risk stratification and 
incorporate demographic and historical features of the patient, measures of the tempo and 
acuity of the presenting illness, and indicators of the extent of myocardial ischemia and 
necrosis.  
Since patients with an acute coronary syndrome are at increased risk of death and nonfatal 
cardiac events, clinicians must assess prognosis on an individual basis to formulate plans for 
evaluation and treatment. The TIMI risk score for UA/NSTEMI is a simple prognostication  
  
Table 2. TIMI Risk Score for Unstable Angina/Non-ST Elevation MI 
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scheme that enables a clinician to categorize a patient's risk of risk of death and ischemic 
events at the critical initial evaluation. A promising clinical application of this score is 
identification of a patient for whom new antithrombotic therapies would be especially 
effective.  
While ECG manifestations are an important component of diagnosis, one should be aware 
of the pitfalls of the ECG. Tables 3, 4 and 5 describe the ECG manifestations of ischemic 








Table 4. ECG changes associated with prior myocardial infarction 
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Table 5. Common ECG pitfalls in diagnosing myocardial infarction 
7. Management 
Patients with an initial ECG reading that reveals new or presumably new ST segment depression 
and/or T wave inversion, although not considered candidates for fibrinolytic therapy, should be 
treated as though they are suffering from MI without ST elevation or unstable angina (a 
distinction to be made subsequently after scrutiny of serial ECGs and serum cardiac marker 
measurements). In patients with a clinical history suggestive of STEMI and an initial 
nondiagnostic ECG reading (i.e., no ST segment deviation or T wave inversion), serial tracings 
should be obtained while the patients are being evaluated in the emergency department.  
Emergency department staff can be alerted to the sudden development of ST segment 
elevation by periodic visual inspection of the bedside ECG monitor, by continuous ST segment 
recording, or by auditory alarms when the ST segment deviation exceeds programmed limits. 
Decision aids such as computer-based diagnostic algorithms, identification of high-risk clinical 
indicators, rapid determination of cardiac serum markers, two-dimensional echocardiographic 
screening for regional wall motion abnormalities, and myocardial perfusion imaging have 
greatest clinical utility when the ECG reading is nondiagnostic. In an effort to improve the 
cost-effectiveness of care of patients with a chest pain syndrome, nondiagnostic ECG reading, 
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and low suspicion of MI but in whom the diagnosis has not been entirely excluded, many 
medical centers have developed critical pathways that involve a coronary observation unit 
with a goal of ruling out MI in less than 12 hours. 
Once the diagnosis of coronary artery disease is made, the management depends upon the 
severity of the underlying severity of the disease. The treating physician has to diagnose the 
clinical scenario appropriately as the treatment largely depends of the initial diagnosis. 
Stable coronary artery disease could be managed conservatively whereas acute coronary 
syndrome has to be managed very aggressively. Select patients have to be considered for 
early invasive strategy too.   
The prehospital care of patients with suspected STEMI is a crucial element bearing directly 
on the likelihood of survival. Most deaths associated with STEMI occur within the first hour 
of its onset and are usually caused by ventricular fibrillation. Accordingly, the importance of 
the immediate implementation of definitive resuscitative efforts and of rapidly transporting 
the patient to a hospital cannot be overemphasized.  
Major components of the delay from the onset of symptoms consistent with acute myocardial 
infarction (MI) to reperfusion include the following: (1) the time for the patient to recognize the 
seriousness of the problem and seek medical attention; (2) prehospital evaluation, treatment, 
and transportation; (3) the time for diagnostic measures and initiation of treatment in the 
hospital (e.g., “door-to-needle” time for patients receiving a thrombolytic agent and “door-to-
balloon” time for patients undergoing a catheter-based reperfusion strategy); and (4) the time 
from initiation of treatment to restoration of flow (Figure 4). Thrombolytic therapy is vital for 
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Adjunctive medical therapy is a critical component of therapy for STEMI and confers benefit in 
addition to that gained by reperfusion therapies, regardless of method of reperfusion (Table 6).  
Ancillary therapy can be used to facilitate and enhance coronary reperfusion or to limit the 
consequences of myocardial ischemia. Early, aggressive use of antiplatelet therapies, such as 
aspirin, and clopidogrel, confers significant additional mortality benefit when given as 
adjuncts to thrombolysis or PCI. Beta-blockers, angiotensin-converting enzyme inhibitors in 
appropriately selected patients, and 3-hydroxy-3-methylglutaryl CoA reductase inhibitors 
(statins) have all been shown to reduce the risk of cardiovascular events and mortality in 
patients who have STEMI. Therapies such as nitroglycerin and morphine have no mortality 
benefit but may improve symptoms and reduce ischemic burden. Calcium-channel blockers 
and prophylactic anti-arrhythmic drug therapy (lidocaine) may increase mortality. The 
suggested benefit of metabolic modulation at the myocyte level with electrolytes, glucose, 
and insulin seen in small, early trials has not been reproduced in larger, randomized studies.  
 
Adapted from Sura AC. et al. 
Table 6. 
 




Although improvements in the management of patients who have STEMI have led to a 
decline in acute and long-term fatality rates, reperfusion and ancillary therapies remain 
underused. Several initiatives (eg. Get With the Guidelines in USA) are designed to improve 
adherence to guidelines and access to appropriate reperfusion therapies. To date, clinical 
advancement is judged on achieving and maintaining epicardial artery patency. New 
fibrinolytics and combination therapies will continue to evolve. There will be technological 
advances and improvement in operator skills for PCI. The ultimate goal for the management 
of STEMI remains unchanged: to open occluded arteries quickly in carefully screened 
patients and in a cost-effective manner. 
9. References 
[1] Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a 
report from the American Heart Association Statistics Committee and Stroke 
Statistics Subcommittee. Circulation 2008; 117:e25. 
[2] Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke 
statistics--2010 update: a report from the American Heart Association. Circulation 
2010; 121:948. 
[3] Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease 
risk and prevalence. Arch Intern Med 2009; 169:1762. 
[4] Deedwania PC, Carbajal EV. Silent myocardial ischemia. A clinical perspective. Arch 
Intern Med 1991; 151:2373. 
[5] Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk 
factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747. 
[6] Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: 
general considerations, the epidemiologic transition, risk factors, and impact of 
urbanization. Circulation 2001; 104:2746. 
[7] Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. 
Indian J Med Res 2006; 124:235. 
[8] Critchley J, Liu J, Zhao D, et al. Explaining the increase in coronary heart disease 
mortality in Beijing between 1984 and 1999. Circulation 2004; 110:1236. 
[9] Rodríguez T, Malvezzi M, Chatenoud L, et al. Trends in mortality from coronary heart 
and cerebrovascular diseases in the Americas: 1970-2000. Heart 2006; 92:453. 
[10] Beaglehole R, Reddy S, Leeder SR. Poverty and human development: the global 
implications of cardiovascular disease. Circulation 2007; 116:1871. 
[11] Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning, 
and their clinical implications: Part 1.  Circulation  2001; 104:2981. 
[12] Downey JM, Cohen MV: Reducing infarct size in the setting of acute myocardial 
infarction.  Prog Cardiovasc Dis  2006; 48:363. 
[13] Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a 
consensus document of The Joint European Society of Cardiology/American 
College of Cardiology Committee for the redefinition of myocardial infarction. J 
Am Coll Cardiol 2000; 36:959. 
[14] Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the 
Redefinition of Myocardial Infarction. Universal definition of myocardial 
infarction. Eur Heart J 2007; 28:2525. 
 




Although improvements in the management of patients who have STEMI have led to a 
decline in acute and long-term fatality rates, reperfusion and ancillary therapies remain 
underused. Several initiatives (eg. Get With the Guidelines in USA) are designed to improve 
adherence to guidelines and access to appropriate reperfusion therapies. To date, clinical 
advancement is judged on achieving and maintaining epicardial artery patency. New 
fibrinolytics and combination therapies will continue to evolve. There will be technological 
advances and improvement in operator skills for PCI. The ultimate goal for the management 
of STEMI remains unchanged: to open occluded arteries quickly in carefully screened 
patients and in a cost-effective manner. 
9. References 
[1] Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a 
report from the American Heart Association Statistics Committee and Stroke 
Statistics Subcommittee. Circulation 2008; 117:e25. 
[2] Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke 
statistics--2010 update: a report from the American Heart Association. Circulation 
2010; 121:948. 
[3] Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease 
risk and prevalence. Arch Intern Med 2009; 169:1762. 
[4] Deedwania PC, Carbajal EV. Silent myocardial ischemia. A clinical perspective. Arch 
Intern Med 1991; 151:2373. 
[5] Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk 
factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747. 
[6] Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: 
general considerations, the epidemiologic transition, risk factors, and impact of 
urbanization. Circulation 2001; 104:2746. 
[7] Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. 
Indian J Med Res 2006; 124:235. 
[8] Critchley J, Liu J, Zhao D, et al. Explaining the increase in coronary heart disease 
mortality in Beijing between 1984 and 1999. Circulation 2004; 110:1236. 
[9] Rodríguez T, Malvezzi M, Chatenoud L, et al. Trends in mortality from coronary heart 
and cerebrovascular diseases in the Americas: 1970-2000. Heart 2006; 92:453. 
[10] Beaglehole R, Reddy S, Leeder SR. Poverty and human development: the global 
implications of cardiovascular disease. Circulation 2007; 116:1871. 
[11] Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning, 
and their clinical implications: Part 1.  Circulation  2001; 104:2981. 
[12] Downey JM, Cohen MV: Reducing infarct size in the setting of acute myocardial 
infarction.  Prog Cardiovasc Dis  2006; 48:363. 
[13] Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a 
consensus document of The Joint European Society of Cardiology/American 
College of Cardiology Committee for the redefinition of myocardial infarction. J 
Am Coll Cardiol 2000; 36:959. 
[14] Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the 
Redefinition of Myocardial Infarction. Universal definition of myocardial 
infarction. Eur Heart J 2007; 28:2525. 
Part 2 




Sadip Pant1, Abhishek Deshmukh1, Pritam Neupane2, 
M.P. Kavin Kumar3 and C.S. Vijayashankar4 
1University of Arkansas For Medical Sciences, Little Rock, AR 
2Medical College of Georgia, Augusta, GA 
3Department of Internal Medicine, Priya Hospital-Heart and  
Diabetic Care Tamilnadu 




1950’s: Clinical reports that transaminases released from dying myocytes could be detected 
via laboratory testing, aiding in the diagnosis of myocardial infarction. The race to define 
clinical markers to aid in the diagnosis, prognosis, and risk stratification of patients with 
potential cardiovascular disease begins. Initial serum markers included AST, LDH, total CK 
and α-hydroxybutyrate. These enzymes are all released in varying amounts by dying 
myocytes. Lack of sensitivity and specificity for cardiac muscle necrosis fuels continued 
research. 
1960’s:CK known to be released during muscle necrosis (including cardiac).Quantitative 
assays were cumbersome and difficult to perform. Total CK designed as a fast, reproducible 
spectrophotometric assay in the late 1960’s.CK isoenzymes are subsequently described: MM, 
MB and BB fractions. 
In 1970’s MB fraction noted to be elevated in and highly specific for acute MI. 
CKMB now measured via a highly sensitive monoclonal antibody assay. It was felt for a 
time that quantitative CKMB determination could be used to enzymatically measure the size 
of an infarct. This has been complicated by release of additional enzymes during 
reperfusion. As CK-MB assays become more sensitive, researchers come to the paradoxical 
realization that it too is not totally cardiac specific. The MB fraction is determined to be 
expressed in skeletal muscle, particularly during the process of muscle regeneration and the 
search for cardiac specificity continues. 
Research turns towards isolation of and development of assays for sarcomeric proteins. 
Myosin light chains were originally isolated and then subsequently abandoned because of 
specificity issues. Troponin I first described as a biomarker specific for AMI in 1987; 
Troponin T in 1989. Now troponins are the biochemical “gold standard” for the diagnosis of 
acute myocardial infarction via consensus of ESC/ACC.  
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Fig. 1. Timeline showing landmark events in the development of cardiac biomarkers 
1.1 Cardiac Markers: What are we looking at? 
A biomarker is defined as a measurable substance or parameter that is an indicator of an 
underlying biological or pathological process. Therefore, depending on the underlying 
process that we are referring to, the cardiac markers can be classified as markers of necrosis, 
markers of ischemia and markers of inflammation. The features of an ideal cardiac marker 
would be: 
 High sensitivity and specificity 
 Rise and fall rapidly after ischemia 
 Able to perform reliably and uniformly 
 Be simple to perform 
 Have turnaround time <60 min 
 Not influenced by functioning of other organs, in particular, functioning of kidney. 
Therefore, cardiac marker is an umbrella term which is used to define present day used 
necrosis markers as well as all the upstream markers of necrosis studied/under study 
including proinflammatory cytokines, cellular adhesion molecules, acute phase reactants, 
plaque destabilization biomarkers, plaque rupture biomarker and prenecrosis ischemia 
biomarkers. This can be simply visualized with the help of following flow diagram: 
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Fig. 2. Flowchart showing significance of biomarkers at various levels in the pathogenesis of 
acute coronary syndrome  
1.2 Markers of cardiac necrosis 
Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain 
and suspected acute coronary syndrome (ACS). The cardiac troponins, in particular, have 
become the cardiac markers of choice for patients with ACS. Indeed, cardiac troponin is 
central to the definition of acute myocardial infarction (MI) in the consensus guidelines from 
the American College of Cardiology (ACC) and the European Society of Cardiology. 
Older Definition of Myocardial Infarction- WHO 1979 
1. Definite acute myocardial infarction-Definite acute myocardial infarction is diagnosed 
in the presence of unequivocal EKG changes and/or unequivocal enzyme changes; the 
history may be typical or atypical. 
2. Possible acute myocardial infarction-Possible acute myocardial infarction is diagnosed 
when serial, equivocal ECG changes persist more than 24 hours, with or without 
equivocal enzyme changes; the history may be typical or atypical. 
3. Old myocardial infarction-Old myocardial infarction is usually diagnosed on an 
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hsCRP, Lp-PLA2,  Hohomocysteine 
Matrix Metalloproteinases, Metal Independent Myeloperoxidases 
Soluble CD40 Lingand, placental growth factor, pregnancy 
associated plasma protein A 
Unbound Free Fatty Acids, Plasma Choline and Whole Blood 
Choline, Ischemia modified albumin
CKMB, Cardiac Troponins, Myoglobin 
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infarction. If there are no residual ECG changes, the diagnosis may be based on earlier, 
typical ECGs or on the presence of prior unequivocal serum enzyme changes. 
Redefinition of Myocardial Infarction- Joint Task Force of the European Society of Cardiology, 
American College of Cardiology Foundation, the American Heart Association, and the 
World Health Federation (ESC/ACCF/AHA/WHF) 2007 
A typical rise and/or gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis, with at least one of the following is required: 
 Ischemic symptoms 
 Development of pathologic Q waves on the ECG 
 ECG changes indicative of ischemia (ST segment elevation or depression) 
 Imaging evidence of new loss of viable myocardium or a new regional wall motion 
abnormality. 
In addition, pathologic findings (generally at autopsy) of an acute MI are accepted criteria. 
Markers of cardiac necrosis have come a long way since 1950s. Some of the markers used in 
the past are no longer in use today. Current markers and those used in the past have been 
outlined in the table below. Those used in the past are not discussed separately further. 
 
Current Cardiac Markers 
 CK-MB 
 Myoglobin 
 CKMB Isoforms 
 Troponin I and T 
Cardiac Markers of the Past 
 Total CK Activity 
 Aspartate Aminotransferase Activity 
 Lactate Dehydrogenase Activity 
 LD1/LD2 Ratio 
Table 1. Various present day and past cardiac biomarkers  
2. Creatine kinase  
The enzyme creatinine kinase (formerly referred to as creatinine phosphokinase) exists as 
three isoenzyme forms: CK-MM, CK- MB, and CK-BB. These isoenzymes are found in the 
cytosol and facilitate the egress of high energy phosphates into and out of mitochondria. 
CK: Dimer composed of 2 monomers:  M (43,000 Da) and B  (44,500 Da)---- > CK BB or CK 
MB or CK MM 
Role: Creatine + ATP <---> ADP + Phosphocreatine + Energy (muscular contraction) 
CK BB : Increased in neurological  diseases ; prostatectomy; digestive cancers 
CK MB : Increased with AMI 
CK MM :Increased in myopathy, hypothyroidism, polymyositis,  rhabdomyolysis, muscle 
trauma, intensive exercise, AMI 
Table 2. Isoenzymes of Creatinine Kinase 
Distribution of CK: Creatine Kinase (CK) isoenzyme activity is distributed in a number of 
tissues. The percentage of CK-MB fraction found in the heart is higher than in most other 
tissues. However, sensitive radioimmunoassays are able to detect small amounts of B 
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chain protein in skeletal muscle, and some muscles have been reported to contain up to 10 
percent B chain protein. Most muscles have much more CK per gram than heart tissue .As 
a result, despite containing only a small percent of B chain protein, skeletal muscle 
breakdown can lead to absolute increases in CK-MB in the plasma. Therefore, skeletal 
muscle damage can confound the diagnosis of an MI, as CK-MB can be released. The 
following are examples: 
 Myocardial injury after cardiopulmonary resuscitation 
 Cardioversion 
 Defibrillation 
 Cardiac and non-cardiac surgical procedures 
 Blunt chest trauma with possible cardiac contusion 
 Cocaine abuse  
Total CK, CK-MB and CK-MB to Total CK ratio: Since CK is widely distributed in tissues, 
elevations in total serum CK lack specificity for cardiac damage, which improves with 
measurement of the MB fraction. The normal range of CK also varies considerably; a 
twofold or greater increase in the CK concentration is required for diagnosis. This criterion 
can be problematic in older individuals who, because of their lower muscle mass, may have 
low baseline serum total CK and, during MI, may have elevated serum CK-MB with values 
of total CK that rise but remain within the normal range. For these reasons, total CK has not 
been used in the diagnosis of myocardial damage for years. CK-MB has high specificity for 
cardiac tissue and was the preferred marker of cardiac injury for many years. An elevated 
CK-MB is relatively specific for myocardial injury, particularly in patients with ischemic 
symptoms when skeletal muscle damage is not present. Assays for CK-MB can be 
performed easily and rapidly. Most assays measure CK-MB mass; such measurements are 
more sensitive than activity assays. The relative index calculated by the ratio of CK-MB 
(mass) to total CK can assist in differentiating false-positive elevations of CK-MB arising 
from skeletal muscle. A ratio of less than 3 is consistent with a skeletal muscle source, while 
ratios greater than 5 are indicative of a cardiac source. Ratios between 3 and 5 represent a 
gray zone. No definitive diagnosis can be established without serial determinations to detect 
a rise. Studies to evaluate the CK-MB relative index compared with the absolute CK-MB 
have revealed increase in specificity but with a loss of sensitivity. The CK-MB/CK relative 
index is useful if patients have only an MI or only skeletal muscle injury, but not if they 
have both. In the combined setting of acute MI and skeletal muscle injury (rhabdomyolysis, 
heavy exercise, polymyositis), the fall in sensitivity is significant. It is worth noting that the 
diagnosis of acute MI must not be based on an elevated relative index alone, because the 
relative index may be elevated in clinical settings when either the total CK or the CK-MB is 
within normal limits. The relative index is only clinically useful when both the total CK and 
the CK-MB levels are increased.  
Timing of Release: Creatinine Kinase starts rising in the blood 4-6 hours after the onset of 
chest pain. It peaks at 10-24 hours and then returns to normal after 48-72 hours. Since CK 
levels return to baseline 48 to 72 hours after infarction, it can be used to detect reinfarction. 
New elevations that occur after normalization are indicative of recurrent injury, again with 
the caveats in regard to sensitivity and specificity indicated above. However, for these 
reasons, CK-MB cannot be used for late diagnosis. 
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Fig. 3. Kinetics of CKMB release after AMI 
Sensitivity and Specificity of CKMB: In AMI, CKMB usually is evident at 4 to 8 hours, peaks at 
15 to 24 hours (mean peak=16×normal) with sensitivity and specificity >97% within the first 
48 hours. By 72 hours, two thirds of patients still show some increase in CK-MB. Sampling 
every 6 hours is more likely to identify a peak value. False negative results may be caused 
by poor sample timing (e.g. only once in 24 hours or sampling <4 hours or >72 hours after 
AMI). Similarly, false positive may be caused by a variety of factors including but not 
limited to myocardial injury after cardiopulmonary resuscitation, cardioversion, 
defibrillation, cardiac and non-cardiac surgical procedures, blunt chest trauma with possible 
cardiac contusion and cocaine abuse.  
CK and coronary reperfusion :The time to peak CK levels and the slope of CK-MB release can 
be used to assess whether reperfusion has occurred after fibrinolysis and, when used in 
conjunction with clinical variables, can predict whether TIMI 0 or 1 and TIMI 2 or 3 grade 
flow is present. The 2004 task force of the ACC/AHA concluded that serial measurements of 
CK-MB can be useful to provide supportive noninvasive evidence of reperfusion after 
fibrinolysis (class IIa recommendation). However, it should be noted that CK-MB criteria 
cannot identify the presence of TIMI 3 flow, which is the only level of perfusion associated 
with improved survival after fibrinolysis. Thus, many may elect invasive evaluation despite 
biomarker evidence of reperfusion. The 2004 ACC/AHA task force recommended specific 
guidelines for the diagnosis of reinfarction after an acute ST elevation MI. Within the first 18 
hours of the initial MI, a recurrent elevation in CK-MB concentration alone should not be 
relied upon to diagnose reinfarction, but should be accompanied by recurrent ST segment 
elevation on ECG and at least one other supporting criterion (such as recurrent chest pain or 
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Fig. 3. Kinetics of CKMB release after AMI 
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biomarker rise and at least one additional criterion is sufficient for the diagnosis. Similar 
criteria were established for patients presenting with possible reinfarction after 
percutaneous coronary intervention or coronary artery bypass grafting.  
3. Cardiac Troponins 
Cardiac Troponins (cTn) control the calcium-mediated interaction of actin and myosin. It 
exists in three isoforms: troponin C, troponin I and troponin T. Troponin C exists in all 
muscle tissues. cTnI is however, completely specific for the heart. cTnT released in small 
amounts by skeletal muscles, though clinical assays do not detect skeletal TnT. Both have 
cytosolic or early releasable and structural pools, with most existing in the structural pool. 
They are more specific compared to CKMB in detection of infarction and are the preferred 
biomarker for the diagnosis of acute MI (Class I recommendation from the ACC/AHA task 
force on diagnosis of AMI). 
 
Characteristics Troponin C Troponin I Troponin T 
Weight 18 KD 26.5 KD 39 KD 





complex to the 
tropomyosin strand 
Cardiac Specificity None Yes Yes 
Table 3. Troponin Characteristics. KD: Kilo Dalton 
3.1 Timing of release 
Cardiac troponins begin rising in the blood 4-6 hours post infarction (same time as CKMB). 
It peaks in 12-24 hours but may take weeks to return to normal. The timing of release, peak 
and normal return as compared to CKMB has been presented in a graphical form below. 
3.2 Sensitivity and specificity of cardiac troponins 
Cardiac troponins are as sensitive as CK-MB during the first 48 hours after acute myocardial 
infarction. The sensitivity is 33% from 0-2 hours, 50% from 2-4 hours, 75% from 4-8 hours 
and approaching 100% from 8 hours after onset of chest pain. The specificity is close to 
100%.  Troponin elevations have been reported in a variety of clinical scenarios other than 
acute coronary syndromes. The following is a list of some of the causes for the elevation of 
troponin in the absence of a thrombotic occlusion of the coronary artery: 
 Tachy- or bradyarrhythmias, or heart block 
 Critically ill patients, especially with diabetes, respiratory failure or sepsis 
 Hypertrophic cardiomyopathy 
 Coronary vasospasm 
 Acute neurological disease, including stroke or subarachnoid hemorrhage 
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 Cardiac contusion or other trauma including surgery, ablation, pacing, implantable 
cardioverter-defibrillator shocks, cardioversion, endomyocardial biopsy, cardiac 
surgery, following interventional closure of atrial septal defects 
 Rhabdomyolysis with cardiac injury 
 Congestive heart failure - acute and chronic 
 Pulmonary embolism, severe pulmonary hypertension 
 Renal failure 
 Aortic dissection 
 Aortic valve disease 
 Apical ballooning syndrome - Takotsubo Cardiomyopathy 
 Infiltrative diseases (ie, amyloidosis, hemochromatosis, sarcoidosis, and scleroderma) 
 Inflammatory diseases (ie, myocarditis or myocardial extension of endo-/pericarditis, 
Kawasaki disease) 
 Drug toxicity or toxins (ie, adriamycin, 5-flurouracil, herceptin, snake venom) 
 Burns, especially if affecting >25 percent of body surface area 
 Extreme exertion 
 Transplant vasculopathy 
The 2007 joint ESC/ACCF/AHA/WHF task force recommends that an elevated value of 
cardiac troponin, in the absence of clinical evidence of ischemia, should prompt a search for 
other causes of myocardial necrosis as listed above. 
3.3 Troponin assays 
The skeletal and cardiac isoforms of troponin T and troponin I are distinct, and skeletal 
isoforms are not detected by the monoclonal antibody-based assays currently in use. This 
specificity for cardiac isoforms is the basis for the clinical utility of cTnT and cTnI assays. 
Contemporary troponin assays are quite sensitive and can detect very small amounts of 
myocardial necrosis (<1 g). Troponin C is not used clinically because both cardiac and 
smooth muscle share troponin C isoforms. The ESC/ACC recommended that the diagnosis 
of MI be based on troponin levels in excess of the 99th percentile of a reference control 
group. As cTnT and cTnI levels are undetectable in most normal subjects, the 99th percentile 
is very low (eg, 0.04 to 0.5 micrograms/L). However, most assays are imprecise at this low 
level, and so it has been recommended that the definition of MI be raised to that value at 
which a specific assay has a coefficient of variation of 10 percent or less. New guidelines 
embrace 99th percentile for two reasons. This level is also low (0.1 to 1.2 micrograms/L), but 
higher than the 99th percentile standard. Due to variations in assay precision and individual 
laboratory policies, the upper limit of normal varies between laboratories, but in all cases is 
above the 99th percentile. 
3.4 Point-of-care assays 
The National Academy of Clinical Biochemistry (NACB) recommendations specify that 
cardiac markers be available on an immediate basis 24 h/d, 7 d/wk, with a turnaround time 
of 1 hour. Point-of-care (POC) devices that provide rapid results should be considered in 
hospitals whose laboratories cannot meet these guidelines. POC assays for CK-MB, 
myoglobin, and the cardiac troponins TnI and TnT are available. Only qualitative TnT 
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assays are available as POC tests, but both quantitative and qualitative POC TnI assays are 
currently marketed. In a multicenter trial, the time to positivity was significantly faster for 
the POC device than for the local laboratory (2.5 h vs 3.4 h).In another multicenter study, 
which evaluated the i-STAT POC TnI assay in comparison with the central laboratory in 
2000 patients with suspected ACS, POC testing reduced the length of stay by approximately 
25 minutes for patients who were discharged from the ED. The sensitivity of current POC 
assays coupled with the benefit of rapid turnaround time make the POC assays attractive 
clinical tools in the ED.  
3.5 Prognostic value of cardiac troponins 
In addition to its use in the diagnosis of MI, an elevated troponin level can identify patients at 
high risk for adverse cardiac events. Specifically, data from a meta-analysis indicated that an 
elevated troponin level in patients without ST-segment elevation is associated with a nearly 4-
fold increase in the cardiac mortality rate. In patients without ST-segment elevation who were 
being considered for thrombolytic therapy, initial TnI levels on admission correlated with 
mortality at 6 weeks, but CK-MB levels were not predictive of adverse cardiac events and had 
no prognostic value. Other studies revealed that an elevated troponin level at baseline was an 
independent predictor of mortality, even in patients with chest pain and acute MI with ST-
segment elevation who were eligible for reperfusion therapy. Finally, the TIMI IIIB, GUSTO 
IIa, GUSTO IV ACS, and FRISC trial all demonstrated a direct correlation between the level of 
TnI or TnT and the mortality rate and adverse cardiac event rate in ACS. 
3.6 High Sensitive Troponin (hsTroponin) 
High-sensitive assay is one which has a total imprecision of less than 10% at the 99th 
percentile and some would propose also being able to quantitate over 50% of normal values 
below that 99th percentile. High-sensitive cTn assays have two differentiating features from 
contemporary cTn assays: 1) detection of cTn in healthy persons and 2) a precise definition 
of what is “normal” (= the 99th percentile). Recent multicenter studies have shown that 
high-sensitive cTn assays improve the early diagnosis of acute myocardial infarction (AMI). 
To achieve the best clinical use, cTn has to be interpreted as a quantitative variable. Rising 
and/or falling levels differentiate acute from chronic cardiomyocyte necrosis. The term 
“troponin-positive” should therefore be avoided. “Detectable” levels will become the norm 
and have to be clearly differentiated from “elevated” levels. The differential diagnosis of a 
small amount of cardiomyocyte necrosis and therefore mild elevation of cTn is broad and 
includes acute and chronic cardiac disorders. The differential diagnosis of a large amount of 
cardiomyocyte necrosis and therefore substantial elevation of cTn is much smaller and 
largely restricted to AMI, myocarditis and Takotsubo cardiomyopathy. Two large 
prospective multicenter studies showed that sensitive and high-sensitive cTn assays have a 
higher diagnostic accuracy compared to contemporary cTn assays at presentation, in the 
diagnosis of AMI.  Earlier “rule in” may reduce morbidity by allowing earlier 
revascularization, earlier transfer to the coronary care unit, and earlier initiation of evidence-
based AMI treatment. Nonetheless, the improvement in sensitivity is at the expense of 
specificity. There is still considerable controversy in regard to how to use these assays to 
detect acute events such as AMI. Hence, at this time it has not been approved for clinical use 
and is yet in research phase. 
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4. Myoglobin 
Myoglobin is a heme protein found in skeletal and cardiac muscle that has attracted 
considerable interest as an early marker of MI. Its low molecular weight accounts for its 
early release profile: myoglobin typically rises 2-4 hours after onset of infarction, peaks at 6-
12 hours, and returns to normal within 24-36 hours. Rapid myoglobin assays are available, 
but overall, they have a lack of cardiospecificity. Serial sampling every 1-2 hours can 
increase the sensitivity and specificity; a rise of 25-40% over 1-2 hours is strongly suggestive 
of acute MI. However, in most studies, myoglobin only achieved 90% sensitivity for acute 
MI, so the negative predictive value of myoglobin is not high enough to exclude the 
diagnosis of acute MI. The original studies that evaluated myoglobin used the WHO 
definition of acute MI that was based on a CK-MB standard. With the adoption of a troponin 
standard for acute MI in the ACC/ESC definition, the sensitivity of myoglobin for acute MI 
is substantially reduced. This significantly diminishes its utility, and a number of studies 
have indicated that contemporary cardiac troponin assays render the use of myoglobin 
measurements unnecessary.  
 
Conditions where myoglobin increases Conditions where myoglobin does 
not increase 
Acute myocardial infarction Non cardiac chest pain 
Vigorous exercise Mild to moderate exercise 
Open heart surgery CHF without acute myocardial 
infarction 
Rhabdomyolysis Cardiac catheterization 
Progressive muscular dystrophy  
Shock  
Renal Failure  
Table 4. Serum myoglobin in various clinical conditions 
4.1 Timing of release, peak and return to baseline of various cardiac markers 
CAD is highly prevalent in patients with CKD, making interpretation of cardiac markers 
important. Despite this, interpretation of elevated cardiac enzymes in patients with renal 
failure is often confusing at best. Elevations in serum troponin often observed in 
asymptomatic patients with chronic kidney disease. Even using the most conservative cutoff 
values, a disproportionate number of patients still have elevated troponins. The mechanism 
for this is unclear. In a 2002 study in Circulation, 733 asymptomatic patients with ESRD were 
evaluated. Using conservative cutoff values, 
- 82% had elevated cTnT  
- 6% had elevated cTnI  
Of those 733 asymptomatic patients on HD, 2-year mortality rates were 52% in those with 
cTnI ≥0.1 µg/dL .These data have been corroborated in a number of smaller studies in 
similar populations. Serial measurements are helpful in the setting of possible ACS. cTnI 
appears to be much less likely to be associated with false positives in the CKD population 
than cTnT, making it the preferred biomarker in this setting. 
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Fig. 4. A comparison of CKMB, cardiac troponins and myoglobin. 
4.2 Markers of inflammation 
Acute coronary syndromes are caused by vulnerable plaques. It is thought that one of the 
driving forces causing atheromatous plaques to rupture or erode, causing a cascade of 
events leading to coronary artery occlusion, is inflammation in the plaques. In this section 
cardiac inflammatory markers are dealt with which is at the verge of entering into clinical 
practice as tool for diagnosing and predicting future cardiovascular events at earlier stage 
and for risk stratification. Highly Sensitive Creative Protein (hsCRP), Myeloperoxidase 
(MPO), Matrix Metalloproteinases (MMP), Pregnancy Associated Protein A(PAPP-
A),Placenta Growth Factor(PIGF) are reviewed. 
4.3 C-Reactive protein (CRP)  
C Reactive Protein is an acute phase reactant synthesized in liver and is elevated in 
inflammatory conditions. Once ligand-bound, CRP can activate the classical compliment 
pathway, stimulate phagocytosis and bind to immunoglobulin receptors. "High-sensitivity" 
only means that the concentration of CRP was determined using an assay designed to 
measure very low levels of CRP. The American Heart Association has defined risk groups as 
follows: Low risk: less than 1.0 mg/L, Average risk: 1.0 to 3.0 mg/L and High risk: above 3.0 
mg/L. Two assays averaged fasting or non fasting, and optimally 2 weeks apart, provide a 
more stable estimate of level of this marker. If a level is greater than 10 mg/L is identified, 
there should be a search initiated for an obvious source of infection or inflammation, which 
could obscure any prediction of coronary risk that might be attributed to the elevated 
level. The landmark study by Liuzzo et al. showed that patients presenting with unstable 
angina and elevated plasma concentrations of CRP had a higher rate of death, MI and need 
for re-vascularisation compared with patients without elevated concentrations.  In more 
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recent trials, other investigators have confirmed the increased risk in ACS associated with 
higher CRP concentrations. In each of the above studies, the predictive value of CRP was 
independent of, and additive to, cardiac troponin. More importantly, CRP was found to 
have prognostic value even among patients with negative cardiac troponin and no evidence 
of myocyte necrosis. Methodological issues have however been highlighted and the 
independence between CRP and troponin release questioned. Therefore , although many 
studies have suggested that low-grade hsCRP elevations are independently associated with 
coronary risk, more complete evidence is needed to validate the use of hs-CRP as a risk 
assessment tool in general practice and as a target for therapy in individual patients . 
4.4 Myeloperoxidase (MPO) 
Myeloperoxidase (MPO) is a hemoprotein that is abundantly expressed in 
polymorphonuclear cells (neutrophils) and secreted during their activation. The presence of 
a peroxidase in the cytoplasmic granules of leukocytes was suggested at the beginning of 
20th century but it was the early 1940s that it was purified for the first time. MPO plays an 
important role in neutrophil microbicidal action through catalyzing chloride ion oxidation 
to hypochlorous acid, which is a potent antimicrobial agent. On the other hand, it was 
demonstrated that MPO causes oxidative modification of low density lipoprotein (LDL) to a 
high uptake form that is considered to be a key event in the promotion of atherogenesis. 
Hence myeloperoxidase is believed to participate in the initiation and progression of 
cardiovascular diseases. MPO possesses potent proinflammatory properties and may 
contribute directly to tissue injury. 
In a study consisted of patients diagnosed with ACS and other heart disease or 
unspecified chest pain, considerably higher MPO concentrations were demonstrated in the 
troponin-negative ACS patients on admission who became troponin-positive after 6h. This 
suggests that level of MPO possessed remarkably higher sensitivity than assessment of cTnI 
alone in all patients with ACS.  MPO levels are associated with the presence of 
angiographically proven coronary atherosclerosis. In addition to clinical history and other 
tools MPO has been approved by FDA as cardiac biomarker to evaluate the patients with 
chest pain and at high risk for coronary artery disease. 
4.5 Matrix metalloproteinases (MMP) 
MMP are endogenous zinc dependent endopeptidases required for structural integrity of 
extracellular matrix of myocardium. TIMP (Tissue Inhibitors of Metalloproteinases) 
regulates MMP. MMPs may degrade myocardial ECM leading to the development of LV 
dilatation and heart failure and their inhibition in experimental models of AMI has been 
associated with reduced LV dilatation and wall stress. In a study of patients with acute 
myocardial infarction, TIMP-1 and MMP-9 correlated with echocardiographic parameters of 
LV dysfunction and remodelling after AMI and identified patients at risk of subsequent LV 
remodeling and associated with severe extensive CAD. 
4.6 Placental Growth Factors (PGF) 
Placental Growth Factor is a member of VEGF (vascular endothelial growth factor) 
subfamily - a key molecule in angiogenesis and vasculogenesis, in particular during the 
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embryogenesis. Placental growth factor expression within human atherosclerotic lesions is 
associated with plaque inflammation and neovascular growth. Recent studies established 
the role of different inflammatory markers such as hsCRP, sr amyloid A, IL-6 not only gets 
elevated during acute coronary syndrome (ACS) but predicts its adverse outcomes. PGF 
was recently shown that it is upregulated in all forms of atherosclerotic lesions. PGIF 
induces the following  
 Vascular smooth muscle cell growth. 
 Recruits macrophages into atherosclerotic lesions. 
 Upregulates production of TNF alpha. 
 Monocyte chemotactic protein 1 by macrophages. 
 Pathological angiogenesis. 
Plasma PIGF levels may be an independent inflammatory biomarker of poor outcome in 
patients with suspected ACS. A single initial measurement of plasma PIGF appears to 
extend the predictive and prognostic information gained from traditional inflammatory 
markers. 
5. Pregnancy associated plasma protein alpha (PAPP-A) 
PAPP-A was originally identified in the serum of pregnant women. PAPP-A is produced by 
placental tissue. Circulating PAPP-A levels increase during pregnancy and they are used in 
the fetal diagnosis of Down syndrome. Only recently has PAPP-A been identified in 
nonplacental tissues. The concentrations in the sera of nonpregnant human beings being 
several orders of magnitude lower than during pregnancy. The physiological role of PAPP-
A is only beginning to be unraveled. PAPP-A is a high-molecular-weight, zinc-binding 
metalloproteinase, which acts as a specific protease of IGF binding protein-4 (IGFBP-
4). There is histological evidence, using specific monoclonal antibodies, that PAPP-A is 
abundantly expressed in both eroded and ruptured coronary plaques, but not in stable 
plaques, in patients who have died suddenly of cardiac causes. Furthermore, accumulating 
evidence suggests that PAPP-A may play a pivotal role in the development of 
atherosclerosis and subsequent plaque instability in ACS patients. PAPP-A is markedly 
elevated in the earliest hours after the onset of symptoms in patients with STEMIs treated 
with heparin and primary percutaneous coronary intervention, and in animal studies, 
heparin administration is associated with a significant increase in PAPP-A levels, 
presumably because of the detachment of PAPP-A from the vessel wall. If future studies 
confirm that concomitant heparin administration also increases PAPP-A levels in humans, 
the prognostic role of PAPP-A in patients with ST elevation myocardial infarction needs to 
be reevaluated.  
5.1 Markers of ischemia 
An ideal marker is one in which there is a specific easily measurable increase that clearly 
aligns with a predictable outcome be it evidence of ischemia, inflammation, myocardial 
necrosis, plaque rupture, plaque destabilization, or heart failure. Because of the underlying 
shared etiologies related to the process of arteriosclerosis and the complexity of the 
pathological processes giving rise to adverse thrombotic outcomes, a single marker that 
 
Novel Strategies in Ischemic Heart Disease 30
relates to each stage is unlikely. Rather more probable would be use of multiple markers 
with varying decision levels to either rule-in or rule-out a clinical decision. As the 
understanding of the niceties between ACS, inflammation, and coronary artery process 
develops, the ongoing search for better cardiac markers will continue. 
5.2 Ischemia modified albumin (IMA) 
The only ischemia marker that has been approved by the FDA is the modified albumin 
(IMA) using the albumin cobalt binding test (ACB) for assessment of myocardial ischemia. 
IMA occurs in 2 forms: 1.in which human serum albumin (HAS) binds mostly copper and 
2.in which the damage to the N-terminus prevents metal binding. Patients without ischemia 
have more available metal binding sites on their HSA, than those from ischemic patients. 
This alteration is most likely due to damage caused by oxidative free radicals prevalent 
during ischemic events, and resulting in altered binding of trace metals resulting in IMA. As 
mentioned earlier, the FDA approved method for IMA (ACB Test by Ischemia Technologies) 
uses cobalt in its assay. Normal HSA will bind cobalt when it is added to a sample, leaving 
little residual cobalt. However, IMA cannot do the same due to its altered binding site. 
Patients having transient ischemic episodes without parallel myocyte death increases IMA 
which causes less cobalt binding and more residual unbound cobalt available. This can 
complex with chromogen (dithiothreitol) which can be measured photometrically. It is 
estimated that approximately 1% to 2% of the total albumin concentration in the normal 
population is IMA compared to 6% to 8% in patients experiencing ischemia. The clinical 
utility of IMA appears to be in its negative predictive value for ischemia and ACS, 
particularly when used in conjunction with other tests. While the optimum cutoff for IMA 
for ruling out ACS is 85kU/L, the manufacturer has suggested a higher value of 100 kU/L 
for risk stratification. Some of the limitations to be taken into consideration includes: a. there 
is an overlap between the normal population and that of individuals with cardiac ischemia; 
b. IMA is not specific for cardiac ischemia; c. false positive can occur in patients with 
cirrhosis, bacterial and viral infections, advanced cancers, stroke and end-stage renal disease 
and d. interpretation of IMA in certain populations, including those with peripheral 
vascular disease and in marathon runners is not yet clear. Hence IMA appears at this time as 
a potential marker in certain clinical situations but a number of possible interferences may 
limit its utility in patients with suspected ACS. 
5.3 Unbound free fatty acids 
Fatty acids are essential building blocks for many lipid molecules and are energy stores that 
can be utilized during times of fasting or increased metabolic demand. Fatty acids exist in 
body as esterified form (bound to glycerol or other alcohol), non-esterified form bound to 
albumin, and to a much smaller extent, as an unbound soluble form. Evidence exists that 
unbound free fatty acids increase significantly in ischemic-related events. It is not certain as 
of today what role the unbound free fatty acid plays in cardiac disease. It possibly partakes 
in the developing necrotic process and is released as a result of cell rupture or other 
precipitating conditions. Currently, a fluorescent probe assay is available but its clinical 
utility at this time is not established. 
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relates to each stage is unlikely. Rather more probable would be use of multiple markers 
with varying decision levels to either rule-in or rule-out a clinical decision. As the 
understanding of the niceties between ACS, inflammation, and coronary artery process 
develops, the ongoing search for better cardiac markers will continue. 
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The only ischemia marker that has been approved by the FDA is the modified albumin 
(IMA) using the albumin cobalt binding test (ACB) for assessment of myocardial ischemia. 
IMA occurs in 2 forms: 1.in which human serum albumin (HAS) binds mostly copper and 
2.in which the damage to the N-terminus prevents metal binding. Patients without ischemia 
have more available metal binding sites on their HSA, than those from ischemic patients. 
This alteration is most likely due to damage caused by oxidative free radicals prevalent 
during ischemic events, and resulting in altered binding of trace metals resulting in IMA. As 
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Patients having transient ischemic episodes without parallel myocyte death increases IMA 
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for risk stratification. Some of the limitations to be taken into consideration includes: a. there 
is an overlap between the normal population and that of individuals with cardiac ischemia; 
b. IMA is not specific for cardiac ischemia; c. false positive can occur in patients with 
cirrhosis, bacterial and viral infections, advanced cancers, stroke and end-stage renal disease 
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5.4 Fatty acid binding proteins (FABPs) 
Fatty acid binding proteins (FABPs) are transport proteins that carry fatty acids and other 
lipophilic molecules like eicosanoids and retinoids across the membranes. They occur in 
nine different isoforms in a predictable tissue distribution and fairly long half-life of several 
days. The heart-type FABP (H-FABP) is released following myocardial death within 6 hours 
and is not specific to the heart, similar to myoglobin. It is released to a smaller extent in 
skeletal muscle, distal tubular cells of the kidney, specific parts of the brain, lactating 
mammary glands, and the placenta.  It has been found that H-FABP may perform better and 
reach its upper reference limit sooner than either myoglobin or troponin. A number of 
enzyme immunoassays are available for H-FABP testing. Its relation to ischemia and 
prognosis for adverse events is likely to expound in near future. 
5.5 Phospholipase  
Phospholipase are the enzymes that release fatty acids from the second carbon group of 
glycerol. They are grouped into 4 major categories: A to D.  Phospholipase A2 and D have 
drawn much attention in their role in assessing ischemia associated coronary artery disease. 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as platelet-activating factor 
acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme that in humans is encoded by 
the PLA2G7 gene. In human atherosclerotic lesions, 2 main sources of Lp-PLA2 can be 
identified, including that which is brought into the intima bound to LDL (from the 
circulation), and that which is synthesized de novo by plaque inflammatory cells 
(macrophages, T cells, mast cells). I A meta-analysis involving a total of 79,036 participants 
in 32 prospective studies found that Lp-PLA2 levels are positively correlated with increased 
risk of developing coronary heart disease and stroke. Recently, there has been a renewed 
interest in this molecule, not for use in cardiac assessment as it was originally approved by 
the FDA, but rather in stroke prediction after it was found that elevated levels of Lp-PLA2 
were associated with an almost 2-fold increase in stroke in the selected population coupled 
with a 6-fold increase in hypertensive individuals. 
Phospholipase D (PLD) is an enzyme that catalyzes the hydrolysis of membrane bound 
phospholipids into phosphatidic acid and choline. In addition, it is also involved in 
endorsement of fibrinogen binding to platelets. Increased levels of plasma (PLCHO) and 
whole blood choline (WBCHO) levels have been seen in tissue ischemia in patients with 
negative troponin values. Choline is not a marker for myocardial necrosis but indicated 
high-risk unstable angina in patients without acute myocardial infarction (sensitivity 86.4%, 
specificity 86.2%). Therefore obtaining levels of both plasma PLCHO and WBCHO may 
prove to be a useful aid in patients suspected of ACS. 
6. Conclusion 
Cardiac markers have been implicated in the diagnosis and risk stratification of patients 
with chest pain and suspected acute coronary syndrome (ACS). Among the markers of 
cardiac necrosis, troponins have become the cardiac markers of choice for patients with 
ACS. In fact, cardiac troponin has become central to the definition of acute myocardial 
infarction (MI) in the consensus guidelines from the American College of Cardiology (ACC) 
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and the European Society of Cardiology (ESC). Current focus is on finding appropriate 
upstream markers which may aid in detection of myocardial ischemia and a variety of 
events involved in the process of pathophysiology of acute coronary syndrome especially in 
relation to plaque destabilization and rupture. The ideal biomarkers that offer early 
detection, risk stratication, selection of therapy, monitoring disease progression, and 
treatment efficacy remain to be elucidated. 
7. References 
[1] Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. 
Circulation 2000; 102:1216. 
[2] Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a 
meta-analysis. Med Sci Sports Exerc 2007; 39:2099. 
[3] Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog 
Cardiovasc Dis 2007; 50:151. 
[4] Müller-Bardorff M, Weidtmann B, Giannitsis E, et al. Release kinetics of cardiac 
troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 
2002; 48:673. 
[5] Carlson RJ, Navone A, McConnell JP, et al. Effect of myocardial ischemia on cardiac 
troponin I and T. Am J Cardiol 2002; 89:224. 
[6] Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating 
troponin in the setting of transient stress test-induced myocardial ischaemia using 
an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009; 30:162. 
[7] Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values 
remain constant after brief exercise- or pharmacologic-induced reversible 
myocardial ischemia. Clin Chem 2008; 54:1234. 
[8] Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is 
MB creatine kinase the choice for the 1990s? Circulation 1993; 88:750. 
[9] Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac 
troponin T and its release kinetics in patients with reperfused and nonreperfused 
myocardial infarction. Am J Cardiol 1991; 67:1360. 
[10] Adams JE 3rd, Schechtman KB, Landt Y, et al. Comparable detection of acute 
myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin 
Chem 1994; 40:1291. 
[11] Adams JE III, Bodor, GS, Davila-Roman, VG, et al. Cardiac troponin I. A marker with 
high specificity for cardiac injury. Circulation 1993; 88:101. 
[12] Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not expressed in fetal 
and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 
41:1710. 
[13] Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms expressed in renal 
diseased skeletal muscle will not cause false-positive results by the second 
generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998; 
44:1919. 
[14] Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin 
assays at low-range concentrations. Clin Chem 2004; 50:327. 
 
Novel Strategies in Ischemic Heart Disease 32
and the European Society of Cardiology (ESC). Current focus is on finding appropriate 
upstream markers which may aid in detection of myocardial ischemia and a variety of 
events involved in the process of pathophysiology of acute coronary syndrome especially in 
relation to plaque destabilization and rupture. The ideal biomarkers that offer early 
detection, risk stratication, selection of therapy, monitoring disease progression, and 
treatment efficacy remain to be elucidated. 
7. References 
[1] Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. 
Circulation 2000; 102:1216. 
[2] Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a 
meta-analysis. Med Sci Sports Exerc 2007; 39:2099. 
[3] Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog 
Cardiovasc Dis 2007; 50:151. 
[4] Müller-Bardorff M, Weidtmann B, Giannitsis E, et al. Release kinetics of cardiac 
troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 
2002; 48:673. 
[5] Carlson RJ, Navone A, McConnell JP, et al. Effect of myocardial ischemia on cardiac 
troponin I and T. Am J Cardiol 2002; 89:224. 
[6] Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating 
troponin in the setting of transient stress test-induced myocardial ischaemia using 
an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009; 30:162. 
[7] Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values 
remain constant after brief exercise- or pharmacologic-induced reversible 
myocardial ischemia. Clin Chem 2008; 54:1234. 
[8] Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is 
MB creatine kinase the choice for the 1990s? Circulation 1993; 88:750. 
[9] Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac 
troponin T and its release kinetics in patients with reperfused and nonreperfused 
myocardial infarction. Am J Cardiol 1991; 67:1360. 
[10] Adams JE 3rd, Schechtman KB, Landt Y, et al. Comparable detection of acute 
myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin 
Chem 1994; 40:1291. 
[11] Adams JE III, Bodor, GS, Davila-Roman, VG, et al. Cardiac troponin I. A marker with 
high specificity for cardiac injury. Circulation 1993; 88:101. 
[12] Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not expressed in fetal 
and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 
41:1710. 
[13] Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms expressed in renal 
diseased skeletal muscle will not cause false-positive results by the second 
generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998; 
44:1919. 
[14] Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin 
assays at low-range concentrations. Clin Chem 2004; 50:327. 
 
Cardiac Biomarkers 33 
[15] Apple FS, Quist HE, Doyle PJ, et al. Plasma 99th percentile reference limits for cardiac 
troponin and creatine kinase MB mass for use with European Society of 
Cardiology/American College of Cardiology consensus recommendations. Clin 
Chem 2003; 49:1331. 
[16] Shi Q, Ling M, Zhang X, et al. Degradation of cardiac troponin I in serum complicates 
comparisons of cardiac troponin I assays. Clin Chem 1999; 45:1018. 
[17] Labugger R, Organ L, Collier C, et al. Extensive troponin I and T modification detected 
in serum from patients with acute myocardial infarction. Circulation 2000; 
102:1221. 
[18] Heeschen C, Goldmann BU, Langenbrink L, et al. Evaluation of a rapid whole blood 
ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 
1999; 45:1789. 
[19] Katrukha AG, Bereznikova AV, Esakova TV, et al. Troponin I is released in bloodstream 
of patients with acute myocardial infarction not in free form but as complex. Clin 
Chem 1997; 43:1379. 
[20] Wu AH, Feng YJ, Moore R, et al. Characterization of cardiac troponin subunit release 
into serum after acute myocardial infarction and comparison of assays for troponin 
T and I. American Association for Clinical Chemistry Subcommittee on cTnI 
Standardization. Clin Chem 1998; 44:1198. 
[21] Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the 
Redefinition of Myocardial Infarction. Universal definition of myocardial 
infarction. Eur Heart J 2007; 28:2525. 
[22] Panteghini M, Gerhardt W, Apple FS, et al. Quality specifications for cardiac troponin 
assays. Clin Chem Lab Med 2001; 39:175. 
[23] Lee TH, Thomas EJ, Ludwig LE, et al. Troponin T as a marker for myocardial ischemia 
in patients undergoing major noncardiac surgery. Am J Cardiol 1996; 77:1031. 
[24] Baum H, Braun S, Gerhardt W, et al. Multicenter evaluation of a second-generation 
assay for cardiac troponin T. Clin Chem 1997; 43:1877. 
[25] Apple FS, Parvin CA, Buechler KF, et al. Validation of the 99th percentile cutoff 
independent of assay imprecision (CV) for cardiac troponin monitoring for ruling 
out myocardial infarction. Clin Chem 2005; 51:2198. 
[26] Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute 
coronary syndromes and the role for serial testing. Am Heart J 2008; 155:208. 
[27] Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease 
and mortality in 70-year-old men: a community-based cohort study. Circulation 
2006; 113:1071. 
[28] Kavsak PA, Newman AM, Lustig V, et al. Long-term health outcomes associated with 
detectable troponin I concentrations. Clin Chem 2007; 53:220. 
[29] Waxman DA, Hecht S, Schappert J, Husk G. A model for troponin I as a quantitative 
predictor of in-hospital mortality. J Am Coll Cardiol 2006; 48:1755. 
[30] Schulz O, Kirpal K, Stein J, et al. Importance of low concentrations of cardiac troponins. 
Clin Chem 2006; 52:1614. 
 
Novel Strategies in Ischemic Heart Disease 34
[31] Wu AH, Fukushima N, Puskas R, et al. Development and preliminary clinical 
validation of a high sensitivity assay for cardiac troponin using a capillary flow 
(single molecule) fluorescence detector. Clin Chem 2006; 52:2157. 
[32] Kavsak PA, MacRae AR, Yerna MJ, Jaffe AS. Analytic and clinical utility of a next-
generation, highly sensitive cardiac troponin I assay for early detection of 
myocardial injury. Clin Chem 2009; 55:573. 
[33] Wilson SR, Sabatine MS, Braunwald E, et al. Detection of myocardial injury in patients 
with unstable angina using a novel nanoparticle cardiac troponin I assay: 
observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009; 158:386. 
[34] Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I 
measured by the high-sensitivity cardiac troponin I access prototype assay and 
the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009; 
54:1165. 
[35] Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity 
cardiac troponin T assay. Clin Chem 2010; 56:254. 
[36] Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations 
of troponin T in patients with stable chronic heart failure. Circulation 2007; 
116:1242. 
[37] Januzzi JL Jr, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in 
acute chest pain patients evaluated with cardiac computed tomography. 
Circulation 2010; 121:1227. 
[38] Diamond GA, Kaul S. How would the Reverend Bayes interpret high-sensitivity 
troponin? Circulation 2010; 121:1172. 
[39] Kavsak PA, Wang X, Ko DT, et al. Short- and long-term risk stratification using a next-
generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an 
emergency department chest pain population. Clin Chem 2009; 55:1809. 
[40] Derdeyn CP. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009; 361:97; 
author reply 98. 
[41] de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a 
highly sensitive assay and cardiac structure and mortality risk in the general 
population. JAMA 2010; 304:2503. 
[42] deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of 
cardiac troponin T using a sensitive assay with incident heart failure and 
cardiovascular mortality in older adults. JAMA 2010; 304:2494. 
[43] Katus HA, Giannitsis E, Jaffe AS, Thygesen K. Higher sensitivity troponin assays: Quo 
vadis? Eur Heart J 2009; 30:127. 
[44] Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin 
T elevation in the general population. Circulation 2006; 113:1958. 
[45] Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T and 
elevated N-terminal pro-B-type natriuretic peptide predict mortality in older 
adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52:450. 
[46] Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll 
Cardiol 2006; 48:1763. 
 
Novel Strategies in Ischemic Heart Disease 34
[31] Wu AH, Fukushima N, Puskas R, et al. Development and preliminary clinical 
validation of a high sensitivity assay for cardiac troponin using a capillary flow 
(single molecule) fluorescence detector. Clin Chem 2006; 52:2157. 
[32] Kavsak PA, MacRae AR, Yerna MJ, Jaffe AS. Analytic and clinical utility of a next-
generation, highly sensitive cardiac troponin I assay for early detection of 
myocardial injury. Clin Chem 2009; 55:573. 
[33] Wilson SR, Sabatine MS, Braunwald E, et al. Detection of myocardial injury in patients 
with unstable angina using a novel nanoparticle cardiac troponin I assay: 
observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009; 158:386. 
[34] Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I 
measured by the high-sensitivity cardiac troponin I access prototype assay and 
the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009; 
54:1165. 
[35] Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity 
cardiac troponin T assay. Clin Chem 2010; 56:254. 
[36] Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations 
of troponin T in patients with stable chronic heart failure. Circulation 2007; 
116:1242. 
[37] Januzzi JL Jr, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in 
acute chest pain patients evaluated with cardiac computed tomography. 
Circulation 2010; 121:1227. 
[38] Diamond GA, Kaul S. How would the Reverend Bayes interpret high-sensitivity 
troponin? Circulation 2010; 121:1172. 
[39] Kavsak PA, Wang X, Ko DT, et al. Short- and long-term risk stratification using a next-
generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an 
emergency department chest pain population. Clin Chem 2009; 55:1809. 
[40] Derdeyn CP. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009; 361:97; 
author reply 98. 
[41] de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a 
highly sensitive assay and cardiac structure and mortality risk in the general 
population. JAMA 2010; 304:2503. 
[42] deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of 
cardiac troponin T using a sensitive assay with incident heart failure and 
cardiovascular mortality in older adults. JAMA 2010; 304:2494. 
[43] Katus HA, Giannitsis E, Jaffe AS, Thygesen K. Higher sensitivity troponin assays: Quo 
vadis? Eur Heart J 2009; 30:127. 
[44] Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin 
T elevation in the general population. Circulation 2006; 113:1958. 
[45] Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T and 
elevated N-terminal pro-B-type natriuretic peptide predict mortality in older 
adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52:450. 
[46] Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll 
Cardiol 2006; 48:1763. 
 
Cardiac Biomarkers 35 
[47] Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I 
assay and risk of recurrent myocardial infarction and death in patients with 
suspected acute coronary syndrome. JAMA 2011; 305:1210. 
[48] Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. 
Circulation 2008; 118:2200. 
[49] Antman, EM, Anbe, DT, Armstrong, PW, et al. ACC/AHA guidelines for the 
management of patients with ST-elevation myocardial infarction. 
www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 
2006). 
[50] Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour 
interval between specimens in the American Heart Association Classification of 
Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem 
2006; 52:812. 
[51] Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B. Diagnostic value of serial 
measurement of cardiac markers in patients with chest pain: limited value of 
adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 
2004; 148:574. 
[52] Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity 
of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J 1998; 
135:245. 
[53] Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction 
with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858. 
[54] Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute 
myocardial infarction. N Engl J Med 2009; 361:868. 
[55] Jaffe, AS and Apple FS. High-sensitivity cardiac troponin: Hype, help, and reality. 
Clinical chemistry 2009; Dec 30. [E pub ahead of print]. 
[56] Antman, EM, Hand, M, Armstrong, PW, et al. 2007 focused update of the ACC/AHA 
2004 Guidelines for the Management of Patients With ST-Elevation Myocardial 
Infarction: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Writing Group to Review New 
Evidence and Update the ACC/AHA 2004 Guidelines for the Management of 
Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008; 51:XXX. 
Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed 
September 18, 2007). 
[57] deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients 
without ischemic electrocardiographic changes: angiographic correlates and long-
term clinical outcomes. J Am Coll Cardiol 2000; 35:1827. 
[58] Ohman EM, Christenson RH, Califf RM, et al. Noninvasive detection of reperfusion 
after thrombolysis based on serum creatine kinase MB changes and clinical 
variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial 
Infarction. Am Heart J 1993; 126:819. 
[59] Christenson RH, Ohman EM, Topol EJ, et al. Assessment of coronary reperfusion after 
thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical 
 
Novel Strategies in Ischemic Heart Disease 36
variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial 
Infarction-7. Circulation 1997; 96:1776. 
[60] Apple FS, Murakami MM. Cardiac troponin and creatine kinase MB monitoring during 
in-hospital myocardial reinfarction. Clin Chem 2005; 51:460. 
[61] Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent 
risk factor for short- and long-term mortality in medical intensive care unit 
patients. Crit Care Med 2008; 36:759. 
[62] Allan JJ, Feld RD, Russell AA, et al. Cardiac troponin I levels are normal or minimally 
elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052. 
[63] Licka M, Zimmermann R, Zehelein J, et al. Troponin T concentrations 72 hours after 
myocardial infarction as a serological estimate of infarct size. Heart 2002; 87:520. 
[64] Panteghini M, Cuccia C, Bonetti G, et al. Single-point cardiac troponin T at coronary 
care unit discharge after myocardial infarction correlates with infarct size and 
ejection fraction. Clin Chem 2002; 48:1432. 
[65] Steen H, Giannitsis E, Futterer S, et al. Cardiac troponin T at 96 hours after acute 
myocardial infarction correlates with infarct size and cardiac function. J Am Coll 
Cardiol 2006; 48:2192. 
[66] Giannitsis E, Steen H, Kurz K, et al. Cardiac magnetic resonance imaging study for 
quantification of infarct size comparing directly serial versus single time-point 
measurements of cardiac troponin T. J Am Coll Cardiol 2008; 51:307. 
[67] Vasile VC, Babuin L, Giannitsis E, et al. Relationship of MRI-determined infarct size and 
cTnI measurements in patients with ST-elevation myocardial infarction. Clin Chem 
2008; 54:617. 
[68] Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus 
troponin I in unstable angina pectoris for cardiac events with meta-analysis 
comparing published studies. Am J Cardiol 1998; 81:1405. 
[69] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in 
patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am 
Coll Cardiol 2001; 38:478. 
[70] Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification 
of patients with acute coronary syndromes in relation to therapeutic efficacy of 
tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic 
Syndrome Management. Lancet 1999; 354:1757. 
[71] James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in 
patients with the acute coronary syndrome: prospective verification in the GUSTO-
IV trial. Am J Med 2003; 115:178. 
[72] Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care 
cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. 
Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 
84:1281. 
[73] Giannitsis E, Müller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts 
clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary 
percutaneous intervention for acute ST-segment elevation myocardial infarction. 
Circulation 2001; 104:630. 
 
Novel Strategies in Ischemic Heart Disease 36
variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial 
Infarction-7. Circulation 1997; 96:1776. 
[60] Apple FS, Murakami MM. Cardiac troponin and creatine kinase MB monitoring during 
in-hospital myocardial reinfarction. Clin Chem 2005; 51:460. 
[61] Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent 
risk factor for short- and long-term mortality in medical intensive care unit 
patients. Crit Care Med 2008; 36:759. 
[62] Allan JJ, Feld RD, Russell AA, et al. Cardiac troponin I levels are normal or minimally 
elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052. 
[63] Licka M, Zimmermann R, Zehelein J, et al. Troponin T concentrations 72 hours after 
myocardial infarction as a serological estimate of infarct size. Heart 2002; 87:520. 
[64] Panteghini M, Cuccia C, Bonetti G, et al. Single-point cardiac troponin T at coronary 
care unit discharge after myocardial infarction correlates with infarct size and 
ejection fraction. Clin Chem 2002; 48:1432. 
[65] Steen H, Giannitsis E, Futterer S, et al. Cardiac troponin T at 96 hours after acute 
myocardial infarction correlates with infarct size and cardiac function. J Am Coll 
Cardiol 2006; 48:2192. 
[66] Giannitsis E, Steen H, Kurz K, et al. Cardiac magnetic resonance imaging study for 
quantification of infarct size comparing directly serial versus single time-point 
measurements of cardiac troponin T. J Am Coll Cardiol 2008; 51:307. 
[67] Vasile VC, Babuin L, Giannitsis E, et al. Relationship of MRI-determined infarct size and 
cTnI measurements in patients with ST-elevation myocardial infarction. Clin Chem 
2008; 54:617. 
[68] Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus 
troponin I in unstable angina pectoris for cardiac events with meta-analysis 
comparing published studies. Am J Cardiol 1998; 81:1405. 
[69] Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in 
patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am 
Coll Cardiol 2001; 38:478. 
[70] Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification 
of patients with acute coronary syndromes in relation to therapeutic efficacy of 
tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic 
Syndrome Management. Lancet 1999; 354:1757. 
[71] James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in 
patients with the acute coronary syndrome: prospective verification in the GUSTO-
IV trial. Am J Med 2003; 115:178. 
[72] Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care 
cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. 
Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 
84:1281. 
[73] Giannitsis E, Müller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts 
clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary 
percutaneous intervention for acute ST-segment elevation myocardial infarction. 
Circulation 2001; 104:630. 
 
Cardiac Biomarkers 37 
[74] Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk 
of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 
140:917. 
[75] Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of 
early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B 
substudy. J Am Coll Cardiol 2000; 36:1812. 
[76] Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of 
subsequent cardiac events in unstable coronary artery disease. The FRISC study 
group. Circulation 1996; 93:1651. 
[77] Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to 
predict the risk of mortality in patients with acute coronary syndromes. N Engl J 
Med 1996; 335:1342. 
[78] Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk 
stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 
1996; 335:1333. 
[79] Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with 
acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N 
Engl J Med 1997; 337:1648. 
[80] Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of 
troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll 
Cardiol 2001; 38:979. 
[81] Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive 
protein and troponin T in patients with unstable angina: a comparative analysis. 
CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina 
REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535. 
[82] Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation 
in relation to long-term mortality in unstable coronary artery disease. FRISC Study 
Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 
343:1139. 
[83] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-
ST elevation MI: A method for prognostication and therapeutic decision making. 
JAMA 2000; 284:835. 
[84] Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T 
to predict benefit from an early invasive strategy in patients with unstable angina 
and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 
2001; 286:2405. 
[85] Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-
brain fraction and comparison with troponin T to predict cardiac risk and benefit of 
an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J 
Am Coll Cardiol 2002; 40:1044. 
[86] Diderholm E, Andrén B, Frostfeldt G, et al. The prognostic and therapeutic implications 
of increased troponin T levels and ST depression in unstable coronary artery 
disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 
2002; 143:760. 
 
Novel Strategies in Ischemic Heart Disease 38
[87] Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in 
patients with refractory unstable angina according to troponin T status. Circulation 
1999; 100:1509. 
[88] Martinez MW, Babuin L, Syed IS, et al. Myocardial infarction with normal coronary 
arteries: a role for MRI? Clin Chem 2007; 53:995. 
[89] Christiansen JP, Edwards C, Sinclair T, et al. Detection of myocardial scar by contrast-
enhanced cardiac magnetic resonance imaging in patients with troponin-positive 
chest pain and minimal angiographic coronary artery disease. Am J Cardiol 2006; 
97:768. 
[90] Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of elevated troponin in 
patients with suspected acute coronary syndrome but no critical epicardial 
coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005; 45:19. 
[91] James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have 
different relations to subsequent mortality and myocardial infarction after acute 
coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916. 
[92] Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for 
clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 
2004; 43:958. 
[93] Mueller C, Neumann FJ, Perruchoud AP, et al. Prognostic value of quantitative 
troponin T measurements in unstable angina/non-ST-segment elevation acute 
myocardial infarction treated early and predominantly with percutaneous coronary 
intervention. Am J Med 2004; 117:897. 
[94] Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for 
early and late risk stratification in patients with acute coronary syndromes. The 
GUSTO-IIa Investigators. Circulation 1998; 98:1853. 
[95] Antman EM. Troponin measurements in ischemic heart disease: more than just a black 
and white picture. J Am Coll Cardiol 2001; 38:987. 
[96] Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev 
Biochem 1985; 54:831. 
[97] Roberts R, Gowda KS, Ludbrook PA, Sobel BE. Specificity of elevated serum MB 
creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am 
J Cardiol 1975; 36:433. 
[98] Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of various human skeletal 
muscles. Clin Chem 1986; 32:1568. 
[99] Neumeier, D. Tissue specific and subcellular distribution of creatine kinase isoenzymes. 
In: Creatine Kinase Isoenzymes, Lang, H (Ed), Springer-Verlag, Berlin/Heidelberg 
1981. p.85. 
[100] Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M 
and B creatine kinase mRNAs. Biochim Biophys Acta 1990; 1049:182. 
[101] Fontanet HL, Trask RV, Haas RC, et al. Regulation of expression of M, B, and 
mitochondrial creatine kinase mRNAs in the left ventricle after pressure overload 
in rats. Circ Res 1991; 68:1007. 
[102] Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin 
Pathol 1991; 95:293. 
 
Novel Strategies in Ischemic Heart Disease 38
[87] Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in 
patients with refractory unstable angina according to troponin T status. Circulation 
1999; 100:1509. 
[88] Martinez MW, Babuin L, Syed IS, et al. Myocardial infarction with normal coronary 
arteries: a role for MRI? Clin Chem 2007; 53:995. 
[89] Christiansen JP, Edwards C, Sinclair T, et al. Detection of myocardial scar by contrast-
enhanced cardiac magnetic resonance imaging in patients with troponin-positive 
chest pain and minimal angiographic coronary artery disease. Am J Cardiol 2006; 
97:768. 
[90] Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of elevated troponin in 
patients with suspected acute coronary syndrome but no critical epicardial 
coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005; 45:19. 
[91] James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have 
different relations to subsequent mortality and myocardial infarction after acute 
coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916. 
[92] Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for 
clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 
2004; 43:958. 
[93] Mueller C, Neumann FJ, Perruchoud AP, et al. Prognostic value of quantitative 
troponin T measurements in unstable angina/non-ST-segment elevation acute 
myocardial infarction treated early and predominantly with percutaneous coronary 
intervention. Am J Med 2004; 117:897. 
[94] Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for 
early and late risk stratification in patients with acute coronary syndromes. The 
GUSTO-IIa Investigators. Circulation 1998; 98:1853. 
[95] Antman EM. Troponin measurements in ischemic heart disease: more than just a black 
and white picture. J Am Coll Cardiol 2001; 38:987. 
[96] Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev 
Biochem 1985; 54:831. 
[97] Roberts R, Gowda KS, Ludbrook PA, Sobel BE. Specificity of elevated serum MB 
creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am 
J Cardiol 1975; 36:433. 
[98] Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of various human skeletal 
muscles. Clin Chem 1986; 32:1568. 
[99] Neumeier, D. Tissue specific and subcellular distribution of creatine kinase isoenzymes. 
In: Creatine Kinase Isoenzymes, Lang, H (Ed), Springer-Verlag, Berlin/Heidelberg 
1981. p.85. 
[100] Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M 
and B creatine kinase mRNAs. Biochim Biophys Acta 1990; 1049:182. 
[101] Fontanet HL, Trask RV, Haas RC, et al. Regulation of expression of M, B, and 
mitochondrial creatine kinase mRNAs in the left ventricle after pressure overload 
in rats. Circ Res 1991; 68:1007. 
[102] Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin 
Pathol 1991; 95:293. 
 
Cardiac Biomarkers 39 
[103] Siegel AJ, Silverman LM, Evans WJ. Elevated skeletal muscle creatine kinase MB 
isoenzyme levels in marathon runners. JAMA 1983; 250:2835. 
[104] Clark GL, Robison AK, Gnepp DR, et al. Effects of lymphatic transport of enzyme on 
plasma creatine kinase time-activity curves after myocardial infarction in dogs. Circ 
Res 1978; 43:162. 
[105] Vatner SF, Baig H, Manders WT, Maroko PR. Effects of coronary artery reperfusion 
on myocardial infarct size calculated from creatine kinase. J Clin Invest 1978; 
61:1048. 
[106] Dillon MC, Calbreath DF, Dixon AM, et al. Diagnostic problem in acute myocardial 
infarction: CK-MB in the absence of abnormally elevated total creatine kinase 
levels. Arch Intern Med 1982; 142:33. 
[107] Heller GV, Blaustein AS, Wei JY. Implications of increased myocardial isoenzyme 
level in the presence of normal serum creatine kinase activity. Am J Cardiol 1983; 
51:24. 
[108] Yusuf S, Collins R, Lin L, et al. Significance of elevated MB isoenzyme with normal 
creatine kinase in acute myocardial infarction. Am J Cardiol 1987; 59:245. 
[109] Puleo PR, Guadagno PA, Roberts R, et al. Early diagnosis of acute myocardial 
infarction based on assay for subforms of creatine kinase-MB. Circulation 1990; 
82:759. 
[110] Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine 
kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994; 
331:561. 
[111] Jaffe AS, Landt Y, Parvin CA, et al. Comparative sensitivity of cardiac troponin I and 
lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. Clin 
Chem 1996; 42:1770. 
[112] Adams JE 3rd, Dávila-Román VG, Bessey PQ, et al. Improved detection of cardiac 
contusion with cardiac troponin I. Am Heart J 1996; 131:308. 
[113] Adams JE 3rd, Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial 
infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330:670. 
[114] Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a 
noncardiac source. Ann Intern Med 1981; 94:341. 
[115] Lenke LG, Bridwell KH, Jaffe AS. Increase in creatine kinase MB isoenzyme levels after 
spinal surgery. J Spinal Disord 1994; 7:70. 
[116] Badsha H, Gunes B, Grossman J, Brahn E. Troponin I Assessment of Cardiac 
Involvement in Patients With Connective Tissue Disease and an Elevated Creatine 
Kinase MB Isoform Report of Four Cases and Review of the Literature. J Clin 
Rheumatol 1997; 3:131. 
[117] Hochberg MC, Koppes GM, Edwards CQ, et al. Hypothyroidism presenting as a 
polymyositis-like syndrome. Report of two cases. Arthritis Rheum 1976; 19:1363. 
[118] Jaffe AS, Ritter C, Meltzer V, et al. Unmasking artifactual increases in creatine kinase 
isoenzymes in patients with renal failure. J Lab Clin Med 1984; 104:193. 
[119] Gutovitz AL, Sobel BE, Roberts R. Progressive nature of myocardial injury in selected 
patients with cardiogenic shock. Am J Cardiol 1978; 41:469. 
 
Novel Strategies in Ischemic Heart Disease 40
[120] Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor 
elevations of creatine kinase-MB level and mortality in patients with acute coronary 
syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet 
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin 
Therapy. JAMA 2000; 283:347. 
[121] Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase 
elevations extends across the whole spectrum of acute coronary syndromes. J Am 
Coll Cardiol 2002; 39:22. 
[122] Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase 
elevation after primary percutaneous coronary intervention for acute myocardial 
infarction. J Am Coll Cardiol 2006; 47:951. 
[123] Galla JM, Mahaffey KW, Sapp SK, et al. Elevated creatine kinase-MB with normal 
creatine kinase predicts worse outcomes in patients with acute coronary 
syndromes: results from 4 large clinical trials. Am Heart J 2006; 151:16. 
[124] Lloyd-Jones DM, Camargo CA Jr, Giugliano RP, et al. Characteristics and prognosis of 
patients with suspected acute myocardial infarction and elevated MB relative index 
but normal total creatine kinase. Am J Cardiol 1999; 84:957. 
[125] Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant 
creatine kinase-MB and troponin measurements in acute coronary syndromes. J 
Am Coll Cardiol 2006; 47:312. 
[126] Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation 
across the spectrum of chest pain syndromes. Am J Cardiol 2003; 91:936. 
[127] Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the 
redefinition of acute myocardial infarction: lessons from the Global Registry of 
Acute Coronary Events (GRACE). Am Heart J 2006; 151:654. 
[128] Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization 
procedures. J Am Coll Cardiol 1998; 31:241. 
[129] Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated 
cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II 
Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and 
Coronary Thrombosis-II. J Am Coll Cardiol 1999; 33:88. 
[130] Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during 
coronary intervention is associated with impaired outcome. Eur Heart J 1999; 
20:1112. 
[131] Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical 
markers of myocardial damage on long-term mortality after percutaneous 
coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 
26:1494. 
[132] Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated 
troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002; 
39:1738. 
[133] Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term 
risk stratification of patients undergoing percutaneous coronary intervention. Eur 
Heart J 2003; 24:1314. 
 
Novel Strategies in Ischemic Heart Disease 40
[120] Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor 
elevations of creatine kinase-MB level and mortality in patients with acute coronary 
syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet 
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin 
Therapy. JAMA 2000; 283:347. 
[121] Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase 
elevations extends across the whole spectrum of acute coronary syndromes. J Am 
Coll Cardiol 2002; 39:22. 
[122] Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase 
elevation after primary percutaneous coronary intervention for acute myocardial 
infarction. J Am Coll Cardiol 2006; 47:951. 
[123] Galla JM, Mahaffey KW, Sapp SK, et al. Elevated creatine kinase-MB with normal 
creatine kinase predicts worse outcomes in patients with acute coronary 
syndromes: results from 4 large clinical trials. Am Heart J 2006; 151:16. 
[124] Lloyd-Jones DM, Camargo CA Jr, Giugliano RP, et al. Characteristics and prognosis of 
patients with suspected acute myocardial infarction and elevated MB relative index 
but normal total creatine kinase. Am J Cardiol 1999; 84:957. 
[125] Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant 
creatine kinase-MB and troponin measurements in acute coronary syndromes. J 
Am Coll Cardiol 2006; 47:312. 
[126] Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation 
across the spectrum of chest pain syndromes. Am J Cardiol 2003; 91:936. 
[127] Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the 
redefinition of acute myocardial infarction: lessons from the Global Registry of 
Acute Coronary Events (GRACE). Am Heart J 2006; 151:654. 
[128] Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization 
procedures. J Am Coll Cardiol 1998; 31:241. 
[129] Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated 
cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II 
Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and 
Coronary Thrombosis-II. J Am Coll Cardiol 1999; 33:88. 
[130] Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during 
coronary intervention is associated with impaired outcome. Eur Heart J 1999; 
20:1112. 
[131] Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical 
markers of myocardial damage on long-term mortality after percutaneous 
coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 
26:1494. 
[132] Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated 
troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002; 
39:1738. 
[133] Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term 
risk stratification of patients undergoing percutaneous coronary intervention. Eur 
Heart J 2003; 24:1314. 
 
Cardiac Biomarkers 41 
[134] Nageh T, Sherwood RA, Harris BM, et al. Cardiac troponin T and I and creatine 
kinase-MB as markers of myocardial injury and predictors of outcome following 
percutaneous coronary intervention. Int J Cardiol 2003; 92:285. 
[135] Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary 
intervention creatine kinase-MB and troponin I elevation in predicting mid-term 
mortality. Am J Cardiol 2004; 93:18. 
[136] Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased 
cardiac troponin concentrations following percutaneous coronary intervention. Am 
J Cardiol 2002; 89:1300. 
[137] Miller WL, Garratt KN, Burritt MF, et al. Baseline troponin level: key to 
understanding the importance of post-PCI troponin elevations. Eur Heart J 2006; 
27:1061. 
[138] Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on 
outcomes following Percutaneous coronary intervention. Circ Cardiovasc Intervent 
2008; 1:9. 
[139] Pierpont GL, McFalls EO. Interpreting troponin elevations: do we need multiple 
diagnoses? Eur Heart J 2009; 30:135. 
[140] Prasad A, Singh M, Lerman A, et al. Isolated elevation in troponin T after 
percutaneous coronary intervention is associated with higher long-term mortality. J 
Am Coll Cardiol 2006; 48:1765. 
[141] Nienhuis MB, Ottervanger JP, Dikkeschei B, et al. Prognostic importance of troponin T 
and creatine kinase after elective angioplasty. Int J Cardiol 2007; 120:242. 
[142] Kleiman NS. Measuring troponin elevation after percutaneous coronary intervention: 
ready for prime time? J Am Coll Cardiol 2006; 48:1771. 
[143] Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of 
abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial 
revascularization therapies study (ARTS). Circulation 2001; 104:2689. 
[144] Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after 
percutaneous or surgical revascularization and three-year mortality. J Am Coll 
Cardiol 2002; 40:1961. 
[145] Januzzi JL, Lewandrowski K, MacGillivray TE, et al. A comparison of cardiac troponin 
T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll 
Cardiol 2002; 39:1518. 
[146] Steuer J, Bjerner T, Duvernoy O, et al. Visualisation and quantification of peri-
operative myocardial infarction after coronary artery bypass surgery with contrast-
enhanced magnetic resonance imaging. Eur Heart J 2004; 25:1293. 
[147] Carrier M, Pellerin M, Perrault LP, et al. Troponin levels in patients with myocardial 
infarction after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:435. 
[148] Croal BL, Hillis GS, Gibson PH, et al. Relationship between postoperative cardiac 
troponin I levels and outcome of cardiac surgery. Circulation 2006; 114:1468. 
[149] Thielmann M, Massoudy P, Jaeger BR, et al. Emergency re-revascularization with 
percutaneous coronary intervention, reoperation, or conservative treatment in 
patients with acute perioperative graft failure following coronary artery bypass 
surgery. Eur J Cardiothorac Surg 2006; 30:117. 
 
Novel Strategies in Ischemic Heart Disease 42
[150] Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry 
Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of 
biochemical markers in acute coronary syndromes. Clin Chem 2007; 53:552. 
 
Novel Strategies in Ischemic Heart Disease 42
[150] Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry 
Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of 
biochemical markers in acute coronary syndromes. Clin Chem 2007; 53:552. 
3 
Inflammatory Biomarkers in 
 Ischemic Heart Disease 
Mette Bjerre 
The Medical Research Laboratories, Institute of Clinical Medicine, 
Faculty of Health Sciences, Aarhus University  
Denmark 
1. Introduction 
Ischemic heart disease (IHD) is one of the main groups within the class of cardiovascular 
diseases (CVD), and IHD is the most common single cause of morbidity and mortality in 
the Western world (Gaziano et al., 2006). According to the American Heart Association 
Statistics Committee one in three individuals has one or more forms of CVD (Rosamond 
et al., 2007).  
The importance of inflammation in the pathogenesis of IHD, such as, acute myocardial 
infarct (AMI) and coronary artery disease (CAD), has long been established. A large body of 
evidence suggests that inflammation plays a key role in CVD, however, the mechanisms in 
the various stages of the pathological process is not completely understood (Carden and 
Granger, 2000). Inflammation is a complex of defensive mechanisms reacting to the entry of 
harmful agents into the organism or cells, in order to eliminate or repair damaged cells or 
tissue and to restore homeostasis. This broad definition indicates that inflammation does not 
only accompany infectious diseases, but also other conditions causing cell, tissue or organ 
damage.  
The identified risk factors for IHD include both lifestyle and biological factors, such as 
smoking, high blood pressure, high cholesterol levels, obesity, and diabetes that all appear 
to exaggerate many of the vascular alterations elicited by ischemia and reperfusion. Diabetes 
and CVD often appear as two sides of a coin: on one side, diabetes has been rated as an 
equivalent of CVD, and conversely, many patients with established CVD suffer from overt 
or incipient diabetes (Ryden et al., 2007). The mortality from AMI is almost increased five-
fold in diabetic patients compared with non-diabetics (Hansen et al., 2007) and diabetes and 
low-grade inflammation is closely related (Flyvbjerg, 2010). Obesity is seen at epidemic 
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increased morbidity and mortality, most importantly from CVD and diabetes (Lavie et al., 
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adequately differentiate individuals at moderate risk. Indeed, not all patients with CVD will 
have conventional risk factors and not all patients with risk factors will develop CVD (Khot 
et al., 2003). Both biomarkers of early disease and plaque instability have therefore been 
sought, and the development of new markers to diagnose and prevent CVD is an important 
public health goal worldwide. However, a recent report showed that the addition of a multi-
marker score including 10 new markers to conventional risk factors added only a moderate 
increase in the ability to grade the risk in the general population (Wang et al., 2006). 
Several inflammatory biomarkers have been shown to represent important cardiovascular 
risk factors, and this review will primarily focus on the complement system, the acute-phase 
reactant C-reactive protein (CRP), and the antimicrobial peptides: -defensins. Whether 
these inflammatory proteins mediate IHD themselves or solely serve as markers of systemic 
inflammation and cardiovascular risk stratification is still intensely studied. 
2. Inflammation and IHD 
Growing evidence indicates that IHD is a broad syndrome with multiple pathogenetic and 
aetiological components, which may not be the same in all patients. Extensive literature 
supports the role of inflammation in IHD (Mehta and Li, 1999; Ross, 1999). Inflammatory 
cells, inflammatory proteins and inflammatory responses from vascular cells are all reported 
to play crucial roles in various stages of a number of CVD (Carden and Granger, 2000). 
Some of the inflammatory mechanisms of IHD include, among others, endothelial 
dysfunction, oxidative stress and vascular calcification, that all seems to play an important 
role for the development of cardiovascular disease.  
Although timely restoration of blood-flow after a myocardial ischemic event is essential to 
prevent irreversible cellular injury, it is widely recognized that the outcome of tissue injury 
not only depends on the duration of the ischemic event, but also on reperfusion as a critical 
factor (Khalil et al., 2006). Paradoxically, the reperfusion exacerbates severe tissue damage, 
especially after longer periods of ischemia. The intensity of the inflammatory reaction in 
post-ischemic tissue can be so strong that the injury response to reperfusion can be 
manifested in distant organs (Carden and Granger, 2000). 
The ischemia-reperfusion injury (IRI) results in a local and systemic inflammatory response 
characterized by the production of reactive oxygen species (ROS), leucocyte-endothelial cell 
adhesion, complement activation, endothelial leucocyte migration, increased micro-vascular 
permeability and decreased endothelial-dependent relaxation (Carden and Granger, 2000). 
Within minutes of reperfusion ROS are generated (Cannon, 2005), stimulating the release of 
cytokines and expression of adhesion molecules on damaged cells in reperfused tissue. Several 
hours after onset of reperfusion, neutrophils and other inflammatory cells are activated 
(Frangogiannis et al., 2002; Frangogiannis, 2007) and adhere to the damaged cell membranes 
(Zimmerman et al., 1990; Vinten-Johansen, 2004) for further enhancement of the inflammatory 
response. Thus, IRI poses major problems in the clinic, and effective therapies are required. 
3. Inflammatory biomarkers 
Recent research has been focused on identifying biomarkers, which alone or in combination 
with other risk markers could be useful in monitoring the treatment and as prognostic 
markers for future coronary syndromes and cardiac death in patients with IHD.  
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In 2001, a National Institute of Health working group defined a biomarker as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological responses to a therapeutic intervention 
(BiomarkersDefinitionsWorkingGroup, 2001). Biomarkers are traditionally specific proteins 
circulating in the body fluids that become altered as a consequence of disease progression or 
the effect of a therapeutic intervention and can be divided into different categories:  
 Disease-predictive  
 Diagnostic  
 Prognostic  
 Disease-associated 
 Therapeutic efficacy.  
A number of inflammatory biomarkers have been associated with cardiovascular diseases. 
Biomarker measurements can help explain empirical results of clinical trials by relating the 
effects of interventions on molecular and cellular pathways to clinical responses, thus 
providing an opportunity for researchers to gain a mechanistic understanding. 
3.1 The complement system  
The complement system is an innate, cytotoxic host defence that normally functions to 
eliminate pathogens and facilitates the clearance of damaged tissue and apoptotic cells. 
However, excessive activation of the system may lead to uncontrolled tissue damage. The 
relevance of complement activation in myocardial ischemia was already proposed more 
than four decades ago (Hill and Ward, 1971). The inflammatory mechanisms by which 
tissue injury after an AMI occurs has not been fully elucidated, but strong evidence obtained 
from animal models, as well as clinical studies, support the hypothesis of a role for the 
complement system in IHD (Bjerre et al., 2008). 
The complement system is a biochemical cascade, which helps clear pathogens from an 
organism, and is thus one part of a larger immune system. Three pathways of complement 
activation have been identified (Figure 1), known as the classical, the alternative and the 
lectin pathway. The classical pathway is initiated by C1q binding to antibody complexes 
(Cooper, 1985) whereas the alternative pathway is initiated by spontaneous and direct 
activation of C3 (Muller-Eberhard, 1988). The lectin pathway is initiated either through 
ficolin (M-, L- or H-ficolin) (Matsushita et al., 2001; Frederiksen et al., 2005), by pattern 
recognition of N-acetyl-glucosamine-rich polysaccharides or through mannan-binding lectin 
(MBL) binding to certain carbohydrate structures (Ikeda et al., 1987; Thiel et al., 1997; 
Holmskov et al., 2003).  
Activation of the complement system promotes three main biological activities (Walport, 
2001): I) recruitment of inflammatory cells by anaphylatoxins (C3a, C4a, and C5a), leading to 
accumulation of activated polymorph nuclear leukocytes directly involved in tissue 
destruction, II) opsonisation of pathogens for phagocytosis by the generation of C3b, and III) 
lysis of the pathogen by the generation of a membrane attack complex (MAC, C5b-9) 
penetrating the cell membrane. The loss of membrane integrity destroys the ability to 
control the concentration of salt within the cell and the cell is killed due to this osmotic 
instability. MAC formed in the absence of target membranes binds to S-protein, which 
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inhibits the membrane-damaging effect, and creates a stable non-lytic soluble C5b-9 form 
(sMAC, sC5b-9) (Fosbrink et al., 2005). 
 
Fig. 1. The complement system can be activated through three pathways, which merge at the 
cleavage of C3, leading to the effector mechanisms: I. recruitment of inflammatory cells, II. 
opsonisation and III. the generation of the membrane attack complex (MAC, C5b-9) for cell 
lysis. 
3.1.1 Role of complement in endothelial function  
Ischemia and reperfusion are potent activators of the complement system and both clinical 
and experimental studies in different organs have shown local deposition of complement 
(Riedemann and Ward, 2003; Arumugam et al., 2004).  It has traditionally been assumed that 
the liver is the source of complement proteins that participate in these events, but 
complement proteins are produced in several organs of the body, including the heart and 
the endothelium.  
The human heart expresses mRNAs, translated into proteins, for all of the components of 
the classical complement pathway (Yasojima et al., 1998b). This production is up-regulated 
in areas of myocardial infarct, and the classical complement pathway was found to be fully 
activated on injured myocardial tissue. In addition, production of C3 and C9 mRNAs and 
their protein products was significantly increased in isolated rabbit heart after reperfusion 
injury, and the production by heart in this circumstance substantially exceeds that of the 
normal liver (Yasojima et al., 1998a). 
Endothelial cells also represent one of the extrahepatic sources of complement components 
and regulators. Due to the strategic position along the surface of the vessel wall, they may 
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supply both the circulating blood and the extravascular fluids with these proteins. Most of 
the information on the production of complement components by endothelial cells has been 
obtained using human umbilical vein endothelial cells (HUVECs). HUVECs cultured in 
serum free media were reported to synthesize functional C3, C5, C6, C8, and C9 and 
assembling of the MAC complex was found, indicating that C7 was produced as well 
(Johnson and Hetland, 1991). The C7 production was later confirmed (Langeggen et al., 
2000) and a small production of C5, C6, C8, and C9 demonstrated by RT-PCR and Northern 
blot was reported (Langeggen et al., 2001). Activation of the complement cascade leads to 
the formation of the C5b-9 complex on the cell surface that can cause cell death. However, 
when the numbers of C5b-9 molecules are limited on host cell membranes, it can activate 
signalling pathways leading to cell cycle activation and cell survival (Niculescu and Rus, 
2001).  
The reduction in the capacity of the endothelium to maintain the homeostasis leads to the 
development of pathological inflammatory processes and vascular diseases. An intact 
endothelium is a fully biocompatible surface that is not recognized by the complement 
system. However, blood contact with a damaged endothelium will lead to a certain degree 
of activation of the defence system. Complement activation results in the formation of 
several biological active components including C3a, C5a, iC3b, and C5b-9. In addition, to 
stimulate inflammatory response C5a have been reported to induce production of 
chemokines and cytokines (Czermak et al., 1999).  
3.1.2 Mechanism of complement in IHD  
Cardiovascular risk factors (e.g., hypercholesterolemia, hypertension, smoking, diabetes, 
stress) cause oxidative stress that alters the endothelial cell capacity (Esper et al., 2006; 
Kyrou and Tsigos, 2007), and thus dysfunction of the endothelium has been implicated in 
the pathophysiology of different forms of CVD (reviewed by (Endemann and Schiffrin, 
2004)). Human endothelial cells have been shown to generate reactive oxygen intermediates 
in response to hyperglycaemia and lead to dysfunction in type 2 diabetic patients (Bellin et 
al., 2006). Endothelial dysfunction has been shown to have a prognostic value in patients 
with chest pain (Neunteufl et al., 2000) and both C-reactive protein (CRP) and C3a were 
found to be elevated in patients with unstable angina pectoris (Kostner et al., 2006). Elevated 
plasma levels of C3 was independently associated with MI after accounting for traditional 
cardiovascular risk factors and CRP in patients with MI, whereas the association of CRP was 
dependent of C3 (Carter et al., 2009). 
A number of in vitro studies using HUVECs have shown that under anoxic conditions the 
endothelial cells become activators of the complement system. Collard and co-workers 
showed increased MBL, C3, and iC3b deposition after hypoxia/reoxygenation (Collard et 
al., 2000; Collard et al., 2001). MBL deposition was attenuated in the presence of MBL 
ligands indicating the presence of MBL neo-epitopes on the surface of the endothelial cells. 
Apoptotic endothelial cells deposited C1 and C3d, thus activating the complement system 
(Mold and Morris, 2001). Experimental studies in porcine and rabbits reported that 
complement activation attenuates endothelium-dependent relaxation (Stahl et al., 1995; 
Lennon et al., 1996). The role of complement was mediated by the formation of C5b-9, but 
not through the generation of the anaphylatoxin C3a and C5a. 
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Hill et al. were the first to report a role for the complement system after an ischemic event in 
a rat model of AMI (Hill and Ward, 1971). The association between AMI and complement 
activation was later confirmed in baboons showing deposition of complement factors in the 
infarcted tissue (Pinckard et al., 1980; McManus et al., 1983). Later, several studies of 
experimental myocardial I/R showed deposition of complement; C1 (Vakeva et al., 1994), 
MBL and C3 (Walsh et al., 2005), C4, C5 (McManus et al., 1983; Crawford et al., 1988), C6 (Ito 
et al., 1996), and C5b-9 (Vakeva et al., 1994). MBL knock-out (KO) mice were protected from 
heart I/R injury, but when reconstituted with human recombinant MBL, I/R injury similar 
to that in wild type mice was found. Mice deficient in C2 and factor B (C2/B KO) were also 
protected form heart I/R injury but no protection was found in C1q or factor D KO mice 
(Walsh et al., 2005). In a murine model of coronary artery ischemia the involvement of 
natural IgM antibodies has been linked to both the classical and the lectin pathways (Zhang 
et al., 2006a; Zhang et al., 2006b). Mice bearing an altered natural IgM repertoire were 
significantly protected based on the reduced infarct size, limited apoptosis of 
cardiomyocytes, and decreased neutrophil infiltration. 
In addition to direct lytic activity, C5b-9 also directly attenuates endothelium-dependent 
(i.e., NO-mediated) relaxation (Stahl et al., 1995). Furthermore, C5b-9 is found to play a role 
in leucocyte activation, adherence and chemotaxis by induction of different cytokines 
(Kilgore et al., 1996; Vakeva et al., 1998). Also, activation of endothelial NF-kB and the 
stimulation of expression of endothelial adhesion molecules have been observed. 
Furthermore, a role for C5b-9 in mediating myocardial apoptosis after ischemia-reperfusion 
was demonstrated in a model of rat myocardial IRI (Vakeva et al., 1998). We have shown 
that increased complement activity as indicated by MBL and sC5b-9 levels, was associated 
with increased risk of cardiac dysfunction in STEMI patients treated with pPCI (Haahr-
Pedersen et al., 2009). High plasma MBL and low plasma sC5b-9 was independently 
associated with increased risk of cardiac dysfunction, likely due to increased complement 
activity during the ischemic and reperfusion process. The predictive value of low peripheral 
plasma sC5b-9 may be explained by an accumulation and activation of sC5b-9 in the 
infarcted myocardium. Furthermore, an elevated plasma sC5b-9 level was found in patients 
with chronic heart failure due to IHD (Bjerre et al., 2010). In addition, an independent 
association between sC5b-9, insulin resistance and endothelial dysfunction was found, 
which may suggest that insulin resistance leading to endothelial activation results in 
activation of the complement system thus damaging the heart. 
3.1.3 Therapeutic inhibition of complement in IHD  
Based on the studies discussed above, regulation of the complement system seems to be of 
great importance. Indeed, several animal studies point to a possible beneficial role of 
complement depletion in the treatment of post-ischemic MI; reviewed by (Bjerre et al., 2008; 
Diepenhorst et al., 2009). Unfortunately, clinical studies focused on complement depletion in 
humans, especially the use of anti-C5 antibodies, primarily Pexelizumab, have largely been 
disappointing and not proven effective in the setting of CVD, discussed in details elsewhere: 
(Bjerre et al., 2008; Diepenhorst et al., 2009; Banz and Rieben, 2011).  
Although much of the preclinical work and data accumulated in the past years have been 
positive, the problem with complement-mediated damage in IR-injury was not “easy to fix”. 
Thus conclusions drawn from animal studies should be extrapolated to the human settings 
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with caution. It may lie in the fact that complement activation represents only a part of the 
cascade of attack directed against the vasculature. An exaggerated blockade of the immune 
system may increase the susceptibility to infections, thus a well-balanced inhibition of the 
complement activation is required in order to avoid side effects of pharmaceutically induced 
modification of the immune system. Direct targeting may be the key to future treatment 
strategies, including targeting of the complement inhibitor to the site of injury by localized 
intravascular application. 
3.2 C-reactive protein  
C-reactive protein (CRP), an acute-phase reactant mainly produced by hepatocytes in 
response to interleukin (IL) 6, is a nonspecific marker of systemic inflammation, and is the 
most intensively studied inflammatory biomarker in CVD. In addition, a large number of 
reports have shown that CRP may be implicated in the pathogenesis of many chronic 
diseases, including diabetes, cancer and alzheimer dementia, and major CVDs, such as, 
coronary heart disease (CHD), AMI and IHD (Clyne and Olshaker, 1999; Hirschfield and 
Pepys, 2003; Lavie et al., 2009b). Of note, CRP levels has been associated with the size of the 
infarct (de Beer et al., 1982). 
The concentration of CRP increases rapidly; it may raise hundreds-fold after acute tissue 
injury or inflammation, and declines rapidly with resolution of the injurious process. In 
healthy persons, normal CRP levels are generally considered to be < 3 mg/L (Shine et al., 
1981). 
3.2.1 High sensitive CRP and IHD 
In the 1990s, rapid and more precise methods of quantifying CRP was established and CRP 
levels measured as low as 0.04 mg/L were possible, referred to as high sensitive (hs) CRP 
(Jaye and Waites, 1997). Low-grade inflammation is found in IHD, and CRP levels are not as 
increased as compared to other inflammatory conditions. Therefore, a cardiovascular risk 
scale according to hsCRP levels is recommended by the American Heart Association and 
Centers for Disease Control and Prevention (Pearson et al., 2003).  
Individuals with hsCRP levels; 
 <1 mg/L are at lower relative risk for cardiovascular events,  
 1 to 3 mg/L are at intermediate risk,  
 >3 mg/L are at higher relative risk.  
In the Copenhagen City Heart study, investigating more than 10,000 apparently healthy 
participants, elevated hsCRP levels were found to be associated with increased risk of IHD. 
In fact, the risk of IHD was more than doubled (HR=2.2, 1.6-2.9) in individuals with CRP 
levels above 3 mg/L as compared to individuals with CRP levels below 1 mg/L (Zacho et 
al., 2008).  
3.2.2 Possible links between hsCRP and IHD 
Inflammation clearly plays a clinically significant role in the development of CVD. 
Consequently, as a marker of inflammation, hsCRP has been studied extensively in patients 
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with CVD. The predictive value of hsCRP has been widely investigated but the results are 
contradictive. More than 20 large prospective trials have shown that hsCRP is an 
independent predictor of future cardiovascular events (Ridker, 2007). In the most recent 
comprehensive meta-analysis studies of cardiovascular risk factors (more than 50 
prospective studies with over 160,000 participants, none of them with a history of coronary 
heart disease or stroke) (Kaptoge et al., 2010), hsCRP was consistently found to be an 
independent predictor of CVD. However, the association with ischemic vascular disease 
depends considerably on conventional risk factors and other markers of inflammation. A 
critical review by Levinson and colleagues argues that hsCRP is poor discrimination over a 
wide range of values when used in conjunction with risk factors for lipoprotein lipids, 
hypertension, metabolic syndrome, and diabetes (Levinson et al., 2004). Danesh and 
colleagues published a study, performed in a high-risk population with nonfatal myocardial 
infarct, which questioned the role of CRP in the assessment of cardiovascular risk. However, 
hsCRP maintained a predictive value after adjustments for smoking and hypertension 
(Danesh et al., 2004). 
A panel of multiple biomarkers, 10 biomarkers in total including hsCRP, was used for 
prediction of death and major cardiovascular event in more than 3000 participants of the 
Framingham Off-spring study followed for 10 years (Wang et al., 2006). As a single marker, 
hsCRP predicted risk of death but no major cardiovascular events after adjusting for other 
biomarkers, and individuals with high multimarker scores had almost 4 times as great a risk 
of death. Nonetheless, the authors concluded that the use of contemporary biomarkers adds 
only moderately to standard risk factors. In the Women’s Health Study, CRP was found to 
be additive to LDL-cholesterol in predicting future CVD in healthy American women 
(n=28,263 apparently healthy postmenopausal women) (Ridker et al., 2000a). Of the 12 
markers measured (including hsCRP and IL-6), hs-CRP was the strongest uni-variant 
predictor of cardiovascular events, and the only plasma marker predicting risk after 
adjustment in a multi-variant analysis. This was confirmed in a large meta-analysis of 
hsCRP as a single biomarker in patients with stable CAD, but the authors concluded that a 
routine measurement of CRP should not be recommended as a single prognostic biomarker 
(Hemingway et al., 2010). However, in combination with other biomarkers, hsCRP seems to 
add significant information to traditional risk factors for CVD, and the value of adding 
hsCRP to standard risk equations was noted in separate cohorts of asymptomatic (middle-
aged or elderly) men and women (Lavie et al., 2009b).  
In the Caerphilly Prospective Heart Disease Study, Mendall and colleagues, showed a 
significant and positive association between CRP and incidents of IHD, not affected by 
ischemia history (Mendall et al., 2000). However, after adjustment of lifestyle risk factors 
(such as smoking and obesity) only the association with all-cause mortality remained 
significant. Plasma hsCRP was not found as an independent predictor of long-term IHD risk 
in a 13-year-follow-up study of men with no previous history of IHD (n=1982) (St-Pierre et 
al., 2005). The authors thus concluded that neither CRP nor the systemic inflammation 
appeared to have a direct role in the development of IHD. But the association of hsCRP with 
IHD may be that CRP levels are raised non-specifically by a variety of exposures that are 
themselves implicated in the pathogenesis of IHD (Figure 2). 
A connection between CRP and activation of the complement system was proposed more 
than 35 years ago, after the discovery of aggregated or ligand-complexed human CRP was 
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A connection between CRP and activation of the complement system was proposed more 
than 35 years ago, after the discovery of aggregated or ligand-complexed human CRP was 
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able to bind to C1q and activate the classical pathway (Kaplan and Volanakis, 1974; Siegel et 
al., 1974; Jiang et al., 1991), thus mediating the functions summarized in Figure 1. CRP was 
later found to co-localize with activated complement fragments in atherosclerotic lesions 
(Bhakdi et al., 1999; Yasojima et al., 2001) and CRP-mediated complement activation in the 
arterial wall may be considered as an important pathogenic feature in CVD.  
 
Fig. 2. Schematic depiction of potential mechanisms of CRP involvement in the pathogenesis 
of IHD. 
A number of pro-inflammatory cytokines have been shown to play roles in the process 
leading to IHD, but IL-6, in particular, appears to have a central role, e.g. by stimulating the 
liver to increase the CRP production. However, even with a strong correlation between IL-6 
and CRP, IL-6 was found to predict future AMI in a group of apparently healthy men 
(Ridker et al., 2000b).  
CRP binds to apolipoprotein-containing lipoproteins like LDL (de Beer et al., 1982) and very 
low-density lipoprotein (VLDL) (Rowe et al., 1984), which may be of considerable 
importance in the pathogenesis of CVD. More recent studies revealed that CRP 
preferentially binds to modified forms of LDL; enzymatically modified LDL (Bhakdi et al., 
1999) and oxidized LDL (Chang et al., 2002), and CRP was reported to mediate LDL uptake 
by macrophages (Zwaka et al., 2001). Opsonisation of LDL lead to monocyte infiltration and 
the formation of foam cells resulting in plaque formation and eventually IHD. 
CRP was found to cause expression of cell adhesion molecules with a significant dose-
dependent expression of ICAM-1, VCAM-1 and E-selectin in human umbilical vein 
endothelial cells (HUVEC) following CRP stimulation (Pasceri et al., 2000). Furthermore, 
production of chemokines monocyte chemoattractant protein-1 (MCP-1), which plays an 
important role in recruitment of monocytes into the vessel wall and thus the formation of 
plaques, was directly induced by CRP (Pasceri et al., 2001).  
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3.2.3 Is CRP a potential therapeutic in prevention of IHD?  
As described in the previous section, CRP is reported to be associated with a wide range of 
biomarkers and risk factors of IHD. Thus, overestimating of the true effect of hsCRP on CVD 
risk, because of confounding effects, constitute a challenge. Support for a role of CRP in the 
pathogenesis of CVD comes primary from epidemiologic studies, which in general have 
observed an association between elevated plasma CRP and cardiovascular events.  
Although hsCRP may not be the ideal marker of IHD, it seems to be very reliable, and 
hsCRP is a simple, non-invasive, commercially available, inexpensive and reproducible 
biomarker. CRP measurement has a lot of advantages; the protein is stable and the 
concentration is not subjected to time-of-the day variations (Meier-Ewert et al., 2001). Thus, 
determination of baseline hsCRP for cardiovascular risk prediction may be performed 
without concern for diurnal variation. 
Availability of drugs to block CRP binding and its effects in vivo would provide a powerful 
tool for determining whether CRP is just a marker or does indeed participate in the 
pathogenesis of CVD complications. Griselli and colleagues (Griselli et al., 1999) showed 
that injection of human CRP in a rat model of AMI enhanced the infarct size, of note rat CRP 
does not activate rat complement, whereas human CRP activate both rat and human 
complement. However, in vivo complement depletion, by cobra venom factor, completely 
abrogated this. A similar effect was later found by administration of a specific synthetic 
CRP-inhibitor, 1,6-bis(phosphocholine)-hexane, which reduced the infarct size and thus 
provided promising results for therapeutic inhibition of CRP (Pepys et al., 2006). 
Statins lower the levels of LDL-cholesterol and CRP. Ridker and colleagues showed, in a 
sub-population (n= 3745) derived from the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) study, 
that patients with low hsCRP levels after statin treatment had improved cardiovascular 
outcome (Ridker et al., 2005). Patients in whom statin therapy resulted in hsCRP levels 
below 2 mg/L overall had better clinical outcomes regardless of the LDL-cholesterol level 
achieved. Recently, a study JUPITER: Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (n=17802), of healthy individuals without history 
of CVD but hsCRP > 2 mg/L and low LDL concentration, showed beneficial effect of 
Rosuvastatin (Ridker et al., 2007; Kones, 2010; Ridker et al., 2010). The study was terminated 
due to a great risk-reduction in AMI, CVD and death from cardiovascular causes, indicating 
that part of the statin effect may be mediated through lowering CRP.  
Aside from whether measurement of CRP is useful in assessments of CVD, studies are 
needed to help determine if CRP is a mediator or a marker of CVD. Zacho et al. showed that 
genetic variants that are associated with a lifelong increased plasma CRP level are not 
associated with increased risk of IHD (Zacho et al., 2008), indicating CRP as a marker but 
not as an actual contributor. 
3.3 Anti-microbial peptides 
The involvement of polymorphonuclear neutrophils (PMNs) in the pathogenesis of CVD 
has received relatively little attention, despite their presence in the atherosclerotic plaques 
(Quinn et al., 2008). PMN counts have been reported as independent risk factors for 
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cardiovascular outcome (Madjid et al., 2004) and during inflammation PMNs are activated 
in order to enhance the inflammatory response and releases antimicrobial peptides into 
circulation.  
Anti-microbial peptides are polypeptides of fewer than 100 amino acids. The human innate 
immune system includes two main families; defensins and cathelicidins. Defensins, also 
termed human neutrophil peptides (HNP) as they are found in large amounts in 
neutrophils, are secreted during phagocytosis as a first line of defence against invading 
organisms (Ganz, 2003).  
3.3.1 -defensins  
Three different classes of defensin are identified in mammals, two of which are found in 
humans; - and -defensin (Ganz, 1987). The human family of -defensins are composed of 
3 closely related gene products, also referred to as human neutrophil peptides 1-3 (HNPs-1-
3) and HNP4, HNP5 and HNP6. The -defensins are cationic peptides, cysteine-rich 
peptides of approximately 3 kDa and are normally sequestered in the granules of 
neutrophils, where they constitute 5% of the total cellular protein and are involved in the 
intracellular killing of prokaryotic organisms (Ganz, 1987). Under normal conditions, only 
small amounts of -defensins (nanomolar range) are found in plasma. However, during 
inflammatory reactions, -defensins are released extracellularly, which could exert harmful 
effects on host cells. Increased plasma concentrations of -defensins have been described in 
several inflammatory diseases (Ganz, 2003; Klotman and Chang, 2006; de Leeuw and Lu, 
2007).  
3.3.2 Possible link between -defensins and IHD  
The cationic nature of the -defensins prefers the negatively charged phospholipids of the 
bacterial membrane as target and avoids the more neutral charged mammalian cell 
membrane. However, both a direct and an indirect chemoattracting role of -defensins has 
been reported for a number of cells (Oppenheim et al., 2003). In addition, -defensin was 
found to promote oxidative stress and induces endothelial dysfunction by reducing the 
endothelium-dependent relaxation in porcine coronary arteries (Kougias et al., 2006). This 
effect is associated with increased superoxide radical production and decreased eNOS 
expression. Also, -defensins is capable of forming complexes with C1q and MBL, thus 
playing a role in the regulation of both the classical and the lectin pathway of complement 
activation (Groeneveld et al., 2007).  
Localization of -defensins were analysed by the use of immunohistochemical staining of 
coronary arteries from patients with severe CVD or normal donor heart tissue (Barnathan et 
al., 1997). Of interest, -defensin was found most prominently in association with intima 
smooth muscle cells of both normal or atherosclerotic vessels. -defensins has been reported as 
an atherogenic agent by enhancing and promoting stable complexes with LDL particles, thus 
stimulating the binding to endothelial and smooth muscle cells (Higazi et al., 1997). In 
addition, in human cerebral vessels obtained during autopsy, -defensin and LDL co-localized 
primary within the atherosclerotic areas, and the staining intensity correlated with the severity 
of the disease. The authors hypothesize that the small -defensins may rapidly cross the 
endothelial barrier and gain access to sub-endothelial matrix and affording the binding of LDL 
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and a complex relative resistant to degradation. Retention of LDL in the arteries may 
predispose to pro-atherogenic modifications, such as, oxidation and internalization by foam 
cells. In addition, an independent negative relationship between high-density lipoprotein 
(HDL) has later been described (Saraheimo et al., 2008). Furthermore, -defensins were found 
to inhibit the fibrionolytic activity by binding to tissue plasminogen activator molecule 
(Kougias et al., 2005). In a small study of patients undergoing elective coronary artery 
catheterization, an accumulation of -defensin in the human skin was described and the 
accumulated amount correlated with the severity of coronary artery disease (Nassar et al., 
2007). Of note, no correlation between CRP and -defensin was found in this study. 
Chronic low-grade inflammation is a hallmark of obesity and diabetes, and has been 
causally linked to the development of premature CVD. In a group of type-1 diabetic 
patients, with a 10-year-follow-up-period of cardiovascular end-points, elevated baseline 
plasma -defensin levels were an independent predictor for cardiovascular morbidity and 
mortality (Joseph et al., 2008). In a recent study, the risk of cardiovascular mortality was 
significantly increased with elevated plasma -defensin levels in patients admitted for 
elective lower extremity artery surgery (Urbonaviciene et al., 2011). Surprisingly, patients 
with high -defensin levels combined with high hs-CRP levels had a five time increased risk 
of cardiovascular death compared to patients in whom only one or none of the peptides was 
elevated. 
4. Perspectives 
Inflammatory biomarkers may have prognostic value for future cardiovascular risk 
stratification among individuals with high risk or a history of IHD, but they may also in 
particular be useful in apparently healthy individuals who might be at higher risk than 
estimated by the traditional risk factor scores. Using a biomarker profile that covers various 
aspects of the complex pathophysiology of IHD may increase the rational basis for 
cardiovascular risk assessment. As decribed above, a multiple inflammatory role of the 
combination of complement activation, CRP, LDL and -defensins may participate in the 
pathogenesis of IHD and other CVD.  
With the emergence of novel biomarkers for inflammation and vascular damage it may be 
possible to characterize different contributions of each of these major mechanisms to short- 
and long-term prognosis following CVD. Hopefully, patients may benefit from different 
therapeutic strategies depending on their personal biomarker profile in the future. So far, 
however, results about which biomarkers are the most suitable for diagnosis or prognosis of 
IHD remain conflicting, and further research within this field is needed. 
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1. Introduction 
The present compilation of scientific publications deals with the evaluation of a parameter 
of myocardial contractility (E´es); the parameter can be exclusively measured using 
ultrasound, i.e. noninvasive and can be used for a load-independent quantification of 
myocardial contractility. 
The standard procedure for measuring left ventricular (LV) contractility is by use of a 
conductance catheter with which LV volume and LV pressure can be determined 
simultaneously. In 1973, Sagawa (1) was the first to use this catheter, which had been 
developed at the University Hospital Leiden, and he was able to show that an elastance 
curve can be determined from a series of loop diagrams which were obtained under acute 
preload reduction. The slope of the elastance curve (Ees) increased when the positive 
inotropic substance isoprenaline was administered (Fig. 1). 
For clinical use, however, the catheter is a monitoring procedure which is too invasive and 
thus involves too many risks; in the past few years there have been considerations to replace 
this procedure with one that is less invasive. 
In 1994, Gorscan (2) presented a study with which he was able to show that LV volume can 
be estimated by continuous echocardiographic determination of the cross-sectional LV area 
and in 1997 Deanault from the same working group (3) showed that LV pressure can be 
approximated with the pressure from the radial artery. They generated a loop diagram from 
these surrogate parameters with which they could estimate LV contractility. In the years 
2001-2003 the mathematicians Danielsen, Ottesen and Paladino (4-6) from the University of 
Roskilde published a model equation from which we deduce that, with simplified 
assumptions, the Doppler sonographic arterial flow would have to change in proportion to 
pressure and we asked ourselves if contractility could also be estimated with a flow-area 
relationship. 
2. Question 
The thoughts presented here are a model for measuring LV contractility as it could be 
determined in the patient, i.e. exclusively based on ultrasound and thus not very invasive.  
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Fig. 1. Determination of the properties of elastance curves  
This raises the question of whether contractility can in fact be estimated using the index E´es, 
which has been deduced from this theoretical model.  
If the elastance of the flow-area relationship is exclusively considered as a surrogate 
parameter to estimate myocardial contractility in the classical sense, then E´es is not a new 
parameter. If it is assumed, however, that the elastance of the flow-area relationship is based 
on a completely new mathematical model, i.e. that of the mathematicians Danielsen, Ottesen 
and Paladino, then we are possibly dealing with a new parameter and deviations between 
the classical parameter Ees and E´es are then starting points for new examinations. 
3. Background 
Ultrasound-based determination of myocardial contractility: theoretical principles 
The ability to actively shorten the cardiac muscle, i.e. of contractility, of the left ventricle is based 
on a complex process (7,8) during which individual mechanisms have to follow one another 
precisely. Muscle contraction is based on mechanisms and interactions associated with muscle 
proteins, enzymes, ions and energy sources. The large-scale structure, as well as the small-scale 
structure of the muscle, are involved in the contractility of the hollow muscular organ which 
forms the left chamber of the heart or left ventricle. Apart from power transmission towards 
contraction, the prevention or diversion of shearing forces is an important task which the 
muscle carries out through mechanisms of mechanical connections, but also through 
mechanisms of regulation by synchronizing the contraction of the muscle fibers. 
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First attempts to describe the contractility of a hollow muscular organ from a mechanical 
point of view date back to Otto Frank in 1985 (9). Frank determined the pressure of the 
individual end-diastolic volumes by conducting experiments with a single chamber frog 
heart as well as the maximum pressure recruitable from this relaxation period (isovolumeric 
maximum) and the maximum ejection fraction (isotonic or isobaric maximum). The curves 
established from this resulted in a pressure-volume diagram in which the maximums to be 
achieved from the relaxation period were connected through the contraction curve (2). Otto 
Frank deduced the cardiac cycle from this: 
 
Fig. 2. LV pressure-volume diagram by Otto Frank. 
The ventricle is filled with volume (preload) and during the process internal pressure in the 
chamber increases. Then the pressure in the chamber increases through contraction along 
the isometric maximum against the closed valve until the valve opens which, during the 
relaxation phase (diastole), prevents reflux from the aorta into the ventricle. While the heart 
is pumping out volume against the arterial load (afterload), it is pumping in the sense of an 
auxotonic contraction; this leads to a further increase of arterial pressure and to a decrease in 
volume through ejection in the ventricle. During the following relaxation phase the pressure 
in the ventricle decreases to reach its resting level and the chamber is filled again. The 
cardiac cycle can thus be described through a pressure-volume relationship which is known 
as the "work diagram" in literature. 
In later experiments, Starling (10) deduced the s-shaped connection between the surface of 
the work diagram and the necessary preload. The two main differences between the concept 
described by Otto Frank and the one developed by Starling are that the contraction of the 
left ventricle cannot only be described as a function of filling or preload, but also as a 
function of time. Another difference is that when it comes to measurements, the left 
ventricular function is always determined in connection with the arterial vascular system 
behind it. 
In 1959, Warner deduced the calculation of ventricular compliance C from the correlation 
described by Frank by relating volume Vv and the corresponding pressure Pv at the end of 



















and thus created a constant. From this formal approach, two different mathematical terms 
for the description of LV contraction can be concluded. In 1961, Seelen (11) described 
contraction through fixed capacitive reactance in series with pressure varying depending on 
time and in 1973, Suga (1) defined ventricular elastance E(t) through an inverse function of 










with the SI-unit [m-4•kg•s-2], while Vd represents constant, diastolic volume. The index (t) in 
this case means that the end-systolic point was determined using an iterative method in 
which the same loop is crossed by a tangent several times and with varying time (time-
varying elastance). In the experimental determination of E(t), the same problems arise as in 
the correlation already developed by Starling. The index E(t) cannot be determined 
separately from the vascular system and it is not a function of time. 
To get around these problems, Beneken 1965 (12) developed a closed-loop model of the 
cardiovascular system, which was based on the work of Liljestrand 1938 (13) and Hill 1922 
(14), and in which contraction of the heart is calculated through the contractile element 
described by Hill, embedded in a three-element windkessel model. Further geometrical 
adjustments yielded an n-element model, which was mathematically described with the 
finite-element method. 
Based on the evaluation described by Hill, Danielsen (4) later developed a model which 
differentiated between an isovolumetric ventricle and an ejecting left ventricle under arterial 
load. In the latter model, the direct proportional correlation between arterial pressure Pa and 
LV outflow Qv was deduced as follows: 




    
with Rs as a global peripheral resistance, R0 as characteristic aortic impedance, Cs as total 
arterial compliance, Ps as systolic pressure and Ps as the change of arterial pressure with 
time. This equation can be transformed to This equation can be transformed to: 
1 1 ( , ),ov s v v
v v v
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     
with Lv as inductance directly above the aortic valve and Qv as a change of flow with time. 
With the simplified assumption that Lv is constant, the above equation can be simplified as 
follows.  
a s o vP P R Q   
With the assumption that R0 is constant and Pa changes in direct proportion to Ps the 
equation is: 
 






and thus created a constant. From this formal approach, two different mathematical terms 
for the description of LV contraction can be concluded. In 1961, Seelen (11) described 
contraction through fixed capacitive reactance in series with pressure varying depending on 
time and in 1973, Suga (1) defined ventricular elastance E(t) through an inverse function of 










with the SI-unit [m-4•kg•s-2], while Vd represents constant, diastolic volume. The index (t) in 
this case means that the end-systolic point was determined using an iterative method in 
which the same loop is crossed by a tangent several times and with varying time (time-
varying elastance). In the experimental determination of E(t), the same problems arise as in 
the correlation already developed by Starling. The index E(t) cannot be determined 
separately from the vascular system and it is not a function of time. 
To get around these problems, Beneken 1965 (12) developed a closed-loop model of the 
cardiovascular system, which was based on the work of Liljestrand 1938 (13) and Hill 1922 
(14), and in which contraction of the heart is calculated through the contractile element 
described by Hill, embedded in a three-element windkessel model. Further geometrical 
adjustments yielded an n-element model, which was mathematically described with the 
finite-element method. 
Based on the evaluation described by Hill, Danielsen (4) later developed a model which 
differentiated between an isovolumetric ventricle and an ejecting left ventricle under arterial 
load. In the latter model, the direct proportional correlation between arterial pressure Pa and 
LV outflow Qv was deduced as follows: 




    
with Rs as a global peripheral resistance, R0 as characteristic aortic impedance, Cs as total 
arterial compliance, Ps as systolic pressure and Ps as the change of arterial pressure with 
time. This equation can be transformed to This equation can be transformed to: 
1 1 ( , ),ov s v v
v v v
RQ P Q P t V
L L L
     
with Lv as inductance directly above the aortic valve and Qv as a change of flow with time. 
With the simplified assumption that Lv is constant, the above equation can be simplified as 
follows.  
a s o vP P R Q   
With the assumption that R0 is constant and Pa changes in direct proportion to Ps the 
equation is: 
 
Measurement of Myocardial Contractility in the Ischemic Heart – A Disease Immanent Uncertainty 67 
a vP Q  
Olufsen (15) showed in his one-dimensional dynamic model of the systemic arteries that, 
corresponding to the Navier-Stokes equation, pressure changes directly proportional to flow 
in large vessels such as the arteria carotis communis. The model-based experimental 
examinations confirm that the flow generated through the left ventricle is the connecting 
link between the heart and vessel blood system. 
Against this backdrop, our work group had the idea of developing an index E'es,, analogous 
to E(t), based on the iteratively determined end-systolic points on the work diagram. This 












with the SI unit [s-1]. The ventricular volume, measured during several cardiac cycles, can 
be determined using ultrasound technology by estimating it with the help of the surface A 
in the transgastral short-axis-view. Blood flow Q can be estimated through the blood flow 
velocity F in the arteria carotis communis measured with the Doppler technology. This then 











The deduced index E'es displays the following important differences compared to the index 
Ees : 
1. By implementing blood flow velocity, the index becomes a function of time. 
2. By measuring blood flow velocity in a large artery, the index becomes connected to the 
vascular system. 
3. Through the measuring method used, the index E'es can be completely determined in a 
noninvasive way, as both F and A are ultrasound parameters. 
Measuring methods used 
The measuring methods used in this context are conductance and ultrasound methods. 
Using these methods, myocardial contractility was measured. 
Conductance catheter method 
A conductance catheter was used for the simultaneous recording of LV pressure and the 
volume signal (16). The catheter consists of pressure-conductivity transducers. While the 
blood pressure signal was mechanically measured at the tip of the catheter using a pressure 
transducer and was subsequently transformed into electric impulses, determination of 
volume is carried out electromagnetically by measuring the conductivity of the surrounding 
compartments. The catheter consists of four electrodes and one pressure sensor. The 
electrodes are fitted below the pressure sensor in pairs. The measurement of cardiac blood 
volumes using these electrodes is based on an electric field which is established through the 
outer electrodes in the left ventricle. Two potential differences at the inner electrodes are 
continuously recorded to measure the conductance between the electrodes in the ventricle. 
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With the formula 
2
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intraventricular volume V(t) is calculated. With a being a volume calibration factor, p being 
the electric resistance of blood, L being the distance between the electrodes, Gi describing the 
overall conductance and Gpi describing the conductance of the surrounding tissue; this 
conductance is called "parallel conductance". This calculation makes a continuous and in 
vivo recording of volumes in real-time possible. 
Ultrasound method 
Using the ultrasound-Doppler method, the flow velocity of erythrocytes can be measured 
with the help of the Doppler effect. The Doppler effect arises because echoes reflected by the 
erythrocytes have higher or lower frequencies than the signals sent out, depending on the 
flow velocity and flow direction. The differences in frequency are implemented 
electronically in readable and recordable curves. In the continuous-wave Doppler (CW 
Doppler) technique, which is used for detection, one transmitter and one receiver work 
simultaneously and continuously in the transducer. By mixing it with suitable high 
frequency signals and with electronic filters, the spectrum of the Doppler frequencies or 
velocities and the direction can be determined from the returning wave in the evaluation 
electronics. The disadvantage of this method is that it is not possible to determine the base 
range of the Doppler echo; however, even relatively high velocities can be recorded. 
With the two-dimensional, light-modulated presentation of the echoes, an immediately visible, 
animated picture is generated through energy and intensity proportional light points that vary 
according to brightness and as a result of a scan carried out in two directions and in layers. 
Tissue structures become visible because the points that are represented in shades of gray in 
relation to the intensity of the echo - as far as they originate from comparable structures - flow 
together to form areas and lines. The semi-automatic detection of contours serves to detect 
endocardial interfaces within the "region of interest" (ROI). Semi-automatic contour tracking is 
based on a seeded ROI algorithm which combines all adjacent pixels within a user-defined 
signal intensity area. The selected (seed) pixel is the starting point. In automatic segmentation, 
a small ROI can be positioned in the area of interest. The signal intensity area important for the 
growth algorithm is automatically taken from the ROI statistics (minimum to maximum 
value). The area defined in this way can be corrected interactively. For an ROI correction, the 
boundaries are activated by a click of the mouse. These boundaries can also be corrected 
interactively. After having selected the acoustic windows relevant for the approximation of 
volume - transgastral short-axis-view of the left ventricle - the window setting at an end-
diastolic phase image was adjusted to achieve an ideal contrast for the detection of endocardial 
boundaries. This window setting as well as the curves of the ventricular area presented in the 
ultrasound image were then checked in all phase images of the cardiac cycle. This setting was 
used for the following examinations. 
Measuring parameters 
End-systolic elastance is derived from the end-systolic pressure-volume relation (ESPVR). 
The elastance model was introduced by Sagawa and Suga. (17). Using isolated rabbit hearts, 
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they made the observation that the end-systolic pressure volume coordinates move along a 
straight line in the case of acute preload reduction. This could also be observed when acute 
preload reduction occurred at different levels of dilatation of the left ventricle (Fig. 1) is it a 
picture legend? A difference is made between two elastances: time-dependent elastance Emax 
and time-varying elastance Ees. 
In this model, Emax describes the slope of the end-systolic linear regression curves.  
In this context the time-dependent elastance E(t) from the equation 
( )( )
( ) ( )
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is determined, with P(t) = instantaneous intraventricular pressure; V(t) = instantaneous 
intraventricular volume; V0 = volume, if P(t) = 0. Ees is elastance at the point in time when 
E(t) reaches its maximum, i.e. when active contraction is at its maximum. Ees is calculated 
from the slope of the linear regression curves, which is time-varying and results from the 





The calculation of maximum is repeated several times through fixed point iteration until the 
slope of the line is constant. Ees is determined if, in case of fluctuations in afterload, the time 
in which the end-systolic state is reached fluctuates and consequently ESPVR does not 
exactly meet the angle of the loop diagram and Emax is calculated from points which lie 
ahead of the end-systolic one. Emax is then steeper than Ees. While Emax is the basis for models 
concerning the mathematical adjustment of the left ventricular function, Ees is used for the 
experimental quantification of LV contractility. The calculation formula for the indices Emax 
and Ees is not presented in a consistent manner in literature, however. The index E´es was 
determined analogous to the index Ees, with the difference that the flow-volume diagram 
was the basis for calculation 
A positive inotropic effect, induced through dobutamine, can be observed through an 
increase of Ees, i.e. an increase in the slope of the linear regression curves. The opposite 
occurs in decreasing inotropy, when it is triggered by a β- receptor blocker like esmolol (Fig. 
1) is it a picture legend?, for instance. 
Hemodynamic interventions 
The main goal of the studies were the controlled, targeted and pathophysiological 
interventions with sequential application of dobutamine, esmolol, akrinor, hydroxyethyl 
starch and sodium nitroprusside, with which the degree of correspondence of the two 
measuring methods was determined. The properties of these substances, which will be 
described in the following section, were the reason for them being used. 
Modification of contractility through dobutamine and esmolol 
Dobutamine has the effect of an α1-, β1- and β2-agonist, while β1 stimulation of the heart is 
the most immediate effect. The main effects of dobutamine result from this, i.e. the increase 
of contractility of the myocardial cells and a dosage-dependent marked increase in heart 
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rate. This leads to increased stroke volume (SV) and cardiac output (CO). The substance has 
a short half-life period of approx. 2 minutes and is broken down in inactive metabolites. It is 
thus applied per continuitatem. needs spell check here – it is the latin spelling and ok!.  
Esmolol has the effect of a β1-antagonist and is thus cardioselective at the myocardium. The 
main effects are a decrease in heart rate and the inhibition of contractility. This leads to a 
decrease in stroke volume and in cardiac output. The half-life period is only approx. 9 
minutes, as esmolol, in contrast to other beta blockers, is not broken down in an organ-
dependent way, but is metabolized by esterases hydrolases. For this reason, esmolol has to 
be administered in a continuous or repetitive way. 
Modification of load through hydroxyethyl starch, akrinor and sodium nitroprusside 
In statistics or kinematics, load is a unit of measurement for the force that works on a 
medium. Accordingly and as far as the left ventricle is concerned, preload is the force that 
results in the extension of fibers at the end of diastole or directly before systole and which is 
limited by the maximum resting length of the muscle fiber. Afterload is a force influencing 
the ventricle; this force counteracts ejection out of the ventricle into the cardiovascular 
system. In practice, preload is referred to as the end-diastolic volume in the heart. The fact 
that the standard index Ees is load-independent , i.e. that changes in preload and afterload of 
the left ventricle mostly do not change the contractility index over wide periods, is an 
important characteristic of this measurement. Changes in load induce changes in contraction 
force, contractility remains unchanged, however. 
Hydroxyethyl starch is a synthetically produced polymer and, like dextrane, and gelatine is 
used for the substitution of intravascular volume. End-diastolic volume was thus increased.  
Akrinor is a fixed combination of the two active ingredients cafedrin and theodrenaline. 
Blood pressure is primarily increased through an alpha-receptor-mediated, arterial 
vasoconstriction. Then contractility and heart rate are slightly increased through a less 
intense stimulation of beta receptors.  
Apart from inhibiting guanylate cyclase and consecutively releasing nitric oxide in the 
smooth musculature of the vascular wall, sodium nitroprusside has a vasodilative effect on 
both at the resistance vessels of the arterial system and at the capacitance vessels of the 
venous system. Due to the short half-life period of less than 10 minutes, continuous 
administration is necessary. 
4. Determination of preload recruitable stroke work and elastance by the 
relation of arterial blood flow velocity to left ventricular area 
The question whether contractility can be estimated with a flow-area relationship was the 
starting point for this study. 
In a first animal experiment, 8 Göttinger minipigs were studied in an open chest 
preparation. An arterial manometer was placed in the femoral artery and a microtip catheter 
for the measurement of LV pressure was advanced into the left ventricle from the apex. A 
flexible TEE probe was fixed on the myocardium to sonographically estimate volume with 
LV area measurement. Finally, the arteria carotis communis was dissected to fix a U-shaped 
8-MHz CW Doppler probe on it. Then an inferior vena cava occlusion was performed to 
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reduce preload. A central venous catheter was implanted for the pharmacological 
intervention. Via this catheter, contractility was sequentially increased by the administration 
of dobutamine, it was decreased by the administration of the beta-blocker esmolol and 
preload was significantly increased with a plasma expander. A software exclusively 
developed by the Institute of Experimental Physics was used for data acquisition as well as 
data presentation and analysis (Fig. 3). During the examination we began to realize that we 





Fig. 3. Diagram for the experiment set-up of the study "Determination of Preload 
Recruitable Stroke Work and Elastance by the Relation of Arterial Blood Flow Velocity to 
Left Ventricular Area". 
The data in table 2 (3b) show that the change in contractility was reliably detected through 
the change of slope of the individual elastance curves. A change of preload through the 
plasma expander did not influence the slope of the elastance curves. 
To sum up, this study showed that contractility can be estimated with parameters which are 
deduced from flow-area relationships. 
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Fig. 3b. Feasibility study - Results 
5. Time-varying elastance concept applied to the relation of carotid arterial 
flow velocity and left ventricular area 
In the previous study, changes in inotropy could in fact be detected with the help of the 
flow-area relationship and the following study was to answer the question as to how this 
procedure corresponds to the standard procedure. 
In an animal experiment, 25 Göttinger minipigs were studied in a closed chest preparation. 
After a puncture of the femoral artery, the conductance catheter was placed in the left 
ventricle under fluoroscopy. The cross-sectional LV area was determined in this study using 
a transthoracic probe and the arteria carotis communis was studied as before. A pulmonalis 
catheter was used for the calibration of the conductance catheter and a Forgarty catheter, 
which was advanced into the inferior vena cava, was used for preload reduction. The central 
venous catheter served as a line for the pharmacological interventions. Like in the previous 
study, contractility was sequentially increased by the administration of dobutamine, it was 
decreased by the administration of the beta-blocker esmolol and preload was significantly 
increased with a plasma expander. Additionally, afterload reduction was induced through 
akrinor. 
For the collection and processing of data, software developed by Paul Steendijk from the 
experimental cardiology of the University Leiden was used in this study. Pressure volumes 
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and flow-area relationships could be described using this software. The elastance of the LV 
pressure-volume relationship is referred to as Ees in literature and we called the elastance of 
the flow-area relationship E´es. 
 
Fig. 4. Diagram for the experiment set-up of the study "Time-Varying Elastance Concept 
Applied to the Relation of Carotid Arterial Flow Velocity and Left Ventricular Area" 
 
Fig. 4b. Validational study (Conductance-Catheter) – Results 
In relation to the initial values, the values obtained from both procedures displayed changes 
in inotropy. A regression analysis was carried out using the pooled data. A significant linear 
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correlation between the two measuring methods became evident. The Blant-Altman analysis 
showed that both methods correspond to each other acceptably. 
6. The relationship between carotid blood-flow velocity and left ventricular 
area during acute regional ischemia 
This study was to answer the question as to how the two measuring methods would 
correspond to each other in the case of a myocardial wall motion abnormality. 
 
Fig. 5. Diagram for the experimental set-up of the study "The Relationship between Carotid 
Blood-flow Velocity and Left Ventricular Area during Acute Regional Ischemia". 
In an animal experiment, 11 Göttinger minipigs were studied in a closed chest preparation. 
We advanced a coronary occlusion-perfusion catheter into the ramus circumflexus of the left 
coronary artery from the arteria femoralis. This catheter makes it possible to occlude a 
coronary artery while at the same time perfusing it with arterial blood using an adjustable 
roller pump. Standardized reduction of myocardial wall motion in the circulation area of the 
coronary artery was monitored by determining the systolic, radial strain rate. The strain rate 
is the rate of myocardial deformation and thus a unit of measurement for myocardial 
function. As the arteria femoralis was being used by the catheter, we advanced the 
conductance catheter through the right arteria carotis communis. Apart from that, 
preparation was the same as in the previous study. 
Fig. 4 shows the loop diagram under normal perfusion and under ischemic conditions. The 
segmental loops of the conductance catheter deform under ischemia in the corresponding 
areas. This deformation was used for the calculation of an internal flow fraction, which 
arises when myocardial contraction cannot be completely transformed into an arterial flow.  
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Fig. 5b. Validational study during regional ischemia - Results 
As the graph is directly taken from another journal, please get the copyright. I do realize 
that the author for this chapter is also the author for that article. However, the copyright 
need to be obtained as a formality from the journal.  Table 1 (III 5b) shows that both 
procedures, independent of myocardial perfusion, could detect changes in inotropy. What 
stands out, however, is that the application of a plasma expander under myocardial 
ischemia leads to significant changes of the slope of the flow-area relationship compared to 
the initial values. The internal flow fraction also changed significantly under these 
conditions. Regression analysis in Fig. 5 (do you mean 5b? 5 is not a statistical analysis 
under ischemic conditions showed a decrease in the regression coefficient, linear correlation 
remained significant, however. The Bland-Alman analysis in Fig. 6 showed that the 
correspondence of the two parameters decreases. 
The results of the study carried out showed that a valid assessment of myocardial 
contractility is possible with the flow-area relationship. Myocardial wall motion 
abnormalities constitute a limitation of the procedure. 
7. Dobutamine induces ineffective work in regional ischaemic myocardium: 
An experimental strain rate imaging study 
This study is to answer the question as to whether the results of the previous study can also 
be reflected by parameters of regional contractility. 
In an animal experiment, 11 Göttinger minipigs were studied in a closed chest preparation. 
We advanced a coronary occlusion-perfusion catheter into the ramus circumflexus of the left 
coronary artery from the arteria femoralis. This catheter makes it possible to occlude a 
 
Novel Strategies in Ischemic Heart Disease 76
coronary artery while at the same time perfusing it with arterial blood using an adjustable 
roller pump. Standardized reduction of myocardial wall motion in the circulation area of the 
coronary artery was monitored by determining the strain rate. Apart from that, radial strain 
of the myocardium during systole was also determined. Strain is a unit of measurement for 
myocardial deformation. As the arteria femoralis was occupied by the catheter, we 
advanced the conductance catheter through the right arteria carotis communis. 
The results show that a decrease of radial strain in the ischemic region can be documented 
under regional ischemia. Parallel to this, regional ischemia led to an increase in radial strain 
in the non ischemic myocardium. The stimulation of contractility with dobutamine 
intensifies the effect. 
The present results confirm those of the previous study, i.e. that regional ischemia of the 
myocardium of 30% does not lead to a decrease of global contractility because contractility 
of the myocardium of the non-ischemic region is increased in a compensatory way. The 
increase of internal flow fraction is based on this effect, as has been shown in the previous 
study. 
8. The relationship between carotid arterial flow and the left ventricular area 
is valid to indicate contractility in states of cerebral autoregulation and 
decreased arterial pressure 
The present study is based on the question as to whether both measuring methods 
correspond under the condition of an arterial hypotension. Hypotension can activate 
mechanisms which, independent of systemic blood pressure, ensure constant blood flow in 
important organs such as the heart. To determine the flow-area relationship, we measure 
flow velocity in large vessels which supply the brain with blood; for this reason these 
mechanisms could have an effect on the flow-area relationship. 
In an animal experiment, we studied 9 merino sheep and measured cortical microperfusion 
(flux) with the laser Doppler and we also determined tissue oxygen partial pressure (p(ti)O2) 
and tissue metabolism through microdialysis. We proceeded as in a validation study, the 
difference being that we fixed the TEE probe onto the myocardium with a minithoracotomy. 
Arterial blood pressure was, on the one hand, decreased by esmolol and on the other hand 
by the pure vasodilator sodium nitroprusside. Both pharmaceuticals were dosed in such a 
way that a mean arterial pressure of 50mmHg could be maintained for 20 minutes. 
The table shows that the hypotension triggered by sodium nitroprusside did not lead to any 
other changes of the circulatory system and of the cortical and myocardial parameters. The 
hypotension triggered by esmolol, however, led to a decrease in cardiac output and to an 
increase in LV end-diastolic pressure. This was associated with a decrease in cortical 
microcirculation as well as with a decrease in tissue oxygen partial pressure. During the 
decrease in tissue oxygen partial pressure, the metabolites of the anaerobic metabolism 
increased. Furthermore an increase in internal flow fraction (IFFsys) could be observed, 
indicating myocardial wall motion abnormalities. The hypotension triggered by esmolol led 
to a critical decrease of oxygen being supplied to the cortex and to the myocardium. 
As in the previous studies, a linear correlation between flow-area relationship and LV 
pressure could be detected under the influence of sodium nitroprusside. The correlation 
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between the two relationships was acceptable as the Bland-Altman analysis shows. The 
decrease of contractility induced by esmolol was also detected through the flow-area 
relationship. But the degree of correlation and the degree of correspondence of both 
parameters decreased significantly. This decrease probably results from an increase of the 
internal flow fraction as an indication of myocardial wall motion abnormalities. This 
correlation could already be detected in the previous studies. It remains unclear, however, 
which hemodynamic constellation led to the wall motion abnormalities – the increase in 
end-diastolic volume and/ or the decrease of cardiac output. Both parameters determine 
myocardial perfusion. 
 
Fig. 6. Diagram for the experiment set-up of the study "The Relationship between Carotid 
Arterial Flow and the Left Ventricular Area is valid to indicate contractility in states of 
cerebral autoregulation and decreased arterial pressure 
An increase in end-diastolic volume is connected with an increase in left ventricular radius. 
According to the law of Laplace, the increase in radius is tantamount to an increase in 
myocardial wall tension in diastole. During diastole the myocardium is perfused an increase 
in wall tension can lead to a decrease of coronary blood flow which means that oxygen 
supply is higher than oxygen demand. In this context, myocardial wall motion 
abnormalities can occur as an indication of hypoperfusion. A decrease in cardiac output is 
directly connected to a decrease of oxygen supply to all organs, i.e. also to the myocardium, 
which can result in insufficient oxygen supply. 
The results of the study carried out showed that a valid assessment of myocardial 
contractility is possible with the flow-area relationship. 
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Fig. 6b. Validational study during arterial hypotension - Results 
9. Association of increased myocardial contractility and elevated  
end-diastolic wall tension with short-term myocardial ischemia:  
A pressure-volume analysis 
The present study is to answer the question whether myocardial hypoperfusion can be 
triggered by an LV hypervolemia, even if arterial pressure as well as cardiac output are in 
an "adequate" range - as literature usually calls it. 
To answer this question, 15 Göttinger minipigs were studied in an open chest preparation. A 
catheter was placed in the arteria femoralis to measure pressure and a probe ,similar to 
those used for transoesophageal echocardiography, was fixed on the myocardium. A 
microtip catheter was inserted from the apex of the left ventricle for continuous pressure 
measurement. A catheter for microdialysis was implanted into the myocardium in the flow 
area of the left coronary artery. Finally, the arteria carotis communis was dissected to fix a 
U-shaped 8-MHz CW Doppler probe on it. A catheter in the femoral vein was used for 
pharmacological interventions. 
Myocardial contractility was increased permanently through continuous application of 
dobutamine. A steady state was assumed after 20 minutes. Esmolol was administered in 
such a way that the heart rate - in relation to frequency - was lowered by at least 25% for 20 
minutes under continuous infusion of dobutamin. Subsequently esmolol application was 
stopped so that dobutamin could again unfold its contractility-increasing effect. For 
comparison, only Esmolol was subsequently administered to another group - to the same 
amount as dobutamine and esmolol had been administered in the dobutamin-esmolol 
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group. As expected, the table shows that when dobutamine and esmolol are administered at 
the same time, the heart rate decreases and contractility decreases later as well. Through the 
decrease in heart rate, LV volume increases in this phase and thus - according to the law of 
Laplace - diastolic myocardial wall tension increases as well. Dobutamine initially 
stimulates contractility but despite sufficient arterial pressure and cardiac output, oxygen 
supply is still lower than oxygen demand. Oxygen demand is then lowered by the decrease 
in contractility and the indications of hypoperfusion recede under identical wall tension. 
When the effect of esmolol starts to wear off, the contractility-stimulating effect of 
dobutamin comes back first and later the heart rate increases again. During this phase, 
increased wall tension leads to myocardial hypoperfusion again. Esmolol alone induces 
increased wall tension but no myocardial hypoperfusion. 
The results of the present study show that an increase in myocardial wall tension alone is 
not necessarily associated with myocardial hypoperfusion. If, however, oxygen demand 
increases in this situation, or, as in the previous study, cardiac output and arterial pressure 
are reduced, the oxygen supply to the myocardium can sink below its oxygen demand. In 
this context, myocardial wall motion disorders can form as an indication of such an 
imbalance which in turn can lower the correlation of the two relations. 
10. Conclusion and outlook 
The results of the examination carried out allow the conclusion that a valid estimation of 
myocardial contractility is possible. Myocardial wall motion abnormalities limit the 
measuring accuracy of this new procedure. These myocardial wall motion abnormalities can 
occur if increased LV end-diastolic volume is associated with low cardiac output or an 
increased myocardial oxygen requirement. 
In further investigations we would like to try to answer the question as to whether the acute 
afterload reduction necessary for the determination of elastance can also be induced through 
a Valsalva maneuver. 
By using a 3-dimensional transoesophageal echocardiography, we would like to answer the 
question if measuring accuracy can possibly be significantly improved. On the one hand, 
using 3-dimensional echocardiography, similar to what is possible with a conductance 
catheter, could make it possible to determine internal flow fraction and consequently to 
develop a corrective factor for measurement. On the other hand, using 3-dimensional 
echocardiography makes it possible to estimate intraventricular volumes much more 
precisely than with the cross-sectional LV area. 
Finally the use of this procedure should be verified in clinical studies. 
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1. Introduction 
In 1965 WHO experts singed out coronary heart disease (CHD) in a separate group. It was 
dictated by the growing epidemic incidence rate and high mortality from disease 
complications. Besides, it was urgent to take measures to treat the disease. However, the end 
of the XX century and the beginning of the XXI century have not brought any significant 
changes. The heart and vessel diseases complicated by atherosclerosis are still one of the 
main problems in most countries. The main reasons are high incidence of disease, stabile 
director disability and mortality among employable population. Each year, cardiovascular 
diseases cause 4.3 million deaths in Europe in general, and over 2 million in the EU, 
accounting for 48 and 42% of the total number of deaths respectively. Mortality from 
coronary heart disease among of men in the age of 65 is 3 times higher than among women. 
In older age mortality rate is equalized, and after 80 years of age it is 2 times higher among 
women. 
In its essence, all the pathophysiological manifestations of coronary heart disease are caused 
by an imbalance between myocardial oxygen demand and oxygen delivery. 
CHD may start abruptly with myocardial infarction (MI) or sudden cardiac death (SCD), but 
almost 50% of patients suffer immediately a chronic form of coronary heart disease. It is 
called exertional angina [2, 3]. In absolute figures it means approximately 30,000 – 40,000 
patients with angina per 1 million population [4]. According to some reports men suffering 
angina live on average eight years less than those who do not have this pathology [5].  
According to epidemiological studies, CHD patients suffer blood circulation blocking in 
most cases; it leads to approximately 90% sudden deaths. About half of patients with 
diagnosticated CHD die suddenly without a preceding pain syndrome. 
Meanwhile, M.R.Cowie and others [2002] argue, the main risk factor for sudden death is left 
ventricular dysfunction. The prognosis of chronic heart failure (CHF) is still extremely 
serious, regardless of its etiology, but you should agree with J.N. Cohn and others [1999] 
who wrote that “…coronary disease may be an independent predictor of poor prognosis for 
patients suffering heart failure”. Traditionally, CHF was considered to have connection with 
systolic dysfunction, however, in recent years the main subject of research of clinicians and 
physiologists is mechanisms of myocardium diastolic dysfunction (DD) development and 
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its role in the onset of heart failure. Nowadays heart failure is considered as a syndrome 
which develops from various pathological heart changes, neuroendocrinal regulation 
disorders and represents a complex of circulatory reactions because of systolic or diastolic 
cardiac dysfunction. 
About 50% of patients with chronic heart failure die within 5 years after the onset of clinical 
symptoms despite the use of combination therapy. According to the Framingham study, 
75% of men with CHF and 62% of women die within 5 years after establishing diagnosis. 
Only half of patients with CHF die from heart failure which is refractory to therapy. The 
second half of patients with heart failure dies suddenly because of ventricular 
tachyarrhythmia. Oxymortia is the main death mechanism (in 30-80% of cases) among 
patients with CHF of II-III of functional class [8]. These facts allowed us to formulate an 
assumption that heart failure is the most the arrhythmogenic factor in cardiology and the 
most important sign of sudden death risk [9, 10]. 
Thus, the prediction and solution of sudden cardiac death (SCD) problem is only possible 
with the full study of the structural abnormalities and functional diseases which cause life-
threatening arrhythmias acoording to modern model. Pathological changes of myocardium 
go with various dysfunctions of electrical heart activity. They are prognostically unfavorable 
in terms of the occurrence of fatally dangerous rhythm disturbances. The validity of the 
assumption is based on the fact that electrophysiological alternation of cells and cell 
membranes boosts the development of electrical heart instability (EHI) after the cases of 
transient coronary heart disease and myocardial infarction having developed in areas of 
myocardial dysfunction.  
Though this problem is intensively investigated, the search of pathogenic mechanisms 
causing electrophysiological properties disorder and associated with pathological 
electrocardiographic and electrophysiological phenomena going with structural remodeling 
of myocardium in CHD is still important. 
The research objective was to study the indicators characterizing electrical instability of 
myocardium suffered by CHD patients who have diastolic heart failure. 
According to protocol adopted by local Ethical Committee a number of patients who had 
suffered myocardial infarction more than a year ago took part in the research. They had a 
stabile clinical course of coronary heart disease and clinical implications of chronic cardiac 
failure syndrome with left ventricle ejection fraction of 45% during the previous month. 
Each patient signed an agreement to take part in our research as a volunteer. We observed 
the group of 128 patients (36 women and 92 men). The average age of patients was 57.3±5.6 
years. 
The elimination criteria were coronary revascularization or cerebral stroke during the last 6 
months, symptoms of VI class cardiac failure according to NYHA classification, clinically 
significant cardiac defects and lung diseases, dysfunctions of liver and nephros, atrial 
fibrillation. 
Besides standard clinical research, we did the whole complex of work including 
electrocardiography in 12 derivations, echocardiography, Holter monitoring, registration of 
average signaling electrocardiography with identification of ventricular late potential, 
analysis of variability of cardiac rhythm, evaluation of ventricle repolarization-interval 
dispersion Q-T (QTd), resolved interval Q-T (QTC). 
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We evaluated left ventricular geometry and left atrium (end-diastolic size - EDD, size - ESD; 
end-systolic volume  - EDV, end-systolic volume -  ESV; left ventricular mass index – LVMI, 
relative thickness of the left ventricular wall; left atrium volume change index); left 
ventricular systolic function (ejection fraction - EF, %; stroke index – SI, ml/m2; systolic 
shortening`s fraction of the front-back size aortic ventricle - ΔS,%); myocardium regional 
contractility (diacrisis of zone with regional contractility dysfunction). We used ultrasound 
cordis investigation with Doppler spectral echocardiography mode and color Doppler 
mapping. 
Analyzing  left ventricular diastolic function we studied indeces of transmitral diastolic flow 
in incipient and delayed diastole (Е, А, m/s), their ratio (Е/А), time of flow delay(DT, ms) 
and flow acceleration during the phase of rapid inflow(АТ, ms), is ovolumic relaxation time 
(IVRT, ms) and duration of diastole (ET, ms) -  Figure 1.  
 
Fig. 1. Estimation of trancmitral diastolic flow 
We also evaluated blood flow at the mouth of the pulmonary veins (D, cm / s; Ar, cm / s; 
Adur / Ar) – Figure 2. 
We used tissue Doppler sonography to detect signs of inflow disorder, loss of elasticity, the 
increase of the left ventricular rigidity. We defined the maximum speed of mitral annulus: 
peak systolic speed - S '(cm / s) peak speed of incipient diastolic relaxation - E' (cm / s) peak 
speed in atrial systole phase - A '(cm / s), the ratio of maximum speed of incipient LV inflow 
(E) to the maximum speed of the fibrous ring kinesis in incipient diastole (E') - Figure 3.  
 




Fig. 2. Еstimation of bloodstream at the mouth of the pulmonary veins 
 
S' (cm/s) – peak diastolic speed; E' (cm/s) – peak speed of incipient diastolic relaxation; A' (cm/s) – 
peak speed in atrial systole phase. 
Fig. 3. Fibrous ring`s movement of the mitral valve in pulse-wave mode histic doppler 
Using Holter monitoring ECG we took into account the nature of rhythm disturbance and 
asequence, we estimated the quantity of pain assessed and painless ischemic episodes, the 
daily duration of ischemia, the maximum depth of segment ST depression. 
Time-line analysis of ventricular late potential was performed by method of M. Simson 
[1981].  We calculated numerical quantitative values of three indicators: the duration of the 
filtered complex QRS (HF QRS-Dauer), the rms amplitude of the last 40 ms of the complex 
QRS (RMS 40), the duration of the low amplitude signals at the end of the filtered complex 
QRS (LAH Fd). We took HF QRS-Dauer which is more than 114 ms, RMS 40 which is less 
than 25 mV, LAH Fd which is more than 38 ms as pathological parameters of the signal 
averaged ECG - Figure 4.  
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Fig. 4. Analysis of the signal-averaged ECG with  elimination late potentials of the ventricles 
Performing heart rate variability analysis we evaluated rMSSD (mean square difference 
between the duration of contiguous sinus intervals RR, BB 50 (proportion of contiguous 
sinus intervals RR which differ more than 50ms,%), SDNN (standard derivation of average 
duration of sinus intervals RR, ms). 
Performing spectral analysis of heart rate variability analysis we estimated frequency 
ranges: high frequency (HF), low frequency (LF), the ratio of sympathetic and 
parasympathetic influences on heart rate variability (LF/HF). 
We examined the following heart rate turbulence indicants:  
 turbulence onset (TO,%). We estimated the value-of sinus rhythm acceleration after 
ventricular arrhythmia;  
 turbulence slope (TS, ms / RR). We studied the intensity of the sinus rhythm 
deceleration, following its quickening. 
In assessing ventricular repolarization we calculated corrected interval Q-T (QTs) using 
Bazeta. The dispersion of the interval Q-T (QTd) was defined as the difference between the 
maximal and minimal value of Q-T interval in different leads of standard ECG. 
T-test of Student, entry criteria applied by static data handing. Gotten results have been 
presented in the form of an average arithmetical significance ± is standart devition. 
Differences considered reliable at p< 0,05.  
In case of CHD left ventricle diastole indices and diastole functions undergo complex 
changes which are connected with both worsening of diastolic disorders and the 
development of hemodynamic adaptive responses acting through an increase in pressure in 
the left atrium and/or left ventricular end diastolic pressure and leading to the formation of 
various types of diastolic dysfunction. 
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We divided our patients into 3 groups according to the type of diastolic dysfunction of left 
ventricle: the first group (n=36) included patients with abnormal relaxation of left ventricle, 
the second group (n=28) consisted of patients with pseudonormal type of diastolic 
dysfunction and the third group (n=22) was formed from the patients who suffered 
restrictive type of diastolic dysfunction of left ventricle. 
The average duration of disease was 6.9 3.9 years (3 to 12 years). Medical history and 
electrocardiographic criteria indicated macrofocal myocardial infarction (with Q tooth) 
suffered  by 68 patients (53.1%).9 out of 68 patients had a chronic aneurysm of the anterior 
wall according to electrocardiographic and echocardiographic features. Fine-focal MI 
(without Q tooth) is marked in 60 cases according to medical documentation (hospital 
records, discharge summary). 82 patients (64%) had coronary heart disease accompanied by 
arterial hypertension (AH). 92 patients (72%) had burdened familial history. Lipid exchange 
violations were indicated in 112 cases (87.5%). 
Figure 1 shows the gradation of patients with different variants of the left ventricle diastolic 
dysfunction according to functional classes of chronic heart failure (CHF). 42 patients had 







I FC II FC III FC
diastolic dysfunction of abnormal relaxation type pseudonormal type of diasto
restrictive type of diastolic dysfunction
 
Fig. 5. The gradation of patients suffering coronary heart disease with left ventricle diastolic 
dysfunction according to functional classes of chronic heart failure (CHF). 
In cases of heart failure clinical manifestations we have received the relation of r = 0,620 (p 
<0.01) of the frequency of CHF FC to the type of diastolic dysfunction. When FC increases 
the disturbances of LV DF become more pronounced: restrictive type of LV DD was 
detected in III FC (51% observations); in I FC it was observed on 11.4%; patients had the 
type of abnormal relaxation in 9.5% and 64.3% respectively, pseudonormal type was 
detected in 21.6% and 55% of cases. 
The analysis of the structural and geometric parameters of left heart chambers (Table 1) 
showed that group III had an increase of the dilation of the cavities of the left ventricle and 
left atrium, increased left ventricle myocardial mass, reduction in contractile function 
 
Novel Strategies in Ischemic Heart Disease 
 
86
We divided our patients into 3 groups according to the type of diastolic dysfunction of left 
ventricle: the first group (n=36) included patients with abnormal relaxation of left ventricle, 
the second group (n=28) consisted of patients with pseudonormal type of diastolic 
dysfunction and the third group (n=22) was formed from the patients who suffered 
restrictive type of diastolic dysfunction of left ventricle. 
The average duration of disease was 6.9 3.9 years (3 to 12 years). Medical history and 
electrocardiographic criteria indicated macrofocal myocardial infarction (with Q tooth) 
suffered  by 68 patients (53.1%).9 out of 68 patients had a chronic aneurysm of the anterior 
wall according to electrocardiographic and echocardiographic features. Fine-focal MI 
(without Q tooth) is marked in 60 cases according to medical documentation (hospital 
records, discharge summary). 82 patients (64%) had coronary heart disease accompanied by 
arterial hypertension (AH). 92 patients (72%) had burdened familial history. Lipid exchange 
violations were indicated in 112 cases (87.5%). 
Figure 1 shows the gradation of patients with different variants of the left ventricle diastolic 
dysfunction according to functional classes of chronic heart failure (CHF). 42 patients had 







I FC II FC III FC
diastolic dysfunction of abnormal relaxation type pseudonormal type of diasto
restrictive type of diastolic dysfunction
 
Fig. 5. The gradation of patients suffering coronary heart disease with left ventricle diastolic 
dysfunction according to functional classes of chronic heart failure (CHF). 
In cases of heart failure clinical manifestations we have received the relation of r = 0,620 (p 
<0.01) of the frequency of CHF FC to the type of diastolic dysfunction. When FC increases 
the disturbances of LV DF become more pronounced: restrictive type of LV DD was 
detected in III FC (51% observations); in I FC it was observed on 11.4%; patients had the 
type of abnormal relaxation in 9.5% and 64.3% respectively, pseudonormal type was 
detected in 21.6% and 55% of cases. 
The analysis of the structural and geometric parameters of left heart chambers (Table 1) 
showed that group III had an increase of the dilation of the cavities of the left ventricle and 
left atrium, increased left ventricle myocardial mass, reduction in contractile function 
Electrical Heart Instability Evaluation in Conditions 
of Diastolic Heart Failure Suffered by Coronary Heart Disease Patients 
 
87 
(ejection fraction of III group was more than 45% but less than 50%, in group I it was 50%) in 
comparison with group I. 
Indicators I group II group III group 
Number of patients, n 59 36 33 
Е, m/s 0.65±0.06* 0.81±0.03 1.07±0.05** 
А, m/s 0.93±0.09* 0.65±0.02 0.36±0.03* 
Е/А, 0.82±0.05* 1.25±0.02 3.15±0.08** 
АТ, ms 99.47±2.1 94.1±3.2 97.3±3.3 
DT, ms 267.6±11.4* 169.6±7.9 143.5±3.2** 
IVRT, ms 116.8±7.4* 88.3±2.3 58.9±4.8** 
Ar, cm/s 24.1±2.2 36.6±1.3 55.3±1.6 
SI, ml/m2 40.3±2.8 41.2±1.4 41.7±2.6 
EDVI, ml/m2 82.1±5.3* 85.8±4.58 100.8±6.7 
ESVI, ml/m2 37.85±2.1* 39.2±1.1 41.61±2.5 
LVEF, % 55.93±2.7* 53.1±2.17 49.6±2.06 
ESVILA, ml/m2 39.5±2.3* 44.37±3.2 50.43±3.61 
ICVLA,% 37.65±1.5 * 34.1±2.1 24.9±2.7 
LVMI, g/m2 126.35±9.7* 132.1±6.3 148.2±11.1 
left ventricular RT, cm 0.44±0.06* 0.45±0.05 0.50±0.02 
SI – stroke index, EDVI - end-diastolic volume index, ESVI - end systolic volume index, LVEF - left 
ventricular ejection fraction, ESVILA - end systolic volume index of left atrium, the ICVLA - an indicator of 
changes in the volume of the left atrium, LVMI - left ventricular mass index, left ventricular RT is the 
relative thickness of the left ventricular wall, *-p <0.05 - reliability of differences between patients with 
DD of abnormal relaxation type and patients with pseudonormal type of DD, ** p <0.05 - reliability of 
differences between the group of patients with restrictive type of DD and the groups with pseudonormal 
type of DD and abnormal relaxation,  - p <0.05 - reliability of the indicator difference between group with 
DD of abnormal relaxation type and groups with DD of pseudonormal and restrictive type. 
Table 1. Echocardiographic indicators of patients with coronary heart disease 
We believe that one of the determinants of heart failure is diastolic dysfunction of the heart, 
which can be viewed both as the initial stage and as a pathophysiological link in the "vicious 
circle" of circulatory inefficiency, which affects negatively on the prognosis of patients with 
coronary heart disease [11]. 
The violation of left ventricular diastolic properties is essential, along with other structural 
and functional changes (dilation and hypertrophy), which form the concept of 
“remodeling”. Patients had eccentric hypertrophy (43.75% of cases) and concentric 
hypertrophy of LV (37.5% of cases) as predominant types of LV remodeling after MI. 
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We established the correlation between the severity of LV DD and exponent change in the 
volume of the left atrium - r = -0.43 (p = 0.032), with left ventricular ejection fraction - r = -
0.48 (p <0.04), with an index of end diastolic volume - r = 0,51 (p = 0.02), with left ventricular 
mass index - r = 0.45 (p = 0.034). 
We associate the appearance and progression of LV DD with violation of diastolic relaxation 
on the back of acute or long-lasting ischemia with increased stiffness of the myocardium, 
including the location of postinfarction scar. We spotted the following law: a degree of LV 
DF disorder was growing in patients having macrofocal myocardial infarction versus 
patients having fine-focal myocardial infarction, respectively, it was 30.5% with abnormal 
relaxation type and 69.5% (p = 0.047), 58.3% and 41.7% (p = 0.05) with pseudonormal, 87.9% 
and 12.1% (p = 0.0476) with restrictive type. We believe that patients with previous Q-
infarction had long-lasting deterioration of LV function during myocardial hibernating, 
which is characterized by a chronic reduction in cardiomyocyte contractility, while their 
viability is maintained. In these conditions viable myocardium which is far from infarction 
zona undergoes diastolic myocardial stress. 
We detected the dependence of manifestation degree of diastolic dysfunction with an index 
of contractility WMSI - r = 0.91 (p = 0.01) among patients with a history of MI. We pointed 
the positive correlation of restrictive type of LV DD with Q- myocardial infarction r = 0.638 
(p <0.001). In group III (restrictive type) Q-infarction occurred in 87.9% of cases, which is 
significantly lower in comparison with group I – 30.5%, p <0.01. 
In conditions of limited blood flow the possibility of injury and death of cardiomyocytes 
because of their necrotization and apoptosis [12] is the main unfavorable result of 
myocardial hypoxia in case of coronary heart disease. However, death of cardiomyocytes is 
accompanied by compensatory hypertrophy of survived myocardial cell and the 
development of connective tissue [13]. There is an opinion that left ventricle hypertrophy 
may lead to myocardial dysfunction. It is an individual risk factor for high cardiovascular 
case rate, including ischemia myocardial infarction, heart failure, ventricular arrhythmias 
and sudden death. 
We tend to assume that the process of cardiac remodeling affects all myocardium 
components. Changes occur at the level of cardiac myocytes and in the extracellular matrix. 
Typically, ischemic myocardial injuries develop leading to the coagulation and apoptosis. In 
this case, as approved by the J.Soto, G.Beller [2001], responsive genes are activated 
immediately, especially c-fos, and the program of "programmed death", apoptosis, starts to 
run. In the peripheral areas ischemic injury usually results in colliquative necrosis with cell 
edema and myocytolysis. It is especially true for reperfusion injury. The formation of 
connective tissue (fibrosis) may have redundant diffuse or interstitial nature in addition to 
substitution (focal), with interstitial spread perivascular. 
Different biomechanical properties of myocardium in chronic ischemic zone and so-called 
intact myocardium generate special effects according to the type of stress concentration on 
their border. The type of stress concentration is connected with further progression of 
degenerative and sclerotic changes, significant changes in the shape and size of remodeled 
heart chambers. Further LV remodeling with the expansion of the cavity in postinfarction 
period is caused by involving of myocardium in the "transition zone" in the process of 
remodeling. The data obtained from pathophysiological studies suggest that patients 
suffering coronary heart disease have clinical picture determined by not only the 
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heterogeneity of causes, but also the diversity of adaptive and disadaptive changes in 
metabolism and contractile condition of cardiomyocytes [16]. The most significant adaptive 
myocardium reactions in response to myocardial ischemia include the “new ischemic 
syndromes”: hibernate, stupor. 
The defining condition for the occurrence of lethal arrhythmias is considered to be structural 
disease of heart, which becomes electrically unstable under the influence of various 
functional factors. Ischemia and necrosis, hypertrophy and dilatation of the ventricles, the 
inflammation and swelling of the myocardial tissue can act as the structural changes that 
determine the development of ventricular tachycardia. According to the results of many 
studies [17, 18, 19] these changes constitute anatomical substrate for appearance of 
malignant arrhythmias with the participation of the various triggering and modulating 
factors. 
Ventricular late potential with a stable disease course was recorded among 35 patients 
(27.3%) with a history of MI (Table 2). We believe that structural cardiomyocyte changes, 
programmed apoptosis and secondary hypertrophy, increased diastolic stiffness and active 
myocardium relaxation violation, reactive changes of connective tissue skeleton of the 
myocardium, decrease in diastolic filling and remodeling with segmental structure 
violation, i.e. all these processes, lead to the formation of electrical myocardium 
heterogeneity and cause greater frequency of recording of late potentials among CHD 
patients in conditions of progression of LV DD: with abnormal relaxation (18.6%), with 
pseudonormal type (27.8%), and restrictive type of LV DD (42.4%, p <0.05). 
Indicator 
Variations of diastolic dysfunction 
Type I Type II Type III 
The number of patients, n 59 36 33 
The number of patients with 
ventricle late potential, n 11 10 14 
The number of patients with 
ventricular arrhythmia, n 50 35 33 
analysis of ventricular extrasystole 
I gradation,  n/% 29/49.1% 10/27.8% 2/6.1% 
IIgradation,  n/% 7/11.9% 7/19.4% 5/15.1% 
IIIgradation,  n/% 10/16.9% 13/36.1% 12/36.4% 
IV-V gradations, n/% 4/6.8% 5/13.9% 14/42.4% 
analysis of Q-T interval 
RRNN, ms 810 ± 64 798 ± 98 753 ± 132 
QTс, ms 405.5 ± 5.2* 422.3 ± 2.6** 450.2 ± 5.4 
QTd, ms 39.7  ± 2.7* 49.6 ± 3.3** 64.2 ± 3.1 
I type- LV DD of abnormal relaxation type, II type - LV DD of pseudonormal type; III type - LV DD of 
restrictive type, VLP ventricular late potential, VA- ventricular arrhythmia, RRNN - the duration of 
sinus RR intervals; n /% - the absolute number of patients with given symptom/percentage of the 
number of patients of this group. 
Table 2. The comparative analysis of ventricular arrhythmias, cardiac late potentials, QT 
intervals among patients with coronary heart disease 
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Ventricular arrhythmias are considered to be one of the factors determining the poor 
prognosis and high mortality among CHD patients. Ventricular arrhythmias may be the 
cause of death among patients with heart failure symptoms even in conditions of adequate 
control of decompensation symptoms. 
Cardiac arrhythmias were detected among 99.2% of patients (Table 2), while 
supraventricular arrhythmias (SA) were detected among 7% of patients, ventricular 
arrhythmias were detected among 56.2% of patients, a combination of ventricular 
arrhythmias (VA) with various forms of supraventricular arrhythmias (SA) were indicated 
among 36% of patients. Complex forms of VA (ventricular extrasystole of grades IV-V) were 
found in 23 cases (18%). Polymorphic ventricular extrasystole was detected among 35 CHD 
patients with left ventricular diastolic dysfunction (27.3%). In 41 cases (32%) the revealed 
ventricular extrasystole was assigned to I gradation when the frequency of episodes did not 
exceed 220 per day. 
Having analyzed ventricular arrhythmias we noted the following law: early, paired, volley 
ventricular extrasystoles were detected among patients with slow fragmented activity more 
frequently in comparison with patients without ventricular late potential, respectively, 19 
(54.3%) and 4 (4.3%) with χ2 = 7.4, p <0.001. 
Ventricular late potential and ventricular arrhythmias were recorded more often with an 
increase in the degree of diastolic dysfunction and end-diastolic volume of left ventricle. 
When DD had a restrictive type, ventricular extrasystole was found in 100% of cases and 
ventricular extrasystole of IV-V grades was detected among 14 patients (42.4%), 13 of them 
had a diagnosed slow fragmented activity at the end of the ventricular complex. In group I 
(with abnormal left ventricular relaxation) ventricular extrasystole was observed among 
84.7% of patients and complex forms of ventricular extrasystole were detected among 4 
patients with abnormal rates of Holter ECG (6.8%). 
The most common mechanism for tachyarrhythmias of high grades is the mechanism of re-
entry momentum. It means the presence of unilateral and delayed passage of the 
depolarization wave front because of the violation of inter-cell contacts in parallel-oriented 
fibers [20], proliferation heterogeneity and fragmentation of the depolarization wavefront, 
which is a marked by ventricular late potential. That's what we explain the significant 
prevalence of complex forms of ventricular extrasystole among patients with slow 
fragmented ventricular activity (54.3%). 
To study the effect of reversible ischemia on myocardial electrophysiological properties we 
analyzed daily myocardial ischemia and indicators of Holter ECG among patients with 
coronary heart disease  having left ventricular DD. Correlation analysis revealed the 
dependence of the daily duration of ischemia on the duration of filtered set of HF QRS 
Dauer (r = 0.53, p = 0.01), with duration of low-amplitude signals at the end of filter-
centered complex QRS LAH Fd (r = 0.49 p = 0.03), duration of painless myocardial ischemia 
with HF QRS Dauer (r = 0.57, p = 0.01). A positive correlation was obtained by estimating 
the depth of segment depression in HF QRS-Dauer (r = 0.45, p = 0.03), with LAH Fd (r = 
0.41, p = 0.05); number of painless ischemic episodes per day with HF QRS-Dauer (r = 0.51, 
p = 0.04). 
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The results confirm that the presence of slow fragmented activity focus, marked by 
ventricular late potential is connected with heterogeneous areas of myocardium in CHD 
patients: profound disturbances in the processes of relaxation and recovery of 
cardiomyocytes occur in both acute and chronic ischemia because of degenerative changes 
and apoptosis. But it should be noted that studying the complex mechanisms of late 
potentials formation and the functions and metabolism of cardiac muscle, we traditionally 
pay much attention to cardiomyocytes. However, we tend to assume that extracellular 
matrix plays a insignificant role in the genesis of fragmented ventricular activity. Fibrosis is 
an essential component of cardiac muscle remodeling; the development of reparative 
(replacement) fibrosis may not only violate cardiomyocytes supply but also impede the 
electrical contact between them [21] in case of ischemia and myocardial necrosis. 
The results of our studies have shown that myocardial dysfunction in ischemic area leads 
to the inhomogeneity of repolarization processes in conditions of limited coronary blood 
flow. However, the increase of QT dispersion in patients with coronary heart disease is 
associated with the duration of daily myocardial ischemia (DMI). We received a positive 
relationship of DMI with QTd (r = 0.485, p = 0.05). When the DMI was more than 60 
minutes the duration of QTc and QTd interval was 449.2±4.1 ms and 67.2±2.7ms, p 
<0.05,when the DMI was 30 to 60 min analogous figures corresponded to the values of 
412.5±3,2ms and 46.8± 2,4 ms. 
While studying QTd we observed higher values in patients with ventricular arrhythmia of 
III-V grades (67.5±4.2 ms) in comparison with patients without ventricular arrhythmia 
(44.3±2.5ms), p <0,05. The analysis revealed a dependence of the variance of QT interval 
with gradation of ventricular extrasystole (r = 0.6432, p <0.01), with exponents of Holter 
ECG: LAH Fd (r = 0.4831, p <0.05) HF QRS-Dauer (r = 0.5744, p <0.05). 
The proportion of patients with restrictive type of LV DD with QTc interval which was over 
440 ms (69%), and QTd which was more than 50 ms (72%) was significantly higher in 
comparison with those values in group II, it was 30.6% and 33% (p<0.05) respectively, and 
in Group I it was  19% and 17% (p<0.03) respectively. 
The performance analysis of electrical and structural remodeling among patients 
havingcoronary heart disease with different variants of left ventricular DD allowed us to 
establish a clear pattern (Figure 6): ventricular late potential and ventricular arrhythmias of 
higher grades were detected more often with increasing degree of diastolic function 
disturbance. Inhomogeneity of repolarization processes was heightened with an increase in 
QT interval dispersion. In our view, the resulting dependence reflects inhomogeneity of 
repolarization processes and depolarization of the ventricles in chronic ischemia, the 
conditions for malignant arrhythmias in CHD patients having left ventricular DD were 
created. We assume that the electrical stability of myocardium and its global-sustaining 
capacity are integral characteristics that determine the functioning of the heart as a self-
regulating system. The violation of bioelectrical activity of the myocardium inevitably leads 
to its mechanical failure. 
The discussion of the pathogenesis of coronary heart disease was always connected with 
neurogenic component. The theory of “punctuated antagonism” of the interaction of two 
divisions of the autonomic nervous system (ANS) and their impact on the regulation of the 
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pacemaker in the sinus node (SN) is complicated by the activity of all the structures of the 
peripheral segmental heart ANS. In conditions of limited coronary blood flow morpho-
functional component is considered to be slowly-varied, and pathologically altered 
regulation of heart rate variability is one of the earliest and most obligate manifestations of 
ischemic process [22, 23]. Sympathetic distress is a critical drop in power of neurohumoral 
regulation with a shift in the sympathovagal balances to the sympathetic component. It is 
regarded as a predictor of sudden death which is independent from left ventricular ejection 
fraction [22]. 
 
DD of Type I - diastolic dysfunction according to the type of abnormal relaxation, DD of Type II- 
diastolic dysfunction of pseudonormal type, DD of Type III - diastolic dysfunction of restrictive type; 
EDVI LV - end-diastolic volume index of left ventricle, EF LV - ejection fraction left ventricular, QTd - 
the dispersion of Q-T interval. 
Fig. 6. The performance analysis of structural and geometrical and eletrical remodeling in 
CHD patients with left ventricle diastolic dysfunction. 
Assessing the neurohumoral regulation of heart rate, we conducted the analysis of 
quantitative indicators of HRV and HRT (Table 3). 
HRV indices in the group with impaired relaxation did not differ significantly from those in 
the group with pseudonormal type, once-reliable differences were obtained in comparison 
with III group of diastolic heart failure. 
Rates BB50, SDNN index, rMSSD are drastically reduced in patients of group III. These 
values indicate a disorder of vagal protective effect on the value of "threshold of heart 
fibrillation". Disorders of neurohumoral regulation were diagnosed in conditions of the 
restrictive version of the DD LV, they pointed the increased sympathetic activity (SDNN – 
24.7±3,2ms, LF/HF – 5.46±0,61 conventional units, ВВ50 - 0%).  
During our study we pointed out the following pattern: autonomic imbalance with 
increased sympathetic activity grew with an increase in the degree of LV DD. The excess of 
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the balance of ANS of sympathetic type  LF / HF  was observed in 39% of patients in group 
I who had abnormal left ventricular relaxation, it was detected in 58.3% of patients in group 
II with pseudonormal type of DD LV  and it was indicated in 94% cases in group III with 
restrictive type, p <0.05.  
And, if the HRV is a proven non-invasive method of quantitative analysis of the functioning 
of ANS in patients with coronary heart disease with preserved sinus rhythm, HRT is a fairly 
new noninvasive method of estimation the modulating autonomic influences on the sinus 
node in patients with ventricular arrhythmias, which  resulted from the progressive fading 
of the carotid baroreflex [24]. Schematically, the formation of HRT can be represented by the 
following sequence: compensatory pause occurs after ventricular extrasystole, and, as a 
result, heart rate and blood pressure increase are caused by baroreflex, then blood pressure 
increase leads to the subsequent decrease in heart rate through baroreflex. 
 
Indicators Group I Group II Group III 
The number of patients, n 59 36 33 
RRNN, ms 810±64 798 ± 98 753 ± 132 
analysis of heart rate variability 
SDNN, ms 41.4± 2.7 36.6± 2.3 24.7± 3.2* 
SDNN index, ms 22.6 ±1.9 19.3 ±1.3 8.7±1.6* 
rMSSD, ms 23.1±2.1 21.1±1.4 16 ±1.3* 
ВВ50, beats per minute 10.3±3.2 8.8±1.4 3.4±1.2* 
LF/HF, conv. 2.93±0.54 3.51±0.68 5.16 ±0.61* 
analysis of heart rate turbulence 
TO more 0% , n/% 10/17 9/25 17/51.5 
TS less 2,5мс/RR, n/% 9/15.2 9/25 16/48.5 
 
RRNN - the average duration of sinus RR intervals between contractions, SDNN-standard deviation 
from the mean duration of RR intervals between sinus contractions, BB50 - the number of adjacent sinus 
RR intervals, which differ by more than 50 ms, SDNN index-average standard deviations, rMSSD - 
square root of the sum of squared differences of successive sinus RR intervals, LF/HF - index of the 
balance of sympathetic and parasympathetic nervous systems; TO is more than 0%; TS is less than 2.5 
ms / RR * - p <0, 05 – the difference is reliable when  indicators of group III are compared with 
indicators of I and II groups. 
Table 3. Quantitative indices of HRV in patients with coronary heart disease 
HRT indicators reflect early acceleration of sinus rhythm (TO) and the subsequent decrease 
in heart rate (TS) after ventricular arrhythmia. Studies in recent years characterized HRT as 
effective method of predicting the outcomes of patients with coronary pathology, which is 
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comparable with HRV, and in some cases it is superior to HRV in its diagnostic capabilities 
[25, 26]. 
During our study we reported the value of TO> 0% in 36 patients (28%) from the group of 
128 patients with previous MI history, we detected TS <2.5 ms / RR in 34 cases (26.6%), and 
we observed the combination of pathological values of TO and TS in 19 cases (14.8%). The 
frequency of registration TO> 0% and TS <2.5 ms / RR significantly dominated in the group 
with restrictive type of LV DD  in comparison with group I (DD type of abnormal 
relaxation) and  group II (DD of pseudonormal type), p <0.05. 
We have established a connection of HRT violation with left atrium volume change 
indicator- r = -0.43 (p = 0.032), with left ventricular ejection fraction- r = -0.49 (p =0.03), with 
end-diastolic volume index - r = 0.51 (p = 0.02), with left ventricular mass index - r = 0.45 (p 
= 0.04). We marked the correlation of TS with HRV indicators: SDNN (r = 0.41, p = 0.02) and 
LH/HF (r = 0.332, p = 0.02). The absolute values of TO significantly correlated with QTd (r = 
0.349, p = 0.04). 
Pathophysiologic ground for coronary heart disease is a discrepancy between myocardial 
oxygen demand and opportunities in meeting the needs in oxygen because of a limitation of 
acute or chronic coronary blood flow. Admittedly, the provision of myocardial blood 
through the coronary arteries occurs in the phase of diastole. That is why we suggest to 
consider diastolic dysfunction not only as an initial stage, but also as a pathological link in 
the "vicious circle" of the development of cardiac events in CHD patients. 
Rates of diastole and its function undergo complex changes caused by the violation of 
diastolic relaxation in the background of acute or chronic ischemia, with increased 
stiffness of the myocardium at the site of postinfarction scar during the coronary heart 
disease. Necrosis of cardiomyocytes and activation of the cascade of biochemical reactions 
which occur in the postinfarction period, cause a significant change in mechanical 
properties of tissues. However, we should take into account different biomechanical 
properties of myocardium in the areas of chronic ischemia and so-called intact (healthy) 
myocardium. The specific effects are generated on their borders according to the type of 
stress concentration. They cause the further progression of degenerative and sclerotic 
changes, the formation of connective tissue in conditions of limited blood flow. In 
conditions of chronic ischemia, the changes occur not only in cardiomyocytes but also in 
cells of connective tissue skeleton. Increased rigidity of myocardium, change in the 
myocardium viscoelastic properties are the consequences of disorganization and 
reorganization of connective tissue skeleton of ischemic nature. Progressive hypertrophy 
and dilation of the heart are accompanied by a further violation of the diastolic left 
ventricular function, then it is accompanied by systolic dysfunction, they cause an 
increase in myocardial oxygen demand and a change in subendocardial blood flow, 
impaired myocardial bioenergetics. 
The evaluation of the changes of myocardium electrophysiological properties seems for us 
to be an important aspect in the search for new diagnostic tests of severity of ischemic 
myocardial damage in patients with coronary heart disease. The validity of these 
approaches is based on the notion that electrophysiological alternation of cells and their 
membranes is associated with remodeling after an episode of ischemia or myocardial 
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infarction and is involved in genesis of arrhythmia That is why we examined the 
relationship of electrical and structural myocardium remodeling with left ventricular 
diastolic function in CHD patients who had myocardial infarction history. 
The analysis of ventricular late potentials and dispersion of QT interval allows to assess 
arrhythmogenic substrate in patients having CHD with left ventricular diastolic 
dysfunction. Persistent deterioration of left ventricular diastolic function during 
myocardium hibernating among CHD patients increases the manifestation of 
inhomogeneity of depolarization and repolarization processes. 
The increase of the sympathetic influence has an effect on myocardium active relaxation and 
diastolic phase structure during the subsequent abuse of metabolic pathways accompanied 
by destabilization of connective tissue skeleton and secondary changes of contractile 
myocardium. Neurohumoral regulation violations caused by diastolic dysfunction in CHD 
patients are the same as when they are generated by heart failure. They are evident in 
increase of sympathetic activity, reduced parasympathetic and pressosensitive activity. 
Even single ventricular extrasystole can be a trigger factor of fatally dangerous arrhythmias 
in conditions of chronic myocardial ischemia with arrhythmogenic substrate, which is the 
marked by ventricular late potential and QTd, when autonomic nervous system is activated 
according to the sympathetic type. 
Complex analysis of parameters reflecting the functional conditions of myocardium and the 
interrelation of electrical and structure-geometrical myocardium remodeling is necessary to 
improve the diagnostics and the prognostication of risk degree among CHD patients in 
conditions of increasing of left ventricle diastolic dysfunction, given the multifactorial 
genesis of the problem of myocardial electrical instability  
The use of integrated risk markers may contribute to the development of an integrated 
approach to risk stratification of SCD and arrhythmic complications prevention in CHD 
patients. 
2. Abbreviations 
ANS - autonomic nervous system  
CHD - coronary heart disease  
CHF - chronic heart failure  
DD  - diastolic dysfunction  
DF - diastolic function  
EDD - end-diastolic size  
EDV -  end-diastolic volume  
ESD  - end- systolic  size   
EHI  - electrical heart instability  
ESV -  end- systolic volume  
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EF - ejection fraction   
HRT -  heart rate turbulence  
HRV - heart rate variability  
IVRT – isovolumic relaxation time  
LV - left ventricle  
LVMI - left ventricular mass index  
MI - myocardial infarction  
SA  - supraventricular arrhythmias 
SCD - sudden cardiac death  
SI – stroke index  
ΔS - systolic shortening’s fraction of the front-back size aortic ventricle 
VA - ventricular arrhythmia 
VLP - ventricular late potential  
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1. Introduction 
Prehospital emergency care personnel can play a crucial role in the identification and 
management of patients presenting with ST Elevation Myocardial Infarction (STEMI). 
Specifically, prehospital thrombolysis by emergency medical personnel such as 
paramedics/nurses/prehospital doctors has been identified as being a successful and safe 
approach for the provision of accelerating reperfusion strategies for acute STEMI. Moreover, 
prehospital thrombolysis has no added specific risks (arguably, it is safer as delayed 
thrombolysis increases the risk of myocardial rupture) as compared to inhospital 
thrombolysis; nor is it an obstacle for later percutaneous coronary intervention (PCI). This 
chapter will focus on the general management of STEMI, the potential benefits related to 
prehospital thrombolysis and alternative, adjunctive therapies and provide some useful 
hints to drug administration. 
Prehospital thrombolysis is an established emergency treatment and has been classified as a 
Class IIa recommendation therapy for acute STEMI by the leading international cardiology 
societies like European Society of Cardiology (2008). Prehospital thrombolysis research is 
ongoing with a large multi-center trial currently recruiting patients in 112 locations 
worldwide – STREAM – Strategic Reperfusion Early After Myocardial Infarction. STREAM 
aims to evaluate, in a proof of concept approach, the outcome of prehospital patients 
presenting with acute STEMI within 3 hours of symptom onset. Following randomization, a 
treatment strategy of early (prehospital) tenecteplase and additional antiplatelet and 
antithrombin therapy followed by catheterization within 6-24 hours with timely coronary 
intervention as appropriate (or by rescue coronary intervention if required) compared to 
primary angioplasty. This intention to treat study will therefore place patients into two 
groups; Group A will receive primary PCI performed according to local standards and 
Group B will receive prehospital thrombolysis supported by optimal supportive adjunctive 
therapy (http://clinical trials.gov.show/NCT00623623). 
2. Development of prehospital thrombolysis 
The first published study of prehospital thrombolysis involved the intravenous 
administration of 750,000 units of streptokinase by physicians was undertaken in 1985. This 
study demonstrated that patients treated less than 1.5 hours after the onset of pain had a 
significantly higher ejection fraction (56±15 vs. 47±14 %; P<0.05), improved infarct-related 
regional ejection fraction (51±19 vs. 34±20 %; P<0.01) and a lower QRS score (5.6±4.9 vs. 
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8.6±5.5; P<0.01) than patients receiving treatment between 1.5 and 4 hours from the onset of 
pain. Patients in the prehospital arm of the study also had better-preserved left ventricular 
function than patients treated in the hospital. The study concluded that thrombolytic 
therapy with streptokinase is most effective when administered within 1.5 hours from onset 
of symptoms of acute myocardial infarction. Although this study produced positive results 
it lacked statistical power (due to small sample size) but it served to highlight the 
importance of timely thrombolysis (Koren et al., 1985). 
Arguably, the Grampian Region Early Anistreplase Trial (GREAT) was the most influential 
prehospital thrombolysis based study. The aim of GREAT was to determine the time saved 
by thrombolysis when initiated at home by trained general practitioners (GPs) / family 
physicians as compared to thrombolysis inhospital. The GPs randomly assigned 
thrombolytic therapy to 311 patients with suspected acute myocardial infarction into two 
groups; prehospital thrombolysis and thrombolysis after arrival at the hospital. GPs selected 
patients on the basis of a history of chest pain from 20 minutes to 4 hours with treatment 
initiated within 6 hours from onset of pain. Patients in the prehospital treatment group 
received thrombolysis up to 130 minutes earlier than patients at hospital (101 vs 240 minutes 
from the onset of symptoms) with a 50% reduction in mortality in the prehospital group; 17 
(10.4%) vs 32 (21.6%). The greatest saving of time was seen in the rural environment as well 
as in areas where there were significant inhospital treatment delays (Rawles, 1994). 
Importantly, during the GREAT study, prehospital thrombolysis was undertaken using a 
single bolus thrombolytic agent.  
Patients enrolled in the GREAT study were followed up at five years where investigators 
noted 25% of the prehospital treatment group had died compared to 36% in the inhospital 
treatment group (Rawles, 1997). The GREAT study reconfirmed the negative impact of time 
delays by demonstrating that delaying thrombolysis by one hour increased the hazard ratio 
of death by 20%, with the equivalent loss of 43 lives per 1000 patients treated at five years. In 
a subset analysis of GREAT patients who met current ECG criteria for thrombolysis 
undertaken  after 10 years, a 16% difference in mortality was maintained between the two 
groups (Rawles, 2003). The benefits seen in GREAT were significantly higher than those 
seen in any other thrombolysis study. The long-term mortality patterns has not been 
replicated in other long-term (inhospital) follow up studies, like ISIS-2 (1988) or GUSTO-1 
(1993).  
Treatment delays and the potential time savings of prehospital thrombolysis are key factors 
in the decision-making process around reperfusion with a meta-analysis by Morrison et al. 
(2000) of six randomized controlled trials clearly demonstrating the impact of the time 
savings to be achieved with prehospital treatment over inhospital treatment. Morrison et al. 
reported on all-cause hospital mortality as well as symptom to treatment time and adverse 
events. Although individual trials failed to demonstrate a statistically significant difference 
in all cause inhospital mortality; the meta-analysis involving 6434 patients showed a pooled 
benefit with prehospital thrombolysis. Morrison et al. demonstrated that prehospital 
thrombolysis saved approximately 60 minutes (p = 0.07) per patient compared to inhospital 
thrombolysis (104 versus 162 minutes) thereby reducing all-cause hospital mortality by 17%. 
If we consider the data from the five year follow up of the GREAT study, such time-savings 
can be extrapolated into significant numbers of lives saved.  
Bjorklund et al. (2006) evaluated treatment delays and outcome in a large cohort of acute 
STEMI patients transported by ambulance who were either thrombolysed by paramedics in 
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the prehospital environment or thrombolysed inhospital. Importantly, Björklund et al. 
utilized data from the Swedish / Register of Cardiac Intensive Care drawing data from 75 
hospitals. Although register based data lacks the scientific controls seen within clinical trials, 
it is arguably more reflective of ‘real life’ clinical care. Following this study, Bjorklund et al. 
were able to conclude that prehospital thrombolysis by paramedics in ambulances was 
associated with reduced time to thrombolysis by almost 1 hour and reduced adjusted 1-year 
mortality by 30%. 
Minimizing treatment delays in the administration of thrombolysis is key to optimizing 
patient outcomes. Although the LATE study (Becker, 1995) demonstrated clinical benefits of 
thrombolysis up to 12 hours, the greatest benefits were seen within 6 hours with the highest 
mortality reduction  seen in those patients treated within the first 3 hours from onset of 
symptoms. The most commonly perceived post thrombolysis risks of stroke or major 
haemorrhage remain static regardless of when within the 12 hour period thrombolytic 
therapy is administered. However, the typically lethal complication of myocardial rupture 
exponentially increases after six hours. As demonstrated in the GREAT, WEST (Armstrong, 
2006) and CAPTIM (Bonnefoy et al., 2009) studies prehospital thrombolysis is more likely to 
recruit patients within the first 6 hours of symptom onset; typically within the first 3 hours 
were the clinical benefit of treatment is at its highest. 
These trails and others help to confirm the feasibility and safety of prehospital thrombolysis 
in a wide variety of circumstances and settings ranging from traditional ambulance services 
through to use by ship-based medical teams (cruise ships) and deployed military medicine. 
However, the choice between reperfusion strategies to manage acute STEMI remains a topic 
of interest. While it is agreed that primary PCI is the best strategy for acute STEMI it is still 
time sensitive and therefore needs to be performed in a timely manner and by experienced 
centres. This is not always achievable in developing countries, in rural health care settings or 
in remote medical facilities such as cruise ships. 
3. Prehospital thrombolysis supported by early intervention 
A number of mixed strategies for reperfusion have been studied; to include prehospital 
thrombolysis (full dose thrombolytic therapy) supported by rescue PCI for failed 
thrombolytic reperfusion (a hybrid reperfusion strategy) plus pre-discharge or 
symptom/ischaemia driven PCI, reduced dose thrombolysis supported by immediate PCI 
(facilitated PCI) and primary PCI. The ASSENT-4 PCI (2006) study demonstrated that 
facilitated thrombolysis, that is,  thrombolysis immediately followed by PCI has been 
proven to be an unsuccessful intervention and will not be discussed further. 
A hybrid reperfusion service involves implementing the best combination of reperfusion 
options to meet the unique requirements of the patient and typically involves early 
prehospital thrombolysis for those patients with the greatest benefit e.g. anterior STEMI 
presenting within 2-3 hours supported by rescue PCI and pre-discharge angioplasty with a 
system of primary PCI for the remaining patients. It must be re-iterated that primary PCI 
does still offer a superior treatment option when it is available in a timely manner.  
The WEST trial investigated the use of a number of different reperfusion strategies, 
immediate prehospital thrombolysis plus usual inhospital care (excluding routine PCI), 
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prehospital thrombolysis with compulsory rescue PCI for failed thrombolysis against 
primary PCI strategy. A key finding of the WEST study was a lower incidence of 
cardiogenic shock in patients who received thrombolysis early (within 3 hours) and the 
importance of prehospital triage/decisions for reperfusion with delays to definitive 
treatment being shorter when a decision was made in the prehospital setting. The WEST 
study also highlighted that thrombolysis used timeously remains an important treatment 
modality in the early management of acute STEMI.  
The larger CAPTIM study used a similar design to the WEST study utilizing prehospital 
triage/decision to prehospital thrombolysis (this time supported by compulsory rescue PCI) 
with pre-discharge coronary intervention compared to primary PCI. The long term 5 year 
follow up of the CAPTIM study confirmed a significant reduction in mortality when 
thrombolysis was administered within 2 hours in the prehospital group when compared 
with primary angioplasty. The relationship between reperfusion strategy and the time from 
symptom onset on 1 year mortality was examined in a pooled analysis of patients from the 
CAPTIM and WEST studies. Mortality benefit was observed time (< 2 hours) (2.8%  vs 6.9%, 
p = 0.021, hazard ratio 0.43, 95% CI 0.20-0.91) emphasizing that time from symptom onset 
was a key determinant when selecting the reperfusion strategy for acute STEMI (Westerhout 
et al., 2011). The optimal design of a hybrid reperfusion service is yet to be determined but 
the data from WEST and CAPTIM would support prehospital thrombolysis within the first 
3 hours as along as all patients were delivered to a receiving hospital with interventional 
cardiology capability. 
Prehospital thrombolysis can clearly be initiated earlier that inhospital thrombolysis or 
primary PCI and it can be performed with limited equipment. In fact, the same minimum 
equipment is required to perform prehospital thrombolysis as is required to identify 
prehospital patients requiring direct admission for primary PCI. Data from WEST 
(paramedic decision-makers), CAPTIM (doctor decision-makers) and projected findings 
from STREAM (paramedic/nurse/doctor decision-makers) are intended to inform the 
debate as to whether a hybrid reperfusion system is appropriate within developed 
countries. Regardless of the reperfusion strategy put into place, empowering the prehospital 
clinician is pivotal to success.  
4. Education, training & equipment 
The efficacy and safety of pre-hospital thrombolysis is dependent on several pre-requisites 
(Birkhead, 2004; Björklund et al., 2006; Mehta et al., 2002; Weaver, 1997; Welsh et al.,  
2006): 
1. Prehospital personnel being trained to recognize symptoms and management of STEMI 
and its early complications (pain, ventricular fibrillation/ventricular tachycardia and 
bradycardic arrhythmias).  
2. Diagnoses of STEMI using a 12 lead ECG with or without computer assistance for 
diagnosis and/or data transmission. 
3. Intravenous access to be established and the administration of reperfusion therapy to be 
initiated within a treatment protocol / clinical guideline and supported by a 
thrombolysis checklist. 
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4. During transportation rhythm monitoring, availability of a defibrillator and advanced 
cardiac life support are mandatory 
5. Pre-alerting receiving hospital of impending arrival of the patient supported by (if 
available) electronic transmission of the 12 lead ECG  
6. Consultation for on-line support can support decision-making  
7. On-going quality assurance 
4.1 Education and training 
The foundation for the practice of thrombolysis requires an understanding of anatomy and 
physiology of cardiovascular system and the pathophysiology of acute coronary syndromes. 
The complications of acute coronary syndromes / acute myocardial infarction must be 
covered as this will prepare the paramedic/nurse/prehospital doctor for complications that 
may arise during clinical practice. The ability to analyze a 12 lead ECG with a particular 
focus on recognition of AMI is required along with an understanding of thrombolytic 
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oil platforms or small remote communities (e.g. Scottish Islands). Such a system is not 
dissimilar to the early use of defibrillation by paramedics where external supervision was 
required before defibrillation was performed. 
5. Protocols, checklists & consent 
5.1 Protocols 
The use of clinicians empowered to make individual thrombolysis decisions removes the 
requirement for fixed protocols, however at the very least an evidence-based clinical 
guidelines for thrombolysis will be required. The availability of a clinical guideline or 
protocol will depend on the level of training provided to the prehospital clinician as 
guidelines support lateral thinking, whereas protocols tend to be more prescriptive.  
The development of the thrombolysis protocol / guidelines needs to incorporate 
adjunctive therapy such as anti-thrombotic agents (e.g. heparin) and anti-platelets agents. 
This is an important aspect of patient care as to date none of the completed prehospital or 
inhospital thrombolysis studies have incorporated optimal anti-platelet and anti-
thrombotic therapy. However, STREAM is currently utilizing the most up-to-date 
thrombolysis strategy. 
5.2 Checklist 
A thrombolysis checklist (Table 1), as part of a protocol / guideline, can support rapid 
decision-making whilst acting as a prompt to steps in the patient’s management. However, 
care must be taken to ensure that the checklist is not overly restrictive as this can lead to 
under treatment of appropriate patients and careful consideration of the checklist layout can 
rapidly identify those patients where prehospital thrombolysis is deemed inappropriate e.g. 
advanced age (Castle et al., 2007a). 
All contra-indications to thrombolysis need to be carefully considered and weighted. Often 
the type and number of contra-indications selected will reflect the risk adverse nature of the 
service delivering prehospital thrombolysis and, therefore, the list of contra-indications may 
change as the prehospital service becomes more established. It is now agreed that previous 
contra-indications such as prior cardiac compressions (Castle et al., 2007b; Cross et al., 1991) 
are no longer barriers to thrombolysis (in fact post cardiac arrest survivors with STEMI 
require urgent reperfusion with either PCI or hrombolysis); nor is diabetic retinopathy. 
(Mahaffey et al., 1997). Furthermore, complete heart block (CHB) is an indicator for rapid 
reperfusion therapy with thrombolysis being an accepted form of treatment as prompt 
reperfusion of the AV node (inferior STEMI with CHB) or intra-ventricular septum/Bundle 
of His (anterior STEMI with CHB) will resolve the arrhythmia thereby removing the need 
for a temporary pacing wire (Castle et al., 2007b) - the very reason typically quoted for with-
holding thrombolytic therapy. All contra-indications to thrombolysis, with the exception of 
myocardial rupture as shown by the LATE Study (1993), are static/not affected by time 
whereas the benefit of thrombolysis is time dependent. Therefore, denying prehospital 
thrombolysis in a patient with STEMI based on one contra-indication only for the patient to 
be transferred to hospital for thrombolytic therapy to be administered will be counter-
productive. 
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 Primary assessment: Can you confirm the following?  Yes  No 
1 The patient is conscious and coherent, and able to understand that clot dissolving drugs will be used?   
2 
The patient has symptoms that are characteristic of a heart attack 
(severe, continuous pain in a typical distribution of 15 minutes duration 
or more without remission)? 
  
3 The symptoms started less than 12 hours ago?NOTE: Consider “stuttering start” MI – many infarcts start this way.   
4 The pain built up over seconds and minutes rather than starting totally abruptly?   
5 Breathing does not influence the severity of the pain?   
6 
The systolic blood pressure is more than 80mmHg and less than 
180mmHg and that the diastolic is below 110mmHg despite treatment? 




The electrocardiogram ECG shows abnormal ST elevation of 2mm or 
more in at least 2 standard leads or in at least 2 adjacent precordial leads,
not including V1? 
NOTE: ST elevation can sometimes be normal in V1 and V2. 
  
8 
The QRS width is 0.16 seconds (4 small squares) or less, and that left 
bundle branch block is absent from the tracing? 
NOTE: RBBB is permitted only with qualifying ST elevation. 
LBBB = QRS 140 ms or greater; small narrow R wave in V1 & V2 with 
big S wave; tall upright monophasic R in standard Lead 1 and V6. 
  
 Secondary assessment (contra-indications): Can you confirm the following?  Yes  No 
9 The patient is not likely to be pregnant, nor has delivered within the last 2 weeks?   
10 The patient has not had an active peptic ulcer within the last 6 months?   
11 The patient has not had a stroke of any sort within the last 12 months and does not have any permanent disability from a previous stroke?   
12 
The patient has no diagnosed bleeding tendency, has had no recent 
blood loss (except normal menstruation) and is not taking warfarin 
(anticoagulant) therapy? 
  
13 The patient has not had any surgical operation, tooth extractions, significant trauma, or head injury within the last 4 weeks?   
14 The patient has not been recently treated for any other serious head or brain condition?   
15 The patient is not being treated for liver failure, renal failure, or any other severe systemic illness?   
Table 1. An example of a thrombolysis checklist 
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5.3 Consent 
It is standard practice to obtain consent from the patient for thrombolytic therapy. The 
complications from thrombolysis are well documented. The patient will need to be 
appraised of the risks in undergoing thrombolysis. A standard statement that is simple, 
clear and concise is used in most established prehospital settings. An example of such a 
statement is as follows (Table 2): 
However, it remains arguable whether a patient in pain or post opiate administration is in a 
position to give informed consent. It, therefore, falls to the attending clinician to ensure that 
they are working in the patient’s best interest. 
Initial Consent 
“It is likely that you are having a heart attack and the best treatment available to you is a 
clot dissolving drug called (specify agent). The quicker you receive this drug, the lower the 
risks of a heart attack-which is why Doctors recommend that the treatment is started as 
soon as possible. These drugs can cause serious side effects in a small minority of patients 
which I can explain to you in more detail if you so wish, but the risks attached to this 
treatment are very much less than the likely benefit. Would you like me to give you the 
injection or would you prefer to have more details?’ 
I hereby consent to the treatment: 
 
________________  _____/_____  ___________________ 
Name of patient   Date / Time  Signature / Thumbprint 
 
In the unlikely event that the patients do want more information they should be given 
the following information: 
 
Further information 
“Treatment at this stage saves the lives of about 1 in every 25 treated. But it can sometimes 
cause serious bleeding. The biggest risk is stroke which affects about 1 patient in every 200 
treated. Some patients also have allergic and other effects that do not usually cause any 
major problems. Would you like me to give you the injection?” 
Table 2. An example of consent 
6. Drugs 
6.1 Thrombolytic agents 
There are a number of thrombolytic agents available, however Tenecteplase (TNK) is the 
only single-use bolus agent available making it the most suitable for prehospital use. 
Despite this, the ideal thrombolytic agent currently does not exist.  
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The characteristics of an “ideal thrombolytic agent” are as follows: 
 Rapid reperfusion (15 - 30 minute) 
 100% efficacy at achieving 100% TIMI 3 in 30 minutes   
 Administered as a single intravenous bolus 
 Lower incidences of intracranial haemorrhage 
 Lower incidences of systemic bleeding and other complications. 
 Specific for recent thrombi 
 Lower incidences for re-occlusion 
 Long-term sustained patency 
 No antigenicity 
 No negative interaction with adjunctive therapy 
 Affordable 
The GUSTO trial (1993) demonstrated the superiority of the accelerated regimen of tissue 
plasminogen activator (tPA, Alteplase) over Streptokinase (STK), however, this came at a 
price of slightly greater risk of intracranial haemorrhage especially in female patients over 
the age of 75 years. However, stroke after thrombolysis is a known risk and in the GUSTO 
trial the stroke rate with STK was 1.19% compared to 1.55% with tPA (Gore et al., 1995). The 
issue of stroke is an important consideration as denying thrombolysis does not decrease the 
stroke rate as STEMI is an independent risk factor for stroke - unrelated to thrombolysis 
primarily due to the higher incidence of atrial fibrillation (AF) and poor left ventricular (LV) 
function caused by STEMI. Therefore, early treatment of STEMI with reperfusion that 
reduces the incidence of AF and LV dysfunction is an important aspect of stroke and 
morbidity reduction. 
Single bolus TNK is now the most widely used thrombolytic agent in the developed world 
partly due to its improved efficacy but also because of ease of administration and variable 
dosing. TNK and Alteplase are equivalent in regard to 30 day mortality, but non-cerebral 
bleeding and blood transfusions are less with TNK.  
The dose of TNK is weight adjusted and administered in a single bolus over 5 seconds as 
compared to 90 minutes of variable rate infusion with tPA or a 30 - 60 minute infusion of 
STK. Although a 30 minute regime for STK exists, it is associated with an increased risk of 
hypotension but by slowing the infusion rate of STK, the incidence of hypotension tends to 
decrease. Reteplase is a more fibrin specific agent administered as a 10 unit twin bolus given 
30 minutes apart. However, the time sensitive nature of the twin bolus administration of 
Reteplase can be problematic. Reteplase is equivalent with reduction in mortality and 
hemorrhage rates achieved with Alteplase.  
The major benefit of the bolus agents lies in the ease of administration and in the simplified 
dosing regimen that reduces the risk of dosing errors. However, the cost of TNK and its 
manufacturer’s recommendation for use up to 6 hours makes the cheaper STK a more 
practical drug of choice for use in the developing world as for each patient treated with 
TNK five patients could be treated with STK (Table 3) (BNF, 2011). Its use as a prehospital 
thrombolytic is worth consideration, particularly in static remote health care settings, 
although its requirement for an infusion plus the incidence of hypotension makes it more 
labour intensive.  
 
Novel Strategies in Ischemic Heart Disease 110 







Fibrin selective No Yes Yes Yes 
Plasminogen binding Indirect Direct Direct Direct 
Duration of infusion 
(minutes) 60 90 10 + 10 
5-10 
seconds 
Half life (minutes) 23 <5 13-16 20 
Fibrinogen breakdown 4+ 1-2+ Not known >tPA 
Early heparin Yes Yes Yes Yes 
Hypotension Yes No No No 
Allergic reactions Yes No No No 







TIMI reflow grade 3 at 90 
min 32 45-54 60 >tPA 
Recommended use Up to 12 hours 
Up to 12 
hours 
Up to 12 
hours 
Up to 6 hours 
(typically used 
up to 12 hours) 
Table 3. Characteristics of commonly used thrombolytic agents. Adapted from Opie (2009). 
There are two key considerations for the use of STK in the prehospital environment. The 
first is duration of infusion and second the requirement for an expensive infusion pump. 
Although an infusion pump offers better control of drug delivery, this is less of an issue 
with STK as the delivery of STK is less time sensitive when compared to tPA. In static 
medical care environments (e.g. remote medical center) the infusion can be completed 
before hospital transfer as STK can be safely delivered without an infusion pump using 
either a small intravenous bag (100/250ml 0.9% saline) or a pediatric burette supported by 
close clinician supervision. The use of a pediatric burette or a 100/250ml bag of saline is not 
an option for administration during ambulance transfer as the low ceilings in ambulances 
lack the height to ensure fluid flow and this is further aggravated by ambulance movement. 
Novel techniques involving the use of low cost drip counters (that restrict flow through an 
administration set) supported by a pressure infusion bag to maintain a constant pressure 
through the drip counter is feasible but as yet, is unproven. 
The second consideration is the much higher incidence of hypotension and bradycardia. 
This is due to the release of bradykinin and not as commonly thought as an allergic reaction 
(although anaphylaxis is more common with STK, it remains rare). Therefore, the treatment 
of hypotension consists of slowing or stopping the infusion and the administration of a 250-
500ml crystalloid bolus. The routine use of intravenous steroids and anti-histamines offers 
no clinical benefit and in the case of intravenous steroids, it may adversely affect patient 
outcome by affecting myocardial scar tissue formation, thereby potentially increasing the 
risk of myocardial rupture. 
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Streptokinase Tenecteplase 
1.5 mega units over 30-60 minutes (requires 
an infusion pump) Single weight adjusted bolus 
Aspirin 300mg Aspirin 300mg 
Clopidogrel age adjusted (75-300mg) Clopidogrel age adjusted (75-300mg) 
No heparin (local policy my vary) 
Weight adjusted heparin bolus followed by 
infusion or weight adjusted subcutaneous 
injection of heparin: 
 
4000 unfractionated heparin bolus 
followed by infusion (an infusion pump is 
mandatory) 
 
Age adjusted enoxaparin. 
Bradycardia (common) reversed by 
atropine 
Bradycardia (less common than STK) 
reversed by atropine 
High risk of drug induced hypotension 
responsive to fluid challenge 
stopping/slowing infusion 
No specific drug induced hypotension 
Labour intensive Not labour intensive 
Affordable (if no infusion pump used) Expensive 
Table 4. Comparison of a STK and TNK treatment regime 
6.2 Adjunctive drug treatment 
6.2.1 Oxygen 
Oxygen is commonly administered during the management of patients during thrombolysis. 
Its routine use in patient with pulse oximetry above 95% has been questioned primarily due to 
the possibility of vasoconstriction and limited evidence of benefit (O'Driscoll, 2008). Oxygen 
remains an important adjunctive therapy in the presence of left ventricular failure although it 
is better provided as part of continuous positive airway pressure. Oxygen should routinely be 
administered  in the presence of arrhythmias (e.g. ventricular tachycardia) (Neumar, 2010), 
hypotension/hypo-perfusion and any post cardiac arrest.  
6.2.2 Analgesia 
Analgesia is a priority therapy in the management of STEMI and intravenous opiates 
(morphine, diamorphine or fentanyl) offer the most effective analgesia although the legal 
framework for administration of these drugs can be problematic resulting in drugs such as 
Tramadol or Nubain being used if legal barriers to opiates do exist. The use of inhaled 
nitrous oxide (Entonox™) remains a useful supplementary analgesic (or primary analgesic if 
prehospital opiates are not available) providing both supplementary oxygen and analgesia 
and the use of Pentrane (common in Australia) is also a useful inhaled analgesic allowing 
higher percentage of inhaled oxygen if required. Thrombolysis also represents effective 
analgesia as the restoration of myocardial blood flow results in pain relief reflecting 
successful reperfusion.  
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Non-pharmacological interventions (re-assurance, calm professional mannerism of the care 
provider) are important aspects of pain relief. The use of rapid road transfer with lights and 
sirens may induce greater patient anxiety (as well as the risk of road traffic collision). If 
prehospital thrombolysis has been administered (with appropriate adjunctive therapy) there 
is little to be gain from rapid transfer to hospital. 
6.2.3 Nitrates 
Although there is no survival benefit to be gained from nitroglycerin it remains a common 
early therapy primarily providing analgesia. Nitroglycerin (0.4mg) is typically administered 
sublingually although intravenous nitrates are also used to manage on-going ischaemic 
chest discomfort, control of hypertension and for the management of pulmonary oedema 
(nitrates are a Class I recommendation for left ventricular failure). Nitrates should not be 
administered to patients who have received phosphodiesterase inhibitor within 24 to 48 
hours and should be administered with care in patients with suspected right ventricular 
infarction as they may induce marked hypotension. Despite this, nitrates are very safe drugs 
for use by prehospital clinicians and it must be remembered that known cardiac patients 
may have already treated themselves with varying doses of nitrates prior to the arrival of 
the prehospital clinician. 
6.2.4 Antiplatelet agents 
Antiplatelets are vital in the management of all acute coronary syndromes (unstable angina, 
non-STEMI and STEMI). Within the context of STEMI management anti-platelet therapy is 
as important as thrombolytic therapy. This is because the intra-coronary thrombus 
responsible for re-infarction tends to be platelet rich and thrombolysis may raise the 
possibility of thrombolytic-induced platelet aggregation (Keeley et al., 2006). 
6.2.4.1 Aspirin 
All patients with suspected acute coronary syndrome (unstable angina, non-STEMI and 
acute STEMI), should be considered for prehospital aspirin treatment as there are relatively 
few contra-indications to a single dose of aspirin (Class I recommendation). Despite this, 
aspirin is often withheld either due to concerns over allergy, adverse drug interactions (e.g. 
Warfarin), confusion due to chronic ongoing use of aspirin or uncertainty of diagnosis. 
Typically unless a patient has a known documented allergic reaction (not just gastric 
irritation) to aspirin or is actively bleeding from a gastrointestinal tract ulcer, aspirin at the 
300mg dose should be given. The choice of 300mg is typically the dose of a single aspirin 
with the administration being initiated as early as possible with consideration being given to 
emergency call takers being empowered to recommend aspirin before the arrival of 
emergency personnel (Class IIb recommendation).  
The benefit of aspirin was established in the ISIS 2 trial (1988) where 162.5 mg aspirin 
resulted in 25 lives saved per 1000 patients primarily by reducing the incidence of re-
infarctions (10 non-fatal re-infarctions per 1000) as well as preventing 3 non-fatal strokes per 
1000 patients. The results from ISIS 2 highlighted that the effectiveness of aspirin alone was 
nearly as effective as STK without aspirin (23% v 25% odds reduction of death) and that by 
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combining aspirin with STK, the magnitude of benefit was highly significant (42% odds 
reduction of death). It is noteworthy that aspirin administration during the ISIS 2 trial was 
anytime within the first 24 hours but a meta-analysis by Freimark et al. (2002) demonstrated 
that early aspirin administration (before thrombolysis) was an independent factor in patient 
survival at 1 year (5% vs 11% survived with early aspirin; odds ratio 0.41; 95% CI 0.21-0.74). 
The benefits of aspirin for acute STEMI are attributed to its inhibition cyclo-oxygenase 
dependent platelet activation. The administration of an initial dose of 160-300mg aspirin 
ideally non-enteric coated formulation chewed is a Class I recommendation for acute 
STEMI. Intravenous or rectal aspirin are also acceptable routes of administration.  
Although over-treatment of patients or the administration of an unnecessary treatment 
cannot be endorsed, the benefits of early use of aspirin in any patient with symptoms 
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(aspirin/clopidogrel) with thrombolytic treatment demonstrated more favorable 
angiographic patency of the infarct related artery and a reduction in mortality. A major 
contributor to mortality reduction was the reduction in the re-infarction rate in those 
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COMMIT data. 
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effect than clopidogrel (Wallentin et al., 2003), but as yet to be studied in conjunction with 
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6.2.5 Anticoagulants 
Heparin is considered to be effective and is routinely given as an adjunct for PCI and 
thrombolytic therapy although it is commonly withheld in the first 24 hours in those 
patients receiving STK. The role of heparin is primarily to reduce re-infarction but the 
combination of dual anti-platelet therapy, thrombolysis and heparin may increase the risk of 
bleeding. The American Heart Association guidelines call for careful weight based dosing of 
heparin with thrombolytic therapy in STEMI (Antman et al., 2008). 
The timing of heparin therapy when using fibrin specific thrombolytic agents (tPA, reteplase 
and TNK) is an important aspect of patient management. In an observational study of the 
United Kingdom (UK) national registry the frequency of re-infarction during hospital 
admission after thrombolytic treatment of 35, 356 STEMI patients during 2005–2006 was 
analyzed. Re-infarction rates with inhospital treatment were similar for reteplase (6.5%) and 
TNK (6.4%) but were higher for those patients treated by paramedics in the community. 
When the interval from prehospital treatment to hospital arrival was greater than 30 
minutes re-infarction rates were 12.5% for reteplase, and 11.4% for TNK. For intervals 
shorter than 30 minutes the re-infarction rates were significantly greater for TNK (9.3% than 
reteplase (4.2%). Overall, re-infarction rates were higher after prehospital treatment with 
TNK than reteplase (9.6% vs 6.6%, p=0.005).  
The differences in re-infarction rates were considered to be primarily due to the different 
uses of adjunctive anti-thrombotic therapy as UK paramedic thrombolysis protocols only 
allowed a single bolus dose of heparin prior to thrombolysis but did not allow for ongoing 
heparinization until arrival inhospital as compared to inhospital practice which resulted in 
either an infusion of UFH (800-1000 IU per hour adjusted to aPTT) or weight adjusted 
LMWH. It was also noted that on arrival at hospital there was often a delay in the 
commencement of heparin therapy, either due to confusion about the prehospital protocol 
or other time related pressures. In addition, clopidogrel was commonly administered early 
in association with inhospital thrombolysis but only after arrival at hospital for those 
patients receiving prehospital thrombolysis (Horne et al., 2009). This may also have been a 
confounding factor as Keeley (2006) noted that thrombolysis induced platelet aggregation 
was a possible cause of re-infarction following thrombolysis. 
UFH has long been regarded as the anti-thrombotic agent of choice in the adjunctive 
treatment of patients with STEMI until the introduction of enoxaparin. The ASSENT-3 PLUS 
Trial (2003) evaluated the feasibility, efficacy and safety of prehospital enoxaparin or UFH 
with tenecteplase. There was a reduction in the composite of 30 day mortality, inhospital re-
infarction or inhospital refractory ischemia in the enoxaparin group (14.2% vs 17.4%., p = 
0.08). However, there was a tendency towards higher rates of intracranial haemorrhage 
(ICH) and major bleeding in the enoxaparin group. The risk for ICH and major bleeding was 
mainly confined to patients > patients over 75 years. It must be noted that in ASSENT-3 
PLUS, the dose of enoxaparin was not weight adjusted. The safety concern of enoxaparin 
among elderly patients was addressed by the ExTRACT-TIMI-25 Trial (2005) that 
randomized more than 20 000 thrombolysed patients to receive either enoxaparin or UFH. 
The ExTRACT-TIMI 25 study was significantly changed from the ASSENT 3 study with 
patients > to greater than 75 years of age not receiving the IV bolus of enoxaparin as well as 
receiving a reduced dose of subcutaneous enoxaparin (75%)  with a maximum ceiling dose 
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of subcutaneous enoxaparin for the patients under 75 being set at 100mg and 75mg for the 
over 75 age group. The primary endpoint of this study was all cause mortality or non-fatal 
reinfarction at 30 days. Treatment with enoxaparin was found to be superior to UFH but 
was associated with an increase with major bleeding episodes. A telephone follow up at 1 
year showed a sustained reduction in mortality or re-infarction when using the enoxaparin 
strategy (Morrow et al., 2010). Data from a meta-analysis from 12 earlier trials involving 
more than 49 000 patients support these results (Murphy et al., 2007). Enoxaparin is 
administered as an initial dose of 30mg intravenous bolus, followed by 1mg/kg 
subcutaneously within 15 minutes and is a Class I recommendation. 
The likely reason for both the reduction in re-infarctions but also the increased risk of 
bleeding associated with enoxaparin is that enoxaparin (in fact all LMWHs) provide more 
predictable anticoagulation. Whereas UFH is both dose and person sensitive typically 
requiring frequent dose changes as dictated by aPTT and commonly results in either under 
or over anti-coagulation. 
Enoxaparin offers a number of operational benefits for use with prehospital thrombolysis; 
primarily the absence of an infusion pump that is required when administering an infusion 
of UFH. Two single 100mg dose syringes of enoxaparin is adequate to support prehospital 
thrombolysis with one syringe being used for the 30mg IV dose followed by subsequent 
subcutaneous dose (the maximum subcutaneous dose of enoxaparin remains 100mg). The 
intravenous dose of enoxaparin can be simply administered by decanting all of a 100mg 
dose of enoxaparin into a 10ml syringe and then diluting with water for injection to a total 
volume of 10mls thereby providing 10mg enoxaparin per ml. A multiple use vial of 
enoxaparin for IV administration is also available. 
6.2.6 Steroids and antihistamines 
The routine administration of steroids and antihistamines to prevent 
hypotension/bradycardia especially in association with Streptokinase complicates the 
administration process and is unlikely to prevent hypotension as the cause of Streptokinase 
induced  hypotension is primarily due to speed of administration (Lew et al., 1985; Tatu-
Chiţoiu et al., 2004) and the action of bradykinin activated by Streptokinase (Hoffmeister et 
al., 1998).  
Tatu-Chiţoiu et al (2004) noted that the incidences of hypotension occurred in nearly half of 
all patients treated with Streptokinase but it did not adversely affect patient outcome 
whereas the prophylactic use if steroids is linked with an increased risk of myocardial 
rupture (Mannisi et al., 1987) and is not recommended by the leading international 
cardiology societies (Van de Werf et al., 2008). 
7. Support systems 
Studies have clearly demonstrated that thrombolytic therapy can be safely administered in 
the prehospital environment by doctors, paramedics and nurses. The most effective system 
will depend on population demographics, geographical factors, the structure and financial 
resources of the emergency medical services. Regardless of who undertakes thrombolysis, 
the personnel need to be capable of rapid diagnosis, early risk stratification, minimal 
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treatment delay and rapid administration of a thrombolytic agent. EMS systems vary 
throughout the world. In 75% of Europe thrombolysis is undertaken by emergency 
physicians while in many other settings like United Kingdom, Australia and United States 
of America, it is undertaken by paramedics. In most countries, the use of non-doctors in the 
prehospital environment seems to be the most practical and cost effective option. 
The practice of paramedic thrombolysis may be undertaken independently or under direct 
supervision depending on the local emergency medical system. A system of consultation 
and 12-lead ECG transmission with CCU nurses/a senior paramedic/specialist clinician 
experienced in STEMI management is highly recommended at the initial implementation of 
thrombolysis and for on-going clinical support in difficult cases (Liem et al., 2007; McLean et 
al., 2008). Furthermore, paramedics can also fast track acute STEMI patients to CCU by by-
passing the emergency department as well as by-passing local hospitals to deliver the 
patient to a hospital with an on-site catheter laboratory for either rescue angioplasty or pre-
discharge angioplasty. These strategies have demonstrated reductions in door-to-balloon 
time and mortality (Afolabi et al., 2007; Bång et al., 2008; Le May et al., 2006).  
The transmission of 12-lead ECG may be challenging and is dependent of the use of cellular 
technology which may result in the inability to transmit the ECG due to poor coverage or 
drop zones. The transmission of the ECG may involve the pairing of cellular phones and 
ECG machines therefore will need to be tested and practiced to prevent user error. 
8. Quality assurance 
An on-going continuous professional development programme which incorporates quality 
improvement measures obtained by on-going monitoring of prehospital thrombolysis via 
clinical audit and feedback should be mandatory for continued safe prehospital 
thrombolysis and staff development. A clinical review team incorporating all role players 
would need to meet regularly to appraise all cases of prehospital thrombolysis. In settings 
where the frequency of the performance of thrombolysis is low, an on-going programme of 
refresher training is essential to maintain skill competence. External surveillance registries 
like MINAP and the Swiss registries provide valuable information on trends in management 
of acute STEMI and should be used to guide treatment timeframes and clinical outcomes.  
9. Other uses for prehospital thrombolysis 
Prehospital thrombolysis is primarily aimed at the treatment of patients with symptoms and 
ECG diagnosis of STEMI. Although this will remain the mainstay of the use of thrombolytic 
therapy, thrombolysis is also used in the treatment of other clinical emergencies. 
9.1 Stroke 
Although stroke thrombolysis is not suitable for initiation in the community due to the need 
for a CT scan and in a small subset of patients an MRI, the early identification of patients 
with a possible stroke is vital. This has required a change in emphasis within emergency 
departments and ambulance services where an acute stroke has now been identified as a 
time-sensitive clinical emergency. The UK has just completed a mass TV awareness 
campaign for the recognition of stroke, building on the brain attack model developed in 
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America. Prehospital clinicians are, therefore, pivotal in the early identification of suspected 
stroke patients typically using the Fast, Arm, Speech, Test (FAST) supported by pre-arrival 
alerts to hospitals equipped to deliver stroke thrombolysis (with 3-4 hours of onset of 
symptoms). 
9.2 Cardiopulmonary resuscitation (CPR) 
The use of thrombolysis during resuscitation is also a potential treatment option but the 
routine administration of thrombolysis during cardiac arrest management is not endorsed 
(Class III recommendation). However, its use to treat a confirmed or suspected massive 
pulmonary embolism or STEMI should be considered on a case-per-case bases (Class IIa 
recommendation) (Neumar, 2010). Confirmation of diagnosis remains challenging but is 
primarily based on clinical history supported by clinical suspicion although the use of 
bedside ECHO for the diagnosis of massive pulmonary embolism is worth consideration 
(typically to look at the right ventricle) but the expertise for this is limited in the prehospital 
environment. 
Following the administration of thrombolytic therapy, during CPR, the period of 
resuscitation should be extended to a minimum of 60 minutes (Neumar, 2010) and this 
protracted period of resuscitation is an important consideration when initiating 
thrombolytic therapy. The administration of thrombolysis during resuscitation does not 
replace the need for effective compressions and supportive ventilation but represents a 
targeted treatment for a small subset of patients. 
10. Conclusion 
Prehospital thrombolysis offers two unique clinical pathways for the patient presenting with 
STEMI. Prehospital thrombolysis can be the preferred reperfusion strategy in developing 
countries or countries without rapid access to primary angioplasty facilities or can provide 
ultra-early reperfusion as part of a hybrid reperfusion service. Key to the success of any 
prehospital service is the recruitment and training of appropriately qualified personnel 
although in remote areas the use of telemedicine and electronic data transmission can 
support the administration of thrombolysis by junior clinicians. Although thrombolysis 
offers significant patient benefits, it needs to be appropriately delivered and supported by 
adjunctive therapy which should include dual anti-platelet therapy for all patients 
supported by heparin (ideally LMWH) as appropriate.  
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1. Introduction 
Worldwide around 7 million people suffer myocardial infarctions per year according to 
White et al. (2008). Around one third of these patients having acute myocardial infarction 
die within the first hour of having symptoms usually due to fatal arrhythmia. 
Characteristic ST segment elevation in the 12 lead electrocardiogram (ECG) accompanied 
by clinical symptoms of chest pain provide the most rapid way to diagnose those patients 
who should receive thrombolysis to help dissolve thrombus and restore blood flow. In 
fact, since the early 1980s, thombolysis has been the cornerstone of treatment for patients 
having ST segment elevation myocardial infarctions (STEMI) by improving outcomes and 
preserving left ventricular function. There are in fact many large randomised clinical trials 
which support early thrombolysis and these can be found in the Fibrinolytic Therapy 
Trialists’ (FTT) Collaborative Group publication from 1994. This document reinforces the 
importance of early reperfusion with 30 lives per 10000 being saved by thrombolysis 
given within 6 hours of presentation and 20 lives per 1000 saved if initiation is between 6 
and 12 hours.  
2. Pathophysiology of myocardial infarction  
Acute myocardial infarction which is commonly known as a heart attack is the interruption 
of blood supply and therefore oxygen to heart muscle thereby potentially causing cell death 
or necrosis. This is usually due to the occlusion of the coronary artery lumen by clot called 
thrombus. This thrombus is formed by the rupture of unstable arteriosclerotic plaque which 
consists of white blood cells (mainly macrophages) which engulf lipids to form foam cells 
covered with a fibrous cap in the arterial wall. The plaque can rupture as a result of many 
factors including the mechanical shear stress from blood flow and flexion and tension of the 
fibrous causing it to be injured and thinned. Rupture exposes adhesion molecules in the sub-
endothelium which form thrombus when exposed to flowing blood. This allows primary 
haemostasis to occur, resulting in platelet adhesion, platelet activation and aggregation 
forming thrombus. Thrombolytic drugs break down this thrombus thereby restoring blood 
flow and preventing further damage to myocardium. It is therefore obvious to see that the 
sooner myocardial infarction is diagnosed and the earlier thrombolysis can be given the 
greater the myocardial salvage. 
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3. Clinical indications 
The indications for thrombolysis in myocardial infarction rely on eliciting a history of 
typical clinical symptoms (mainly but not exclusively chest pain) and diagnosing 
characteristic changes in the 12-lead electrocardiogram (ECG) which is a non-invasive 
means of recording the electrical activity of the heart over seconds using transthoracic 
electrodes. The prompt recognition of the characteristic symptoms and ECG changes are 
required to institute rapid reperfusion therapy through thrombolysis. 
The main clinical symptom of acute myocardial infarction is central or left-sided chest pain 
which can be described as dull, squeezing or tightness. This is called angina pectoris. The 
pain most commonly radiates to the left arm but can radiate to the neck, jaw, epigastrium, 
back and the right side of the chest. The management of myocardial infarction also requires 
prompt relief of the ischaemic pain with oxygen, opiates and sublingual or intravenous 
nitrates which act through vasodilatation. Other symptoms are shortness of breath from left 
ventricular dysfunction and resultant pulmonary oedema due to myocardial ischaemia. The 
remaining symptoms are due to surges of catecholamines from sympathetic overdrive such 
as palpitations, nausea, vomiting, light-headedness, weakness, anxiety and excessive 
sweating termed diaphoresis. Loss of consciousness may also occur and is usually due to 
arrhythmia as a consequence of ischaemia or cerebral hypoperfusion due to poor left 
ventricular output and cardiogenic shock. Notably women tend to report more atypical 
symptoms and so when making a diagnosis clinicians should bare this in mind. To 
complicate matters further around one quarter of patients suffering an acute myocardial 
infarction do not have any symptoms at all. These ‘silent’ myocardial infarctions most 
commonly occur in the elderly and diabetic patients. This can cause problems when 
selecting out patients that are suitable for thrombolysis as the clinician would have to rely 
on the ECG criterion and any other relevant history that is available at that time.  
Other scenarios where a history may be difficult to obtain are patients that are acutely 
breathless from pulmonary oedema or those that have been successfully resuscitated or are 
being resuscitated from cardiac arrest. In these situations if the ECG shows characteristic 
changes and the bleeding risk from chest compressions is felt to be low then an experienced 
clinician can make the decision to proceed with thrombolysis. In cardiac arrests with 
refractory ventricular fibrillation and a prior history of chest pain or ischaemic heart disease 
then also in these cases a decision may be taken to give thrombolysis.  
4. Electrocardiogram criterion 
The ECG criterion for thrombolysis are well validated and need to be met before initiation of 
therapy. As mentioned earlier the ECG is a recording of electrical activity as it spreads 
through the heart muscle. The ECG can be daunting in its interpretation  and in itself a 
massive topic but here we focus specifically on the parts of the ECG that are relevant for 
diagnosing acute myocardial infarction suitable  for thrombolysis. 
Ventricular depolarisation and contraction are represented on the ECG by a waveform 
termed the QRS complex which is later followed by a smaller deflection termed the T wave 
which constitutes ventricular repolarisation and relaxation. In fact, repolarisation begins 
with the ST segment which connects the QRS complex to the T wave. The beginning of the 
ST segment is termed the J point.  
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Fig. 1. An electrocardiogram showing ST elevation in leads III and AVF. 
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The criterion for thrombolysis refer to the QRS complex and ST segments and are as follows: 
1. 1mm of ST segment elevation from the J point in at least 2 contiguous limb leads (I, 
II,III, AVF and AVL) 
2. 2mm of ST segment elevation from the J point in at least 2 contiguous chest leads (any 
two of V1 to V6) 
New onset left bundle branch block. This is recognised as characteristic deflections of the 
QRS complex and an increased width of greater than 120 milliseconds which is 3 small 
squares on the ECG when the recording speed is set to the usual 25mm/second. 
The various limb leads and chest leads pick up electrical signals by literally overlying and 
'pointing' towards various parts of the heart. Therefore   ECG changes in certain leads 
represent ischaemia affecting certain territories or areas of heart muscle. ECG changes in 
leads I and AVR represent ischaemia in the anterior wall of the left ventricle while II, III, and 
aVF represent the inferior aspect of the heart. The V leads or chest leads show if the anterior-
septal area is affected (V1-V4) and the late V leads signify infarction of the lateral wall of the 
ventricle. Leads I and AVL also represent the lateral territory of the heart. The criterion 
requires that these changes are in at least two contiguous leads because this is more likely to 
represent a significant area or 'territory' of myocardium. ST segment changes in a single lead 
are more likely to be due to other causes the most likely being normal variant due to an 
earlier repolarisation of the myocardium. Clinicians also need to bear in mind alternative 
diagnoses which could present with ST elevation by ECG. Acute pericarditis, which is a 
usually benign condition of pericardial inflammation, can present with ST elevation but 
typically the ST segment has a saddle-shaped appearance. The clinical symptoms may also 
mimic myocardial infarction but the classical description is of pain is different in that it is 
sharp and stabbing which varies with respiration and is also positional. Clinically the 
patient may also have an audible rub on auscultation using a stethoscope. This is a scratchy 
noise caused by the inflamed layers of pericardium rubbing against each other. The other 
condition in which ST elevation may be present is when the patient has an outpouching of 
the left ventricle termed an aneurysm. Again the ECG can have a more characteristic 
Clinicians should keep the possibility of these alternative diagnoses at the forefront of their 
minds to avoid misdiagnosis and therefore inappropriate administration of thrombolysis. 
Other ECG changes that accompany ST elevation may also be present and aid the diagnosis 
of acute ST elevation myocardial infarction. The T waves may become hyperacute and lose 
their normal concavity. There may also be the presence of a pathological Q wave at the start 
of the QRS complex which is represented by a negative deflection of at least 1 small square 
on the ECG (40 milliseconds). This is said to represent infarcted non-viable myocardium. 
The other common abnormality which can accompany ST elevation is ST depression in 
reciprocal leads. Essentially, this means that leads looking at the opposite aspect of the heart 
show a mirror image of the leads showing ST elevation. 
5. Contraindications for thrombolysis 
Contraindications to thrombolysis in myocardial infarction can be separated into absolute 
and relative ones. Absolute contraindications are suspected dissecting aortic aneurysm, 
ischaemic stroke within 3 months (except if acute and within 3 hours of symptom onset 
when it is a treatment), intracranial neoplasm or arterio-venous malformation, active 
 
Novel Strategies in Ischemic Heart Disease 
 
126 
The criterion for thrombolysis refer to the QRS complex and ST segments and are as follows: 
1. 1mm of ST segment elevation from the J point in at least 2 contiguous limb leads (I, 
II,III, AVF and AVL) 
2. 2mm of ST segment elevation from the J point in at least 2 contiguous chest leads (any 
two of V1 to V6) 
New onset left bundle branch block. This is recognised as characteristic deflections of the 
QRS complex and an increased width of greater than 120 milliseconds which is 3 small 
squares on the ECG when the recording speed is set to the usual 25mm/second. 
The various limb leads and chest leads pick up electrical signals by literally overlying and 
'pointing' towards various parts of the heart. Therefore   ECG changes in certain leads 
represent ischaemia affecting certain territories or areas of heart muscle. ECG changes in 
leads I and AVR represent ischaemia in the anterior wall of the left ventricle while II, III, and 
aVF represent the inferior aspect of the heart. The V leads or chest leads show if the anterior-
septal area is affected (V1-V4) and the late V leads signify infarction of the lateral wall of the 
ventricle. Leads I and AVL also represent the lateral territory of the heart. The criterion 
requires that these changes are in at least two contiguous leads because this is more likely to 
represent a significant area or 'territory' of myocardium. ST segment changes in a single lead 
are more likely to be due to other causes the most likely being normal variant due to an 
earlier repolarisation of the myocardium. Clinicians also need to bear in mind alternative 
diagnoses which could present with ST elevation by ECG. Acute pericarditis, which is a 
usually benign condition of pericardial inflammation, can present with ST elevation but 
typically the ST segment has a saddle-shaped appearance. The clinical symptoms may also 
mimic myocardial infarction but the classical description is of pain is different in that it is 
sharp and stabbing which varies with respiration and is also positional. Clinically the 
patient may also have an audible rub on auscultation using a stethoscope. This is a scratchy 
noise caused by the inflamed layers of pericardium rubbing against each other. The other 
condition in which ST elevation may be present is when the patient has an outpouching of 
the left ventricle termed an aneurysm. Again the ECG can have a more characteristic 
Clinicians should keep the possibility of these alternative diagnoses at the forefront of their 
minds to avoid misdiagnosis and therefore inappropriate administration of thrombolysis. 
Other ECG changes that accompany ST elevation may also be present and aid the diagnosis 
of acute ST elevation myocardial infarction. The T waves may become hyperacute and lose 
their normal concavity. There may also be the presence of a pathological Q wave at the start 
of the QRS complex which is represented by a negative deflection of at least 1 small square 
on the ECG (40 milliseconds). This is said to represent infarcted non-viable myocardium. 
The other common abnormality which can accompany ST elevation is ST depression in 
reciprocal leads. Essentially, this means that leads looking at the opposite aspect of the heart 
show a mirror image of the leads showing ST elevation. 
5. Contraindications for thrombolysis 
Contraindications to thrombolysis in myocardial infarction can be separated into absolute 
and relative ones. Absolute contraindications are suspected dissecting aortic aneurysm, 
ischaemic stroke within 3 months (except if acute and within 3 hours of symptom onset 
when it is a treatment), intracranial neoplasm or arterio-venous malformation, active 
 
Thrombolysis in Myocardial Infarction 
 
127 
bleeding diathesis, uncontrolled hypertension (systolic>180mmHg or diastolic >100mmHg), 
significant closed-head trauma or facial trauma within 3 months.  
Rigorous cardiopulmonary resuscitation or compressions of greater than 10 minutes 
duration is a relative contraindication to thrombolysis. Other scenarios which require 
precaution include active peptic ulceration, therapeutic anticoagulation with warfarin 
therapy, active menstruation, pregnancy, recent streptococcal infection of less than five 
days, controlled severe hypertension, haemorrhagic or diabetic retinopathy and invasive or 
surgical procedure in the preceding three weeks.  
6. Evidence base for thrombolysis and alternative strategies 
Initially, streptokinase infusion produced conflicting results until the (GISSI) trial in 1986, 
which validated streptokinase as an effective therapy and established a fixed regime for its 
use in acute myocardial infarction. As mentioned earlier the evidence supporting 
thrombolysis as opposed to not giving thrombolysis is outlined in the Fibrinolytic Therapy 
Trialists’ (FTT) Collaborative Group publication from 1994. This combined the data from 9 
trials and included a total of 58,600 patients. Here, the obvious survival advantage of 
thrombolysis in ST segment elevation in myocardial infarction and left bundle branch block 
was established. However, excess deaths were noted in the elderly and those thrombolysed 
after 12 hours of symptom onset.  Most notably, it was clearly seen that the earlier 
thrombolysis was given the greater the benefit. The reason being that the earlier reperfusion 
is achieved the smaller the infarct size and the greater the myocardial salvage, which in turn 
has a significant impact on morbidity and mortality. This has led to targets for thrombolysis 
to be initiated within 20 to 30 minutes of arrival at hospital (‘‘door to needle’’ time) and 
within 60 minutes of calling for help (‘‘call to needle’’ time) across the UK and in Europe.  
Primary percutaneous coronary intervention (PPCI) has evolved as an alternative 
emergency treatment for patients with STEMI. This is an invasive keyhole procedure which 
involves the passing of thin catheters from the femoral or radial arteries in to the aorta and 
then in to the openings of the coronary arteries to act as a conduit for various specialized 
equipment that can be used to treat the acute thrombus. The equipment used for this 
purpose are primarily clot extraction catheters termed extraction catheters, inflatable 
balloons and metal stents which act as a scaffold for keeping the arteries open.  Although 
the number of patients receiving this treatment is steadily increasing because of the 
potential benefits, not all hospitals have the facilities to provide this therapy and so most 
patients in Europe still receive thrombolysis as initial management.  
Once thrombolysis was established as a mode of treatment it was initially given in hospital 
by clinicians but with the extensive data that early thrombolysis yielded better outcomes 
there was a move towards pre-hospital thrombolysis (PHT). This involved emergency 
services giving thrombolysis at the scene on arrival to the patient.  
Meta-analyses of RCTs show that PHT is superior to in-hospital thrombolysis (IHT) as it 
saves on average 30 minutes to 1 hour from the time between calling for medical help and 
initiation of thrombolysis. The time benefit is even more apparent where ambulance 
transport times are long. For this reason IHT is only reserved for those places that that do 
not offer PHT or PPCI. When PPCI is not available or offered around the clock then PHT 
becomes the treatment modality of choice to ensure the maximal myocardial salvage. 
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Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction 
(CAPTIM) compared PHT directly against PPCI.  This showed that if thrombolysis was 
administered within 2 hours of symptom onset mortality data at 30 days strongly favoured 
this treatment over PPCI. However, after 2 hours the trend of outcomes reversed and PPCI 
became the treatment of choice. This was mirrored in the PRAGUE-2 trial which showed the 
benefits of IHT up to 3 hours.  
In contrast to this the Primary Coronary Angioplasty vs. Thrombolysis (PCAT)-2 Trialists 
Collaborative Group meta-analysis looked at IHT versus an invasive strategy and showed 
that PPCI was superior to thrombolysis with lower mortality rates and risk of re-infarction. 
In the USA, guidelines favour the data on PHT over PPCI but also focus on the time factor 
with regards to reperfusion. They recommend that PHT should be given within 30 minutes 
after the arrival of emergency services at the scene and if this is not available and the patient 
is transferred to a hospital without PPCI facility then IHT should be given within 30 minutes 
of arrival at the centre (this is termed to door-to-needle time). If PPCI is offered in the 
hospital then actual disruption of the acute thrombus in the coronary artery should take 
place within 90 minutes (termed door-to-balloon time).  European guidelines differ in that 
they prefer PPCI as the primary mode for reperfusion but with the several caveats. They 
stipulate that the procedure should be performed by a skilled operator in a high volume 
centre (operator performing more than 75 PCIs a year and the centre performing more than 
200 PCIs) within 120 minutes of the first medical contact or within 90 minutes in patients 
receiving medical help within 2 hours from the onset of symptoms. If PPCI is not available 
then thrombolysis should be given within 3 hours of symptom onset with preference given 
to PHT over IHT. 
7. Rescue PCI, routine PCI and facilitated PCI 
When thrombolysis fails then rescue PCI should be considered. In the REACT trial patients 
that had not been successfully treated by thrombolysis after 90 minutes from initiating 
therapy (signified by less than 50% resolution of ST segment resolution by ECG) were 
randomized between conservative management, repeat thrombolysis and rescue PCI. This 
trial showed a clear benefit of the latter in all outcome data including 6 month mortality. 
Rescue PCI should therefore be offered to all patients within 12 hours of symptom onset. 
This may therefore involve patient transfer to a centre that offers a PCI service if not 
available at the hospital where the patient was thrombolysed or where they were taken after 
PHT. The exact definition of failed thrombolysis is controversial but the absence of chest 
pain is considered as misleading as opiates, analgesics and vasodilators may contribute to 
this. Generally accepted markers are taken as ST segment resolution of less than 50-70% and 
the time taken to assess whether thrombolysis has taken effect is between 45 and 90 minutes. 
All patients should receive PCI subsequent to this, ideally within a period of 24 hours, but a 
benefit is even seen up to 30 days as evidenced by the CAPTIM trial. GRACIA-1, CARESS-
in-AMI and the WEST trials all looked at PCI within a quicker time frame after thrombolysis 
and the overall results showed that this was comparable to PPCI outcomes when the post-
thrombolysis PCI was performed within 24 hours. The very recent TRANSFER-AMI trial 
reinforced the benefits of a pharmaco-invasive strategy which compared PCI at 6 hours after 
thrombolysis with ‘standard treatment’ which involved thrombolysis with delayed 
angiography and PCI (after 24 hours). There was a statistically significant reduction in the 
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primary endpoint of combined incidence of death, reinfarction, recurrent ischemia, new or 
worsening heart failure, or cardiogenic shock at 30 days for the pharmaco-invasive strategy 
(11% in the pharmaco-invasive arm vs. 17.2% in the standard treatment arm). There was 
also less recurrent ischaemia (0.2% vs. 2.1%) and reinfarction (3.4% vs. 5.7%) in the 
pharmaco-invasive strategy and fewer congestive heart failure (3.0% vs. 5.6%). On the other 
hand, there were more deaths and more patients experiencing cardiogenic shock in the 
pharmaco-invasive arm but these differences were not statistically significant. There were 
significantly more minor bleeding episodes in the combined strategy arm when compared 
to standard treatment but there was no difference in major bleeding.  It is important to note 
that this pharmaco-invasive strategy is very different to thrombolysis followed by immediate 
PCI. This is called facilitated PCI and in fact has failed to shows clinical benefit and may in 
fact be harmful. The reason for this being that if PCI is performed too early then the 
thrombolytic administered is still active causing increased bleeding risk as well as resulting 
in more acute stent thrombosis (the potentially catastrophic blocking of a stent by thrombus 
within 24 hours of it being deployed) which is caused by the increased platelet activation 
and aggregation which accompanies thrombolytics. 
The ideal setting for PHT in the USA involves an experienced physician being available to 
interpret the ECG by either being part of the Emergency Medical service team on the 
ambulance or being available to review a copy of a transmitted ECG. This has proved harder 
to achieve in Europe where more frequently, trained paramedics decide on whether the 
ECG meets criterion. Some UK studies have shown that this is safe and sometimes even 
better than the physician-assisted model due technological issues when transmitting the 
ECG or failure of mobile phones when trying to communicate to doctors from remote areas. 
However, in contrast a study in Finland has shown that having physicians on site for PHT is 
superior to paramedics alone. A checklist of contraindications should also be gone through 
prior to administration to ensure that the patient is not placed at increased risk of 
catastrophic bleeding. Therefore, this can also be used as a means of identifying those 
patients that are more suitable for PPCI. 
8. Adjunctive therapies for thrombolysis 
Aspirin is well established as an adjunctive therapy to thrombolysis and it is recommended 
that 150 to 325mg of chewable aspirin be given to the patient with thrombolysis. 
Clopidogrel is an oral, thienopyridine class antiplatelet agent which when given at a dose of 
300 mg also provides prognostic benefit. The COMMIT-CCS-2 and CLARITY-TIMI 28 trials 
provided this evidence for adding clopidogrel to aspirin in patients undergoing fibrinolytic 
therapy. 
It is recommended that unfractionated heparin, an intravenous anticoagulant is given 
intravenously with all of the thrombolytics to enhance clot dissolution and decrease the risk 
of re-occlusion. In vitro studies and animal models show discordant results regarding 
concomitant administration of heparin with thrombolysis suggesting that it may enhance, 
inhibit or have no effect. Hsia J et al.(1990) have shown that thrombolysis achieves faster 
lysis with greater vessel patency in combination with heparin (between 7 and 24 hours a 
patent vessel was found in 88% of those receiveing thrombolysis with heparin and aspirin 
vs. 52% in those treated with thrombolysis and aspirin alone). Unfortunately this does not 
translate into clinical outcome with a meta-analysis of the six trials by Muhaffey KW et al. 
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(1996) showing that there were similar rates of mortality and re-infarction before discharge. 
Despite this the general consensus from expert opinion is that heparin is beneficial in 
preventing re-occlusion and that it should be given as a bolus with all thrombolytics other 
than Streptokinase and then be given as a continuous IV infusion. With the advent of low 
molecular weight heparins (LMWHs) which only need once or twice daily subcutaneous 
administration without regular blood monitoring the continuous IV infusion of 
unfractionated heparin has been superseded by these newer anticoagulants. In fact there is 
evidence that the LMWH, Enoxaparin, appears superior to UFH in the EXTRACT-TIMI 25 
trial when given during thrombolysis. In fact, patients under the age of 75 years can be 
given a 30 mg intravenous bolus followed by the subcutaneous dose every 12 hours. In 
practice this intravenous preparation LMWH is less widely available and UFH is more 
commonly given. 
9. Thrombolytics used in clinical practice 
9.1 Streptokinase 
This was the first thrombolytic used in the treatment of STEMI and remains the cheapest 
and most commonly used. Two large trials were pivotal in demonstrating the efficacy of 
Streptokinase as a thrombolytic in myocardial infarction which reduces mortality when 
compared against placebo. The first of these was the GISSI trial mentioned earlier, published 
in 1986 and included 11,712 patients. This trial showed that at 21 days the mortality for 
patients treated with Streptokinase was 10.7% vs 13% for the placebo group which 
represented a statistically significant absolute reduction of 2.3% (risk ratio 0.81; 95% 
confidence ratio [CI] 0.72 to 0.9). The second trial, ISIS-2 trial included 17,187 patients and 
was published 2 years after GISSI in 1988. In this study, vascular mortality at 5 weeks was 
9.2% in the streptokinase group and 12% in those treated with placebo which represented a 
statistically significant absolute reduction of 2.8%. Streptokinase is administered as an IV 
infusion over 1 hour. Streptokinase has a few side-effects which are namely low blood 
pressure termed hypotension, infrequent allergic reactions and sometimes although not 
commonly, anaphylaxis. Patients treated with streptokinase develop anti-streptococcal 
antibodies, which is why patients should only ever receive this drug once in a lifetime. 
9.2 Alteplase 
A meta-analysis of eight trials which compared alteplase with streptokinase found that there 
was no significant difference between the two drugs in terms of mortality up to 35 days. 
However, re-infarction rates were found to be in favour of alteplase but this was offset by a 
doubling in the risk of haemorrhagic stroke (odds ratio 2.13; 95% CI 1.04 to 4.36). In contrast 
to this, streptokinase was associated with a statistically significant higher risk of major 
bleeds than alteplase. However, the definitions of major bleeding varied between the trials 
and so it is difficult to judge the clinical significance of these findings.  
9.3 Alteplase 
Alteplase which is also known as recombinant human tissue plasminogen activator or rtPA 
can be delivered in a standard or accelerated regimen. The accelerated regimen, which is 
much more commonly used especially in PHT because of its ease of administration as it is 
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delivered by an initial IV bolus injection. This is followed by only two IV infusions at 30 
minutes and 60 minutes. The GUSTO-I trial was the only study in the meta-analysis 
mentioned above which looked at the more commonly used accelerated regimen rather than 
the standard regimen. This trial which included over 40000 patients was also the only trial to 
demonstrate superiority over different thrombolytics with an absolute reduction in 
mortality at 30 days of 1.0% (6.3% versus 7.3%; 95% CI 0.4% to 1.6%) in favour of accelerated 
alteplase when compared to streptokinase. However, this benefit was balanced by a 
statistically significantly higher incidence of haemorrhagic stroke (odds ratio 1.42; 95% CI 
1.05 to 1.91). Using a combined outcome measure of mortality and disabling stroke, there 
was in fact a statistically significant absolute advantage of streptokinase over alteplase of 
0.9%;p = 0.006). Interestingly, statistically significant rates of moderate bleeding or worse 
were lower in the alteplase group. Alteplase also fared better with regards to the common 
side effects experienced by streptokinase namely causing less allergic reactions, anaphylaxis, 
and sustained hypotension and these were also statistically significantly lower. Despite this 
a further meta-analysis of nine trials comparing standard alteplase with streptokinase, 
including the findings of GUSTO-I (i.e. accelerated alteplase), found no significant difference 
between the two drugs in terms of mortality up to 35 days (odds ratio 0.94; 95% CI 0.85 to 
1.04). 
9.4 Reteplase 
This is the third most commonly used thrombolytic and one of the easiest to administer as it 
only involves two IV boluses administered 30 minutes apart. The INJECT study involving 
nearly 6000 patients compared reteplase to streptokinase. This study found an absolute 
difference in 35 day mortality of 0.5% (95% CI –1.98% to 0.96%) in favour of reteplase but 
this was not deemed as statistically significant. Similarly to alteplase, when a combined 
outcome measure using overall effects on mortality and disabling stroke is applied to the 
trial data then reteplase may in fact be inferior to streptokinase, as the trial also found a 
statistically significantly lower risk of haemorrhagic stroke in the streptokinase group (odds 
ratio 2.1; 95% CI 1.02 to 4.31). However, the trial also found that the  in the reteplase group 
the rates of heart failure (23.6% vs 26.3%, p<0.05) and allergic reactions (1.1% vs 1.8%, 
p<0.05) were significantly lower. In one small study of 324 patients (RAPID-2), reteplase 
was compared to alteplase and this found that better vessel patency was achieved when 
coronary angiography was the endpoint. Subsequent to this the large GUSTO-III trial 
involving 15,059 was designed to test the clinical superiority of reteplase over accelerated 
alteplase. However, GUSTO-III found no statistically significant difference between the two 
drugs, in terms of survival or adverse effects but at 30 days mortality was 7.5% in the 
reteplase group and 7.2% in the accelerated alteplase group giving an absolute risk 
reduction of 0.23% in favour of accelerated alteplase (95% CI–1.10% to 0.66%). Therefore, 
reteplase cannot be considered as equivalent to accelerated alteplase. 
9.5 Tenectaplase 
This is the easiest of the thrombolytics to administer and only involves a single bolus. 
ASSENT-2 enrolled over 16,000 patients to compare tenecteplase and accelerated alteplase 
and found that 30-day mortality was the same in the tenecteplase group and the accelerated 
alteplase at 6.2% each, thereby showing equivalence in outcomes. In fact there was an 
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absolute difference of 0.03% in favour of accelerated alteplase but this was not statistically 
significant (95% CI -0.55% to 0.61%). However, there was a small but statistically significant 
reduction in the incidence of bleeding with tenecteplase of 26.4% compared with 28.9% in 
the accelerated alteplase group. This resulted in fewer blood transfusions in the tenecteplase 
group (4.3% of patients compared with 5.5% in the accelerated alteplase group.  
In summary, with regards to clinical effectiveness and mortality, standard alteplase and 
reteplase are as effective as streptokinase, and tenecteplase is as effective as accelerated 
alteplase.  According to GUSTO-I, accelerated alteplase is believed to be superior to 
streptokinase and if this is the case then indirectly tenecteplase would also be considered to 
be superior to streptokinase (as tenectaplase was superior to accelerated alteplase in 
ASSENT-2). In practice, cost and availability is a significant issue with regards to what is 
ultimately used and also use may also go unchanged for long periods purely because of a 
specific thrombolytic having historical use in a certain area.  
9.6 Other considerations 
In the elderly, evidence suggests that thrombolysis provides a mortality benefit but that 
there is increased risk of adverse events and poor outcomes in those with advancing age. 
The main risk in the older age group is of intracerebral haemorrhage and this is why a clear 
benefit is seen for PPCI in patients above the age of 75 and in fact the benefit is maintained 
even when there are longer door-to-balloon times. Low body weight has also been found to 
be independently associated with increased mortality and morbidity. With regards to sex, it 
is accepted that there is no difference with regards to efficacy but studies have shown that 
for unknown reasons women are less likely to receive any type of reperfusion (thrombolysis 
or PPCI) than men. Anterior infarcts also seem to show an increased benefit with 
thrombolysis over other territories but this may simply reflect the increased baseline risk in 
this group. Overall, when clinicians are deciding who would benefit from thrombolysis it 
appears that patient selection is key and benefits should be balanced against any potential 
risks. 
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1. Introduction 
Ischemic heart disease (IHD) remains the major cause of morbidity and mortality in 
developed countries, and has joined infectious diseases in developing countries as a leading 
cause of death (WHO 2008). Decades of research have shown conclusively that a number of 
determinants operating from early childhood onwards, most of them associated with 
lifestyle, are responsible for IHD. 
IHD results when the oxygen demand of the myocardium cannot be met due to an 
inadequate blood supply. The most common cause of myocardial ischemia is atherosclerosis 
of epicardial coronary arteries. The major risk factors for atherosclerosis, and therefore IHD, 
are dyslipidemia (i.e., elevated low-density lipoprotein (LDL) and/or low high-density 
lipoprotein (HDL)), diabetes mellitus, hypertension, cigarette smoking, poor dietary habits, 
and lack of physical activity. These risk factors, particularly when more than one co-exists, 
can progressively damage the vascular endothelium, causing dysregulation of its anti-
inflammatory and anti-thrombotic functions. The associated proliferation of underlying 
fibroblasts and vascular myocytes, together with the accumulation of extracellular matrix 
and lipids, result in the formation of what are known as atherosclerotic plaques that lead to 
a reduction in the luminal diameter. Some of the risk factors for atherosclerosis facilitate the 
development of atherosclerotic plaques, while others sustain or accelerate their formation, 
producing the clinical manifestations of IHD (Parthasarathy 2008, Garelnabi 2010). 
By reducing the lumen of blood vessels, atherosclerosis causes an absolute decrease in 
myocardial perfusion in the basal state and hinders the required increase in perfusion when 
the demand for flow is augmented. As this process progressively worsens, the shear stress 
associated with blood flow through the reduced arterial lumen can cause plaques to erode 
or rupture, exposing the intimal layer to the luminal contents and thereby promoting frank 
thrombosis. Platelet activation, mobilization, and recruitment are central to this process. 
Luminal thrombi can trap red blood cells and acutely reduce coronary blood flow, 
producing a sudden myocardial ischemic event referred to as an acute coronary syndrome 
(ACS) that becomes manifest as either unstable angina or myocardial infarction (MI) if there 
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is complete occlusion without prompt reperfusion. MI may also occur with embolization of 
platelet aggregates and/or atherosclerotic debris from a ruptured plaque. 
Coronary blood flow can also be limited by vascular spasm, as well as by congenital 
abnormalities, such as anomalous origin of the left anterior descending coronary artery from 
the pulmonary artery, which may cause myocardial ischemia and infarction in infancy, but 
is very rare in adults.  
Patients with IHD can be grouped into two broad categories: those having chronic coronary 
artery disease (CAD), who most commonly present with stable angina, and those who 
present with ACSs (i.e., unstable angina and MI). Chronic CAD is most commonly caused 
by slowly progressive coronary artery atherosclerosis, whereby a narrowing of the lumen of 
the coronary arteries limits their ability to adequately increase perfusion in response to an 
increase in demand for oxygen (e.g., during exertion). As the disease progresses in severity, 
perfusion of the myocardium can become compromised even at rest. ACSs, on the other 
hand, are the result of acute vasoocclusive events secondary to thrombosis at sites of erosion 
or rupture of atherosclerotic lesions. 
2. Role of platelets in the etiology and pathophysiology of IHD 
2.1 Structure of platelets 
Blood platelets play an essential role in hemostasis, thrombosis, and coagulation of blood. 
They are engaged in a complex repertoire of biochemical and molecular activities designed 
to prevent hemorrhage. 
On Wright-Giemsa-stained blood smears, platelets appear as small, anucleate, ovoid or 
round cells with a pale grayish blue cytoplasm that contains homogeneously distributed 
purple-red granules. After platelet spreading or aggregation, these dispersed granules 
become concentrated in the middle of the cell. 
When platelet morphology is considered under functional subdivisions rather than purely 
anatomic terms, there are three major structural zones of the platelet, each related to specific 
aspect of platelet function. The peripheral zone is involved primarily in adhesion, the solgel 
zone in contraction, and the organelle zone in secretion. 
The volumes of circulating platelets from a single individual are heterogeneous and exhibit 
a log normal size distribution. Circulating platelets have a volume of 7.06 ± 4.85 µm3 
(femtoliters), a diameter of 3.6  0.7 µm (Mean  SD), and a thickness of 0.9  0.3 µm (Paulus 
et al. 1979, Frojmovic et al. 1976). Platelet size varies from one individual to another, 
although abnormally small or large platelets are present only in certain disease states. By 
scanning electron microscopy, circulating blood platelets appear as flat discs, with smooth 
contours and rare spiny filopodia, with random openings of a channel system, which 
invaginates throughout the platelet and is the conduit by which granule contents exocytose 
after stimulation. Although the platelet is anucleate, transmission electron microscopy 
reveals a cytoplasm packed with a number of different organelles essential to maintenance 
of normal hemostasis. Platelets contain four distinct populations of granules: -granules, 
dense bodies, lysosomes, and microperoxisomes. -granules and dense bodies are 
distinguished morphologically from one another by their electron density as revealed by 
electron microscopy. 
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Phospholipids constitute 80% of the total lipid content of platelets, although smaller 
amounts of neutral lipids and glycolipids are also present. Evidence suggests that these 
phospholipids move to the outer membrane leaflet after platelet activation, thereby 
functioning to promote clot formation. Platelet membrane glycoproteins mediate a wide 
number of adhesive cellular interactions. These glycoproteins function as receptors that can 
receive signals from outside the platelet, facilitating cell-cell interactions; binding of specific 
ligands to these receptors results in distinct platelet responses to the external environment. 
Several other proteins are unique to the platelet, including platelet factor 4 (PF4), low-
affinity PF4, -thromboglobulin (-TG), and the calcium-binding proteins thrombospondin, 
calmodulin, and platelet-derived growth factor (PDGF) (Stenberg et al. 1984).  
2.2 Function and biochemistry of platelets 
In terms of dry weight, platelets are composed of approximately 60% protein, 15% lipid, and 
8% carbohydrate. Platelet minerals include magnesium, calcium, potassium, and zinc. 
Platelets contain substantial amounts of vitamin B12, folic acid, and ascorbic acid (Weiss et 
al. 1968). The concentration of sodium and potassium within the platelet are 39 and 138 
mEq, respectively, a gradient against plasma that is maintained by active ion pumping, 
which derives energy from membrane adenosine triphosphatase of the Ouabain-sensitive, 
Na+/K+-dependent type. Potassium apparently is distributed in two discrete metabolic 
compartments (Cooley and Cohen 1967). 
Non-stimulated platelets maintain a low cytoplasmic Ca2+ concentration, by limiting Ca2+ 
transport from plasma and promoting active efflux of this ion from the cell. Two pools of 
calcium are present in platelets: a rapidly-turning over cytosolic pool that is regulated by 
sodium-calcium antiporter in the plasma membrane, and a more slowly-exchanging pool 
that is regulated by a calcium-magnesium-ATPase and is sequestered in a dense tubular 
system. Platelets are therefore able to transport calcium from the cytosol by moving it 
against a gradient into the extracellular space or by sequestration in the dense tubular 
system (Brass 1984, Enouf et al. 1987). 
There are several similarities between the energy metabolism of platelets and that of skeletal 
muscle. Both involve active glycolysis and the synthesis and use of large amounts of 
glycogen, and in both, the major mediator of intracellular energy use is ATP. Platelets, like 
muscle cells, are metabolically adapted to expend large amounts of energy rapidly during 
aggregation, the release reaction, and clot retraction (Karpatkin et al. 1970). 
The presence of platelets in the hemostatic plugs that form to prevent bleeding suggests that 
platelets have a physiological role in hemostasis. Their presence in thrombi and emboli, 
however, suggests that they may have a pathological role as well. Platelets display certain 
properties that may be relevant to hemostasis and thrombosis. They have the capacity to 
adhere to foreign surfaces, they can be induced to aggregate, and they can synthesize or 
release a number of substances. 
Platelet adhesion 
The only structures with which platelets normally interact are red cells, white cells, and the 
endothelial lining of blood vessel walls. All other surfaces are thus foreign to them, but 
platelets have the ability to adhere to such surfaces. Platelets adhere to subendothelial 
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structures that are exposed when the normal endothelial lining of the blood vessel wall is 
injured, which causes the deposition of a monolayer of platelets on the surface of the injured 
vessel. This is followed by the release of pro-coagulation substances, leading to platelet 
aggregation and formation of a fibrin clot over the adhered layer that results in thrombus 
formation (Heptinstall and Hanley 1985). 
Platelet aggregation 
Platelets circulate as disc-shaped cells, but when they come in contact with exposed 
subendothelium, agonists that activate platelets are exposed, generated, or released. These 
agonists include collagen, which is present in subendothelium; thrombin, which is 
generated on the surface of activated platelets and elsewhere; ADP, which is released from 
damaged red blood cells and secreted from activated platelet-dense granules; circulating 
epinephrine; and arachidonic acid, which is released from lipid stores in platelets and 
metabolized to the potent agonist thromboxane A2 (TXA2). These agonists generally cause 
platelets to change shape such that they form long pseudopodia, followed by platelet 
aggregation. Aggregation requires activation of platelet integrin adhesion receptor GP 
IIb/IIIa so that it can bind fibrinogen or von Willebrand factor (vWF) and link adjacent 
platelets together in an aggregate. Platelet agonists induce signal transduction events in 
platelets that cause the above events, although the signal transduction pathways are not 
completely understood (Leslie et al. 1999). 
Platelet release reaction 
Platelets store ATP, ADP, Ca2+, and serotonin in dense granules as well as adhesive proteins 
such as platelet factor 4, -thromboglobulin, platelet-derived growth factor (PDGF), 
fibrinogen, fibronectin, thrombospondin, and vWF in -granules (Siess 1989). Upon 
activation by agonists, platelets undergo a release reaction, thereby secreting their granular 
contents. The release reaction is associated with the production of TXA2, and the extent of 
the secretion depends on the strength of the agonist. Weak agonists (e.g., ADP and 
epinephrine) require both cyclooxygenase activity and primary aggregation to induce 
secretion that is observed at low Ca2+ concentrations (Smith et al. 1973, Banga et al. 1986). 
Agonists of intermediate strength (e.g., platelet activating factor, PAF) can induce secretion 
in the absence of formation of arachidonic acid metabolism and without primary 
aggregation. Interestingly, when collagen is added at low concentrations to platelet 
suspensions, secretion of ATP occurs before the onset of shape change. This secretion is not 
inhibited by cyclooxygenase blockers, but is sensitive to the extracellular Ca2+ concentration 
and is a direct consequence of platelet binding to collagen (Siess et al. 1983, Malmgren 1986). 
Platelet activation 
Some signaling pathways involved in various platelet activation events are reasonably well 
understood, whereas others are not. Many, but not all platelet agonists activate platelets by 
occupying seven transmembrane-spanning, G protein-coupled receptors. Activation of these 
receptors generally results in activation of phospholipase C (PLC). PLC hydrolyzes 
phosphatidyl-inositol-4,5-bisphosphate (PIP2), generating inositol-1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG). Both IP3 and DAG appear to play important roles in pathways 
leading to various aspects of platelet activation. IP3 is believed to interact with specific 
receptors to induce intracellular Ca2+ release from the dense tubular system, an intracellular 
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Ca2+ storage organelle analogous to the sarcoplasmic reticulum in skeletal muscle. However, 
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(TXA2) production and ADP release (Knezevic et al. 1992). DAG interacts directly with 
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leading to the activation of GP IIb/IIIa and fibrinogen binding. Specific inhibitors of PKC 
block fibrinogen binding and platelet aggregation induced by some agonists. Drivers for 
platelet activation include the signaling events that occur downstream of receptors for 
collagen (GP VI and GP Ibα), thrombin (PAR1 and PAR4), adenosine diphosphate (ADP; 
P2Y1 and P2Y12), and thromboxane A2 (TXA2; TP) (Brass 2010). 
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agonists (Hourani and Cusack 1991). ADP causes shape change, granular secretion, and 
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Platelet receptors and MicroRNA signaling 
Platelet receptors are known to interact with external stimuli in the main blood stream 
leading to the regulation of platelet activation. Platelet adhesion receptors are the key 
initiators of platelet activation at sites of vascular injury, where platelets become exposed to 
adhesive proteins in the matrix, or on endothelial cells. Despite significant differences in 
their functions and signaling pathways, several major platelet adhesion receptors share 
many similarities in their signal transduction mechanisms (Li et al. 2010). The most studied 
platelet receptor is platelet integrin GP IIb/IIIa, which is reported to play an essential role in 
thrombus formation through interactions with adhesive ligands and has emerged as a 
primary target for the development of anti-thrombotic agents (Hagemeyer and Peter 2010). 
Successful blockade of this ligand binding has validated GP IIb/IIIa as a therapeutic target 
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MicroRNAs (MiRs) molecules are a novel class of endogenous, small, noncoding RNAs that 
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of their target messenger RNAs (Pan et al. 2010, O’Sullivan et al., 2011). Bioinformatics 
analysis predicts that each MiR can regulate hundreds of targets, suggesting that they play 
an essential role in almost every physiological and pathological pathway. Functionally, an 
individual MiR is important as a transcription factor because it is able to regulate the 
expression of its multiple target genes. MiRs are short (~20 nucleotides long), single-
stranded RNAs initially transcribed by either RNA polymerase II or RNA polymerase III, as 
a long primary MiR transcript (pre-MiR). It is then cleaved in the nucleus by the 
microprocessor complex, Drosha-DGCR8, resulting in a precursor hairpin (pre-miRNA) 
ranging in length from 60 to 110 nucleotides. The pre-MiRNA is exported from the nucleus 
to the cytoplasm by exportin 5-Ran-GTP. In the cytoplasm, Dicer, a member of the RNase III 
family, in complex with TRBP, cleaves the pre-MiR hairpin to a 22 base pair MiR duplex. 
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The mature MiR is incorporated with argonaute (Ago2) proteins into the RNA-induced 
silencing complex (RISC), where MiR guides the complex to partial complementary binding 
sites located in the 3’ untranslated region (UTR) of target mRNAs to suppress gene 
expression. MiRs are able to directly regulate at least 30% of genes in a cell. In addition, 
other genes may also be regulated indirectly by MiRs. Therefore, MiRs are pivotal regulators 
in normal development, physiology, and pathology. Recent studies have identified a 
number of MiRs highly expressed in the vasculature and their expression is dysregulated in 
diseased vessels (Jamaluddin et al. 2011, Haver et al. 2010, Bonauer et al. 2010, Wierda et al. 
2010, Urbich et al. 2008, Fang et al. 2010, Leeper et al. 2011). MiRs are also found to be critical 
modulators of cell differentiation, contraction, migration, proliferation, and apoptosis. 
Accordingly, MiRs have emerged as therapeutic targets in disease. 
Platelets are also reported to have microRNA population that may regulate its activity. It is 
well known that platelets have mRNA and mRNA splicing machinery, and translate mRNA 
into proteins relevant to hemostasis and inflammation (Edelstein and Bray 2011). In silicon 
analysis work from Edelstein and Bray indicates that each platelet MiR targets an average of 
307 distinct mRNAs, concluding in their review that platelet MiRs have ample opportunity 
to regulate platelet function. 
2.3 Role of inflammation and oxidative stress in platelet activation 
Involvement of inflammation in cardiovascular disease is well defined. Circulating platelets 
are affected by this metabolic disruption and by inflammatory mediators synthesized 
and/or released on contact with inflammatory signals. Platelets are known to play a major 
role in this process and have been identified as targets and players in inflammation-induced 
cardiovascular disease (Weksler 1983, Nurden 2011). It has been explicitly established that 
free radicals can cause metabolic disturbances and cell injury in a variety of ways, including 
lipid peroxidation, hydroxyl radical-induced modification of proteins and nucleic acids, 
changes in enzyme activity, and carbohydrate damage. Oxidative modification of lipids can 
be induced in vitro by a wide array of pro-oxidant agents and occurs in vivo during 
atherosclerosis and several other disease conditions (Parthasarathy et al. 2008). Alterations 
in the superoxide and glutathione oxidation-reduction system may lead to depleted 
antioxidant capacity and may result in oxidative stress. Previous studies have suggested 
that platelets and vascular endothelial cells could be the central target as well as the origin 
of oxygen free radicals or its metabolites (Dousset et al. 1983). Measuring the end products 
of lipid peroxidation is one of the most widely accepted assays for oxidative damage. These 
aldehydic secondary products of lipid peroxidation are generally accepted markers of 
oxidative stress. 
Several studies suggest that the basal release of NO by the endothelium contributes to 
regulation of the vascular tone (Antoniades et al. 2008), blood flow, and blood pressure. NO 
inhibits platelet aggregation and adhesion to vascular endothelium. In addition, NO inhibits 
leukocyte adhesion to endothelium (Petidis et al. 2008). Alteration of cellular calcium 
homeostasis is also a critical event in ischemic heart injury. NO released by endothelium or 
synthesized by platelets participates in the regulation of Ca2+ signaling. Elevation of cGMP 
as a result of the activation of guanylate cyclase by NO stimulates a number of mechanisms 
that actively decrease calcium levels within the cell (Joseph et al. 1996). Although the NO-
cGMP signaling system has been immensely investigated, sparse data is available pertaining 
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to the role of platelet NO activity in coronary artery (CAD). We and others have studied the 
NO-cGMP system in patients with CAD, particularly the role of oxidative stress and NO-
mediated platelet response in IHD (Garelnabi et al. 2010, Ikeda et al. 2000, Garelnabi et al. 
2011). These studies have clearly indicated that lipid peroxidation is augmented in patients 
with ischemic heart disease. The increased oxidative stress seen in these patients was 
accompanied by platelet activation and impaired antioxidant enzymes activity. On the other 
hand, platelet aggregation, NO, cGMP, NO synthase activity, plasma NO, and ionized Ca2+ 
was profoundly increased in CAD. The increases in NO-cGMP components may have 
resulted as a compensatory response to ameliorate platelet activity and increased Ca2+ levels 
in CAD patients. Another interesting modulator of platelet activity is the recent description 
of platelet-derived microparticles (PMP) which are known as a heterogeneous population of 
vesicles (<1 mm) generated from the plasma membrane upon platelet activation by various 
stimuli. These PMPs have been shown to not only stimulate the response of platelets, but 
have also been reported to mediate the intercellular transfer of bioactive molecules such as 
lipids, surface receptors, and even enzymes (Siljander 2010). 
3. Classes and mechanism of action of antiplatelet drugs 
The main goals of pharmacological intervention in patients with IHD are to reduce the 
occurrence of anginal attacks by minimizing the rise in blood pressure and heart rate 
associated with physical activity so that patients can go about their daily activities without 
ischemic episodes. Given the prominent role that thrombosis plays in IHD, antiplatelet 
therapy is one of the most important modalities used in its treatment. 
Antithrombotic drugs used for prevention and treatment of thrombosis include: (1) 
antiplatelet drugs, (2) anticoagulants, and (3) fibrinolytic agents. Given the predominance of 
platelets in arterial thrombi, which are the major source of IHD, the treatment and inhibition 
of arterial thrombosis focus mainly on antiplatelet agents, although anticoagulants and 
fibrinolytic drugs are often included in the acute setting. 
Under normal conditions, the actions of vascular endothelial cells maintain platelets in the 
bloodstream in an inactive state, largely by their production of nitric oxide (NO) and 
prostacyclin, but also by their surface expression of adenosine diphosphatase (ADPase), which 
breaks down ADP released via degranulation of activated platelets. With the occurrence of 
injury to the vascular endothelium, production of these substances is compromised and certain 
components of the subendothelial matrix are exposed (e.g., collagen, von Willebrand factor 
(vWF), and fibronectin) to which platelets adhere via receptors constitutively expressed on 
their surface (e.g., GP IIb/IIIa). As discussed above, adhered platelets undergo a 
morphological change and then release the contents of their dense granules (e.g., ADP) and 
synthesize and release thromboxane A2 (TXA2), both of which serve to recruit and activate 
surrounding circulating platelets to the site of vascular injury. 
Disruption of the vascular wall also exposes underlying cells and matrix that express pro-
thrombotic factors to the circulation, which triggers the coagulation cascade. Activated 
platelets enhance coagulation by binding clotting factors and supporting the assembly of 
activation complexes that increase thrombin generation, which in addition to converting 
fibrinogen to fibrin, also acts as a potent platelet agonist and recruits more platelets to the 
site of vascular injury. 
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The most abundant receptor on the surface of platelets is GP IIb/IIIa, which undergoes a 
conformational change upon platelet activation that allows it to bind fibrinogen. Divalent 
fibrinogen molecules link adjacent platelets together to form aggregates, which are meshed 
together via fibrin strands generated via the action of thrombin to form a lattice composed 
of platelets plus fibrin. Antiplatelet drugs target various steps in this process. The most 
commonly used drugs include cyclooxygenase inhibitors, among which aspirin is the most 
common, thienopyridines and functionally related drugs, phosphodiesterase inhibitors, 
adenosine reuptake inhibitors, and GP IIb/IIIa antagonists, all of which are discussed 
below. 
3.1 Cyclooxygenase inhibitors 
The cyclooxygenases (COXs) are a family of isoenzymes responsible for the biosynthesis of 
various important and potent pro-inflammatory and pro-thrombotic mediators called 
eicosanoids, which include prostaglandins, leukotrienes, and thromboxanes. Non-steroidal 
anti-inflammatory drugs (NSAIDs), like aspirin and ibuprofen, exert their effects through 
inhibition of COX, and as such they relieve the symptoms of inflammation (e.g., pain, 
swelling). 
COX converts arachidonic acid (AA, an ω-6 polyunsaturated fatty acid (PUFA)) to 
prostaglandin H2 (PGH2), the parent of the eicosanoids, which can then be converted to the 
other compounds via further enzymatic action that involves radical chemistry and the 
consumption of molecular oxygen. To date, three distinct COX isoenzymes have been 
identified: COX-1, COX-2, and COX-3. COX-1 and COX-3 are products of alternative 
splicing of the same gene, so COX-3 is referred to by some as COX-1b or COX-1 variant 
(COX-1v). Different tissues express varying levels of the different COXs, and although the 
isoenzymes basically catalyze the same transformations, selective inhibition can produce a 
different side-effect profile. COX-1 is nearly ubiquitous among mammalian cells, but COX-2 
is undetectable in most normal tissues and is inducible in macrophages upon their 
activation, as well in endothelial cells at sites of inflammation, where it serves to produce 
prostacyclin, a potent vasodilator and inhibitor of platelet aggregation. COX-2 is also 
upregulated in various types of cancers, so it is believed to play a role in oncogenesis. 
Both COX-1 and -2 also oxygenate two other essential fatty acids – dihomo-γ-linolenic acid 
(DGLA, ω-6) and eicosapentaenoic acid (EPA, ω-3) – to give eicosanoids with less potent 
pro-inflammatory properties than those derived from AA. Both DGLA and EPA 
competitively inhibit oxidation of AA by the COXs, which is believed to be the major 
mechanism by which dietary sources of DGLA and EPA (e.g., fish oil) can reduce 
inflammation. 
The traditional COX inhibitors are not selective for any particular COX, resulting in 
widespread inhibition of eicosanoid synthesis that ultimately reduces inflammation, as well 
as providing antipyretic, antithrombotic, and analgesic effects. However, inhibition of the 
synthesis of gastroprotective prostaglandins can cause gastric irritation and increases the 
risk of development of peptic ulcer disease. 
The development of selective COX-2 inhibitors was originally aimed at blocking the 
production of pro-inflammatory prostaglandins while minimizing any effects on platelet 
and gastric function. Selective inhibition of COX-2 has been accomplished with the 
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“coxibs”, which differ in their selectivity for COX-2 relative to COX-1 by selectively 
binding to a hydrophobic side-pocket on the COX-2 enzyme where a valine takes the 
place of what is an isoleucine on COX-1, allowing access to an otherwise sterically 
hindered site that causes inhibition of the enzyme’s function. Since COX-2 is largely 
expressed selectively in inflamed tissue, there is much less gastric irritation and risk of 
peptic ulceration associated with COX-2 inhibitors. However, the selectivity of COX-2 
causes an imbalance between thromboxane and prostacyclin, resulting in an increased 
risk of thrombosis, MI, and stroke. Thus, by blocking prostacyclin synthesis without 
concomitant inhibition of thromboxane A2 (TXA2) production, highly selective inhibitors 
of COX-2 increase the risk of cardiovascular events. These effects seemed most notable 
with rofecoxib (Vioxx®) and valdecoxib (Bextra®), which were removed from the market 
in 2004 and 2005, respectively. Other COX-2 selective NSAIDs, such as celecoxib 
(Celebrex®), and etoricoxib (Arcoxia®), are still on the market as they continue to be 
investigated for these adverse effects. Even with short-term use, COX-2 inhibitors have 
been found to increase the risk of atherothrombosis, most notably manifested as a 2-to-5-
fold increased risk of myocardial infarction. Furthermore, high-dose regimens of some 
traditional NSAIDs such as diclofenac and ibuprofen are associated with a similar 
increase in risk of vascular events. Thus, although NSAIDs, particularly COX-2 inhibitors, 
have demonstrated benefits, the risks associated with their use should be seriously 
considered when prescribing them to a patient having risk factors and/or a personal or 




Aspirin (acetylsalicylic acid, ASA), is the oldest and most widely used antiplatelet drug due 
to its low cost, wide availability, and proven effectiveness. It is a salicylate drug whose 
mechanism of action serves as the model of most antiplatelet therapeutic strategies. 
Mechanism of action 
Aspirin, a non-selective COX inhibitor, is one of the most commonly used drugs in IHD that 
can reduce the development of thrombosis associated with the rupture of atheromatous 
plaques. Aspirin interferes with the activation of platelets by irreversibly inhibiting COX, 
thereby interfering with the biosynthetic pathway of thromboxanes. Unlike other NSAIDs, 
whose antiplatelet action is transient (i.e., in the order of hours), aspirin irreversibly 
acetylates COX-1 in platelets, thereby inhibiting the biosynthesis of thromboxane A2 (TXA2) 
and in that manner producing a long-lived antithrombotic effect (i.e., days, until new 
platelets are produced by the bone marrow). At higher doses (e.g., 1 g/d), however, aspirin 
also inhibits COX-2, which can ultimately produce a prothrombotic effect by inhibiting the 
synthesis of prostacyclin in endothelial cells. 
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Indications, dosage, and side effects 
Aspirin is widely used for the primary prevention of ischemic events in patients at risk, as well 
as secondary prevention of cardiovascular events in patients with IHD and cerebrovascular 
and peripheral vascular disease. Aspirin is usually administered once a day at a dose between 
75-325 mg, with 75-100 mg being recommended for most indications. When fast platelet 
inhibition is needed, a dose of at least 160 mg should be given orally. Higher doses of aspirin 
have not been shown to be more effective than lower doses, and in fact, reduced efficacy has 
been reported with higher doses. As discussed above, very high doses of aspirin (i.e., 1 g/d) 
can have a paradoxical prothrombotic effect due to the inhibition of COX-2. 
Long-term daily oral enteric-coated aspirin has been demonstrated to reduce (1) the 
incidence of anginal episodes in patients with chronic stable angina, as well as in survivors 
of unstable angina and myocardial infarction (MI), and (2) the risk of recurrent infarction, 
stroke, or cardiovascular mortality by 25% following an MI compared with placebo. It has 
also been established that low doses of aspirin may be given immediately after an MI to 
reduce the risk of another MI or of the death of the myocardium. 
Aspirin is equally effective in men and women, although in men it mainly reduces the risk 
of MI, while in women it lowers the risk of stroke. Although aspirin also raises the risk of 
hemorrhagic stroke and other major bleeds, these events are rare, and are by far outweighed 
by aspirin’s positive effects. 
The most common side effects of aspirin use are gastrointestinal, ranging from simple stomach 
upset, to erosive gastritis, to peptic ulcers with bleeding and perforation, all of which are dose-
dependent. For these reasons, aspirin should never be administered to individuals with a 
history of gastrointestinal bleeding or severe stomach upset. Although the use of enteric-
coated or buffered aspirin may relieve some of these symptoms, they do not eliminate the risk 
of gastrointestinal complications due to the inhibition of gastroprotective prostaglandins as 
part of the actions of aspirin. The overall risk of major bleeding with aspirin is low, however, 
estimated at 1-3% per year, but is increased when aspirin is given in conjunction with 
anticoagulants (e.g., warfarin). In these situations, a lower dose of aspirin should be given (e.g., 
75-100 mg/d). In patients with a documented history of peptic ulcer disease caused by 
Helicobacter pylori infection, treatment of the infection and administration of a proton pump 
inhibitor (PPI) may reduce the risk of aspirin-induced gastrointestinal bleeding. Aspirin 
should also never be given to individuals with a history of allergic responses to salicylates, 
particularly those associated with bronchospasm. 
3.2 Thienopyridines 
A second class of antiplatelet drugs commonly used in IHD is the thienopyridines. These 
structurally related drugs have similar benefits as aspirin in patients with stable chronic 
IHD and may be used instead of aspirin when aspirin is contraindicated. The 
thienopyridines include clopidogrel (Plavix®), ticlopidine (Ticlid®), and prasugrel (Effient®). 
A structurally unrelated but functionally similar drug is ticagrelor (Brilinta®). 
Mechanism of action 
The thienopyridines are prodrugs that must first be metabolized by the hepatic cytochrome 
P450 enzyme system before they can exert any biological activity, so their onset of action can 
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be delayed for several days. They interfere with the aggregation of platelets by 
competitively and irreversibly inhibiting the adenosine diphosphate (ADP) chemoreceptor 
P2Y12 on the surface of platelets, which is crucial for the conformational change that 
activates GP IIb/IIIa and ultimately leads to platelet aggregation and cross-linking by fibrin. 
3.2.1 Clopidogrel (Plavix®) 
 
Clopidogrel is an oral thienopyridine marketed under the trade name Plavix by Bristol-
Myers Squibb and Sanofi-Aventis as 75 mg oral tablets. 
Indications, dosage, and side effects 
Clopidogrel is indicated for the prevention of vascular ischemic events in patients with 
symptomatic atherosclerosis, acute coronary syndromes, and MI. When compared with 
aspirin in patients with recent ischemic stroke, MI, or peripheral arterial disease, clopidogrel 
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it is also considerably more expensive and not as readily available. It is also used, together 
with aspirin, for the prevention of thrombotic events after placement of intracoronary stents, 
or as an alternative to aspirin in patients who have a contraindication for aspirin. 
Combination therapy consisting of aspirin and clopidogrel has been shown to reduce 
morbidity and mortality in patients with angina and it also reduces the risk of thrombosis in 
patients who have undergone coronary artery stenting (the risk of gastrointestinal bleeding in 
these patients can be reduced by also prescribing a PPI while on this combination therapy). 
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to inhibit complementary pathways of platelet activation and is associated with a highly 
statistically significant 20% relative risk reduction when comparing each drug alone. 
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clopidogrel be given for 1-3 months after the implantation of a bare metal stent. With the use 
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Although aspirin and clopidogrel may help prevent coronary thrombosis associated with 
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“aspirin resistance” has been noted in up to 10% of patients, more frequently in patients 
treated with lower doses of aspirin. In these cases, the use of higher doses of aspirin and/or 
combination therapy with clopidogrel should be considered. Although the routine 
management of patients with IHD is medical, many patients show greater improvement 
after undergoing interventional coronary revascularization. These invasive procedures 
should not take the place of the required ongoing modification of risk factors and medical 
therapy but rather should be performed in combination with them. 
Combination therapy of aspirin and clopidogrel increases the risk of major bleeding to 
about 2% per year, a risk that will exist even if the daily dose of aspirin is reduced to 100 
mg. Thus, the combination of clopidogrel and aspirin should only be used when there is a 
clear benefit. For example, combination therapy has not been shown to reduce the risk of 
acute ischemic stroke relative to clopidogrel alone or to reduce the risk of primary 
cardiovascular events when compared to aspirin alone. 
As mentioned above, the onset of action of clopidogrel is slow, so even though platelet 
inhibition can be seen within a few hours after a single oral dose of the drug, a loading-dose 
between 300-600 mg is commonly given when prompt inhibition of the ADP receptors is 
desired, which is continued as a once daily oral dose of 75 mg for maintenance. 
The documented adverse effects of clopidogrel include bleeding, severe neutropenia, and 
thrombotic thrombocytopenic purpura (TTP). Patients with a history of resolved aspirin-
related peptic ulcers who received aspirin plus a PPI (e.g., esomeprazole) were shown to 
have a lower incidence of recurrence of peptic bleeding when compared to patients 
receiving clopidogrel instead. Another study suggested that prophylaxis with PPIs when 
undergoing treatment with clopidogrel following an acute coronary syndrome (ACS, i.e., 
unstable angina or MI) may increase the incidence of adverse cardiac events, perhaps as a 
result of the inhibition of the cytochrome P450 variant CYP2C19, which is required for the 
conversion of clopidogrel to its pharmacologically active form. However, even after some 
government health agencies issued a statement on a potential drug interaction between 
clopidogrel and PPIs, people within the cardiology community manifested concerns 
regarding the possible existence of flaws in the studies that served as the basis for these 
conclusions and subsequent warnings, putting into question the veracity of an adverse drug 
interaction between clopidogrel and PPIs. 
Clopidogrel, was issued a black box warning from the FDA on March 12, 2010 because it is 
estimated that 2-14% of the US population have low levels of the CYP2C19 liver enzyme 
needed to activate clopidogrel and, therefore, may not get the full effect from the drug. 
However, there are tests available to predict if a patient will be susceptible to this reduced 
pharmacological effect. 
3.2.2 Ticlopidine (Ticlid®) 
 
 
Ticlopidine is an oral thienopyridine marketed under the trade name Ticlid by Roche 
Pharmaceuticals as 250 mg oral tablets.  
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Indications, dosage, and side effects 
Ticlopidine is typically administered as an oral twice-daily dose of 250 mg. Like aspirin, 
ticlopidine is more effective than placebo at reducing the risk of cardiovascular death, MI, 
and stroke in patients with atherosclerotic disease, but due to its delayed onset of action, 
ticlopidine is not recommended for patients with acute MI. Ticlopidine has been routinely 
used in addition to aspirin after coronary artery stenting, and as a substitute for aspirin in 
patients with a contraindication to aspirin. However, because ticlopidine is less potent than 
clopidogrel and is associated with greater risk of hematologic disorders (e.g., neutropenia, 
TTP, thrombocytopenia, aplastic anemia), it has largely been replaced by clopidogrel. Due to 
the known hematologic side effects, which usually become manifest within the first few 
months of beginning therapy, frequent blood counts must be carefully performed when 
taking ticlopidine. As with clopidogrel, it is contraindicated in patients having 
hypersensitivity reactions to thienopyridines, as well as bleeding disorders, active bleeding, 
and liver disease. 
3.2.3 Prasugrel (Effient®) 
 
 
Prasugrel is an oral thienopyridine marketed under the trade names Effient, Efient, Apagrel, 
and Prasita. It was developed by Daiichi Sankyo Co. and is currently marketed in the United 
States in cooperation with Eli Lilly and Co. as 5 mg and 10 mg oral tablets. 
Indications, dosage, and side effects 
Prasugrel was approved for patients with acute coronary syndrome who will be undergoing 
a percutaneous coronary intervention (PCI) to reduce the occurrence of cardiovascular 
thrombotic events. Prasugrel is faster than clopidogrel at inhibiting ADP-induced platelet 
aggregation and does so to a greater extent than both normal and higher doses of 
clopidogrel in healthy individuals, as well as in patients with coronary artery disease, 
including those undergoing PCI. Unlike clopidogrel, prasugrel has not been shown to 
produce a lesser effect in patients who have a low level of hepatic CYP2C19 enzyme. 
Prasugrel should be administered as a single 60 mg oral loading dose and then continued at 
a dose of 10 mg orally once daily. Patients should also take aspirin (75-325 mg) per day. 
A study published in the New England Journal of Medicine that compared prasugrel with 
clopidogrel in patients with acute coronary syndromes, both in combination with aspirin, 
found that prasugrel was a more potent anti-platelet agent, demonstrating a 1.2-fold 
reduction in the combined rate of cardiovascular mortality, nonfatal myocardial infarction, 
and nonfatal stroke. However, prasugrel was associated with a 1.6-fold rate of serious 
bleedings and 4-fold rate of fatal bleedings, even though overall mortality did not differ 
between the two patient groups. 
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3.2.4 Ticagrelor (Brilinta®) 
 
Ticagrelor is an oral cyclopentyltriazolopyrimidine (CPTP) agent marketed under the trade 
names Brilinta, Brilique, and Possia. The drug was approved for use in the European Union 
on December 3, 2010 and by the US Food and Drug Administration on July 20, 2011, being 
marketed in the United States by AstraZeneca as 90 mg oral tablets. 
In contrast to the other antiplatelet drugs clopidogrel, ticlopidine, and prasugrel, ticagrelor 
is a reversible allosteric inhibitor that does not require hepatic activation, making it a better 
choice for patients with hepatic insufficiency or those carrying low levels or genetic variants 
of the CYP2C19. Due to its reversible mode of action, ticagrelor is both faster and shorter 
acting than clopirogrel, making it a easier to discontinue (e.g., surgery, hypersensitivity), but 
typically requiring more frequent dosing, which can present an issue with compliance. 
In a study by AstraZeneca, ticagrelor was associated with ~2% lower mortality rate than 
clopidogrel in patients with ACS and it was found that taking ticagrelor displayed a lower 
mortality rate from vascular causes, heart attack, or stroke. However, patients taking 
ticagrelor was associated with 1.5% higher propensity of non-lethal bleeding. 
Indications, dosage, and side effects 
Treatment with ticagrelor should be initiated as an oral loading dose of 180 mg, and then 
continued at 90 mg orally twice daily. Patients should also take aspirin (75-100 mg) daily. 
Ticagrelor is indicated for the prevention of thrombotic events in patients with ACS or MI, 
in combination with aspirin unless the latter is contraindicated. Compared with clopidogrel, 
ticagrelor significantly reduces the mortality rate in patients with ACS. The drug is 
contraindicated in patients with hepatic insufficiency and a history of pathological bleeding. 
It also should not be given in combination with other drugs that affect the CYP3A4 liver 
enzyme, since the drug is metabolized by CYP3A4 and is mainly excreted via bile and feces.  
The most common side effects of ticagrelor are dyspnea as well as bleeding (e.g., 
gastrointestinal, nasal, subcutaneous/dermal). To date, less than 1% of patients taking 
ticagrelor have reported allergic reactions. 
Inhibitors of hepatic CYP3A4 enzyme (e.g., ketoconazole and (?) grapefruit juice), increase 
blood plasma levels of ticagrelor and can therefore cause bleeding and other adverse effects. 
Conversely, activators of hepatic CYP3A4 (e.g., rifampicin and (?) St. John’s wort), can 
reduce the effectiveness of ticagrelor. Furthermore, drugs that are also metabolized by 
CYP3A4 (e.g., simvastatin), will display higher plasma levels, which can result in an 
increase of the side effects of these drugs when combined with ticagrelor. 
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3.2.5 Thienopyridine resistance 
There is variability among different individuals in the ability of the thienopyridines to 
inhibit ADP-induced platelet aggregation. To a certain extent this variability reflects genetic 
polymorphisms in the CYP isoenzymes associated with the metabolic activation of these 
drugs. For example, individuals carrying the CYP2C19*2 allele have been shown to display 
a lower responsiveness to clopidogrel, in a similar fashion as those having a lower activity of 
hepatic CYP3A4. These observations have resulted in the proposal that genetic testing may 
lead to the identification of individuals that may experience resistance to the effects of 
thienopyridines. 
3.3 Phosphodiesterase inhibitors and adenosine reuptake inhibitors 
As the name implies, phosphodiesterase inhibitors interfere with the function of the enzyme 
phosphodiesterase, which breaks down the intracellular second messenger cyclic adenosine 
monophosphate (cAMP). This results in increased levels of cAMP, ultimately leading to the 
inhibition of platelet activation and vasodilation. 
3.3.1 Cilostazol (Pletal®) 
 
 
Cilostazol is an oral phosphodiesterase inhibitor marketed under the trade name Pletal. The 
drug is marketed in the United States by Otsuka Pharmaceutical Co. as 50 and 100 mg oral 
tablets. Cilostazol is not used in the treatment of ischemic heart disease but rather in the 
relief of intermittent claudication in patients with peripheral vascular disease. 
3.3.2 Dipyridamole (Persantine® and Aggrenox® (in combination with aspirin)) 
 
 
Dypyridamole is an oral phosphodiesterase inhibitor marketed as a single drug under the 
trade name Persantine, and as an extended-release combination with low-dose aspirin 
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under the name Aggrenox. Persantine drug is marketed in the United States by Boehringer 
Ingelheim Pharmaceuticals, Inc. as 25, 50, and 75 mg oral tablets, while Aggrenox contains 
200 mg of extended-release dipyridamole and 25 mg of aspirin. 
Dypiridamole also inhibits the reuptake of adenosine by platelets, red blood cells, and 
vascular endothelial cells, as well as the enzyme adenosine deaminase, which metabolizes 
adenosine into inosine. Both of these effects increase the extracellular concentration of 
adenosine, which causes smooth muscle relaxation and is, at least in part, responsible for the 
vasodilatory effects of dipyridamole. Persantine causes vasodilation when given at high 
doses over a short time and it inhibits thrombosis when given long term by also acting as a 
thromboxane synthase inhibitor.  
Indications, dosage, and side effects 
The recommended dose of dipyridamole is 75-100 mg four times daily as an adjunct to 
warfarin therapy. Dipyridamole is a relatively weak antiplatelet agent on its own and thus is 
not used for the treatment of IHD. However, dipyridamole has been shown to increase 
myocardial perfusion and left ventricular function in patients with ischemic 
cardiomyopathy. In combination with low-dose aspirin (i.e., Aggrenox) it is used for 
prevention of stroke in patients with a history of transient ischemic attacks given as a twice-
daily dose. 
When given by intravenous infusion over 3-5 minutes, dipyridamole is associated with a 
rapid increase in the local concentration of adenosine in the coronary circulation, which has 
a vasodilatory effect. However, this vasodilation largely occurs in healthy coronary arteries, 
while those arteries that are stenosed remain so. This results in an imbalance of coronary 
perfusion that can become clinically manifest by symptoms of chest pain as well as 
electrocardiographic signs of ischemia. 
Dipyridamole combined with aspirin reduces the risk of stroke by 22.1% compared with 
aspirin and by 24.4% compared with dipyridamole alone in patients with a history of 
cerebrovascular disease (i.e., TIA and/or stroke). With regard to secondary prevention in 
patients with a history of ischemic stroke, combination therapy resulted in 13% of patients 
having vascular death, stroke, or MI as opposed to 16% of those treated with aspirin alone. 
Based on all this data, Aggrenox is often used for stroke prevention. However, because it 
has vasodilatory effects, combination therapy of dipyridamole with aspirin (i.e., Aggrenox) 
should not be used for the prevention of stroke in patients with symptomatic coronary 
artery disease. A triple therapy of aspirin, clopidogrel, and dipyridamole has been 
investigated, but an increase in adverse bleeding events was observed with this 
combination. 
The major side effects documented with the use of dipyridamole are gastrointestinal, 
headache, facial flushing, dizziness, and hypotension, which often disappear with continued 
use of the drug. 
3.4 GP IIb/IIIa receptor antagonists 
As a member of the integrin family of adhesion receptors, GP IIb/IIIa is found on the 
surface of platelets and megakaryocytes. With about 80,000 copies, GP IIb/IIIa is the most 
abundant receptor on platelets. GP IIb/IIIa consists of a non-covalently linked heterodimer 
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that is inactive on resting platelets. When platelets are activated, a signal transduction 
pathway triggers a conformational change on the receptor that leads to its activation. 
Activated GP IIb/IIIa can bind other adhesion molecules (e.g., fibrinogen, vWF) under 
conditions of high shear stress. Binding is mediated by an Arg-Gly-Asp (RGD) sequence 
found on both fibrinogen and vWF, and by a Lys-Gly-Asp (KGD) sequence located within a 
unique dodecapeptide domain on fibrinogen. Once GP IIb/IIIa is bound to fibrinogen 
and/or vWF, adjacent platelets can be bridged together and lead to platelet aggregation. 
Abciximab, eptifibatide, and tirofiban all target the GP IIb/IIIa receptor, but as described 
below, they are structurally and pharmacologically distinct. Abciximab has a long half-life 
and can be detected on the surface of platelets for a couple of weeks, while eptifibatide and 
tirofiban have shorter half-lives. 
All of the GP IIb/IIIa antagonists are administered by intravenous (IV) infusion following 
an IV bolus. The dosage of eptifibatide and tirofiban must be reduced in patients with renal 
insufficiency since they are cleared by the kidneys. 
The most serious complications of GP IIb/IIIa inhibitors are bleeding and 
thrombocytopenia, which is immunoglobulin-mediated as a result of antibodies directed 
against neoantigens on GP IIb/IIIa that form upon binding of the drug. 
3.4.1 Abciximab (ReoPro®) 
Abciximab is manufactured by Centocor and distributed by Eli Lilly. As with all of the GP 
IIb/IIIa antagonists, it is administered by intravenous (IV) infusion. It is a humanized 
murine monoclonal immunoblogulin Fab fragment directed against the activated form of 
GP IIb/IIIa that binds to the activated receptor with high affinity and blocks the binding of 
adhesion molecules.  
Indications, dosage, and side effects 
Abciximab is used in the setting of percutaneous coronary interventions (e.g., angioplasty, 
with or without stenting) to prevent platelet aggregation and thrombosis. It is administered 
as an IV bolus at 0.25 mg/kg, 10 to 60 min before PCI followed by continuous infusion of 
0.125 µg/kg/min (to a max of 10 µg/min) for 12 h. Its use is associated with a reduction in 
both the incidence of ischemic complications, as well as the necessity for repeated 
interventional procedures within the first thirty days. Patients with diabetes and chronic 
renal insufficiency can be given abciximab, but its use is contraindicated in patients who 
shall be undergoing an emergent surgical procedure (e.g., coronary artery bypass grafting), 
since bleeding time may remain elevated for up to 12 hours. 
Abciximab has a relatively short half-life (i.e., ~10-30 min), but its pharmacological effects on 
platelet function persist for up to 48 hours after cessation of IV infusion, followed by a low 
degree of GP IIb/IIIa receptor blockade that can continue for up to two weeks. 
Many of the side effects of abciximab are due to its anti-platelet effects, including an 
increased risk of bleeding (e.g., gastrointestinal hemorrhage). Thrombocytopenia is a rare 
but known serious risk that occurs in up to 5% of individuals receiving the drug, which can 
be severe in ~1% of these patients. Abciximab-induced thrombocytopenia can typically be 
treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for 
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seven days after initial drug administration. Transfusing platelets is the only known 
treatment and may have limited effectiveness as the drug may also bind to the new platelets. 
Platelet counts, which should average 250,000-400,000, can effectively drop to zero. 
In addition to targeting the GP IIb/IIIa receptor, abciximab also inhibits the closely related 
v3 receptor, which binds vitronectin, and M2, a leukocyte integrin. In contrast, eptifibatide 
and tirofiban are specific for GP IIb/IIIa. Inhibition of v3 and M2 may impart abciximab 
with anti-inflammatory and/or antiproliferative properties that extend beyond the 
inhibition of platelets. 




Tirofiban is marketed the United States by Medicure Pharma and the rest of the world by 
Irokocardio International SARL under the brand name Aggrastat as a parenteral solution for 
intravenous administration in dosages of forms 5 mg and 12.5 mg. Tirofiban is a non-
peptidic tyrosine derivative that mimics the RGD motif found on the ligands of GP IIb/IIIa. 
Indications, dosage, and side effects 
Tirofiban is administered intravenously with an initial dose of 0.4 µg/kg/min for the first 30 
minutes, followed by a maintenance dose of 0.1 µg /kg/min as a constant IV infusion for 12-
24 hours following PCI. Tirofiban, in combination with aspirin and heparin, is indicated in 
the treatment of patients with acute coronary syndromes (i.e., unstable angina or acute MI), 
including those who may be undergo subsequent percutaneous coronary intervention, to 
reduce the occurrence of further ischemic damage, new myocardial infarction, and 
mortality. 
Tirofiban has a fast onset and short duration of action, with coagulation parameters 
returning to normal within 4-8 hours after intravenous infusion is stopped. 
The major side effect of tirofiban seen in clinical trials was bleeding, both locally and 
systemically, with major bleeding occurring in 1.4% of patients and minor bleeding in 
10.5%. About 4.0% of patients needed a transfusion to stop intractable bleeding and to 
improve anemia secondary to it. Thrombocytopenia was seen in patients given tirofiban and 
heparin at a rate of about 1.5%, compared to only 0.8% in those receiving heparin alone. This 
side effect was usually reversible within a few days. Positive fecal and urine hemoglobin 
tests were also seen. After the drug entered the market, there have been reports of 
intracranial and retroperitoneal bleeding, pulmonary hemorrhage, spinal-epidural 
hematoma, and hypersensitivity reactions including acute anaphylaxis. Fatal bleedings have 
been rarely reported. 
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seven days after initial drug administration. Transfusing platelets is the only known 
treatment and may have limited effectiveness as the drug may also bind to the new platelets. 
Platelet counts, which should average 250,000-400,000, can effectively drop to zero. 
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and tirofiban are specific for GP IIb/IIIa. Inhibition of v3 and M2 may impart abciximab 
with anti-inflammatory and/or antiproliferative properties that extend beyond the 
inhibition of platelets. 
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reduce the occurrence of further ischemic damage, new myocardial infarction, and 
mortality. 
Tirofiban has a fast onset and short duration of action, with coagulation parameters 
returning to normal within 4-8 hours after intravenous infusion is stopped. 
The major side effect of tirofiban seen in clinical trials was bleeding, both locally and 
systemically, with major bleeding occurring in 1.4% of patients and minor bleeding in 
10.5%. About 4.0% of patients needed a transfusion to stop intractable bleeding and to 
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3.4.3 Eptifibatide (Integrilin®) 
 
 
Eptifibatide is a cyclic heptapeptide that binds GP IIb/IIIa because it contains the KGD 
motif. It is manufactured by Millennium Pharmaceuticals and co-promoted by Schering-
Plough/Essex. Eptifibatide is supplied as a sterile solution in 10-mL vials containing 20 mg 
of the drug, and 100-mL vials containing either 75 mg or 200 mg of eptifibatide. 
Indications, Dosage, and Side Effects 
The recommended adult dosage of eptifibatide in patients with acute coronary syndrome 
that have normal renal function is an intravenous bolus of 180 µg/kg as soon as possible 
following diagnosis, followed by a continuous infusion of 2.0 µg/kg/min for up to 72 hours 
until hospital discharge or initiation of coronary artery bypass graft (CABG) surgery. For 
patients who are to undergo a percutaneous coronary intervention (PCI) while receiving 
eptifibatide, the infusion should be continued up to hospital discharge, or for up to 18 to 24 
hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. 
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (i.e., death and/or 
myocardial infarction) in patients with unstable angina or non-ST-segment elevation (i.e., 
non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary 
syndromes) both in patients who are to receive non surgery (conservative) medical 
treatment and those undergoing percutaneous coronary intervention (PCI). The drug is 
always applied together with aspirin or clopidogrel and (low molecular weight or 
unfractionated) heparin. 
The side effects of eptifibatide are very similar to those of abciximab. 
4. Ongoing trials of antiplatelet therapy 
According to the International Committee of Medical Journal Editors (ICMJE): 
“Any research study that prospectively assigns human participants or groups of humans to 
one or more health-related interventions to evaluate the effects on health outcomes.” 
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Over the past ten years, government agencies and the IMCJE have issued laws and 
directives on the subject of trial registration. All parties have consistently agreed that the 
purpose of trial registration is to promote the public good by ensuring that the existence and 
design of clinically directive trials are publicly available. The registration effort began with the 
development of a publicly available website, ClinicalTrials.gov, which is a service of the NIH, 
developed by the National Library of Congress. 
In 1997, the FDA/NIH began requiring registration for only a limited number of trials. In 
September, 2007, the Food and Drug Amendments Act (Title VIII. Sec. 801) significantly 
expanded the scope of clinical trials that must be registered. Penalties for failing to register 
“applicable trials” may include civil monetary penalties. 
In 2004, the International Committee of Medical Journal Editors (ICMJE) defined trials that 
must be registered in order to be considered for publication in journals that adhere to ICMJE 
standards. In 2007 the ICMJE expanded the definition of trials that must be registered. 
Scores of journals (not limited to medical journals) have adopted the registration policy. 
The best way to obtain information about clinical trials in platelet activation in ischemic 
heart disease is by accessing two renowned sources: 
http://clinicaltrials.gov 
http://www.clinicaltrialresults.org/ 
Clinicaltrials.gov is a site organized by US government and their webpage states: 
“ClinicalTrials.gov offers up-to-date information for locating federally and privately 
supported clinical trials for a wide range of diseases and conditions. A clinical trial (also 
clinical research) is a research study in human volunteers to answer specific health 
questions.” 
ClinicalTrials.gov currently contains 112,970 trials sponsored by the National Institutes of 
Health, other federal agencies, and private industry. Studies listed in the database are 
conducted in all 50 States and in 175 countries. ClinicalTrials.gov receives over 50 million 
page views per month and 65,000 visitors daily. 
The U.S. National Institutes of Health (NIH), through its National Library of Medicine 
(NLM), has developed this site in collaboration with the Food and Drug Administration 
(FDA), as a result of the FDA Modernization Act, which was passed into law in November 
1997. See the FDA document - Guidance for Industry: Information Program on Clinical 
Trials for Serious or Life-Threatening Diseases and Conditions (March 2002). 
This site allows for selection of all important characteristics of clinical trial to be displayed. 
We can choose any combination of next characteristics: condition, intervention, sponsor, 
gender, age group, phase, number enrolled, funded by, study type, study design, NCT ID, 
other IDs, first received date, start date, completion date, last updated date, last verified 
date, acronym, primary completion date, and outcome measure. 
The second site, http://www.clinicaltrialresults.org/, can be used as excellent source of 
slides, movies, reports, and other useful information about clinical trials. The ‘cardiology’ 
section contains divisions into subspecialty news, with listing about: acute coronary 
syndromes, angina, anticoagulants, antiplatelet agents, antithrombins, congestive heart 
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failure, electrophysiology, imaging, interventional cardiology, prevention, and patient 
resources. Since access to these sources is in the public domain, we decided not to cite 
individual trials by other sources although we went deeper and extracted information from 
from individual trials. We advise our readers to visit these two sites frequently. 
A reasonably informative overview of ongoing trials of antiplatelet therapy is supposed to 
list name and registry number for trial, to describe study population, specify primary end 
point, and define study arms. This data is presented in table 4.1 
Clinical Trial (Registry 
No.) Study Population Primary End Point Study Arms 
ACCOAST (NCT01015287)
4,100 patients with 
NSTEMI planned 
to undergo PCI 
CV death, MI, stroke, 
urgent revascularization, 
or GP IIb/IIIa inhibitor 
bailout at 7 days 
Randomized to pre-treatment 
with prasugrel (30 mg at time 
of diagnosis with additional 
30 mg atPCI) vs. prasugrel (60 
mg) at PCI. Maintenance 
therapy in both arms will be 
10 mg daily with dose 
reduction to 5 mg in patients 





elective PCI with 
DES 
 
Death, MI, stroke, urgent 
coronary 
revascularization, or stent 
thrombosis assessed at 1 
yr; death, MI, stroke, 
urgent coronary 
revascularization, or stent 
thrombosis at 6–18 
months after second 
randomization 
Initial randomization to 
tailored antiplatelet therapy 
with VerifyNow P2Y12 vs. 
standard dual antiplatelet 
therapy. Subsequent 
randomization after 12 
months of patients who 
remain eventfree to 
discontinuation of antiplatelet 














CV death, MI, or target 
vessel revascularization at 
6 months and 1 yr 
Randomized to 75 mg of 
clopidogrel or 150 mg of 
clopidogrel 
DAPT (NCT00977938) 20,645 subjects undergoing PCI 
CV death, MI, and stroke 
at 33 months; stent 
thrombosis at 33 months
Subjects in the overall cohort 
who are free from death, MI, 
stroke, repeat 
revascularization, stent 
thrombosis, or major bleeding 
at 12 months will be 
randomized to 18 additional 
months of dual antiplatelet 
therapy or aspirin and placebo 
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Clinical Trial (Registry 
No.) Study Population Primary End Point Study Arms 
GRAVITAS 
(NCT00645918) 
2,783 subjects after 
DES placement for 






CV death, MI, and 
definite/ probable stent 
thrombosis at 6 months 
Patients with high residual 
platelet reactivity will be 
randomized to receive 
standard-dose clopidogrel (75 
mg daily) or high-dose 
clopidogrel (600 mg load, 150 
mg daily). A random sample 
of patients without high 
residual platelet reactivity will 
also be enrolled and will 








No pre-specified primary 
end point 
Randomized to clopidogrel 
(300/600 mg load, followed by 
75 mg daily) or elinogrel (80 
mg IV bolus administered 
before PCI, followed by twice 
daily dosing of oral 50 mg, 100 
mg, or 150 mg) 
LANCELOT 201 
(NCT00312052) 
Phase II trial of 
600 patients with 
CAD 
Safety and tolerability (6 
months) 
Randomized to E5555 (50 mg, 




Phase II trial of 
600 patients with 
CAD 
Safety and tolerability (12 
weeks) 
Randomized to E5555 (50 mg, 
100 mg, or 200 mg daily) or 
placebo 
TRA-CER (NCT00527943) 12,500 subjects with ACS 
CV death, MI, stroke, 
recurrent ischemia with 
repeat hospital stay, and 
urgent coronary 
revascularization at end 
of study 
Randomized to SCH 530348 
(40 mg loading dose, 2.5 mg 




with history of 
CAD, CVA, or 
PAD 
CV death, MI, stroke, and 
urgent coronary 
revascularization at end 
of study 
Randomized to SCH 530348 
(2.5 mg daily) vs. placebo 
TOPAS-1 (NCT00914368)
Phase II trial of 
450 patients who 
have either had or 
not had stent 
thrombosis or MI 
within 6 months 




P2Y12 (PRU) and VASP 
(PRI, %) cutoff level of 
platelet inhibition in 
patients with and without 
clinical events. 
All subjects will undergo 
platelet function testing with 
both VerifyNow P2Y12 and 
VASP assays 
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Clinical Trial (Registry 
No.) Study Population Primary End Point Study Arms 
TRIGGER-PCI 
(NCT00910299) 





after elective PCI 
with DES 
CV death or MI at 6 
months 
Randomized to prasugrel (60 
mg load, 10 mg daily) vs. 








CV death, MI, or stroke at 
end of study 
Randomized to prasugrel  
(30 mg load ifadministered, 
followed by 5 mg or 10 mg 
maintenance) or  
clopidogrel (300 mg load if 
administered, followed  
by 75 mg daily) 
Table 4.1 
5. Abbreviations 
ACCOAST: Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation 
Myocardial Infarction Trial 
ACS: acute coronary syndrome 
ARCTIC: Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a 
Common Antiplatelet Treatment for DES Implantation, and Interruption Versus 
Continuation of Double Antiplatelet Therapy Trial 
ARMYDA: Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty 
CIPAMI: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients with 
Acute Myocardial Infarction 
CAD: coronary artery disease 
CLARITY-TIMI: Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in 
Myocardial Infarction 
CREDO: Clopidogrel for the Reduction of Events During Observation 
CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events 
CURRENT/OASIS: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent 
Events/Optimal Antiplatelet Strategy for Interventions 
CV: cardiovascular 
CVA: cerebrovascular accident 
DANTE: Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition 
DAPT: Dual Antiplatelet Therapy 
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DES: drug-eluting stents 
GP IIb/IIIa: glycoprotein IIb/IIa 
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay—Impact On Thrombosis 
And Safety 
INNOVATE-PCI: A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous 
and Oral P2Y12 Inhibitor, in Non-Urgent PCI 
LANCELOT 201: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular 
Inflammation in Subjects With Coronary Artery Disease 
LANCELOT 202: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular 
Inflammation in Subjects With Acute Coronary Syndrome 
MI: myocardial infarction 
NSTE-ACS: non–ST-segment elevation acute coronary syndrome 
NSTEMI: non–ST-segment elevation myocardial infarction 
PAD: peripheral artery disease 
PCI: percutaneous coronary intervention 
PRI: platelet reactivity index 
PRINCIPLE: Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation 
and Aggregation 
PRU: platelet reactivity unit 
STEMI: ST-segment elevation myocardial infarction 
TIMI: Thrombolysis In Myocardial Infarction 
TOPAS-1: Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis 
TRA-CER: Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke 
in Patients With Acute Coronary Syndrome 
TRA-2P-TIMI 50: Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and 
Stroke in Patients With Atherosclerosis 
TRIGGER-PCI: Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement 
on Clopidogrel to Guide Alternative Therapy With Prasugrel 
TRILOGY-ACS: Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome 
Subjects 
TRITON: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet 
Inhibition with Prasugrel 
VASP: Vasodilator-stimulated phosphorprotein 
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1. Introduction 
Refers to myocardial, vascular, or electrophysiological dysfunction that is induced by the 
restoration of blood flow to previously ischemic tissue. Tissue damage caused when blood 
supply returns to the tissue after a period of ischemia. The absence of oxygen and nutrients 
from blood during the ischemic period creates a condition in which the restoration of 
circulation results in inflammation and oxidative damage through the induction of oxidative 
stress rather than restoration of normal function. 
Early reperfusion of ischemic myocardium is an accepted approach for the management of 
patients with acute coronary syndromes. In addition, surgical interventions requiring 
interruption of blood flow to the heart, out of necessity, must be followed by restoration of 
perfusion. Reperfusion, although essential for tissue and/or organ survival, is not without 
risk due to the extension of cell damage as a result of reperfusion itself. 
Since rupture of the plasma membrane is a prominent feature of necrosis and ischemia-
reperfusion injury and is a lethal event, it is worth considering what might lead to rupture 
of the plasma membrane. Rupture of the plasma membrane could be facilitated by calpain 
or some other protease cleavage of the cytoskeleton. Complete loss of ATP would also 
inhibit ion pumps, which would result in swelling perhaps rupturing the plasma 
membrane, particularly if the cytoskeleton has been weakened (Murphy & Steenbergen, 
2008).  
It is possible that a combination of protease activation with loss of ATP, ion dysregulation 
and cell swelling all conspire to rupture the plasma membrane. A rise in cytosolic free Ca2+ 
concentration [Ca2+]i has been consistently observed in ischemia and early reperfusion. A 
rise in [Ca2+]i will lead to activation of calpains, which could be involved in cleaving 
proteins leading to plasma membrane rupture. Calpain activates the proapoptotic BID, and 
also cleaves Atg5, shifting the balance from autophagy to apoptosis. An increase in [Ca2+]i 
and ROS can lead to activation of an inner mitochondrial large-conductance channel known 
as the Mitochondrial permeability transition (MPT). Opening of this channel would lead to 
loss of ATP and mitochondrial function, which would quickly lead to mitochondrial 
swelling and release of cytochrome c, which could activate apoptosis. If a large number of 
mitochondria in a cell undergo opening of the MPT, the cell will lose the capacity to make 
ATP, and the cell will lose ion homeostasis, resulting in cell swelling, membrane rupture, 
and cell death (Murphy & Steenbergen, 2008).  
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Platelet-dependent thrombus formation is a key event in the pathogenesis of acute 
myocardial infarction (AMI). Platelets mediate both thrombotic occlusion of the entire 
epicardial coronary artery and also accumulate in the microcirculation resulting in 
impairment of microcirculation and provoking myocardial ischemia during reperfusion 
(Gawaz, 2004).. 
Despite an improved understanding of the pathophysiology of this process and encouraging 
preclinical trials of multiple agents, most of the clinical trials to prevent reperfusion injury 
have been disappointing. Despite these problems, adjunctive therapies to limit reperfusion 
injury remain an active area of investigation. In these studies vitamin E has been tried to 
ameliorate lethal reperfusion injury. 
2. Protective effects of vitamin E against myocardial ischemia/reperfusion 
injury in rats 
Prevention of ischemia-reperfusion (I/R) injury is crucial for successful cardiac surgery. In 
cardiac surgery, it is reported that pharmacological agents can be administered prior to 
ischemia, enabling them to exert their protective effects on mitochondria prior to ischemia 
and reperfusion. The role of α-tocopherol (vitamin E) as a chain-breaking antioxidant is well 
characterized in vitro; it is considered the major lipophilic antioxidant in the human body, 
specifically by its reaction with peroxyl free radicals (Navarro et al., 2005). It has been 
demonstrated that vitamin E deficiency is responsible for increased myocardial injury 
caused by oxidative stress and that I/R of the heart is associated with a blunting in cardiac 
α-tocopherol levels (Altavilla et al., 2000). Vitamin E has been extensively assayed in 
experimental animal diseases, and in the protection and treatment of human diseases. 
Research provided evidence that vitamin E intake much higher than the current 
recommended dietary allowance could contribute to or improve human health. It has been 
reported that dietary requirements to prevent deficiency and maintain apparent health is 
substantially less than optimal amounts necessary to provide protection against 
degenerative conditions and chronic diseases. Results of a number of studies suggested that 
increased vitamin E intake is associated with decreased risk of coronary heart disease, and 
certain types of cancer as well as enhancement of immune function (Ricciarelli et al., 2002 ; 
Dong et al., 2009). Literatures concerning safety, and tolerance of oral vitamin E 
demonstrated that vitamin E is relatively nontoxic (Dong et al., 2009; Hanson et al., 2007). In 
a 91-day study of rats receiving up to 316-443 mg vitamin E/animal/day, vitamin E had no 
adverse effects on weight gain, food intake, organ weights, hematology or serum chemistry 
values (Krasavage et al., 1977). In the heart and cardiovascular system, nitric oxide (NO) 
plays a significant role. The specific roles of NO in the heart in general and on cardiac 
mitochondria in particular remain controversial. It has been reported that both endogenous 
and exogenous sources of NO exert important modulatory effects on mitochondrial function 
(Davidson & Duchen, 2006). Nitric oxide donors have been shown to induce a powerful 
cardioprotection against I/R injury in mice (Wang et al., 2005). However, literature 
reporting varying results of NO therapy, with some investigators reporting cardioprotective 
effects, whereas others report cardiotoxic effects ( Bell et al., 2003). Mitochondrial 
permeability transition (MPT) is a nonspecific pore in the inner mitochondrial membrane. It 
has been reported that the opening of the MPT converts the mitochondria from an organelle 
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that provides adenosine triphosphate to sustain heart function into an instrument of cell 
death by apoptosis if the insult is mild, and to necrosis if the insult is profound (Halestrap et 
al., 2004). It is hypothesized that a major component of I/R injury is necrotic cell death, 
which is widely thought to be the consequence of opening the MPT as reported by  previous 
literature (Costa et al., 2006). Functional recovery of the Langendorff-perfused heart from 
ischemia inversely correlates with the extent of the opening, and inhibition of the MPT 
provides protection against reperfusion injury (Halestrap et al., 2004). Previous literature 
(Kim et al., 2006) reported that radical oxygen species (ROS) generated during early 
reperfusion is the primary activator of the MPT, and cardiomyocyte death. Some recently 
developed, intracellularly targeted scavengers have been reported to provide some 
reduction in infarct size (Sheu et al., 2006). Antioxidants such as vitamins C, and E have also 
been suggested to scavenge ROS and reduce ischemic injury (Qin et al., 2006). A study, 
therefore, was performed with the following objectives, first, to determine whether a short 
course of oral administration of vitamin E in a megadose as compared to a NO donor 
nitroglycerin (GTN) can provide sufficient protection of the heart against reperfusion 
induced injury, and second, to determine whether a combined regimen of vitamin E and a 
NO donor confound superior protection to the hearts against this insult, and to investigate 
the effect of each of these pharmacological preconditioning agents on mitochondria and 
MPT. 
2.1 Methods  
This study was undertaken on  female Wistar rats weighing 150-200 gm. Rats were allocated 
into 4 groups: a- Control group, non-treated , b- GTN-treated group, rats received GTN 
intraperitoneal 25 minutes before sacrifice, in a dose of 120 μg/kg bw  (Zhou et al., 2002) ,c- 
Vit E-treated group, rat received vitamin E by oral tubal feeding 16-20 hours before sacrifice, 
in a dose of 250mg/rat d- Vit E and GTN-treated group, rats received vitamin E and GTN as 
in both GTN-treated group and vit E -treated group.  
Experimental procedures; On the day of the experiments, rats were weighed and injected 
intraperitoneally with heparin sodium, 1000 IU. One hour later, the rats were anesthetized 
with thiopental sodium 40 mg/kg intraperitoneally.  
In vitro studying of isolated hearts: Hearts were excised and perfused in a Langendorff 
preparation with the standard Krebs-Henselite Bicarbonate (KHB) buffer, pH 7.4 
equilibrated with O2:CO2 (95%:5%) at 37 º C (Ayobe &Tarazi, 1983). After 20 minutes 
stabilization period, baseline cardiac activities were recorded using isometric force 
transducer connected to a two-channel oscillograph. 
Ischemia Reperfusion Technique:: After recording baseline cardiac activity, 30 minutes of 
ischemia was induced by stopping the perfusing fluid, and at 30-minute reperfusion, the 
cardiac activity was recorded again. 
Cardiac activity was assessed by the following parameters: heart beating rate (BR), rate of 
tension development (dT/dt) and half relaxation time (1\2 RT). Myocardial flow rate (MFR) 
was measured at the same intervals by timed volumetric collection. Results were expressed 
as the percentage change of the measured parameters relative to baseline values to 
normalize individual differences between basal values among each group.  
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The cardiac chambers were weighed. The ventricles were used to isolate mitochondria. 
Mitochondria were isolated by conventional procedures of differential centrifugation. 
Hydrolysis of mitochondrial nicotinamide adenine dinucleotide (NAD +) directly reflects 
MPT opening. The NAD+ was measured after perchloric acid extraction (Di Lisa et al., 2001; 
Yamazaki et al., 2004). The malondialdehyde (MDA) was estimated in cardiac homogenates 
by the double heating method of Draper and Hadley (Draper & Hadley, 1990). Data for 
MDA and NAD+ was calculated by non-parametric Mann –Witney test.  
Electron microscopic study: Parts of the lower half of the left ventricle were fixed in 4% 
glutaraldehyde, dehydrated and embedded in resin. Sections of 60 nm thickness were cut on 
copper grids and stained with uranyl acetate followed by lead citrate for examination by the 









































Fig. 1. The malondialdehyde (MDA) and mitochondrial nicotinamide adenine dinucleotide   
(NAD +) levels after 30 minutes reperfusion in control rats, nitroglycerine-treated rats 
(GTN), vit E-treated rats and vit E & GTN-treated rats. Data are presented as means  SD   
P = 0.004 as compared to control rats. 
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Fig. 2. Showing irregular, disorted myofilaments. They appear loose and 
discontinuous.Mitochondiae are pleomorphic and idely spaced (controll group x60000). 
Arrow shows disruption in the mitochondrial membrate (x15000). 
 
 
Fig. 3. Myofilaments appear irregular but more dense. (NTG group x6000). Inset – 
mitochondriae show disrupted cristae and arrow shows discontinuous mitochondrial 
membrane (x15000). GTN group – group received nitroglycerin 
 




Fig. 4. Showing regular dense and continuous myofilaments. (Vit E group x6000). Inset – 
mitochondriae are regular in shape. They reveal transverse, parallel cristae.Arrow shows 
continuous mitochondrial membrane. (x15000). Vit E group – received vitamin E. 
 
Fig. 5. Showing regular and dense myofilaments (GTN and Vit E group x6000.). Inset – 
mitochondriae are electron dense with unclear cristae. (x15000). GTN and Vit E group – 
received nitroglycerin and vitamin E. 
 




Fig. 4. Showing regular dense and continuous myofilaments. (Vit E group x6000). Inset – 
mitochondriae are regular in shape. They reveal transverse, parallel cristae.Arrow shows 
continuous mitochondrial membrane. (x15000). Vit E group – received vitamin E. 
 
Fig. 5. Showing regular and dense myofilaments (GTN and Vit E group x6000.). Inset – 
mitochondriae are electron dense with unclear cristae. (x15000). GTN and Vit E group – 






(n=7) %BR %dT/dt %½RT %MFR 
Control -16.21±4.93 -23.75±6.88 22.85±9.84 -21.78±13.07 
GTN-tr. -21.16±11.04 22.94±20.64 46.43±19.57 -53.31±9.74 
Vit E-tr. 15.37±26.21 39.66±24.43a 10.71±12.02 -17.57±17.68b 
Vit E and 
GTN-tr. -15.10±7.11 38.48±23.67
a 14.29±5.04 -25.44±4.24 
Data are presented as mean ± SEM. n: is the number of rats. a:Significance calculated by least significant 
difference (LSD) at P=0.03 from control group, b:Significance calculated by LSD at P=0.04 between vit E-
tr., and GTN-tr groups. BR - beating rate, dT/dt - rate of tension development, ½ RT -half relaxation 
time, MFR - myocardial flow rate.  
Table 1. Percentage changes from baseline values of cardiac activity at 30 minutes 
reperfusion after 30 minutes of ischemia (I/R) of perfused hearts isolated from; control rats, 
GTN-treated rats (GTN-tr.),vitamin E-treated rats (vitE-tr.), and vitamin E & nitroglycerin-
treated rats (vit E and  GTN-tr.). 
2.2 Effects of vitamin E versus nitroglycerine on I/R injury 
Our results demonstrated that a short course of vitamin E treatment induced preconditioning 
in the hearts. The vitamin E therapy, enhanced contractile, and vascular recovery, and 
attenuated oxidative stress in cardiac tissue, as demonstrated by the decrease of MDA in 
cardiac tissue. Moreover, this therapy protected the hearts against MPT opening as indicated 
by significant increase of NAD+ in cardiac tissue. Histological examination showed less 
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induced contractile dysfunction and tissue injury. Peroxynitrite (ONOO–), the reacting product 
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suggested that ONOO– might be formed excessively in post-ischemic myocardial tissue. In the 
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the conditions of ONOO– formation. Therefore, we suggest that exogenous NO failed to 
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significant increase of NAD+ content in isolated hearts from GTN-supplemented rats indicated 
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Previous literature (Dhalla et al., 2000) reported a depletion of endogenous antioxidants in the 
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investigators have failed to observe such results. The slow incorporation of vitamin E into 
tissues, due to its marked lipophilicity, is probably responsible for its failure as a 
cardioprotective compound as shown during the acute administration of α-tocopherol after 
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I/R injury induced in the pig (Altavilla et al., 2000). Several studies reinforce the importance of 
localization and timing in cardioprotection. Delivery of the antioxidants to the right 
compartment in the right time period is very difficult to achieve in controlled animal studies, 
and even more difficult in patients. As a result of the controversy in the animal studies, and 
the failed clinical trials, it is often concluded that inhibition of ROS will not influence infarct 
size. A more realistic assessment is that to have a significant benefit in reducing infarct size 
requires the correct delivery of mitochondrial targeted antioxidants perhaps in conjunction 
with other therapies. So in this study, we tried to give the animals vitamin E in a large dose, 
with a sufficient time to provide its effects. The demonstration that prior exposure to a low 
concentration of H2O2 protects against MPT opening may be of pathophysiological importance 
for cardioprotection (Costa et al., 2006). By the same reasoning, in preconditioning, we 
speculate the need for an antioxidant that attenuates the large burst of oxidative stress at the 
start of reperfusion without completely neutralizing free radicals. 
We suggest that vitamin E as a physiological antioxidant acted to scavenge free radicals 
without completely neutralizing them, thereby affording a significant preconditioning 
effect. Reduction of free radical formation inhibits MPT opening, thereby affording 
preconditioning. This is clearly demonstrated in the current study, since there was a 
significant increase of NAD+ content of reperfused hearts in the vitamin E-treated groups. 
Histological examination confirmed this result, as it revealed marked protection of the 
normal structure of myocytes and mitochondria. Addition of GTN treatment to vitamin E 
attenuated its cardioprotective effect. In summary, the findings of the present study provide 
evidence that a short course of vitamin E treatment protected the heart against reperfusion-
injury compared to a NO donor. The MPT is an important target of this protection.  
3. Effects of vitamin E treatment on age-associated changes in cardiac 
responses to the injury of post I/R 
Aging is one of the most important risk factors for the development of cardiovascular 
disease. Aging is characterized by loss of myocytes, remodeling and impaired contractile 
function in the heart. The rate of programmed cell death in the left ventricle increases with 
age (Kwak et al., 2006). Meanwhile the aged heart faces a high risk of free radical injury 
owing to slow generation of antioxidant enzymes by its cells, and a general decline in this 
system may be another reason for the development of myocardial dysfunction (Asha Devi et 
al.,  2003 a ). 
It is well established that nitric oxide (NO), is constitutively generated within the heart, not 
only by the endothelium but also by the myocytes (Balligand et al., 1995). Numerous 
previous animal studies have reported that there is a loss of NO biological activity and /or 
biosynthesis during aging (Matz et al., 2000). 
Oxygen free radicals increase in concentration upon reperfusion of ischemic cardiac tissue 
(Xia et al., 1996). It is well established that these reactive species can interact with and 
damage various cellular components (Berlett & Stadtman, 1997). Free radical production in 
the heart has also been reported to increase with age (Sohal et al., 1990). Thus, although 
restoration of blood flow is the sole method for salvaging ischemic tissue, oxidative damage 
may occur during reoxygenation and contribute to ischemia–reperfusion injury.  
Regular exercise is a key component of cardiovascular risk prevention strategies. Physical 
activity is known to cause generation of free radicals. Exercise training in old animals failed 
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to enhance antioxidant activity (Hatao et al., 2006). However swim training especially at 
low-intensity, was found to be beneficial as a major protective adaptation against oxidative 
stress particularly in the older myocardium (Kiran et al., 2004). The tocopherols (major 
vitamers of vitamin E) are believed to play a role in the prevention of human aging-related 
changes, and are of particular interest, mainly because of their antioxidative properties 
(Asha Devi   et al., 2003 b).  
From the aforementioned data, it seems possible that free radical - mediated injury is a 
major issue in the increase of aging related reperfusion-induced myocardial dysfunction. 
Exercise training program could not always protect the aging heart satisfactorily. We tried 
to test the hypothesis that using an antioxidant as vitamin E could lead to better protection 
of the aging hearts as compared with exercise training.  
Therefore, a study was conducted to compare the effects of vitamin E treatment versus 
swim- exercise training on age- associated changes in cardiac responses to the injury of post 
I/R.  
3.1 Methods 
This work was undertaken on female Wistar rats aged 16-18 months. Rats were allocated 
into 3 groups: a) Control group of aged rats, b) Exercise -trained aged rats subjected to daily 
physical exercise by swimming in the water tank, for 2 hours daily, 6 days aweek for 2 
weeks, and c) Vitamin E-treated aged rats subjected to daily injection of vitamin E (300 
mg/kg) intraperitoneally, 6 days aweek for 2 weeks.  
The swim-training program adopted was according to Refaat et al., (1989), in a swimming 
tank, filled with water and maintained at thermoneutral temperature of 30°c. A motor fan in 
the tank stirs strong water currents. This ensures uniformity of temperature and forces the 
rats to swim actively all the time. 
3.1.1 Experimental procedures 
They were done as previously described (Ayobe &Tarazi, 1983). Peak developed tension  per 
left ventricular weight as well as coronary flow rate per left ventricular weight were calculated 
relative to left ventricular weight (PT/LV,  g /100mg)& (CF/LV, ml /100mg/min). 
Nitrate concentration in coronary effluents, as a stable product of nitric oxide (NO), was 
measured by an endpoint one-step enzymatic assay using nitrate reductase, as described by 
Bories and Bories, (1995), and modified in tissues by Kassim, (1997).  
3.1.2 Effects of exercise on cardiac weights and post Ischemia-reperfusion (I/R) 
responses 
In this study, exercise was found to exert a trophic effect on cardiac chambers manifested by 
significant increase of the absolute & relative weights of atria, right ventricle, and left 
ventricle. Swimming is well recognized for its effectiveness in inducing myocardial 
hypertrophy (Evangelista et al., 2003). Exercise can protect cardiac function of the aging 
heart by protection against; loss of cardiac myocytes, reduction in number of myonuclei, 
reactive hypertrophy of remaining myocytes, and increased connective tissue in left 
ventricle (LV) of the aging rat heart. This protection is achieved through attenuation of age-
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induced elevation in Bax/Bcl-2 ratio, thereby inhibits apoptosis (Asha Devi et al., 2003a), 
and exerts its trophic effect.  
Although exercise-trained rats had significant increase in LV and LV/BW that indicates LV 
hypertrophy, they showed Peak developed tension similar to control which could be 
attributed to the increase of free radical in aged rats induced by exercise. Oxygen free 












































Fig. 6. Mean values± SEM of: absolute weights (mg) of atria (AT), right ventricle (RV), left 
ventricle (LV), and their relative weights (mg/g) (AT/BW), (RV/BW), (LV/BW) in control 
rats       , exercise-trained rats       , and vit. E-treated rats      .      
a. Significance calculated by least significant difference (LSD) at P < 0.05 from control 
group. 
b. Significance calculated by LSD at P < 0.05 between vit E-treated, and exercise-trained 
groups 
The results of ischemia-reperfusion of isolated hearts from both control and exercise-trained 
aged rats have shown the lack of tolerance to ischemia-reperfusion injury as regard 
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inotropic activities as well as myocardial flow rate. This could be explained in view of the 
increase in free radicals generation induced by exercise, even if small, was added to the 
increased free radicals generation induced by aging exceeding the antioxidant defense 
capacity of the heart leading to loss of beneficial cardio-protective effect of exercise on 
ischemia-reperfusion injury (Hatao et al., 2006).  




































Fig. 7. Mean absolute and percent values ± SEM of: heart beating rate(HR), Peak developed 
tension(PT), Peak developed tension per left ventricular weight(PT/LV), Time to peak 
tension (TPT), Half relaxation time(½ RT), and Coronary flow rate per left ventricular 
weight (CF/LV), at 30 minutes reperfusion of hearts isolated from control rats        , exercise- 
trained rats       , and vit. E- treated rats       .       
a. Significance calculated by least significant difference (LSD) at P < 0.05 from control 
group. 
b. Significance calculated by LSD at P < 0.05 between vit E-treated, and exercise-trained 
groups 
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The increased free radicals generation such as superoxide anion could react with NO to 
form peroxynitrate, decreasing NO biological activity. Peroxynitrate molecule by itself 
might play a significant role in oxidative tissue damage. This is supported in this study by 
the absence of increase of nitrates in the coronary effluent from exercise- trained aged rats at 
30 min reperfusion.  
 
Fig. 8. Mean values ±SEM of nitrates in coronary effluents (nmol/100mg LV/min) at 
baseline values, and 30 minutes of reperfusion in control rats       , exercise-trained rats      , 
and vit. E-treated rats      .  
a. Significance calculated by least significant difference (LSD) at P < 0.05 from control 
group. 
b. Significance calculated by LSD at P < 0.05 between vit E-treated, and exercise-trained 
groups 
Also, the heart beating rate of the exercise-trained rats could not be preserved after 30 min 
of reperfusion. This could be attributed to the increased free oxygen radicals in these rats, 
since oxyradicals have been implicated as a possible cause of reperfusion arrhythmias 
(Tanguy et al., 1998). However, the rate of relaxation of hearts excised from exercise-trained 
rats showed better tolerance to I/R after initial intolerance, and such improvement is in 
accordance to a recent report by Libonati et al., (2005), who found that sprint training in rats 
improves post-ischemic left ventricular diastolic stiffness due to up-regulation of 
myocardial glycolysis, with ATP production that protects the heart from ischemia-
reperfusion as it plays an important role in actin-myosin rigor bond dissociation, and 
regulating myocardial diastolic function. 
Effects of vitamin E on cardiac weights and Post Ischemia-Reperfusion (I/R) responses: 
Vitamin E has been reported to stimulate upregulation at the expression level of B cl-2 
gene, B cl-2 molecule is involved in the inhibition of apoptosis (Azzi et al., 2004). 
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Therefore, vitamin E by preventing apoptosis of myocardial cells could be expected to 
induce hypertrophy of the heart (trophic effect). However in case of vitamin E–treated 
rats, results have shown that the effect of vitamin E on the rate of growth of right and left 
ventricles was not similar. While the rate of growth of right ventricle was increased by the 
anti-apoptosis effects of vitamin E. The increase in left ventricle & left ventricle/ body 
weight was insignificant. This could be attributed to the favorable effects of vitamin E on 
reduction of blood pressure and blood viscosity (Costa et al., 2005). These two factors 
have been claimed to induce growth of left ventricle during aging (Ghali et al., 1997). 
Thereby, by eliminating these two factors, the rate of growth of left ventricle was 
decreased under the influence of vitamin E supplementation counteracting its trophic 
effect in aged rats.  
In contrast to aged control rats and exercise-trained aged rats, the isolated hearts from 
vitamin E-treated rats showed better tolerance as regard inotropic activity, especially force 
generation measured as peak developed tension as well as coronary flow rate. In 
accordance, Venditti et al., (1999) showed a protective action of vitamin E treatment against 
lipid peroxidation and cardiac dysfunction associated with ischemia- reperfusion in rats. 
Vitamin E decreases free radical deleterious effect on cell membrane, proteins, DNA, and 
decreases both ROS mediated direct ischemia-reperfusion mediated injury, as well as 
peroxynitrite-mediated injury and thereby preserving NO through preventing its 
inactivation by its transformation to peroxynitrite (Kamat, 2006). In support, this study 
showed significant increase of nitrates in coronary effluent from vitamin E- treated aged rats 
measured at 30 min of reperfusion.  
In view of the aforementioned data, vitamin E proved to be a cardio-protective agent as it 
attenuated the injury of post ischemia-reperfusion on the aged myocardium. This beneficial 
effect of vitamin E could be partially attributable to preservation of NO biological activity by 
preventing its transformation to the toxic compound peroxynitrite. 
On the other hand, the swim-training program adopted in this study, as regard tolerance to 
ischemia-reperfusion apart from improvement of half relaxation time, the swim-training 
program did not show other promising cardio-protective effects against cardiac changes 
associated with the aging process. 
Therefore, vitamin E supplementation could be recommended to aged people especially 
patients suffering from ischemic heart disease. Vitamin E could be used either alone or in 
combination with exercise training taking into consideration the duration and intensity of 
exercise program. 
Vitamin E and platelet function 
Platelets play a critical role in the pathophysiology of reperfusion (Gawaz, 2004). Platelet 
function is not static during ischemia-reperfusion. Instead, during ischemia regional platelet 
aggregability is increased. Systemic and regional platelet aggregability also increases during 
myocardial reperfusion. The mechanism of these responses is unknown but may be related 
to regional endothelial dysfunction created by ischemia. The response observed could also 
be explained by the release of proaggregatory mediators in the coronary and/or systemic 
circulation during ischemia-reperfusion (Gurbel et al., 1995).  
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Reperfusion induces an important inflammatory response, characterized by a massive 
production of free radicals and by the activation of the complement and leucocyte 
neutrophils (Gourdin et al., 2009). Platelets and neutrophils act synergistically in provoking 
postreperfusion cardiac dysfunction (Lefer et al., 1998). Activated platelets play an 
important role in the process of myocardial ischemia-reperfusion injury, and platelet-
derived P-selectin is a critical mediator (Xu et al., 2006), whereas platelet P-selectin promotes 
platelet interactions with leukocytes. Because platelets release potent proinflammatory 
chemokines and modulate leukocyte function, platelet accumulation in the postischemic 
microvasculature might significantly contribute to the manifestation of I/R injury (Massberg 
et al., 1998). 
Reperfusion of the tissue, subsequent to ischemia, results in burst of oxygen consumption 
with consequent generation of oxygen derived free radicals; the oxidant-anti oxidant status 
of the tissue is thrown out of balance and multi dimensional free radical mediated damage 
ensues. Since vitamin E is a potent natural anti-oxidant, its administration is expected to 
restore the imbalance. 
Effect of administration of 600 mg vitamin E each day, for six days, was observed on activity 
of some of the anti-oxidant enzymes and levels of malondialdehyde (as an index of free 
radical mediated damage) in the platelets of patients reperfused after myocardial infarction. 
It has been found that vitamin E administration significantly lowers the level of 
malondialdehyde in the patients. Vitamin E administration increases the activities of anti 
oxidant enzymes (superoxide dismutase, glutathione reductase and catalase) tested both in 
the patients and healthy controls. However, lowering of lipid peroxidation upon 
administration of vitamin E is specific for patients. These findings exhibit beneficial role of 
vitamin E administration in the management of the patients reperfused after myocardial 
infarction (Dwivedi et al., 2005). 
The results of Chen et al, (2002) suggested that the reduction of myocardial I/R injury with 
vitamin E supplementation may be the result of the inhibition of polymorphonuclear 
neutrophil (PMN) CD11b expression.  
Vitamin E supplementation in healthy subjects or patients with hypercholesterolemia was 
shown to diminish platelet function as assessed by ex vivo platelet aggregation of 11- 
dehydrothromboxane B2, a marker of in vivo platelet activation (Calzada et al., 1997; Davi et 
al., 1997). Celestini et al., (2002) demonstrated that vitamin E can potentiate the antiplatelet 
activity of aspirin by inhibiting the early events of platelet activation pathway induced by 
collagen. 
A study from our laboratory was to examine the possibility that vitamin E administration 
could exert an effect on blood elements and platelet aggregation. 
Materials and Methods  
Albino rats of both sexes weighing 180- 220 gm fed on a standard rat diet and fasted for 18- 
24 hours before sacrifice were used in this study. 
In vivo study: A total of 30 rats were used in this study. They were divided in two groups. 
Group I: Saline control group; rats in this group were injected with saline instead of vitamin 
E, daily for 5 consecutive days. Group II: vitamin E treated group; rats were injected with 
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vitamin E (300 mg/kg b.w.) intraperitoneally for five consecutive days. After 5 days all 
injections were stopped for 2 days. By the seventh day rats were anesthetized with 
pentobarbitone in a dose of 40 mg/kg b.w. 
Collection of blood samples: blood samples were obtained by arterial puncture from the 
abdominal aorta. One ml samples were collected into tubes containing EDTA for 
examination of RBCs and platelet counts, hemoglobin content and hematocrite values. 
Another blood samples were collected in chilled plastic tubes containing sodium citrate 
3.8gm/100 ml (9 volumes of blood to 1 volume of sodium citrate) and gently shaken. These 
blood samples were used for study of platelet aggregation. The citrated blood was 
centrifuged at 1500 r.p.m. for 5 min. The supernatant platelet rich plasma (PRP) was 
pipetted into clean plastic tubes. The remaining blood sample was centrifuged at 10,000 
r.p.m. for 10 min. to prepare platelet poor plasma (PPP). Standard PRP: the number of 
platelets in PRP was counted using coulter T-660 counter. The platelet number was adjusted 
to a standardized number of 3 x 105 platelet per µl by dilution with autologus platelet poor 
plasma. 
Aggregation study: platelet aggregation was performed using Chrono-Log automatic 
aggregometer (model 540-VC, Chrono-Log Corp, Harvertown, USA) coupled with 
computer and printer. ADP as an aggregating agent was used at a final concentration of 10 
uM. The maximum aggregation was recorded after 3 min. 
In vitro of vitamin E on platelet aggregation 
Collection of blood samples: blood was collected from normal rats, anaesthetized by 
pentobarbitone, by arterial puncture from abdominal aorta into chilled tubes containing 
sodium citrate 3.8 gm%. Preparation of standard PRP was carried out as described in the in 
vivo experiments. 
The in vitro effect of vitamin E on ADP- induced platelet aggregation was studied by 
exposing PRP to rising concentrations of the vitamin 1,2,3,4 and 5 mg/ml. Equal volumes of 
saline were added to control samples. 
Aggregation study: was carried as described above in vivo experiments. 
Statistical analysis of the data was done using Student's "t" test for unpaired data according to 
Fisher and Yates (1957) P  0.05 was considered significant. 
Regression study: linear regression analysis was used to relate different parameters to a 
certain outcome (platelet aggregation) to find out the highest beta coefficient and the most 
important factor affecting this outcome. This analysis was performed on SPSS windows 
version eight. 
Results 
Table 1 portrays the results of in vivo effects of vitamin E on hematological parameters. 
RBCs count, Hb content and PCV showed slight and insignificant changes in vitamin E 
treated rats compared to their saline controls. The number of platelets was insignificantly 
decreased in vitamin E treated animals. However platelet aggregation induced by ADP 
showed a significant decrease (P  0.05) in this group (table 2 and figure 9).  
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Regression analysis: as seen in fig. 10, multiple regression analysis of platelet aggregation 
against other parameters. Only a significant negative correlation between platelet number 
and platelet aggregation was seen in vitamin E treated group (P  0.03). 
In vitro effect of vitamin E on platelet aggregation: the platelet aggregation effect of ADP in 
presence of rising concentration of vitamin E showed significant inhibition (P 0.01) only 
when vitamin E was added at a final concentration of 5 mg/ml. Addition of vitamin E in 
smaller concentrations of 2- 4 mg/ml final concentration produced insignificant inhibition of 
platelet aggregation. Almost no effect was seen when vitamin E was added at a final 















(15) 6.54±0.3 12.24±0.5 36.15±1.2 1146±71.12 68.1±1.9 
Vitamin E treated 
rats 
(15) 
6.33±0.2 11.93±0.3 35.3±0.9 1068±53.1 58.9±4 
P NS NS NS NS  0.05 
Data are mean± SEM In parenthesis is the number of observations   NS: non significant 
Table 2. Red blood cell count (RBCs), hemoglobin level (Hb), packed cell volume (PCV), 
platelet count and platelet aggregation in saline control and vitamin E treated rats. 
Additions to normal PRP 
 Final concentration of vitamin E 
Saline control 
 1mg/ml 2mg/ml 3mg/ml 4mg/ml 5mg/ml 
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Regression analysis: as seen in fig. 10, multiple regression analysis of platelet aggregation 
against other parameters. Only a significant negative correlation between platelet number 
and platelet aggregation was seen in vitamin E treated group (P  0.03). 
In vitro effect of vitamin E on platelet aggregation: the platelet aggregation effect of ADP in 
presence of rising concentration of vitamin E showed significant inhibition (P 0.01) only 
when vitamin E was added at a final concentration of 5 mg/ml. Addition of vitamin E in 
smaller concentrations of 2- 4 mg/ml final concentration produced insignificant inhibition of 
platelet aggregation. Almost no effect was seen when vitamin E was added at a final 
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Fig. 9. Tracing of ADP- induced platelet aggregation of Vitamin E-treated rats (B) compared 
to saline treated rats (A). 
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Fig. 10. Correlation between platelet aggregation and platelet count among vitamin E-
treated rats and saline treated rats (by multiple regression analysis) 
 




Fig. 11. Tracing of ADP- induced platelet aggregation of normal rats PRP in presence of 
vitamin E in concentrations of 1, 2, 3, 4 and 5 mg/ml respectively (B- F) compared to saline 
control (A) 
The data reported here demonstrated that administration  of megadose of vitamin E (300 
mg/kg for one week) to rats, produced slight and nonsignificant changes in red blood cell 
counts, hemoglobin content, packed cell volume. Platelet counts showed an insignificant 
decrease. However, the platelet aggregation responses to ADP of PRP from treated rats were 
significantly inhibited. This finding shows the safety of vitamin E in this supra-physiological 
dose of 300 mg/kg on blood parameters tested. 
On addition of vitamin E to normal PRP in vitro, the platelet aggregating effect of ADP 
showed significant inhibition only when vitamin E was added at a final concentration of 5 
mg/ml. Addition of vitamin E in smaller concentrations of 2- 4 mg/ml produced 
insignificant inhibition of platelet aggregation. Almost no effect was seen when vitamin E 
was added at a final concentration of 1 mg/ml. 
From these data, it can be concluded that this supra physiological dose of vitamin E is safe 
concerning the blood parameters tested.  
The observation in the present study that vitamin E when added in vitro to normal rat 
PRP caused significant inhibition of platelet aggregation in response to ADP; illustrate 
that vitamin E by itself exerts a direct antiplatelet effect. Higashi & Kikuchi (1974) were 
the first to demonstrate that vitamin E inhibits the aggregation of platelets using 
hydrogen peroxide as the aggregating stimulus. Subsequent studies by Steiner & 
Anastasi, (1976) demonstrated that vitamin E also inhibited platelet aggregation response 
to epinephrine, collagen and ATP. Moreover, Freedman and Keaney, (2001) found that 
platelet incorporation of vitamin E both in vitro and in vivo leads to dose-dependent 
inhibition of platelet aggregation in response to agonists such as arachidonic acid and 
phorbol ester.  
 




Fig. 11. Tracing of ADP- induced platelet aggregation of normal rats PRP in presence of 
vitamin E in concentrations of 1, 2, 3, 4 and 5 mg/ml respectively (B- F) compared to saline 
control (A) 
The data reported here demonstrated that administration  of megadose of vitamin E (300 
mg/kg for one week) to rats, produced slight and nonsignificant changes in red blood cell 
counts, hemoglobin content, packed cell volume. Platelet counts showed an insignificant 
decrease. However, the platelet aggregation responses to ADP of PRP from treated rats were 
significantly inhibited. This finding shows the safety of vitamin E in this supra-physiological 
dose of 300 mg/kg on blood parameters tested. 
On addition of vitamin E to normal PRP in vitro, the platelet aggregating effect of ADP 
showed significant inhibition only when vitamin E was added at a final concentration of 5 
mg/ml. Addition of vitamin E in smaller concentrations of 2- 4 mg/ml produced 
insignificant inhibition of platelet aggregation. Almost no effect was seen when vitamin E 
was added at a final concentration of 1 mg/ml. 
From these data, it can be concluded that this supra physiological dose of vitamin E is safe 
concerning the blood parameters tested.  
The observation in the present study that vitamin E when added in vitro to normal rat 
PRP caused significant inhibition of platelet aggregation in response to ADP; illustrate 
that vitamin E by itself exerts a direct antiplatelet effect. Higashi & Kikuchi (1974) were 
the first to demonstrate that vitamin E inhibits the aggregation of platelets using 
hydrogen peroxide as the aggregating stimulus. Subsequent studies by Steiner & 
Anastasi, (1976) demonstrated that vitamin E also inhibited platelet aggregation response 
to epinephrine, collagen and ATP. Moreover, Freedman and Keaney, (2001) found that 
platelet incorporation of vitamin E both in vitro and in vivo leads to dose-dependent 
inhibition of platelet aggregation in response to agonists such as arachidonic acid and 





Although it is best known for its antioxidant activity the exact mechanism of the antiplatelet 
effect of vitamin E is not exactly known and one of the following mechanisms may operate. 
First, it can be attributed to altered metabolism of prostaglandins. The vascular generation 
of prostacyclin (PGI2) is higher and the platelet thromboxane A2 generation is lower than 
normal. This view is supported by the findings of Steiner and Anastasi (1976) and others 
(Karpen et al., 1981; Pritchard et al., 1982; Pignatelli et al., 1999) that vitamin E inhibits 
platelet thromboxane A2 synthesis. On the other hand, PGI2 synthesis is stimulated possibly 
by reduction of cellular peroxide level (Gilbert et al., 1983). Second, the inhibition of platelet 
aggregation can be explained by the ability of vitamin E to inhibit intracellular mobilization 
of sequestrated calcium from the dense tubular system of the cytoplasm (Srivastava, 1986). 
Third, by its membrane stabilizing action, vitamin E would impair platelet release reaction. 
This view is supported observations of Feki et al., (2001) that vitamin E by its antioxidant 
effect, protects molecules and tissue against the deleterious effect of free radicals and also 
contributes to the stabilization of biological membranes. Fourth, unrelated to its antioxidant 
action, vitamin E was shown to inhibit protein kinase C (PKC) in various cell types with 
consequent inhibition of platelet aggregation (Azzi et al., 2002; Freedman et al., 1996; 
Freedman and Keaney, 2001). Further, vitamin E includes inhibitory effects are the result of 
specific interactions with component of the cell e.g. proteins, enzymes and membranes 
(Ricciarelli et al., 2002). 
Vitamin E attenuated P-selectin expression on activated human platelets and thus inhibited 
the P-selectin–dependent function, platelet–mononuclear cell (MNC) interaction. The 
mechanism probably was related to the inhibition of PKC activity in platelets. Since P-
selectin is an important atherothrombogenic adhesion molecule, this finding will provide us 
new insights into the mechanism by which dietary vitamin E inhibits thrombosis and 
atherogenesis and thereby reduces the risk of coronary artery diseases (Murohara et al, 
2004).  
Although these studies from our laboratory have shown that vitamin E administered in 
megadose, could provide a protective effect against the cardiac responses to the injury of 
post I/R. Further studies should be conducted to test the possibility of using vitamin E in 
cardiac surgery. 
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1. Introduction  
Connexin (Cx) is the basic unit in the composition of gap junction channels but also exist in 
non-junctional unapposed hemichannels (Hc). The gap junction channels are formed by 
apposition of two hexameric CxHc from adjacent cells and play an essential role in cardiac 
function by allowing conduction of electrical impulse and exchange of biologically 
important molecules between myocytes. While most CxHc are engaged in gap junction 
formation, some unapposed Hc are present in association with various organelles 
(mitochondria, ER, etc.) but also in sarcolemma where they connect the intracellular and 
extracellular spaces. Recent evidence indicates that unapposed Hc in the plasma membrane 
perform functions different from those achieved by gap junction channels, mainly by 
providing pathways between the cytosol and the extracellular space allowing movement of 
ions and other small metabolites (Bennett et al., 2003; Goodenough & Paul, 2003), release of 
ATP and NAD+ (Bruzzone et al., 2001; Cotrina et al., 1998), regulation of cell volume (Quist 
et al., 2000), and the activation of survival pathways (Plotkin et al., 2002). These Hc are 
therefore believed to play a prominent role in cellular ion homoeostasis and signalling.  
In normal myocardium, most of the Cx43 are phosphorylated (van Veen et al., 2001). 
However, under ischemic stress, the amount of non-phosphorylated Cx43 increases (Beardslee 
et al., 2000). Phosphorylation causes the unapposed Cx43Hc to close whereas, conversely, 
Cx43 dephosphorylation increases Hc conductance and permeability (Bao et al., 2007; 
Contreras et al., 2002; John et al., 1999b; Kondo et al., 2000; Li et al., 2001), an effect that can 
result in abnormal elevation of intracellular sodium and calcium loads (Li et al., 2001), release 
of ATP (Braet et al., 2003a; Braet et al., 2003b; Contreras et al., 2002), osmotic imbalance (John et 
al., 1999b; Li et al., 2001; Quist et al., 2000), swelling of myocytes (Jennings et al., 1986; 
Steenbergen et al., 1985; Tranum-Jensen et al., 1981) and lead to irreversible tissue injury 
(Shintani-Ishida et al., 2007) and cell death. Several kinases are involved in Cx43 
phosphorylation (Cottrell et al., 2003; Duncan & Fletcher, 2002; Shi et al., 2001; TenBroek et al., 
2001; Warn-Cramer et al., 1998), including protein kinase C (PKC) (Lampe et al., 2000). In 
humans and many other mammalian species, PKC is the protein kinase for which Cx43 
contains the largest number of phosphorylation sites. For instance, rat Cx43 contains 14 
putative sites for PKC whereas only 3 have been reported for PKA, 4 for PKG, and 3 for MAPK 
(van Veen et al., 2001). A major physiological importance of the PKC resides in the existence of 
multiple PKC isoforms that can selectively affect particular targets in different conditions. The 
apparent preferential activation in response to different conditions and stimuli suggests that 
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various PKC isoforms have specific cellular and cardiovascular functions. For instance, data 
from several laboratories (Chen et al., 2001a; Dorn et al., 1999; Gray et al., 1997; Inagaki et al., 
2003; Inagaki et al., 2005; Liu et al., 1999; Tanaka et al., 2004; Tanaka et al., 2005) shows that 
selective activation of PKC isoform provides protection against ischemia damage, whereas 
activation of PKC aggravates the injury. Indeed, PKC-selective modulator drugs are currently 
under development for the treatment of a variety of diseases involving PKC isoforms (Bar-Am 
et al., 2007; Casellini et al., 2007; Serova et al., 2006).  
Until recently, unapposed CxHc were thought to remain closed and that their opening would 
induce metabolic stress and cell death. In fact, in the first study of Hc opening, which was 
conducted in Xenopus oocytes expressing Cx46, non-selective inward current, swelling, and 
cell death were observed (Paul et al., 1991). Subsequently, the opening of CxHc and 
consequent cell death following an ischemic insult were reported in different cell models 
including myocytes (Kondo et al., 2000; Li et al., 2001; Shintani-Ishida et al., 2007), astrocytes 
(Contreras et al., 2002; John et al., 1999a; John et al., 1999b), and renal tubule cells (Vergara et 
al., 2003). The involvement of Cx43Hc was also reported in cell lines, such HEK293 (John et al., 
1999b) and HeLa (Contreras et al., 2002) cells, transfected with Cx43 that became more 
susceptible to death by simulated ischemia than non-transfected cells, a difference ascribable 
to Cx43Hc opening. Therefore, the delineation of PKC targets in the heart and the 
characterization of the functional role of the various PKC isoforms in the modulation of these 
targets will offer a mechanistic insight into the pathogenesis of ischemia/reperfusion injury 
and aid in the development of novel pharmacological interventions for cardioprotection. 
The assessment of the functional role of PKC isoforms in the modulation of Cx43Hc and the 
role of Cx43Hc in cardiac protection against ischemia/reperfusion injury have largely been 
limited by the fact that selective modulators for PKC isoforms and selective inhibitors for 
Cx43Hc have not been available until recently. Therefore, two major objectives of the present 
study aimed respectively: 1) to determine the functional role of PKC isoforms - especially those 
involved in heart protection - in the regulation of Cx43Hc; and, 2) to reveal the importance of 
the inhibition of Cx43Hc in protection against ischemia/reperfusion injury. To this end, two 
unique sets of synthetic peptides were utilized in the course of the research: 1) a matrix of PKC 
isoform-selective activator and inhibitor peptides. In combination with the patch clamp 
technique, the peptides were individually delivered into the cytosol of the ion channels-
deficient tsA201 cells exogenously expressing Cx43 to activate/inhibit each of the PKC 
isoforms and assess their specific roles in the modulation of Cx43Hc. 2) a pair of structural 
Cx43-mimetic peptides, Gap26 and Gap27. These peptides are presumed to have the ability to 
block Cx43Hc by binding to their extracellular loops and to have little or no immediate effects 
on gap junction channels (Evans et al., 2006; Leybaert et al., 2003; Martin et al., 2005; Pearson et 
al., 2005). The consequent effects of Cx43Hc inhibition following the administration of 
structural Cx43-mimetic peptides and their therapeutic potentials were assessed in isolated 
cardiomyocytes and in intact rat hearts under ischemic settings. 
The use of Cx43-mimetic peptides to study unapposed CxHc encloses several benefits 
compared to other currently used techniques and represents an attractive pharmacological 
tool for in vivo studies. The specificity that Cx43-mimetic peptides have vis-à-vis Cx43Hc, 
and to a lesser extent gap junction channels, denotes a therapeutic advantage over PKC 
peptides and other compounds (e.g. heptanol) that are also involved in cardioprotection but 
concurrently affect a variety of other intracellular substrates. Furthermore, the accessibility 
to the binding sites on the extracellular loops of Cx43Hc eliminates the need to conjugate Cx 
peptides with cell penetrating carriers which may exert toxic effect on cells and delay the 
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delivery process (Zorko & Langel, 2005). Finally, the use of transgenic or knockout animal 
models has been widely utilized to study the roles of multiple cell proteins and ion 
channels; however, using such techniques to identify the role of specific Cx during 
ischemia/reperfusion is challenged by the fact that sustained loss of Cx43 severely affects 
gap junctional communication and alters cardiac development. Therefore, we believe that if 
our hypothesis is confirmed, these peptides will represent a promising pharmacological tool 
with which to counteract cell death in the cardiac ischemia/reperfusion pathology. 
2. Knowledge to date 
2.1 Structure and expression of connexins in the heart 
There is at least twenty-one known types of Cx identified in human (Goodenough & Paul, 
2003; Saez et al., 2003; Willecke et al., 2002) usually named according to their molecular 
weight (Beyer et al., 1987). Each Cx is composed of four transmembrane segments, two 
extracellular and one intracellular loop as well as one amino-terminal and one carboxy-
terminal regions located in the cytosol (Fig. 1). Connexins differ in the length of their 
cytosolic carboxy terminus, which is characterized by the presence of several 
phosphorylation sites. A connexin-formed Hc consists of an oligomeric assembly of six 
connexins that delineate an aqueous pore. Several connexins are expressed in cardiac 
myocytes in different amounts and combinations depending on regions of the heart (Zipes  
& Jalife , 2004). The ventricular muscle fibres express abundant amounts of Cx43 but only 
trace levels of Cx45 and no detectable Cx40. Most studies of connexins in the heart have 
focused on their role in gap junctions, but a few studies have also characterized Cx43Hc 
properties in isolated cardiac myocytes (John et al., 1999b; Kondo et al., 2000).  
2.2 Unapposed Cx43Hc opening in ischemia/reperfusion injury 
The conductance and permeability of Hc, as well as gap junction channels, are regulated by 
intracellular protons changes (Ek-Vitorin et al., 1996; Morley et al., 1997; Spray & Burt, 1990) 
and calcium concentrations (Spray et al., 1985; Spray & Burt, 1990) but also via 
phosphorylation of specific serine, threonine and tyrosine residues by several kinases 
(Lampe & Lau, 2000) especially PKC (Bowling et al., 2001; Doble et al., 2000; Lampe et al., 
2000).  As indicated above, the conductance and permeability of the unapposed Cx43Hc are 
increased once Cx43 becomes dephosphorylated (Burt & Spray, 1988; Lau et al., 1991; Saez et 
al., 1986), while being reduced with increased Cx43 phosphorylation (Kwak & Jongsma, 
1996). The dephosphorylation of Cx43 has been proposed as a key mechanism to open Hc 
during metabolic inhibition in cortical astrocytes in culture (Fig. 2) (Contreras et al., 2002). 
While Cx43 is phosphorylated under physiological conditions (Schulz et al., 2003; van Veen 
et al., 2001) and remains so in the first few minutes of ischemia (Schulz et al., 2003), 
subsequent dephosphorylation of Cx43 occurs with increasing duration of myocardial 
ischemia (Beardslee et al., 2000; Jain et al., 2003; Jeyaraman et al., 2003; Miura et al., 2004; 
Schulz et al., 2003) a process that has been associated with the opening of unapposed 
Cx43Hc (John et al., 1999b; Li et al., 2001) which results in metabolic stress and cell death. 
Based on single Hc conductance measurements, it was suggested that opening of only 50 Hc 
is sufficient to drown the cell with Na+ (John et al., 1999b). As a result, Na+ overload induces 
the activation of reverse Na+-Ca++ exchange and hence promotes intracellular Ca++ 
accumulation (Barry & Bridge, 1993; Silverman & Stern, 1994), irreversible cell injury and 
arrhythmogenic transient inward currents (Tani & Neely, 1989). Altogether, these data 
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endorse the theory of the involvement of the unapposed Hc in ischemic-induced injury and 
support our hypothesis that inhibition of Hc during ischemia is an important determinant 
for cardioprotection against ischemia/reperfusion injury. 
 
Fig. 1. Connexin 43 structures. A, secondary structure of Cx43 with insert showing a 
tridimensional view from the top; B, a single Hc is formed by the association of six connexins 
to form central permeable pore; C, a gap junction channel is formed when two Hc from 
adjacent cells appose and form a pathway between the cytosols of the neighbouring cells. 
Ischemic preconditioning. The phosphorylation status of total Cx43 is affected by brief 
episodes of ischemia which reduce the adverse effects of subsequent myocardial ischemia 
(Cohen et al., 1991; Murry et al., 1986; Shiki & Hearse, 1987). In fact, ischemic preconditioned 
hearts from pigs (Schulz et al., 2003), rabbits (Miura et al., 2004), and rats (Jain et al., 2003) 
show preserved total Cx43 phosphorylation levels following prolonged ischemia. PKC is 
generally acknowledged as a key mediator of ischemic preconditioning (Schulz et al., 2003). 
One of the aims of this study is to establish that specific PKC isoforms are involved in the 
cascade of events leading to the preservation of the Cx43 phosphorylated state and 
cardioprotection. While cardioprotection is generally thought to involve phosphorylation of 
Cx43 gap-junction channels (Chen et al., 2005; Garcia-Dorado et al., 1997; Garcia-Dorado et 
al., 2004; Li et al., 2002; Rodriguez-Sinovas et al., 2006; Schwanke et al., 2002; Schwanke et 
al., 2003), experiments on isolated myocytes provided evidence that efficient ischemic 
preconditioning does not require the existence of gap junction channels (Li et al., 2004). 
Accordingly, we further hypothesize that unapposed Cx43 Hc (through their opening) are 
involved in ischemia-induced cell damage. 
Other potential end-effectors of ischemic damage. Although this chapter focuses on the 
role of PKC isoform-dependent Cx43 HC phosphorylation in cardioprotection, one should 
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be aware that several other mechanisms have been implicated in ischemia/reperfusion 
injury and cardioprotection. These include, but are not limited to, Na/H exchanger, 
mitochondrial permeability transition pore (MPTP) and KATP channels. While inhibition of 
Na/H exchanger has been shown to be beneficial for protection against ischemia (Xiao & 
Allen, 2000), PKC activation during ischemic preconditioning induces enhancement rather 
than inhibition of the Na/H exchanger (Kandasamy et al., 1995). The involvement of Na/H 
exchanger in heart conditioning is therefore uncertain (Avkiran, 1999). Another potential 
end-effector in ischemia-related protection is the MPTP (Hausenloy et al., 2002). While it has 
been proposed that MPTP inhibition in ischemia/reperfusion underlies the protection 
against injury in isolated rat hearts (Hausenloy et al., 2002), only a single study, thus far, has 
provided direct evidence for attenuated MPTP opening in preconditioned heart (Javadov et 
al., 2003). A significant number of studies support the involvement of the mitochondrial 
KATP channels in cardiac protection against ischemia (Gross & Fryer, 1999; Liu & O'Rourke, 
2001; Sato & Marban, 2000). It has been suggested that opening of mitochondrial KATP  
 
Fig. 2. Hemichannels activation. During ischemic stress, the decrease in PKC activity leads 
to increase in the dephosphorylated forms of Cx43, this causes the activation of Cx43Hc.  
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channels causes mitochondrial depolarisation, resulting in attenuated Ca overload during 
ischemia (Weiss et al., 2003). However, the protective effect of this reduction has never been 
experimentally demonstrated. Nevertheless, it should be noted here, that KATP channels are 
also modulated by PKC (Wang & Ashraf, 1999). Indeed, other end-effectors were also 
proposed to be directly involved in protection against ischemia/reperfusion injury. These 
include cGMP/PKG, calpains, cytoskeleton, and the tumor necrosis factor; the definitive 
evidence for their role on cardioprotection remains however obscure. 
2.3 Function and regulation of CxHc 
Currents from Hc have been successfully characterized in various native cell types (Hofer & 
Dermietzel, 1998; Kondo et al., 2000; Stout et al., 2002; Vergara et al., 2003) as well as in 
Xenopus oocytes (Ebihara & Steiner, 1993; Gomez-Hernandez et al., 2003; Gupta et al., 1994; 
Pfahnl et al., 1997; Pfahnl & Dahl, 1999; White et al., 1999; Zoidl et al., 2004) and in mammalian 
expression systems (Bukauskas et al., 2006; Contreras et al., 2003; Valiunas, 2002). Basically, 
they behave like large conductance ion channels that share properties with gap junction 
channels in terms of permeability and gating (DeVries & Schwartz, 1992; Li et al., 1996; Trexler 
et al., 1996). Nevertheless, opening of these channels is significantly facilitated by exposure to 
calcium-free extracellular solutions (DeVries & Schwartz, 1992; Li et al., 1996), membrane 
depolarization (Hofer & Dermietzel, 1998), or metabolic inhibition (Contreras et al., 2002; John 
et al., 1999b). Cx43Hc have been implicated in diverse functions including volume regulation 
(Quist et al., 2000), efflux of NAD+ and ATP (Bruzzone et al., 2001; Cotrina et al., 1998; Stout et 
al., 2002), influx of Na+ and Ca2+ ions (Contreras et al., 2002; John et al., 1999b; Kondo et al., 
2000) and activation of survival pathways (Plotkin et al., 2002). 
Under resting conditions, Hc are predominantly in a closed state but their gating can be 
regulated by several factors, including by phosphorylation of Cx43 (Saez et al., 2005). 
Several functional states of single Cx43Hc have been described; closed Hc, fully open Hc, 
and an intermediate state between the fully open and the closed states (Contreras et al., 
2003). On western blot, Cx43 exhibits three bands reflecting the presence of three functional 
states of Cx43: a highly phosphorylated, a partially phosphorylated and a non-
phosphorylated state (Hertzberg et al., 2000; Musil et al., 1990; Saez et al., 1997; VanSlyke & 
Musil, 2000). Although Cx43 is a target protein for several kinases (Lampe & Lau, 2000), we 
are particularly interested in modulation by individual PKC isoforms. Because activation of 
PKC and/or inhibition of PKC prior to, during or even following an ischemic insult was 
shown to confer cardioprotection against injury (Chen et al., 2001a; Dorn et al., 1999; Gray et 
al., 1997; Inagaki et al., 2003; Inagaki et al., 2005; Liu et al., 1999; Tanaka et al., 2004; Tanaka 
et al., 2005); we believe that this protective effect is due, at least in part, to the inhibitory 
effect that PKC exerts on Cx43Hc (Bao et al., 2004a; Bao et al., 2004b). Therefore, we 
investigated the functional role of the PKC, as well as the other cardiac PKC isoforms, in 
the modulation of Cx43Hc. 
2.4 PKC Isoform-selective activator and inhibitor peptides 
PKC consists of a family of at least twelve closely related isoforms (McDonald et al., 1994; 
Nishizuka, 1988; Osada et al., 1992) which regulate biochemical processes by phosphorylation 
of cellular proteins on serine or threonine residues. Molecular cloning has revealed that PKC 
family can be divided into three major groups (Fig. 3). The conventional PKCs or cPKC consist 
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investigated the functional role of the PKC, as well as the other cardiac PKC isoforms, in 
the modulation of Cx43Hc. 
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Nishizuka, 1988; Osada et al., 1992) which regulate biochemical processes by phosphorylation 
of cellular proteins on serine or threonine residues. Molecular cloning has revealed that PKC 
family can be divided into three major groups (Fig. 3). The conventional PKCs or cPKC consist 
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of , I, II and  and have activity strongly dependent on calcium (Ca), phospholipid, and 
diacylglycerol (DG) (Nishizuka, 1988). The second group (novel PKC or nPKC) comprises the 
, ,  and  isoforms and exhibits Ca-independent activity. And finally, members of the 
atypical PKC group or aPKC,  and / are insensitive to DG, phorbol esters and Ca. There is 
also a PKC that does not fit into any of the above groups and is sensitive to phospholipids 
and phorbol esters but insensitive to Ca. Remarkable progress has been made in 
understanding how extracellular stimuli act as upstream triggers to induce activation of 
particular PKC isoforms in cardiomyocytes (endothelin, phenylephrine, etc.) (Clerk et al., 1994; 
Clerk & Sugden, 2001; Rybin et al., 1999). Moreover, there is much evidence supporting the 
concept that PKC functions in an isoform-dependent manner and that specific cardiac 
manifestations depend on the activation of individual isoforms, not the activity of the entire 
PKC family (Chen et al., 2001a; Clerk & Sugden, 2001; Hahn et al., 2002; Mochly-Rosen & 
Gordon, 1998). Indeed,  the  successful  development of isoform-specific modulator peptides 
and their use in combination with patch clamp technology (Hu et al., 2000; Xiao et al., 2001; 
Xiao et al., 2003) have empowered the investigation of isoform-selective roles of PKC family in 
ion channels modulation. Briefly, activator peptides by binding to one particular PKC isoform 
cause a conformational change of the enzyme structure which exposes its catalytic site, and 
enables its anchoring to the target molecule. On the opposite side, inhibitor peptides mimic 
structurally the PKC isoform binding site on the target protein or the target protein binding 
site on PKC and therefore inhibit the function of that particular PKC isoform. The specificity 
and sequences of the activator and inhibitor peptides of PKC isoforms are listed in Table 1. 
These peptides can be obtained through commercial custom peptide synthesis. 
 
Fig. 3. Protein kinase C superfamily, classes of various PKC isoforms with corresponding 
structures. 
 




Peptide Specificity Sequence 
αC2-4 αPKC inhibitor S-L-N-P-Q-W-N-E-T 
βIV5-3 βIPKC inhibitor K-L-F-I-M-N 
βIIV5-3 βIIPKC inhibitor Q-E-V-I-R-N 
βC2-2 βPKC activator S-V-E-I-W 
δV1-1 δPKC inhibitor S-F-N-S-Y-E-L-G-S-L 
εV1-2 εPKC inhibitor E-A-V-S-L-K-P-T 
εV1-7 εPKC activator H-D-A-P-I-G-Y-D 
ηV1-2 ηPKC inhibitor E-A-V-G-L-Q-P-T 
Pentalysine control K-K-K-K-K 
Table 1. PKC modulator peptides. List of the available PKC isoform-specific modulator 
peptides with their sequences and specificity. 
2.5 Previous findings and implication for the current study  
Previous data from several laboratories show that selective translocation/activation of the 
PKC isoform provides protection against ischemic injury during ischemic/hypoxic 
preconditioning (Chan et al., 1995; Chou & Messing, 2005; Dorn et al., 1999; Gray et al., 1997; 
Liu et al., 1999; Ytrehus et al., 1994) and post-conditioning (Penna et al., 2006b; Philipp et al., 
2006; Zatta et al., 2006) in different experimental paradigms. On the basis of the beneficial 
effects of PKC translocation/activation and the fact that it can form a complex with Cx43 
and phosphorylate the protein (Ping et al., 2001), we put forth that this particular isoform is 
critically involved in protection against ischemic injury. Therefore, the elucidation of the 
functional protective role of PKC may allow for the identification of pharmacological 
agents that mimic the PKC isoform action on one particular target, i.e. Cx43Hc, without 
affecting other key molecules in cellular function. Certainly, other isozymes have been 
demonstrated to phosphorylate Cx43, notably PKC (Bowling et al., 2001), but the 
functional implications in Cx43Hc regulation has not been assessed. 
2.6 Structural Cx-mimetic peptides as inhibitors of CxHc function 
Another experimental strategy using a different set of peptides has been utilized in the 
course of this study: the structural mimetics of Cx43. The conventional gap junction blockers 
(as heptanol) that are available to date act on both whole gap junction channels and 
unapposed Hc. Interestingly, Cx-mimetic peptides have recently emerged as powerful tools 
capable of blocking primarily the unapposed Cx43Hc by mimicking short amino acids 
sequences on the extracellular loops of Cx (references (Braet et al., 2003a; Evans et al., 2006; 
Leybaert et al., 2003; Martin et al., 2005; Pearson et al., 2005) testing ATP release from 
various non-cardiac cell types). Here, we investigated the consequent effect of two Cx43-
mimetic peptides, Gap26 and Gap 27, on the electrophysiology of Cx43Hc exogenously 
expressed in the tsA201 cells using the patch clamp technique. In addition, we have 
designed multiple experimental protocols to assess the therapeutic potentials of these 
peptides against ischemia/perfusion injury in various settings including isolated cell model 
and intact hearts. 
Initially, the Cx-mimetic peptides were designed with the intention of selectively blocking 
gap junction channels by intercepting the apposition of pairs of Hc from adjacent cells (Dahl 
et al., 1994; Warner et al., 1995), but have subsequently emerged as potent blockers for the 
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unapposed CxHc with little or no immediate effect on gap junction (Braet et al., 2003a; 
Evans et al., 2006; Leybaert et al., 2003; Martin et al., 2005; Pearson et al., 2005).  
Particularly, Gap26 and Gap27 peptides have recently emerged as powerful tools that block 
unapposed Cx43Hc (Braet et al., 2003a; Evans et al., 2006; Leybaert et al., 2003; Martin et al., 
2005; Pearson et al., 2005) by mimicking short amino acids sequences on the first 
(VCYDKSFPISHVR) and second (SRPTEKTIFII) extracellular loops of Cx43, respectively 
(Fig. 4). Both sequences contain conserved motifs that are involved in connexin-connexin 
interaction in gap junction channels (Dahl et al., 1992; Warner et al., 1995). These motifs are 
not consistently found in other cell surface proteins suggesting that Gap26 and Gap 27 
specifically interact with Cx43 without interfering with other Cx or surface proteins (Braet et 
al., 2003a; Isakson et al., 2006; Warner et al., 1995). In fact, the selective affinity of Gap26 and 
Gap27 toward Cx43Hc was first reported in 2003 by Braet and collaborators (Braet et al., 
2003a; Braet et al., 2003b). In their studies, Gap26 and Gap27 were shown to selectively block 
the uptake of a reporter dye and the release of ATP in brain endothelial cells and Cx43-
expressing HeLa cells without reducing gap junctional coupling. Subsequently, Cx-mimetic 
peptides were shown to consistently suppress the bi-directional permeability, i.e. dye 
uptake and ATP release, of the unapposed CxHc without affecting gap junctional coupling 
in several cell types including brain endothelium, retinal epithelium, and bladder cancer  
 
Fig. 4. Connexin 43 and its structural-mimetic peptides. Gap26 and Gap27 mimic the 
structure of first (EL 1) and second (EL 2) extracellular loops of Cx43, respectively. 
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epithelium cells, as well as transfected HEK293, HeLa, C6 glioma and ECV304 cell lines (De 
Vuyst et al., 2006; Leybaert et al., 2003; Pearson et al., 2005). Although, the mechanism that 
underlies the affinity of Cx-mimetic peptides toward Hc is currently not known, a possible 
explanation could be the accessibility of the extracellular loops of unapposed Hc compared 
to those of gap junction channels which are engaged in the Hc-Hc apposition and are 
therefore less accessible for interactions with exogenous peptides. On the other hand, it is 
still not clear how binding of these peptides to connexins causes a block of the Hc. 
3. Experimental design and methods 
In summary, this study was designed to test the hypothesis that the cardioprotective effect 
attributed to PKC activation is mediated, at least in part, through the closure of the unapposed 
Cx43Hc and their decreased conductance. Specifically, the study aims to assess the following: 
1. Unapposed Cx43Hc function is selectively and differentially regulated by various 
isoforms of PKC. Particularly, phosphorylation of Cx43 by PKC inhibits unapposed 
Cx43Hc. 
2. Inhibition of the Cx43Hc, using the synthetic structural Cx43-mimetic peptides Gap26, 
confers sustained cardioprotection against ischemia/reperfusion injury by 
counteracting the ischemia-induced dephosphorylation effect on the unapposed 
Cx43Hc. 
Therefore, our specific objectives are summarized as follows: 
1. To dissect functional roles that individual PKC isoforms exert in the modulation of 
Cx43Hc using the unique matrix of PKC isoform-specific activator and inhibitor 
peptides in tsA201 cells transiently transfected with Cx43. 
2. To test whether Cx43-mimetic peptide, Gap26, confers resistance to isolated rat 
ventricular myocytes against ischemia-induced cell death. 
3. To test whether Gap26 confers cardioprotection against ischemia/reperfusion to the 
perfused intact heart.  
3.1 Dissection of functional roles of PKC isoform 
The matrix of PKC isoforms-specific modulator peptides (Table 1) was utilized to dissect and 
interrogate the individual PKC isoform roles in the modulation of Cx43Hc. Cx43Hc-mediated 
currents are recorded from transfected tsA201 cells using the patch clamp technique in whole 
cell configuration as described (Hawat & Baroudi, 2008). Cx43Hc currents were induced by 
incubating cells in a low-Ca bath solution. The selective inhibitor and activator peptides of 
PKC isoforms were individually applied to the intracellular space through the patch pipette. 
For each experiment, the cell was dialyzed with a different activator or inhibitor peptide (0.1 
M) for at least five minutes to allow for peptide to access the cytoplasm. The implication of a 
specific PKC isoform in Cx43Hc modulation is predicted by the capability of the 
corresponding activator peptide to reduce currents or the inhibitor peptide to abolish current 
inhibition induced by a general PKC activator, the phorbol myristate acetate (PMA, 10 nM 
applied in the bath solution). The PMA-induced PKC activation effect on Cx43Hc currents was 
assessed in the presence of each of the inhibitor peptides separately. To substantiate the 
specificity of PMA vis-à-vis PKC activation, the effect of PMA was compared with an inactive 
phorbol ester, the 4PDD, that possesses all characteristics of PMA except for its capacity to 
activate PKC. Appropriate time was allowed for steady-state current levels to be reached 
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before the application of PMA or 4PDD. As negative controls, we used a scrambled version 
of active peptides to assess their effect on Cx43Hc-induced currents.  
3.2 Study on isolated cardiomyocytes 
To assess the functional effect of the Cx43-mimetic peptide Gap26 directly on Cx43Hc, 
currents were recorded using patch clamp from transfected tsA201 cells. Since peptides 
exert their effect by binding to the extracellular loops, these were added to the extracellular 
bath solution (0.5 M). To determine the sensitivity of isolated myocytes to simulated 
ischemia/reperfusion, freshly isolated cardiac myocytes were incubated with saline, Gap26 
or scrambled GAP26 (sGap26) 10 min before or 30 min after the initiation of ischemia as 
described (Hawat et al., 2010). Briefly, cells were pelleted by low speed centrifugation for 1 
min and were washed twice with incubation buffer. Under these conditions, most of the 
non-myocyte cells remain in the supernatant, producing a pellet that contains >95% 
myocytes (Chen et al., 1999; Hawat et al., 2010). To simulate ischemic stress, cells were 
transferred to microcentrifuge tubes, washed twice with degassed glucose-free incubation 
buffer and pelleted as before. After centrifugation, 90% of supernatant was removed and 
microballoons were layered over the remaining buffer to create an air-tight environment. 
Tubes were incubated at 37oC for 180 min the damage to cardiac myocytes was assessed by 
trypan blue dye exclusion assay as previously described (Armstrong et al., 1994; Armstrong 
et al., 1997). The staining should correlate with myocytes rounding indicating cell death.  
3.3 Study on intact heart 
Using Langendorff technique, isolated Sprague-Dawley rat hearts were subjected to 20-min 
control stabilization followed by 40 min regional ischemia by ligation of the left anterior 
descending (LAD) coronary artery and then 180 min reperfusion by removing the ligation. 
The Cx43 structural mimetic peptide (0.5 M) was administered either 10 min prior to the 
onset of ischemia or 30 min after (this is 10 min before reperfusion), as described (Hawat et 
al., 2010). For control, s Gap26 was utilized. Evans blue perfusion was used to determine the 
region at risk. The left ventricle was sectioned into 2-mm slices and incubated with 
triphenyltetrazolium chloride (TTC) to estimate the injured (infracting) myocardial zone. 
The results were confirmed by histology. Myocardial perfusate flow was also determined by 
measuring the volume of perfusate recovered from Langendorff-perfused heart during 1 
min at 10 min after LAD occlusion or 10 min after reperfusion and compared to basal MPF 
(BMPF) as previously desrcibed (Hawat et al., 2010). 
4. Results 
4.1 PKC-mediated inhibition of Cx43Hc currents is primarily mediated through PKC 
isoform 
Application of the general PKC activator, PMA, in the bath solution consistently inhibited 
Cx43Hc currents (Fig. 5A, 5B, 5C). Averaged data show that PMA resulted in Cx43Hc current 
reduction by 74.0±4.3% (n=6, P<0.05). Superfusion of tsA201 cells with 4αPDD, an inactive 
phorbol ester analog that does not activate PKC, did not significantly affect Cx43Hc current 
amplitude (increase of 2.0±1.5%, n=5, P=NS; Fig. 5D), indicating that the PMA effect reported 
above is indeed mediated via PKC activation. To dissect the role of individual PKC isoforms in 
the regulation of Cx43Hc, we tested the ability of five PKC isoform-specific inhibitor peptides 
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to antagonize the effect of PMA, i.e. αC2–4, βIV5–3, βIIV5–3, δV1–7, and ɛV1–2 targeting α-,  
βI-, βII-, δ-, and ɛ-PKC isoforms, respectively. Each of the tested peptides targets a 
corresponding native PKC isoform in tsA201 cells. Importantly, when cells were dialysed with 
the specific inhibitor peptide of the 'cardioprotective' ɛPKC, the PMA-induced current 
inhibition was completely abolished (118.5±15.8%, n=6, significantly different from the 
reference PMA effect; Fig. 5E) , this was in contrast with the other tested PKC isoforms 
inhibitors. In the presence of scrambled ɛV1–2, the inhibitory effect of PMA on Cx43Hc 
currents was not significantly different compared with the PMA effect alone (69.4±4.7%, n=3, 
P=NS). On the other hand, using an ɛPKC activator peptide ɛV1–7 (0.1 μM) alone was able to 
cause a 75.7±2.6% reduction in the basal Cx43Hc current (n=3, P<0.05; Fig. 5F), thus confirming 
the involvement of ɛPKC in Cx43Hc inhibition. Detailed results are reported (Hawat & 
Baroudi, 2008).  
 
Fig. 5. Cx43Hc modulation by PMA and PKC. A, whole-cell currents recorded from a 
typical tsA201 cell transfected with Cx43. B, traces from a non-transfected cell. Time course 
recording plotting Cx43Hc current amplitudes against time in the presence of C, PMA;. D, 
4PDD; E, PMA and the PKC-specific inhibitor peptide; and F, PKC activator peptide. 
4.2 Gap26 inhibits Cx43Hc currents 
Because we believed inhibition of Cx43Hc by PKC may represent the basic key mechanism 
of cardioprotection during ischemic preconditioning, we next investigated the functional 
effect of the presumably specific inhibitor of Cx43Hc, the mimetic Gap26 peptide, on 
Cx43Hc mediated currents recorded from individual tsA201 cells transiently expressing 
Cx43. In Fig. 6A, a representative time course recording shows rapid Cx43Hc currents 
reduction when Gap26 was introduced in the bath solution. A steady-state inhibition was 
reached in all experiments. Averaged data indicate that Gap26 caused 60.1±4.6% (n=5, 
P<0.05) current reduction. In the presence of sGap26 peptide, the amplitude of Cx43Hc 
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currents did not vary over a similar time frame (99.0±1.1%, n=5, P>0.05) (Fig. 6B). The 
histogram (Fig. 6C) summarizes the effects of both peptides on normalized Cx43Hc currents. 
Curves representing the current–voltage (I–V) relationship for Cx43Hc in the absence and in 
the presence of Gap26 are illustrated in Fig. 6D. I–V data were elicited by depolarizing cells 
with voltage steps ranging from +0 to +90 mV.  
Because connexin 40 (Cx40) and connexin 45 (Cx45) may also form hemichannels in the 
heart, we examined whether Gap26 has effects on currents recorded from tsA201 cells 
transfected with either connexin isoforms. Importantly, the application of Gap26 did not 
cause a significant reduction in currents mediated by Cx40Hc (0.7±1.6%, n=4, P>0.05) or 
Cx45Hc (0.2±0.7%, n=4, P>0.05) over a time frame similar to that used in Cx43Hc 
experiments (Hawat et al., 2010). 
 
Fig. 6. Cx43Hc-mediated whole-cell current inhibition by Gap26 recorded from individual 
tsA201 cells. A, time course recording plotting current amplitudes in presence of Gap26 
against time. B, a control time course recording in presence of sGap26. Insert in A and B 
show current traces recorded at time points indicated by arrows a and b. Current 
amplitudes are normalized against control and are represented in arbitrary units (a.u.). C, a 
histogram summarizing effects of Gap26 and sGap26 in comparison to basal current. D, 
current-voltage relationship obtained from tsA201 cells in absence and in presence of Gap26. 
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4.3 Connexin 43 mimetic peptide confers resistance to intact heart against ischemia 
injury 
We next assessed the effect of Gap26 on intact ischemic heart. Administration of Gap26 before 
ischemia significantly decreased infarct size from 36.3±2.1 of area at risk in untreated hearts 
(n=7) to 18.8±1.9% (n=6, P<0.05) (Fig. 7A). In order to assess the peptide capability to 
counteract an existing ischemia, a separate group of hearts was studied in which Gap26 was 
introduced 30 min after the LAD coronary occlusion. Similarly, the infarct size was 
significantly reduced to 16.2±0.8% (n=7, P<0.05) of area at risk. These results correspond to 
infarct size reductions by 48.2% and 55.4% when Gap26 was introduced before or during 
ischemia, respectively. The size of area at risk to total ventricles did not change significantly in 
both experimental groups (41.3±4.5%, n=6, P>0.05 and 40.6±3.2%, n=7, P>0.05, respectively) 
compared to the group of untreated hearts (44.8±2.0%, n=7) (Fig. 7B). As negative control,  
 
Fig. 7. Effect of synthetic peptides on intact hearts subjected to regional ischemia by LAD 
ligation. a Histogram representing the proportion of infarct zone to the area at risk, b 
histogram representing the proportion of area at risk to total ventricles. Values obtained 
from ischemic hearts in the presence of Gap26 or sGap26 added either 10 min before (n=6 
and n=3, respectively) or 30 min after (n=7 and n=4, respectively) the occlusion of LAD are 
reported. *P<0.05 indicates statistically significant difference in comparison to untreated 
hearts (n=7). Photographs of TTC-stained heart sections after 40 min ischemia and 180 min 
reperfusion representing c untreated heart, d heart treated with Gap26 introduced 10 min 
before LAD occlusion, and e Gap26 introduced 30 min after LAD occlusion. c–e The infarct 
zone is the whitish area delimited with white dashed lines; the area at risk corresponds to 
the red region including the infarct zone; and the perfused area is in dark blue 
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sGap26 was also tested. Administration of sGap26 did not statistically affect the size of infarct 
area to area at risk when introduced before ischemia (41.1±3.0%, n=3, P>0.05) or during 
ischemia (39.2±2.0%, n=4, P>0.05) in comparison to untreated hearts (36.3±2.1%, n=7). The 
global size of total ventricles was comparable between groups of untreated hearts and hearts 
treated with Gap26 or sGap26 (data not shown). Percentage values for different heart areas 
obtained from various experimental groups are listed in Table 1. Transversal slices obtained 
from hearts representing the groups of untreated hearts, hearts treated with Gap26 before 
ischemia, and hearts treated with Gap26 during ischemia are shown in Fig. 7C, 7D, 7E. 
In order to investigate the effect of Gap26 on the function of Langendorff-perfused hearts, 
we compared the MPF measured 10 min after LAD occlusion and 10 min after reperfusion 
to the BMPF. The BMPF is determined for each heart during normal conditions, i.e., 
before LAD occlusion in the absence of Gap26. Application of Gap26 to non-ischemic 
hearts during 1 h did not cause significant changes to MPF (data not shown). Importantly, 
addition of Gap26 in the perfusion solution increased MPF during reperfusion of ischemic 
hearts from 65.7±5.1% (n=7) of BMPF in untreated hearts to 89.8±4.9% (n=7, P<0.05) and 
86.7±4.8% (n=4, P<0.05) in hearts treated with Gap26 before or during ischemia, 
respectively (Fig. 8). As negative control, sGap26 did not affect MPF when introduced 
before or during ischemia. Values for MPF variations in different experimental groups are 
listed in Table 2. 
 
Fig. 8. Percentages of MPF measured at 10 min after LAD occlusion (open columns) or at 10 
min after reperfusion (filled columns) to BMPF. The groups shown correspond to the 
untreated hearts (n=7), hearts treated with Gap26 before ischemia (n=7), hearts treated with 
Gap26 during ischemia (n=4), hearts treated with the inactive sGap26 before ischemia (n=3), 
and heart treated with sGap26 during ischemia (n=4). ¤P<0.05 indicates data significantly 
different from untreated hearts. §P<0.05 indicates data significantly different from MPF 
during ischemia. 
 




Table 2. Percentage values for heart areas and myocardial perfusate flows. 
4.4 Effect of Gap26 on isolated cardiomyocytes 
In order to elucidate the cellular basis for the Gap26-mediated cardioprotection observed in 
intact hearts, we investigated the effect of the peptide on isolated cardiomyocytes from adult 
rat hearts subjected to simulated ischemia–reperfusion. Application of Gap26 in the bath 
solution either 10 min before or 30 min after the initiation of simulated ischemia increased 
the number of surviving cardiomyocytes after 180 min reperfusion from 28.4±6.5% of total 
cells (n=8) to 53.1±6.8% (n=8, P<0.05) and 55.0±6.5% (n=8, P<0.05), respectively (Fig. 9A). 
The percentage of surviving cells did not differ statistically between groups treated with 
Gap26 before or during simulated ischemia. As negative control, the percentage of surviving 
cells following application of sGap26 before ischemia (22.9±6.9%, n=8) or during ischemia 
(26.0±6.6%, n=8) did not differ significantly in comparison to untreated cells (28.4±6.5%,  
 
 
Fig. 9. Effect of Gap26 on viability of isolated adult rat cardiomyocytes during simulated 
ischemia–reperfusion. a The percentage of surviving cells to total cells after reperfusion was 
determined in the absence or presence of Gap26 or sGap26 added to the bath solution before 
or during ischemia (n=8 in each group). Data are expressed as mean ± SEM of eight 
experiments using myocytes from three different animals. b Mitochondrial dysfunction was 
determined with the MTT test (n=5 in each group, obtained from a single rat heart). *P<0.05 
indicates significant difference in comparison to untreated cells. §P<0.05 indicates 
significant difference in comparison to control. 
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n=8, P>0.05). In order to substantiate these findings, we assessed mitochondrial activity in 
each experimental group of cardiomyocytes using the colorimetric MTT assay. To alleviate 
comparison, results are expressed as percentages of the mitochondrial activity measured in 
a control group of cardiomyocytes maintained at normoxic conditions during a similar time 
frame. Simulated ischemia–reperfusion reduced mitochondrial activity in untreated 
cardiomyocytes to 49.7±1.2%, n=5, P<0.05 in comparison to the control cardiomyocytes 
100.0±1.2%, n=5. Treatment of cardiomyocytes with Gap26 prevented partially but 
significantly this mitochondrial dysfunction when introduced before or during ischemia 
(83.0±1.1%, n=5, P<0.05 and 82.1±1.1%, n=5, P<0.05, respectively). Application of sGap26 did 
not prevent the mitochondrial dysfunction when applied before ischemia (50.3±1.0%, n=5, 
P>0.05) or during ischemia (51.8±0.9%, n=5, P>0.05) in comparison to untreated cells. 
Results obtained from the different experimental groups are illustrated in the histogram 
(Fig. 9B). 
5. Discussion 
5.1 PKC isoform selective modulation of Cx43Hc  
The first important observation here was the unraveling of selective and differential 
implication of PKC isoforms in the modulation of Cx43Hc conductance. The ɛPKC was 
found to be the isoform predominantly involved in the modulation of Cx43Hc conductance 
after PMA superfusion.  
Cx43Hc dephosphorylation (Beardslee et al., 2000; Jain et al., 2003; Jeyaraman et al., 2003; 
Miura et al., 2004; Schulz et al., 2003) and opening (John et al., 1999b; Kondo et al., 2000; 
Shintani-Ishida et al., 2007) have been proposed as key mechanisms underlying cell injury in 
response to simulated ischemia in cardiomyocytes. Preservation of Cx43 phosphorylation by 
selective activation of the ɛPKC isoform occurs in response to ischemic pre- (Chou & 
Messing, 2005; Liu et al., 1999; Ytrehus et al., 1994) and postconditioning (Penna et al., 2006a; 
Philipp et al., 2006; Zatta et al., 2006), in which brief episodes of ischemia reduce the adverse 
effects of subsequent or preceding myocardial ischemia, respectively. As the function of 
multiple proteins may be affected by PKC, delineation of the isoform-specific regulation of 
downstream targets, e.g. Cx43Hc, is indeed important to improve our understanding of the 
pathogenesis of ischemic heart disease and to identify new opportunities for drug 
development.  
5.2 Cx43 mimetic peptide protects heart against myocardial infarction  
In this context, another important finding was the rapid depression of Cx43Hc conductance 
in response to the application of the Cx43 mimetic peptide Gap26. To date, the involvement 
of unequivocally identified unapposed Hc in CxMPs-mediated phenomena, such as 
regulation of ATP release and calcium propagation, is still debated (Dahl, 2007). Therefore, 
we demonstrated here for the first time that superfusion of the ion channel-deficient tsA201 
cells, transiently expressing Cx43, with Gap26 readily inhibits Cx43Hc-mediated currents 
recorded from individual cells. This observation complements with previous studies 
reporting on the inhibitory effect of Gap26 on the permeability of Cx43Hc (Braet et al., 
2003b; Gomes et al., 2005; Leybaert et al., 2003; Pearson et al., 2005), the second major 
functional characteristic of connexin channels besides conductance. Although not 
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surprisingly, this result represents the most direct evidence reported so far for the Gap26 
inhibitory effect on Cx43Hc. Curiously, this inhibition occurred using a peptide 
concentration that is 1,000 times lower than what has previously been utilized to block Hc 
currents (0.5 μM in this study versus 500 μM in (Romanov et al., 2007)). Occasionally, the 
specificity of CxMPs toward Hc has been challenged (Wang et al., 2007). Therefore, we 
tested the effect of Gap26 on Hc of Cx40 and Cx45 which are also present in the heart. 
Importantly, Gap26 did not affect currents from Cx40Hc or Cx45Hc.  
The most important finding however was the protection that Gap26 conferred to intact rat 
heart against regional ischemia induced by LAD coronary occlusion. We showed that 
administration of Gap26 prior to LAD occlusion resulted in more than 48% reduction of 
infarct size compared to untreated hearts. Similarly, Gap26 reduced infarct size by 55% 
when administered during ischemia. We also showed that the salutary effect of Gap26 
extends to heart function by increasing the MPF during reperfusion by nearly 37% and 32% 
when the peptide was administered before or during LAD occlusion, respectively, in 
comparison to untreated hearts. These results indicate that whereas Gap26 can confer 
resistance to “normal” hearts against subsequent ischemia, it also has the capability to 
salvage injured hearts when administered after the occurrence of ischemia. Hypothetically, 
we ascribe these effects to the presumable Gap26-mediated inhibition of cardiomyocytic 
Cx43Hc opened by ischemic stress. Indeed, Gap26 is also known to inhibit Cx43 GJCs when 
used at relatively high concentrations and/or following prolonged exposure (Evans et al., 
2006). Nonetheless, all experiments in this study were performed using low concentration of 
Gap26 (0.5 μM) previously shown to selectively inhibit Hc without directly affecting GJCs 
(Clarke et al., 2009; Verma et al., 2009). Therefore, we consider that neither the peptide 
concentration nor the duration of exposure to Gap26 (which varied depending on protocols 
between ∼3 and 4 h) was sufficient to modulate GJCs in the studied hearts. In concordance 
with the fact that death of cardiomyocytes, and therefore myocardial injury, principally 
occurs during reperfusion (Gottlieb et al., 1994; Shintani-Ishida et al., 2007; Zhao et al., 2000), 
both structural and functional improvements in intact hearts did not differ significantly 
whether Gap26 was introduced before occlusion or before reperfusion.  
To investigate the cellular basis of the protection of intact hearts, we assessed the effect of 
Gap26 on isolated cardiomyocytes subjected to simulated ischemia–reperfusion. We found a 
nearly twofold increase in the number of surviving cells when Gap26 was administered 
either before or during the simulated ischemia. A similar increase was previously noted in 
isolated neonatal rat cardiomyocytes treated with Gap26 prior to simulated ischemia 
(Shintani-Ishida et al., 2007). Clearly, both observations underscore the capability of Gap26 
to confer protection to cardiomyocytes in the absence of direct intercellular communication, 
precisely through GJC, and therefore point to the inhibition of unapposed Hc as the 
underlying mechanism of cardioprotection. Altogether, these results strongly suggest that 
the observed cardioprotection conferred by Gap26 is most likely mediated by the specific 
inhibition of Cx43Hc opened by the ischemic stress. 
6. Perspective 
The non-junctional Cx43 have previously been associated with ischemic preconditioning-
mediated cardioprotection (Li et al., 2004; Padilla et al., 2003). This effect has been related to 
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increase in Cx43 phosphorylation (Hatanaka et al., 2004; Hund et al., 2007; Miura et al., 2004; 
Schulz et al., 2003). Interestingly, different studies pointed to the isozyme εPKC as a principal 
mediator of ischemic preconditioning-mediated cardioprotection (Gray et al., 1997; Hund et 
al., 2007; Inagaki et al., 2003; Liu et al., 1999; Ping et al., 1997; Saurin et al., 2002). Here, we 
showed using a unique set of PKC isozyme-specific modulator peptides that εPKC, among 
other PKC isozymes, selectively inhibits the conductance of Cx43Hc. These data prompt us to 
believe that inhibition of Cx43Hc represents a fundamental basis for the cardioprotection 
conferred by ischemic preconditioning. In the light of our findings using Cx43 mimetic peptide 
Gap26 and given the ubiquitous expression of PKC and the abundance of its substrates within 
cells and throughout tissues, we put forth that the selective inhibition of the abnormally open 
Cx43Hc, which we believe are solely localized in the ischemic region of the heart, would be 
more suitable to mimic pharmacologically the cardioprotection conferred by ischemic 
preconditioning than to modulate PKC isozymes as previously proposed (Chen et al., 2001a; 
Chen et al., 2001b). The accessibility of CxMP binding sites from extracellular space, which 
circumvents the need of conjugating the peptides with transmembrane carriers and the 
limitations deriving from their use, is indeed another therapeutic advantage over the use of 
intracellular modulators. Certainly, studies using more elaborated experimental models are 
needed to substantiate the therapeutic potentials of Gap26.  
7. Conclusion 
In conclusion, we demonstrate for the first time that administration of Gap26 prior to 
ischemia prevents injury by making intact heart more resistant to ischemic stress. Moreover, 
usage of Gap26 as a treatment following occurrence of ischemia reduces cardiac tissue 
damage and improves intact heart function. The discovery of new agents capable to make 
heart more resistant to ischemia and/or to improve its recovery after injury caused by 
ischemia will certainly be promising tools to fight ischemic heart disease. 
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1. Introduction 
Cardiovascular disease still remains the leading cause of deaths worldwide in both males 
and females. A variety of factors have been associated to play a role in the development of 
this disease, such as an individual’s genetic background and continual life style factors. 
Life style factors (including diet) have greatly influenced the occurrence and progression 
of this disease. The medical profession has made great efforts to adequately address and 
to continually stress to their patients an altered life style to confront the non-genetic 
factors, in order to potentially minimize their risk for cardiovascular disease. This 
campaign has centered on a continual direction for refinements in diet, regular exercise, 
smoking cessation, and to control blood pressure to lower their risk for cardiovascular 
disease.  
The World Health Organization has reported that approximately 17 million people die of 
cardiovascular diseases, including myocardial infarcts and strokes, every year. [1] The most 
common type of cardiovascular disease is atherosclerosis, which has shown to progress 
overtime. This progression involves the narrowing of our arteries, which ultimately limits 
the delivery of oxygen to viable tissue beds. [2] Atherosclerosis is not confined to a sole 
anatomic region; for it can eventually progress to involve many arterial vessels in our 
circulation, producing not only heart disease, but cerebrovascular and peripheral vascular 
devastating pathological sequelae. Financially, cardiovascular diseases have taxed 
economies and current trends have shown its continued burden on healthcare dollars 
worldwide.  
The progression of coronary arterial atherosclerosis has the potential to eventually 
produce myocardial ischemia, reflected in clinical symptoms of angina or chest pain. This 
atherosclerotic state produces a decrease in blood flow to the myocardium, producing a 
decrease availability of oxygenated blood to these muscular regions of the heart. 
Clinically, patients afflicted with coronary artery disease/myocardial ischemia can 
experience symptoms of angina or chest pain, commonly during and following stressful 
situations; however, some unfortunately can even have episodes at rest. Furthermore, 
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with the progression of coronary artery disease and the development of significant 
coronary arterial atherosclerosis, patients are susceptible of sustaining an acute 
myocardial infarction or live with a chronic, debilitating condition, which has the 
potential of advancing into the development of heart failure.  
Along with significant myocardial ischemic coronary arterial disease, many patients can 
experience functional abnormalities, such as diastolic dysfunction or an abnormality in 
ventricular relaxation. This ventricular dysfunctional condition has continued to be a 
challenging clinical problem for physicians because as of today, there is not yet an 
approved effective, solely directed therapy for myocardial diastolic dysfunction. Current 
medical investigations have found that left ventricular diastolic dysfunction is more 
prevalent than expected. Redfield et al. reported in 2042 randomly selected adults over 
the age of 45 that 21% had mild and 7% had at least moderate diastolic dysfunction. Six 
percent had moderate or severe diastolic dysfunction with a normal ejection fraction. [3] 
This has been supported by additional published studies that have shown that diastolic 
dysfunction exists with its prevalence varying with age. Fischer et al. found diastolic 
dysfunction in 2.8% of individuals between 25-35 years of age and increasing to 15.8% 
among those older than 65 years of age. Compared to women, men had a higher rate of 
diastolic abnormalities (13.8% vs. 8.6%). Factors associated with diastolic abnormalities 
have included arterial hypertension, evidence of left ventricular hypertrophy and 
coronary artery disease. Additionally, diastolic dysfunction has been related to a higher 
body mass index, high body fat and diabetes mellitus. [4] Unfortunately, when diastolic 
dysfunction develops early in the post myocardial infarction clinical period, these patients 
tend to have a poorer outcome.  
Myocardial ischemia is a common entity in the development of congestive heart failure 
(CHF) and many of these patients will have a component of diastolic dysfunction. Clinically, 
at least half of patients diagnosed with CHF will have a degree of diastolic dysfunction 
solely or in combination with systolic dysfunction. These CHF patients with diastolic 
dysfunction can have a challenging therapeutic course and a less favorable clinical outlook. 
Ingwall and Weiss proposed that the failing heart is energy starved. However, this theory is 
not novel. This theory was previously proposed, but was not actively pursued because it 
was unclear whether ATP levels really decreased and if these levels did decrease in the 
failing heart, then the remaining pool of ATP compounds should be sufficient to satisfy 
myocardial ATP-requiring reactions. [5] Currently, there appears to be renewed interest in 
this hypothesis; that the failing heart is energy starved. The advancement in biophysical 
tools, such as nuclear magnetic resonance (NMR) spectroscopy and positron emission 
tomography (PET) scans have aided in providing a better understanding of this myocardial 
energy/functional relationship.  
2. Cellular energy and function during and following myocardial ischemia: A 
potential role for D-ribose 
2.1 Pre-clinical investigations 
All cells require high energy phosphates, predominantly ATP, to maintain their integrity 
and function. Normally, the cellular supply of ATP meets tissue demands. Glycolysis and 
 
Novel Strategies in Ischemic Heart Disease 220 
with the progression of coronary artery disease and the development of significant 
coronary arterial atherosclerosis, patients are susceptible of sustaining an acute 
myocardial infarction or live with a chronic, debilitating condition, which has the 
potential of advancing into the development of heart failure.  
Along with significant myocardial ischemic coronary arterial disease, many patients can 
experience functional abnormalities, such as diastolic dysfunction or an abnormality in 
ventricular relaxation. This ventricular dysfunctional condition has continued to be a 
challenging clinical problem for physicians because as of today, there is not yet an 
approved effective, solely directed therapy for myocardial diastolic dysfunction. Current 
medical investigations have found that left ventricular diastolic dysfunction is more 
prevalent than expected. Redfield et al. reported in 2042 randomly selected adults over 
the age of 45 that 21% had mild and 7% had at least moderate diastolic dysfunction. Six 
percent had moderate or severe diastolic dysfunction with a normal ejection fraction. [3] 
This has been supported by additional published studies that have shown that diastolic 
dysfunction exists with its prevalence varying with age. Fischer et al. found diastolic 
dysfunction in 2.8% of individuals between 25-35 years of age and increasing to 15.8% 
among those older than 65 years of age. Compared to women, men had a higher rate of 
diastolic abnormalities (13.8% vs. 8.6%). Factors associated with diastolic abnormalities 
have included arterial hypertension, evidence of left ventricular hypertrophy and 
coronary artery disease. Additionally, diastolic dysfunction has been related to a higher 
body mass index, high body fat and diabetes mellitus. [4] Unfortunately, when diastolic 
dysfunction develops early in the post myocardial infarction clinical period, these patients 
tend to have a poorer outcome.  
Myocardial ischemia is a common entity in the development of congestive heart failure 
(CHF) and many of these patients will have a component of diastolic dysfunction. Clinically, 
at least half of patients diagnosed with CHF will have a degree of diastolic dysfunction 
solely or in combination with systolic dysfunction. These CHF patients with diastolic 
dysfunction can have a challenging therapeutic course and a less favorable clinical outlook. 
Ingwall and Weiss proposed that the failing heart is energy starved. However, this theory is 
not novel. This theory was previously proposed, but was not actively pursued because it 
was unclear whether ATP levels really decreased and if these levels did decrease in the 
failing heart, then the remaining pool of ATP compounds should be sufficient to satisfy 
myocardial ATP-requiring reactions. [5] Currently, there appears to be renewed interest in 
this hypothesis; that the failing heart is energy starved. The advancement in biophysical 
tools, such as nuclear magnetic resonance (NMR) spectroscopy and positron emission 
tomography (PET) scans have aided in providing a better understanding of this myocardial 
energy/functional relationship.  
2. Cellular energy and function during and following myocardial ischemia: A 
potential role for D-ribose 
2.1 Pre-clinical investigations 
All cells require high energy phosphates, predominantly ATP, to maintain their integrity 
and function. Normally, the cellular supply of ATP meets tissue demands. Glycolysis and 
Myocardial Ischemia: Alterations in Myocardial Cellular 
Energy and Diastolic Function, a Potential Role for D-Ribose 221 
the tricarboxylic acid cycle pathways produce ATP compounds with glucose as the starting 
substrate. However, cells can also rely on alternative pathways, such as the hexose 
monophosphate shunt or pentose phosphate pathway for the production of energy 
molecules. [6] As stated, the supply of ATP is essential to preserve cellular cardiac energy 
and function; and without these levels of ATP, a myocyte’s integrity and function is 
jeopardized. When myocytes are subjected to ischemia, there is a depletion in energy stores, 
which can potentially decrease intracellular reactions, including cellular function. 
Obviously, if this ischemic insult is severe enough, viability can be affected. Besides this 
assumed immediate depletion in ATP levels, numerous studies have shown that this 
depletion in myocardial ATP levels from ischemia lasts for a considerable time period due 
to slow adenine nucleotide synthesis, of which this delay in ATP recovery is reflected in 
abnormal function. [7] Because of these published findings, future developed methods 
directed at enhancing the recovery of this energy deficiency due to ischemia should strongly 
be considered in the therapeutic management of myocardial ischemic diseases.  
There is a direct interaction between adequate myocardial ATP levels and the development 
of ventricular dysfunction, predominantly diastolic dysfunction. Calcium plays a major role 
in this interaction, which is an energy dependent process. Adenosine triphosphate provides 
the energy for this interaction between cytosolic calcium and the sarcoplasmic reticulum. 
Depleted ATP levels can result in calcium remaining fixed to troponin longer in diastole, 
producing a state of diastolic dysfunction or altered ventricular compliance. Following 
ischemia, a return in diastolic function may be limited by the availability of the high energy 
phosphate, ATP. [8] Theoretically, efforts to maximize the recovery of myocardial ATP 
levels during and following ischemia could aid in minimizing the functional untoward 
effects following ischemia. 
Research over decades has explored the relationship of myocardial ATP levels during and 
following ischemia. Most of these initial myocardial ischemic studies involved acute 
isolated heart models, mainly Langendorff or Neely preparations. Reibel and Rovetto 
reported in isolated perfused rat hearts that a moderate ischemic insult (10-30 minutes) 
resulted in a 50-70% decrease in myocardial ATP levels. [9] The recovery of myocardial 
ATP levels following ischemia is not prompt with reperfusion. Hours to days are required 
for substantial recovery, depending upon the degree of the ischemic insult. Kloner et al. 
found that the recovery of ATP compounds after 15 minutes of coronary occlusion in the 
healthy canine heart was only 75% restored after three days with one week required for 
full recovery. [10] Likewise, Zimmer concurred that an extended time period is required 
for the recovery of depressed myocardial energy levels, as well as a measured 
improvement in the alteration in mechanical function following ischemia. [11] Even 
though these isolated myocardial experimental models have provided important findings, 
they have limitations due to the nature of the isolated heart preparation. Therefore, 
experiments involving an intact animal model would be essential to support these initial 
isolated heart preparation findings. Short term investigations involving an intact animal 
model found similar findings in measured myocardial adenine nucleotide levels following 
ischemia. Twelve to 30 minutes of myocardial ischemia produced a substantial drop in 
ATP levels with a significant decrease in total adenine nucleotides, and days were 
required for total recovery. [12]  
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However, to fully appreciate this important energy-functional relationship, a chronic 
animal model to measure both myocardial energy levels and function would be ideal to 
better understand the long term effects of ischemia. A chronic canine animal model was 
developed to provide the means for long term assessment of myocardial energy levels and 
function during and following ischemia. [13-15] Using this chronic model, 20 minutes of 
normothermic myocardial ischemia produced a significant decrease (approximately 50%) 
in ATP levels, which was accompanied with a state of left ventricular diastolic 
dysfunction. Furthermore, the data from this chronic animal study confirmed that the 
effects of myocardial ischemia have a long term effect. Researchers reported that there was 
a substantial delay, over one week, in myocardial energy levels and functional recovery 
following a moderate, reversible ischemic insult. [13-15] 
Ward et al. reported that myocardial precursor availability is an important limiting factor in 
the recovery of myocardial ATP molecules following an ischemic insult. [15] Many 
researchers have investigated various substrates and methods in replenishing depressed 
levels of ATP following ischemia. Investigations with adenine nucleotide precursor 
substrates have included adenosine, 5-amino-4-imidazolecarboxamide riboside, inosine, 
adenine, D-ribose, as well as an adenine degradative enzymatic inhibitor (erythro-9-(2-
hydroxy-3-nonyladenine hydrochloride). However, these studies have reported mixed 
results in the recovery of energy molecules and function following ischemia. The majority of 
these precursors have at best shown a minimal improvement in both ATP recovery and 
function. However, this was not the case when investigating the effects of D-ribose during 
and following myocardial ischemia. D-ribose, a natural occurring pentose carbohydrate, 
supplementation demonstrated in numerous animal studies its significant benefit in 
enhancing the return in ATP levels and improved function following global and regional 
myocardial ischemia. Zimmer and Gerlach reported that supplementation with D-ribose in 
adult, isolated rat hearts resulted in an increase rate of adenine nucleotide synthesis. [16] 
Pasque et al. found similar results in isolated, perfused, working rat hearts subjected to 15 
minutes of ischemia, followed by 2-15 minutes of myocardial work. D-ribose 
supplementation improved the recovery in myocardial ATP levels along with a mean 
percent improvement in functional recovery. [17] St. Cyr et al. also observed the benefits of 
D-ribose and adenine in a chronic animal model. Supplementation with D-ribose and 
adenine following 20 minutes of global ischemia resulted in 85% return in ATP levels as 
compared to no ATP recovery without D-ribose and adenine. [18]  
In the same chronic canine model design described by St.Cyr et al. with additional 
functional instrumentation, Schneider et al. reported similar ATP benefits with D-ribose 
and adenine, as well as improvements in left ventricular non-compliance/diastolic 
dysfunction following 20 minutes of global myocardial ischemia. [13,19] Further 
investigations revealed the sole benefits of D-ribose during and following ischemia. 
Tveter et al. investigated the benefits of D-ribose alone in a chronic canine model, in 
which hearts were subjected to a moderate (20 minutes) global myocardial ischemic 
insult. They found that D-ribose solely produced similar benefits in both myocardial 
energy levels and functional recovery following global ischemia, as was previously 
reported with D-ribose and adenine. [20] D-ribose appeared to solely enhance the 
recovery of myocardial adenine nucleotide levels, improve diastolic dysfunction and the 
adenine nucleotide pool following ischemia. 
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A significant restrictive or narrowing of a coronary arter(ies) can potentially result in an 
acute occlusion or an acute myocardial infarct, for which myocardial dysfunction post 
infarct can be present. Following infarction, some of these hearts can experience a continual 
decline in function, leading to the development of heart failure. The remote myocardium not 
involved in the infarcted tissue is subjected to an increased workload, which can severely 
tax its myocardial energy supply, which over time can affect remodeling. Zimmer et al. 
reported in adult rats that a decline in left ventricular hemodynamics occurs following 
myocardial infarction. They observed a progressive decline in left ventricular systolic 
pressure, a decline in left ventricular dP/dtmax, elevated left ventricular end diastolic 
pressure, and lower cardiac outputs and stroke volume indices post infarction. Upon 
supplying the substrate D-ribose, there was an improvement in the above measured left 
ventricular hemodynamic parameters with stimulation in adenine nucleotide synthesis. [21] 
Likewise, Befera et al. observed similar findings with the supplementation of D-ribose 
following acute myocardial infarction in adult rats. They found an improvement in left 
ventricular function in the remote left ventricular areas when supplying D-ribose. There was 
increased contractility and myocardial wall thickness with less ventricular dilatation with D-
ribose supplementation. [22] 
These two pre-clinical, animal studies reported that D-ribose prevented or delayed the 
development of left ventricular dysfunction following acute myocardial infarction. Hence, 
the question posed is: might D-ribose offer an additional benefit, if supplemented prior to a 
myocardial infarction? When D-ribose was supplied pre-infarction, Gonzalez et al. reported 
that providing D-ribose in adult rats resulted in a significant reduction in the created left 
ventricular infarct area and a significant improvement in left ventricular function when 
assessed at 6 hours post infarct. Left ventricular systolic pressure and contractility were 
restored to normal levels with a significant improvement in measured parameters of left 
ventricular relaxation with supplemental D-ribose. [23]  
2.2 Clinical D-ribose evaluation 
The observed positive energy enhancing and functional benefits associated with D-ribose in 
the pre-clinical investigations initiated subsequent clinical studies to further assess its 
potential in patients afflicted with cardiovascular diseases. Because of the benefits of D-
ribose during and following ischemia, researchers investigated this potential in enhancing 
the identification of hibernating myocardium. Hibernating myocardium represents regional 
areas of myocardial dysfunction due to prolonged hypoperfusion or ischemia. This 
condition can be reversed upon restoration of a more adequate level of blood flow to these 
regions. Theoretically, efforts to aid in the identification of these regions can help in the 
management strategies for revascularization. Current methods in identifying these regions 
include Thallium-201 scans, dobutamine stress echocardiography, PET, and magnetic 
resonance imagery. Hibernating myocardium is likely to be associated with lower levels of 
myocardial ATP; and therefore, supplementation with an adenine nucleotide agent might 
aid in further identifying these viable regions. D-ribose has demonstrated a benefit in this 
identification process. Before undertaking clinical investigations, pre-clinical animal studies 
demonstrated the identification benefit of D-ribose in hibernating myocardium. In the 
clinical realm, Perlmutter et al. reported that D-ribose identified more reversible defects 
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using Thalium-201 scans. [24] Other clinical studies have supported this finding. Hegewald 
et al. found that D-ribose also increased the detection of viable ischemic myocardial regions 
using SPECT Thallium imaging. [25] More recently, Sawada et al. demonstrated that the 
supplementation of D-ribose provided anti-ischemic effects with improving the 
identification of wall motion dysfunctional abnormalities during dobutamine stress 
echocardiography. [26]  
Previously reported positive pre-clinical animal studies demonstrating the benefits of D-
ribose during and following ischemia generated additional clinical investigative interest. 
Since D-ribose has shown in animal studies to enhance the recovery in ATP levels and 
improve function following myocardial ischemia, Pliml et al. argued that there is significant 
impairment in ATP levels in the ischemic myocardium. The current lack of therap(ies) 
directed to the restoration or preventing further decrease in these myocardial energy 
compounds lead the researchers to design a study in which patients with stable coronary 
artery disease underwent serial treadmill exercise testing while supplementing with D-
ribose. D-ribose demonstrated significant benefits in increasing treadmill exercise time 
before the onset of angina and/or ischemic electrocardiographic changes. [27] 
Myocardial ischemia is an etiological factor in the development of CHF and reports have 
proposed that the failing heart is energy starved. [5] Because of D-ribose’s ability to 
enhance the recovery of myocardial ATP levels and improve diastolic dysfunction 
following ischemic, Omran et al. investigated the role of D-ribose in class II-III CHF 
patients. They reported both objective and subjective benefits with D-ribose. There was an 
improvement in diastolic dysfunctional parameters, as assessed by serial 
echocardiographic examinations; and subjectively, the patients experienced an improved 
quality of life and physical function. [28]  
Commonly, CHF patients complain of shortness of breath and fatigue. As their failure 
progresses, patients have a decrease in their ventilatory efficiency. Carter et al. found that 
supplementation with D-ribose enabled class II-III CHF study patients with left ventricular 
dysfunction to maintain their VO2max, improve their ventilatory efficiency and experience a 
positive trend in their daily quality of life assessment. [29] Vijay et al. concurred in a 
separate clinical study the positive benefits of D-ribose in class II-IV CHF patients. They 
observed significant improvements in ventilatory efficiency in class III-IV patients with a 
positive, but not statistically significant, .trend in improved ventilator efficiency in class II 
patients. [30] 
The use of D-ribose has also been explored in cardiovascular surgery. Alterations in 
myocardial function have been observed in the post-ischemic interval following surgery. 
Wyatt et al. found that the use of a cardioplegic solution containing adenosine, 
hypoxanthine and D-ribose during intra-operative ischemia maintained myocardial 
energy levels during ischemia and with reperfusion resulted in enhanced functional 
recovery post operatively. [31] Vance et al. reported that parenteral use of D-ribose in 
patients undergoing elective aortic valve replacement with or without accompanying 
coronary arterial bypass grafting resulted in the maintenance in ejection fraction 
postoperatively, unlike the decline in ejection fraction observed in the patients not 
receiving D-ribose. They concluded that the treatment regimen of D-ribose preserved left 
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using Thalium-201 scans. [24] Other clinical studies have supported this finding. Hegewald 
et al. found that D-ribose also increased the detection of viable ischemic myocardial regions 
using SPECT Thallium imaging. [25] More recently, Sawada et al. demonstrated that the 
supplementation of D-ribose provided anti-ischemic effects with improving the 
identification of wall motion dysfunctional abnormalities during dobutamine stress 
echocardiography. [26]  
Previously reported positive pre-clinical animal studies demonstrating the benefits of D-
ribose during and following ischemia generated additional clinical investigative interest. 
Since D-ribose has shown in animal studies to enhance the recovery in ATP levels and 
improve function following myocardial ischemia, Pliml et al. argued that there is significant 
impairment in ATP levels in the ischemic myocardium. The current lack of therap(ies) 
directed to the restoration or preventing further decrease in these myocardial energy 
compounds lead the researchers to design a study in which patients with stable coronary 
artery disease underwent serial treadmill exercise testing while supplementing with D-
ribose. D-ribose demonstrated significant benefits in increasing treadmill exercise time 
before the onset of angina and/or ischemic electrocardiographic changes. [27] 
Myocardial ischemia is an etiological factor in the development of CHF and reports have 
proposed that the failing heart is energy starved. [5] Because of D-ribose’s ability to 
enhance the recovery of myocardial ATP levels and improve diastolic dysfunction 
following ischemic, Omran et al. investigated the role of D-ribose in class II-III CHF 
patients. They reported both objective and subjective benefits with D-ribose. There was an 
improvement in diastolic dysfunctional parameters, as assessed by serial 
echocardiographic examinations; and subjectively, the patients experienced an improved 
quality of life and physical function. [28]  
Commonly, CHF patients complain of shortness of breath and fatigue. As their failure 
progresses, patients have a decrease in their ventilatory efficiency. Carter et al. found that 
supplementation with D-ribose enabled class II-III CHF study patients with left ventricular 
dysfunction to maintain their VO2max, improve their ventilatory efficiency and experience a 
positive trend in their daily quality of life assessment. [29] Vijay et al. concurred in a 
separate clinical study the positive benefits of D-ribose in class II-IV CHF patients. They 
observed significant improvements in ventilatory efficiency in class III-IV patients with a 
positive, but not statistically significant, .trend in improved ventilator efficiency in class II 
patients. [30] 
The use of D-ribose has also been explored in cardiovascular surgery. Alterations in 
myocardial function have been observed in the post-ischemic interval following surgery. 
Wyatt et al. found that the use of a cardioplegic solution containing adenosine, 
hypoxanthine and D-ribose during intra-operative ischemia maintained myocardial 
energy levels during ischemia and with reperfusion resulted in enhanced functional 
recovery post operatively. [31] Vance et al. reported that parenteral use of D-ribose in 
patients undergoing elective aortic valve replacement with or without accompanying 
coronary arterial bypass grafting resulted in the maintenance in ejection fraction 
postoperatively, unlike the decline in ejection fraction observed in the patients not 
receiving D-ribose. They concluded that the treatment regimen of D-ribose preserved left 
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ventricular function peri-operatively. [32] More recently, oral D-ribose was added to a 
metabolic designed protocol for patients undergoing off pump coronary artery bypass 
revascularization procedures. Perkowski et al. found that this D-ribose metabolic protocol 
resulted in lower mortality and morbidities, along with a significant early postoperative 
improvement in cardiac index in patients undergoing “off pump” coronary artery 
revascularization. [33]  
3. Summary 
Even with the advances in cardiovascular medical technologies over decades, 
cardiovascular disease still ranks as the leading cause of death worldwide for both males 
and females. Myocardial ischemia, a factor in cardiovascular disease, has continued to be a 
leading cause of deaths in middle to elderly aged individuals. With continued current 
aggressive education, there have been strides in addressing the cardiovascular risk factors in 
this disease, including refinements in diet, regular exercise, smoking cessation, and blood 
pressure control. However, the underlying metabolic energy deficiency found with 
myocardial ischemia still requires further attention.  
Every cell requires adequate levels of high energy phosphates, i.e. ATP, to maintain its 
integrity and function. Myocardial ischemia lowers myocardial ATP levels, which has 
shown to reflect functional abnormalities. Relaxation of the myocardium, occurring during 
diastole, requires adequate ATP levels for the normal flux of calcium interacting with the 
sarcoplasmic reticulum. Without adequate levels of myocardial ATP, a state of ventricular 
diastolic dysfunction or non-compliance develops. Over decades research has centered on 
developing strategies in replenishing deficient levels of ATP during and following 
myocardial ischemia. The abundance of research has entertained on providing metabolic 
substrates to regenerate ATP compounds following ischemia. The results of these numerous 
investigations have been mixed; however, supplementation with D-ribose, a natural 
occurring pentose carbohydrate, has been found to not only to enhance the recovery of ATP 
levels, but to aid in improving the state of ventricular diastolic dysfunction following 
myocardial ischemia. D-ribose has shown to improve ventricular compliance following 
ischemia, for which there is not an approved marketed device or pharmaceutical that can 
offer this functional benefit.  
The clinical therapeutic cardiovascular uses of D-ribose continue to expand. Published 
studies have reported its potential benefits, such as in acute and chronic myocardial 
ischemic conditions, identifying hibernating myocardium, in CHF patients, and its use in 
the peri-operative cardiovascular surgical patient. The literature has provided support 
that supplemental D-ribose may offer the means to enhance the recovery of myocardial 
cellular energy with functional benefits in patients afflicted with ischemic cardiovascular 
disease.  
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1. Introduction 
Coronary artery disease is the highest contributor to morbidity and premature death in the 
developed world (Nabel, 2003; Fuster et al., 1992; Melo et al., 2004). Cardiac function is 
compromised in patients that survive an initial ischemic event and this progressive 
myocardial impairment leads to heart failure (Liu et al., 2007; Sugamura and Keaney, 2011; 
Jessup and Brozena, 2003). High levels of reactive oxygen species (ROS) contribute to the 
process of disease progression in both myocardial ischemia and in models of heart failure. 
ROS play a role in short term responses (stunning and arrhythmias) as well as long term 
responses (infarction) to ischemia with reperfusion. The primary source of ROS in 
myocardial ischemia is from mitochondria of cardiac cells with additional ROS arising from 
neutrophils that infiltrate ischemic regions (Sugamura and Keaney, 2011). There have been 
promising preclinical studies employing some antioxidant enzymes but there are no 
currently accepted clinical applications of these enzymes for myocardial ischemia (Downey, 
1990; Zweier et al., 1987, Otani et al., 1986; Papaharalambus and Griendling, 2007; 
Vivekananthan et al., 2003). It is likely that the responses in the ischemic heart are more 
complicated than was initially realized and other  antioxidant based strategies have to be 
developed. Our work has focused on two protective agents that act to prevent the 
detrimental effects of oxidative stress in the ischemic heart. The first cardio-protectant is  
methionine methionine sulfoxide reductase A (MsrA), a member of the Msr family of 
enzymes. The other major enzyme in the Msr family is MsrB and these two enzymes differ 
in their substrate stereo-specificity. The Msr family of enzymes  can protect cells in two 
ways: 1) by repairing oxidative damage to critical methionine  (Met) residues in proteins 
which have been oxidized to methionine sulfoxide (met(o)), and 2) by functioning as part of 
an ROS scavenger system in which Met residues in proteins function as catalytic 
antioxidants. MsrA has been studied in most detail and shown to protect bacterial and 
animal cells against oxidative damage (for review see Weissbach et al., 2005). The studies 
with MsrA led to investigations with the drug sulindac, a known non-steroidal anti-
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inflammatory drug (NSAID), that is a substrate for the Msr system (Etienne et al. 2003; 
Brunell et al. 2011). Sulindac protects the heart against ischemic infarction through a newly 
described activity as a pharmacological preconditioning agent (Moench et al., 2009). 
2. Antioxidant therapies and oxidative stress in heart disease 
ROS normally produced as a by-product of the electron transport chain are now considered 
to be a major factor in aging and age related diseases (Bokov et al., 2004). In the heart high 
levels of ROS have been implicated in both ischemic damage and in the progression of heart 
failure (Giordano, 2005). Preclinical studies for ischemic heart disease employing 
antioxidants although still at an early stage have shown some promise (Sugamura and 
Keaney, 2011; Bolli et al., 2004; Cannon, 2005). For example heme oxygenase -1 (HO-1) based 
gene therapy has been proposed as a therapeutic strategy for ischemic heart disease because 
the enzyme has a clear antioxidant capacity (Liu et al., 2007). In addition, the products of 
heme metabolism, carbon monoxide and bilirubin have been reported to possess cyto-
protective properties (Poss and Tonegawa, 1997; Stocker et al., 1987). Cardiac expression of 
HO-1 increased Akt phosphorylation and decreased infarct size in a mouse model of 
ischemia/reperfusion. Knockdown of the bilirubin producing enzyme biliverdin reductase 
increases apoptosis of cardiac cells subjected to hypoxia /re-oxygenation and decreases Akt 
phosphorylation. Thus the protection afforded by HO-1 involves activation of Akt that is 
dependent upon biliverdin reductase (Pachori et al., 2007). 
Other antioxidant enzymes that have shown potential for protection against ischemic 
damage include extracellular superoxide dismutase (EC-SOD-1), thioredoxin (Trx), and 
glutathione peroxidase (GSHPx) (Agrawal et al., 2004; Yoshida et al., 1996; Turoczi et al., 
2003; Maulik et al., 1999). Gene transfer of EC-SOD-1 by direct intra myocardial injection 
using an AAV vector resulted in high level cardio-protection in rats at 7 days following 
ischemia and reperfusion injury (Agrawal et al., 2004). Using the rat working heart model of 
transient global ischemia it has been shown that thioredoxin is substantially decreased, 
whereas preconditioning by non-lethal ischemia elicited up-regulation of Trx expression 
and induced tolerance against severe ischemic stress (Turoczi et al., 2003). Likewise Trx-1 
overexpressing mice were found to have reduced myocardial infarct size after a prolonged 
ischemia episode (Turoczi et al., 2003). Glutathione peroxidase (GSHPx) knockout mice have 
been shown to be more susceptible to ischemic damage than wild type mice, whereas 
GSHPx overexpressing mice are protected against myocardial ischemic damage (Maulik et 
al., 1999). 
In models of heart failure the contribution of ROS has been demonstrated to contribute to 
hypertrophic adaptations and to apoptosis (Li et al., 2002; Kwon et al., 2003; Giordano, 
2005). Cardiac hypertrophy can be either a physiological adaptation or part of the pathology 
that ultimately progresses to heart failure (Giordano, 2005). ROS signaling has been 
implicated in hypertrophic growth associated activation of MAPKs (Sabri et al., 2003; Ghosh 
et al., 2003). For example, inhibition of ROS by chemical antioxidants prevents A-II induced 
hypertrophy (Nakamura et al., 1998; Delbosc et al., 2002). ROS induced alterations in 
transcription factor activation has been reported in cardiac hypertrophy and several studies 
point to a role for ROS in the induced chromatin remodeling in the failing heart (Giordano, 
 
Novel Strategies in Ischemic Heart Disease 230 
inflammatory drug (NSAID), that is a substrate for the Msr system (Etienne et al. 2003; 
Brunell et al. 2011). Sulindac protects the heart against ischemic infarction through a newly 
described activity as a pharmacological preconditioning agent (Moench et al., 2009). 
2. Antioxidant therapies and oxidative stress in heart disease 
ROS normally produced as a by-product of the electron transport chain are now considered 
to be a major factor in aging and age related diseases (Bokov et al., 2004). In the heart high 
levels of ROS have been implicated in both ischemic damage and in the progression of heart 
failure (Giordano, 2005). Preclinical studies for ischemic heart disease employing 
antioxidants although still at an early stage have shown some promise (Sugamura and 
Keaney, 2011; Bolli et al., 2004; Cannon, 2005). For example heme oxygenase -1 (HO-1) based 
gene therapy has been proposed as a therapeutic strategy for ischemic heart disease because 
the enzyme has a clear antioxidant capacity (Liu et al., 2007). In addition, the products of 
heme metabolism, carbon monoxide and bilirubin have been reported to possess cyto-
protective properties (Poss and Tonegawa, 1997; Stocker et al., 1987). Cardiac expression of 
HO-1 increased Akt phosphorylation and decreased infarct size in a mouse model of 
ischemia/reperfusion. Knockdown of the bilirubin producing enzyme biliverdin reductase 
increases apoptosis of cardiac cells subjected to hypoxia /re-oxygenation and decreases Akt 
phosphorylation. Thus the protection afforded by HO-1 involves activation of Akt that is 
dependent upon biliverdin reductase (Pachori et al., 2007). 
Other antioxidant enzymes that have shown potential for protection against ischemic 
damage include extracellular superoxide dismutase (EC-SOD-1), thioredoxin (Trx), and 
glutathione peroxidase (GSHPx) (Agrawal et al., 2004; Yoshida et al., 1996; Turoczi et al., 
2003; Maulik et al., 1999). Gene transfer of EC-SOD-1 by direct intra myocardial injection 
using an AAV vector resulted in high level cardio-protection in rats at 7 days following 
ischemia and reperfusion injury (Agrawal et al., 2004). Using the rat working heart model of 
transient global ischemia it has been shown that thioredoxin is substantially decreased, 
whereas preconditioning by non-lethal ischemia elicited up-regulation of Trx expression 
and induced tolerance against severe ischemic stress (Turoczi et al., 2003). Likewise Trx-1 
overexpressing mice were found to have reduced myocardial infarct size after a prolonged 
ischemia episode (Turoczi et al., 2003). Glutathione peroxidase (GSHPx) knockout mice have 
been shown to be more susceptible to ischemic damage than wild type mice, whereas 
GSHPx overexpressing mice are protected against myocardial ischemic damage (Maulik et 
al., 1999). 
In models of heart failure the contribution of ROS has been demonstrated to contribute to 
hypertrophic adaptations and to apoptosis (Li et al., 2002; Kwon et al., 2003; Giordano, 
2005). Cardiac hypertrophy can be either a physiological adaptation or part of the pathology 
that ultimately progresses to heart failure (Giordano, 2005). ROS signaling has been 
implicated in hypertrophic growth associated activation of MAPKs (Sabri et al., 2003; Ghosh 
et al., 2003). For example, inhibition of ROS by chemical antioxidants prevents A-II induced 
hypertrophy (Nakamura et al., 1998; Delbosc et al., 2002). ROS induced alterations in 
transcription factor activation has been reported in cardiac hypertrophy and several studies 
point to a role for ROS in the induced chromatin remodeling in the failing heart (Giordano, 
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2005). ASK-1 provides a link between oxidative stress and hypertrophy since following 
activation by ROS, Ask1 induces activation of p38-MAPK and JNK causing apoptosis 
(Izumiya et al., 2003). The apoptotic process is central to heart failure and the effect of ROS 
on apoptosis is dependent upon the levels of ROS produced (Kwon et al., 2003). It is clear 
that high levels of ROS will elicit apoptosis via JNK and p38-MAPKs, whereas low levels of 
ROS can function as signaling molecules and help to protect cells under certain 
physiological conditions, as is the case with ischemic preconditioning discussed below 
(Kwon et al., 2003; Das, 2001; Hool, 2006; Murry et al., 1986; Yellon and Downey, 2002; Bolli, 
2000).  
3. MsrA and cellular protection 
Of the amino acids in proteins that can be oxidized by ROS, Met is one of the most sensitive, 
being converted to methionine sulfoxide (Met(o)) (Weissbach et al., 2005). Since the sulfur in 
Met(o) has a chiral center this chemical oxidation yields a mixture of the R and S epimers, 
Met-R-(o) and Met-S-(o), as shown in Figure 1.  
 
Fig. 1. Products of methionine oxidation. 
Further oxidation of Met(o), leads to the formation of methionine sulfone, which has been 
detected in proteins at very low levels and its significance is not known. As also shown in 
Figure 1 Met(o) in proteins can be reduced back to Met by the Msr enzymes. The two main 
members are MsrA and MsrB, which reduce the S epimer and R epimer of Met(o), 
respectively. It is now known that there is one msrA gene in mammalian cells and three 
msrB genes, the latter referred to as MsrB1, 2 and 3 (Vougier et al., 2003; Kim and 
Gladyshev, 2004; Hansel et al., 2005). 
Although MsrA was first discovered more than 30 years ago in studies on protein synthesis in 
bacteria (Brot et al.,1981),  its important role in protecting cells against oxidative damage only 
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became apparent in the early 1990's after the MsrA gene was cloned from both Escherichia coli 
and bovine liver (Rahman et al., 1992; Moskovitz et al., 1996). When MsrA was knocked out in 
E. coli the organism grew normally, but was extremely sensitive to oxidizing agents 
(Moskovitz et al., 1996, St. John et al., 2001). Since then there have been several studies 
demonstrating that over-expressing MsrA in animal cells can protect them against oxidative 
damage (Moskovitz et al., 1998; Kantorow et al., 2004; Yermolaieva et al., 2000) and lead to 
extended life span in both flies and yeast (Ruan et al., 2002, Koc et al., 2004) . As one example 
in cells in culture, over-expression of MsrA by transfection of PC12 cells with an adenovirus 
vector encoding MsrA resulted in a greater tolerance for oxidative stress following hypoxia 
with re-oxygenation (Yermolaieva et al., 2004). MsrA overexpressing cells showed significantly 
lower levels of ROS and apoptosis than cells infected with no virus or control plain virus. In 
Drosophila, overexpression of MsrA was protective against oxidative stress. When the MsrA 
transgene was over-expressed the flies were found to be more resistant to paraquat induced 
oxidative stress and  when the MsrA was predominantly expressed in the nervous system 
there was a dramatic increase in lifespan (Ruan et al., 2002) (Figure 2).  
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To determine the effect of MsrA in protecting against hypoxia/re-oxygenation damage in 
cardiac cells we transduced primary rat cardiac myocytes with an MsrA encoding 
adenovirus (Prentice et al., 2008). In cells over-expressing MsrA, apoptotic cell death 
resulting from hypoxia/re-oxygenation was decreased by greater than 45% relative to cells 
expressing control virus (Figure 3). 
The protection of cardiac myocytes in culture against hypoxia/re-oxygenation stress by 
MsrA over-expression points to MsrA as a potential therapeutic agent for treatment of 
ischemic heart disease (Prentice et al., 2008). 
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Fig. 3. Protection of cardiac myocytes following hypoxia /reoxygenation by sulindac as 
measured by levels of LDH released. **p<0.01 vs air control virus (N=6). *p<0.01 vs 
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There were corresponding changes in calcium transients in MsrA-/- cardiac myocytes 
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diseased hearts either from dilated cardiomyopathy or from myocardial ischemia and such 
ultrastructural changes have been associated with aging and senescence (Trillo et al., 1978; 
Schaper et al., 1991; Scholz et al., 1994; Terman et al., 2004) . This study indicates that there is a 
serious defect in mitochondrial function in the hearts of MsrA-/- mice resulting in 
compromised contractility and cellular dysfunction, especially under stress (Nan et al., 2010). 
 
Fig. 4. MsrA knockout (MsrA -/-) mice show decreased contractility when stressed by high 
frequency (2Hz) or with hydrogen peroxide treatment. (a) Raw traces of sarcomere 
contraction under 0.5 Hz or 2 Hz stimulation. (b) Shortening amplitude with 0.5Hz and 2 
Hz. (c) Raw traces of sarcomere contraction with or without H2O2 treatment. (d) Shortening 
amplitude in cardiomycytes with or without H2O2 treatment. Data are presented as 
mean+/- SD and obtained from 25-30 cells (3 mice per group); *p<0.05. From Nan et al.,2010 
Previous studies had demonstrated that approximately 75% of MsrA was targeted to the 
cytosol and 25% to the mitochondria (Kim et al., 2010; Vougier et al., 2003). A recent study 
by Zhao et al., (2011) examined the role of MsrA in different cellular compartments and 
assessed whether the enzyme would protect against ischemia reperfusion damage in the 
Langendorff heart. The investigators employed transgenic mice that overexpressed MsrA 
either in the myocardium or in the cytosol. A surprising finding was that mitochondrial 
targeted MsrA was not protective in the Langendorff model against ischemia/reperfusion. 
By contrast the cytoplasmic form of MsrA was protective, but the effect was dependent on 
myristoylation of the enzymes. It was proposed that myristoylation may facilitate targeting 
of MsrA to its protein targets to elicit myocardial protection. 
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4. Dual function of the Msr system 
It was initially thought that the main role of the Msr system was to repair oxidative 
damage to proteins in which critical met residues were oxidized to met(o). There has been 
ample evidence that this is an important function of the Msr system. Once again most of 
the studies have been done with MsrA. There are now a long list of proteins and peptides 
whose activities are altered by Met oxidation in vitro (Brot and Weissbach, 2000) and 
many examples of how the activity can be restored in part by MsrA. One of the first 
examples was the oxidation of Met 358 in alpha one proteinase inhibitor. This enzyme, 
which may play a role in emphysema, loses its protease inhibitor activity when this Met is 
oxidized and the activity can be restored by MsrA (Abrams et al., 1981). More recently, 
oxidation of met residues in proteins has been reported to cause a major change in 
function of a number of proteins. As examples, in a shaker ShC/B voltage gated 
potassium channel, when a key methionine residue in the inactivation ball is oxidized, the 
channel activation is slowed down, but this process is reversed by MsrA (Ciorba et al., 
1997). A methionine in the C terminus of calmodulin is selectively oxidized by hydrogen 
peroxide (Yao et al., 1996). The extent of oxidative modification was found to correlate 
with loss of CaM dependent activation of the plasma membrane Ca-ATPase. The protein 
calcium/calmodulin (Ca2+ CaM) dependent protein kinase II (CamKII) links increases in 
intracellular calcium to activation of ion channels, transcriptional responses and cell fate 
decisions. A recent study analyzing the role of CaMKII in heart demonstrated that 
CamKII is a common signaling point for increased apoptosis regulated by ROS, 
catecholamine signaling and angiotensin-II (Ang-II) (Erickson et al., 2008). MsrA was 
found to be essential for reversing CaMKII methionine oxidation in the ischemic heart in 
vivo. 
However, Levine et al. (1996), in their studies on glutamine synthetase,  first introduced the 
important concept that the Msr system could be part of a ROS scavenger mechanism. In this 
mechanism, Met residues in proteins, even when not at an active site, can be oxidized to 
Met(o) and in the process  destroy a ROS molecule. The Msr system could then regenerate 
the Met which could once again be oxidized by an ROS molecule. Thus, the Met residues in 
proteins could function as catalytic anti-oxidants dependent on the Msr system. There are 
now several cell culture studies to support this mechanism. In PC12 cells over-expression of 
MsrA lowers the level of ROS in the cells and in lens and retinal cells knocking out of MsrA 
leads to higher ROS levels (Yermolaieva et al., 2004; Marchetti et al., 2006). 
5. Sulindac is a substrate for the Msr enzymes 
If Met residues in proteins could function as catalytic anti-oxidants based on the Msr system 
it seemed reasonable that other substrates of the Msr enzymes might function in cells as 
catalytic anti-oxidants. One such compound that was shown to be a substrate for MsrA was 
sulindac, a known NSAID (Duggan et al., 1977). The structure of sulindac and its 
metabolites is shown in Figure 5. Sulindac is a prodrug that must be reduced to sulindac 
sulfide which is the active NSAID. Since sulindac is also a mixture of the R and S epimers 
the metabolism of both epimers has been recently elucidated as shown in Figure 5 (Brunell 
et al., 2011).  
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Fig. 5. Metabolism of the sulindac epimers. The R and S epimers of sulindac can be oxidized 
to sulindac sulfone and reduced to sulindac sulfide. From Brunell et al. 2011. 
The reduction of the S epimer is catalyzed by MsrA and as seen in Figure 6, the R epimer 
is reduced by an enzyme in liver that has the properties of MsrB (Brunell et al., 2011). 
Sulindac can also induce the P450 system  and be oxidized by the P450 system to sulindac 
sulfone (Ciolino et al., 2008; Brunell et al., 2011). Sulindac sulfone is not an NSAID and is 
not a substrate for the Msr system. It seemed reasonable to see whether sulindac might 
function as a catalytic anti-oxidant and protect cells against oxidative damage. In our 
preliminary experiments several normal cells were not protected by sulindac after 
exposure to oxidative stress, but normal lung cells were (Marchetti et al., 2009). An 
unexpected finding was that under similar conditions colon and lung cancer cell lines, 
that were pretreated with sulindac, showed enhanced killing of these cells when exposed 
to oxidative stress. The protective effect of sulindac with normal lung cells and the 
enhanced killing with the cancer cell lines was not due to the NSAID activity of sulindac 
or did it involve the Msr system since sulindac sulfone gave a similar effect as sulindac 
(Marchetti et al., 2009). As will be shown below, using cardiac cells, the protection seen 
against oxidative damage by sulindac is by an ischemic preconditioning mechanism 
(Moench et al., 2009). 
6. Sulindac causes cardiac protection by ischemic preconditioning 
Pharmacological preconditioning has been reported to occur in response to certain drugs 
that mimic the effects of ischemic preconditioning, a process known to elicit protective 
responses against myocardial stunning and infarction. Ischemic preconditioning has been 
reported to elicit an early phase of protection from 0-2 hours after the initial stimulus as well 
as a late phase of preconditioning from 1 -7 days after ischemia (Kuzuya et al., 1993; Marber 
et al., 1993; Bolli, 2000). A number of pharmacological agents can induce preconditioning 
include cytokines, opioids, adenosine, nitric oxide donors and bradykinin although these 
agents may differ in their capacity to protect against infarction, stunning or both infarction 
and stunning (Bolli, 2000). 
The mechanisms of early preconditioning have been shown to involve NO activation of 
soluble guanylyl cyclase (GC), activation of PKG and opening of mitochondrial ATP 
dependent potassium channels (K-ATP channels) (Costa et al., 2008). Subsequent generation 
of ROS from the mitochondrion results in activation of PKC (Costa et al., 2008; Baines et al., 
1997; Tritto et al., 1997). The mediation events of early preconditioning have been shown to 
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involve inhibition of the formation of the mitochondrial permeability transition pore, and in 
some cases, such as with protection by adenosine, this mediation involves PKC activation 
and PKG activation (Costa et al., 2008). 
Late preconditioning is triggered through the action of NO as well as through ROS release 
(Bolli, 2001; Bolli et al., 1997). PKC epsilon translocates to the membrane fraction which is 
then followed by activation of the MAPK signaling cascade (Xuan et al., 2007). 
Downstream events include phosphorylation of STAT1/3 and activation of STAT 
dependent genes which include the COX-2 gene. Other events that mediate late 
preconditioning include NO release (through a PKG dependent mechanisms and opening 
of mitochondrial K(ATP) channels (Bernardo et al., 1999; Ockaili et al., 1999). It has been 
reported that the NO that mediates late preconditioning is derived from inducible NOS 
(iNOS). Some of the components involved in ischemic preconditioning are summarized in 
Figure 6. 
 
Fig. 6. Overview of mechanisms of preconditioning involving PKC, iNOS and mitochondrial 
pro-survival events. 
In investigating the role of sulindac as a protective agent we examined the effect of sulindac 
treatment on neonatal rat cardiac myocytes subjected to hypoxia and re-oxygenation and in 
an ex vivo Langendorff model of myocardial ischemia (Moench et al., 2009). We 
demonstrated that sulindac (<100uM) afforded high level protection of cardiac myocytes 
subjected to hypoxia and re-oxygenation (Figure 7). 
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Fig. 7. Sulindac protects cardiac myocytes against oxidative damage. Cardiac myocytes were 
exposed to hypoxia for 24 h and reoxygenation for 20 h to elicit oxidative stress in the 
presence or absence of sulindac. Lactate dehydrogenase (LDH) levels (shown as absorbance 
units) were measured in the media as an index of cell death and levels were compared to 
those for untreated myocytes (*,P<0.05 vs. no drug; n=6, **, p<0.01 vs. no drug; n=6). From 
Moench et al., 2009. 
In the Langendorff experiments rats were fed sulindac for 2 days prior to removal of the 
heart which was then subjected to 45 minutes of ischemia followed by 2 hours of 
reperfusion with oxygenated buffer (Figure 8). Sulindac was highly protective against 
myocardial ischemia through mechanisms that did not involve Cox inhibition or its anti-
inflammatory capacity.  
As an example, the NSAID ibuprofen was not capable of protecting against no flow 
ischemia in the Langendorff model. Furthermore the oxidized form of sulindac, sulindac 
sulfone, which as mentioned,  is not an NSAID was found to give significant protection 
against ischemic damage. Through the use of a PKC inhibitor and a ROS scavenging agent 
we have demonstrated that sulindac protects the heart from ischemic stress by acting as a 
pharmacological preconditioning agent. PKC is known to mediate preconditioning either by 
ischemia or by pharmacological agents and in our studies daily administration of the PKC 
blocker chelerytherine removed the protection provided by sulindac (Figure 8). The  
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Fig. 8. Effect of feeding sulindac  on infarct size after ischemia and reperfusion as measured by 
TTC staining. Where indicated  the PKC inhibitor chelerythrine was administered to the 
animals. (A) Graph represents percent of heart that was infarcted (*, P<0.01 compared to no-
drug control; n=4, **., P<0.01 compared to sulindac treated hearts; n=4). (B) Representative 
sections from langendorff hearts subjected to 45 min ischemia and 2h reperfusion showing 
viable tissue (red) and infarcted tissue (white). From Moench et al. 2009. 
mechanism of sulindac protection appear to involve the following steps: 1) ROS increase as 
a trigger for subsequent signaling, 2) signaling through PKC, 3) induction of expression of 
downstream gene products including iNOS and Hsp27. Ongoing experiments are 
addressing more specifically the PKC isoforms involved in the protective action of sulindac, 
in addition to identifying mitochondrial signals that may contribute to the pro-survival 
response. 
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As noted above, a remarkable property of sulindac is its ability to kill cancer cells in the 
presence of an oxidant while being able to protect certain normal cells through 
pharmacological preconditioning (Marchetti et al., 2009; Moench et al., 2009). It is notable 
that a similar phenomenon has recently been reported for the PDE-5 inhibitor sildenafil (Das 
et al., 2010). This drug was found to enhance the doxorubicin induced killing of prostate 
cancer cells while also protecting cardiac cells from doxorubicin induced cardiomyopathy. 
The mechanisms of doxorubicin induced killing of cancer cells involved enhanced 
generation of ROS (Das et al., 2010). It will be important in future studies to determine the 
ways by which  sulindac and sildenafil are capable of modifying the effects of increased 
ROS  in cardiac cells leading to cell survival while also sensitizing cancer cells to oxidative 
stress resulting in killing of these cells. 
7. Final thoughts 
Antioxidant based approaches have already shown potential as strategies for the 
treatment of heart disease and interventions that increase intracellular MsrA have been 
protective in cardiac cells either through preventing an increase in ROS levels or through 
modifying important protein targets. Future therapies that are likely to be successful 
using the MsrA system may need to focus on activation of endogenous MsrA through 
applying pharmacological activators of MsrA identified from library screening 
procedures. A recent study by Minniti and colleagues (Minniti et al., 2009) noted that the 
MsrA promoter is activated by FOXO3A (De Luca et al., 2010). On the basis of this finding 
a potentially powerful strategy for increasing MsrA expression would involve transfer of 
FOXO3A protein into cells as a highly permeable TAT-FOXO3A-fusion protein which in 
turn would translocate to the nucleus and activate the MsrA gene. A simpler and more 
direct avenue for increasing MsrA levels would be to transfer a TAT-MsrA fusion protein 
directly into cells.  
Regarding sulindac, although there has been serious concern that NSAIDs cause cardiac 
damage, here we demonstrate that at the concentrations used sulindac can, in fact, afford 
cardiac protection through preconditioning mechanisms. This is very likely due to the fact 
that a substantially lower dose is needed for preconditioning than was previously employed 
for anti-inflammatory applications. Future approaches based on the preconditioning 
properties of sulindac may involve metabolites or derivatives that are not NSAIDs and do 
not inhibit COX 1 or COX2. One such metabolite, sulindac sulfone, has been shown to be 
lacking in NSAID activity but has the cardiac protectant activity (Moench et al., 2009). As 
there is a very significant need clinically for effective cardioprotective agents our recent 
studies on cell culture and in vivo models showing high level cardiac protection by  MsrA 
and by sulindac may point to the future application of these agents as important therapeutic 
breakthroughs for heart disease. 
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Hepatic Lipid Accumulation by High Cholesterol 
Diet is Inhibited by the Low Dose Fish Oil in 
Male C57BL/6J Mice 
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Atherosclerotic diseases such as ischemic heart disease and cerebral infarction account for 
the major causes of death in many countries. It is well known that hyperlipidemia is closely 
associated with these diseases (Kodama, 1990). Fish oil consumption reduces lipogenesis 
and induces fatty acid oxidation in liver(Rustan, 1990; Halminski, 1991), and ameliorates 
plasma and hepatic lipid levels (Nestel, 1990). These effects of fish are greatly attributed to 
the action of n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) or 
docosahexaenoic acid (DHA). Several studies have reported that n-3 PUFA decreases the 
expression of genes coding for lipogenesis enzymes such as fatty acid synthase (FAS), 
acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) through the lowering of 
sterol regulatory element binding protein-1 (SREBP-1) (Kim, 1999; Shimano, 1999; Nakatani, 
2002). In addition, n-3 PUFA activates the peroxisome proliferator-activated receptor α 
(PPARα) (Krey, 1997). PPARα is a ligand-activated transcription factor that regulates the 
expression of genes involved in triglyceride hydrolysis and fatty acid oxidation (Latruffe, 
1997; Nakatani, 2002; Schoonjans, 1996), such as acyl-CoA oxidase (AOX), lipoprotein lipase 
(LPL), medium-chain acyl-CoA dehydrogenase (MCAD), acyl-CoA synthetase (ACS), and 
uncoupling protein-2 (UCP-2).  
Cholesterol is crucial for the components of animal cell membranes, and for the synthesis of 
bile acid and steroid hormone. Cholesterol in the inner cavity of the small intestine are 
entered in to epithelial cells by Niemann-Pick C1 like-1 (NPC1L1) protein on the brush 
border of epithelial cells of the small intestine (Davis, 2004), and cholesterol is released into 
the lymph duct. It is well known that cholesterols, including 22- and 24-hydroxy cholesterol, 
act as ligands for liver X receptor (LXR)  (Schultz, 2000). LXR, a nuclear receptor, forms a 
heterodimer together with the retinoid X receptor (RXR) and combines with LXR element 
(LXRE) at the promoter of target genes to control transcription. LXR target genes include 
cholesterol 7-hydroxylase (CYP7A1), ATP-binding cassette transporter (ABC)A1, ABCG1, 
and SREBPs, which are highly involved in cholesterol metabolism (Repa, 2000; Peet, 1998). 
We previously indicated that 20en% fish oil diet dramatically inhibited hepatic lipids 
accumulation in female C57BL/6J mice fed 2% cholesterol (Hirako, 2010). In this study, we 
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determined whether 2 or 5en% fish oil, eqivalent to 10 or 25% of the total fat energy, 
improves lipid metabolism in high cholesterol diet fed male C57BL/6J mice. Mice were 
given SO diet consisted of 20en% safflower oil, 2FO diet consisted of 2en% fish oil plus 
18en% safflower oil, 5FO diet consisted of 5en% fish oil plus 15en% safflower oil, and 
SO/CH, 2FO/CH, 5FO/CH are consisted of SO, 2FO, 5FO with 2%cholesterol. The body fat 
composition of mice was examined radiographically using an X-ray CT for experimental 
animals. Blood parameter and hepatic lipids were measured using enzymatic methods. 
Hepatic mRNA expression levels were measured by real-time RT-PCR. 
2. Results and discussion  
2.1 Body weight and tissue weight did not change with the low dose fish oil feeding in 
male C57BL/6J mice  
Final body weights were not significantly different among the groups. No large difference in 
weights of the white adipose tissue around the uterus and brown adipose tissue from the 
interscapular region between the groups was observed. In previous study, we reported that 
body weight gain was significantly decreased in female C57BL/6J mice fed 20 en% fish oil 
(Hirako, 2010). However, our study observed that 5 en% fish oil feeding in female C57BL/6J 
mice did not modify body weights (data not shown). These results revealed that 2 and 5 en% 
fish oil feeding in male C57BL/6J mice did not modify body weight and adipose tissue weight  
 
 
Representative X-ray CT images of mice fed SO, SO/CH, 2FO, 2FO/CH, 5FO, and 5FO/CH for 8 
weeks, at the L3 level (upper). The areas indicated with pink, yellow, and light-blue are visceral fat, 
subcutaneous fat, and muscle, respectively. CT-estimated amounts of visceral fat and subcutaneous fat 
in the abdominal area of L2–L4(bottom). Values represent means ± S.D. (n=5). Means with different 
letters are different at the p<0.05 level by Fisher’s protected least significant difference (PLSD) test. 
Fig. 1. CT-based fat tissues composition analysis of 16-week-old male C57BL/6J mice.  
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as well as female C57BL/6J mice. CT scan analysis showed that visceral and subcutaneous 
fat mass were significantly increased in the 5FO and 5FO/CH groups, but not changed by 
cholesterol feeding (Figure 1). Meanwhile, these levels were high in all group compared 
with the fat mass in the female C57BL/6J mice (0.45±0.28cm3 visceral fat in male C57BL/6J 
mice fed the SO diet and 0.24±0.13 cm3  visceral fat in female C57BL/6J mice fed the SO diet).  
2.2 Hepatic tissue histology and lipid levels modified with the low dose fish oil 
feeding in male C57BL/6J mice 
Although the liver weight significantly increased in the SO/CH group compared with the 
SO group, there was no difference in the fish oil groups compared with the SO group (SO: 
0.96 ± 0.10, SO/CH: 1.31 ± 1.2, 2FO: 1.00 ± 0.13, 2FO/CH: 1.11 ± 0.12, 5FO: 0.92 ± 0.08, 
5FO/CH: 1.12 ± 0.12, p<0.05). The liver size in the SO/CH group had enlarged, and the 
entire surface had a pale color, suggestive of increased lipid storage. In contrast, the livers of 
the 2FO/CH and 5FO/CH groups were less pale and had a normal reddish appearance 
(data not shown). The hepatic tissues showed numerous lipid droplets in the livers of 
SO/CH group. However, these lipid droplets were markedly decreased in the 2FO/CH and 
5FO/CH groups (Figure 2A). These results in the microscopic images of hepatic tissue were 
confirmed in hepatic lipid content reductions. Hepatic TG levels in both 2FO/CH and 
5FO/CH group significantly decreased to about 50% of that in the SO/CH group. Hepatic 
TC levels also decreased by about 40% in both 2FO/CH and 5FO/CH group compared with 
the SO/CH group(Figure 2B). Fabbrini suggested that hepatic lipid accumulation is 
considered a risk factor for fatty liver and steatohepatitis, which promote the development  
 
 
H&E-stained liver sections (A), total cholesterol (TC) and triglycerides (TG) (B) in mice fed SO, SO/CH, 
2FO, 2FO/CH, 5FO, and 5FO/CH for 8. Values represent means ± S.D. (n=5). Means with different 
letters are different at the p<0.05 level by Fisher’s protected least significant difference (PLSD) test. 
Fig. 2. Liver tissue histology and lipid levels of 16-week-old male C57BL/6J mice.  
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of insulin resistance, dyslipidemia, and cardiovascular disease (Fabbrini, 2010). In this 
study, lipid deposition caused by high cholesterol feeding significantly decreased in the 
2FO/CH and 5FO/CH groups, in which low dose fish oil was used as the lipid source. We 
confirmed that the 2 en% fish oil exerts ameliorating effects on hepatic lipid accumulation 
due to dietary cholesterol consumption in male C57BL/6J mice. 
2.3 The hepatic mRNA levels of lipid metabolism-regulating genes modfied with the 
fish oil or cholesterol feeding in male C57BL/6J mice 
The hepatic mRNA levels of lipid metabolism-regulating genes are shown in Table 1. The 
mRNA levels of SREBP-1c, which is transcription factor of genes related to lipogenesis, were 
not significantly changed in all groups. Low dose fish oil or cholesterol feeding did not 
particularly affect in FAS mRNA. However, SCD1 mRNA levels significantly decreased in 
the fish oil groups regardless of the addition the addition of cholesterol, compared with the 
SO/CH group. Previous studies showed that fish oil feeding decreases SREBP1c mRNA 
expression and/or mature protein production and results in the inhibition of SREBP1 target 
genes, such as ACC, FAS, and SCD-1 (Kim, 1999; Nakatani, 2002).  In this study, different 
results were observed, suggesting that the inhibitory effect of fish oil on fatty acid 
biosynthesis is more clear at high dose fish oil. 
 
The mRNA expression levels in liver of  male C57BL/6J mice fed SO, SO/CH, 2FO, 2FO/CH, 5FO, and 
5FO/CH for 8 weeks. Values represent means ± S.D. (n=4-5). Means with different letters are different 
at the p<0.05 level by Fisher’s protected least significant difference (PLSD) test.  
Table 1. Expression of genes associated with lipid metabolism in the liver  
The mRNA levels of PPARα and AOX, genes involved in fatty acid oxidation, were 
significantly higher in the fish oil groups regardless of the addition of cholesterol. However, 
the mRNA levels of UCP-2, which is involved in heat production, were unaffected by low 
dose fish oil or cholesterol feeding. The mRNA levels of ABCG5 and ABCG8, genes 
involved in cholesterol transport into the bile, were significantly induced with the 
cholesterol addition . Biliary cholesterol excretion increases due to the upregulation of these 
genes (Repa, 2002). These increases in ABCG5 and ABCG8 mRNA by cholesterol feeding are 
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crucial for the maintenance of cholesterol homeostasis. Indeed, the mRNA levels of CYP7A1, 
the rate-limiting gene in bile acid synthesis, were significantly increased in all cholesterol-
supplemented groups. However, no such increases were observed in the expression of 
CYP8B1 mRNA. The synthesis of bile acid in the liver is important in the catabolic pathway 
of cholesterol. The bile acid systhesis is controlled by CYP7A1 (Berge, 2000). In this study, 
the mRNA levels of CYP7A1 were not significantly affected by fish oil feeding, but its levels 
significantly increased when cholesterol was added. This is consistent with previous 
observation that CYP7A1 mRNA level is increased on the addition of cholesterol to maintain 
the homeostasis of cholesterol. 
3. Conclusion 
Body weight gains and adipose tissue weights did not change with the low dose fish oil 
feeding in male C57BL/6J mice. Hepatic triglyceride and total cholesterol levels of the 
SO/CH group were dramatically increased compared to the SO group. However, in 
2FO/CH and 5FO/CH groups, the hepatic lipids were significantly decreased compared to 
the SO/CH group. Low dose fish oil or cholesterol feeding did not particularly affect in 
SREBP-1C and FAS mRNA levels. But, PPARα and AOX mRNA levels were significantly 
higher in the fish oil groups regardless of the cholesterol addition. The present study 
indicates that low dose fish oil obviously improved the hepatic lipid accumulation by high 
cholesterol diet. And, this improving effect is partly due to the fatty acid degradation, which 
was facilitated by increased expression of fatty acid oxidation-related genes, such as AOX. 
4. Acknowledgments 
We would like to thank NOF Corporation (Tokyo, Japan) for providing FO.  
5. References 
Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, 
Hobbs HH. Accumulation of dietary cholesterol in sitosterolemia caused by 
mutations in adjacent ABC transporters. Science 2000; 290: 1771-1775 
Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund 
EG, Detmers PA, Graziano MP, Altmann SW. Niemann-Pick C1 Like 1 
（NPC1L1） is the intestinal phytosterol and cholesterol transporter and a key 
modulator of whole-body cholesterol homeostasis. J Biol Chem 2004; 279: 33586-
33592 
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, 
metabolic, and clinical implications. Hepatology 2010; 51: 679-689 
Halminski MA, Marsh JB, and Harrison EH: Differential effects of fish oil, safflower oil and 
palm oil on fatty acid oxidation and glycerolipid synthesis in rat liver. J Nutr, 1991; 
121: 1554-1561 
Hirako S, Kim HJ, Arai T, Chiba H, Matsumoto A. Effect of concomitantly used fish oil and 
cholesterol on lipid metabolism. J Nutr Biochem 2010; 21: 573-579 
Kim HJ, Takahashi M, Ezaki O: Fish oil feeding decreases mature sterol regulatory element-
binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse 
 
Novel Strategies in Ischemic Heart Disease 252 
liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J 
Biol Chem, 1999; 274: 25892-25898 
Kodama K, Sasaki H, Shimizu Y. Trend of coronary heart disease and its relationship to 
risk factors in a Japanese population: a 26-year follow-up, Hiroshima/Nagasaki 
study. Circ J, 1990; 54: 414-421 
Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, 
eicosanoids, and hypolipidemic agents identified as ligands of peroxisome 
proliferator-activated receptors by coactivator-dependent receptor ligand assay. 
Mol Endocrinol, 1997; 11: 779–791 
Latruffe N, Vamecq J: Peroxisome proliferators and peroxisome proliferator activated 
receptors (PPARs) as regulators of lipid metabolism. Biochimie, 1997; 79: 81–94 
Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O; Mechanism for 
peroxisome proliferator-activated receptor-alpha activator-induced up-regulation 
of UCP2 mRNA in rodent hepatocytes. J Biol Chem, 2002; 277: 9562–9569 
Nestel PJ. Effects of N-3 fatty acids on lipid metabolism. Annu Rev Nutr, 1990; 10:149-167 
Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. 
Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear 
Oxysterol Receptor LXRα. Cell 1998; 93: 693-704 
Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-
binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors 
alpha and beta. J Biol Chem 2002 ; 277: 18793-18800 
Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, 
Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-
binding protein-1c gene （SREBP-1c） by oxysterol receptor, LXRα and LXRβ. 
Genes Dev 2000; 14: 2819-2830 
Rustan AC, Nossen JO, Christiansen EN, and Drevon CA: Eicosapentaenoic acid reduces 
hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-
coenzyme A:1,2- diacylglycerol acyltransferase. J Lipid Res, 1988; 29: 1417-1426 
Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) 
and their effects on lipid metabolism and adipocyte differentiation. Biochim 
Biophys Acta, 1996; 1302: 93–109 
Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, 
Mangelsdorf DJ, Lustig KD, Shan B.Role of LXRs in control of lipogenesis. Genes 
Dev 2000; 14: 2831-2838 
Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, 
Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N. Sterol regulatory 
element-binding protein-1 as a key transcription factor for nutritional induction of 
lipogenic enzyme genes. J Biol Chem 1999; 274: 35832-35829 
 
Novel Strategies in Ischemic Heart Disease 252 
liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J 
Biol Chem, 1999; 274: 25892-25898 
Kodama K, Sasaki H, Shimizu Y. Trend of coronary heart disease and its relationship to 
risk factors in a Japanese population: a 26-year follow-up, Hiroshima/Nagasaki 
study. Circ J, 1990; 54: 414-421 
Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, 
eicosanoids, and hypolipidemic agents identified as ligands of peroxisome 
proliferator-activated receptors by coactivator-dependent receptor ligand assay. 
Mol Endocrinol, 1997; 11: 779–791 
Latruffe N, Vamecq J: Peroxisome proliferators and peroxisome proliferator activated 
receptors (PPARs) as regulators of lipid metabolism. Biochimie, 1997; 79: 81–94 
Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O; Mechanism for 
peroxisome proliferator-activated receptor-alpha activator-induced up-regulation 
of UCP2 mRNA in rodent hepatocytes. J Biol Chem, 2002; 277: 9562–9569 
Nestel PJ. Effects of N-3 fatty acids on lipid metabolism. Annu Rev Nutr, 1990; 10:149-167 
Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. 
Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear 
Oxysterol Receptor LXRα. Cell 1998; 93: 693-704 
Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-
binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors 
alpha and beta. J Biol Chem 2002 ; 277: 18793-18800 
Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, 
Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-
binding protein-1c gene （SREBP-1c） by oxysterol receptor, LXRα and LXRβ. 
Genes Dev 2000; 14: 2819-2830 
Rustan AC, Nossen JO, Christiansen EN, and Drevon CA: Eicosapentaenoic acid reduces 
hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-
coenzyme A:1,2- diacylglycerol acyltransferase. J Lipid Res, 1988; 29: 1417-1426 
Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) 
and their effects on lipid metabolism and adipocyte differentiation. Biochim 
Biophys Acta, 1996; 1302: 93–109 
Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, 
Mangelsdorf DJ, Lustig KD, Shan B.Role of LXRs in control of lipogenesis. Genes 
Dev 2000; 14: 2831-2838 
Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, 
Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N. Sterol regulatory 
element-binding protein-1 as a key transcription factor for nutritional induction of 
lipogenic enzyme genes. J Biol Chem 1999; 274: 35832-35829 
14 
Cardiac Protection with Targeted Drug Delivery 
to Ischemic-Reperfused Myocardium 
Michael Galagudza 
V. A. Almazov Federal Heart, Blood and Endocrinology Centre  
Russian Federation 
1. Introduction 
The concept of targeted drug delivery implies selective accumulation of the drug in the 
tissue affected by the pathological process after systemic administration of the drug and its 
carrier with minimal effect of the former on the intact organs and tissues (Lammers et al., 
2010). The idea of targeted delivery has been first suggested by Paul Erhlich in 1906 when he 
introduced the concept of «magic bullet» which is directed against target cells only without 
any damage to healthy tissue (Erhlich, 1906). In the current medical practice, most of the 
drugs are administered orally or parenterally, resulting in natural biodistribution and 
systemic effect on the organism. This type of distribution is justified for the drugs which act 
on the systemic mechanisms of disease development and progression. At the same time, in 
case of focal pathological processes such as tumor growth, inflammation and ischemia it 
may be more clinically attractive to ensure the local rise in the drug concentration within the 
pathological area thus avoiding the putative side effects on neighboring tissues. This point 
can be illustrated by several examples. It is known that the administration of antitumor drug 
doxorubicin is associated with severe cardiomyopathy, suppression of myelo- and 
megakaryopoiesis, nausea, vomiting, and development of alopecia (Carvalho et al., 2009). 
Encapsulation of doxorubicin into liposomes resulted in dramatic reduction of these dose-
limiting side effects (Leonard et al., 2009). The implementation of site-specific drug delivery 
may also benefit female patients receiving estrogens for treatment of osteoporosis. Along 
with desirable effect on the bone, estrogens may cause some unwanted effects, especially 
increased risk of uterine bleeding and development of endometrial cancer (Romer, 2006). 
One might suggest that bone-targeted delivery of estrogens will decrease the probability of 
these side effects. The application of nano-sized particles for drug transport may offer a new 
means of delivering drugs selectively into the affected tissue. 
Typical nanoparticulate carrier for targeted drug delivery comprises several functional 
elements. The major part of the carrier is drug-loaded nanoparticle. An important step in 
nanocarrier fabrication is the functionalization of its surface which implies binding of the 
targeting ligands to the nanoparticle surface. Targeting ligand ensures specific interaction of 
the nanoparticle with the complementary molecules on the surface membrane of the target 
cell. In order to facilitate the process of functionalization and prevent rapid clearance of 
nanoparticles by the reticulo-endothelial system, the surface of the nanoparticle is often 
covered with biocompatible coating such as polyethylene glycol. The nanoparticles can be 
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additionally labeled with radioactive isotopes or fluorescent dyes which allows 
visualization of their accumulation in the damaged tissue. Successful targeted drug delivery 
with use of nanoparticulate carriers can bring solutions to several serious problems. In 
particular, it may result in reduced toxicity, increased solubility and stability of the drugs. 
To date, the research on targeted drug delivery has been mostly concentrated on the 
development of tumor-targeted nanomedicines (Ali et al., 2011). It might be hypothesized 
that targeted drug delivery strategy approved in oncology can be applied in other clinical 
fields, now not for destruction but for the sake of salvage of reversibly injured cells, in 
particular of those destined otherwise to die within the area of myocardial ischemia-
reperfusion. One reasonable approach to the problem may be targeted intramyocardial 
delivery of the agents (i.e., certain angiogenic growth factors, erythropoietin, ATP-sensitive 
potassium channel openers, etc.), either covalently and/or non-covalently bound to the 
nanoparticulate carriers. Thus, the purpose of this chapter is to provide an account of 
acquired knowledge on nanoparticle-based targeted drug delivery with particular emphasis 
on heart targeting. Besides, the original experimental data on the fabrication of silica 
nanoparticles which can be used as prototype carriers for cardioprotective drugs are 
presented. We also present the data on silica nanoparticle biodistribution, biodegradation, 
and acute toxicity. Finally, the preliminary evidence for enhanced infarct size limitation with 
use of silica nanoparticle-bound adenosine is provided. 
2. Major types of nanocarriers for targeted drug delivery 
The various types of nano-sized particles can be utilized for transport of drugs into the 
diseased tissues. Liposomes, drug-polymer conjugates, polymeric micelles, dendrimers, 
nanoshells, and nucleic acid-based carriers can all be used as nanocarriers for drugs (Wang 
et al., 2008). Among them, drug-polymer conjugates and liposomes are currently most 
commonly used for drug delivery in the clinical settings and collectively amount to at least 
80% of all nanopharmaceuticals available on the market. The choice of the material for 
nanocarrier fabrication mainly depends on the chemical structure of the drug to be 
transported, characteristics of the target tissue and the route of nanocarrier administration 
into the organism (Ganta et al., 2008). It is generally accepted that the properties of ideal 
nanocarrier should include biocompatibility, biodegradability, and evasion of rapid uptake 
by the macrophages. 
2.1 Liposomes 
Liposomes are spherical membrane structures that consist of a phospholipid bilayer which 
can entrap aqueous solutions. In the past decade, considerable information has been 
accumulated on the therapeutic applications of liposomes (Fenske & Cullis, 2008). By now, 
there are 9 liposomal drugs approved for clinical use. Liposomal doxorubicin and 
daunomycin are successfully used for treatment of cancer while liposomal amphotericin 
remains to be a cornerstone for the treatment of some fungal infections. 
2.2 Polymer-drug conjugates 
Peptides and the drugs with low molecular weight are often characterized by the short half-
life in the circulation thus requiring repeated administration and, furthermore, can exhibit 
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non-specific adverse effect on organs and tissues. Binding of the drugs with polymer 
nanocarriers may reduce these negative effects. Despite the fact that a great number of 
diverse polymers have been initially considered for drug delivery, the very few of them 
have been finally approved for clinical applications. Polyethylene glycol is the most 
universal polymer drug carrier. It has been introduced in the clinical practice in the early 90s 
and has rapidly become popular as drug vehicle because of its capability to increase the 
stability of drugs in the plasma, improve solubility of hydrophobic drugs and reduce their 
immunogenicity. Apart from polyethylene glycol, gamma-polyglutamic acid, N-(2-
hydroxypropyl) methacrylamide and certain polysaccharides with linear structure are 
currently viewed as promising polymeric drug carriers (Sanchis et al., 2010). Tissue-
recognition ligands engrafted on the polyethylene glycol chain conjugated with the drug 
may facilitate targeted delivery of the entire complex into the tissue of interest. 
2.3 Dendrimers 
Dendrimers represent three-dimensional highly branched polymeric macromolecules with 
the diameter varying from 2.5 to 10 nm. Dendrimers can be synthesized from both synthetic 
and natural monomers, e. g. amino acids, monosaccharides and nucleotides. High surface 
area, narrow range of polydispersity and abundance of functional groups on the outer shell 
of dendrimers make them an attractive tool for targeted drug delivery (for review, see 
Cheng et al., 2008). Two classes of dendrimers are most commonly used for biomedical 
applications – polyamidoamines and polypropyleneimines. Although polycationic 
macromolecules such as dendrimers were shown to be moderately toxic for living cells, the 
attachment of polyethylene glycol (PEGylation) to the dendrimer can overcome this 
limitation. The methods of drug binding to the surface of dendrimer include covalent 
conjugation and electrostatic adsorption. Besides, low molecular weight drugs can be placed 
into the cavities within the dendrimer molecules being temporarily immobilized there with 
hydrophobic forces, hydrogen and covalent bonds. 
2.4 Polymeric nanoparticles  
Biodegradable polymeric nanoparticles were extensively studied as drug carriers. This type 
of nanocarriers is usually synthesized by means of self-assembly of copolymers consisting of 
two or more blocks with different hydrophobicity. In the aqueous environment, these 
copolymers spontaneously form micellar structures with hydrophilic shell and hydrophobic 
core (Torchilin, 2007). Hydrophobic core may serve as an ideal container for water-insoluble 
drugs while the hydrophilic shell can be additionally modified for attachment of water-
soluble drugs. Polymeric nanoparticles can in principle transport not only low molecular 
weight hydrophilic and hydrophobic drugs but also the macromolecules such as proteins 
and nucleic acids (Perez et al., 2001). The kinetics of the release of nanoparticle-bound drug 
depends on the duration of nanoparticles residence in the organism and characteristics of 
their microenvironment. Polylactide, polyglycolide and poly(ε–caprolactone) as well as their 
diblock copolymers with polyethylene glycol at different molar ratios are most commonly 
used for fabrication of biodegradable nanoparticles. In general, biodegradable polymeric 
nanoparticles maintain therapeutic drug concentration in the tissue of interest for a longer 
period of time than other nanocarriers. This feature makes them suitable platforms for 
transport of highly toxic, water insoluble and unstable drugs. 
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2.5 Metallic nanoshells  
Metallic nanoshells typically consist of dielectric core and thin metallic shell which increases 
their biocompatibility and optical absorption. The resonance frequency at which the 
nanoshells demonstrate maximal absorption of energy and its minimal dissipation strongly 
depends on the ratio between the diameter of the core and the thickness of the metallic layer 
on the surface of the particle. Gold nanoshells heated with use of near-infrared light were 
successfully used for photothermal destruction of tumors in vivo (Hirsch et al., 2003). 
Similarly, thermosensitive polymer hydrogels and optically active nanoshells may be used 
for targeted delivery of drugs. For instance, Arias et al. (2006) developed nanoshells 
consisting of magnetic core (carbonyl iron) and biodegradable coating 
(polybutylcyanacrylate) designed for controlled release of 5–fluorouracil in the tumor tissue. 
2.6 Nucleic acid-based nanoparticles 
RNA and DNA can also play a role of macromolecular carriers for delivery of the drugs. For 
fabrication of nucleic acid nanoparticles, modified chains of RNA or DNA with non-linear 
shape are utilized. One of the studies on this topic provided the description of 100 nm 
multifunctional complex on the basis of DNA designed for consecutive targeted delivery of 
the drug, visualization of the pathologic focus and gene therapy (Li et al., 2004). The effects 
of RNA nanoparticles (25-40 nm) containing inactive RNA within the core, RNA aptamers 
as targeting ligands and small interfering RNA for inhibition of tumor cells were 
investigated in another recent study (Khaled et al., 2005). 
3. Passive and active targeting 
Two main strategies currently utilized for site-specific drug delivery are passive and active 
tissue targeting. In passive targeting, nanoparticles of specific size and charge are 
nonspecifically accumulated within the affected tissue because of the special characteristics 
of its vascular bed. Good example of passive targeting is selective accumulation of 
PEGylated nanoparticles within the tumor tissue after their intravenous administration. This 
phenomenon is explained by the increased permeability of the tumor microvessels which, in 
turn, is due to defective endothelial lining and local fenestrations of basement membrane. 
These observations were first made by Matsumura & Maeda (1986) in the murine solid 
tumors and are usually referred to as enhanced permeability and retention phenomenon. 
Due to the enhanced permeability and retention phenomenon, systemic administration of 
polymer-drug conjugates results in 10-100-fold higher concentration of the drug in the 
tumor tissue than after administration of aqueous solution of the drug. Enhanced 
permeability and retention effect has been observed not only in tumors but also in chronic 
inflammation and infection. Furthermore, it is well established that nanoparticles without 
polymer coating are rapidly eliminated from the circulation because of the uptake by the 
reticulo-endothelial system elements. This fact provides a rationale for passive targeting of 
liver and spleen in chronic inflammatory diseases associated with prolonged persistence of 
pathogens within the macrophages (e.g.candidiasis , listeriosis, leishmaniasis, brucellosis, 
etc.). Stimuli-responsive nanoparticles have recently emerged as another feasible approach 
to passive targeting (Ganta et al., 2008).  
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It has been shown that nanoparticles diameter and charge can have a significant impact on 
their ability to accumulate in the damaged tissue. For instance, van Vlerken et al. (2007) 
suppose that the most intensive and prolonged accumulation within the tumor is typical for 
positively charged nanoparticles with diameter of less than 200 nm.  
Active targeting employs nanoparticles with specific targeting ligands which selectively 
bind to biomarkers on target cells. These biomarkers include integrins αVβ5 and αVβ3 which 
are expressed on the tumor cells and endothelial cells of the tumor vessels.  It is documented 
that integrins αVβ5 and αVβ3 specifically interact with arginine-glysine-aspartic acid (RGD) 
tripeptide sequence. It follows, therefore, that the attachment of RGD peptide to the surface 
of antitumor drug-loaded nanoparticles may result in their targeted delivery to the tumor 
tissue. Other variants of targeting ligands are considered in the following section. 
4. Tissue-recognition ligands 
Monoclonal antibodies and their fragments, aptamers, peptides and low molecular weight 
compounds may function as tissue-recognition ligands. Considerable efforts have been 
directed towards developing targeted drug delivery systems with use of monoclonal 
antibodies. Synthetic monoclonal antibodies are most commonly used for this purpose. For 
example, the conjugation of fluorescent polystyrene nanoparticles with monoclonal 
antibodies against platelet endothelial cell adhesion molecule-1 resulted in efficient 
internalization of the entire complex into the endothelial cells (Garnacho et al., 2008). It was 
shown in this study that the fate of the nanoparticle (presence of endocytosis, intracellular 
trafficking, and fusion of vesicles with lysosomes) was dependent on the type of the 
monoclonal antibody epitope against platelet endothelial cell adhesion molecule-1. On the 
basis of these data, one might suggest that the drugs can be delivered not only in the 
affected cells but also in the specific intracellular compartments. 
The use of native monoclonal antibodies for tissue targeting is limited by their considerable 
immunogenicity. In this connection, the development of chimeric and humanized 
monoclonal antibodies is of importance. The use of monoclonal antibodies as targeting 
ligands has several other disadvantages such as high cost of monoclonal antibodies 
fabrication and significant variability of their specificity from batch to batch. Antigen 
recognition fragments such as Fab fragments, single-chain variable fragments, minibodies, 
diabodies, and nanobodies may become an alternative to antibodies. Nanobodies are the 
smallest antibody-derived structures which are produced from the variable domain of the 
heavy chain of single-domain immunoglobulins and retain the ability to recognize specific 
antigen. Nanobodies seem to be optimal tissue recognition ligands since they have small 
size and low immunogenicity. Qiu et al. (2007) produced low-molecular weight antibody 
mimetics by virtue of fusion between two complementarily-determining regions of the 
prototype antibodies. Obtained mimetics with molecular weight of 3 kDa were 
characterized by the better distribution pattern than corresponding antibodies, suggesting 
that these mimetics may be used as highly specific targeting ligands. 
Aptamers are small nucleic acid molecules which may function as specific receptors for low-
molecular weight organic substances. The selection of aptamers specific for certain 
molecular target is a laborious and complicated procedure consisting of several stages. One 
of the major stages is the enrichment of combinatorial oligonucleotide libraries including up 
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to 1015 random sequences resulting in the identification of aptamers specifically interacting 
with target molecule. The advantages of aptamers include low molecular weight (around 15 
kDa) and low immunogenicity leading to improved pattern of tissue distribution (Zhou & 
Rossi, 2011). It is worth noting that the technology of aptamer synthesis can be easily scaled 
to industrial production, as opposed to synthesis of monoclonal antibodies. It has been 
shown that RNA aptamers for recognition of vascular endothelial growth factor can cause 
regression of tumor microvessels and demonstrate high stability in plasma of the monkey 
(Ruckman et al., 1998). Anti-vascular endothelial growth factor aptamer pegaptanib has 
been approved by the American Food and Drug Administration in 2004 for clinical use in 
the patients with age-related macular degeneration. This fact underscores rapid 
advancement of aptamers from the bench to clinical applications. 
In the last years, with the advent of combinatorial peptide libraries, the peptide targeting 
ligands are becoming more and more widespread. The peptides can bind to target molecule 
with very high specificity and affinity. For instance, cyclic peptide cilengitide, an integrin-
targeting RGD peptide, is currently being tested in the phase I/II clinical trial for therapy of 
recurrent and/or metastatic squamous cell cancer of the head and neck (Vermorken et al., 
2011).  
Low-molecular weight compounds may also serve as efficient tissue-recognition ligands 
because of their low cost and negligible immunogenicity. One of the most intensively 
studied molecules within this group is folic acid. Folate is especially helpful for tumor 
targeting since tumor cells are over-expressing folate receptor on their surface. Folic acid has 
been used for tumor-targeted delivery of cytostatics immobilized on different types of 
nanoparticulate carriers (e. g., polymeric nanoparticles, liposomes, dendrimers, etc.). 
Various methods of binding targeting ligand with the nanoparticle surface have been 
suggested, which can be generally divided into covalent and non-covalent techniques. 
Covalent binding has been suggested more than 25 years ago for immobilization of proteins 
on the surface of liposomes. Protein conjugation with the nanoparticle is usually mediated 
through the bifunctional polyethylene glycol which contains hydrophobic anchor for 
fixation in the liposomal coating and molecular spacer with amino or sulfhydryl moieties for 
drug binding. Specific interaction between protein A and Fc-fragments of monoclonal 
antibodies as well as the biotinylation of the nanoparticles and their subsequent conjugation 
with ligand-streptavidin complex can both be used for non-covalent binding of nanoparticle 
with targeting ligand. 
5. Heart targeting with nanoparticulate carriers 
Much of the work on targeted drug delivery has focused on cancer treatment. The reasons 
for this include high morbidity and mortality due to cancer as well as focal tumor growth 
associated with severe alterations in tumor molecular phenotype, thus making possible the 
design of highly selective targeting ligands. However, it can be hypothesized that the 
concepts of passive and active targeted drug delivery can be applied efficiently to any type 
of focal pathological process including ischemia-reperfusion and inflammation. Ischemic 
heart disease is generally thought to be a major cause of morbidity and mortality 
worldwide. It follows, therefore, that prevention and/or alleviation of myocardial ischemia-
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reperfusion injury remains to be among the most important goals of the medical care. One 
solution to the problem might be direct delivery of cardioprotective drugs into the ischemic 
myocardium.  
At present, there is some, albeit limited, published evidence that the ischemic heart can be 
actively and passively targeted with drug-loaded liposomes. In particular, anti-myosin 
monoclonal antibody-doped liposomes containing ATP were administered to the isolated 
rat heart prior to global ischemia-reperfusion (Verma et al., 2006), which was associated 
with better postischemic contractile recovery. Intracoronary infusion of non-targeted ATP-
loaded liposomes before regional ischemia-reperfusion resulted in significant reduction in 
infarct size as compared to controls in rabbit model (Verma et al., 2005). One possible 
limitation of these studies is that drug-loaded nanocarriers were administered prior to 
ischemia instead of administering at the end of ischemia or at the early stage of reperfusion. 
It seems justified that myocardial nanoparticle accumulation is most intensive at the time of 
reperfusion. Therefore, one can also expect to get the best result as to the extent of 
myocardial protection when infusing nanoparticle-loaded drug at this time. There are 
several lines of evidence in support of this notion. First, myocardial cell injury associated 
with exposure/expression of injury markers required for active targeting becomes more 
pronounced after reperfusion. Second, myocardial reperfusion initiates the inflammatory 
response associated with increased microvascular permeability, the latter being a major 
prerequisite of passive targeting. Third, reperfusion is accompanied by reactive hyperemia 
which may contribute to better delivery of nanocarriers to the area of interest. Fourth, early 
stage of reperfusion itself strongly contributes to the formation of irreversible myocardial 
injury (Yellon & Hausenloy, 2007). Hence, the release of nanoparticle payload at this narrow 
time interval may prevent or block some of the mechanisms of lethal reperfusion injury. 
Thus, in order to optimize the pharmacokinetic profile of the heart-targeted drug delivery 
system, it should be administered at the final stage of ischemia or at the very beginning of 
reperfusion. In conclusion, the timing of nanoparticle-loaded cardioprotective drug 
administration is crucial for successful heart targeting. 
In the study of Scott et al. (2009), the vascular endothelial growth factor-loaded liposomes 
functionalized with monoclonal antibodies against P-selectin were administered 
intravenously to the rats after permanent coronary artery ligation. The authors showed 
increased density of capillaries within the infarct area 4 weeks after infarction and better 
post-infarct left ventricular function. Despite positive findings, it is difficult to extrapolate 
the results of this study to the current clinical practice since it was performed with use of 
permanent ischemia model without reperfusion. At the same time, current gold standard for 
treatment of acute coronary syndrome is prompt myocardial revascularization. Besides, the 
benefits of applied treatment regimen might be explained rather by the improved 
neovascularizarion of peri-infarct area, and not by the direct prevention of cardiac myocyte 
death within the ischemic area.    
Important results were obtained in a landmark study by Takahama et al. (2009) who used 
liposomal adenosine for treatment of myocardial ischemia-reperfusion in rats. Adenosine-
loaded liposomes were infused intravenously for 10 minutes starting 5 minutes prior to 
myocardial reperfusion. Selective accumulation of liposomes within the ischemic-reperfused 
area was verified with electron microscopy, optical fluorescence, and radionuclide imaging. 
Besides, liposomal adenosine administration was associated with more significant infarct 
size limitation and less severe arterial hypotension as compared to free adenosine treatment. 
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The research of our group working at the Institute of Experimental Medicine, V.A. Almazov 
Federal Heart, Blood and Endocrinology Centre is focused on the development of both 
active and passive techniques of heart targeting. We hypothesized that local accumulation of 
drug-loaded nanoparticles within the ischemic area of the heart may be achieved by 
selective binding of the annexin V to the nanoparticle surface (Fig. 1).  
 
Fig. 1. Proposed algorithm of active targeted drug delivery into the ischemic cardiac muscle 
Annexin V is a naturally expressed protein that binds to phosphatidylserine in a calcium-
dependent fashion. Phosphatidylserine is normally localized on the inner surface of the 
plasmalemma, but it is translocated on the exterior cell surface when sublethal cell injury 
occurs (Vance & Steenbergen, 2005). Annexin V is widely used as one of the marker proteins 
for cell injury and apoptotic cell death in vitro. Besides, the intravenous administration of 
annexin V conjugated with fluorescent probe to the dogs subjected to 1 hour regional 
ischemia and 1 hour reperfusion resulted in bright fluorescence of ischemic area indicative 
of site-specific conjugate accumulation (Ohnishi et al., 2006). Specific interaction of the 
nanoparticle-anchored annexin V with phosphatidylserine would potentially result in the 
binding of nanoparticles to the cardiomyocyte membrane with their subsequent 
accumulation in the area of interest. 
Apart from active heart targeting with use of annexin V as a tissue-recognition ligand, we 
also feel that ischemic-reperfused myocardium may offer an advantage of passive targeting. 
The basic idea is that the nanoparticulate carriers, if administered in proper time (see above), 
can be retained within the ischemic-reperfused area of the heart owing to local 
inflammatory response and severely increased microvascular permeability. In this regard, 
the functional characteristics of myocardial microvessels are more or less similar to those of 
the tumor. Therefore, it seems not unlikely that drug-loaded nanoparticles can tend to 
accumulate within the ischemic-reperfused area of the heart just because of the raised 
permeability of myocardial capillaries. 
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5.1 Fabrication, characterization, and surface modification of silica nanoparticles  
Among inorganic drug carriers, nanodisperse silica, titania, zirconia, and iron oxide as well 
as fullerenes and carbon nanotubes have been considered to be the most promising. In our 
studies, the prototype carriers for antiischemic drugs are suggested to be nanodispersed 
silica particles. It has been shown before that silica nanomaterials are characterized by fairly 
good biocompatibility and biodegradability (Slowing et al., 2008). Chemical modification of 
silica nanoparticle surface can be performed with use of two different synthetic approaches, 
namely, immobilization and chemical assembly. In immobilization strategy, the modifier is 
attached to the carrier surface with use of a single-stage reaction. Chemical assembly 
represents another approach toward synthesis of engrafted surface compounds that has 
recently emerged as a promising alternative to immobilization strategy. Chemical assembly 
is based on multistage synthesis of engrafted chemical compounds on the surface of solid 
phase particles which play a role of matrices. The major advantage of chemical assembly in 
comparison to immobilization is the larger diversity of functional groups that can be applied 
to the matrix surface. 
Taking into account the above considerations, we suppose that nanodisperse silica of the 
Aerosil type may be a perspective drug carrier for biomedical applications. In our studies, 
the standard pyrogenic highly dispersed silica (Aerosil A380 mark obtained from Vekton, 
Russia) was used throughout experiments. Surface area of silica nanoparticles was 
determined with use of Brunauer-Emmett-Teller (BET) method and averaged from 170 to 
380 m2/g (Galagudza et al., 2010). The mean particle diameter varied from 6 to 13 nm. The 
technique of silica nanoparticle functionalization included three sequential steps: 
modification of silica nanoparticles with (3-aminopropyl)triethoxysilane, hydrolysis of 
unreacted alkoxysilane groups, and binding of fluorescein. Chemosorption of (3-
aminopropyl)triethoxysilane was performed from the gaseous phase with use of dried 
nitrogen as a carrier gas. The synthesis was done in the vertical quartz flow reactor at 220°C 
during 2 hours. Hydrolysis of the unreacted alkoxysilane groups was achieved with water 
vapor at 150°C during 1 hour. The covalent binding of fluorescein to the aminated silica was 
done using carbodiimide technique during 1 hour. The surface reactions were controlled 
with infrared spectroscopy. The amount of fluorescein bound to the surface of silica 
nanoparticles was determined spectrophotometrically at λ=490 nm. Fluorescein content 
within the samples of modified silica nanoparticles varied from 0.01 to 0.02 mmol/g. 
Another fluorescent dye that can be used for labeling of silica nanoparticles is considered to 
be indocyanine green. This fluorophore has an absorption band in the near-infrared region 
(λ=780 nm). We have developed the technique of indocyanine green immobilization on the 
surface of aminated silica. Then, fluorescently labeled silica nanoparticles were used for 
biodistribution studies. 
The above-described techniques of matrix synthesis of engrafted surface compounds can be 
easily applied for Aerosil modification. Combination of the molecular layering method with 
chemical assembly of engrafted organic compounds is especially promising for 
development of targeted nanopharmaceuticals. With use of this approach, thin layers of 
inorganic substances possessing magnetic properties can be laid on the Aerosil surface with 
subsequent modification of the latter by the organic compounds containing active centers 
crucial for immobilization of drug molecules. We believe that the use of chemically modified 
silica as a prototype carrier for targeted drug delivery holds great promise because of 
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several advantages, such as biocompatibility and biodegradation, low cost, and detailed 
account on the techniques of surface immobilization of drugs, fluorophores, and targeting 
ligands. 
5.2 Acute toxicity, biodistribution and biodegradation of silica nanoparticles  
To investigate the acute toxicity of silica nanoparticles experimentally, we studied the acute 
hemodynamic effects of nanoparticle formulations in the rat model. For this purpose, the 
suspensions of silica and fluorescein-doped silica nanoparticles in 0,9% sodium 
hydrochloride solution were prepared and administered intravenously 3 times with 20-
minute intervals between infusions. Control animals received vehicle. Measurements of 
heart rate, mean arterial pressure and pulse arterial pressure were done throughout the 
experiments. In all groups of animals, there were no significant alterations in heart rate over 
time. The first infusion of any tested nanoparticle formulation had no effect on 
hemodynamic parameters. Furthermore, there were no statistically significant differences in 
mean arterial pressure between the baseline time point and the end of the experiment. 
However, the second and the third infusions of silica nanoparticles evoked transient 
increases of mean arterial pressure. There were significant increases in pulse arterial 
pressure in the animals that received silica nanoparticles at the end of the observation. 
Administration of fluorescein-labeled silica nanoparticles resulted in increase of pulse 
arterial pressure too, while pulse arterial pressure in controls was unaffected throughout the 
entire experiment. Thus, intravenous infusion of silica nanoparticle formulations caused 
mild changes in systemic hemodynamic parameters which appears to be indicative of 
appropriate biocompatibility of these nanomaterials. 
Biodistribution of silica nanoparticles was studied with use of optical fluorescence. 
Fluorescein and indocyanine green were used for fluorescent labeling of silica nanoparticles. 
The animals received intravenous infusion of fluorescently labeled nanoparticles suspended 
in normal saline at a volume of 1 ml for 10 minutes. 20 minutes after the end of infusion, the 
animals were sacrificed by an overdose of anesthesia, and the following organs were 
removed for subsequent measurements: heart, brain, liver, spleen, lung, and kidney. Control 
animals were treated with the vehicle. The registration of fluorescence was performed using 
FLUM3 setup for fluorescent imaging of small animals and biopsy specimens consisting of 
the mercury lamp illuminator and TV camera 285. The fluorescence of fluorescein- and 
indocyanine green-labeled nanoparticles was elicited by the use of band-pass interference 
filters of 435 and 780 nm, respectively. The images obtained in the experiments with 
fluorescein-labeled nanoparticles were split into RBG channels. Channel G has been chosen 
as target channel. The relative change in the level of fluorescence (i. e., percent change from 
control, ΔG, %) has been calculated as follows: ΔG=(G2 – G1)/G1, where G1 is the level of 
(auto)fluorescence in controls, G2 – the level of fluorescence in animals treated with 
fluorescein-labeled silica nanoparticles. In the experiments with indocyanine green-labeled 
nanoparticles, black-and-white images were obtained, and the relative change in the level of 
fluorescence (i. e., percent change from control, ΔF, %) was calculated as described above. 
The biodistribution data are shown in the Table 1. It should be noted that exposure of organ 
samples to UV light (λ=435 nm) for detection of fluorescein-doped nanoparticles was 
associated with significant deal of auto fluorescence which may interfere with the desired 
signal. Despite that, we observed predominant accumulation of fluorescein-labeled 
 
Novel Strategies in Ischemic Heart Disease 262 
several advantages, such as biocompatibility and biodegradation, low cost, and detailed 
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nanoparticles within the lung, spleen and liver, that is, in the organs of reticulo-endothelial 
system. The use of indocyanine green was helpful in avoiding the high level of auto 
fluorescence because this fluorophore is excited at λ=780 nm. Generally, we found the 
highest accumulation of indocyanine green-labeled nanoparticles within the liver and 
kidney. Therefore, we recommend the use of infrared fluorophores for fluorescent labeling 
of silica nanoparticles and investigation of their biodistribution. 
 
Organ 
















Heart 12±0.5 22±0.4 81±3.9 90±13.2 106±7.0 18±9.3 
Brain 26±0.5 35±0.5 77±7.0 115±7.1 119±13.4 5±2.8 
Liver 14±0.6 1213±193.0 8311±1232.0 95±31.5 113±24.8 22±14.6 
Spleen 16±9.9 20±4.2 62±27.0 81±10.2 99±7.1 23±6.8 
Lung 29±5.7 127±24.8 357±123.0 88±6.0 113±2.1 30±11.4 
Kidney 16±5.7 164±21.2 1018±373.0 76±0.4 82±6.2 9±6.7 
Table 1. Distribution of indocyanine green- and fluorescein-labelled silica nanoparticles at 
the organ level of Wistar rats after 30 min of dose administration 
Silica nanoparticle biodegradation was studied both in vitro and in vivo. When designing the 
experiments, we speculated that silica nanoparticles are undergoing biodegradation due to 
gradual erosion of their surface resultant in the formation of water-soluble salts of silicic 
acid which are excreted from the organism by the kidney (Fig. 2).  
 
Fig. 2. Hypothetical mechanism of silica nanoparticle biodegradation 
The suspension of Aerosil A380 in Krebs-Henseleit buffer having electrolyte composition 
similar to that of blood plasma with final concentration of silica nanoparticles 2 mg/ml and 
pH=7,4 was used for investigation of biodegradation in vitro. The experiments were 
performed in the settings of continuous stirring in the polymer 100 ml glass. The 
temperature of the media was maintained at 37°C by means of water jacketing. The samples 
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were continuously gassed with carbogen (95% О2 and 5% СО2). Total incubation time was 
equal to 15 hours. The samples were taken each 5 hours and analyzed for silicate content 
spectrophotometrically after reaction with molybdenum blue. The concentration of silicate 
in samples increased logarithmically with time. With use of mathematical analysis, we 
derived the value which corresponds to 95% biodegradation of silica and equals to 41 day. 
These data fit well to the results of Finnie et al. (2009) who studied biodegradation of sol-gel 
mesoporous silica microparticles. It has been shown in this study that silica microparticles 
are rapidly degraded in physiological buffer. Besides, the authors demonstrated that the 
addition of plasma proteins to the buffer retarded biodegradation by 20-30%. It follows, 
therefore, that in vivo biodegradation might be slower than in the in vitro settings. 
In vivo biodegradation of silica nanoparticles was studied in the male Wistar rats weighting 
200-250 g. Silica nanoparticles were infused intravenously at a dose of 2 mg/ml and volume 
of 1 ml followed by sampling of the liver at 1 h, 10, 20, and 30 days after infusion. The 
controls were animals received intravenous infusion of 1 ml of vehicle. Liver samples were 
dried at 90°C during 24 h to obtain constant weight. The liver was chosen for sampling and 
analyses on the basis of biodistribution experiments which showed maximal accumulation 
of silica in this organ. Quantitative analysis of silicon content within the samples was 
performed with atomic absorption spectroscopy. The mineralizat obtained after drying was 
analyzed on the atomic absorption spectrometer with electrothermic atomization and 
Zeman correction. Silicon content within the mineralizat was recalculated for the dry sample 
weight and expressed in µg/g. Silicon content in the liver of the rats according to the results 
of atomic absorption spectroscopy is shown on the Fig. 3.  
 
Fig. 3. Biodegradation of silica nanoparticles in vivo: silicon content in the liver at different 
durations after infusion of nanoparticles 
Silicon content in the liver of healthy rats averaged 4.4±1.55 µg/g. At 1 hour after silica 
nanoparticles infusion silicon content was increased up to 282.3±62.65 µg/g. 10 and 20 days 
after silica nanoparticle infusion silicon content in the liver was significantly lower 
(81.5±9.25 and 30.2±7.48 µg/g, respectively). This dynamics of silica dissolution is consistent 
with the data obtained in the in vitro model. However, at 30 days after silica nanoparticle 
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administration we failed to see any additional decrease in silicon tissue content (31.5±11.87 
µg/g). This fact might be accounted for by the higher stability of the intracellular pool of 
silica nanoparticles, produced as a result of their phagocytosis by the Kupffer cells and, to a 
lesser extent, silica nanoparticle internalization into hepatocytes and other liver cells. It 
remains unclear, however, whether this increased silicon content in the liver cells affects 
liver function or not. 
5.3 Passive heart targeting with silica nanoparticles 
For investigation of passive heart-targeted drug delivery with silica nanoparticles, we first 
studied biodistribution of unmodified nanoparticles in the rats with regional myocardial 
ischemia-reperfusion. For this purpose, the animals were randomly allocated into one of 
three groups: 1) controls (these animals received intravenous infusion of saline), 2) silica 
nanoparticle-treated animals (2 mg/ml, 1 ml intravenously) with sham surgical procedure; 
3) silica nanoparticle-treated animals with myocardial ischemia-reperfusion. Regional 
myocardial ischemia was induced by 30-minute left coronary artery ligation followed by 60 
minutes of reperfusion. Silica nanoparticles were infused for 10 minutes starting 5 minutes 
prior to reperfusion (Fig. 4). The left ventricle of the heart and liver were sampled at the end 
of the experiments, rinsed and dried at 90°C during 24 h to obtain constant weight. Silicon 
content in the organ samples was done with atomic absorption spectroscopy as described 
above. 
 
Fig. 4. Biodistribution of non-modified silica nanoparticles in rat model of myocardial 
ischemia-reperfusion. SNP – silica nanoparticles, IR – ischemia-reperfusion 
In controls, silicon content was found to be significantly higher in myocardial tissue then in 
the liver (32±2.8 vs. 4±2.3 µg/g, respectively, p<0.05) (Fig. 4). Of note, physiological role of 
this fact is currently unknown. Silica nanoparticle administration to sham-operated rats 
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resulted in dramatic rise in liver silicon content as compared to controls (163±19.5 vs. 4±2.3 
µg/g, respectively, p<0.01), while myocardial silicon concentration remained unaffected 
(27±9.7 vs. 32±2.8, respectively, p>0.05). Administration of silica nanoparticles to the animals 
with cardiac ischemia-reperfusion was associated with significant increase in myocardial 
silicon content in comparison to sham-operated animals (125±28.2 vs. 32±2.8 µg/g, 
respectively, p<0.05). Thus, the first evidence that non-modified silica nanoparticles can 
accumulate within the anatomical area at risk after regional myocardial ischemia-
reperfusion was provided in this study.  
The next series of experiments was performed to study the hemodynamic effects of 
nanoparticle-bound and free adenosine. Adenosine adsorption on the surface of silica 
nanoparticles was achieved by mixing the suspension of silica nanoparticles in 0.9% sodium 
chloride and adenosine solution in the same vehicle. The samples thus prepared were 
subjected to 10-minute sonication and left at +4ºC overnight. Silica nanoparticle-bound 
adenosine was administered to the rats intravenously for 10 minutes at a dose of 300 
μg/kg×min. Control animals received 10-minute intravenous infusion of adenosine at a 
dose of 300 μg/kg×min. Mean blood pressure was registered before the beginning of drug 
infusion, at 5th and 10th minutes of infusion, and at 5th and 10th minutes of recovery. The data 
on blood pressure values are shown in Table 2. The extent of blood pressure decrease was 












Free ADO 125±12 82±7 85±9 128±5 119±13 
ADO+SNP 131±8 108±14* 113±11* 134±12 130±10 
Table 2. Attenuation of adenosine-induced hypotension after its immobilization on the 
surface of silica nanoparticles. MBP – mean blood pressure, ADO – adenosine, SNP – silica 
nanoparticles. * - p<0.05 vs. free adenosine 
 
Fig. 5. Representative blood pressure recording showing different blood pressure response 
to free and silica nanoparticle-bound adenosine. Initial free adenosine infusion was followed 
by recovery period and infusion of silica-nanoparticle bound adenosine. After recovery, one 
more episode of adenosine infusion was performed. ADO – adenosine, SNP – silica 
nanoparticles 
The final series of experiments was focused on investigation of the effect of free adenosine 
and nanoparticle-bound adenosine on infarct size. Five minutes prior to the end of 30-minte 
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ischemia, animals received either 10-minute adenosine infusion at a dose of 300 μg/kg×min 
or infusion of adenosine adsorbed on silica nanoparticles in the equivalent dose. Control 
animals were treated with vehicle. Myocardial area at risk and infarct size were determined 
after 90 minutes of reperfusion with use of Evans blue and triphenyltetrazolium chloride 
staining, respectively. There were no differences in risk area between groups (Fig. 6).  
 
Fig. 6. Increased infarct-limiting effect of adenosine after its immobilization on silica 
nanoparticles. ADO – adenosine, SNP – silica nanoparticles 
Adenosine infusion caused significant reduction in infarct size as compared to controls 
(29±6,2 vs. 63±7,3%, respectively, p<0.01). Administration of adenosine adsorbed on silica 
nanoparticles resulted in additional significant decrease in infarct size in comparison to free 
adenosine (18±4.2 vs. 29±6,2, respectively, p<0.05). 
In conclusion, adsorption of adenosine on silica nanoparticles results in its passive delivery 
to the ischemic area of the heart which, in turn, leads to more pronounced infarct size 
limitation and attenuation of hemodynamic side effect typical for the drug used. 
5.4 Candidate drugs for heart-targeted delivery 
Several groups of drugs with different mechanisms of action might potentially be targeted 
to the heart with nano-sized carriers (Table 3). One of the most efficient means of 
myocardial protection known to date is ischemic preconditioning, a phenomenon which 
describes dramatically increased heart tolerance to prolonged ischemia occurring after one 
or several brief episodes of ischemia-reperfusion (Galagudza et al., 2008). It is well 
established that preconditioning can elicit several cardioprotective effects including infarct-
limitation, reduction of ischemic and reperfusion arrhythmias, prevention of endothelial 
dysfunction and attenuation of stunning. The mechanisms of preconditioning include 
generation of chemical triggers during brief bouts of ischemia, their interaction with 
corresponding sarcolemmal G-protein-coupled receptors with subsequent activation of 
multiple intracellular kinases, and, eventually, engagement of putative mitochondrial 
effectors responsible for initiation of energy-sparing processes. It has been shown that such 
preconditioning triggers as adenosine, bradykinin, and opioid peptides are all able to mimic 
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the preconditioning response when administered exogenously. However, their clinical use 
at doses required for preconditioning-like response is hampered by the high risk of 
dangerous side effects. For example, intravenous administration of adenosine is associated 
with arterial hypotension and bradycardia (Takahama et al., 2009), while administration of 
bradykinin might lead to hypotension and bronchial spasm (Homma & Irvin, 1999). It 
follows, therefore, that targeted delivery of preconditioning mimetics or synthetic agonists 
of G-protein-coupled receptors might contribute to improved safety and efficacy profile of 
these compounds, especially taking into account the encouraging results with heart-targeted 
delivery of adenosine (Takahama et al., 2009). 
 
Mechanism Drug/ligand 
Activation of G-protein-coupled receptors 
(preconditioning) 
Bradykinin, opioids, adenosine and 
synthetic ligands of corresponding 
receptors 
Activation of tyrosine kinase receptors 
(angiogenesis, cardiac myocyte proliferation?) 
Insulin, insulin-like growth factor-1, 
transforming growth factor-β1, 
erythropoietin, vascular endothelial 
growth factor, etc. 
Inhibition of mitochondrial permeability 
transition pore opening (attenuation of 
reperfusion injury, antiapoptotic effect) 
Cyclosporine 
Activation of peroxisome proliferator-
activated receptors gamma (reduction of 
inflammation, improved endothelial function) 
Rosiglitazone, pioglitazone 
Opening of ATP-sensitive potassium channels 
(improved mitochondrial function) 
Nicorandil 
Nitric oxide signaling pathway 
(preconditioning, vasodilation) 
Nitric oxide donors, atorvastatin, 
atrial natriuretic peptide, etc. 
Table 3. Candidate drugs for ischemic heart targeting 
Another group of compounds demonstrating cardioprotective effects are growth factors 
which interact with tyrosine kinase receptors. Such molecules as insulin, insulin-like growth 
factor-1, transforming growth factor-β1, erythropoietin, vascular endothelial growth factor, 
and fibroblast growth factor may not only induce cytoprotective effect when administered 
either prior or just after index ischemia, but also possess late cardioprotective effects due to 
stimulation of angiogenesis and attenuation of inflammation (Boucher et al., 2008; Ueda et 
al., 2010). Again, heart-targeted delivery of growth factors may result in better outcome 
because of local increase in the concentration and reduction of such side effects as 
hypotension and hypersensitivity reactions. 
One more key player in the mechanisms of ischemia-reperfusion myocardial injury is 
mitochondrial permeability transition pore (mPTP). mPTP represents multiprotein complex 
localized in the inner mitochondrial membrane which functions as voltage-dependent 
nonselective channel. The probability of mPTP opening is very low during in both normal 
and ischemic environment. However, at reperfusion mPTP becomes opened thus making 
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inner mitochondrial membrane permeable for water, ions, and molecules with molecular 
weight up to 1.5 kDa. Major stimuli for mPTP opening are increased calcium concentration, 
mitochondrial matrix pH>7.0, increased concentration of reactive oxygen species, and 
mitochondrial membrane depolarization (Di Lisa et al., 2011). mPTP opening results in 
immediate complete depolarization of mitochondrial membrane and, therefore, loss of 
electrochemical gradient. In this situation, ATP synthase starts to degrade ATP in a futile 
attempt to regenerate membrane potential. Besides, massive swelling of mitochondrial 
matrix may contribute to mechanical rupture of the organelles with resultant release of 
several pro-apoptotic molecules normally retained in the intermembrane space. It follows 
that mPTP opening at the early moments of reperfusion can lead to development of lethal 
reperfusion injury by means of both necrosis and apoptosis. mPTP inhibitors were shown to 
be cardioprotective in experimental and clinical settings. Intravenous administration of 
mPTP inhibitor cyclosporine to the patients with acute ST-elevation myocardial infarction 
just prior to percutaneous coronary intervention resulted in significant reduction in infarct 
size as compared to controls (Piot et al., 2008). Cyclosporine is commonly used for immune 
suppression, and its prolonged use is associated with several serious side effects including 
renal failure, hepatotoxicity, infection, and increased risk of tumor development. Thus, it is 
of prime importance to develop the technique of targeted delivery of cyclosporine to the 
ischemic heart which may help to attenuate its systemic toxicity. 
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors that function as 
transcription factors for numerous genes. In terms of myocardial ischemia-reperfusion 
injury, activation of PPARγ with either endogenous ligands or thiazolidinedione derivatives 
has been shown to be cardioprotective (Di Paola & Cuzzocrea, 2007). Potential mechanisms 
of PPARγ-mediated cardioprotection include inhibition of the activation of nuclear 
transcription factor κB, stimulation of endothelial NO-synthase function, and increased 
expression of heme oxygenase-1. Decreased function of nuclear transcription factor κB in the 
ischemic-reperfused heart is supposed to be beneficial since this transcription factor 
positively regulates a battery of proinflammatory genes, all of which contribute to 
secondary injury in the infarcted area.  
ATP-sensitive potassium channels have been believed to be major end effectors of ischemic 
preconditioning in the late 90s. There are two main populations of ATP-sensitive potassium 
channels, that is, sarcolemmal and mitochondrial. Currently, the cardioprotective role of 
sarcolemmal ATP-sensitive potassium channels has been unequivocally proved while there 
is some debate as to the role of mitochondrial channels (Hanley & Daut, 2005). Several ATP-
sensitive potassium channel openers were shown to exert preconditioning-like protective 
effect in the experimental models. However, the only drug from this group that is approved 
for use in humans is nicorandil. The results of IONA trial demonstrated reduced incidence 
of acute coronary syndrome in the patients with stable angina receiving nicorandil. It seems, 
therefore, that targeted delivery of nicorandil to the heart might further strengthen its 
cardioprotective effect. 
Finally, pharmacological modulation if nitric oxide (NO)-dependent pathway in the heart is 
also of interest. It has been shown that endogenous NO participation in the mechanisms of 
cardiac protection if unlikely but exogenous supplementation of the heart with NO can 
mimic the protective effect of preconditioning (Dawn & Bolli, 2002). NO-dependent 
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mechanisms were also proposed for infarct-limiting effect of atorvastatin (Atar et al., 2006) 
and atrial natriuretic peptide (Okawa et al., 2003). 
In conclusion, the list of cardioprotective drugs which might be delivered to the heart with 
nanocarriers is incomplete. By now, hundreds of drugs were shown to be cardioprotective 
in the preclinical models. However, very few of them were proved to be effective in the 
patients with coronary artery disease. The reasons for this failure are multiple and analyzed 
elsewhere, but at least one is the fact that many drugs have significant side effects which 
hinder the process of clinical translation. Recent evidence indicates that some side effects 
can be substantially reduced when the drug is navigated to the tissue of interest by the 
nanocarrier. Targeted delivery concept holds promise for development of new efficient and 
safe therapies for ischemic heart disease. 
6. Perspectives and future work 
Although the concept of targeted drug delivery to the ischemic heart seems to be generally 
coherent, it is evident that large questions lie ahead. Systemic administration of 
multifunctional drug carriers results in their selective accumulation in the target tissues with 
normal blood flow. It might be problematic to achieve the minimal effective dose of the 
nanopharmaceutical within the tissue subjected to critical ischemia. This problem may be 
solved by the increased residence time of nanocarriers within the adjacent to ischemic 
tissues providing diffusion of the drug into the poorly vascularized area. Alternative 
solution may involve increased loading of the nanoparticles with payload and/or targeting 
ligands. On the other hand, intensive functionalization of nanoparticles may result in better 
recognition by the immune system and faster clearance by the reticulo-endothelial system.  
Insufficient evidence is currently available on the clinical effectiveness of nanoparticulate 
drug carriers. Additional studies are required to elucidate the pharmacokinetics of 
nanocarriers as well as their biodistribution and putative toxicity. All newly developed 
nanosystems for targeted delivery possess unique properties requiring individual testing. 
The refinement of the techniques of nanocarrier fabrication is aimed at ensuring of better 
uptake of nanoparticles by the target cells, formation of higher gradient of drug between 
injured and intact tissue, and more complete avoidance of drug toxicity. The 
accomplishment of these goals will be a major step in development of an ideal tool for 
targeted delivery of the drug into the tissue of interest. 
7. Conclusion 
Concepts of passive and active targeting can be applied to the development of targeted drug 
delivery to the ischemic myocardial tissue. Targeted delivery of various cardioprotective 
agents to the ischemic cardiac muscle with use of nanoparticles seems to be a challenging 
approach to treatment of coronary artery disease.  
Silica nanoparticles are non-toxic materials that might be potentially used as carriers for 
heart-targeted drug delivery. Silica nanoparticles can be functionalized with use of the 
techniques of immobilization and chemical assembly. Immobilization of adenosine on the 
surface of silica nanoparticles resulted in enhancement of free adenosine-mediated infarct 
size limitation in the animal model. Furthermore, hypotensive effect of adenosine was 
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elsewhere, but at least one is the fact that many drugs have significant side effects which 
hinder the process of clinical translation. Recent evidence indicates that some side effects 
can be substantially reduced when the drug is navigated to the tissue of interest by the 
nanocarrier. Targeted delivery concept holds promise for development of new efficient and 
safe therapies for ischemic heart disease. 
6. Perspectives and future work 
Although the concept of targeted drug delivery to the ischemic heart seems to be generally 
coherent, it is evident that large questions lie ahead. Systemic administration of 
multifunctional drug carriers results in their selective accumulation in the target tissues with 
normal blood flow. It might be problematic to achieve the minimal effective dose of the 
nanopharmaceutical within the tissue subjected to critical ischemia. This problem may be 
solved by the increased residence time of nanocarriers within the adjacent to ischemic 
tissues providing diffusion of the drug into the poorly vascularized area. Alternative 
solution may involve increased loading of the nanoparticles with payload and/or targeting 
ligands. On the other hand, intensive functionalization of nanoparticles may result in better 
recognition by the immune system and faster clearance by the reticulo-endothelial system.  
Insufficient evidence is currently available on the clinical effectiveness of nanoparticulate 
drug carriers. Additional studies are required to elucidate the pharmacokinetics of 
nanocarriers as well as their biodistribution and putative toxicity. All newly developed 
nanosystems for targeted delivery possess unique properties requiring individual testing. 
The refinement of the techniques of nanocarrier fabrication is aimed at ensuring of better 
uptake of nanoparticles by the target cells, formation of higher gradient of drug between 
injured and intact tissue, and more complete avoidance of drug toxicity. The 
accomplishment of these goals will be a major step in development of an ideal tool for 
targeted delivery of the drug into the tissue of interest. 
7. Conclusion 
Concepts of passive and active targeting can be applied to the development of targeted drug 
delivery to the ischemic myocardial tissue. Targeted delivery of various cardioprotective 
agents to the ischemic cardiac muscle with use of nanoparticles seems to be a challenging 
approach to treatment of coronary artery disease.  
Silica nanoparticles are non-toxic materials that might be potentially used as carriers for 
heart-targeted drug delivery. Silica nanoparticles can be functionalized with use of the 
techniques of immobilization and chemical assembly. Immobilization of adenosine on the 
surface of silica nanoparticles resulted in enhancement of free adenosine-mediated infarct 
size limitation in the animal model. Furthermore, hypotensive effect of adenosine was 
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attenuated after its adsorption on silica nanoparticles. Additional studies will be required to 
demonstrate silica nanoparticle biocompatibility in the chronic experiments.  
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1. Introduction 
The majority of patients who require intervention for coronary artery disease are adequately 
treated by percutaneous coronary interventions (PCI) or coronary artery bypass grafting 
(CABG). However, a major reason for failure of these treatments is their dependency on 
luminal size and coronary outflow. Methods stimulating myocardial angiogenesis and new 
vessel formation that are not dependent on vessel caliber therefore provide an important 
alternative means of treatment. Topical negative pressure (TNP) has been used in the 
treatment of chronic and problematic wounds since the beginning of the 1990´s, and has 
been shown to increase blood flow and stimulate angiogenesis in the underlying tissue. 
Because of TNP´s stimulating effect on blood flow and angiogenesis TNP has been tried to 
be applied directly onto the myocardium, referred to as myocardial topical negative 
pressure (MTNP) to increase myocardial blood flow and reduce myocardial ischemia, and 
reduce myocardial infarction (Lindstedt et al. 2008a, Lindstedt et al. 2008b, Lindstedt et al. 
2007c, Lindstedt et al. 2007a, Lindstedt et al. 2007b, Lindstedt et al. 2008c, Lindstedt et al. 
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2. Development of the topical negative pressure technique 
Topical negative pressure (TNP) therapy (also called vacuum-assisted closure (VAC) 
therapy, vacuum sealing or vacuum therapy) has developed from the standard surgical 
procedure of vacuum-assisted drainage to remove blood or serous fluid from a wound or 
surgical site. In essence, the TNP technique is very simple. A piece of foam, with an open 
structure, is inserted into the wound cavity and a wound drain with lateral perforations is 
placed on top of it. The entire area is then covered with a transparent adhesive membrane, 
which is firmly secured to the healthy skin around the wound margin. When the exposed 
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end of the drain tube is connected to a vacuum source, fluid is drawn from the wound 
through the foam into a reservoir for subsequent disposal. The plastic membrane prevents 
the ingress of air and allows a partial vacuum to form within the wound, reducing its 
volume and facilitating the removal of fluid.  
The practice of exposing a wound to sub-atmospheric pressure for an extended period of 
time to promote healing was first described by Fleischmann et al. in 1993, following the 
successful use of this technique in 15 patients with open fractures. They reported that the 
treatment resulted in, “efficient cleaning and conditioning of the wound, with marked 
proliferation of granulation tissue”. No bone infections occurred in any of the patients, 
although one developed a soft tissue infection, which subsequently resolved with further 
treatment. In two further papers, Fleischmann and his colleagues described the treatment of 
25 patients with compartment syndromes of the lower limb and 313 patients with various 
types of acute and chronic infections. Further success with topical negative pressure 
treatment in Germany was reported by Muller following the treatment of 300 patients with 
infected wounds. 
In these early studies, negative pressure was achieved by the use of conventional methods 
such as wall suction equipment or surgical vacuum bottles. Both these systems are 
associated with practical problems in terms of the delivery, control and maintenance of the 
required levels of negative pressure, as discussed by Banwell et al. . In 1995, a commercial 
system for vacuum-assisted closure was introduced in the United States. This equipment, 
called the VAC®, was designed to overcome some of the problems described by Banwell. 
The heart of the system is a microprocessor-controlled vacuum unit that is capable of 
providing controlled levels of continuous or intermittent sub-atmospheric pressure ranging 
from -25 to -200 mmHg.  
In early studies no attempts were made to investigate the physiological mechanisms behind 
the observed clinical effects, or to determine the optimum level of pressure. A seminal study 
by Morykwas et al. addressed both these issues using a series of animal studies. Deep 
circular defects, 2.5 cm in diameter, produced on the backs of pigs were dressed with open-
cell polyurethane-ether foam with a pore size ranging from 400-600 µm. In the first series of 
experiments, a laser Doppler technique was used to measure blood flow in the 
subcutaneous tissue and muscles surrounding the wounds as these were exposed to 
increasing levels of negative pressure, applied both continuously and intermittently. Their 
results indicated that while an increase in blood flow equivalent to four times the baseline 
value occurred with a negative pressure of -125 mmHg, blood flow was inhibited by the 
application of negative pressures of -400 mmHg and above. A negative pressure of -125 
mmHg was therefore used in subsequent studies. The rate of granulation tissue production 
under negative pressure was determined using the same model by measuring the reduction 
in wound volume over time. Compared with control wounds dressed with saline-soaked 
gauze, significantly increased rates of granulation tissue formation were observed with the 
application of both continuous (63.3  26.1%) and intermittent (103% 35.3%) negative 
pressure.  
The observation that intermittent or cycled treatment appeared to be more effective than 
continuous therapy is interesting, although the reasons for this are not fully understood. 
Two possible explanations were advanced by Philbeck et al.. They suggested that 
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intermittent pressure application results in rhythmic perfusion of the tissue, which is 
maintained because the process of capillary autoregulation is not activated. They also 
suggested that as cells that are undergoing mitosis must go through a cycle of rest, cellular 
component production and division, constant stimulation may cause the cells to ‘ignore’ the 
stimulus. Intermittent stimulation allows the cells time to rest and prepare for the next cycle. 
For this reason, it has been suggested that cyclical negative pressure should be used 
clinically, although some authors suggest that this should follow a 48-hour period of 
continuous vacuum to bring about a rapid initial cleansing effect. Following these 
investigations, Morykwas and colleagues postulated that multiple mechanisms might be 
responsible for the effects observed. In particular, they suggested that the removal of 
interstitial fluid decreased localized oedema and increased blood flow, which in turn 
decreased bacterial levels in tissue. It has since been proposed that the application of sub-
atmospheric pressure produces mechanical deformation or stress within the tissue resulting 
in protein and matrix molecule synthesis and enhanced angiogenesis. Using the rabbit ear as 
a model, Fabian et al. provided further evidence of the stimulatory effects of sub-
atmospheric pressure on the production of granulation tissue, and also demonstrated a 
trend towards enhanced epithelialisation. In experimental partial-thickness burns in pigs, 
sub-atmospheric pressure was shown to prevent progressive tissue damage in the zone of 
stasis that surrounds the area of the initial injury. This effect was demonstrable within 12 
hours of injury, with treatment times as short as six hours being sufficient to exert a 
measurable effect. The authors proposed that the removal of oedema fluid, containing 
suspended cellular debris, osmotically active molecules and biochemical mediators released 
following the initial injury, may lessen the obstruction of blood flow.  
Numerous other papers have described the use of TNP in the treatment of a variety of 
wound types, including extensive degloving injuries, infected sternotomy wounds and 
various soft tissue injuries prior to surgical closure, and in burn wound management. 
3. Physiological basis of TNP 
Numerous theories have been advanced to explain the physiological basis of the marked 
improvement in clinical outcomes achieved with TNP. Two basic, broad mechanisms have 
been proposed to account for the increased rate of granulation tissue formation and 
accelerated healing rate: a fluid-based mechanism and a mechanical mechanism. 
Application of a controlled vacuum to the wound interface facilitates the removal of excess 
interstitial fluid due to the higher pressure gradient. This physically results in a decrease in 
interstitial pressure. When the interstitial pressure falls below the capillary pressure, the 
capillaries reopen and flow to the periwound tissue is restored. This same mechanism is 
responsible for the success of the vacuum technique for decompression of both muscle 
compartment and abdominal compartment syndrome. All non-bound soluble factors will 
also be removed with the fluid, including inhibiting factors and promoting factors. 
Numerous descriptions have been presented of the change in concentration of various 
factors over time. Factors measured range from growth factors to metalloproteinases to C-
reactive protein. The interactions between the soluble factors related to wound healing, and 
also those factors and interactions that inhibit or delay healing, are extremely complex. The 
same factor can both promote and inhibit wound healing, depending on the concentration 
and timing during the healing process. Moreover, the negative pressure and increase in 
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blood flow to the wound bed have been shown to accelerate the formation of granulation 
tissue. Interestingly, intermittent application of sub-atmospheric pressure has produced 
superior results, possibly due to mitigation of the cellular desensitization that occurs with 
exposure to continuous sub-atmospheric pressure. Although it is likely that each of these 
factors plays a role in the action of TNP, the application of mechanical forces to the wound 
site is probably the most significant mechanism of action. 
Mechanical force is known to be responsible for the induction of cell proliferation and 
division. Plastic surgeons use tissue expansion to obtain soft-tissue envelopes in 
reconstructive surgery, while orthopaedic surgeons and maxillofacial surgeons use 
distraction osteogenesis to lengthen bones. Ingber et al. have shown that for cells to respond 
to soluble mitogenic factors and proliferate, they must be extended, leading to isometric 
tension, either by adherence to a stiff substrate or by external application of mechanical 
forces. Only stretched cells can divide and proliferate in response to soluble growth factors, 
whereas cells that are not stretched and assume a more spherical shape are cell-cycle 
arrested and tend to undergo apoptosis. It has also been shown in vitro that directional 
growth of capillary sprouts is promoted by the application of tension in three-dimensional 
angiogenesis models. The applied forces deform the extracellular matrix and, as cells are 
anchorage-dependent, the cells in the stretched tissue are deformed. Cell deformation has 
been shown to cause a wide variety of molecular responses, including changes in ion 
concentration and permeability of membrane ion channels, release of secondary messengers, 
stimulation of molecular pathways, and alterations in gene expression. Moreover, it is 
known that vascular endothelial cells express a different array of genes depending on 
whether they have been exposed to static, laminar or turbulent flow. It is apparent that cells 
are able to sense mechanical forces and respond through the regulation of specific genes and 
the induction of cellular programs. The exact mechanisms behind these effects are not fully 
understood, but are probably related to conformational changes in the cytoskeleton in 
response to mechanical forces. This behavior provides a natural mechanism for tissue 
homeostasis, where tissue mass expands, cells are stretched and are thus stimulated to 
divide. 
The application of negative pressure may promote wound angiogenesis by directly 
stimulating endothelial cells. For example, the application of TNP may cause local wound 
hypoxia, which is a potent stimulator of vascular endothelial growth factor (VEGF) 
production, the major endothelial cell mitogen. Alternatively, TNP may activate signal 
transduction pathways leading to endothelial cell division and growth factor production 
since endothelial tension causes capillary sprouting, gene expression, and changes in matrix 
metalloproteinase (MMP) activity. While TNP may directly stimulate endothelial 
proliferation by local hypoxia or cell deformation, increased wound angiogenesis may be an 
indirect effect of the TNP-mediated reduction in MMP activity. Although low levels of 
MMPs have been shown to favour angiogenesis, elevated MMP activity inhibits 
neovascularization and is associated with chronic wounds. Specifically, the levels of the 
gelatinases MMP-9 and MMP-2 are significantly higher in nonhealing wounds, but return to 
normal as wound healing progresses towards closure. In addition, chronic wound exudates 
that inhibit endothelial activity will instead stimulate angiogenesis after treatment with an 
MMP inhibitor. A reduction in MMP activity may promote endothelial proliferation by 
lowering MMP-mediated angiostatin and endostatin production. Alternatively, the 
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inhibition of a MMP-propagated inflammatory cascade may provide an environment more 
favorable to capillary growth. 
Mechanical properties seem to have a greater influence on clinical efficacy than fluid-based 
properties, according to a recently published article, in which the authors showed that the 
application of mechanical shear stresses was able to activate the VEGF pathway without any 
VEGF being present in the culture fluid  
4. Application of TNP directly onto the myocardium 
It was first described by Lindstedt et al that application of a negative pressure directly onto 
the myocardium resulted in an increase in blood flow in the underlying myocardium. In this 
first study microvascular blood flow in the myocardium was measured by laser Doppler 
flowmetry (LDF). The LDF probes were located 5-6 mm lateral to the middle part of the left 
anterior descending (LAD) , 5-6 mm down into the myocardial wall, and measurements 
were made before and after application of a MTNP of -50 mmHg. A significant increase was 
seen in all the animals when the myocardium was exposed to MTNP of -50 mmHg. The 
increase in blood flow was seen both in non-ischaemic myocardium (normal myocardium), 
in ischemic myocardium (after 20 minutes of LAD occlusion), and also in reperfused 
myocardium (formerly ischaemic myocardium after 20 minutes of reperfusion). In all the 
settings the increase in microvascular blood flow appeared immediately when MTNP was 
applied. In another study myocardial blood flow was measured using ultrasonic flow meter 
probes at the proximal part of the left anterior descending artery (LAD), the circumflex 
coronary artery (CCX) and the right coronary artery (RCA), before and after application of 
MTNP of -50 mmHg. Measurements were performed during normal conditions (non 
ischemic) and after occlusion of the LAD, i.e. ischemic conditions. The results implying that 
MTNP increases the total amount of coronary blood flow to the myocardium. Interestingly, an 
increase in myocardial perfusion measured by LDF, when the MTNP was applied, correlated 
to an increase in coronary blood flow in every animal. A non-uniform or a decrease in the total 
coronary blood flow might hypothetically cause ischemia in parts of the myocardium not 
exposed to MTNP. Since the present results shows a significant increase in the total amount of 
coronary blood flow, the authors believe that ischemic areas are not likely to occur. However, 
local effects in the myocardium could not be deduced from the study. 
When applying different negative pressures to periwound tissues (skeletal muscle and 
subcutaneous tissue) may causes different changes in blood flow. When the negative 
pressure exceeds a specific level it seems to constringe the vessels in periwound tissue and a 
decrease in local blood flow is seen. Morykwas et al has previously reported that the 
microvascular blood flow to a wound increased to four times the baseline value when a 
negative pressure of 125 mm Hg was applied, whereas it was inhibited at negative pressures 
of 400 mm Hg and above. The changes in blood flow is thought to be related to local effects, 
since the blood flow at a distance of 4.5 cm from the wound edge was not affected by the 
negative pressure between -50 and -200 mmHg. A zone of relative hypoperfusion has been 
observed close to the wound edge. Hypoperfusion induced by TNP is thought to depend on 
tissue density, distance from the negative pressure source, and the amount negative 
pressure applied. In the myocardium, however, MTNP between -25 and -50 mmHg have 
been shown to induce a significant increase in blood flow, whereas MTNP between -75 and -
150 mmHg have not been shown to induce any significant blood flow changes in the 
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underlying myocardium. The differences in blood flow pattern between periwound tissue 
and myocardium might be due to the differences in tissue histology, where the myocardium 
has a higher density than periwound tissue. The absence of increase in blood flow when the 
myocardium is exposed to pressures between -75 and -150 mmHg might, in part be due to, 
counteract forces. Hypothetic pressures above -150 mmHg might have led to constringe of 
the vessels, thus reducing the microvascular blood flow to the exposed myocardium. In a 
study, comparing the two negative pressures -25 and -50 mmHg, both pressures resulted in 
a significant increase in myocardial blood flow, and no significant difference could be 
observed between the two pressures.  However, the increase in blood flow was greater in 
normal myocardium when the pressure of -25 mmHg was used. Furthermore, in ischemic 
myocardium the increase was greater when using -50 mmHg. The study, however, only 
contained six animals, and the difference might have been significant in a larger study. The 
authors believe that the optimal MTNP in clinical perspective might be -50 mmHg, since 
ischemic conditions would be of greater interest than normal. 
As earlier mentioned, a zone of relative hypoperfusion has been observed in studies when 
TNP is applied on wounds. The zone of hypoperfusion is believed to appear close to the 
negative pressure source. When MTNP, a large zone of hypoperfusion, would theoretically 
cause ischemia in the epicardium that would theoretically cause ischemia. In wound healing 
the effect of hypoperfusion or ischemia close to the negative pressure source might be 
beneficial to wound healing, since hypoxia has been shown to be a strong factor for 
stimulating VEGF and new vessel formation. In MTNP however, a zone of hypoperfusion 
would probably not be desirable. Interestingly, three different studies on animals have 
shown a significant increase in epicardial blood flow when exposed to MTNP of -50mmHg. 
MTNP between -75 and -150mmHg did not; in any of the studies induce a significant change 
in myocardial blood flow. Probably because the amount of negative pressure applied is to 
large, resulting in an obstruction of the vessels. Consequently, no hypoperfusion could be 
observed during MTNP in either normal, ischemic, or reperfused myocardium during both 
normo- and hypo-thermia. The absence of hypoperfusion could possibly be explained by the 
higher density of myocardium than wound tissue. It could however also possibly be 
explained by the release of vasodilators close to the negative pressure source. Another 
possible explanation is that the increase in blood flow is due to a redistribution of the 
microvascular blood flow to the epicardium caused by natural physiological microvascular 
mechanisms in the myocardial wall, as seen during for example systolic blood pressure 
below 50 mmHg. Another possible explanation is that the negative force is greater closer to 
the vacuum source and subsequently decreases with distance.  
Argenta et al. investigated in 2010 if MTNP applied onto the myocardium followed acute 
myocardial infarction could decrease the size of myocardial infarction in an animal model. 
They induce ischemia by 75 minutes of left main coronary artery occlusion and thereafter 
three hours of reperfusion. Animals were assigned to one of three groups: (A) untreated 
control; treatment of involved myocardium for 180 minutes of MTNP with (B) -50 mmHg, or 
(C) -125 mmHg. Treatment of the ischemic area with MTNP for 180 minutes significantly 
reduced infarct size (area of necrosis/area at risk) in both treatment groups compared to 
control. Total area of cell death was reduced by 65% with -50 mmHg treatment and 55% in 
the -125 mmHg group. They concluded that treatment of ischemic myocardium with MTR, 
for a controlled period of time during reperfusion, successfully reduced the extent of 
myocardial death after acute myocardial infarction. 
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5. Ischemic heart disease; clinical application of TNP 
The majority of patients who require intervention for coronary artery disease are adequately 
treated by PCI or CABG. However, a major reason for failure of these treatments is their 
dependency on luminal size and coronary outflow. Methods of stimulating new vessel 
formation in the myocardium that are not dependent on vessel caliber therefore provide an 
important alternative treatment. A large group of patients suffer from refractory angina 
pectoris. Conventional treatment such as PCI and CABG has not been successful in these 
patients. Various other therapies have been tried, such as percutaneous myocardial laser 
revascularization, and enhanced external counter-pulsation, with varying success. Even 
spinal cord stimulation has been used in an attempt to ease their ischaemic pain. However, a 
satisfactory means of treating these patients has yet to be found. A new form of treatment 
resulting in new collateral vessel formation would thus be of interest for these patients.  
Numerous studies have evaluated the efficacy of gene therapy in the treatment of ischemic 
heart disease for the restoration of myocardial function by stimulation of angiogenesis and 
collateral vessel formation. VEGF has been found to be one of the most interesting growth 
factors in therapeutic angiogenesis. Interestingly, the mechanical forces exerted by TNP 
stimulate the endogenous production of VEGF. 
In patients with acute coronary syndrome and coronary vessel occlusion, it is of great 
importance to improve or, if possible, restore the blood flow to the ischemic myocardium to 
protect it from ischemic stress and, in some cases, acute coronary infarction. Most patients 
are successfully treated with conventional methods such as PCI or CABG. However, these 
procedures do not result in satisfactory results in all patients due to extensive coronary 
disease or small vessel caliber. Furthermore, the procedure is not suitable for some patients 
due to their advanced age, renal failure, or other complicating factors. In some cases of acute 
ST elevation myocardial infarction there is no reflow during PCI. No-reflow situations may 
also arise during saphenous vein graft intervention, and rotational atherectomy. During no-
reflow, epicardial flow is reduced due to obstructions at the microvasculature level. This no-
reflow condition is usually transient, but patients with refractory no-reflow are associated 
with a markedly increased risk of 30-day mortality, compared with patients in whom no-
reflow is transient. MTNP of -50 mmHg significantly increased the microvascular blood 
flow in both the epicardium and the myocardium. Interestingly, MTNP increases both the 
velocity and volume of blood flow by opening up the capillary beds. Furthermore, the 
method is not dependent on vessel caliber. 
6. Conclusion 
In conclusion, MTNP increases blood flow to the heart during normal, ischemic and 
reperfused conditions during both normo- and hypo-thermia. Interestingly, MTNP increases 
blood flow both in the endocardium and in the epicardium of the myocardial wall. The 
authors believe that MTNP may in the future represent an alternative treatment for patients 
with coronary artery disease and in particular patients with refractory angina pectoris. 
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1. Introduction 
Ischemic heart disease continues to be a leading cause of death in most countries, with the 
death rate in men almost twice as high as that of women. Following an ischemic event, the 
primary clinical strategy is to quickly restore blood flow to the heart muscle, myocardial 
reperfusion, using drug therapy (thrombolytics) or percutaneous coronary intervention. The 
damage that follows ischemia-reperfusion is triggered by increased production of oxygen 
free radicals at the time of reperfusion when blood flow is restored (Ambrosio et al. 1993; 
Marczin et al. 2003) and impaired myocardial antioxidant defences, leading to 
cardiomyocyte apoptosis and increased infarct size.  
Hyperglycaemia and high plasma levels of aldosterone are two critical factors that produce 
poor outcomes following an ischemic event and reperfusion strategies. Diabetes is now the 
fastest growing disease worldwide, and a public health concern globally given the aging 
population -currently affecting more than 240 million people worldwide, and the number is 
predicted to rise to more than 360 million by 2030, according to the World Health 
Organization. Global health expenditure on diabetes is estimated to rise to USD 490 billion 
(Zhang et al. 2010) and cardiovascular disease is the major cause of death. In adults with 
type 2 diabetes, cardiovascular disease is responsible for 65-75% of deaths due to 
myocardial infarction and end stage renal disease; and the age-adjusted relative risk for 
cardiovascular complications in type 1 diabetes may exceed that of type 2 (Nadeua et al. 
2010). Although first line treatment for diabetes is anti-hyperglycaemic agents, additional 
therapeutic strategies are needed. In addition, during hypoglycaemia there is an increase in 
aldosterone production (Adler et al. 2010) and there is emerging evidence of a relationship 
between aldosterone and insulin resistance.  
High plasma aldosterone levels during percutaneous coronary intervention double the risk 
of mortality and are an independent risk factor for mortality (Beygui et al. 2006). 
Inappropriately elevated aldosterone levels produce cardiac and vascular inflammation and 
fibrosis, leading to remodelling and disease via activation of mineralocorticoid receptors 
(MR) (Brilla et al. 1990; Young et al. 1995). Recent experimental studies (Mihailidou et al. 
2009) show that during myocardial ischemia-reperfusion, cardiac damage is aggravated by 
activation of mineralocorticoid receptors by both aldosterone (Fig.1) and cortisol (Fig. 2).  
 




Reproduced from Mihailidou et al. (2009) with permission 
Fig. 1.  
 
Reproduced from Mihailidou et al. (2009) with permission  
Fig. 2.  
Current therapies, such as antagonism of the renin-angiotensin-system, mitigate the 
cardiorenal complications of diabetes but do not suppress aldosterone production. 
Aldosterone levels increase (“aldosterone breakthrough”) in 10-53% patients and recent 
studies suggest an association between aldosterone production and insulin resistance in 
normotensive subjects (Balkau et al. 1998), indicating aldosterone is an independent risk 
factor for myocardial damage. The results from RALES (Randomised ALdactone Evaluation 
Study, Pitt et al. 1999), EPHESUS (Eplerenone Post acute Myocardial Infarction HEart 
Failure SUrvival and efficacy Study, Pitt et al. 2003), and recently EMPHASIS-HF 
(Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, Zannad et 
al. 2011) provide strong evidence that preventing MR activation increases survival and 
decreases hospitalization in patients with heart failure and acute myocardial infarction. In 
these trials 32% of patients were diabetic.  
Since patients with diabetes have a 2-3 fold increased risk of ischemic heart disease, any new 
drug therapy for lowering glucose levels in this population must be evaluated in terms of its 
safety for use in patients with cardiovascular disease. It would be advantageous if this 
medication is shown to have cardio-protective effects, and to ensure there isn’t aggravated 
cardiac damage following a heart attack. Glucagon-Like Peptide-1 (GLP-1) agonists are a 
relatively new class of anti-hyperglycaemic medications for the management of patients 
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with diabetes. These agents also elicit a cytoprotective effect on beta cells leading to 
preservation and survival of beta-cell mass (Tschen et al. 2009; 2011; Brubaker & Drucker 
2004). The impact of these new therapeutic agents on cardiovascular disease remains 
unclear. Controlled large clinical studies of GLP-1 agonists on cardiovascular outcomes 
following ischemic heart disease for patients with diabetes are currently in progress. 
Whether there is added benefit of combining GLP-1 agonists with a mineralocorticoid 
receptor antagonist has not been examined.   
Given the increasing aging populations globally, increased incidence of both type 1 and type 
2 diabetes and elevated mortality in patients with high plasma aldosterone levels, this 
chapter will provide a review of our current understanding of the incidence of ischemic 
heart disease in both type 1 and type 2 diabetes; mechanisms involved and new treatment 
strategies. These include the GLP-1 agonists and mineralocorticoid receptor antagonists as 
potential additional therapeutic strategies to reduce cardiovascular complications of 
diabetes. 
2. Ischemic heart disease and diabetes 
Cardiovascular disease is the major cause of disease burden and death globally and along 
with diabetes and cancer make up two-thirds of all deaths globally, according to the World 
Health Organization’s report for 2011 World Health Statistics. The impact of hyperglycemia 
in patients with acute myocardial infarction (AMI) varies with age, with higher risk for in-
hospital mortality among younger patients (Nicolau et al. 2011). Hyperglycemia was 
associated with 7.6-fold increased odds for in-hospital death in patients younger than 50 
years, compared with a 3.5-fold increased risk in those aged 50-60 years. Worldwide, there is 
a higher risk of diabetes or cardiovascular disease in rural areas than in urban areas (Wan et 
al. 2007). The prevalence of type 2 diabetes is increasing dramatically due to the aging 
population, obesity and physical inactivity. Although Type 1 diabetes is less common and 
usually has onset in younger subjects, age-adjusted relative risk for cardiovascular 
complications in type 1 may exceed type 2 diabetes (Nadeau et al. 2010).  
Patients with either type 1 or type 2 diabetes have significantly higher mortality and 
morbidity following acute myocardial infarction than do the rest of the population, with 
increasing focus on hyperglycemia contributing directly to the excessive cardiovascular risk 
in patients with diabetes. The hazard ratio for major cardiovascular disease (CVD) was 
reported to be 3.6 (95% CI 2.9–4.5) in men with type 1 diabetes compared with those without 
diabetes (Soedamah-Muthu et al. 2006), while men with type 2 diabetes, the hazard ratio 
was 3.3 (95% CI 2.5– 4.5) and 10.1 (6.7–17.4) in women. (Juutilainen et al. 2008). Clinically, 
elevated but non-diabetic blood glucose levels increase cardiovascular mortality risk (Balkau 
et al. 1998). During myocardial reperfusion injury, hyperglycaemia increases cardiomyocyte 
apoptosis in both human (Frustaci et al.2000) and animal models (Fiordaliso et al. 2000; Sheu 
et al. 2007) of diabetes. Restoring blood flow to the ischemic myocardium is accompanied be 
increased oxygen free radicals (Ambrosio et al. 1993; Brown et al. 1988) and impaired 
myocardial antioxidant defence capacity leading to tissue injury (Leichtweis et al 2001), and 
therefore additional therapeutic strategies are needed to complement glycemic control.  
Inflammation also promotes reperfusion injury (Kawaguchi et al. 2011), and both type 1 and 
type 2 diabetes include inflammatory components: type 1 diabetes is an auto-immune 
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disease (Atkinson and Eisenbarth, 2001), and more recently type 2 diabetes has also been 
considered an auto-inflammatory condition (Donath and Shoelson, 2011) leading to an 
increase production of pro-inflammatory mediators including pro-inflammatory cytokines 
IL-6 and TNF-α. Activation of TNF-, activates apoptosis, and amplifies the innate immune 
response. The innate immune response has been identified to interact with danger 
associated molecular patterns (DAMPs) found on proteins released by necrotic cells 
following ischemia-reperfusion that include HMGB1 and heat shock proteins via toll like 
receptors (TLRs). This interaction activates NFsignalling promoting innate immune cell 
infiltration into the myocardium, increased cytokine production and increased pro-
apoptotic activity through caspase 3/7 and hence further aggravating reperfusion injury 
(Arslan et al., 2010). Additionally CD4+ T-cells have been identified to infiltrate the 
myocardium during reperfusion and through the release of cytokine IFN- promote 
infiltration of innate immune cells, in particular macrophages and neutrophils, the effector 
cells of the immune response to reperfusion injury (Yang et al., 2006). This increase in 
adaptive and innate immune responses in diabetes promotes activity of the complement 
system, which also further aggravates reperfusion injury (van der Pals et al., 2010).  
3. Mechanisms involved in hyperglycaemia-aggravated ischemic heart 
disease 
During prolonged ischemia ATP levels decrease leading to reduced Na+/K+ ATPase and 
sarcoplasmic reticulum (SR) Ca2+ pump activity and cystolic Na+ and Ca2+ retention. 
Additionally the decreasing oxygen supply during ischemia leads to an increased reliance 
on anaerobic glycolysis evident in the increased production of anaerobic-glycolysis by-
products and hydrogen ions (H+), thus decreasing cellular pH and lactate in the ischemic 
myocardium (van der Vusse et al. 1987). The increase in H+ in the myocardium promotes the 
activity of the sodium (Na+)/H+ exchanger leading to further increase in sodium retention, 
This is followed by calcium entry through the activity of the Na+/Ca2+ exchanger; increased 
Ca2+ opens the ryanodine receptor further increasing cytosolic Ca2+ referred to as Ca2+ 
overload (Cannell et al. 1995) triggering cell death. ROS production also promotes Ca2+ 
overload through its interaction with various Ca2+-related ion channels, including increasing 
the open probability of the ryanodine receptor found on the sarcoplasmic reticulum via 
oxidation of key thiol groups within the protein (Boraso & Williams, 1994), Ca2+ leakage 
through lipid perioxidation of phospholipid membranes (Burton et al.1990) and stimulation 
of the Na+-Ca2+ exchanger (Shi et al. 1989) through both lipid perioxidation and oxidation of 
thiol groups within the exchanger protein. 
Increased production of reactive oxygen species (ROS) (Arroyo et al., 1987; Steenbergen et 
al., 1987) during reperfusion triggers increased uncoupling of mitochondria complex I (Rolo 
and Palmeira, 2006, Tanaka et al., 2000). Additionally diabetes is associated with decreased 
antioxidant capacity measured by both direct enzyme activity by total plasma anti-oxidant 
capacity (TRAP) assay and indirectly by measures of lipid peroxidation such as lipid 
hydroperoxides and conjugate dienes (Likidlilid et al., 2007, Marra et al., 2002, Santini et al., 
1997; Santos et al., 2011) and calcium  overload  (Steenbergen et al., 1987),  leading to cell 
death and cardiac damage (Chen et al., 2002). Clinically, the Prevention of REStenosis with 
Tranilast and its Outcomes (PRESTO) trial found that diabetic patients had increased 
incidence of mortality and myocardial infarction 9 months after percutaneous coronary 
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intervention (Mathew et al., 2004). Diabetic patients with hypertension were at a greater risk 
of adverse outcomes following percutaneous coronary intervention (Lingman et al., 2011) 
Hyperglycaemia that is not controlled can lead to abnormal cardiac contractile dysfunction, 
with decreased Ca2+ sensitivity of contractile proteins. Animal studies show that there is 
increased post-translational modification of contractile proteins with phosphorylation of 
myofilament proteins troponin I and troponin T resulting in decreased Ca2+ sensitivity 
(Akella et al., 1995). Myocardial tissue collected from diabetic and non-diabetic patients 
undergoing coronary artery bypass surgery showed that the presence of diabetes decreased 
Ca2+ sensitivity (Jweied et al. 2005). Diabetic patients also have a higher risk of developing 
hypertension than normoglycaemic individuals. Sodium (Na+) retention has been identified 
as a possible cause of this increased risk of hypertension due to increased Na+ -glucose co-
transporter activity found in the renal tubules of diabetic patients (Nosadini et al., 1993). 
Hyperglycaemia and hypertension have an additive effect on long-term cardiovascular risk, 
and when both are present there is greater risk of microvascular complications, including 
nephropathy and retinopathy, and macrovascular complications such as atherosclerosis. 
During ischemia-reperfusion (refer Fig. 3), there is programmed loss of cardiomyocytes, 
apoptosis, with rates of 2–12% reported in the border zone of human myocardial infarcts 
(Ottaviani et al., 1999; Olivetti et al., 1996). This loss of viable tissue leads to structural 
remodelling of the heart and deteriorating cardiac function. Both acute stress 
hyperglycaemia (Suleiman et al., 2005) and diabetes (Mathew et al., 2004; Muhlestein et al., 
2003) aggravate injury following reperfusion of the ischemic myocardium. Hyperglycaemia 
increases cardiomyocyte apoptosis, both acutely as shown by recent studies (Wong et al. 
2011) as well as after prolonged exposure in diabetic animals (Fiordaliso et al. 2000; Sheu et 
al. 2007) and human tissue (Frustaci et al. 2000). Aggravated reperfusion injury correlates 
with increased apoptosis in the area at risk (Crow et al. 2004). Clinically, elevated but non-
diabetic blood glucose levels also increase cardiovascular mortality risk (Balkau et al. 1998).  
Apoptosis is up-regulated in hyperglycaemic cellular models of ischemia, where cardiac 
myocytes are deprived of serum and placed in hypoxic conditions (Bonavita, 2003, Aki et al., 
2010). Bonavita et al 2003 identified activation of pro-apoptotic mediators of Bid and Bax 
and down-regulation of anti-apoptotic mediator Bcl-xl in H9c2 rat cardiomyoblast cell line. 
Further support is provided by Aki et al. (2010) using H9c2 cells in hypoxic hyperglycaemic 
conditions that showed AIF release through ATP depletion promoting chromatin 
condensation and DNA fragmentation. Receptor for Advanced Glycation End products 
(RAGE) expression has been identified to be crucial to the promotion of apoptosis and 
reperfusion injury via increased c-Jun N-terminal Kinases (JNK) signalling promoting pro-
apoptotic caspase-3 activation and cytochrome-c release (Aleshin et al., 2008). 
As well as apoptosis, when cells have been exposed to sustained damage, there is necrosis of 
myocardial tissue, which is aggravated by hyperglycaemia. Hyperglycaemia-activated ROS 
promote the production of methylgloxal a side product of many metabolic pathways; 
increase in methygloxal promotes the NF- to bind to the promoter region of RAGE (Yao 
and Brownlee, 2010). Increased RAGE expression and increased induced nitric oxide 
synthase (iNOS) expression, increase nitric oxide production (NO) (Bucciarelli et al., 2006). 
NO and ROS species combine to form peroxynitrate, increasing high mobility group box 1 
(HMGB1) release, a marker of necrotic cell death, although mechanisms has not been 
defined (Loukili et al., 2011). 
 




Fig. 3. Ischemia-reperfusion induced signal transduction pathway leading to apoptosis in 
cardiac myocytes. 
4. New treatment strategies during ischemic heart disease  
First line treatment for diabetes is anti-hyperglycaemic agents, with insulin the anti-
hyperglycaemic agent for type 1 diabetes and in some type 2 diabetes cases. Intensive 
glycaemic control clinically delayed development of microvascular complications in type 2 
diabetic patients in the United Kingdom Prospective Diabetes Study (UKPDS, 1998a), but 
did not lead to a reduction in cardiovascular events; a subgroup of patients treated with 
metformin had a 39% reduction in myocardial infarction, although there were only a small 
number of events. Patients with Type 1 diabetes in the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study only 
showed a reduction in risk of any cardiovascular complications by 42% only years after 
recruitment (The Diabetes Control and Complications Trial/Epidemiology of Diabetes 
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Interventions and Complications Research Group, 2003). In the large randomised clinical 
trials, ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation) and ACCORD (Action to Control Cardiovascular 
Risk in Diabetes), intensive glycemic control compared to standard glucose-lowering targets 
in type 2 diabetes led to a reduction in risk for microvascular complications, although the 
optimum treatment for minimising the risk of cardiovascular complications was not 
defined. Metformin is routinely used in type 2 diabetes and has some cardiovascular 
benefits in obese type 2 diabetic patients (UKPDS, 1998b). In a pre-clinical study, acute stress 
hyperglycaemia aggravated infarct area and apoptosis following ischemia-reperfusion 
whereas perfusion with insulin decreased apoptosis and reduced reperfusion injury (Wong 
et al., 2011).  
4.1 GLP-1 agonists  
Glucagon-like peptide 1 (GLP-1) agonists are an exciting new class of anti-hyperglycaemic 
medication that not only lower glucose levels, but also reduce weight and have protective 
effects on pancreatic islets. Since the insulinotropic and insulinomimetic effects of GLP-1 are 
mitigated at plasma glucose concentrations of 3.9 mmol/L, this minimizes the risks of 
hypoglycemia and the need for glucose infusion. Therefore, the pharmacological properties 
of GLP-1 are attractive as a means to stimulate myocardial glucose uptake during post-
ischemic contractile dysfunction. Currently, there are limited clinical studies to confirm the 
impact of GLP-1 agonists on cardiovascular events in subjects with type 2 diabetes. 
Glucagon like peptide-1 (GLP-1) agonists, mimic the action of the incretin GLP-1 upon its 
binding to the GLP-1 receptor, which has been shown to be expressed in cardiomyocytes 
(Ban et al., 2008). GLP-1 also promotes the release of insulin, whilst inhibiting the release of 
glucagon, both these effects occur postprandial.  
Several animal studies involving murine and canine models have examined the effects of 
GLP-1 agonists on the ischaemic myocardium (Timmers et al. 2009; Noyan-Ashraf et al. 
2009; Kristensen et al. 2009; Ban et al. 2010). Most, but not all of these studies suggest that 
GLP-1 agonists may have beneficial effects on the myocardium following an ischemic insult. 
These benefits ranged from reduction in infarct size to improvement in left ventricular 
function, although the mechanisms for the cardio-protective action are not well understood. 
In addition, most studies used non-diabetic animal models, where the hearts were subjected 
to normal glucose levels and transient administration of GLP-1 agonists. In a recent study 
(Noyan-Ashraf et al. 2009), Liraglutide conferred cardio-protection over Metformin despite 
equivalent degrees of glycaemic control. In this study, diabetes was induced in mice by 
using streptozotocin, and therefore a model of Type I diabetes. The cardioprotective 
properties of GLP-1 agonist are independent of its glycaemic control properties and 
inactivate a key pro-apoptotic protein BAD mediated via PKB/AKT signalling, thus 
decreasing apoptosis and reperfusion injury (Timmers et al. 2009). The effects of GLP-1 on 
outcomes following acute coronary occlusion for subjects with Type 2 diabetes have yet to 
be defined.  
4.2 Mineralocorticoid receptor antagonists 
High plasma aldosterone levels during percutaneous coronary intervention double the risk 
of mortality and are an independent risk factor for mortality (Beygui et al. 2006). Pre-
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clinically the administration of aldosterone increased reperfusion injury by promoting 
apoptosis (Mihailidou et al., 2009). Aldosterone at inappropriate levels promotes 
inflammation and cardiovascular remodelling via activation of mineralocorticoid receptors 
(MR). Aldosterone has also been reported to trigger oxidative stress, inflammation, 
thrombosis and sudden cardiac death (Rajagopalan et al. 2002; Struthers 2001). ACE 
inhibitors or angiotensin receptor antagonists mitigate the cardiorenal complications of 
diabetes but do not suppress aldosterone production. Aldosterone levels increase 
(“aldosterone breakthrough”) in 10-53% patients, indicating aldosterone is an independent 
risk factor for myocardial damage.  
Recent studies show aldosterone interferes with insulin signalling pathways and reduces 
expression of insulin-sensitizing factors adiponectin and peroxisome proliferator activated 
receptor (Wada et al. 2009; Guo et al. 2008). Blockade of the mineralocorticoid receptor 
increased adiponectin and peroxisome proliferator-activated receptor- in adipose tissue 
leading to improved insulin sensitivity in obese, diabetic ob/ob and db/db mice (Guo et al. 
2008; Hirata et al. 2009). Further confirmation of cross talk between aldosterone and insulin 
signalling pathways is that insulin resistance improved with treatment in patients with 
primary hyperaldosteronism (Catena et al. 2006). Spironolactone has also been shown to be 
effective in decreasing albuminuria in patients with type 2 diabetes with proteinuria who 
were being treated with ACE inhibitors. (Davidson et al. 2008). Although the mechanism 
was not defined, an anti-inflammatory action was proposed. 
The relationship between aldosterone, glucose metabolism and insulin resistance is poorly 
explored. The results from RALES (Randomised ALdactone Evaluation Study), EPHESUS 
(Eplerenone Post acute Myocardial Infarction HEart Failure SUrvival and efficacy Study) 
[Pitt et al. 2003], and recently EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization 
and Survival Study in Heart Failure) provide strong evidence that preventing 
mineralocorticoid receptor activation increases survival and decreases hospitalization in 
patients with heart failure and acute myocardial infarction. In these trials 32% of patients 
were diabetic, highlighting a potential benefit of MR antagonist use to minimise 
cardiovascular complications in diabetic patients in addition to anti-hyperglycaemic 
treatment. Subgroup analysis of EPHESUS showed the beneficial effects of eplerenone were 
also found in patients with diabetes (O’Keefe et al. 2008). Diabetic patients treated with 
eplerenone had a higher rate of absolute risk reduction, compared with patients without 
diabetes, for both end-point of death from cardiovascular causes or hospitalization for 
cardiovascular events (5.1 vs. 3.5%). 
5. Conclusion 
There is an enormous public health problem emerging given the increasing aging 
population who are at highest risk of having an acute ischemic event and with diabetes the 
fastest growing disease, the proportion of people at risk of cardiovascular disease is 
therefore increasing dramatically. Globally health expenditure on diabetes is estimated to 
rise, with the health burden growing - currently 300 million people with diabetes 
worldwide, despite preventative strategies. Additional therapies are required and the 
results from clinical trials to determine the cardiovascular effects of the new anti-
hyperglycemic agents, GLP-1 agonists are eagerly anticipated. Mineralocorticoid receptor 
antagonists, spironolactone and eplerenone have demonstrated specific actions at low doses, 
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preventing end-organ damage. In particular, diabetic patients showed greater absolute 
cardiovascular risk reduction. Provided there is monitoring of plasma K+, there is potential 
for use of MR antagonists in diabetes. 
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The long-term outcomes of biomedical advances in cardiology and surgery, the focus of this 
book, fall short of their potential unless coupled with changes in patients’ lifestyle 
behaviors. Within the context of a busy, resource- and time-constrained practice, this 
chapter presents practical and effective evidence-informed strategies for health education 
that can be readily implemented by the cardiologist and surgeon. Given the unequivocal 
link between lifestyle behaviors and ischemic heart disease, ‘healthy living’ not only 
promises to augment a patient’s health overall and reduce the need for drugs and surgery 
but, when biomedical interventions are indicated, it can augment their outcomes.  
Based on epidemiological indicators this century, effective health education needs to be a 
clinical competency that is practiced systematically and inter-professionally and whose 
outcomes are routinely and quantitatively evaluated over time. Strategies that are most 
amenable to being integrated into cardiology practice involve initiating and supporting such 
education rather than the cardiologist or surgeon necessarily being the primary educator. 
Clinicians need practical effective strategies; these include expedient means of assessing the 
patient’s needs, targeting and tailoring health education to these needs, identifying patient 
learning outcomes, and following-up systematically. 
2. The ultimate knowledge translation gap  
Although the associations among lifestyle behaviors (primarily smoking, nutrition and 
exercise) and health and ischemic heart disease are well documented (see reviews Dean et 
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al. 2009a; Dean et al. 2009b; Joint WHO/FAO Expert Consultation, 2002; Neuhouser et al. 
2002; World Health Organization, 2002, & 2011; Yusuf et al. 2004; Yusuf et al. 2005), most 
adults and many children have one or more risk factors for ischemic heart disease. In the 
adult population, risk factors are often coupled with one or more manifestations of the 
condition. This trend is projected to reduce life expectancy this century for the first time in 
recorded history (Olshansky et al. 2005). The persisting gap between the scientific 
community’s knowledge about the associations between lifestyle and health, and the 
prevalence of chronic lifestyle-related conditions is not acceptable (Glasgow et al. 2004), nor 
socially and economically sustainable (World Health Organization, 
www.who.int/mediacentre/factsheets/fs172/en/). Health education that is effective and 
seamlessly supported by an inter-professional team is needed to bridge this ultimate 
knowledge translation gap.   
The pandemic of lifestyle-related conditions reflects multiple influences ranging from the 
capacity of health professionals to educate patients effectively, and the adherence of patients 
to health recommendations. Patient adherence to the most fundamental evidence-based 
lifestyle and health knowledge appears marginal at best even when they are confronted by 
the proverbial wake-up call (Blanchard et al. 2008). Of interest is that adverse lifestyle 
practices such as smoking, suboptimal nutrition, overweight and obesity, sedentary 
behavior, lack of regular physical activity, suboptimal sleep and undue stress now 
contribute to several of the ten leading causes of premature death in North America and in 
other high-income countries. With westernization this trend is appearing increasingly in 
middle- and low-income countries (Beaglehole & Yach, 2003; Mortality Country Fact Sheets, 
2006) that stand to benefit from the western experience. Given the common lifestyle 
behavior pathway and associated low-level inflammation associated with a western lifestyle 
and related conditions (Bruunsgaard, 2005), effectively educating patients about lifestyle 
changes related to health risks and the risk of ischemic heart disease or its manifestations 
would help to reduce the prevalence of other chronic lifestyle-related conditions such as 
hypertension, stroke, type 2 diabetes mellitus, obesity, and even cancer (Dean et al. 2011).  
Although health professionals have a major role in promoting public health policy, this 
topic extends beyond the scope of this chapter, hence, is addressed elsewhere.  
2.1 Lifestyle behaviors associated with ischemic heart disease 
All of the most deleterious health risk lifestyle behaviors, namely, smoking, suboptimal 
nutrition, obesity, inactivity, sleep deprivation and excess stress, are implicated in the 
pathoetiology of ischemic heart disease (Soler et al. 2010). Smoking has been described as 
the leading cause of preventable premature death (Mokdad et al. 2004). About twenty 
percent of American adults continue to smoke despite widespread public health campaigns 
and health policy legislation (Dube et al. 2010). Further, two thirds of the population is 
overweight or obese.  And, although physical inactivity has long been known to be 
deleterious to health and claimed to be the leading public health priority this century (Blair, 
2009; Thompson et al. 2003), prolonged periods of being sedentary has been identified as an 
independent risk factor for lifestyle-related conditions (Healy et al. 2008; Jakes et al. 2003; 
Stannard & Johnson, 2004; Biddle et al. 2010; Thorpe et al. 2010). Lastly, many North 
Americans have been reported to be chronically sleep deprived (Coren, 2009), and have 
stress levels long been known to be deleterious to health (DeLongis, 1988).  One or more of 
these risk factors in combination can contribute to ischemic heart disease. 
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the leading cause of preventable premature death (Mokdad et al. 2004). About twenty 
percent of American adults continue to smoke despite widespread public health campaigns 
and health policy legislation (Dube et al. 2010). Further, two thirds of the population is 
overweight or obese.  And, although physical inactivity has long been known to be 
deleterious to health and claimed to be the leading public health priority this century (Blair, 
2009; Thompson et al. 2003), prolonged periods of being sedentary has been identified as an 
independent risk factor for lifestyle-related conditions (Healy et al. 2008; Jakes et al. 2003; 
Stannard & Johnson, 2004; Biddle et al. 2010; Thorpe et al. 2010). Lastly, many North 
Americans have been reported to be chronically sleep deprived (Coren, 2009), and have 
stress levels long been known to be deleterious to health (DeLongis, 1988).  One or more of 
these risk factors in combination can contribute to ischemic heart disease. 
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Although the literature has focused on adults, the pandemic of lifestyle risk factors for 
ischemic heart disease in children is also well documented (Berenson et al. 1998). Children 
with adverse lifestyle practices constitute the new wave of adults with this condition who 
will manifest signs and symptoms at an earlier age; a trend that is changing priorities in 
pediatric practice. This trend has implications for health education involving the family 
given the shared lifestyle of adults and their children (Gidding et al. 1999) as well as the 
need for the health care community to support public health initiatives related to smoking 
cessation, healthy eating and active living. 
2.2 Health living is the best revenge 
Few clinicians would argue the benefits of a healthy lifestyle to overall health and wellbeing, 
and risk factor reduction for ischemic heart disease and its prevention. What appears to be 
less well appreciated however are the effect sizes of healthy living practices. Small changes 
in weight and physical activity for example can reap appreciable benefits with respect to 
risk reduction of lifestyle-related conditions, reversing pathology in some cases, as well as 
managing these conditions (Dean, 2009a; Dean, 2009b; World Health Organization, 2003). 
Knowledge of these relative effects sizes can provide powerful incentives to clinicians in 
motivating their patients and to the patients themselves.  
In one exemplary study of over 23,000 people between 35 and 65 years old, Ford and 
colleagues (Ford et al. 2009) reported that over an eight year period, people who did not 
smoke; had a body mass index of less than 30; were physically active for a minimum of 3.5 
hours a week; and ate healthily had an 81% lower risk of myocardial infarction; an outcome 
few medical advances could achieve. Further, by following these non-stringent lifestyle 
practices, type 2 diabetes mellitus was reduced by 93%, stroke by 50% and cancer by 36%. 
Even if not all four health factors were present, risk of developing a chronic lifestyle-related 
condition decreased commensurate with an increase in the number of positive lifestyle factors. 
Health behavior change with respect to diet and exercise has also long been known to 
normalize blood pressure and blood lipids, and help reverse atherosclerosis (American 
College of Sports Medicine, 2009 and 2010; American Heart Association, 2003; Ornish, 1998; 
Ornish et al. 1998). Nutritional regimens such as Mediterranean type diets and the DASH 
diet (Dietary Approaches to Stop Hypertension) are highly evidence based in terms of their 
capacity to control risk factors for ischemic heart disease and type 2 diabetes mellitus (Sofi et 
al, 2008; Sacks et al, 1995; Appel et al, 1997). Given these compelling findings that few if any 
drugs can replicate systematically, health behavior change needs to be viewed and 
expediently practiced with the same rigor and precision as the prescription of drugs or 
conducting a surgical procedure.  
Hypertension is a major contributing factor in ischemic heart disease for which diet and 
exercise can address in many cases (Task Force for the Management of Arterial 
Hypertension, 2007). Even reducing daily salt intake as little as one-third has been projected 
to reduce the cases of hypertension in the United States by 11 million cases annually (25% 
reduction), and associated health care costs by $1.7 billion (Report of the Institute of 
Medicine of the National Academy of Sciences, 2010). 
Obesity is a strong independent risk factor for hypertension (Shaper, 1996), and both 
conditions are strongly associated with ischemic heart disease. Strategies for sustained 
weight management and control have shifted from calorie restriction to good nutrition.   
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2.3 Health education as a clinical competency 
Effective patient health education is aimed at not only reducing a patient’s need for drug 
therapy, surgery, or both, but minimizing the social and economic burdens of ischemic heart 
disease to his or her family and community. Promoting healthy lifestyle behaviors targets 
the causes or principal factors that contribute to ischemic heart disease, which is distinct to a 
primary focus on reducing its signs and symptoms. Further, ‘healthy living’ minimizes the 
indications for drugs and surgery and the degree of their invasiveness and, if indicated, may 
augment their outcomes. 
2.4 Cardiologists as health educators 
Medical curricula are overwhelmed and replete with the need to assimilate the exponential 
growth of biomedical knowledge. Despite the evidence supporting the unequivocal benefits 
of healthy lifestyle practices on health and curbing chronic lifestyle-related conditions, 
attention to patient education as a competency pales in comparison with other topics in 
medical curricula. 
Notwithstanding, cardiologists and surgeons are pre-eminently qualified to prescribe drugs or 
perform surgery. They and the public are bombarded continuously with a dizzying array of 
new advances. Such advances include that heralded in the popular press recently to announce 
a new drug class that blocks cholesterol protein, ‘Drugmakers are racing to develop a new 
class of medicines they believe could be the biggest weapon against heart disease since statins 
were introduced in the 1980s’ (Pierson, 2011). Despite the potential contribution of such 
advances, the unequivocal potency of lifestyle behavior change and inarguably its superior 
effects, should not be minimized nor lost sight of in the face of such news headlines. However, 
the discordance between the efficacy of healthy lifestyle behaviors to prevent, in some cases 
reverse, as well as manage lifestyle-related conditions such as ischemic heart disease, and the 
effectiveness of people actually changing their lifestyles when fully aware of the detrimental 
effect of unhealthy lifestyles, is well known to every clinician. This supports the need for 
health professionals to develop competency in advising and educating patients with respect to 
long-term multiple health behavior change. Their effectively practicing collectively and 
seamlessly will help maximize the outcomes of ‘healthy living’. 
Health professionals practicing in the third millennia remain committed to the Hippocratic 
tenets of ‘first, do no harm’, and ‘the function of protecting and developing health must rank 
even above that of restoring it when it is impaired’. To meld the two, that is, practice health 
promotion within the context of contemporary biomedical practice, elevates health 
education to a bone fide clinical competency in the interest of best practice. Best practice in 
cardiology can be described as effective health education coupled with biomedical 
advances. The goal of the cardiologist and the surgeon is to maximize the outcomes of 
medical and surgical procedures and prevent recurrences of cardiac episodes, as well as 
promote the patient’s overall health and wellbeing.  
Cardiologists and surgeons have become gatekeepers to a substantial proportion of society 
in need of lifestyle behavior modification. Although patients are often perceived by 
physicians and surgeons as viewing lifestyle behavior change as arduous, requiring 
discipline and deprivation, some patients are quite motivated to change (Alegrante et al. 
2008), e.g., 70% of smokers have been reported wanting to quit (Centers for Disease Control, 
2002). Some physicians believe that if their patients simply adhere to their medications most 
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of the time, this will have the greatest chance of reducing their complaints. However, even 
with the proverbial wake-up call with a diagnosis of a chronic lifestyle-related life-
threatening condition, adherence of patients to ‘healthy living’ practices is alarmingly low 
(Blanchard et al. 2008). A major step toward enabling patients to effect sustained health 
behavior change is for clinicians to understand their own perceived and actual barriers to 
successfully educating their patients, as well as those of the patients to changing. 
To effect sustained lifestyle behavior changes in their patients, clinicians need basic 
knowledge about the processes of teaching and learning. Even brief advice by health 
professionals that is targeted and tailored can be effective in terms of its priming effect on 
health behavior change (Kreuter et al. 2000). With respect to smoking cessation, brief advice 
can augment quit rates (Bodner & Dean, 2009). Additional benefits can be achieved when 
the cardiologist or surgeon has rapport with the patient, personalizes the health education 
messages, and most importantly follows up (Shah et al. 2008). Further, clinicians who adopt 
‘healthy living’ practices themselves not only are more inclined to advise their patients 
about lifestyle behavior change, but serve as powerful role models whose advice is viewed 
by patients as being more credible (Frank et al. 2000; Paice et al. 2002; Watts, 1990).  
When viewed as a clinical competency, the elements of health behavior change parallel 
those of invasive biomedical intervention, and can be applied as systematically and 
stringently. Thus, comparable to assessing, evaluating and following up with a patient 
following biomedical intervention, the cardiologist or surgeon can ask questions such as the 
following to establish whether a health education intervention is making a difference:  
 What outcomes can I quantify and chart to monitor the patient’s short- and long-term 
improvements? 
 Given changes in the targeted health behaviors can be outcomes themselves, how can I 
quantify changes over time with respect to smoking, diet, weight, sedentary activity, 
physical activity and exercise?  
 How have the outcomes of my medical/surgical management been augmented by the 
patient’s health behavior changes?  
 How might my medical and/or future surgical management need to be modified given 
improvements in a patient’s health behaviors and health outcomes? 
3. Elements of health education as a clinical competency 
Clinical competencies are described and evaluated under the categories of knowledge and 
skills.  
3.1 Health promotion practice as a clinical competence: Knowledge 
With respect to health behavior change, cardiologists and surgeons as educators need to be 
knowledgeable about and capable of assessing and evaluating health and health behaviors 
(in addition to the usual risk factor assessment/evaluations of ischemic heart disease and its 
manifestations) (Table 1). Also, effective health educators have specific attributes such as 
rapport with the learner and have the learner’s trust. Effective educators also assess their 
learners so they can target and tailor the information to be learned to their unique needs 
(Rollnick et al. 1999).  
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Knowledge of Health  
Definition of the World Health Organization: 
‘A complete state of physical, emotional and social wellbeing’ (WHO, 1948) 
International Classification of Functioning, Disability and Health, 2002) 
 
Tools: 
Standardized outcomes measures (questionnaires, e g, health-related quality of life and life 
satisfaction) 
Knowledge of Health-related Behavior Assessment/Evaluation 
Tools:  
Health behaviors including smoking questionnaires such as WISDOM and The Why Test, 
nutrition logs and physical activity logs in accordance with nutrition and activity pyramids 
that describe optimal serving sizes and parameters of acceptable activity for health, sleep 
questionnaires and stress questionnaires 
Knowledge of Risk Factor Assessment/Evaluation for the Lifestyle-related Conditions 
Tools (according to usual clinical practice): 
Ischemic heart disease risk factor assessments such as Grundy, et al. (2002) and Harvard 
School of Public Health (2011) 
Knowledge of the Assessment/Evaluation of the Manifestations of Lifestyle-related 
Conditions  
Tools (according to usual clinical practice): 
Established medical and surgical history taking, assessment and evaluation methods often 
related to cardiovascular dysfunction and impairments 
Table 1. Health promotion practice as a clinical competency: knowledge. 
3.2 Health promotion practice as a clinical competence: Health behavior change skills  
Health education interventions and skills that promote ‘healthy living’ can be implemented 
readily within the context of cardiology practice appear in Table 2. The focus of such 
approaches to health education of patients within a biomedical framework have evolved 
from the leading behavior change theories. Emphasis is given to efficient strategies that 
require minimal time and resources, yet have the potential for substantial benefit to the 
patient. Behavioral change theories include Reasoned Action and Planned Behavior 
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(Achterberg et al. 2010; Elder et al. 1999), Social Cognitive Theory (Bandura, 1977; Bandura, 
1995), and the Transtheoretical Model (Prochaska and DiClemente, 1982). Attention is paid 
to the patient’s stage of readiness to change behavior so the education can be tailored to this 
stage, motivational interviewing which views motivation as dynamic and capable of being 
augmented, and the tenets of giving meaningful feedback and reinforcement. Although the 
table identifies health education strategies that frequently appear in the literature because of 
their clinical feasibility, we do not suggest that one strategy is superior to another. Rather, 
like medical and surgical interventions, the patient and context are considered. 
 
Physician as Role Model 
 Exploit in a professional manner: 
 Position of authority 
 Credibility in delivery health message 
Frank et al. 2000 






 Active listening 
 Personal 
Clark et al. 1995 
Shah et al. 2008 
Stott & Pill, 1990 
Assessment/Evaluation of Patient’s Health Behavior Related 
Knowledge and Behaviors (quantitatively, for ease of comparison 
with the patient over time) 
 Baseline (objective tests and outcome measures; patient logs, 
diaries and graphs) 
 Serial measurements (of variables above) 
 Follow-up (of variables above) 
Tulloch et al. 2006 
Motivational Interviewing (culturally modified as indicated) 
 Identify resistance to change 
 Understand the patient’s motivation (e.g., decision balance 
analysis) 
 Listen to the patient 
 Empower the patient 
Poirier et al. 2004 
Lee et al. 2011 
Rosengren, 2009 
Stewart & Fox, 2011 
Stages of Readiness to Change 
 Pre-contemplative: not thinking about changing 
 Contemplative: thinking about changing 
 Preparation: preparing to change 
 Action: implementing behavioral change 
 Maintenance: maintaining behavioral change 
 (Relapse: reverted to negative behavior change) 
Prochaska & 
DiClemente, 1982 
Steptoe et al. 2001 
The 5 A’s of Behavioral Change 
 Assess: Evaluate behavior change status (and progress) 
 Advise: Personally relevant behavioral recommendations 
 Agree: Set specific collaborative, feasible goals 
 Assist: Anticipate barriers, problem-solve solutions, and 
complete action plan 
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Decision Balance Analysis 
 
 
 Of Changing Behavior Of Not Changing Behavior
Pros   
Cons   
 
 
Goal: Identify Barriers and Facilitators  
 Reduce the barriers to health behavior change 
 Increase the facilitators
Seymour et al. 2011 
Feedback  
Objective, timely, and regular, e.g., body weight, step counts with 














10000 steps/day:  




Social Contagion Health Effect 
Framingham Study database: 
If your friends are overweight you are likely to be overweight, 




Assessing the Learner 
 Socioeconomic status 
 Literacy and numeracy 
 Culture, ethnicity, language, attitudes and beliefs about 
lifestyle-related health behaviors such as smoking, healthy 
eating, weight, sedentary behavior, physical activity, sleep and 
stress 
Lantz et al. 1998 
Rollnick et al. 1999 
Learner-oriented Teaching and Education 





 Interactive, e.g., web-based instructional material and sources
Rollnick et al. 1999 
Table 2. Health promotion practice as a clinical competency: Health behavior change skills. 
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3.3 Decision-making tree to augment patient health and outcomes with health 
education 
The role and skills required by cardiologists and surgeons to be health educators are 
somewhat distinct to those of professionally trained health educators given health 
promotion is practiced within the context of biomedical care. Clinicians need to be able to 
readily assess a patient’s lifestyle practices, specifically, what needs to change, and then 
decide how to effect such change most expediently. The extent of health education required 
and engagement of the cardiologist or surgeon varies from patient to patient.  
A schematic of a decision-making tree to augment patient health and outcomes with health 
education is shown in Figure 1. Health education is effected at two levels: initiated and 
supported/reinforced or both. After the health education assessment, if education needs to 
be initiated, the practitioner establishes the degree to which he or she takes responsibility for 
this and for referring to other professionals who can implement a targeted program. Even if 
the patient is referred or has been receiving health education, the practitioner supports or 
reinforces this initiative. He or she continues to monitor the educational strategies that have 
been implemented, and provides essential follow-up. Such follow-up may be as simple as 
asking the patient about changes that have been made to requisitioning laboratory 
testing/imaging to assess its outcomes, comparable to following up drug and surgical 
interventions.  
 
Fig. 1. Decision making tree for cardiologists and surgeons to augment their patient 
outcomes by initiating and supporting lifestyle-related health behavior changes. 
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3.4 The patient, the strategy, and their interface 
Countries where ischemic heart disease is most prevalent tend to be high income. These 
countries are increasingly multicultural. This dimension influences a patient’s perception 
about his or her heart disease, beliefs about its origins and its management. Interventions 
that a patient believes in will inevitably have greater benefit due to a placebo effect. Western 
biomedical interventions may be subject to being both over and undervalued depending on 
culture and ethnicity as well as individual personal factors. People from collectivisitic 
cultures for example may not perceive they have as much control over the management of 
their signs and symptoms as someone from an individualistic culture (Hofstede, 2001). 
Patients who believe that the ‘will of God’ is paramount may experience less self efficacy in 
determining the outcome of his or her ischemic heart disease, and potentially less receptive 
to health education. Cultures vary widely with respect to attitudes about smoking and its 
social acceptability, food, and physical activity. In addition, cultures vary on the 
acceptability of sleep deprivation and high stress. These differences are not insurmountable. 
Rather, knowledge of these individual patient distinctions will better able the health 
educator including the clinician to tailor and target the educational content consistent with 
the patient’s needs.  
Other determinants of learning that inform the type of teaching that is indicated include 
language, literacy, age, and potentially gender (Glanz et al. 2002). Learners also vary with 
respect to such preferences as reading to learn, experiencing, having someone provide 
feedback, and interactive learning, or some combination. Thus, a brochure or web-based 
material even if translated to a patient’s native language, may be ineffective due to these 
other factors. Although it may appear time consuming to evaluate the learner to such a 
degree, benefits of a teaching moment may be considerably compromised without taking a 
few moments to evaluate the learner specifically and the learner’s preferred learning style. 
Across all learning preferences however the follow up that is conducted systematically and 
predictably is important if learning and behavior change is to be effective and sustained 
over time.  
Because of the specialized care that cardiologists and cardiac surgeons provide, the teaching 
learning process realistically cannot be initiated, implemented and followed up by a single 
person. Other team members need to partner seamlessly with medical and surgical teams to 
ensure that health and health behaviors are assessed, and health behavior change strategies 
that are targeted and tailored to the individual, are followed up. For some patients, little 
time will be required of the cardiologist or surgeon to ensure the appropriate health 
education is in place and follow up is conducted over the time the patient is being seen, 
because of the input of other appropriately qualified support. Patients can readily be 
referred to well qualified network of professionals including counselors, nutritionists, nurse 
practitioners, and physical therapists who report back to the referring practitioner to ensure 
continuity and follow up are sustained.  
Some patients from some ethnic groups may prefer practitioners from their cultural group 
who speak the same language. This may be preferable for not only ensuring accurate 
information for the medical or surgical history and examination but also for the 
effectiveness of health education. Without common language, the effectiveness of health 
education can be compromised significantly.  
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4. Other factors that influence the provision of best practices 
Time, resources and reimbursement are often cited as reasons perceived by physicians and 
surgeons for not being able to implement new innovations and practice patterns outside the 
conventional biomedical model. The interview and dialogue conducted systematically 
between the physician or surgeon and patient can set the stage for effective health education 
leading to ‘healthy living’.  
Motivational interviewing is a patient-centered communication tool that has received 
considerable attention at the clinical level in terms of serving as a basis for health behavior 
change. The overarching philosophy of motivational interviewing is the partnership 
between the patient and clinician. Patient behavior change is viewed as a collaboration or 
shared endeavor between patient and clinician. The patient’s internal motivations for 
change are identified at the outset (Martins & McNeil, 2009; Pollak et al. 2011; Rollnick et al. 
2008). Patients are often resistant or ambivalent to change. For example, a patient with 
ischemic heart disease who smokes may be fearful about his condition yet feels he cannot or 
will not give up smoking, despite his awareness that smoking is endangering his health.  For 
this patient, a health education message delivered using an ‘expert-recipient’ style may 
strengthen his resistance to quit smoking. Clinicians using motivational interviewing are 
empathetic; they anticipate and recognize their patients’ ambivalence about and resistance 
to quit smoking. Where inconsistencies exist between a patient’s values and behavior (e.g., 
my health is important to me, but I want to continue to smoke), the clinician acknowledges 
the inconsistency and enables the patient to articulate, explore and resolve such 
inconsistency. This can be achieved by evoking the patient’s internal motivations pertaining 
to his personal goals and values, and link these to changing health behavior (Britt et al. 2004, 
Rollnick et al. 2008; Pollak et al. 2011). For example, the clinician may question the patient 
about how motivated he is to quit smoking, followed by how confident he feels about 
succeeding. If the clinician determines that her patient is highly motivated but lacks 
confidence, she may ask him what might explain his high motivation to quit, yet lack of 
confidence to do so. She can follow up by asking him how she can help to increase his 
confidence. The autonomy of the patient is acknowledged and respected throughout the 
interaction, i.e., the patient is free to make his own choices, including whether or not to 
change his behavior and, if he chooses to do so, how he can (Rollnick et al. 2008; Pollak et al. 
2011).  Finally, the skills of motivational interviewing can substantially increase the 
confidence of medical students to effect patient’s health behavior change and provide 
counseling to patients (Poirier et al. 2004). 
Although knowledge per se is not a strong predicted of health behavior change, credible 
reading materials have a role in effectively educating some patients. Simple inexpensive 
props such as the nutrition and physical activity pyramids (United States Department of 
Health and Human Services, 2011) can be mounted on the wall in the office and discussed 
with the patient. Colorful oversized copies for hanging on the wall or refrigerator can be 
sent home. Personal attention and personalizing of the health messages can be highly 
effective communication attributes of clinicians. 
Reimbursement and fee for service is a concern in some countries. Although best practice is 
hailed as a priority in most countries, health promotion practice needs to be a central 
component given it can prevent cardiac events, and augment medical and surgical 
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outcomes.  If the power of ‘healthy living’ and its promotion are neglected, best practice is 
forfeited. The health professional community needs to ensure that evidence-based best 
practices are available to all patients; these extend well beyond drugs and surgery.  
5. Conclusion 
Within the context of busy, resource and time constrained cardiology practices, this chapter 
presents evidence-informed strategies for effective patient health education. Outcomes of 
the biomedical advances in cardiology and cardiac surgery, the focus of this book, fall short 
of their potential unless patients are able to effect long-term lifestyle behavior changes. 
Given the unequivocal link between lifestyle behaviors and ischemic heart disease, ‘healthy 
living’ not only augments a patient’s overall health but, in turn, reduces the need for drugs 
and surgery. When these interventions are indicated, health behavior change may augment 
their outcomes. Ischemic heart disease is less a pathology and more a physiological response 
to lifestyle practices. In this century, it behooves health professionals including cardiologists 
and surgeons to support each other in addressing the underlying causes of ischemic heart 
disease in addition to addressing the resulting impairments. Clinicians can work with other 
team members to better solidify their efforts and improve their individual outcomes. Finally, 
because the lifestyle-related risk factors of ischemic heart disease are common to other 
leading chronic conditions such as hypertension, stroke, renal dysfunction, type 2 diabetes 
mellitus, obesity and cancer, cardiologists and surgeons who systematically and 
aggressively integrate health promotion into their practices, can also reduce the risk factors 
and potential manifestations of these other prevalent conditions. 
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Given the unequivocal link between lifestyle behaviors and ischemic heart disease, ‘healthy 
living’ not only augments a patient’s overall health but, in turn, reduces the need for drugs 
and surgery. When these interventions are indicated, health behavior change may augment 
their outcomes. Ischemic heart disease is less a pathology and more a physiological response 
to lifestyle practices. In this century, it behooves health professionals including cardiologists 
and surgeons to support each other in addressing the underlying causes of ischemic heart 
disease in addition to addressing the resulting impairments. Clinicians can work with other 
team members to better solidify their efforts and improve their individual outcomes. Finally, 
because the lifestyle-related risk factors of ischemic heart disease are common to other 
leading chronic conditions such as hypertension, stroke, renal dysfunction, type 2 diabetes 
mellitus, obesity and cancer, cardiologists and surgeons who systematically and 
aggressively integrate health promotion into their practices, can also reduce the risk factors 
and potential manifestations of these other prevalent conditions. 
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1. Introduction 
Ischemic heart disease (IHD) is both the most common and the most costly form of 
cardiovascular disease (CVD) in the United States (US).1-2 In 2010, the estimated prevalence 
of IHD among American adults aged ≥20 years was 7.9% (9.1% in men and 7.0% in 
women),1 and the aging of the US population should drive prevalence even higher in the 
future. Fortunately, the IHD death rate has declined in recent decades, but it remains the 
leading cause of hospital admissions and the single largest killer of American men and 
women, causing 1 of every 6 deaths.1-3 Not surprisingly, spending to treat IHD has increased 
more than 40% over the past 25 years.4 For 2010, the total economic burden of IHD was 
estimated to be $177 billion, $96 billion in direct medical costs and $81 billion in indirect 
costs. Well over half of the direct costs ($57 billion) were for inpatient care.1 Thus, 
information on the costs of hospitalizations involving IHD may be helpful in developing 
strategies to contain the growth in the disease’s economic burden. 
To date, researchers have used a variety of approaches in investigating the health care costs of 
IHD.4-15 For example, in the US, Hodgson and Cohen used a prevalence-based approach to 
demonstrate that IHD accounted for just over one half of health care expenditures for heart 
disease in 1995 ($38.7 billion of $75.9 billion.)5 Russell et al., using a variety of data sources and 
a Markov model, estimated incidence-based first-year treatment costs of IHD in the US for that 
same year at $5.54 billion.6 More recently, Menzin and coworkers estimated the average cost 
(in 2005 dollars) of initial hospitalization for acute coronary syndromes to be $22,921, and their 
estimate for re-hospitalization for IHD was $28,637.7 In other industrialized countries, the 
economic burden of IHD has also been very high. For example, in the United Kingdom (UK), 
Liu and associates estimated the total 1-year cost (1999) of IHD to be £7.06 billion, the highest 
of any disease in the UK. The total direct health care costs of IHD were £1.73 billion, of which 
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implications for deciding how to allocate resources and, similarly, for evaluating the cost-
effectiveness of prevention programs at the community level.  
To address these gaps, we used a large administrative dataset to explore the cost of 
hospitalization for patients with IHD; to make this a valuable exercise we classified the 
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patients in several different ways by IHD diagnosis and also examined the apparent effects 
of sex, age, and a variety of comorbidities as well as 2 procedures. The estimated costs of 
hospitalization should provide some insights on why the inpatient costs of IHD have been 
so high and how the increases in costs can be contained.  
2. Methods  
The study population was selected from the 2005 MarketScan Commercial Claims and 
Encounters inpatient dataset, which contains over 1 million records for patients aged 64 or 
younger from self-insured employers, including state governments. The advantages of using 
data from MarketScan are the large samples, the detailed diagnostic codes for medical 
services, and the listings of hospitalization costs that are based on payment to providers.16 
The MarketScan dataset has been used by many other researchers investigating the health 
and economic burden of CVD.7, 17-21 
Using codes from the International Classification of Diseases, 9th revision (ICD-9) (Table 1), 
we identified hospitalizations with a primary or secondary diagnosis of IHD among patients 
aged 18 to 64 years enrolled in non-capitated health insurance plans. We excluded patients 
younger than 18 because of the low prevalence of IHD in that age group. We excluded 
patients in capitated health insurance plans because their costs of hospitalization would not 
reflect the medical services provided to them. To limit the influence of extreme values for 
hospitalization costs we also excluded those hospitalizations with costs below the 1st or 
above the 99th percentile. 
 
IHD Classification, Comorbidity, or 
Procedure ICD-9 code 
Ischemic heart disease, all 410.xx - 414.xx
Acute myocardial infarction 410.xx
Other coronary heart disease 411.xx - 414.xx
Heart failure 
40201, 40211, 40291, 40401, 40403, 40411, 40413, 
40491, 40493, 4280, 4281, 4289, 42820, 42821, 42822, 
42823, 42830, 42831, 42832, 42833, 42840, 42841, 
42842, 42843
Stroke 430.xx - 438.xx
Diabetes 250.xx
Symptoms involving respiratory 
system and other chest symptoms 786.xx 
Cardiac dysrhythmias 427.xx
Hypertension 401.xx, 402.xx, 403.xx, 404.xx, 405.xx
Hyperlipidemia 272.xx
Percutaneous coronary intervention 00.66, 36.01−36.09 plus CPT-4 codes 92980−92982, 92984, 92995, 92996
Coronary artery bypass graft 36.10−36.19 plus CPT-4 codes 33510−33519, 33521−33523, 33533−33536
IHD: ischemic heart disease; ICD-9, International Classification of Diseases, Ninth Revision; 
CPT: Current Procedural Terminology. 
Table 1. Diagnostic codes for ischemic heart disease and selected comorbidities and 
procedures 
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For all the hospitalizations in the study we further identified whether the IHD was an acute 
myocardial infarction (AMI) or not (non-AMI). The comorbidities used for our analyses 
(expressed as diagnoses in Tables 2 and 3) were heart failure, stroke, diabetes, cardiac 
dysrhythmias, hypertension, hyperlipidemia, and symptoms involving the respiratory 
system and other chest symptoms. In addition to these health conditions, we identified 
hospitalizations with a percutaneous coronary intervention (PCI) or a coronary artery 
bypass graft (CABG) because these procedures were (and remain) quite expensive. 
We analyzed the costs for 3 groups of hospitalizations: 1) those with either a primary or 
secondary diagnosis of IHD; 2) those with a primary diagnosis of IHD, including those in 
which there was also a secondary diagnosis of IHD; and 3) hospitalizations with a 
secondary diagnosis of IHD in which the primary diagnosis was not IHD. For each study 
sample, we calculated the costs by various diagnosis classifications in four subgroups: men, 
women, patients aged 18-44, and patients aged 45-64. 
Hospitalization costs were considered to be total payments to providers rather than hospital 
charges to reflect the true economic burden of hospitalizations. In this study we included all 
costs for physician services, all diagnostic tests, therapeutics, supplies, and room fees.  
For cost comparisons, we used the Wilcoxon 2-sample test for the analysis, and a 
Bonferroni correction to protect against inflation of the type I error rate due to multiple 
testing was made for costs. Significance was assumed when the 2-tailed probability value 
was <0.001. For the regression analysis, we used the PROC GLM (General linear model) 
procedure for the cost regression model and PROC GENMOD (General model) for logit 
estimation. The regression model was run for the 3 groups of hospitalizations previously 
defined: 1) those with either a primary or secondary diagnosis of IHD; 2) those with a 
primary diagnosis of IHD, including those in which there was also a secondary diagnosis 
of IHD; and 3) hospitalizations with a secondary diagnosis of IHD in which the primary 
diagnosis was not IHD. We also ran a logit regression for IHD as the primary diagnosis 
versus IHD as the secondary diagnosis. The logit model was used to investigate the 
factors potentially influencing the probability of having a primary diagnosis of IHD 
(versus a secondary diagnosis of IHD). All the statistical analyses were performed using 
SAS, version 9.2.  
3. Results  
Among the 63,864 cases of IHD we identified, 33,316 (52%) hospitalizations had a primary 
diagnosis of IHD and their average costs were $24,079, 30,548 cases (48%) had a secondary 
diagnosis of IHD (their primary diagnosis was not IHD) and their average costs were 
$16,113 (Table 2 and Table 3). In both of these major diagnostic status groups, the costs 
were higher for AMI than for non-AMI, higher for men than for women, and increased 
with age.  
Overall, 31% (n=10,261) of the hospitalizations in which the primary diagnosis was IHD 
were AMI, with the costs averaging $27,507 (Table 2). This cost was $4,954 higher (p <0.001) 
than the average for non-AMI cases ($22,553). The cost differences between the AMI and 
non-AMI cases were similar among each of the 4 subgroups defined by sex or age. For both 
AMI and non-AMI cases the costs were $4.1-4.5 thousand higher in men than in women. 
Costs increased with age, but the increase was small for AMI cases. 
Among the hospitalizations with a primary diagnosis of IHD, 82.5% also had a secondary 
diagnosis of IHD; 58.4% had symptoms involving the respiratory system and other chest  
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Data are means expressed in U.S. dollars +/- standard deviation. N = 33,316. IHD: ischemic heart 
disease; AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary 
artery bypass graft surgery. 
Table 2. Mean costs of hospitalizations for patients with primary diagnosis of ischemic heart 
disease, by sex and age  
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Data are means expressed in U.S. dollars +/- standard deviation. N = 30,548. IHD:ischemic heart 
disease; AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary 
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Table 3. Mean costs of hospitalizations for patients with ischemic heart disease as a 
secondary but not a primary diagnosis, by sex and age 
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symptoms; 32.5%, hypertension; 26.2%, hyperlipidemia; 15.9%, diabetes; 14.0%, cardiac 
dysrhythmias; 8.3%, heart failure; and 4.0%, stroke (Table 2). All the co-morbidities except 
symptoms involving the respiratory system/chest were associated with increased inpatient 
costs. Among these 6 secondary diagnoses (comorbidities) the cost was the highest for 
stroke ($34,978) and lowest for hypertension ($26,049). This pattern held for the male and 
female groups and for those aged 45-64, but in the 18-44 group the cost for heart failure was 
marginally higher than that for stroke. 
Overall, a hospitalization with PCI had a cost approximately $1,100 greater than one 
without that procedure, but there were large differences in cost between the PCI and “no 
PCI” groups for women and the younger age group (18-44). The costs of hospitalizations 
with CABG averaged $46,757, more than twice the average for stays without CABG 
($19,622). This pattern held true for all groups delimited by sex or age.  
Among hospitalizations with a secondary but not a primary diagnosis of IHD (Table 3), the 
mean cost was about $8,900 higher for an AMI stay ($24,281) than for a non-AMI 
hospitalization ($15,405). Similar patterns were seen for the 4 groups defined by sex or age, 
and the costs were higher for men and those aged 45-64 than for women and the younger 
group, respectively. Among the 8 subgroups defined by AMI status and either sex or age, 
the highest costs were $24,881(45-64, AMI) and $24,867 (men, AMI), and the lowest was 
$12,195 (18-44, non-AMI).  
Overall, having a primary diagnosis of cardiac dysrhythmias, heart failure, or diabetes 
increased costs (Table 3), while primary diagnoses of hypertension, respiratory/chest 
symptoms, and stroke were associated with lower costs. Stroke, however, was associated 
with higher costs in women and the younger population. The cost of hospitalization with 
PCI averaged $28,966, almost twice the cost of cases without PCI ($15,719). Hospitalizations 
with CABG cost $60,281, essentially 4 times the cost of hospitalizations without CABG. The 
cost differences between CABG and no CABG were similar across all 4 groups defined by 
sex or age.  
The regression analysis indicated that the cost of hospitalization increased significantly with 
age (p =0.01 for age 18-39, p <0.001 for age 40-54) for IHD as a secondary diagnosis, but 
analyses of IHD as either the primary or secondary diagnosis or as the primary diagnosis 
did not find a significant age gradient (p >0.01) (Table 4). Costs were always higher for men 
than for women (p <0.001), especially for hospitalizations with a primary diagnosis of IHD 
with a cost difference of $4,822. After controlling for age, sex, urbanization, geographic 
region, and the Charlson Comorbidity Index, the cost of hospitalizations with the primary 
diagnosis of IHD was $7,319 higher than for those with a secondary diagnosis of IHD. For 
hospitalizations with a primary diagnosis of IHD, all the comorbidities increased the costs 
except for respiratory/chest symptoms, albeit the findings for diabetes and heart failure 
were not statistically significance at the 0.001 level.  
Cardiac dysrhythmias and stroke were the most expensive comorbidities for 
hospitalizations with the primary diagnosis of IHD, and heart failure was the most 
expensive for hospitalizations when IHD was listed as a secondary diagnosis. Both PCI and 
CABG were associated with higher costs, especially CABG, which was the largest 
contributor to costs for both IHD as the primary and as a secondary diagnosis. The logit 
results revealed that after controlling for Charlson comorbidity index and region, in a 
comparison with patients aged 55-64 years, patients aged 18-39 were less likely and those 
aged 40-54 more likely to have a primary diagnosis of IHD rather than a secondary 
diagnosis of that disease. Men had a higher probability than women of having the diagnosis 
of IHD be primary (last column of table 4).  
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PCI - 1,527.3 (0.0002) 
13,140.0 
(0.0002) - 
CABG - 26,164.0 (<0.0001) 
44,053.0 
(<0.0001) - 
Values in parentheses are p values. IHD: ischemic heart disease; PCI: percutaneous coronary 
intervention; CABG; coronary artery bypass graft; Ref: reference; All the comorbidities (heart failure, 
stroke, diabetes, hypertension, symptoms involving respiratory system and other chest symptoms, 
cardiac dysrhythmias, and hyperlipidemia) refer to the secondary diagnosis for hospitalizations with 
the primary diagnosis of IHD, and refer to the primary or secondary diagnosis for hospitalizations with 
a secondary diagnosis of IHD. 
Table 4. Coefficient estimates of hospitalization costs and diagnosis status for patients with a 
diagnosis of ischemic heart disease  
4. Discussion 
Using a large administrative dataset, we analyzed the costs of hospitalizations in patients 
diagnosed with IHD and obtained detailed information on a variety of measures. Our cost 
information on IHD classified by AMI, primary and secondary diagnosis statuses, and 
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comorbidities is the first of its kind to be reported. More important, while many authors 
have detailed the costs of CABG and PCI procedures over the years, our study is 
unique in reporting the costs of hospitalization for IHD patients who underwent these 
procedures by age, sex, and diagnostic status and controlling several major comorbidities of 
IHD.  
We used ICD-9 codes to define IHD; earlier investigations by other researchers were 
hampered by not clearly defining this disease, and few considered IHD as a secondary 
diagnosis. We found, as expected, that the hospitalizations in which IHD was the primary 
diagnosis were far more expensive, on average, than the cases in which IHD was only a 
secondary diagnosis, but we found that the latter accounted for 48% of the hospital stays of 
interest. Thus, there is considerable merit in examining these hospitalizations in terms of 
their economics. More broadly, the information set forth in the present report should be 
valuable for identifying with greater precision the drivers of costs incurred by patients 
hospitalized with IHD.  
Our cost estimates for hospitalizations with a primary diagnosis of IHD ($24,079 on average, 
$27,507 for AMI and $22,553 for non-AMI) are comparable to those in the literature. In a 
study that used data from 1995, Russell and associates estimated the cost of fatal AMI at 
$17,532 and nonfatal AMI at $15,540.6 More recently, Menzin and coworkers estimated the 
cost of IHD at just under $23 thousand for initial hospitalization but about $5,700 higher for 
re-hospitalization in 2005.7 Our finding that costs were higher for AMI hospitalizations than 
for those classified as non-AMI, while expected, adds further to the literature; of additional 
interest was the fact that the cost gap between AMI and non-AMI hospitalizations when 
IHD was the primary diagnosis was much larger for those aged 18-44 than it was for the 
other major subgroups (men, women, and those aged 45-64). 
Our findings that stroke, heart failure, and cardiac dysrhythmias drive up the costs of 
hospitalization when IHD is the primary diagnosis are consistent with the literature but still 
of great interest. We also found that hyperlipidemia was associated with higher costs as 
expected. Patients with hyperlipidemia were often referred for lipid-lowering therapy, 
which incurred costs from medication, clinical visits, and lab tests. As for diabetes, in a 
study in the UK, Currie and coworkers found that 16.9% of IHD admissions (primary 
diagnosis) had a secondary diagnosis of diabetes and accounted for 16% of the costs of the 
disease.10 Our results were somewhat similar: 15.9% of IHD admissions (primary diagnosis) 
had diabetes; we also found that those with diabetes had costs $5,067 higher than those who 
did not. Perhaps surprisingly, in our regression analysis, diabetes did not drive up the cost 
of IHD hospitalization significantly when IHD was a secondary diagnosis or even when it 
was the primary diagnosis. This finding deserves more exploration, as diabetes is a risk 
factor for many kinds of vascular disease and a known predictor of poorer outcomes for 
CABG surgery.  
Nichols and Brown, who also explored the costs associated with a combination of CVD and 
diabetes, found higher costs in patients with diabetes than in those without that disease, and 
they reported that diabetes patients with CVD incurred more costs earlier in life than 
patients with diabetes but no CVD.22 Elsewhere, Rosen and colleagues found that for 
patients with IHD in 2000-2002, costs when they also had hypertension were an additional 
$1,900 (our result was $2,920 for 2005), and when they had diabetes in addition to IHD they 
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were $3,300 more (our result was $5,067 for 2005). These authors also found that the annual 
costs attributable to IHD were an additional $30,000 in the year an AMI occurred, and $4,000 
in each subsequent year (in large part due to revascularization procedures).4  
In our study, PCI increased the costs dramatically for patients with a secondary (but not a 
primary) diagnosis of IHD, and CABG increased the costs by 10s of thousands of dollars 
regardless of whether the IHD diagnosis was primary or secondary. Our mean cost for IHD 
as a primary diagnosis was $46,757 when there was CABG surgery, $19,622 when there was 
not. Wittels and coworkers, reporting more than 2 decades ago, found that the 5-year cost 
per case was $32,465 for CABG surgery and $26,916 for angioplasty. Researchers have 
investigated the factors influencing the high costs of CABG and have concluded that length 
of stays, race, age, prescription are the major factors.23-25 Given the high cost of CABG 
surgery, reducing the number of procedures and/or lowering the unit costs might be cost-
effective strategies in containing the overall costs associated with IHD.  
Our finding in the logit model that men were more likely than women and patients aged 40-
54 more likely than those either 18-39 or 55-64 to have IHD as the primary diagnosis rather 
than a secondary diagnosis is of great interest and adds to the literature on IHD among 
American adults. We found that the economic burden of IHD was higher among men than 
women, and this finding about the likelihood of primary versus secondary diagnosis would 
be consistent with that. Further, because men and persons aged 40-54 are major participants 
in the workforce, these results may suggest high indirect costs associated with IHD for these 
subpopulations.  
The variety of new findings from the present study notwithstanding, several limitations 
should be considered in interpreting the results. First, the costs reported for IHD with a 
specific comorbidity could not be allocated explicitly into the cost of IHD and the cost of the 
comorbidity, and the causal relationships between IHD and its comorbidities were 
unknown. Thus, the estimated costs for IHD with a comorbidity should be interpreted as the 
costs associated with IHD when that comorbidity was present rather than the costs of IHD 
plus the costs of that comorbidity. Fortunately, researchers have proposed ways of 
attributing hospitalization costs to specific diseases when the comorbidity issues are 
significant,26 and such research in the case of IHD should be conducted.  
Second, our sample population was of patients aged 18-64 years, while most previous 
studies focused on persons aged 65 years or older because of the higher prevalence of IHD 
and the greater costs for this age group. However, our results showed that although there 
was a tendency toward increased costs with greater age, the cost differences between age 
groups were not large, and our cost estimates were comparable with those in the literature. 
Third, the hospitalization costs were direct medical costs only, while the literature has 
shown that about half of the total economic burden of IHD is represented by indirect costs 
such as those for informal care and loss of productivity. Thus, the hospitalization costs were 
very conservative estimates of the total economic burden of IHD. Quantifying the costs of 
informal care and productivity loss associated with IHD is needed to have a better 
understanding of the full economic burden of IHD. Fourth, our data did not allow us to 
identify the hospitalizations as an initial admission or a readmission. Thus, we were unable 
to investigate the cost relationship between IHD initial admissions and readmissions. 
Finally, all of the patients had insurance coverage and thus were not representative of the 
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broad US population, a good portion of which has no health insurance. All of these factors 
may limit the generalization of our results to the general population. 
5. Conclusions  
Inpatient costs for IHD in the US are high, especially for hospitalizations among patients 
who had an AMI. Cardiac dysrhythmias, heart failure, and stroke are major factors 
associated with increased costs for patients with IHD. CABG surgery greatly increases the 
cost of IHD hospitalization, as does PCI if IHD is a secondary diagnosis only. The high costs 
we report here provide economic justifications for the development of more effective 
programs to prevent CVD. New strategies for the comprehensive prevention and control of 
IHD and its associated comorbidities such as cardiac dysrhythmias, heart failure, and stroke 
could curb hospitalizations and decrease the use of cardiac procedures for IHD and thereby 
control the associated medical costs. 
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broad US population, a good portion of which has no health insurance. All of these factors 
may limit the generalization of our results to the general population. 
5. Conclusions  
Inpatient costs for IHD in the US are high, especially for hospitalizations among patients 
who had an AMI. Cardiac dysrhythmias, heart failure, and stroke are major factors 
associated with increased costs for patients with IHD. CABG surgery greatly increases the 
cost of IHD hospitalization, as does PCI if IHD is a secondary diagnosis only. The high costs 
we report here provide economic justifications for the development of more effective 
programs to prevent CVD. New strategies for the comprehensive prevention and control of 
IHD and its associated comorbidities such as cardiac dysrhythmias, heart failure, and stroke 
could curb hospitalizations and decrease the use of cardiac procedures for IHD and thereby 
control the associated medical costs. 
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1. Introduction 
Prospective studies show that persons with depression are at increased risk for coronary 
artery disease, myocardial infarction (MI) and cardiac death (Anda et al. 1993; Barefoot and 
Schroll 1996; Ferketich et al. 2000; Penninx et al. 2001). This high rate is at least partly related 
to a greater activation of platelets resulting in an increased risk of thrombosis, which can 
partly explain the relation between these events (Laghrissi-Thode et al. 1997). Moreover, 
clinical depression can occur in 30-60% of MI patients and 15-20% develop major depression 
(Guck et al. 2001; Meneses et al. 2007) following MI. Evidence for a poor prognosis  
is particularly strong in MI patients with depressive symptoms (Ahern et al. 1990;  
Forrester et al. 1992; Frasure-Smith et al. 1993; Frasure-Smith et al. 1995; Bush et al. 2001; 
Lespérance et al. 2002): the risk of cardiac death in the 6 months after acute MI is 
approximately 4 times greater in patients with depression compared to non-depressed 
control subjects (Frasure-Smith et al. 1993). A 3.5-fold risk is still present years after MI 
(Lespérance et al. 2002).  
Despite a lower quality of life and poor prognosis for survival, only a few patients with 
post-MI depression are treated for their affective disorder (Schleifer et al. 1989; Frasure-
Smith et al. 1993; Lespérance et al. 1996; Honig and Maes 2000). This unfortunate situation 
has been attributed either to the fact that symptoms of depression are unrecognized because 
of the overlap with sequelae of hospitalization for MI (e.g., sleep disturbances, fatigue, 
feelings of guilt, loss of appetite, preoccupation with death) (Katon and Sullivan 1990; 
Freedland et al. 1992; Frasure-Smith et al. 1993), or because symptoms of depressive 
disorder in post-MI patients are not always typical (Honig et al. 1997). It has also been 
suggested that physicians may hesitate to treat a depression considered to be a normal and 
transient reaction to a life-threatening event and the associated hospitalization period 
(Fielding 1991; Littman 1993). Furthermore, some physicians may avoid prescribing 
antidepressant medication for patients who have sustained an MI, because of the potential 
interaction or unwarranted adverse cardiac events reported for classic (i.e., tricyclic) 
antidepressants (Glassman et al. 1993). Still, the mechanisms by which MI is so often 
followed by depression is little investigated and poorly understood. For this reason, we 
have undertaken the task to develop an experimental animal model to advance the 
knowledge on post-MI depression.  
 
Novel Strategies in Ischemic Heart Disease 334 
2. An experimental model of post-myocardial infarction depression 
On a pathophysiological point of view, the occurrence of post-MI depression lead us to 
search for common threads between the ischemic heart and the brain structures associated 
with depression. More specifically, we designed our experimental strategy toward 
documenting biochemical modifications in the brain limbic system as well as the behavioral 
modifications following an acute MI. 
2.1 Myocardial infarction and pro-inflammatory processes 
Ischemia occurs when coronary arteries blood flow is interrupted, which leads to reversible 
changes at the cellular level (swelling of mitochondrial matrix, intracellular fluid 
accumulation, etc). If ischemia persists, irreversible damage appears: membrane integrity is 
affected and intracellular substances are released, leading to an inflammatory reaction 
associated with a significant influx of neutrophils in the ischemic myocardium (Chatelain et 
al. 1987) and ultimately will be replaced by macrophages (Yu et al. 2003). After a prolonged 
period of ischemia, almost all the cells present in the ischemic region will die which can lead 
to heart failure if myocardial damage is extended. 
Reperfusion of cardiac ischemic tissue is associated with a massive inflammatory response 
characterized by the release of chemotactic and inflammatory substances. The accumulation 
of neutrophils is rapid for the first six hours of reperfusion and diminishes to insignificant 
levels after 24 hours of reperfusion (de Lorgeril et al. 1990). The inflammatory response 
observed during the reperfusion period is more intensive that the one observed during the 
ischemic period (Chatelain et al. 1987). The reperfusion period of ischemic cardiac tissue is 
also associated with apoptosis, i.e., programmed cell death. This may appear paradoxical at 
first hand since apoptosis induces cell death without inflammation. It is known, however, 
that pro-inflammatory substances are released by jeopardized myocardium, which leads to 
the apoptotic process. Indeed, acute MI is associated with high production of pro-
inflammatory cytokines (TNF-, IL-1, IL-6 and IL-8) by monocytes, and inflammatory 
mononuclear cells infiltrate the border zone, cardiomyocytes and endothelial cells (Francis 
et al. 2004). This represents parts of an intrinsic myocardial stress response system to tissue 
injury that may contribute not only to wound healing but also to secondary injury (Marx et 
al. 1997; Gwechenberger et al. 1999; Irwin et al. 1999; Kato et al. 1999; Pudil et al. 1999; Deten 
and Zimmer 2002; Hillis et al. 2003; Tziakas et al. 2003).  
The rapid increase in pro-inflammatory cytokine expression after MI is accompanied by a 
simultaneous local and systemic increase of catecholamines (Bürger et al. 2001), which can 
contribute to cytokine expression. Recent confirmation has been obtained with the 
attenuation of IL-1 mRNA expression in cardiac tissue in presence of propranolol, a -
adrenergic receptor antagonist (Deten et al. 2003). This shows that MI can elicit a quick and 
intensive inflammatory response that may alter the blood-brain barrier (Wann et al. 2004) or 
intestinal permeability (Arseneault-Bréard et al. 2011). It has been reported that increased 
cytokine synthesis (mainly TNF-) may be observed in the brain following MI, and this 
could be prevented by the intraperitoneal administration of pentoxifylline (Francis et al. 
2004). In parallel, we have observed that MI affects the integrity of the intestinal barrier and 
this could be prevented by the administration of probiotics, possibly by altering the balance 
between pro- and anti-inflammatory cytokines (Arseneault-Bréard et al. 2011). 
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Because reperfusion needs to be performed upon cardiac arrest and since there is an 
inflammatory response observed early after the onset of reperfusion, we used the reperfused 
MI as the basis of our model. Smaller infarct size, better survival rate, rapidly recovering 
animals, and great clinical relevance are among the different advantages of using a short 
period of ischemia followed rapidly by reperfusion compared to a permanent occlusion. 
2.2 Post myocardial infarction depression and apoptosis 
Post-mortem brains of depressed patients show DNA fragmentation and neuronal 
apoptosis, suggesting enhanced neuronal vulnerability in depression (Lucassen et al. 2006). 
Neuronal loss and reduced neurogenesis have also been observed in animal models of 
mood disorders (Gould and Tanapat 1999; Czeh et al. 2001; Lucassen et al. 2006). A decrease 
in the volume of the hippocampus, amygdala and prefrontal cortex is one of the 
neuropathological signs described in depression in which apoptosis may play a role 
(Sapolsky 1996; Drevets 2000; Strakowski et al. 2002). Neuronal cell death may occur via 2 
mechanisms: a) an acute form, or necrosis, that is rapid; and b) a delayed form, through 
apoptosis (Yuan and Yankner 2000). The former cannot be prevented efficiently because it 
tends to be prominent after more extreme conditions, such as ischemic insults or mechanical 
injury while the later is tightly regulated and dependent of the presence of energy (Yuan 
and Yankner 2000). Apoptotic cells are characterized by a reduction of volume, cytoplasmic 
shrinkage, DNA fragmentation, cell rounding and membrane bledding (Kerr et al. 1972). 
Apoptotic cells can ultimately break into membrane-contained apoptotic bodies, which can 
be phagocytosed by neighboring cells or phagocytes, which explains the difficulty of 
documenting apoptosis in vivo (Wyllie et al. 1980). 
Clinical evidence has demonstrated the presence of apoptosis in the brain of persons with 
depression. In one investigation, cell death was observed in the entorhinal cortex, 
subiculum, dentate gyrus and hippocampus (CA1 and CA4) in 11 out of 15 depressed 
patients without obvious massive cell loss (Lucassen et al. 2001). An imbalance between 
neurogenesis and cell death may thus contribute to some extent to the brain volume changes 
in depression or, alternatively, cell death may be present for a limited time followed by 
regeneration (Malberg et al. 2000). In another study, the same authors suggested that the 
contribution of cell death may have been underestimated, since antidepressant treatments 
are now known to be anti-apoptotic (Lucassen et al. 2004). Since then, 3 investigations have 
responded to this comment: a) The antidepressant Desipramine is associated with cultured 
hippocampal neural stem cell neuroprotection against lipopolysaccharide-induced 
apoptosis by inhibiting inflammatory processes in vitro (Huang et al. 2007); b) Desipramine 
and Fluoxetine increase Fibroblast Growth Factor-2 activity, a growth factor involved in 
maturation, synaptic connectivity, neurogenesis and survival of catecholamine neurons in 
the cortex and hippocampus (Bachis et al. 2008); c) Our own data, showing that Sertraline, 
an antidepressant with selective serotonin reuptake inhibition properties, blocks early post-
MI apoptosis in the limbic system (Wann et al. 2009). The anti-apoptotic effect of 
antidepressants was also reported in 2 other recent studies in rats (Huang et al. 2007; Bachis 
et al. 2008). Although apoptosis is difficult to document in human clinical cases (because 
patients are usually treated with antidepressants), another set of evidence indicates that the 
lymphocytes (Ivanova et al. 2007) or blood leukocytes (Szuster-Ciesielska et al. 2008) of 
depressed patients manifest a higher proportion of apoptotic elements compared to healthy 
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controls. It is also observed that proapoptotic serum activity is elevated in depressed 
patients (Politi et al. 2008), again suggesting a link between apoptosis and depression. 
Moreover, it has been found that mood-regulating molecules, such as Lithium and 
Valproate, increase the expression of Bcl2, an anti-apoptotic cytoprotective protein. Bcl2 
shuts off the apoptotic signal transduction pathway upstream of caspase activation 
(Chinnaiyan et al. 1996). It is also reported that antidepressant treatments themselves can 
increase neurogenesis in the rat hippocampus (Malberg et al. 2000) and prevent apoptosis 
(Lucassen et al. 2004; Nahon et al.). Apoptosis thus holds a key position in our experimental 
strategic plan to better understand the pathophysiology of post-MI depression. 
2.2.1 Intracellular mechanisms of apoptosis 
Multiple cellular pathways can trigger apoptosis, involving caspase activation or not 
(MacFarlane and Williams 2004) and two pathways of caspase activation have been 
described: extrinsic and intrinsic (figure 1). The extrinsic and intrinsic pathways of caspase 
activation differ according to the mechanism by which initiator caspases (see below) are 
activated, whereas effector caspases (caspase-3, -6 and -7) are common in both pathways 
(Adams 2003).  
The extrinsic pathway is initiated by ligand binding to death receptors, such as tumor 
necrosis factor (TNF), Fas or TNF-related apoptosis-inducing factor receptors (TRAIL) 
(Thorburn 2004). The formation of death-inducing signaling complexes (DISC) is the key 
element. These complexes are formed by the activated receptor FAS-associated death 
domain protein (FADD) or TRAIL-associated death domain protein (TRADD). Pro-caspase-
8 is then recruited to the complexes to form DISC, resulting in auto-cleavage and caspase-8 
activation (Wang and El-Deiry 2003). Activated caspase-8, in turn, cleaves and activates 
downstream effector caspases, such as caspase-3, leading to the cleavage of cellular proteins 
and cell death. Active caspase-8 can cleave Bid, a member of the Bcl-2 family, and cleaved 
Bid can amplify the death signal by promoting the release of apoptogenic proteins from the 
mitochondria (Luo et al. 1998).  
The intrinsic pathway or mitochondria-dependent pathway can be activated by chemicals, 
drugs, irradiation and cell stress such as hypoxia (Jeong and Seol 2008). Independently of 
signals that trigger the intrinsic pathway, mitochondria in the target organelle, resulting in 
the release of cytochrome c and the loss of mitochondrial membrane potential (Reyland 
2007). Cytochrome c, together with apoptotic protease activating factor 1 (Apaf-1), ATP and 
pro-caspase-9, forms apoptosomes and elicits caspase-9 activation (Jeong and Seol 2008). 
Apoptosis is suppressed through heterodimerization of anti-apoptotic Bcl2 proteins, such as 
Bcl2 and Bcl-xL, with pro-apoptotic proteins, such as Bak and Bax; thus, the ratio of pro- and 
anti-apoptotic proteins is an important determinant of cell fate (Reyland 2007). Apoptotic 
stimuli alleviate the Bcl2-mediated suppression of pro-apoptotic Bax and Bak, allowing these 
proteins to oligomerize into transmembrane pores in the mitochondria, induce cytochrome c 
release and activate caspases.  
Caspase activation is also regulated by the release of mitochondrial proteins, such as the 
inhibitor of apoptosis proteins (cIAP1, cIAP2, XIAP) that suppress activated caspases, and 
Second Mitochondrial Activator of Caspases SMAC/DIABLO that binds and reduces IAPs 
(Salvesen and Duckett 2002; Shi 2002). Finally, a group of mitochondrial proteins that induce 
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apoptosis independently of caspase activation has been identified (Lorenzo and Susin 2004; 
Bras et al. 2005). These include apoptosis-inducing factor (Lorenzo and Susin 2004; Bras et 
al. 2005) and endonuclease G (Li et al. 2001), which are released from the mitochondria in 
response to an apoptotic signal and translocate to the nucleus to trigger nuclear 
condensation and DNA fragmentation (Lorenzo and Susin 2004).  
 
Fig. 1. Intrinsic and Extrinsic pathways of apoptosis. The extrinsic pathway involves 
receptor-mediated caspase-8 activation with subsequent effector caspase-3 activation. 
Within the intrinsic apoptosis pathway, caspase-3 is activated after cytochrome c release 
from the mitochondria and the formation of complexes called apoptosome that consist of 
caspase-9, Apaf1, ATP and cytochrome C. The release of apoptogenic factors from the 
mitochondria, such as cytochrome c, is regulated by Bcl2 family proteins.  
2.3 Apoptosis in the limbic system after myocardial infarction  
Apoptosis has been observed in the limbic system after myocardial infarction (Wann et al. 
2006; Kaloustian et al. 2009). We have documented the presence of apoptotic cells in the 
limbic system mainly in the amygdala, 3 days after the onset of reperfusion whereas no 
substantial apoptosis was observed in the sham group. In presence of MI, amygdala 
presents an increase in the activity of caspase-3 as compared to the sham group, as well as 
a higher Bax/Bcl2 ratio and a significant number of TUNEL positive cells. In order to be 
more precise in the localization of the presence of apoptosis at 3 days post-MI, we 
evaluated the presence of apoptosis in 9 different regions of the brain, using the 
cerebellum as a control structure  (Wann et al. 2009): prefrontal and frontal cortices, CA1, 
CA3 and dentate gyrus of the hippocampus, lateral and medial amygdala and anterior 
and posterior hypothalamus. Our data indicate an increase of apoptosis in 7 of these 
regions (prefrontal and frontal cortices, CA1, dentate gyrus, lateral and medial amygdala 
and anterior hypothalamus). The next step of our investigation was to determine the 
kinetic of apoptosis in these regions during the first week after the onset of reperfusion 
(Kaloustian et al. 2008). Apoptosis was detected in the CA1 region as soon as 15 minutes 
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after the onset of reperfusion, followed 24 hours later by the medial amygdala. Seven days 
after the onset of reperfusion, the frontal cortex is the only region where apoptosis is 
present.  
As explained above, apoptosis can be triggered via intrinsic and extrinsic pathways. In a 
series of experiments designed to dissect the respective contribution of these two pathways, 
we found that caspase-9 activity was increased as soon at 15 minutes after the onset of 
reperfusion in the CA1, indicating that the intrinsic pathway is rapidly activated in this 
region (Rondeau et al. 2011).  This result can be explain by the sensitivity of this region to 
hypoxia (Sugawara et al. 1999) which can be induced by MI. However at the same moment, 
the dentate gyrus presents an activation of caspase-8, (extrinsic pathway) but no activation 
of caspase-9 or caspase-3, indicating that: 1) intrinsic pathway is not activated in this region; 
2) apoptosis is beginning in dentate gyrus at this moment. At three days post-MI, caspase-3 
and -8 are activated in the hippocampus and amygdala regions. Overall, these data indicate 
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2.4 Cytokines, depression and post-myocardial infarction 
Since the extrinsic mechanism of apoptosis is activated in the limbic system after MI and 
because apoptosis can be attenuated by pentoxifylline (Wann et al. 2006), an inhibitor of 
cytokine synthesis, we hypothesized that pro-inflammatory cytokines could be involved in 
the pathophysiology of post-MI depression. The following paragraphs summarize some of 
the supporting evidence. 
Cytokines are a heterogeneous group of short-acting soluble proteins, glycoproteins and 
peptides. These regulatory proteins are secreted by a variety of cell types including white 
blood cells (lymphocytes and monocytes or macrophages) and somatic cells (O'Brien et al. 
2004). Cytokines are multipotent and have pleiotropic effects not only in the immune system 
but also the CNS (Oprica et al. 2005); they contribute to immune responses of the body, help 
maintaining homeostasis, and mediate inflammation. Cytokines are associated with the 
membrane or the extracellular matrix, and toggle between the soluble and membrane forms 
(Sprague and Khalil 2009). Different cell types can secrete the same cytokine and a single 
cytokine can act on several cell types (pleiotropy), producing multiple biological activities 
depending on cell type, time and context (Hirano 1999) or inducing the synthesis of 
additional cytokines. Cytokines are redundant in their activity, meaning that similar 
functions might be stimulated by different cytokines (Ozaki and Leonard 2002). Because of 
the redundancy, the pathophysiological role of cytokines may be difficult to assess. In 
addition, cytokines are often produced in a cascade of events engaged in diverse modes of 
action: autocrine (when acting on cells that secrete), paracrine (when acting on cells near  
those that secrete) and endocrine (when acting on cells far from those that secrete) (Sprague 
and Khalil 2009). Cytokines can also act synergistically (two or more cytokines acting 
together) or antagonistically (cytokines causing opposing activities). 
Cytokines bind to specific receptors at picomolar to nanomolar concentrations to activate 
and modulate functions at the cellular and tissular levels. Cytokine receptors are present in 
different structures of the limbic system. For example, IL-1 receptors are found in the 
hypothalamus and the hippocampus; IL-6 receptors are located in the hippocampus, 
hypothalamus, the dentate gyrus and piriform cortex (Vitkovic et al. 2000); TNF receptors 
are located in the hippocampus, cortex, amygdala, the basal ganglia (Vitkovic et al. 2000) 
and are also expressed by oligodendrocytes (Tchelingerian et al. 1995). 
Recent advances in the field of psychoneuroimmunology suggest that major depression may 
alter immune function. Conversely, abnormal immune system may play a role in the 
etiology of depression (Maes et al. 1993). The immune system function in depressed patients 
involves both the hyperactivity of pro-inflammatory cytokines and anti-inflammatory 
cytokines (Grippo and Johnson 2002).  
The administration of endotoxins in humans increases serum levels of pro-inflammatory 
cytokines and induces anxiety, mood changes and decreased memory skills, (Reichenberg et 
al. 2001). In rodents, pro-inflammatory cytokines induce the so-called "sickness behavior", 
which includes aspects of depression such decreased appetite, weight loss, fatigue, loss of 
libido, sleep disturbances and reduced social contacts (Krueger et al. 1984; Yirmiya et al. 
2000; Dantzer 2001). In humans, the direct administration of pro-inflammatory cytokines 
such as TNF- (Spriggs et al. 1988), IFN-(Niiranen et al. 1988) and IL-1  (Cunningham and 
De Souza 1993) leads to symptoms of depression such as irritability, fatigue, lethargy, loss of 
appetite psychomotor retardation and sleep disturbances. In patients with depression, the 
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activation of the immune system translates into an augmentation in the number of 
circulating lymphocytes and phagocytic cells, immune cells by-products such as 
prostaglandin E2, complement proteins and increased concentrations of pro-inflammatory 
cytokines (Maes 1995; Irwin, Mak et al. 1999; Maes 1999; Maes, Song et al. 1999; Nunes, 
Reiche et al. 2002; Zorrilla, Valdez et al. 2001; Tuglu, Kara et al. 2003; (Maes 1995; Zorrilla et 
al. 2001; O'Brien et al. 2004). 
Another potential action of the pro-inflammatory cytokines that may contribute to 
depression is by an action on indoleamine 2,3-dioxygenase (IDO) (Wirleitner et al. 2003). 
IDO is an enzyme induced by pro-inflammatory cytokines (IL-1, IFN- and TNF-) and that 
is involved in the catabolism of tryptophan, the precursor of serotonin (Russo et al. 2003; 
Wirleitner et al. 2003). The net result is a reduced synthesis and availability of serotonin in 
the brain, thus facilitating depression (Heyes et al. 1992; Wichers and Maes 2002). 
Blocking cytokine synthesis with PTX (Wann et al. 2006) or, more recently, with a TNF- 
blocker (Kaloustian et al. 2009) significantly reduced apoptosis in the limbic system. The 
presence of pro-inflammatory cytokines at the limbic level can be explained by different 
mechanisms. The first possibility refers to modifications in endothelial permeability. Indeed, 
it has been reported that TNF- disrupts endothelial cell lining integrity in various organs, 
including the anterior cingulate gyrus (Worrall et al. 1997). The pattern of selective plasma 
protein extravasation induced by TNF- injection is similar to the pattern of MI-induced 
leakage (ter Horst et al. 1997). A second possibility is that circulating pro-inflammatory 
cytokines trigger the transcription of genes in cells of the blood-brain barrier, including NF-
kB and cyclooxygenase-2 (COX-2), the limiting enzyme for the formation of prostaglandins 
(Laflamme and Rivest 1999). Prostaglandins, such as PGE2, can diffuse across the brain 
parenchyma and stimulate the hypothalamic-pituitary-adrenal axis and corticotropin-
releasing-factor activity (Rivest 2001; Banan et al. 2002). Moreover, it has been reported that 
COX-2 expression is associated with increased PGE2 tissue levels and neuronal apoptosis (Li 
et al. 2003; Sasaki et al. 2004). In another study, PGE2 induced caspase-dependent apoptosis 
in rat cortical cells (Takadera et al. 2002). Our results (Wann et al. 2006) show biochemical 
changes in the hippocampus and amygdala, limbic regions that express high levels of PGE2 
receptors. This suggested that COX-2 inhibition can be a significant element in our model 
(Zhang and Rivest 1999). A third possibility is the presence of a carrier that mediates the 
transport of cytokines into the brain across the blood-brain barrier (Banks et al. 1995; 
Kronfol and Remick 2000; Banks 2001). The fourth possibility refers to "central cytokines 
induced by peripheral cytokines" via afferent nerves activated by myocardial ischemia 
(Francis et al. 2004). It was derived from the fact that cytokines are relatively large protein 
molecules (≈15 kDa for interleukin-1 (IL-1) and TNF-), the hydrophilic nature of which 
does not allow crossing of the blood-brain barrier. According to these authors, transmission 
of the cytokine signal to the brain could be due to epicardial afferences, since destruction of 
these nerves by phenol prevents the induction of brain cytokine expression in the 
hypothalamus and hippocampus (Layé et al. 1995; Hansen et al. 1998; Francis et al. 2004). 
Among these different hypotheses, we believe that neurotransmission, via afferent nerves, is 
probably the more interesting: 1. we observed apoptosis, via activation of the caspase-8 
pathway (extrinsic pathway) as early as after 15 min of reperfusion in some specific regions 
of the limbic system (dentate gyrus); 2.  pro-inflammatory cytokines increased in the brain 
as early as 30 min after the onset of myocardial ischemia, but could be blocked by the 
destruction of afferent epicardial nerves with phenol (Francis et al. 2004). 
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2.5 Hypothalamic-pituitary adrenal axis-dependent mechanism 
The regulation of the hypothalamic-pituitary adrenal (HPA) axis plays a major role in 
metabolic homeostasis and its overactivation by stress is associated with deleterious effects 
to the brain (Bluthe et al. 1999; Bluthe et al. 2006). Dysregulation of the HPA axis is part of 
the pathophysiology of depression.  
The classic description of the HPA axis includes 3 main components (Bao et al. 2008): 1) The 
hypothalamus, that secretes the corticotropin-releasing hormone (CRH) upon a stressful 
situation; 2) the pituitary gland that reacts to CRH by producing growth hormone, prolactin 
and the adrenocorticotropic hormone (ACTH); 3) the adrenal glands (also named suprarenal 
glands), that react to ACTH by producing and releasing glucocorticoid (GC), mainly cortisol 
in humans and corticosterone in rodents (Carvalho and Pariante 2008), epinephrine and 
norepinephrine. A feedback loop makes the hypothalamus capable of monitoring cortisol 
blood levels and inhibits the release of CRH when cortisol levels are too high; in depression, 
this feedback mechanism may be altered so that CRH is still released despite high amounts of 
circulating cortisol (Pariante and Lightman 2008). Cortisol activates two types of receptors, the 
high-affinity mineralocorticoid receptors (MRs) and the low affinity glucocorticoid receptors 
(GRs); MRs are thus activated by low (basal) levels of GC while GRs are activated as GC 
concentrations increase, i.e. after stress. MRs and GRs apparently activate different genes and 
elicit different, sometimes opposing, actions: high levels of corticosterone induce apoptosis 
through the activation of GRs via the direct regulation of the extrinsic and intrinsic apoptosis 
pathways while low doses of corticosterone can prevent cell death through MRs activation, 
conferring a neuroprotective role for these receptors (Crochemore et al. 2005; Herr et al. 2007; 
Krugers et al. 2007; Yu et al. 2008). More specifically, studies revealed that activation of the 
GRs mediates hippocampus neuron- and volume-reducing actions of GC whereas stimulation 
of the MRs abrogates the neurodegenerative actions of the GRs agonists (Yu et al. 2008). High 
levels of GC can affect the survival of immature neurons, decreasing neurogenesis in the 
dentate gyrus (Wong and Herbert 2004).  
Hyperactivity of the HPA leads to depression because dysregulation of GC can affect brain 
regions involved in the physiopathology of depression (Herbert et al. 2006). Activation of 
GRs by the agonist dexamethasone induces apoptotic death of neurons, while activation of 
MRs would tend to induce neuronal survival (Crochemore et al. 2005). The hypotheses to 
explain the effect of antidepressants on the HPA is that such treatment could increase the 
expression and the function of GRs, and promote its nuclear translocation (Pariante 2006). 
No effects of antidepressants on MRs are noted (Lai et al. 2003). The administration of 
tricyclic antidepressants or serotonin reuptake inhibitors (SSRIs) are accompanied by an 
increase in mRNA of GRs in various tissues and neurons (Pepin et al. 1989). Desipramine (a 
tricyclic antidepressant) showed an increase in function and nuclear translocation of GRs 
(Pariante et al. 1997). The tricyclic antidepressant imipramine and the SSRI fluoxetine inhibit 
the CRH gene promoter (Budziszewska et al. 2002). With effective antidepressant treatment, 
75% of patients who did not respond to the dexamethasone suppression test now do 
(Heuser et al. 1996), while remaining unresponsive often suffer a relapse (Zobel et al. 2001).  
We now know that growth hormone and prolactin stimulate the immune response while 
cortisol inhibits the immune response, the inflammatory response and natural killer cells 
(NKC). Depression is associated with an increase of secretion of IL-1, TNF- and IFN- 
(Smith 1991; Maes et al. 1993; Maes 1995). Hyperactivity of the HPA axis accompanies this 
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phenomenon (Connor and Leonard 1998) and, in turn, IL-1, IL-6, interferon and TNF 
activate the HPA axis (Turnbull and Rivier 1995).  
Cytokines are also released following MI and they will reach the paraventricular nucleus of 
the hypothalamus, stimulating the synthesis and secretion of stress-related glucocorticoids 
(Turnbull and Rivier 1995). Increased plasma levels of pro-inflammatory cytokines such as 
IL-1 and IL-6 in patients with depression are correlated with hyperactivity of the HPA axis 
and the severity of symptoms (Maes 1995; Maes 1999). 
The immune system can also influence the HPA axis response through various mechanisms 
involving pro-inflammatory cytokines: for example they may contribute to resistance to GC 
(cortisol unable to induce the negative feedback loop) by a decrease in GR function or 
sensitivity to GC (Miller et al. 1999) or inhibit GR translocation to the nucleus and decreases 
the transcription of genes induced by GR (Pariante et al. 1999). GC resistance following 
exposure to cytokines can be induced via the MAP kinase pathway: 1) ERK and JNK can 
inhibit GR function directly, by phosphorylation, or indirectly, through cofactors (Rogatsky 
et al. 1998); 2) NF-kB can directly interact with GR at the nuclear level or may decrease its 
function indirectly by competing for the same coactivators (McKay and Cidlowski 1999). 
Cytokines also activate the JAK-STAT pathway, which can GR functions by a direct protein-
protein interaction (Rogatsky and Ivashkiv 2006; Pace and Miller 2009).  
We have measured the level of corticosterone in our model, 2 weeks post-MI and we have 
observed that myocardial infarction induces an increase in plasmatic concentrations of 
corticosterone. However, the contribution of HPA axis in our model seems to be modest since 
attenuation of the depressive behavior has been observed with Escitalopram whereas no 
significant effect was detected in the plasmatic concentration of corticosterone (Bah et al. 2011). 
2.6 Neurotrophic factors in depression 
The reduction of hippocampal volume in depression is related to a dysregulation of 
neurogenic and neurotrophic factors (Duman and Monteggia 2006). The chronic 
administration of antidepressants increases neurotrophic factors and facilitates neurogenesis 
in the hippocampus, thus reducing the damage described above (Dranovsky and Hen 2006). 
The brain-derived neurotrophic factor (BDNF) is more particularly frequently cited as 
playing a significant role in that respect. 
BDNF belongs to the family of Nerve Growth Factors (NGF). Physiologically, neurotrophins 
are initially synthesized as precursor protein (or pro-neurotrophin) and transformed into 
mature proteins (Mowla et al. 2001). All neurotrophins have a common structure and a 
structure variable that determines their specific receptors and their biological action arising 
(Heumann 1994).  
BDNF mRNA is expressed in the hippocampus, septum, hypothalamus, cortex and 
noradrenergic brainstem nuclei (Castren et al. 1995; Katoh-Semba et al. 1997). This 
distribution overlaps with immunohistochemical localization of BDNF itself in the rat 
cerebral cortex, hippocampus, basal forebrain, striatum, hypothalamus, cerebellum 
(Kawamoto et al. 1996) as well as in the parietal and entorhinal cortices, amygdala and in 
the somatic nuclei (Wetmore et al. 1991). 
BDNF is decreased in patients with depression (Karege et al. 2002) and antidepressants regulate 
the transcription of its mRNA (Dias et al. 2003). Moreover, the chronic administration of 
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antidepressants increases BDNF in the limbic system, including the hippocampus (Nibuya et al. 
1999). The mRNA expression of TrkB, the BDNF receptor, is altered in the rat hippocampus or 
cortex after repeated stress (Nibuya et al. 1999) and after treatment with antidepressants 
(Saarelainen et al. 2003).  Impaired BDNF or TrkB signaling in rats does not lead to behavioral 
signs of depression, but lessened the behavioral response to antidepressants (Saarelainen et al. 
2003). In addition, increased neurogenesis in the hippocampus is required to find behavioral 
effects of antidepressants in animal models of depression (Santarelli et al. 2003).  
In our rat model of post-MI depression, BDNF levels were found to be increased in the 
dentate gyrus of the hippocampus 2 days post-MI and in the medial amygdala 7 days post-
MI, suggesting a potential role of BDNF in this model (Kaloustian et al. 2008). 
3. Behavior observed in experimental model of post-MI depression 
One of the major challenges in developing a model of a mental health disorder is at the 
behavioral level, trying to establish variables that mimic the clinical picture found in 
humans. In the particular case of post-MI depression, the challenge is increased by the fact 
that physical fitness should not interfere with the behavioral dependant variables. The major 
concern is that the damage induced to the heart by the ischemia may affect the performance 
of the animals and, with these constraints in mind, we elected to use an acute model of heart 
infarct, thus by-passing the physical impact of chronic heart failure. Moreover, since 
experimental acute MI involves thoracotomy, sham operated rats are used as controls and 
tasks involving physical fitness are tested. In our model, reperfusion is rapidly reinstated 
and the surgical procedure can be summarized as follows. A left thoracotomy is performed 
and the left anterior descending coronary artery is occluded. Ischemia is confirmed by ST 
segment alterations and ventricular subepicardial cyanosis. After 40 min of occlusion, the 
ligature is loosened so that the myocardial tissue can be reperfused. Reperfusion is 
confirmed by the disappearance of cyanosis. This procedure induces an infarct size that 
routinely approximates 25% of the left ventricle. A control (sham-operated) group of rats is 
submitted to the same thoracotomy protocol but without actual coronary artery occlusion.  
Behavioral tests that we have chosen were selected on the basis of face validity with regards 
to the human clinical picture and proven to be reliable and sensitive to antidepressant 
treatments as shown by previously published results from other groups using different 
models of depression.  In the present model, this is a rather long process that has started less 
than 10 years ago and will obviously need a few more years before it is firmly established. 
Nonetheless, we believe we have accumulated enough converging evidence to suggest that 
our model replicates a significant portion of the human post-MI depressive syndrome. In the 
following paragraphs we will describe behavioral tasks that are commonly used in 
behavioral models of depression and that were included in the test battery for our own post-
MI depression model. Like most models of depression, the post-MI syndrome appears 2-3 
weeks after the experimental procedure aimed at inducing depression and tests are now 
routinely administered in that interval following reperfusion.  
3.1 Forced swim test 
This test was first developed by Porsolt (Porsolt et al. 1977; Porsolt et al. 1978a; Porsolt et al. 
1978b) as a procedure for validating antidepressant efficacy. It models behavioral despair 
and learned helplessness, as rats are natural swimmer. In our experiments, rats are 
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individually placed in a clear plastic cylindrical pool (45 cm tall x 25 cm diameter) filled 
with 30 cm of water maintained at 22-25°C. Rats are tested for two consecutive days (15 min. 
on the first day and 5 min. on second day). Time spent swimming, trying to escape and 
being immobile on day 15 post surgery are the dependant variables. During the initial 
period of this test, rats will usually present an intense activity followed by a characteristic 
immobile posture, moving occasionally to keep at least their nose above the waterline. 
Depression has been positively correlated with the length of immobility during the second 
trial on the test. The Forced swim test has a good predictive validity to detect antidepressant-
like activity (Arunrut et al. 2009). Antidepressants usually decrease immobility. 
In our model, we observe that 14 days after the onset of reperfusion, the animals with MI 
present more immobility than the group of sham-operated control animals (figure 3A). This 
effect can be reversed by different interventions, as we will discuss later. We also 
determined if the myocardial infarct size influenced the behavioral results. Plotting 
swimming time against MI size, expressed as percent of the left ventricle, showed no 
relation between the two variables (figure 3B). This is further evidence that infarct size 
observed in our model had no influence on motor performance in the Forced Swim test.  
 
Fig. 3. A: Performance of rats in the forced swim test. Escape and swimming time is similar 
between groups whereas the time of immobility is significantly higher in the MI group. * 
indicates p < 0.05. n=16-18 per group. B: Relationship between infarct size (expressed as the 
proportion of infarcted tissue in the left ventricle) and immobility time in the forced swim 
test. The slope of the relationship is non-significant, p = 0.44 with a r2 = 0.02. 
3.2 Morris water maze 
This is a test of motor performance and spatial memory requiring an intact hippocampus 
(Morris 1984). Rats are placed in a pool (150 cm diameter, 50 cm deep) filled to 25 cm with 
water maintained at 22°C–25°C and made opaque with powder milk. A submerged 
platform is placed just below the surface of the water. The rats are tested on 4 trials each 
day, 5 minutes apart, for 6 consecutive days (i.e., 14–19 days after surgery). The number of 
quadrants crossed, the number of successful trials and the time taken to reach the platform 
are recorded. Our results indicate no significant difference between MI and sham group, 
suggesting that MI: a) has no effects on hippocampus-dependant spatial memory; b) has no 
effects on the swimming capacity of experimental rats (Wann et al. 2007). 
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individually placed in a clear plastic cylindrical pool (45 cm tall x 25 cm diameter) filled 
with 30 cm of water maintained at 22-25°C. Rats are tested for two consecutive days (15 min. 
on the first day and 5 min. on second day). Time spent swimming, trying to escape and 
being immobile on day 15 post surgery are the dependant variables. During the initial 
period of this test, rats will usually present an intense activity followed by a characteristic 
immobile posture, moving occasionally to keep at least their nose above the waterline. 
Depression has been positively correlated with the length of immobility during the second 
trial on the test. The Forced swim test has a good predictive validity to detect antidepressant-
like activity (Arunrut et al. 2009). Antidepressants usually decrease immobility. 
In our model, we observe that 14 days after the onset of reperfusion, the animals with MI 
present more immobility than the group of sham-operated control animals (figure 3A). This 
effect can be reversed by different interventions, as we will discuss later. We also 
determined if the myocardial infarct size influenced the behavioral results. Plotting 
swimming time against MI size, expressed as percent of the left ventricle, showed no 
relation between the two variables (figure 3B). This is further evidence that infarct size 
observed in our model had no influence on motor performance in the Forced Swim test.  
 
Fig. 3. A: Performance of rats in the forced swim test. Escape and swimming time is similar 
between groups whereas the time of immobility is significantly higher in the MI group. * 
indicates p < 0.05. n=16-18 per group. B: Relationship between infarct size (expressed as the 
proportion of infarcted tissue in the left ventricle) and immobility time in the forced swim 
test. The slope of the relationship is non-significant, p = 0.44 with a r2 = 0.02. 
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250 ml bottles for five consecutive days (i.e., 14-18 days postsurgery): one containing tap water 
and the other containing a 1% sucrose solution. The position of the bottles is alternated each 
day. Volume intake (in ml) is estimated by weighing bottles each morning, at light onset. 
Contrary to most publication, rats are not deprived of water before running the test because 
we fear it might interfere with bodily functions. Anhedonia is operationally defined as a 
reduction in sucrose intake compared to a control group and untreated MI rats are found to 
take less sucrose solution than sham animals. In this case, it can be assumed that the physical 
condition of the animal has no significant effects on the results.  
3.4 Social interaction test 
It is known that depressed individuals have fewer interactions with congeners. In this test, 
two rats are placed together in a new, clean shoebox for 10 min. During this period, the 
following measures are taken for each of the two rats: duration and number of interactions 
with the other rat, number of grooming events and number of rearings. Sham rats are found 
to interact more with congeners than MI rats (figure 4). 
 
Fig. 4. Social interaction test. The data indicate that MI rats interact less than the sham group 
with their congeners.  Time is expressed in seconds. n = 16 per group. *indicates p < 0.05 for 
Sham vs MI. 
3.5 Passive avoidance step-down foot shock 
This test is based on contextual memory and emotional memory, and depressed rats are 
known to show a decreased efficiency in response to a repeated aversive stimulus. It is a 
reliable behavioral indicator of depression in rats and it is also sensitive to the therapeutic 
action of antidepressants (Joly and Sanger 1986; van Riezen and Leonard 1991). For this test, 
the rat is placed on a plexiglass platform (14 X 19 cm). An electrifiable grid (14 X 14 cm) is 
alongside and 2.5 cm lower than the plexiglass platform. Initially, both sham and MI rats 
begin to wander around immediately, exploring the platform and the grid. When the animal 
places four feet on the electrifiable grid, it receives a mild, brief shock (5 mA for 1 sec) and is 
removed from the test box. After 30 sec, the rat is placed again on the platform. If the rat 
remains on the platform without going onto the grid for one minute, it is removed from the 
test box for 30 sec. Criterion is reached when the rat avoids going onto the grid for three 
consecutive trials. We have found that the number of trials and the time to succeed the test 
is significant higher in the MI rats compared to sham animals (figure 5).  
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Fig. 5. Passive avoidance step-down foot shock test. In the passive avoidance step-down foot 
shock test, MI rats take more time to succeed in the test than the sham group (*p < 0.05).  
n = 16 per group. 
3.6 Voluntary exercise-training cage 
As an additional test to determine if MI affects the physical condition of experimental animals 
at baseline, we used a voluntary exercise-training cage (threadmills), using the distance 
travelled by 24 hours as the dependent variable. Measures were taken before and 2 weeks 
post-MI and the results indicate no differences between tests, i.e., more than 2 km/day (figure 
6). Moreover the distance travelled at different moments of the day is similar between the two 
conditions. These results suggest that: 1) MI does not interfere with total spontaneous 
locomotion per 24 hour; 2) that circadian patterns may not be affected either. 
 
Fig. 6. Distance in km travelled by rats during a day in voluntary exercise-training cage. 
Open circles represented the distance travelled by the rats 2 weeks after the thoracotomy but 
without myocardial ischemia. The square represents the distance travelled by MI rats, 2 
weeks post-MI whereas the triangle represented the same MI rats but before any 
manipulations. No significant difference are observed between conditions. 
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3.7 Sleep 
In humans, depression is accompanied by sleep disorders, including difficulties initiating 
and maintaining sleep, less slow-wave sleep (SWS) together with a facilitation of rapid eye 
movement (REM) sleep, also known as paradoxical sleep (PS) (Benca et al. 1992). These sleep 
disorders have also been documented in rat models of depression, such as learned 
helplessness (Adrien et al. 1991), chronic, mild stress (Willner 2005), olfactory bulbectomy 
(Song and Leonard 2005), Flinders Sensitive Line (Overstreet et al. 2005), and the neonatal 
clomipramine model of endogenous depression (Vogel et al. 1990). Compared to sham rats, 
MI rats displayed a longer latency to sleep onset and to PS and fewer minutes in PS. The 
number of cholinergic neurons in the pedunculo-pontine tegmentum (PPT) area of MI rats, 
an area known to control PS, was decreased by 20% compared to sham rats while the 
number of latero-dorsal tegmentum (LDT) cholinergic neurons was not different (Bah et al. 
2010).  
These results partially replicate the sleep disorders observed in clinical depression and 
reveal that acute MI is accompanied, within 2 weeks, by PS-specific insomnia. 
4. Treatment of post-MI depression 
The pathophysiology of depression has been classically associated with monoamines, with 
more emphasis on serotonin (Leonard 2000; Delgado 2004): impaired serotoninergic 
neurotransmission is thought to be a major element in the pathophysiology of depression 
and SSRI antidepressants restore central serotoninergic neurotransmission. Monoaminergic 
theories of depression appear today, however, to be only one part of the story. It is known, 
for example, that pro-inflammatory cytokines influence serotonin metabolism in the central 
nervous system (Dunn 1992; Palazzolo and Quadri 1992; Cho et al. 1999) and studies have 
shown that antidepressants suppress the action of pro-inflammatory cytokines (Bengtsson et 
al. 1992; Xia et al. 1996). Moreover, pro-inflammatory cytokines such as IL-1, IFN-α, IFN-γ 
and TNF- upregulate the serotonin transporter, thus causing a depletion of extracellular 
serotonin (Ramamoorthy et al. 1995; Morikawa et al. 1998; Mossner et al. 1998; Wichers and 
Maes 2002), whereas IL-4 (an anti-inflammatory cytokine) induces a reduction of serotonin 
reuptake like antidepressants do (Mossner et al. 2001; O'Brien et al. 2004). It is therefore not 
surprising that inhibition of pro-inflammatory cytokines is not only beneficial for the 
remission of depressive symptoms, but also to reduce the inflammation caused by 
myocardial infarction (Frangogiannis et al. 2002). 
In animal models, administration of cytokines or cytokine inducers is associated with 
depressive symptoms (Dunn et al. 2005). Conversely, the administration of anti-
inflammatory cytokines such as IGF-1 or IL-10 antagonizes the effects of cytokine inducers 
and lowers the symptoms of depression (Bluthe et al. 1999; Bluthe et al. 2006). Patients with 
depression have high levels of circulating inflammatory cytokines, including IL-1, IL-6 and 
TNF- (Dowlati et al. 2009), and low levels of anti-inflammatory cytokines (Sutcigil et al. 
2007). Despite the fact that small amounts of peripherally-released pro-inflammatory 
cytokines make it to the brain, it seems sufficient to induce depression in humans (Wilson 
and Warise 2008). It has been shown in patients with Cushing's syndrome that infliximab, a 
TNF- inhibitor, reduces symptoms of depression before improving disease-specific 
symptoms (Lichtenstein et al. 2002).  
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The following paragraphs will review therapeutic strategies we have used in order to 
control for symptoms of depression in our animal model.  
4.1.1 Tricyclic antidepressant (desipramine) 
Desipramine is a tricyclic molecule that inhibits norepinephrine and serotonin reuptake, 
together with antidepressant properties (Katz et al. 2004). In our model, desipramine also 
reduces depressive-like symptoms such as behavioral despair as assessed by the Forced swim 
test as well as anhedonia as assessed by the Sucrose preference test. Interestingly, desipramine 
reduces apoptosis in models of stress-induced depressive disorders (Bachis et al. 2008) and we 
have found a significant negative correlation between swimming time on the Forced swim test 
and the Bax/Bcl2 ratio, a pro-apoptotic index, in the prefrontal cortex of MI depressed rats, 
suggesting again  a link between apoptosis and depressive behavior (Wann et al. 2007). 
4.1.2 Selective serotonin reuptake inhibitors (SSRIs) 
4.1.2.1 Sertraline 
The antidepressant SSRI fluoxetine inhibits apoptosis by blocking mitochondrial 
permeability transition pores (Nahon, et al., 2005) in vitro and we have shown that sertraline 
blocks post-MI apoptosis in vivo at three days post-MI, in different regions of the limbic 
system (Wann et al. 2009). At the behavioral level, MI rats showing signs of anhedonia (i.e., 
decreased sucrose intake) and despair (decreased swimming, increased immobility) 
improved with sertraline as they do in other models like chronic mild stress (Grippo, et al., 
2006), social defeat or subordination (Rygula, et al., 2005).  
4.1.2.2 Escitalopram 
Escitalopram, an enantiomer of citalopram, is another SSRI antidepressant (Wu et al. 2009; 
Pan et al. 2011). In our model, we observed that escitalopram reduces the levels of pro-
inflammatory cytokines (see above) and attenuates depressive-like behavior in MI rats 
without modifying their sleep (Bah et al., 2011). 
These results with antidepressants together with the evidence cited in the previous sections 
suggest that cytokines and apoptosis could involve in the pathophysiology of depression, 
including after a MI. 
4.2 Pentoxifylline  
Pentoxifylline (PTX), a methylxantine-derivative and non-specific phosphodiesterase inhibitor 
with combined anti-inflammatory and anti-fibrogenic properties (Gutierrez-Reyes et al. 2006; 
Danjo et al. 2008), lowers circulating pro-inflammatory cytokines such as TNF-, IL-1 and IL-
6 (Raetsch et al. 2002), via a cyclic adenosine monophosphate (cAMP)-dependent mechanism. 
Systemically administered PTX in MI rats reduce apoptosis in the limbic system at three days 
post-MI (Wann et al. 2006) and attenuates depressive-like behavior at 14 day, indicating the 
importance of pro-inflammatory cytokines in both events (Bah et al., 2011b).  
4.3 Nutritional interventions 
A loss of equilibrium between pro-and anti-inflammatory proteins could be involved in the 
pathophysiology of depression (Szelenyi and Vizi 2007). Our previous work has shown that 
 
Novel Strategies in Ischemic Heart Disease 348 
The following paragraphs will review therapeutic strategies we have used in order to 
control for symptoms of depression in our animal model.  
4.1.1 Tricyclic antidepressant (desipramine) 
Desipramine is a tricyclic molecule that inhibits norepinephrine and serotonin reuptake, 
together with antidepressant properties (Katz et al. 2004). In our model, desipramine also 
reduces depressive-like symptoms such as behavioral despair as assessed by the Forced swim 
test as well as anhedonia as assessed by the Sucrose preference test. Interestingly, desipramine 
reduces apoptosis in models of stress-induced depressive disorders (Bachis et al. 2008) and we 
have found a significant negative correlation between swimming time on the Forced swim test 
and the Bax/Bcl2 ratio, a pro-apoptotic index, in the prefrontal cortex of MI depressed rats, 
suggesting again  a link between apoptosis and depressive behavior (Wann et al. 2007). 
4.1.2 Selective serotonin reuptake inhibitors (SSRIs) 
4.1.2.1 Sertraline 
The antidepressant SSRI fluoxetine inhibits apoptosis by blocking mitochondrial 
permeability transition pores (Nahon, et al., 2005) in vitro and we have shown that sertraline 
blocks post-MI apoptosis in vivo at three days post-MI, in different regions of the limbic 
system (Wann et al. 2009). At the behavioral level, MI rats showing signs of anhedonia (i.e., 
decreased sucrose intake) and despair (decreased swimming, increased immobility) 
improved with sertraline as they do in other models like chronic mild stress (Grippo, et al., 
2006), social defeat or subordination (Rygula, et al., 2005).  
4.1.2.2 Escitalopram 
Escitalopram, an enantiomer of citalopram, is another SSRI antidepressant (Wu et al. 2009; 
Pan et al. 2011). In our model, we observed that escitalopram reduces the levels of pro-
inflammatory cytokines (see above) and attenuates depressive-like behavior in MI rats 
without modifying their sleep (Bah et al., 2011). 
These results with antidepressants together with the evidence cited in the previous sections 
suggest that cytokines and apoptosis could involve in the pathophysiology of depression, 
including after a MI. 
4.2 Pentoxifylline  
Pentoxifylline (PTX), a methylxantine-derivative and non-specific phosphodiesterase inhibitor 
with combined anti-inflammatory and anti-fibrogenic properties (Gutierrez-Reyes et al. 2006; 
Danjo et al. 2008), lowers circulating pro-inflammatory cytokines such as TNF-, IL-1 and IL-
6 (Raetsch et al. 2002), via a cyclic adenosine monophosphate (cAMP)-dependent mechanism. 
Systemically administered PTX in MI rats reduce apoptosis in the limbic system at three days 
post-MI (Wann et al. 2006) and attenuates depressive-like behavior at 14 day, indicating the 
importance of pro-inflammatory cytokines in both events (Bah et al., 2011b).  
4.3 Nutritional interventions 
A loss of equilibrium between pro-and anti-inflammatory proteins could be involved in the 
pathophysiology of depression (Szelenyi and Vizi 2007). Our previous work has shown that 
 
Post-Myocardial Infarction Depression 349 
a reduction of circulating pro-inflammatory cytokines attenuates post-MI depressive-like 
behavior. Since diet can be used to modify the balance between pro- and anti-inflammatory 
cytokines, we hypothesized that targeted diets could attenuate post-MI depression.  
4.3.1 Probiotics 
The probiotics Lactobacillus helveticus and Bifidobacterium longum can reverse MI-induced 
apoptosis in the limbic system  (Girard et al. 2009) by a mechanism that could include a 
reduction of pro-inflammatory cytokines. It has been observed that of L. helveticus R0052 
reduces IL-1, IL-6 but not significantly TNF-(Cazzola et al. 2010) whereas B. longum R0175 
can reduce IL-8 and TNF-(Wagar et al. 2009) indicating that each strain has a specific effect 
on pro-inflammatory cytokines synthesis while they possibly are ineffective against stress 
(Diop et al. 2008; Girard et al. 2009; Messaoudi et al.). We combined both strains and found 
significant therapeutic effects on post-MI behavior, including behavioral despair (Forced swim 
test), passive avoidance and socialization Arseneault-Bréard et al. 2011).  
4.3.2 Polyunsaturated fatty acids omega-3 
Polyunsaturated fatty acids (PUFA) omega-3 are found mostly in the retinal and neuronal 
membranes. The lack of adequate levels of PUFA omega-3, and more particularly DHA, 
during brain development results into cognitive deficits (McNamara and Carlson 2006). 
Altered membrane concentration of PUFA omega-3 is also observed in depression (Peet et 
al. 1998; Mamalakis et al. 2006). Moreover, a recent study by Lespérance et al (2011) 
observed a clear benefit of PUFA omega-3 supplementation among patients with a major 
depressive episode but without comorbid anxiety disorders. Another study found that 
PUFA omega-3 had a similar effect on depression as the SSRI antidepressant fluoxetine, 
while the combination (EPA and fluoxetine) resulted in a superior effect than either of them 
alone (Jazayeri et al. 2008). The influence of PUFA omega-3 on psychiatric disorders has 
yielded mechanistic hypotheses, one of which involves the anti-inflammatory properties of 
fatty acids, in accordance with the fact that increased cytokine levels are associated with 
depression (Orr and Bazinet 2008; Kiecolt-Glaser 2010). A second hypothesis, based on 
PUFA omega-3 depletion studies, involves a modulation of monoaminergic 
neurotransmission (Chalon 2006) since a profound PUFA omega-3 deficiency is able to alter 
several neurotransmission systems such as dopaminergic and serotonergic. PUFA omega-3 
may also improve depression via an anti-apoptotic neuroprotective mechanism. Indeed, 
DHA facilitates the activation and translocation of Akt, an anti-apoptotic protein (Akbar et 
al. 2005). Moreover, PUFA omega-3 induces the expression of the Bcl-2 anti-apoptotic 
protein and reduces the activation of caspase-3 (Bazan 2009; Sinha et al. 2009). In the more 
specific case of post-MI depression, it can be mentioned that omega-3 fatty acid levels were 
found to be lower in plasma and red blood cell membrane of depressed patients with acute 
coronary syndromes than non-depressed patients (Schins et al. 2007; Amin et al. 2008). Our 
own results show that an PUFA omega-3-rich diet reduces post-MI apoptosis in the limbic 
system (Rondeau et al. 2011) and depressive behavior (unpublished observations). 
5. Conclusions 
The data obtained over the last few years indicate that post-MI apoptosis occurs in the 
limbic system rapidly after the onset of reperfusion and our working hypothesis is that 
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increased cytokines levels in the CNS are involved. Whether neurogenesis or HPA axis 
plays a significant role in the picture of post-MI depression is not yet clearly established and 
needs to be further investigated. In Figure 7 we propose a model to explain the etiology and 
consequences of post-MI depression. It is our hope that converging evidence will eventually 
lead to a better knowledge of how the heart and brain connection operates to allow post-MI 
occurring and possibly show the way for effective treatment strategies. 
 
Fig. 7. Myocardial ischemia induces an increase in pro-inflammatory cytokines in the 
circulation and the limbic system. These cytokines may have access to brain via several 
routes (see text). Pro-inflammatory cytokines modulate different signaling pathways known 
to be involved in the development of depression including:  
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1. Presence of apoptosis and degenerating neurons; 
2. Altered metabolism of neurotransmitters; 
3. Reduction of neurogenesis by an action on BDNF. 
Stress acting on heart, intestine or brain tissue contributes to the augmentation of pro-
inflammatory cytokines by the activation of the NF-kB or the increase of the release 
norepinephrine.  
Activation of different kinases such as P38 or MAP kinase inhibit the function of 
glucocorticoid receptor, releasing NF-kB from negative regulation by glucocorticoids 
released as a result of the HPA axis in response to stress. 
PUFA-omega-3, PTX, escitalopram, probiotics reduce the circulating level of pro-
inflammatory cytokines and apoptosis in the limbic system. These treatments as well as 
sertraline and desipramine could also attenuate the depressive-like behavior observed after 
myocardial infarction. 
NE: Norepinephrine; DA: Dopamine; 5HT: Serotonin; BDNF: Brain-derived NEurotrophic 
Factor; CRH: corticotropin-releasing hormone; ACTH: adrenocorticotropic hormone; GR: 
Glucocorticoids receptor; AchR: Aceylcholine receptor, AR; A-adrenergic receptor; AR: b-
adrenergic receptor, PTX: Pentoxifylline 
6. References 
Adams, J. M. (2003). "Ways of dying: multiple pathways to apoptosis." Genes Dev 17(20): 
2481-2495. 
Adrien, J., C. Dugovic, et al. (1991). "Sleep-wakefulness patterns in the helpless rat." Physiol 
Behav 49(2): 257-262. 
Ahern, D. K., L. Gorkin, et al. (1990). "Biobehavioral variables and mortality or cardiac arrest 
in the Cardiac Arrhythmia Pilot Study (CAPS)." Am J Cardiol 66(1): 59-62. 
Akbar, M., F. Calderon, et al. (2005). "Docosahexaenoic acid: a positive modulator of Akt 
signaling in neuronal survival." Proc Natl Acad Sci U S A 102(31): 10858-10863. 
Amin, A. A., R. A. Menon, et al. (2008). "Acute coronary syndrome patients with depression 
have low blood cell membrane omega-3 fatty acid levels." Psychosom Med 70(8): 
856-862. 
Anda, R., D. Williamson, et al. (1993). "Depressed affect, hopelessness, and the risk of 
ischemic heart disease in a cohort of U.S. adults." Epidemiology 4(4): 285-294. 
Arseneault-Bréard, J., I. Rondeau, et al. (2011). "Combination of Lactobacillus helveticus 
R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction 
depression symptoms and restores intestinal permeability in a rat model." Br J 
Nutr: 1-7. 
Arunrut, T., H. Alejandre, et al. (2009). "Differential behavioral and neurochemical effects of 
exercise, reboxetine and citalopram with the forced swim test." Life Sci. 
Bachis, A., M. I. Cruz, et al. (2008). "Chronic unpredictable stress promotes neuronal 
apoptosis in the cerebral cortex." Neurosci Lett 442(2): 104-108. 
Bachis, A., A. Mallei, et al. (2008). "Chronic antidepressant treatments increase basic 
fibroblast growth factor and fibroblast growth factor-binding protein in neurons." 
Neuropharmacology. 
Bah, T. M., M. Benderdour, et al. (2011). "Escitalopram reduces circulating pro-inflammatory 
cytokines and improves depressive behavior without affecting sleep in a rat model 
of post-cardiac infarct depression." Behav Brain Res 225(1): 243-251. 
 
Novel Strategies in Ischemic Heart Disease 352 
Bah, T.M., F. Laplante,  B.P. Wann, R. Sullivan, G. Rousseau, R. Godbout (2010). 
"Paradoxical sleep insomnia and decreased cholinergic neurons after myocardial 
infarction in rats." Sleep 33(12): 1703-1710. 
Bah, T.M., S. Kaloustian, R. Godbout, G. Rousseau.(2011b). Pretreatment with 
pentoxifylline has antidepressant-like effects in a rat model of acute myocardial 
infarction. Behavioral Pharmacology 22(8): 779-784. 
Banan, A., L. Zhang, et al. (2002). "PKC-zeta prevents oxidant-induced iNOS upregulation 
and protects the microtubules and gut barrier integrity." Am J Physiol Gastrointest 
Liver Physiol 283(4): G909-922. 
Banks, W. A. (2001). "Anorectic effects of circulating cytokines: role of the vascular blood-
brain barrier." Nutrition 17(5): 434-437. 
Banks, W. A., A. J. Kastin, et al. (1995). "Passage of cytokines across the blood-brain barrier." 
Neuroimmunomodulation 2(4): 241-248. 
Bao, A. M., G. Meynen, et al. (2008). "The stress system in depression and 
neurodegeneration: focus on the human hypothalamus." Brain Res Rev 57(2): 531-
553. 
Barefoot, J. C. and M. Schroll (1996). "Symptoms of depression, acute myocardial infarction, 
and total mortality in a community sample." Circulation 93(11): 1976-1980. 
Bazan, N. G. (2009). "Cellular and molecular events mediated by docosahexaenoic acid-
derived neuroprotectin D1 signaling in photoreceptor cell survival and brain 
protection." Prostaglandins Leukot Essent Fatty Acids 81(2-3): 205-211. 
Benca, R. M., W. H. Obermeyer, et al. (1992). "Sleep and psychiatric disorders: A meta-
analysis." Arch. Gen. Psychiatry 49: 651-668. 
Bengtsson, B. O., J. Zhu, et al. (1992). "Effects of zimeldine and its metabolites, 
clomipramine, imipramine and maprotiline in experimental allergic neuritis in 
Lewis rats." J Neuroimmunol 39(1-2): 109-122. 
Bluthe, R. M., N. Castanon, et al. (1999). "Central injection of IL-10 antagonizes the 
behavioural effects of lipopolysaccharide in rats." Psychoneuroendocrinology 24(3): 
301-311. 
Bluthe, R. M., K. W. Kelley, et al. (2006). "Effects of insulin-like growth factor-I on cytokine-
induced sickness behavior in mice." Brain Behav Immun 20(1): 57-63. 
Bras, M., B. Queenan, et al. (2005). "Programmed cell death via mitochondria: different 
modes of dying." Biochemistry (Mosc) 70(2): 231-239. 
Budziszewska, B., L. Jaworska-Feil, et al. (2002). "Effect of antidepressant drugs on the 
human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells." 
Pol J Pharmacol 54(6): 711-716. 
Bürger, A., M. Benicke, et al. (2001). "Catecholamines stimulate IL-6 synthesis in rat cardiac 
fibroblasts." Am. J. Physiol. 281: H14-H21. 
Bush, D. E., R. C. Ziegelstein, et al. (2001). "Even minimal symptoms of depression increase 
mortality risk after acute myocardial infarction." Am J Cardiol 88(4): 337-341. 
Carvalho, L. A. and C. M. Pariante (2008). "In vitro modulation of the glucocorticoid 
receptor by antidepressants." Stress 11(6): 411-424. 
Castren, E., H. Thoenen, et al. (1995). "Brain-derived neurotrophic factor messenger RNA is 
expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of 
adult rat brain and is increased by osmotic stimulation in the paraventricular 
nucleus." Neuroscience 64(1): 71-80. 
 
Novel Strategies in Ischemic Heart Disease 352 
Bah, T.M., F. Laplante,  B.P. Wann, R. Sullivan, G. Rousseau, R. Godbout (2010). 
"Paradoxical sleep insomnia and decreased cholinergic neurons after myocardial 
infarction in rats." Sleep 33(12): 1703-1710. 
Bah, T.M., S. Kaloustian, R. Godbout, G. Rousseau.(2011b). Pretreatment with 
pentoxifylline has antidepressant-like effects in a rat model of acute myocardial 
infarction. Behavioral Pharmacology 22(8): 779-784. 
Banan, A., L. Zhang, et al. (2002). "PKC-zeta prevents oxidant-induced iNOS upregulation 
and protects the microtubules and gut barrier integrity." Am J Physiol Gastrointest 
Liver Physiol 283(4): G909-922. 
Banks, W. A. (2001). "Anorectic effects of circulating cytokines: role of the vascular blood-
brain barrier." Nutrition 17(5): 434-437. 
Banks, W. A., A. J. Kastin, et al. (1995). "Passage of cytokines across the blood-brain barrier." 
Neuroimmunomodulation 2(4): 241-248. 
Bao, A. M., G. Meynen, et al. (2008). "The stress system in depression and 
neurodegeneration: focus on the human hypothalamus." Brain Res Rev 57(2): 531-
553. 
Barefoot, J. C. and M. Schroll (1996). "Symptoms of depression, acute myocardial infarction, 
and total mortality in a community sample." Circulation 93(11): 1976-1980. 
Bazan, N. G. (2009). "Cellular and molecular events mediated by docosahexaenoic acid-
derived neuroprotectin D1 signaling in photoreceptor cell survival and brain 
protection." Prostaglandins Leukot Essent Fatty Acids 81(2-3): 205-211. 
Benca, R. M., W. H. Obermeyer, et al. (1992). "Sleep and psychiatric disorders: A meta-
analysis." Arch. Gen. Psychiatry 49: 651-668. 
Bengtsson, B. O., J. Zhu, et al. (1992). "Effects of zimeldine and its metabolites, 
clomipramine, imipramine and maprotiline in experimental allergic neuritis in 
Lewis rats." J Neuroimmunol 39(1-2): 109-122. 
Bluthe, R. M., N. Castanon, et al. (1999). "Central injection of IL-10 antagonizes the 
behavioural effects of lipopolysaccharide in rats." Psychoneuroendocrinology 24(3): 
301-311. 
Bluthe, R. M., K. W. Kelley, et al. (2006). "Effects of insulin-like growth factor-I on cytokine-
induced sickness behavior in mice." Brain Behav Immun 20(1): 57-63. 
Bras, M., B. Queenan, et al. (2005). "Programmed cell death via mitochondria: different 
modes of dying." Biochemistry (Mosc) 70(2): 231-239. 
Budziszewska, B., L. Jaworska-Feil, et al. (2002). "Effect of antidepressant drugs on the 
human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells." 
Pol J Pharmacol 54(6): 711-716. 
Bürger, A., M. Benicke, et al. (2001). "Catecholamines stimulate IL-6 synthesis in rat cardiac 
fibroblasts." Am. J. Physiol. 281: H14-H21. 
Bush, D. E., R. C. Ziegelstein, et al. (2001). "Even minimal symptoms of depression increase 
mortality risk after acute myocardial infarction." Am J Cardiol 88(4): 337-341. 
Carvalho, L. A. and C. M. Pariante (2008). "In vitro modulation of the glucocorticoid 
receptor by antidepressants." Stress 11(6): 411-424. 
Castren, E., H. Thoenen, et al. (1995). "Brain-derived neurotrophic factor messenger RNA is 
expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of 
adult rat brain and is increased by osmotic stimulation in the paraventricular 
nucleus." Neuroscience 64(1): 71-80. 
 
Post-Myocardial Infarction Depression 353 
Cazzola, M., T. A. Tompkins, et al. (2010). "Immunomodulatory impact of a synbiotic in 
T(h)1 and T(h)2 models of infection." Ther Adv Respir Dis 4(5): 259-270. 
Chalon, S. (2006). "Omega-3 fatty acids and monoamine neurotransmission." Prostaglandins 
Leukot Essent Fatty Acids 75(4-5): 259-269. 
Chatelain, P., J. Latour, et al. (1987). "Neutrophil accumulation in experimental myocardial 
infarcts: relation with extent of injury and effect of reperfusion." Circulation 75: 
1083-1090. 
Chinnaiyan, A. M., K. Orth, et al. (1996). "Molecular ordering of the cell death pathway: Bcl-
2 and Bcl-xL function upstream of the Ced-3 like apoptotic proteases." J. Biol. 
Chem. 271: 4573-4576. 
Cho, L., M. Tsunoda, et al. (1999). "Effects of endotoxin and tumor necrosis factor alpha on 
regional brain neurotransmitters in mice." Nat Toxins 7(5): 187-195. 
Connor, T. J. and B. E. Leonard (1998). "Depression, stress and immunological activation: the 
role of cytokines in depressive disorders." Life Sci 62(7): 583-606. 
Crochemore, C., J. Lu, et al. (2005). "Direct targeting of hippocampal neurons for apoptosis 
by glucocorticoids is reversible by mineralocorticoid receptor activation." Mol 
Psychiatry 10(8): 790-798. 
Cunningham, E. T., Jr. and E. B. De Souza (1993). "Interleukin 1 receptors in the brain and 
endocrine tissues." Immunol Today 14(4): 171-176. 
Czeh, B., T. Michaelis, et al. (2001). "Stress-induced changes in cerebral metabolites, 
hippocampal volume, and cell proliferation are prevented by antidepressant 
treatment with tianeptine." Proc Natl Acad Sci U S A 98(22): 12796-12801. 
Danjo, W., N. Fujimura, et al. (2008). "Effect of pentoxifylline on diaphragmatic contractility 
in septic rats." Acta Med Okayama 62(2): 101-107. 
Dantzer, R. (2001). "Cytokine-induced sickness behavior: mechanisms and implications." 
Ann. NY Acad. Sci 933: 222-234. 
de Lorgeril, M., G. Rousseau, et al. (1990). "Spacial and temporal profiles of neutrophil 
accumulation in the reperfused ischemic myocardium." Am J Cardiovasc Pathol 
3(2): 143-154. 
Delgado, P. L. (2004). "How antidepressants help depression: mechanisms of action and 
clinical response." J Clin Psychiatry 65 Suppl 4: 25-30. 
Deten, A., H. C. Volz, et al. (2003). "Effect of propanolol on cardiac cytokine expression after 
myocardial infarction in rats." Mol. Cell. Biochem. 251: 127-137. 
Deten, A. and H.-G. Zimmer (2002). "Heart function and cytokine expression is similar in 
mice and rats after myocardial infarction but differences occur in TNF 
expression." Pflugers Arch - Eur. J. Physiol. 445: 289-296. 
Dias, B. G., S. B. Banerjee, et al. (2003). "Differential regulation of brain derived neurotrophic 
factor transcripts by antidepressant treatments in the adult rat brain." 
Neuropharmacology 45(4): 553-563. 
Diop, L., S. Guillou, et al. (2008). "Probiotic food supplement reduces stress-induced 
gastrointestinal symptoms in volunteers: a double-blind, placebo-controlled, 
randomized trial." Nutrition Research 28: 1-5. 
Dowlati, Y., N. Herrmann, et al. (2009). "A Meta-Analysis of Cytokines in Major 
Depression." Biol Psychiatry. 
Dranovsky, A. and R. Hen (2006). "Hippocampal neurogenesis: regulation by stress and 
antidepressants." Biol Psychiatry 59(12): 1136-1143. 
 
Novel Strategies in Ischemic Heart Disease 354 
Drevets, W. C. (2000). "Neuroimaging studies of mood disorders: implication for a neural 
model of major depression." Biol. Psychiatry 48: 813-829. 
Duman, R. S. and L. M. Monteggia (2006). "A neurotrophic model for stress-related mood 
disorders." Biol Psychiatry 59(12): 1116-1127. 
Dunn, A. J. (1992). "Endotoxin-induced activation of cerebral catecholamine and serotonin 
metabolism: comparison with interleukin-1." J Pharmacol Exp Ther 261(3): 964-969. 
Dunn, A. J., A. H. Swiergiel, et al. (2005). "Cytokines as mediators of depression: what can 
we learn from animal studies?" Neurosci Biobehav Rev 29(4-5): 891-909. 
Ferketich, A. K., J. A. Schwartzbaum, et al. (2000). "Depression as an antecedent to heart 
disease among women and men in the NHANES I study. National Health and 
Nutrition Examination Survey." Arch Intern Med 160(9): 1261-1268. 
Fielding, R. (1991). "Depression and acute myocardial infarction: a review and 
reinterpretation." Soc Sci Med 32(9): 1017-1028. 
Forrester, A. W., J. R. Lipsey, et al. (1992). "Depression following myocardial infarction." Int J 
Psychiatry Med 22(1): 33-46. 
Francis, J., Y. Chu, et al. (2004). "Acute myocardial infarction induces hypothalamic cytokine 
synthesis." Am. J. Physiol. 286: H2264-H2271. 
Francis, J., Z.-H. Zhang, et al. (2004). "Neural regulation of the proinflammatory cytokine 
response to acute myocardial infarction." Am. J. Physiol. 287: H791-H797. 
Frangogiannis, N. G., C. W. Smith, et al. (2002). "The inflammatory response in myocardial 
infarction." Cardiovasc Res 53(1): 31-47. 
Frasure-Smith, N., F. Lespérance, et al. (1993). "Depression following myocardial infarction. 
Impact on 6-month survival." JAMA 270(15): 1819-1825. 
Frasure-Smith, N., F. Lespérance, et al. (1995). "The impact of negative emotions on 
prognosis following myocardial infarction: is it more than depression?" Health 
Psychol 14(5): 388-398. 
Freedland, K. E., P. J. Lustman, et al. (1992). "Underdiagnosis of depression in patients with 
coronary artery disease: the role of nonspecific symptoms." Int J Psychiatry Med 
22(3): 221-229. 
Girard, S. A., T. M. Bah, et al. (2009). "Lactobacillus helveticus and Bifidobacterium longum 
taken in combination reduce the apoptosis propensity in the limbic system after 
myocardial infarction in a rat model." Br J Nutr 102(10): 1420-1425. 
Glassman, A. H., S. P. Roose, et al. (1993). "The safety of tricyclic antidepressants in cardiac 
patients. Risk-benefit reconsidered." JAMA 269(20): 2673-2675. 
Gould, E. and P. Tanapat (1999). "Stress and hippocampal neurogenesis." Biol Psychiatry 
46(11): 1472-1479. 
Grippo, A. J. and A. K. Johnson (2002). "Biological mechanisms in the relationship between 
depression and heart disease." Neurosci Biobehav Rev 26(8): 941-962. 
Guck, T. P., M. G. Kavan, et al. (2001). "Assessment and treatment of depression following 
myocardial infarction." Am Fam Physician 64(4): 641-648. 
Gutierrez-Reyes, G., P. Lopez-Ortal, et al. (2006). "Effect of pentoxifylline on levels of pro-
inflammatory cytokines during chronic hepatitis C." Scand J Immunol 63(6): 461-
467. 
Gwechenberger, M., L. H. Mendoza, et al. (1999). "Cardiac myocytes produce interleukin-6 
in culture and in viable border zone of reperfused infarctions." Circulation 99: 546-
551. 
 
Novel Strategies in Ischemic Heart Disease 354 
Drevets, W. C. (2000). "Neuroimaging studies of mood disorders: implication for a neural 
model of major depression." Biol. Psychiatry 48: 813-829. 
Duman, R. S. and L. M. Monteggia (2006). "A neurotrophic model for stress-related mood 
disorders." Biol Psychiatry 59(12): 1116-1127. 
Dunn, A. J. (1992). "Endotoxin-induced activation of cerebral catecholamine and serotonin 
metabolism: comparison with interleukin-1." J Pharmacol Exp Ther 261(3): 964-969. 
Dunn, A. J., A. H. Swiergiel, et al. (2005). "Cytokines as mediators of depression: what can 
we learn from animal studies?" Neurosci Biobehav Rev 29(4-5): 891-909. 
Ferketich, A. K., J. A. Schwartzbaum, et al. (2000). "Depression as an antecedent to heart 
disease among women and men in the NHANES I study. National Health and 
Nutrition Examination Survey." Arch Intern Med 160(9): 1261-1268. 
Fielding, R. (1991). "Depression and acute myocardial infarction: a review and 
reinterpretation." Soc Sci Med 32(9): 1017-1028. 
Forrester, A. W., J. R. Lipsey, et al. (1992). "Depression following myocardial infarction." Int J 
Psychiatry Med 22(1): 33-46. 
Francis, J., Y. Chu, et al. (2004). "Acute myocardial infarction induces hypothalamic cytokine 
synthesis." Am. J. Physiol. 286: H2264-H2271. 
Francis, J., Z.-H. Zhang, et al. (2004). "Neural regulation of the proinflammatory cytokine 
response to acute myocardial infarction." Am. J. Physiol. 287: H791-H797. 
Frangogiannis, N. G., C. W. Smith, et al. (2002). "The inflammatory response in myocardial 
infarction." Cardiovasc Res 53(1): 31-47. 
Frasure-Smith, N., F. Lespérance, et al. (1993). "Depression following myocardial infarction. 
Impact on 6-month survival." JAMA 270(15): 1819-1825. 
Frasure-Smith, N., F. Lespérance, et al. (1995). "The impact of negative emotions on 
prognosis following myocardial infarction: is it more than depression?" Health 
Psychol 14(5): 388-398. 
Freedland, K. E., P. J. Lustman, et al. (1992). "Underdiagnosis of depression in patients with 
coronary artery disease: the role of nonspecific symptoms." Int J Psychiatry Med 
22(3): 221-229. 
Girard, S. A., T. M. Bah, et al. (2009). "Lactobacillus helveticus and Bifidobacterium longum 
taken in combination reduce the apoptosis propensity in the limbic system after 
myocardial infarction in a rat model." Br J Nutr 102(10): 1420-1425. 
Glassman, A. H., S. P. Roose, et al. (1993). "The safety of tricyclic antidepressants in cardiac 
patients. Risk-benefit reconsidered." JAMA 269(20): 2673-2675. 
Gould, E. and P. Tanapat (1999). "Stress and hippocampal neurogenesis." Biol Psychiatry 
46(11): 1472-1479. 
Grippo, A. J. and A. K. Johnson (2002). "Biological mechanisms in the relationship between 
depression and heart disease." Neurosci Biobehav Rev 26(8): 941-962. 
Guck, T. P., M. G. Kavan, et al. (2001). "Assessment and treatment of depression following 
myocardial infarction." Am Fam Physician 64(4): 641-648. 
Gutierrez-Reyes, G., P. Lopez-Ortal, et al. (2006). "Effect of pentoxifylline on levels of pro-
inflammatory cytokines during chronic hepatitis C." Scand J Immunol 63(6): 461-
467. 
Gwechenberger, M., L. H. Mendoza, et al. (1999). "Cardiac myocytes produce interleukin-6 
in culture and in viable border zone of reperfused infarctions." Circulation 99: 546-
551. 
 
Post-Myocardial Infarction Depression 355 
Hansen, M. K., P. Taishi, et al. (1998). "Vagotomy blocks the induction of interleukin-1ß (IL-
1ß) mRNA in the brain of rats in response to systemic IL-1ß." J. Neuroscience 18: 
2247-2253. 
Herbert, J., I. M. Goodyer, et al. (2006). "Do corticosteroids damage the brain?" J 
Neuroendocrinol 18(6): 393-411. 
Herr, I., N. Gassler, et al. (2007). "Regulation of differential pro- and anti-apoptotic signaling 
by glucocorticoids." Apoptosis 12(2): 271-291. 
Heumann, R. (1994). "Neurotrophin signalling." Curr Opin Neurobiol 4(5): 668-679. 
Heuser, I. J., U. Schweiger, et al. (1996). "Pituitary-adrenal-system regulation and 
psychopathology during amitriptyline treatment in elderly depressed patients and 
normal comparison subjects." Am J Psychiatry 153(1): 93-99. 
Heyes, M. P., K. Saito, et al. (1992). "Quinolinic acid and kynurenine pathway metabolism in 
inflammatory and non-inflammatory neurological disease." Brain 115 ( Pt 5): 1249-
1273. 
Hillis, G. S., C. A. Terregino, et al. (2003). "Inflammatory cytokines provide limited early 
prognostic information in emergency department patients with suspected 
myocardial infarction." Ann. Emerg. Med. 42: 337-342. 
Hirano, T. (1999). "Molecular basis underlying functional pleiotropy of cytokines and 
growth factors." Biochem Biophys Res Commun 260(2): 303-308. 
Honig, A., R. Lousberg, et al. (1997). "[Depression following a first heart infarct; similarities 
with and differences from 'ordinary' depression]." Ned Tijdschr Geneeskd 141(4): 
196-199. 
Honig, A. and M. Maes (2000). "Psychoimmunology as a common pathogenic pathway in 
myocardial infarction, depression and cardiac death." Curr Opin Psychiatry 13: 661-
664. 
Huang, Y. Y., C. H. Peng, et al. (2007). "Desipramine activated Bcl-2 expression and inhibited 
lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem 
cells." J Pharmacol Sci 104(1): 61-72. 
Irwin, M. W., S. Mak, et al. (1999). "Tissue expression and immunolocalization of tumor 
necrosis factor-alpha in postinfarction dysfunctional myocardium." Circulation 99: 
1492-1498. 
Ivanova, S. A., V. Y. Semke, et al. (2007). "Signs of apoptosis of immunocompetent cells in 
patients with depression." Neurosci Behav Physiol 37(5): 527-530. 
Jacobson, M. D., M. Weil, et al. (1997). "Programmed cell death in animal development." Cell 
88(3): 347-354. 
Jazayeri, S., M. Tehrani-Doost, et al. (2008). "Comparison of therapeutic effects of omega-3 
fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in 
major depressive disorder." Aust N Z J Psychiatry 42(3): 192-198. 
Jeong, S. Y. and D. W. Seol (2008). "The role of mitochondria in apoptosis." BMB Rep 41(1): 
11-22. 
Joly, D. and D. J. Sanger (1986). "The effects of fluoxetine and zimeldine on the behavior of 
olfactory bulbectomized rats." Pharmacol Biochem Behav 24(2): 199-204. 
Kaloustian, S., T. M. Bah, et al. (2009). "Tumor necrosis factor-alpha participates in apoptosis 
in the limbic system after myocardial infarction." Apoptosis 14(11): 1308-1316. 
Kaloustian, S., B. P. Wann, et al. (2008). "Apoptosis time course in the limbic system after 
myocardial infarction in the rat." Brain Res 1216: 87-91. 
 
Novel Strategies in Ischemic Heart Disease 356 
Karege, F., G. Perret, et al. (2002). "Decreased serum brain-derived neurotrophic factor levels 
in major depressed patients." Psychiatry Res 109(2): 143-148. 
Kato, K., T. Matsubara, et al. (1999). "Elevated levels of proinflammatory cytokines in 
coronary artery thrombi.." Int. J. Cardiol. 70: 267-273. 
Katoh-Semba, R., I. K. Takeuchi, et al. (1997). "Distribution of brain-derived neurotrophic 
factor in rats and its changes with development in the brain." J Neurochem 69(1): 
34-42. 
Katon, W. and M. D. Sullivan (1990). "Depression and chronic medical illness." J Clin 
Psychiatry 51 Suppl: 3-11; discussion 12-14. 
Katz, M. M., J. L. Tekell, et al. (2004). "Onset and early behavioral effects of 
pharmacologically different antidepressants and placebo in depression." 
Neuropsychopharmacology 29(3): 566-579. 
Kawamoto, Y., S. Nakamura, et al. (1996). "Immunohistochemical localization of brain-
derived neurotrophic factor in adult rat brain." Neuroscience 74(4): 1209-1226. 
Kerr, J. F., A. H. Wyllie, et al. (1972). "Apoptosis: a basic biological phenomenon with wide-
ranging implications in tissue kinetics." Br J Cancer 26(4): 239-257. 
Kiecolt-Glaser, J. K. (2010). "Stress, food, and inflammation: psychoneuroimmunology and 
nutrition at the cutting edge." Psychosom Med 72(4): 365-369. 
Kronfol, Z. and D. G. Remick (2000). "Cytokines and the brain: implications for clinical 
psychiatry." Am J Psychiatry 157(5): 683-694. 
Krueger, J. M., M. L. Karnovsky, et al. (1984). "Peptidoglycans as promoters of slow-wave 
sleep. II. Somnogenic and pyrogenic activities of some naturally occurring 
muramyl peptides; correlations with mass spectrometric structure determination." J 
Biol Chem 259(20): 12659-12662. 
Krugers, H. J., S. van der Linden, et al. (2007). "Dissociation between apoptosis, 
neurogenesis, and synaptic potentiation in the dentate gyrus of adrenalectomized 
rats." Synapse 61(4): 221-230. 
Laflamme, N. and S. Rivest (1999). "An essential role of interleukin-1ß in mediatong NF-B 
activity and COX-2 transcription in cells of the blood-brain barrier in response to a 
systemic and localized inflammation but not during endotoxemia." J. Neuroscience 
19: 10923-10930. 
Laghrissi-Thode, F., W. R. Wagner, et al. (1997). "Elevated platelet factor 4 and beta-
thromboglobulin plasma levels in depressed patients with ischemic heart disease." 
Biol Psychiatry 42(4): 290-295. 
Lai, M., J. A. McCormick, et al. (2003). "Differential regulation of corticosteroid receptors by 
monoamine neurotransmitters and antidepressant drugs in primary hippocampal 
culture." Neuroscience 118(4): 975-984. 
Layé, S., R. M. Bluthé, et al. (1995). "Subdiaphramagtic vagotomy blocks induction of IL-1ß 
mRNA in mice brain in response to peripheral LPS." Am. J. Physiol. 268: R1327-
R1331. 
Leonard, B. E. (2000). "Evidence for a biochemical lesion in depression." J Clin Psychiatry 61 
Suppl 6: 12-17. 
Lespérance, F., N. Frasure-Smith, et al. (2011). "The efficacy of omega-3 supplementation for 
major depression: a randomized controlled trial." J Clin Psychiatry 72(8): 1054-1062. 
Lespérance, F., N. Frasure-Smith, et al. (1996). "Major depression before and after 
myocardial infarction: its nature and consequences." Psychosom Med 58(2): 99-110. 
 
Novel Strategies in Ischemic Heart Disease 356 
Karege, F., G. Perret, et al. (2002). "Decreased serum brain-derived neurotrophic factor levels 
in major depressed patients." Psychiatry Res 109(2): 143-148. 
Kato, K., T. Matsubara, et al. (1999). "Elevated levels of proinflammatory cytokines in 
coronary artery thrombi.." Int. J. Cardiol. 70: 267-273. 
Katoh-Semba, R., I. K. Takeuchi, et al. (1997). "Distribution of brain-derived neurotrophic 
factor in rats and its changes with development in the brain." J Neurochem 69(1): 
34-42. 
Katon, W. and M. D. Sullivan (1990). "Depression and chronic medical illness." J Clin 
Psychiatry 51 Suppl: 3-11; discussion 12-14. 
Katz, M. M., J. L. Tekell, et al. (2004). "Onset and early behavioral effects of 
pharmacologically different antidepressants and placebo in depression." 
Neuropsychopharmacology 29(3): 566-579. 
Kawamoto, Y., S. Nakamura, et al. (1996). "Immunohistochemical localization of brain-
derived neurotrophic factor in adult rat brain." Neuroscience 74(4): 1209-1226. 
Kerr, J. F., A. H. Wyllie, et al. (1972). "Apoptosis: a basic biological phenomenon with wide-
ranging implications in tissue kinetics." Br J Cancer 26(4): 239-257. 
Kiecolt-Glaser, J. K. (2010). "Stress, food, and inflammation: psychoneuroimmunology and 
nutrition at the cutting edge." Psychosom Med 72(4): 365-369. 
Kronfol, Z. and D. G. Remick (2000). "Cytokines and the brain: implications for clinical 
psychiatry." Am J Psychiatry 157(5): 683-694. 
Krueger, J. M., M. L. Karnovsky, et al. (1984). "Peptidoglycans as promoters of slow-wave 
sleep. II. Somnogenic and pyrogenic activities of some naturally occurring 
muramyl peptides; correlations with mass spectrometric structure determination." J 
Biol Chem 259(20): 12659-12662. 
Krugers, H. J., S. van der Linden, et al. (2007). "Dissociation between apoptosis, 
neurogenesis, and synaptic potentiation in the dentate gyrus of adrenalectomized 
rats." Synapse 61(4): 221-230. 
Laflamme, N. and S. Rivest (1999). "An essential role of interleukin-1ß in mediatong NF-B 
activity and COX-2 transcription in cells of the blood-brain barrier in response to a 
systemic and localized inflammation but not during endotoxemia." J. Neuroscience 
19: 10923-10930. 
Laghrissi-Thode, F., W. R. Wagner, et al. (1997). "Elevated platelet factor 4 and beta-
thromboglobulin plasma levels in depressed patients with ischemic heart disease." 
Biol Psychiatry 42(4): 290-295. 
Lai, M., J. A. McCormick, et al. (2003). "Differential regulation of corticosteroid receptors by 
monoamine neurotransmitters and antidepressant drugs in primary hippocampal 
culture." Neuroscience 118(4): 975-984. 
Layé, S., R. M. Bluthé, et al. (1995). "Subdiaphramagtic vagotomy blocks induction of IL-1ß 
mRNA in mice brain in response to peripheral LPS." Am. J. Physiol. 268: R1327-
R1331. 
Leonard, B. E. (2000). "Evidence for a biochemical lesion in depression." J Clin Psychiatry 61 
Suppl 6: 12-17. 
Lespérance, F., N. Frasure-Smith, et al. (2011). "The efficacy of omega-3 supplementation for 
major depression: a randomized controlled trial." J Clin Psychiatry 72(8): 1054-1062. 
Lespérance, F., N. Frasure-Smith, et al. (1996). "Major depression before and after 
myocardial infarction: its nature and consequences." Psychosom Med 58(2): 99-110. 
 
Post-Myocardial Infarction Depression 357 
Lespérance, F., N. Frasure-Smith, et al. (2002). "Five-year risk of cardiac mortality in relation 
to initial severity and one-year changes in depression symptoms after myocardial 
infarction." Circulation 105(9): 1049-1053. 
Li, L. Y., X. Luo, et al. (2001). "Endonuclease G is an apoptotic DNase when released from 
mitochondria." Nature 412(6842): 95-99. 
Li, R. C., B. W. Row, et al. (2003). "Cyclooxygenase 2 and intermittent hypoxia-induced 
spatial deficits in  the rats." Am. J. Respir Crit. Care Med. 168: 469-475. 
Lichtenstein, G. R., M. Bala, et al. (2002). "Infliximab improves quality of life in patients with 
Crohn's disease." Inflamm Bowel Dis 8(4): 237-243. 
Littman, A. B. (1993). "Review of psychosomatic aspects of cardiovascular disease." 
Psychother Psychosom 60(3-4): 148-167. 
Lorenzo, H. K. and S. A. Susin (2004). "Mitochondrial effectors in caspase-independent cell 
death." FEBS Lett 557(1-3): 14-20. 
Lucassen, P. J., E. Fuchs, et al. (2004). "Antidepressant treatment with tianeptine reduces 
apoptosis in the hippocampal dentate gyrus and temporal cortex." Biol. Psych. 55: 
789-796. 
Lucassen, P. J., V. M. Heine, et al. (2006). "Stress, depression and hippocampal apoptosis." 
CNS Neurol Disord Drug Targets 5(5): 531-546. 
Lucassen, P. J., M. B. Müller, et al. (2001). "Hippocampal apoptosis in major depression is a 
minor event and absent from subareas at risk for glucocorticoid overexposure." 
Am. J. Pathol. 158: 453-468. 
Luo, X., I. Budihardjo, et al. (1998). "Bid, a Bcl2 interacting protein, mediates cytochrome c 
release from mitochondria in response to activation of cell surface death receptors." 
Cell 94(4): 481-490. 
MacFarlane, M. and A. C. Williams (2004). "Apoptosis and disease: a life or death decision." 
EMBO Rep 5(7): 674-678. 
Maes, M. (1995). "Evidence for an immune response in major depression: a review and 
hypothesis." Prog Neuropsychopharmacol Biol Psychiatry 19(1): 11-38. 
Maes, M. (1999). "Major depression and activation of the inflammatory response system." 
Adv Exp Med Biol 461: 25-46. 
Maes, M., E. Bosmans, et al. (1993). "Interleukin-1 beta: a putative mediator of HPA axis 
hyperactivity in major depression?" Am J Psychiatry 150(8): 1189-1193. 
Malberg, J. E., A. J. Eisch, et al. (2000). "Chronic antidepressant treatment increases 
neurogenesis in adult rat hippocampus." J. Neuroscience 20: 9104-9110. 
Mamalakis, G., M. Kiriakakis, et al. (2006). "Depression and serum adiponectin and adipose 
omega-3 and omega-6 fatty acids in adolescents." Pharmacol Biochem Behav 85(2): 
474-479. 
Marx, N., F. J. Neumann, et al. (1997). "Induction of cytokine expression in leukocytes in 
acute myocardial infarction." J. Am. Coll. Cardiol. 30: 165-170. 
McKay, L. I. and J. A. Cidlowski (1999). "Molecular control of immune/inflammatory 
responses: interactions between nuclear factor-kappa B and steroid receptor-
signaling pathways." Endocr Rev 20(4): 435-459. 
McNamara, R. K. and S. E. Carlson (2006). "Role of omega-3 fatty acids in brain 
development and function: potential implications for the pathogenesis and 
prevention of psychopathology." Prostaglandins Leukot Essent Fatty Acids 75(4-5): 
329-349. 
 
Novel Strategies in Ischemic Heart Disease 358 
Meneses, R., M. C. Almeida, et al. (2007). "Depression in patients with myocardial 
infarction." Rev Port Cardiol 26(11): 1143-1165. 
Messaoudi, M., R. Lalonde, et al. (2011). "Assessment of psychotropic-like properties of a 
probiotic formulation ( Lactobacillus helveticus R0052 and Bifidobacterium longum 
R0175) in rats and human subjects." Br J Nutr 105(5): 755-764. 
Miller, A. H., C. M. Pariante, et al. (1999). "Effects of cytokines on glucocorticoid receptor 
expression and function. Glucocorticoid resistance and relevance to depression." 
Adv Exp Med Biol 461: 107-116. 
Morikawa, O., N. Sakai, et al. (1998). "Effects of interferon-alpha, interferon-gamma and 
cAMP on the transcriptional regulation of the serotonin transporter." Eur J 
Pharmacol 349(2-3): 317-324. 
Morris, R. (1984). "Developments of a water-maze procedure for studying spatial learning in 
the rat." J. Neuroscience Methods 11: 47-60. 
Mossner, R., S. Daniel, et al. (2001). "Modulation of serotonin transporter function by 
interleukin-4." Life Sci 68(8): 873-880. 
Mossner, R., A. Heils, et al. (1998). "Enhancement of serotonin transporter function by tumor 
necrosis factor alpha but not by interleukin-6." Neurochem Int 33(3): 251-254. 
Mowla, S. J., H. F. Farhadi, et al. (2001). "Biosynthesis and post-translational processing of 
the precursor to brain-derived neurotrophic factor." J Biol Chem 276(16): 12660-
12666. 
Nahon, E., A. Israelson, et al. (2005). "Fluoxetine (Prozac) interaction with the mitochondrial 
voltage-dependent anion channel and protection against apoptotic cell death." 
FEBS Lett 579(22): 5105-5110. 
Nibuya, M., M. Takahashi, et al. (1999). "Repeated stress increases catalytic TrkB mRNA in 
rat hippocampus." Neurosci Lett 267(2): 81-84. 
Niiranen, A., R. Laaksonen, et al. (1988). "Behavioral assessment of patients treated with 
alpha-interferon." Acta Psychiatr Scand 78(5): 622-626. 
O'Brien, S. M., L. V. Scott, et al. (2004). "Cytokines: abnormalities in major depression and 
implications for pharmacological treatment." Hum Psychopharmacol 19(6): 397-403. 
Oprica, M., S. Zhu, et al. (2005). "Transgenic overexpression of interleukin-1 receptor 
antagonist in the CNS influences behaviour, serum corticosterone and brain 
monoamines." Brain Behav Immun 19(3): 223-234. 
Orr, S. K. and R. P. Bazinet (2008). "The emerging role of docosahexaenoic acid in 
neuroinflammation." Curr Opin Investig Drugs 9(7): 735-743. 
Overstreet, D. H., E. Friedman, et al. (2005). "The Flinders Sensitive Line rat: a selectively 
bred putative animal model of depression." Neurosci Biobehav Rev 29(4-5): 739-
759. 
Ozaki, K. and W. J. Leonard (2002). "Cytokine and cytokine receptor pleiotropy and 
redundancy." J Biol Chem 277(33): 29355-29358. 
Pace, T. W. and A. H. Miller (2009). "Cytokines and glucocorticoid receptor signaling. 
Relevance to major depression." Ann N Y Acad Sci 1179: 86-105. 
Palazzolo, D. L. and S. K. Quadri (1992). "Interleukin-1 inhibits serotonin release from the 
hypothalamus in vitro." Life Sci 51(23): 1797-1802. 
Pan, Y. J., M. Knapp, et al. (2011). "Cost-effectiveness comparisons between antidepressant 
treatments in depression: Evidence from database analyses and prospective 
studies." J Affect Disord. 
 
Novel Strategies in Ischemic Heart Disease 358 
Meneses, R., M. C. Almeida, et al. (2007). "Depression in patients with myocardial 
infarction." Rev Port Cardiol 26(11): 1143-1165. 
Messaoudi, M., R. Lalonde, et al. (2011). "Assessment of psychotropic-like properties of a 
probiotic formulation ( Lactobacillus helveticus R0052 and Bifidobacterium longum 
R0175) in rats and human subjects." Br J Nutr 105(5): 755-764. 
Miller, A. H., C. M. Pariante, et al. (1999). "Effects of cytokines on glucocorticoid receptor 
expression and function. Glucocorticoid resistance and relevance to depression." 
Adv Exp Med Biol 461: 107-116. 
Morikawa, O., N. Sakai, et al. (1998). "Effects of interferon-alpha, interferon-gamma and 
cAMP on the transcriptional regulation of the serotonin transporter." Eur J 
Pharmacol 349(2-3): 317-324. 
Morris, R. (1984). "Developments of a water-maze procedure for studying spatial learning in 
the rat." J. Neuroscience Methods 11: 47-60. 
Mossner, R., S. Daniel, et al. (2001). "Modulation of serotonin transporter function by 
interleukin-4." Life Sci 68(8): 873-880. 
Mossner, R., A. Heils, et al. (1998). "Enhancement of serotonin transporter function by tumor 
necrosis factor alpha but not by interleukin-6." Neurochem Int 33(3): 251-254. 
Mowla, S. J., H. F. Farhadi, et al. (2001). "Biosynthesis and post-translational processing of 
the precursor to brain-derived neurotrophic factor." J Biol Chem 276(16): 12660-
12666. 
Nahon, E., A. Israelson, et al. (2005). "Fluoxetine (Prozac) interaction with the mitochondrial 
voltage-dependent anion channel and protection against apoptotic cell death." 
FEBS Lett 579(22): 5105-5110. 
Nibuya, M., M. Takahashi, et al. (1999). "Repeated stress increases catalytic TrkB mRNA in 
rat hippocampus." Neurosci Lett 267(2): 81-84. 
Niiranen, A., R. Laaksonen, et al. (1988). "Behavioral assessment of patients treated with 
alpha-interferon." Acta Psychiatr Scand 78(5): 622-626. 
O'Brien, S. M., L. V. Scott, et al. (2004). "Cytokines: abnormalities in major depression and 
implications for pharmacological treatment." Hum Psychopharmacol 19(6): 397-403. 
Oprica, M., S. Zhu, et al. (2005). "Transgenic overexpression of interleukin-1 receptor 
antagonist in the CNS influences behaviour, serum corticosterone and brain 
monoamines." Brain Behav Immun 19(3): 223-234. 
Orr, S. K. and R. P. Bazinet (2008). "The emerging role of docosahexaenoic acid in 
neuroinflammation." Curr Opin Investig Drugs 9(7): 735-743. 
Overstreet, D. H., E. Friedman, et al. (2005). "The Flinders Sensitive Line rat: a selectively 
bred putative animal model of depression." Neurosci Biobehav Rev 29(4-5): 739-
759. 
Ozaki, K. and W. J. Leonard (2002). "Cytokine and cytokine receptor pleiotropy and 
redundancy." J Biol Chem 277(33): 29355-29358. 
Pace, T. W. and A. H. Miller (2009). "Cytokines and glucocorticoid receptor signaling. 
Relevance to major depression." Ann N Y Acad Sci 1179: 86-105. 
Palazzolo, D. L. and S. K. Quadri (1992). "Interleukin-1 inhibits serotonin release from the 
hypothalamus in vitro." Life Sci 51(23): 1797-1802. 
Pan, Y. J., M. Knapp, et al. (2011). "Cost-effectiveness comparisons between antidepressant 
treatments in depression: Evidence from database analyses and prospective 
studies." J Affect Disord. 
 
Post-Myocardial Infarction Depression 359 
Pariante, C. M. (2006). "The glucocorticoid receptor: part of the solution or part of the 
problem?" J Psychopharmacol 20(4 Suppl): 79-84. 
Pariante, C. M. and S. L. Lightman (2008). "The HPA axis in major depression: classical 
theories and new developments." Trends Neurosci 31(9): 464-468. 
Pariante, C. M., B. D. Pearce, et al. (1997). "Steroid-independent translocation of the 
glucocorticoid receptor by the antidepressant desipramine." Mol Pharmacol 52(4): 
571-581. 
Pariante, C. M., B. D. Pearce, et al. (1999). "The proinflammatory cytokine, interleukin-
1alpha, reduces glucocorticoid receptor translocation and function." Endocrinology 
140(9): 4359-4366. 
Peet, M., B. Murphy, et al. (1998). "Depletion of omega-3 fatty acid levels in red blood cell 
membranes of depressive patients." Biol Psychiatry 43(5): 315-319. 
Penninx, B. W., A. T. Beekman, et al. (2001). "Depression and cardiac mortality: results from 
a community-based longitudinal study." Arch Gen Psychiatry 58(3): 221-227. 
Pepin, M. C., S. Beaulieu, et al. (1989). "Antidepressants regulate glucocorticoid receptor 
messenger RNA concentrations in primary neuronal cultures." Brain Res Mol Brain 
Res 6(1): 77-83. 
Politi, P., N. Brondino, et al. (2008). "Increased proapoptotic serum activity in patients with 
chronic mood disorders." Arch Med Res 39(2): 242-245. 
Porsolt, R. D., G. Anton, et al. (1978a). "Behavioural despair in rats: a new model sensitive to 
antidepressant treatments." Eur J Pharmacol 47(4): 379-391. 
Porsolt, R. D., A. Bertin, et al. (1978b). "Behavioural despair" in rats and mice: strain 
differences and the effects of imipramine." Eur J Pharmacol 51(3): 291-294. 
Porsolt, R. D., M. le Pichon, et al. (1977). "Depression: a new animal model sensitive to 
antidepressant treatments." Nature 266: 730-732. 
Pudil, R., V. Pidrman, et al. (1999). "Cytokines and adhesion molecules in the course of acute 
myocardial infarction." Clin Chim Acta 280(1-2): 127-134. 
Raetsch, C., J. D. Jia, et al. (2002). "Pentoxifylline downregulates profibrogenic cytokines and 
procollagen I expression in rat secondary biliary fibrosis." Gut 50(2): 241-247. 
Ramamoorthy, S., J. D. Ramamoorthy, et al. (1995). "Regulation of the human serotonin 
transporter by interleukin-1 beta." Biochem Biophys Res Commun 216(2): 560-567. 
Redei, E. E., N. Ahmadiyeh, et al. (2001). "Novel animal models of affective disorders." 
Semin. Clin. Neuropsychiat 6: 43-67. 
Reichenberg, A., R. Yirmiya, et al. (2001). "Cytokine-associated emotional and cognitive 
disturbances in humans." Arch Gen Psychiatry 58(5): 445-452. 
Reyland, M. E. (2007). Protein kinase C and apoptosis. Apoptosis, Cell signaling , and 
human Diseases. R. Srivastava. Totowa, NJ, Humana Press. 2: 31-55. 
Rivest, S. (2001). "How circulating cytokines trigger the neural circuits that control the 
hypothalamic-pituitary-adrenal axis." Psychoneuroendo 26: 761-788. 
Rogatsky, I. and L. B. Ivashkiv (2006). "Glucocorticoid modulation of cytokine signaling." 
Tissue Antigens 68(1): 1-12. 
Rogatsky, I., S. K. Logan, et al. (1998). "Antagonism of glucocorticoid receptor 
transcriptional activation by the c-Jun N-terminal kinase." Proc Natl Acad Sci U S A 
95(5): 2050-2055. 
 
Novel Strategies in Ischemic Heart Disease 360 
Rondeau, I., S. Picard, et al. (2011). "Effects of different dietary omega-6/3 polyunsaturated 
fatty acids ratios on infarct size and the limbic system after myocardial infarction." 
Can J Physiol Pharmacol 89(3): 169-176. 
Russo, S., I. P. Kema, et al. (2003). "Tryptophan as a link between psychopathology and 
somatic states." Psychosom Med 65(4): 665-671. 
Saarelainen, T., P. Hendolin, et al. (2003). "Activation of the TrkB neurotrophin receptor is 
induced by antidepressant drugs and is required for antidepressant-induced 
behavioral effects." J Neurosci 23(1): 349-357. 
Salvesen, G. S. and C. S. Duckett (2002). "IAP proteins: blocking the road to death's door." 
Nat Rev Mol Cell Biol 3(6): 401-410. 
Santarelli, L., M. Saxe, et al. (2003). "Requirement of hippocampal neurogenesis for the 
behavioral effects of antidepressants." Science 301: 805-809. 
Sapolsky, R. (1996). "Why stress is bad for your brain." Science 273: 749-750. 
Sasaki, T., K. Kitagawa, et al. (2004). "Amelioration ofhippocampal neuronal damage after 
transient forebrain ischemia in cyclooxygenase-2-deficient mice." J. Cereb Blood 
Flow Metab. 24: 107-113. 
Schins, A., H. J. Crijns, et al. (2007). "Altered omega-3 polyunsaturated fatty acid status in 
depressed post-myocardial infarction patients." Acta Psychiatr Scand 115(1): 35-40. 
Schleifer, S. J., M. M. Macari-Hinson, et al. (1989). "The nature and course of depression 
following myocardial infarction." Arch Intern Med 149(8): 1785-1789. 
Shi, Y. (2002). "Mechanisms of caspase activation and inhibition during apoptosis." Mol Cell 
9(3): 459-470. 
Sinha, R. A., P. Khare, et al. (2009). "Anti-apoptotic role of omega-3-fatty acids in developing 
brain: perinatal hypothyroid rat cerebellum as apoptotic model." Int J Dev Neurosci 
27(4): 377-383. 
Smith, R. S. (1991). "The macrophage theory of depression." Med Hypotheses 35(4): 298-306. 
Song, C. and B. E. Leonard (2005). "The olfactory bulbectomised rat as a model of 
depression." Neurosci Biobehav Rev 29(4-5): 627-647. 
Sprague, A. H. and R. A. Khalil (2009). "Inflammatory cytokines in vascular dysfunction and 
vascular disease." Biochem Pharmacol 78(6): 539-552. 
Spriggs, D. R., M. L. Sherman, et al. (1988). "Recombinant human tumor necrosis factor 
administered as a 24-hour intravenous infusion. A phase I and pharmacologic 
study." J Natl Cancer Inst 80(13): 1039-1044. 
Stock, H. S., K. Ford, et al. (2000). "Gender and gonadal hormone effects in the olfactory 
bulbectomy animal model of depression." Pharmacol. Biochem. Behav. 67: 183-191. 
Strakowski, S. M., C. M. Adler, et al. (2002). "Volumetric MRI studies of mood disorders: do 
they distinguish unipolar and bipolar disorder?" Bipolar Disorders. 4: 80-88. 
Sugawara, T., M. Fujimura, et al. (1999). "Mitochondrial release of cytochrome c corresponds 
to the selective vulnerability of hippocampal CA1 neurons in rats after transient 
global cerebral ischemia." J Neurosci 19(22): RC39. 
Sutcigil, L., C. Oktenli, et al. (2007). "Pro- and anti-inflammatory cytokine balance in major 
depression: effect of sertraline therapy." Clin Dev Immunol 2007: 76396. 
Szelenyi, J. and E. S. Vizi (2007). "The catecholamine cytokine balance: interaction between 
the brain and the immune system." Ann N Y Acad Sci 1113: 311-324. 
 
Novel Strategies in Ischemic Heart Disease 360 
Rondeau, I., S. Picard, et al. (2011). "Effects of different dietary omega-6/3 polyunsaturated 
fatty acids ratios on infarct size and the limbic system after myocardial infarction." 
Can J Physiol Pharmacol 89(3): 169-176. 
Russo, S., I. P. Kema, et al. (2003). "Tryptophan as a link between psychopathology and 
somatic states." Psychosom Med 65(4): 665-671. 
Saarelainen, T., P. Hendolin, et al. (2003). "Activation of the TrkB neurotrophin receptor is 
induced by antidepressant drugs and is required for antidepressant-induced 
behavioral effects." J Neurosci 23(1): 349-357. 
Salvesen, G. S. and C. S. Duckett (2002). "IAP proteins: blocking the road to death's door." 
Nat Rev Mol Cell Biol 3(6): 401-410. 
Santarelli, L., M. Saxe, et al. (2003). "Requirement of hippocampal neurogenesis for the 
behavioral effects of antidepressants." Science 301: 805-809. 
Sapolsky, R. (1996). "Why stress is bad for your brain." Science 273: 749-750. 
Sasaki, T., K. Kitagawa, et al. (2004). "Amelioration ofhippocampal neuronal damage after 
transient forebrain ischemia in cyclooxygenase-2-deficient mice." J. Cereb Blood 
Flow Metab. 24: 107-113. 
Schins, A., H. J. Crijns, et al. (2007). "Altered omega-3 polyunsaturated fatty acid status in 
depressed post-myocardial infarction patients." Acta Psychiatr Scand 115(1): 35-40. 
Schleifer, S. J., M. M. Macari-Hinson, et al. (1989). "The nature and course of depression 
following myocardial infarction." Arch Intern Med 149(8): 1785-1789. 
Shi, Y. (2002). "Mechanisms of caspase activation and inhibition during apoptosis." Mol Cell 
9(3): 459-470. 
Sinha, R. A., P. Khare, et al. (2009). "Anti-apoptotic role of omega-3-fatty acids in developing 
brain: perinatal hypothyroid rat cerebellum as apoptotic model." Int J Dev Neurosci 
27(4): 377-383. 
Smith, R. S. (1991). "The macrophage theory of depression." Med Hypotheses 35(4): 298-306. 
Song, C. and B. E. Leonard (2005). "The olfactory bulbectomised rat as a model of 
depression." Neurosci Biobehav Rev 29(4-5): 627-647. 
Sprague, A. H. and R. A. Khalil (2009). "Inflammatory cytokines in vascular dysfunction and 
vascular disease." Biochem Pharmacol 78(6): 539-552. 
Spriggs, D. R., M. L. Sherman, et al. (1988). "Recombinant human tumor necrosis factor 
administered as a 24-hour intravenous infusion. A phase I and pharmacologic 
study." J Natl Cancer Inst 80(13): 1039-1044. 
Stock, H. S., K. Ford, et al. (2000). "Gender and gonadal hormone effects in the olfactory 
bulbectomy animal model of depression." Pharmacol. Biochem. Behav. 67: 183-191. 
Strakowski, S. M., C. M. Adler, et al. (2002). "Volumetric MRI studies of mood disorders: do 
they distinguish unipolar and bipolar disorder?" Bipolar Disorders. 4: 80-88. 
Sugawara, T., M. Fujimura, et al. (1999). "Mitochondrial release of cytochrome c corresponds 
to the selective vulnerability of hippocampal CA1 neurons in rats after transient 
global cerebral ischemia." J Neurosci 19(22): RC39. 
Sutcigil, L., C. Oktenli, et al. (2007). "Pro- and anti-inflammatory cytokine balance in major 
depression: effect of sertraline therapy." Clin Dev Immunol 2007: 76396. 
Szelenyi, J. and E. S. Vizi (2007). "The catecholamine cytokine balance: interaction between 
the brain and the immune system." Ann N Y Acad Sci 1113: 311-324. 
 
Post-Myocardial Infarction Depression 361 
Szuster-Ciesielska, A., M. Slotwinska, et al. (2008). "Accelerated apoptosis of blood 
leukocytes and oxidative stress in blood of patients with major depression." Prog 
Neuropsychopharmacol Biol Psychiatry 32(3): 686-694. 
Takadera, T., H. Yumoto, et al. (2002). "Prostaglandin E2 induces caspase-dependent 
apoptosis in rat cortical cells." Neurosciences Letters 317: 61-64. 
Tchelingerian, J. L., M. Monge, et al. (1995). "Differential oligodendroglial expression of the 
tumor necrosis factor receptors in vivo and in vitro." J Neurochem 65(5): 2377-2380. 
ter Horst, G. J., G. J. Nagel, et al. (1997). Selective blood brain barrier dysfunction after 
intravenous injection of rTNF in the rat. Neurochemistry; Cellular, molecular and 
clinical aspects. A. Teelken and J. Korf. New York, Plenum Press. 
Thorburn, A. (2004). "Death receptor-induced cell killing." Cell Signal 16(2): 139-144. 
Turnbull, A. V. and C. Rivier (1995). "Regulation of the HPA axis by cytokines." Brain Behav 
Immun 9(4): 253-275. 
Tziakas, D. N., G. K. Chalikias, et al. (2003). "Anti-inflammatory cytokine profile in acute 
coronary syndromes: behavior of interleukin-10 in association with serum 
metalloproteinases and proinflammatory cytokines." Inter. J. Cardiol. 92: 169-175. 
van Riezen, H. and B. E. Leonard (1991). Effect of psychotropic drugs on the behavior and 
neurochemistry of olfactory bulbectomized rats. Psychopharmacology of 
anxiolytics and antidepressants. F. E. New York, Pergamon: 231-250. 
Vitkovic, L., J. Bockaert, et al. (2000). ""Inflammatory" cytokines: neuromodulators in normal 
brain?" J Neurochem 74(2): 457-471. 
Vogel, G., D. Neill, et al. (1990). "A new animal model of endogenous depression: a 
summary of present findings." Neurosci Biobehav Rev 14(1): 85-91. 
Wagar, L. E., C. P. Champagne, et al. (2009). "Immunomodulatory properties of fermented 
soy and dairy milks prepared with lactic acid bacteria." J Food Sci 74(8): M423-430. 
Wang, S. and W. S. El-Deiry (2003). "TRAIL and apoptosis induction by TNF-family death 
receptors." Oncogene 22(53): 8628-8633. 
Wann, B. P., T. M. Bah, et al. (2007). "Vulnerability for apoptosis in the limbic system after 
myocardial infarction in rats: a possible model for human postinfarct major 
depression." J Psychiatry Neurosci 32(1): 11-16. 
Wann, B. P., T. M. Bah, et al. (2009). "Behavioural signs of depression and apoptosis in the 
limbic system following myocardial infarction: effects of sertraline." J 
Psychopharmacol 23(4): 451-459. 
Wann, B. P., S. G. Béland, et al. (2004). "Permeability in the limbic system following 
myocardial infarction in the rat." Society for Neuroscience 34th Annual meeting: 
#568.564. 
Wann, B. P., M. Boucher, et al. (2006). "Apoptosis detected in the amygdala following 
myocardial infarction in the rat." Biol Psychiatry 59(5): 430-433. 
Wetmore, C., Y. H. Cao, et al. (1991). "Brain-derived neurotrophic factor: subcellular 
compartmentalization and interneuronal transfer as visualized with anti-peptide 
antibodies." Proc Natl Acad Sci U S A 88(21): 9843-9847. 
Wichers, M. and M. Maes (2002). "The psychoneuroimmuno-pathophysiology of cytokine-
induced depression in humans." Int J Neuropsychopharmacol 5(4): 375-388. 
Willner, P. (2005). "Chronic mild stress (CMS) revisited: consistency and behavioural-
neurobiological concordance in the effects of CMS." Neuropsychobiology 52(2): 90-
110. 
 
Novel Strategies in Ischemic Heart Disease 362 
Willner, P., A. Towell, et al. (1987). "Reduction of sucrose preference by chronic 
unpredictable mild stress, and its restoration by tricyclic antidepressant." 
Psychopharmacology 93: 358-364. 
Wilson, D. R. and L. Warise (2008). "Cytokines and their role in depression." Perspect 
Psychiatr Care 44(4): 285-289. 
Wirleitner, B., G. Neurauter, et al. (2003). "Interferon-gamma-induced conversion of 
tryptophan: immunologic and neuropsychiatric aspects." Curr Med Chem 10(16): 
1581-1591. 
Wong, E. Y. and J. Herbert (2004). "The corticoid environment: a determining factor for 
neural progenitors' survival in the adult hippocampus." Eur J Neurosci 20(10): 
2491-2498. 
Worrall, N. K., K. Chang, et al. (1997). "TNF- causes reversible in vivo systemic vascular 
barrier dysfunction via NO-dependent and -independent mechanisms." Am. J. 
Physiol. 273: H2565-H2574. 
Wu, E. Q., P. E. Greenberg, et al. (2009). "Treatment persistence, healthcare utilisation and 
costs in adult patients with major depressive disorder: a comparison between 
escitalopram and other SSRI/SNRIs." J Med Econ 12(2): 124-135. 
Wyllie, A. H., J. F. Kerr, et al. (1980). "Cell death: the significance of apoptosis." Int Rev Cytol 
68: 251-306. 
Xia, Z., J. W. DePierre, et al. (1996). "Tricyclic antidepressants inhibit IL-6, IL-1 beta and 
TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T 
cells." Immunopharmacology 34(1): 27-37. 
Yirmiya, R., Y. Pollak, et al. (2000). "Illness, Cytokines, and depression." Ann. NY Acad. Sci 
USA 917: 478-487. 
Yu, C.-M., K. W.-H. Lai, et al. (2003). "Expression of macrophage migration inhibitory factor 
in acute ischemic myocardial injury." J. Histochem. Cytochem. 51: 625-631. 
Yu, S., F. Holsboer, et al. (2008). "Neuronal actions of glucocorticoids: focus on depression." J 
Steroid Biochem Mol Biol 108(3-5): 300-309. 
Yuan, J. and B. A. Yankner (2000). "Apoptosis in the nervous system." Nature 407(6805): 802-
809. 
Zhang, J. and S. Rivest (1999). "Distribution, regulation and colocalization of the genes 
encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses 
to systemic inflammation." Eur J Neurosci 11(8): 2651-2668. 
Zobel, A. W., T. Nickel, et al. (2001). "Cortisol response in the combined 
dexamethasone/CRH test as predictor of relapse in patients with remitted 
depression. a prospective study." J Psychiatr Res 35(2): 83-94. 
Zorrilla, E. P., G. R. Valdez, et al. (2001). "Changes in levels of regional CRF-like-
immunoreactivity and plasma corticosterone during protracted drug withdrawal in 
dependent rats." Psychopharmacology (Berl) 158(4): 374-381. 
 
Novel Strategies in Ischemic Heart Disease 362 
Willner, P., A. Towell, et al. (1987). "Reduction of sucrose preference by chronic 
unpredictable mild stress, and its restoration by tricyclic antidepressant." 
Psychopharmacology 93: 358-364. 
Wilson, D. R. and L. Warise (2008). "Cytokines and their role in depression." Perspect 
Psychiatr Care 44(4): 285-289. 
Wirleitner, B., G. Neurauter, et al. (2003). "Interferon-gamma-induced conversion of 
tryptophan: immunologic and neuropsychiatric aspects." Curr Med Chem 10(16): 
1581-1591. 
Wong, E. Y. and J. Herbert (2004). "The corticoid environment: a determining factor for 
neural progenitors' survival in the adult hippocampus." Eur J Neurosci 20(10): 
2491-2498. 
Worrall, N. K., K. Chang, et al. (1997). "TNF- causes reversible in vivo systemic vascular 
barrier dysfunction via NO-dependent and -independent mechanisms." Am. J. 
Physiol. 273: H2565-H2574. 
Wu, E. Q., P. E. Greenberg, et al. (2009). "Treatment persistence, healthcare utilisation and 
costs in adult patients with major depressive disorder: a comparison between 
escitalopram and other SSRI/SNRIs." J Med Econ 12(2): 124-135. 
Wyllie, A. H., J. F. Kerr, et al. (1980). "Cell death: the significance of apoptosis." Int Rev Cytol 
68: 251-306. 
Xia, Z., J. W. DePierre, et al. (1996). "Tricyclic antidepressants inhibit IL-6, IL-1 beta and 
TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T 
cells." Immunopharmacology 34(1): 27-37. 
Yirmiya, R., Y. Pollak, et al. (2000). "Illness, Cytokines, and depression." Ann. NY Acad. Sci 
USA 917: 478-487. 
Yu, C.-M., K. W.-H. Lai, et al. (2003). "Expression of macrophage migration inhibitory factor 
in acute ischemic myocardial injury." J. Histochem. Cytochem. 51: 625-631. 
Yu, S., F. Holsboer, et al. (2008). "Neuronal actions of glucocorticoids: focus on depression." J 
Steroid Biochem Mol Biol 108(3-5): 300-309. 
Yuan, J. and B. A. Yankner (2000). "Apoptosis in the nervous system." Nature 407(6805): 802-
809. 
Zhang, J. and S. Rivest (1999). "Distribution, regulation and colocalization of the genes 
encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses 
to systemic inflammation." Eur J Neurosci 11(8): 2651-2668. 
Zobel, A. W., T. Nickel, et al. (2001). "Cortisol response in the combined 
dexamethasone/CRH test as predictor of relapse in patients with remitted 
depression. a prospective study." J Psychiatr Res 35(2): 83-94. 
Zorrilla, E. P., G. R. Valdez, et al. (2001). "Changes in levels of regional CRF-like-
immunoreactivity and plasma corticosterone during protracted drug withdrawal in 
dependent rats." Psychopharmacology (Berl) 158(4): 374-381. 
20 
Cytochrome P450 Epoxygenase CYP2J2 G-50T 
Polymorphism is an Independent Genetic 
Prognostic Risk Factor and Interacts with 
Smoking Cessation After Index Premature 
Myocardial Infarction 
Ping-Yen Liu1,2, Yi-Heng Li1 and Jyh-Hong Chen1 
1Division of Cardiology, Departments of Internal Medicine, 
 2Institute of Clinical Medicine, National Cheng Kung University Hospital, Tainan 
Taiwan 
1. Introduction 
Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids 
(EETs). One human cytochrome P450 enzyme, CYP2J2, is abundantly expressed in coronary 
artery endothelial and smooth muscle cells, and in cardiac myocytes (Wu et al., 1996; Imig, 
2000). One of the primary products of the NADPH-dependent epoxidation of arachidonic 
acid by CYP2J2 is the production of 11, 12-EET. This eicosanoid has potential anti-
inflammatory effects by inhibiting endothelial nuclear factor- B, a transcription factor 
associated with the induction of many pro-inflammatory gene products in the vasculature 
(Imig, 2000; Node et al., 1999). Other EETs, including 5,6-, 8,9-, 11,12-, and 14,15-EETs have 
important vasodilatation properties via mechanism of smooth muscle cells relaxation (Fang 
et al., 2002; Pinto et al., 1987; Spieker & Liao, 2005; Liu et al., 2006). More recently, the 
additional vascular protective effects of EETs, including anti-thrombotic, antimigratory, 
antioxidant, and antiapoptotic effects, have also been observed (Gauthier et al., 2004; Sun et 
al., 2002). 
Recently, a novel genetic variant G-50T of this novel gene CYP2J2 was found to be 
associated with coronary artery disease (CAD) (Spieker et al., 2004). This mutation could 
functionally result in the loss of binding of the Sp1 transcription factor to the CYP2J2 
promoter and a decreased activity in CYP2J2 promoter. The plasma concentrations of stable 
EETs metabolites were also lower in individuals with the G-50T polymorphism. However, 
the role of this novel gene variant in myocardial infarction (MI), especially premature MI, is 
still not well investigated. 
Of the common environmental factors known to be associated with risk of acute MI, 
smoking is widely acknowledged to make a major contribution (Manson et al., 1992; Teng et 
al., 1994). Smoking can disturb lipoprotein metabolism by increasing insulin resistance and 
lipid intolerance, and is implicated in the production of small dense low-density lipoprotein 
(Craig et al., 1989; Eliasson et al., 1997; Barua et al., 2002). The smoking-associated risk of MI 
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has been reported to be greater in subgrouping subjects with several genetic variants 
background (Li et al., 2002; Liu et al., 2005; Humphries et al., 2002). 
We thus hypothesized that those who with the T allele may have higher inflammatory 
status, and thus have higher risk for plaque rupture or occurrence of MI, especially at a 
younger age. We also speculated that there should be an additive interaction between the 
effect of smoking behavior and the genetic variation for the onset of premature MI. 
Smoking cessation could gradually improve the endothelial function and fibrinolytic status 
(Tsiara et al., 2003). However, successful cessation of smoking after MI and its interaction 
with this candidate gene for the subsequent events after index MI was still undefined. Thus, 
we hypothesized that premature MI patients carrying genetic polymorphism, especially 
genetic variant G-50T of this novel gene CYP2J2, might have a higher risk for subsequent 
coronary events. In addition, smoking cessation might interact with these gene variations for 
the prognosis after patients’ index MI in Taiwan. 
2. Methods 
2.1 Study subjects 
2.1.1 Study population  
We enrolled 200 patients (mean age 42.2±2.5 years; 84% men) with documented MI onset 
prior to age of 45 years. The patients were recruited after their first MI. Diagnosis of MI was 
based on ischemic chest symptoms, typical electrocardiographic changes and elevation of 
serum creatine kinase and its MB isoenzyme, when more than twice the upper level of 
normal. Coronary angiography was performed using the Judkin’s method within 2 weeks 
after the onset of symptoms. Coronary stenosis is defined as  50% diameter narrowing.  
2.1.2 Control population  
The control group was recruited by sex-matched 200 patients (mean age 42.5±2.1 years) 
from consecutive subjects admitted to our hospital for routine health examinations. They 
did not show any clinical or electrocardiographic evidence of MI or CAD. They also had no 
history of cerebrovascular disease or peripheral arterial disease. Written informed consents 
were obtained from all patients and this study was in agreement with guidelines approved 
by the research committee of National Cheng-Kung University Hospital.  
2.1.3 Background of population  
All patients and controls included in this study are Han Chinese/Taiwanese from the same 
geographic area. The demographic data and the presence of traditional coronary risk factors, 
including hypertension, diabetes mellitus, smoking and serum cholesterol, were collected 
from all study participants.  
2.1.4 Data collection & history recording  
For patients with MI, these data were taken from the medical records at the time of 
admission for acute MI; for control subjects, they were collected at the time of hospital 
admission for routine health examinations. They were considered to have hypertension if 
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elevated blood pressure (>140/90 mmHg) were measured on 3 occasions or if they were 
already being treated with anti-hypertensive agents. They were defined as having diabetes 
mellitus (DM) if they had a fasting blood glucose level > 110 mg/dl or were already being 
treated for DM. All study participants were classified as either smokers (including current 
or ex-smokers) or non-smokers. The total cholesterol level was determined at the beginning 
of the study. 
2.1.5 Blood collection  
The blood sampling time in the study group was at least 2 weeks after the onset of acute MI. 
In the control group, the blood samples were taken during coronary angiography study. All 
patients with impaired renal function, malignancy, connective tissue disease or chronic 
inflammatory disease were excluded. The blood samples were drawn into a 5-ml EDTA 
glass tube and centrifuged at 2200 g for 15 minutes to separate the plasma contents. The 
buffy coat after centrifugation was obtained and deoxyribonucleic acid (DNA) in each 
sample was isolated by the method we used before (Liu et al., 2007). The DNA samples were 
stored at –70 degree C until use. 
2.1.6 Genomic amplification by PCR  
Patient’s DNA was isolated from the whole-blood samples by the phenol-chloroform 
extraction method. A 273-bp promoter region proximal to the transcriptional start site was 
amplified with primers described previously (King et al., 2002). The sequence products were 
resolved on an ABI 377 automated sequencer. The promoter polymorphism G-50T was 
verified by direct sequencing. The numbering of the polymorphisms refers to the GenBank 
sequence AF272142 (accession number). 
2.1.7 Functional EET analysis  
Eicosanoids were extracted from plasma samples 3 times with ethyl acetate after acidification 
with acetic acid. After evaporation, saponification with 0.4N KOH in methanol, and re-
extraction, concentrations of the stable EETs metabolite 14,15-dihydroxyeicosatrienoic acid 
(DHET) were determined by an ELISA kit (Detroit R&D) (Liu et al., 2007; Spieker et al., 2004). 
2.1.8 Smoking habits definition  
Individuals were classified according to their smoking status; a current smoker was defined 
as any person who smoked regularly (at least one cigarette per day and/or one cigar or one 
pipe per week). Subjects who had smoked at least one cigarette per day and/or one cigar or 
one pipe per week in the past were classified as former smokers. Never smokers were those 
who had never smoked any tobacco product regularly. Subjects were considered to have 
achieved smoking cessation if they were reported non-smoking from the quitting day until 
the end of the 6-month period. 
2.1.9 Follow-up study  
Patients received regular follow-up care in our cardiology ward or clinics for at least 6 
months with a maximum of 13 years or until occurrence of one of the following coronary 
events: recurrent angina pectoris, non-fatal MI, or cardiac death. Recurrent angina pectoris 
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was defined as recurrent chest pain with ischemic ECG changes lasting >10 min despite 
antiangina therapy. Diagnosis of recurrent MI was the same as for index MI (see Study 
population). Cause of death was determined from hospital records. In this study, the follow-
up data were available for a total of 162 (95.3%) premature MI patients. Eight patients (4.7%) 
were not available for follow-up. The reasons included: 3 (1.8%) patients moved back to 
their primary residency region and we were unable to follow-up; 3 (1.8%) patients died of 
non-cardiovascular events, including two (1.2%) in traffic accidents and one (0.6%) by 
suicide; two (1.2%) patients were lost or changed their telephone numbers without detailed 
medical records. Those event-free patients who we were unable to follow-up completely 
were included in the event-free group. Their follow-up periods were defined between the 
index MI and their last clinic visit. 
2.1.10 Statistical analysis  
Data on age and cholesterol levels were presented as mean value ± standard deviation (SD). 
The values of DHET were presented as median ± SD. The difference between the groups was 
analyzed by the unpaired Student’s t test. The differences in the frequencies of smoking, 
hypertension, hyperlipidemia, diabetes mellitus, and CYP2J2 G-50T genotypes were analyzed 
by Fisher’s exact test. 2 analyses were used to test deviations of genotype distribution from 
Hardy-Weinberg equilibrium and to determine allele or genotype frequencies between 
patients and control groups. The risk factors that appear to be possible significant predictors 
(p<0.05) in the single-variant analyses were included in the multiple logistic regression 
analyses. Multivariate analyses were conducted with multiple logistic regression methods, and 
adjusted estimations of conditioned relative risk and 95% confidence intervals (CIs) were done. 
The Kaplan–Meier method (log-rank test) was applied in subsequent event-free analysis. All 
statistical analyses were performed using SPSS Advanced Statistics 13.0 for Window. In this 
study, a value of p<0.05 was taken to be statistical significance. 
3. Results 
3.1 Comparison of traditional CAD risk factors between MI and control groups 
We compared the control and premature MI group for traditional CAD risk factors, 
including hypertension, diabetes mellitus, smoking and serum cholesterol levels (Table 1).  
 
Characteristics Control (n=200) Premature MI (n=200) 
Age (yrs) 42.5±2.1 42.2±2.1 
Men/Women 167/33 168/32 
Systemic hypertension (%) 46 (23.0) 60 (30.0) † 
Diabetes mellitus (%) 9 (4.5) 26 (13.0)* 
Smoker (%) 89 (44.5) 154 (77.0)* 
Total cholesterol (mg/dL) 182±37.5 210±34.5 
Triglycerides (mg/dL) 135±32.1 136±30.8 
HDL cholesterol (mg/dL) 46±10.5 41±10.1 
LDL cholesterol (mg/dL) 120±29.3 128±21.5 
Data are presented as number (%) of patients or mean ± standard deviation. HDL = high-density 
lipoprotein; LDL = low-density lipoprotein; MI = myocardial infarction. *: p<0.001; †: p<0.01.  
Table 1. Clinical characteristics of study subjects  
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There were no significant differences in the age between these 2 groups (p = 0.890). The 
frequency of smoking (p <0.001), diabetes mellitus (p <0.001) and hypertension (p <0.01) 
were significantly higher in premature MI patients. However, the traditional CAD risk 
factor such as total cholesterol level was similar between 2 groups. 
3.2 Distribution of CYP2J2 G-50T genotypes 
Table 2 shows the distribution of CYP2J2 G-50T genotype in both premature MI patients and 
control subjects. The frequency of the T allele was significantly higher in the premature MI 
than the control group (16.0% vs. 12.0%, p<0.01; odds ratio (OR) 2.15, 95% [CI] 1.30 to 6.80). 
There was a significantly higher prevalence of the T allele genotype (GT+TT) among 
patients with premature MI in comparison to the control subjects (28.0% vs. 22.0%; OR 2.0, 
95% [CI] 1.3 to 6.8, p = 0.01). The distributions of genotype in both the premature MI group 
and control group were compatible with the Hardy-Weinberg equilibrium. 
 Control (n=200) Premature MI (n=200) OR (95% CI) P value 
TT 4 (2.0) 8 (4.0)   
GT 40 (20.0) 48 (24.0)   
TT+GT 44 (22.0) 56 (28.0) 2.0 (1.3-6.8) 0.01 
GG 156 (78.0) 144 (72.0)   
T allele frequency 0.12 0.16  0.01 
Data are presented as number (%) of patients. CI = confidence interval; GG = homozygous G allele of 
CYP2J2 G-50T gene; GT = heterozygous allele of CYP2J2 G-50T gene; MI = myocardial infarction; TT = 
homozygous T allele of CYP2J2 G-50T gene; OR = odds ratio. 
Table 2. Frequency of genotypes of CYP2J2 G-50T gene in control subjects and patients with 
premature myocardial infarction  
3.3 Identification of independent risk factors of MI 
Table 3 shows the results of multiple logistic regression analysis for identifying the 
independent risk factors of premature MI. Hypertension, DM, smoking and CYP2J2 genotype 
were all used as independent variables. Multiple logistic regression analysis showed that the T 
allele was an independent risk factor (OR 1.78, 95% CI 1.12 to 6.40, p = 0.02), as well as 
smoking (OR 3.05, 95% CI 1.55 to 7.25, p<0.01), diabetes mellitus (OR 3.24, 95% CI 1.22 to 6.55, 
p<0.01) and hypertension (OR 1.95, 95% CI 1.13 to 5.73, p<0.01) for the premature onset of MI. 
 
 OR for MI 95% CI P value 
Smoking 3.05 1.55-7.25 <0.01 
Diabetes mellitus 3.24 1.22-6.55 <0.01 
Hypertension 1.95 1.13-5.73 <0.01 
CYP2J2 G-50T polymorphism 1.78 1.12-6.40 0.02 
CI = confidence interval; GG = homozygous G allele of CYP2J2 G-50T gene; GT = heterozygous allele of 
CYP2J2 G-50T gene; MI = myocardial infarction; TT = homozygous T allele of CYP2J2 G-50T gene; OR = 
odds ratio. 
Table 3. Risk factors of premature myocardial infarction identified by multiple logistic 
regression analysis  
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Moreover, there was a synergistic effect between smoking and T allele of CYP2J2 genotype 
on the occurrence of MI. (Table 4.) Among patients who did not smoke, the T allele was 
associated with a higher risk of young MI (OR 1.43, 95% CI 1.2 to 6.2). Smoking carrier with 
the G allele was associated with a 3-fold higher risk for premature MI (OR 3.78, 95% CI 3.3 
to 10.6). Furthermore, smoking carriers of the T allele of CYP2J2 allele had a significantly 5.6-
fold higher risk of premature MI (OR 5.55, 95% CI 4.3 to 13.7) when compared with non-
smoking and G allele genotype carriers. 
 
Smoking CYP2J2 G-50T genotype Control (n=200)
Premature MI 
(n=200) OR 95% CI 
No GG 87 36 1  
No GT+TT 24 10 1.43 1.2-6.2 
Yes GG 69 108 3.78 3.3-10.6 
Yes GT+TT 20 46 5.55 4.3-13.7 
 
Data are presented as number of patients. CI = confidence interval; GG = homozygous G allele of 
CYP2J2 G-50T gene; GT = heterozygous allele of CYP2J2 G-50T gene; MI = myocardial infarction; TT = 
homozygous T allele of CYP2J2 G-50T gene; OR = odds ratio 
Table 4. Association between smoking and CYP2J2 G-50T genotype on premature 
myocardial infarction  
3.4 Functional analysis of EET metabolites  
To further investigate the functional role of the G-50T polymorphism, we measured the 
plasma concentrations of the major CYP2J2-dependent epoxidation product from 
arachidonic acid. Given the instability of the primary products, EETs, concentration of the 
stable metabolite 14,15-DHET was determined after extraction from plasma samples. 
Median DHET plasma concentrations were significantly lower in samples from premature 
MI subjects with the G-50T polymorphism when compared with G allele individuals (6.2 ± 
1.2 ng/mL vs. 10.8 ± 2.5 ng/mL; p = 0.025). Among premature MI subjects, the median 
DHET plasma concentrations were significantly lower among smoking carriers with the G-
50T polymorphism (3.3 ± 1.0 ng/mL vs. 6.8 ± 1.3 ng/mL; p = 0.001). However, this effect 
was not significant for subjects without gene variation (G allele carriers) (10.2 ± 1.3 ng/mL 
vs. 10.8 ± 2.4 ng/mL; p = 0.18). (Fig 1) 
Median DHET plasma concentrations were significantly lower in samples from premature 
MI subjects with the G-50T polymorphism when compared with G allele individuals. 
Among premature MI subjects, the median DHET plasma concentrations were significantly 
lower among smoking carriers with the G-50T polymorphism. However, this effect was not 
significant for subjects without gene variation (G allele carriers). Median DHET levels were 
significantly lower among CYP2J2 G-50T polymorphism compared with G allele 
individuals. The median DEHT levels were significantly lower among smoking carriers with 
T allele subjects, but not among G allele ones. DHET = dihydroxyeicosatrienoic acid; MI = 
myocardial infarction. 
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Fig. 1. Plasma concentrations of the 14, 15-dihydroxyeicosatrienoic acid (DHET), a major 
CYP2J2-dependent epoxidation product from arachidonic acid among premature 
myocardial infarction subjects.  
3.5 The follow-up clinical and angiographic characteristics analyses 
During a mean period of 4.43 years (from 0.5 to 13 years) follow-up, cardiac events occurred 
in 48 (28.2%) patients, including four (2.4%) with cardiac death, 24 (14.1%) with recurrent 
MI, and 20 (11.7%) with recurrent angina pectoris. The baseline and the available follow-up 
clinical and angiographic characteristics are shown in Table 5. 
With similar mean follow-up periods, most of the clinical manifestations and treatment 
regimens were no different before and after follow-up in both groups that with-event and 
without-event, except that usage frequencies of both angiotensin-converting enzyme 
inhibitors (ACEI) and statin were higher after follow-up in both groups (P < 0.05, compared 
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treatment P value 
Hypertension 29 (60.4) 31 (64.5) 0.14 36 (31.5) 38 (33.3) 0.15 
Diabetes 
mellitus 19 (39.5) 21 (43.8) 0.08 20 (17.5) 28 (24.5) 0.06 












13532 13740 0.28 13629 13739 0.54 
Triglycerides, 
mg/dL 13236 13756 0.42 13543 13656 0.77 
LVEF (%) 58.8±9.8 57.9±10.1 0.35 60.1±13.5 59.1±11.5 0.40 
Angiography 43 (89.9) 44 (91.6) 0.67 100 (87.7) 94 (82.4) 0.58 
PCI 25 (52.0) 29 (60.4) 0.44 60 (52.6) 59 (51.7) 0.38 
CABG 6 (12.5) 8 (16.7) 0.40 18 (15.8) 19 (16.7) 0.28 
CAD       
Single-vessel 24 (50.0) 26 (54.1) 0.32 64 (56.1) 60 (52.6) 0.85 
LAD 16 10  34 26  
LCX 3 7  9 15  
RCA 5 9  21 19  
Double-vessel 13 (27.1) 13 (27.1) 1.00 30 (26.3) 32 (28.0) 0.61 
Triple-vessel 10 (20.8) 8 (16.7) 0.44 22 (19.2) 23 (20.1) 0.22 
Medications       
β-blocker 19 (39.5) 24 (50.0) 0.06 91 (79.8) 97 (85.0) 0.10 
ACEI 10 (20.8) 20 (41.6) 0.04 69 (60.5) 80 (70.1) 0.06 
Statin 10 (20.8) 18 (37.5) 0.03 42 (36.8) 60 (52.6) 0.04 
With similar mean follow-up periods, most of the clinical manifestations and treatment regimens were 
no different before and after follow-up in both groups that with-event and without-event, except that 
usage frequencies of both angiotensin-converting enzyme inhibitors and statin were higher after follow-
up in both groups. Under these therapeutic profiles, patients’ blood pressures and fasting sugar levels 
were also similar in both groups after follow-up. Values are expressed as number (%) or mean ± SD. 
ACEI = angiotensin-converting enzyme inhibitor; CABG = coronary artery bypass graft surgery; CAD = 
coronary artery disease; CI = confidence intervals; ECG = electrocardiograms; HDL = high density 
lipoproteins; LAD = left anterior descending artery; LCX = left circumflex artery; LDL = low density 
lipoproteins; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous 
coronary interventions; RCA = right coronary artery. 
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Compared with event-free group, subjects with event during the follow-up period had 
significantly higher genetic prevalence rate of T allele (TT+GT) (Event vs. event-free 
subjects: 58.3% vs. 42.1%, p=0.02) as well as the whole T allele frequency (Event vs. event-
free: 42.7% vs. 29.8%, p=0.02). 
CYP2J2 genotypes With event (n=48) Event-free (n=114) P value 
TT+GT 11+17 (58.3) 16+30 (42.1) 0.02 
GG 20 (41.6) 68 (60.0)  
T allele relative frequency 41/96 (42.7) 68/228 (29.8) 0.02 
Compared with event-free group, subjects with event during the follow-up period had significantly 
higher genetic prevalence rate of T allele (TT+GT) as well as the whole T allele frequency. Values are 
expressed as n (%). 
Table 6. Frequencies of CYP2J2 G-50T genotypes in groups with or without cardiac events 
after index myocardial infarction  
Kaplan–Meier analysis demonstrated a significantly lower probability (23.5% vs. 34.6%, log-
rank P=0.04) of developing clinical coronary events among patients with the polymorphism 
of CYP2J2 promoter G-50T genotype (Fig. 2). 
 
Fig. 2. Kaplan-Meier survival curve for subsequent coronary events after index acute 
myocardial infarction for the patients carrying TT or GT allele (A) (or GG allele for (B)) at 
their CYP2J2 gene (after modified risk with age, diabetes mellitus, smoking, hypertension, 
and medication usage with ACEI or β-blockers). 
For traditional risk factors, patients in event groups had significantly higher prevalence rates 
of DM, hypertension and initial severe Killip’s status (>II) (all P < 0.05, see Table 7). The mean 
cholesterol level was also higher in the event group. Compared with the event group, patients 
without events received more medications such as ACEI, β-blocker and statin. The success rate 
of smoking cessation was higher in the event-free group (52.0% vs. 19.5%). 
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However, the event-free group patients received more frequent procedures of coronary 










Age (years) 40.3 ± 4.8 39.7 ± 4.4 0.43 
Sex (male) 91 (79.8) 42 (87.5) 0.50 
Family history 23 (20.1) 10 (20.8) 0.73 
Hypertension 36 (28.9) 29 (60.4) <0.01 
Diabetes mellitus 20 (17.5) 19 (39.5) <0.01 
Smoking 100 (87.7) 42 (87.5) 0.77 
Total cholesterol, mg/dL 191.4 ± 33.2 209.0 ± 35.3 <0.01 
HDL-cholesterol, mg/dL 42  11 44  9 0.22 
LDL-cholesterol, mg/dL 133  32 136  30 0.34 
Triglycerides, mg/dL 135  37 138  44 0.25 
Status of MI    
Q wave in EKG 98 (85.9) 36 (75.0) 0.47 
Peak CK level (U/L) 2845 ± 1988 2975 ± 2354 0.38 
LVEF (%) 55.4 ± 11.5 54.8 ± 12.3 0.64 
LVEF <45% 26 (22.8) 14 (29.1) 0.06 
Thrombolytic therapy 89 (78.0) 36 (75.0) 1.00 
Primary PTCA 19 (16.6) 8 (16.7) 1.00 
Coronary angiography 107 (93.8) 44 (91.6) 1.00 
PCI 61 (53.5) 25 (52.0) 0.89 
CABG 18 (15.8) 6 (12.5) 0.81 
VT/Vf at MI 9 (7.8) 4 (8.3) 0.91 
Killip’s classification  II 26 (22.8) 23 (47.9) <0.01 
Medication usage after MI    
β-blocker 91 (79.8) 19 (39.5) <0.01 
ACEI 69 (60.5) 10 (20.8) <0.01 
Statin 42 (36.8) 10 (20.8) 0.03 
Patients in event groups had significantly higher prevalence rates of DM, hypertension and initial 
severe Killip’s status (>II). The mean cholesterol level was also higher in the event group. Compared 
with the event group, patients without events received more medications such as ACEI, β-blocker and 
statin. The success rate of smoking cessation was higher in the event-free group. The event-free group 
patients received more frequent procedures of coronary bypass surgery in our MI group. Values are 
expressed as number (%) or mean ± SD. CK = creatine kinase; Vf = ventricular fibrillation; VT = 
ventricular tachycardia.  
Table 7. Comparison between patient groups with- or without- subsequent cardiac events 
during follow-up period after index myocardial infarction  
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Univariate Cox regression analyses of the clinical characteristics and genetic backgrounds of 
premature MI patients are shown in Table 8. Finally, we included the variables as DM, 
hypertension, smoking cessation after MI, multiple (>2-vessel) coronary disease, medical 
therapies with β-blockers, ACEI, or statins in traditional risk factors; and the polymorphism 
of CYP2J2 promoter G-50T genotype in genetic factors in the multiple logistic regression 
analysis. For clinical consideration, we also included factors such as treatment by 
thrombolysis or primary angioplasty or none into this survival analyses. That analysis 
showed that the polymorphism of CYP2J2 promoter G-50T genotype, DM, smoking 
cessation and use of ACEI were independent survival predictors (Table 9). 
 
 Hazard ratios (95% CI) p value 
Genetic variables 
CYP2J2 G-50T 2.78 (1.50-5.00) <0.01 
Traditional variables 
Age (>40 years-old) 1.59 (0.94-3.08) 0.07 
Sex (male) 0.66 (0.18-2.18) 0.51 
Family history vs. non-history 0.72 (0.35-1.55) 0.38 
Systemic hypertension 2.09 (1.39-5.05) <0.01 
Diabetes mellitus 2.71 (1.46-4.89) <0.01 
Smoking behavior before MI 1.89 (0.82-3.01) 0.55 
Smoking cessation after MI 0.21 (0.11-0.40) <0.01 
Total cholesterol > 200mg/dL 1.41 (0.50-1.98) 0.22 
Anterior MI vs. other wall 1.47 (0.81-1.95) 0.25 
LVEF (<45%) 0.68 (0.36-1.30) 0.25 
Thrombolytic therapy 1.42 (0.62-6.39) 0.57 
Primary PTCA 1.17 (0.93-8.78) 0.10 
Coronary angiography 0.46 (0.78-4.76) 0.88 
PCI procedure 0.53 (0.39-2.54) 0.70 
CABG 0.87 (0.72-1.32) 0.89 
VT/Vf at MI 0.77 (0.79-2.69) 0.72 
Killip’s classification  II 1.88 (1.33-6.62) <0.01 
Multiple (>2-vessel) disease 2.96 (0.84-7.25) 0.42 
Medication usage after MI   
Not-using β-blocker 2.34 (1.51-3.17) 0.01 
Not-using ACEI 7.19 (2.84-10.2) <0.01 
Not-using statin 1.65 (1.02-2.93) 0.01 
Table 8. Univariate analyses of traditional and genetic risk factors with Cox proportional 
hazards models for subsequent cardiac events. Values are expressed as number (%) or mean 
± SD.  
 




 Hazard ratios (95% CI) p value 
Not-using ACEI 10.5 (2.08-14.18) <0.01 
Diabetes mellitus 2.41 (1.23-6.95) 0.01 
Smoking cessation after MI 0.33 (0.15-0.81) 0.01 
Not-using statin 1.45 (1.02-2.95) 0.04 
CYP2J2 G-50T 2.51 (1.09-5.78) 0.03 
Not-using β-blocker 1.46 (0.99-3.29) 0.06 
Multiple vessel disease 1.76 (0.88-7.56) 0.26 
Systemic hypertension 1.57 (0.84-3.57) 0.32 
Thrombolytic therapy 1.52 (0.25-8.40) 0.50 
LVEF <45% 1.34 (0.87-10.56) 0.55 
Primary PTCA 1.08 (0.80-10.12) 0.43 
Killip’s classification  II 1.48 (0.59-8.76) 0.34 
Age (>40 years-old) 1.32 (0.50-2.22) 0.65 
The variables as DM, hypertension, smoking cessation after MI, multiple (>2-vessel) coronary disease, 
medical therapies with β-blockers, ACEI, or statins in traditional risk factors; and the polymorphism of 
CYP2J2 promoter G-50T genotype in genetic factors were put in the multiple logistic regression 
analysis. That analysis showed that the polymorphism of CYP2J2 promoter G-50T genotype, DM, 
smoking cessation and use of ACEI were independent survival predictors. Values are expressed as 
number (%) or mean ± SD.  
Table 9. Multivariate analysis with Cox regression method assessing both traditional and 
genetic risk factors for subsequent cardiac events  
3.6 The modification effect and gene–environment interaction of smoking cessation  
We also analyzed the effect of smoking cessation after the smoker’s index MI. We divided 
the smoking patients into two groups, based on their successful smoking cessation or not 
after the index MI and found that successful smoking cessation could improve the outcome 
(successful smoking cessation: event vs. event-free, 25% vs. 46.3%, HR 0.26, 95% CI 0.11 to 
0.42; current smoking after index MI: event vs. event-free, 60% vs. 28.4%, HR 3.91, 95% CI 
2.37 to 8.86; P=0.003 for HR difference). Gene–environment interactions were analyzed for 
the polymorphism of CYP2J2 promoter G-50T genotype. Among the successful smoking 
cessation subjects, the risk of subsequent cardiovascular events was 1.6-fold higher among 
the G allele subgroup when compared with the T allele carrying subjects. With the same 
genetic background as T genotype, their risk was also 2.1-fold higher among current 
smokers. However, among patients who carried the G allele, the current smoking behavior 
increased the risk to 7.2-fold higher (Fig. 3). It seems that the risk could be lower after 
smoking cessation, even among high-risk gene carrying patients. 
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Fig. 3. Modification and interaction effects of the CYP2J2 G-50T gene polymorphism and the 
cessation of smoking for the risk of subsequent cardiac events 
4. Discussion 
The present study investigates the association between the polymorphism of CYP2J2 
promoter G-50T genotype and the onset of premature MI in Taiwanese population. We 
found a higher frequency of T allele in patients with premature MI than in control subjects. 
There was a significant synergistic interaction between this polymorphism and the smoking 
behavior for the onset of MI at younger age in Taiwan.  
4.1 Mechanism of the association between the polymorphism of the CYP2J2 promoter 
G-50T genotype and premature MI 
The polymorphism of CYP2J2 promoter G-50T gene has been described among different 
disease status groups, including hypertension and CAD (Spieker et al., 2004; King et al., 2005). 
Spieker et al had demonstrated a functional relevance of this genetic variant by the method of 
electrophoretic mobility shift assays in human umbilical vein endothelial cells (Spieker et al., 
2004). They found a functional consequence of reduced Sp1-DNA binding on transcriptional 
activation of the CYP2J2 gene by using transfection studies in vitro. The construction 
containing the wild type promoter induced a 2-fold higher promoter activity compared with 
the mutant G-50T construct cells. In subjects of documented CAD, the frequency of the G-50T 
polymorphism was much higher. In our study, we also demonstrate that patients with CYP2J2 
G-50T allele have higher possibility of premature MI. In addition, the T allele in the promoter 
region of CYP2J2 gene may functionally reduce EETs activities in the atherosclerotic 
vasculature, which was supported by the evidence of relationship between the genotype G-
50T and the reduced EETs activities in these MI patients. This gene-phenotype association of 
the G-50T mutation in this promoter region could be considered as one of the possible causes 
to enhance the vulnerability of the atherosclerotic plaque under stimulation.  
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4.2 The synergistic effects of the CYP2J2 G-50T genotype and smoking behavior 
In our subgroup analysis, we also demonstrate this gene-environment interaction between 
smoking behavior and the CYP2J2 G-50T polymorphism. Among non-smoker groups, the risk 
of MI in patients with T allele (CYP2J2 GT+TT) is significantly higher when compared with the 
CYP2J2 GG genotype patients (OR 1.43 and 1.0, respectively). The smoking behavior alone can 
increase 3-fold risk of MI in patients with lower activity of CYP2J2 GG genotype at the 
promoter region. However, those smokers carrying the T allele polymorphism had a 5.6-fold 
higher risk of young MI when compared with non-smoking non-carriers.  
Arachidonic acid metabolites contribute to the regulation of vascular tone and therefore 
tissue blood flow (Imig 2000; Gauthier et al., 2004). The vascular endothelium metabolizes 
arachidonic acid by cytochrome P450 epoxygenases to epoxyeicosatrienoic acids or EETs. In 
the vasculature, EETs are key components of cellular signaling cascades that cumulate in the 
activation of smooth muscle potassium channels to induce membrane hyperpolarization 
and vascular relaxation. Smoking habit might induce the hypercoagulable state by 
increasing platelet aggregability and had been recognized as a potent risk factor for 
premature MI (Teng et al., 1994).  
In current gene-phenotype functional study, we successfully demonstrated that this genetic 
variant could influence the active EETs metabolites concentrations among premature MI 
subjects. Patients carrying T allele at promoter region of CYP2J2 gene thus had lower 
median value of 14,15 EETs concentrations, which might protect their coronary 
vasculatures. In addition, smoking could alter the metabolites of arachidonic acid (Ye et al., 
2004). This effect was observed, in our study, more significantly among CYP2J2 G-50T 
polymorphism carriers whom probably were more prone to the oxidative stress damage due 
to their impaired EETs functions. These combination effects might explain the possible 
mechanism for the synergistic effect of smoking behavior and the functional change of EETs 
activities by polymorphism with different genotypes in its promoter gene. 
4.3 Modification effects of smoking cessation and its association with gene variation 
on prognosis 
Smokers have twice the risk of dying of coronary heart disease or stroke, and the risk 
diminishes by half in the first year after cessation. After 5–15 years of smoking cessation, the 
risk of both stroke and heart disease drops to the level of never-smokers. Previous studies 
usually used the history of smoking rather than current status of smoking for analysis (Li et al., 
2002; Sacks et al., 1996). Our study analyzed the influence of smoking cessation on the 
prognosis following MI and found that those who kept on smoking could have a higher risk 
for subsequent coronary events when compared with those who stopped smoking. Moreover, 
among patients carrying higher risk genetic background, which indicated the T allele gene, the 
benefit was even greater from smoking cessation. It seems that a gene–environment 
modification relationship exists between smoking behavior and the CYP2J2 gene variation.  
In fact, the smoking behavior alone is a potent risk factor for MI at a young age (Teng et al., 
1994; Liu et al., 2003). Smoking, in supporting of our current in vitro and in vivo findings, can 
also reduce the activities of DHET and may explain partially the possible mechanism for the 
smoking behavior alone or its interaction with gene variation to change the CYP2J2 gene 
activity. Our findings also suggest that successful smoking cessation is very important and 
can improve the cardiovascular outcome, especially among those patients carrying high-risk 
genes. 
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to their impaired EETs functions. These combination effects might explain the possible 
mechanism for the synergistic effect of smoking behavior and the functional change of EETs 
activities by polymorphism with different genotypes in its promoter gene. 
4.3 Modification effects of smoking cessation and its association with gene variation 
on prognosis 
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diminishes by half in the first year after cessation. After 5–15 years of smoking cessation, the 
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usually used the history of smoking rather than current status of smoking for analysis (Li et al., 
2002; Sacks et al., 1996). Our study analyzed the influence of smoking cessation on the 
prognosis following MI and found that those who kept on smoking could have a higher risk 
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activity. Our findings also suggest that successful smoking cessation is very important and 
can improve the cardiovascular outcome, especially among those patients carrying high-risk 
genes. 
Cytochrome P450 Epoxygenase CYP2J2 G-50T Polymorphism is an Independent 




There was a significant association between the polymorphism of G-50T genotype in the 
promoter region of CYP2J2 gene and premature MI in Taiwan. Both the CYP2J2 G-50T 
genotype and smoking were independent risk factors for young MI population. A synergistic 
effect between these two risk factors for the premature onset of MI had been shown in 
subgroup analyses. In addition, there was a significant association between the CYP2J2 G-50T 
genotype and the prognosis after index premature MI. Successful smoking cessation after MI 
also could reduce the incidence of recurrent coronary events, especially among high-risk 
genetic background populations. Such findings lend credence to the concept that genetics and 
environment should not be viewed as independent risk factors for a particular disease; rather, 
environment and genetics interact with each to determine overall health.  
6. Acknowledgement 
This study was supported in part by the Multidisciplinary Center of Excellence for Clinical 
Trial and Research (DOH100-TD-B-111-002), Department of Health, Executive Yuan, Taiwan 
and by the Grant 98-2314-B-006-047-MY3 from National Science Council, Executive Yuan, 
Taipei, Taiwan 
7. References 
Barua, R.; Ambrose, J.; Saha, D. & Eales-Reynolds L. (2002). Smoking is associated with 
altered endothelial-derived fibrinolytic and antithrombotic factors, an in vitro 
demonstration. Circulation, Vol. 106, pp. 905-908. 
Craig, M.; Palomaki, G. & Haddow, J. (1989). Cigarette smoking and serum lipid and 
lipoprotein concentrations: an analysis of published data. Br Med J, Vol. 298, pp. 
784-788.  
Eliasson, B.; Mero, N.; Taskinen M.; & Smith U. (1997). The insulin resistance syndrome and 
postprandial lipid intolerance in smokers. Atherosclerosis, Vol. 129, pp. 79-88. 
Fang, X.; Weintraub, N.; Oltman, C.; Stoll, L.; Kaduce, T.; Harmon, S.; Dellsperger, K.; 
Morisseau, C.; Hammock, B. & Spector, A. (2002). Human coronary endothelial 
cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J 
Physiol Heart Circ Physiol, Vol. 283, pp. H2306-H2314.  
Gauthier, K.; Falck, J.; Reddy, L. & Campbell, W. (2004). 14,15-EET analogs: characterization 
of structural requirements for agonist and antagonist activity in bovine coronary 
arteries. Pharmacol Res; Vol. 49, pp. 515-524.  
Humphries, S.; Marin, S.; Cooper, J. & Miller, G. (2002). Interaction between smoking and 
the stromelysi-1 (MMP3) gene 5A/6A promoter polymorphism and risk of 
coronary heart disease in healthy men. Ann Hum Genet, Vol. 66, pp. 343-352. 
Imig, J. (2000). Epoxygenase metabolites. Epithelial and vascular actions. Mol Biotechnol, Vol. 
16, pp. 233-251. Review.  
King, L.; Gainer, J.; David, G.; Dai, D.; Goldstein, J.; Brown, N. & Zeldin, D. (2005). Single 
nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of 
hypertension. Pharmacogenet Genomics, Vol. 15, pp 7-13. 
King, L.; Ma, J.; Srettabunjong, S.; Graves, J.; Bradbury, J.; Li, L.; Spiecker, M.; Liao, J.; 
Mohrenweiser, H. & Zeldin, D. (2002). Cloning of CYP2J2 gene and identification of 
functional polymorphisms. Mol Pharmacol, Vol. 61, pp. 840-852. 
 
Novel Strategies in Ischemic Heart Disease 
 
378 
Li, Y.; Chen, J.; Tsai, W.; Chao, T.; Guo, H.; Tsai, L.; Wu, H. & Shi, G. (2002). Synergistic 
effect of thrombomodulin promoter –33G/A polymorphism and smoking on the 
onset of acute myocardial infarction. Thromb Haemost, Vol. 87, pp. 86-91. 
Liu, P.; Li, Y.; Chao, T.; Wu, H.; Lin, L.; Tsai, L. & Chen, J. (2007). Synergistic effect of 
cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset 
of premature myocardial infarction. Atherosclerosis, Vol. 195, pp. 199-206. 
Liu, P.; Li, Y.; Tsai, W.; Tsai, L.; Chao, T.; Wu, H. & Chen, J. (2005). Stromelysin-1 promoter 
5A/6A polymorphism is an independent genetic prognostic risk factor and 
interacts with smoking cessation after index premature myocardial infarction. J 
Thromb Haemost, Vol. 3, pp. 1998-2005. 
Liu, P.; Tsai, W.; Lin, L.; Li, Y.; Chao, T.; Tsai, L. & Chen, J. (2003). Time domain heart rate 
variability as a predictor of long-term prognosis after acute myocardial infarction. J 
Formos Med Assoc, Vol. 102, pp. 474-479. 
Manson, J.; Tosteson, H.; Ridker, P.; Satterfield, S.; Hebert, P.; O'Connor, G.; Buring, J. & 
Hennekens, C. (1992). The primary prevention of myocardial infarction. N Engl J 
Med, Vol. 326, pp. 1406-1416.  
Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. & Liao, J. (1999). Anti-
inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. 
Science, Vol. 285, pp. 1276-1279.  
Pinto, A.; Abraham, N. & Mullane, K. (1987). Arachidonic acid-induced endothelial-
dependent relaxations of canine coronary arteries: contribution of a cytochrome P-
450-dependent pathway. J Pharmacol Exp Ther, Vol. 240, pp. 856-863.  
Sacks, F.; Pfeffer, M.; Moye, L.; Rouleau, J.; Rutherford, J.; Cole, T.; Brown, L.; Warnica, J.; 
Arnold, J.; Wun, C.; Davis, B. & Braunwald, E. (1996). The effect of pravastatin on 
coronary events after myocardial infarction in patients with average cholesterol 
levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, Vol. 335, 
pp. 1001-1009. 
Sun, J.; Sui, X.; Bradbury, J.; Zeldin, D.; Conte, M. & Liao, J. (2002). Inhibition of vascular 
smooth muscle cell migration by cytochrome p450 epoxygenase-derived 
eicosanoids. Circ Res, Vol. 90, pp. 1020-1027.  
Spiecker, M.; Darius, H.; Hankeln, T.; Soufi, M.; Sattler, A.; Schaefer, J.; Node, K.; Borgel, J.; 
Mugge, A.; Lindpaintner, K.; Huesing, A.; Maisch, B.; Zeldin, D. & Liao, J. (2004). 
Risk of coronary artery disease associated with polymorphism of the cytochrome 
P450 epoxygenase CYP2J2. Circulation, Vol. 110, pp. 2132-2136.  
Spiecker, M. & Liao, J. (2005). Vascular protective effects of cytochrome p450 
epoxygenase-derived eicosanoids. Arch Biochem Biophys, Vol.433, pp. 413-420. 
Review.  
Teng, J.; Lin, L.; Tsai, L.; Kwan, C. & Chen, J. (1994). Acute myocardial infarction in young 
and very old Chinese adults: clinical and therapeutic implications. Int J Cardiol, Vol. 
44, pp. 29-36. 
Tsiara, S.; Elisaf, M. & Mikhailidis, D. (2003). Influence of smoking on predictors of vascular 
disease. Angiology, Vol. 54, pp. 507-530. 
Wu, S.; Moomaw, C.; Tomer, K.; Falck, J. & Zeldin, D. (1996). Molecular cloning and 
expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase 
highly expressed in heart. J Biol Chem, Vol. 271, pp. 3460-3468.  
Ye, Y.; Liu, E.; Shin, V.; Wu, W.; Luo, J. & Cho, C. (2004). Nicotine promoted colon cancer 
growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated 
signal pathway. J Pharmacol Exp Ther, Vol. 308, pp. 66–72. 
 
Novel Strategies in Ischemic Heart Disease 
 
378 
Li, Y.; Chen, J.; Tsai, W.; Chao, T.; Guo, H.; Tsai, L.; Wu, H. & Shi, G. (2002). Synergistic 
effect of thrombomodulin promoter –33G/A polymorphism and smoking on the 
onset of acute myocardial infarction. Thromb Haemost, Vol. 87, pp. 86-91. 
Liu, P.; Li, Y.; Chao, T.; Wu, H.; Lin, L.; Tsai, L. & Chen, J. (2007). Synergistic effect of 
cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset 
of premature myocardial infarction. Atherosclerosis, Vol. 195, pp. 199-206. 
Liu, P.; Li, Y.; Tsai, W.; Tsai, L.; Chao, T.; Wu, H. & Chen, J. (2005). Stromelysin-1 promoter 
5A/6A polymorphism is an independent genetic prognostic risk factor and 
interacts with smoking cessation after index premature myocardial infarction. J 
Thromb Haemost, Vol. 3, pp. 1998-2005. 
Liu, P.; Tsai, W.; Lin, L.; Li, Y.; Chao, T.; Tsai, L. & Chen, J. (2003). Time domain heart rate 
variability as a predictor of long-term prognosis after acute myocardial infarction. J 
Formos Med Assoc, Vol. 102, pp. 474-479. 
Manson, J.; Tosteson, H.; Ridker, P.; Satterfield, S.; Hebert, P.; O'Connor, G.; Buring, J. & 
Hennekens, C. (1992). The primary prevention of myocardial infarction. N Engl J 
Med, Vol. 326, pp. 1406-1416.  
Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. & Liao, J. (1999). Anti-
inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. 
Science, Vol. 285, pp. 1276-1279.  
Pinto, A.; Abraham, N. & Mullane, K. (1987). Arachidonic acid-induced endothelial-
dependent relaxations of canine coronary arteries: contribution of a cytochrome P-
450-dependent pathway. J Pharmacol Exp Ther, Vol. 240, pp. 856-863.  
Sacks, F.; Pfeffer, M.; Moye, L.; Rouleau, J.; Rutherford, J.; Cole, T.; Brown, L.; Warnica, J.; 
Arnold, J.; Wun, C.; Davis, B. & Braunwald, E. (1996). The effect of pravastatin on 
coronary events after myocardial infarction in patients with average cholesterol 
levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, Vol. 335, 
pp. 1001-1009. 
Sun, J.; Sui, X.; Bradbury, J.; Zeldin, D.; Conte, M. & Liao, J. (2002). Inhibition of vascular 
smooth muscle cell migration by cytochrome p450 epoxygenase-derived 
eicosanoids. Circ Res, Vol. 90, pp. 1020-1027.  
Spiecker, M.; Darius, H.; Hankeln, T.; Soufi, M.; Sattler, A.; Schaefer, J.; Node, K.; Borgel, J.; 
Mugge, A.; Lindpaintner, K.; Huesing, A.; Maisch, B.; Zeldin, D. & Liao, J. (2004). 
Risk of coronary artery disease associated with polymorphism of the cytochrome 
P450 epoxygenase CYP2J2. Circulation, Vol. 110, pp. 2132-2136.  
Spiecker, M. & Liao, J. (2005). Vascular protective effects of cytochrome p450 
epoxygenase-derived eicosanoids. Arch Biochem Biophys, Vol.433, pp. 413-420. 
Review.  
Teng, J.; Lin, L.; Tsai, L.; Kwan, C. & Chen, J. (1994). Acute myocardial infarction in young 
and very old Chinese adults: clinical and therapeutic implications. Int J Cardiol, Vol. 
44, pp. 29-36. 
Tsiara, S.; Elisaf, M. & Mikhailidis, D. (2003). Influence of smoking on predictors of vascular 
disease. Angiology, Vol. 54, pp. 507-530. 
Wu, S.; Moomaw, C.; Tomer, K.; Falck, J. & Zeldin, D. (1996). Molecular cloning and 
expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase 
highly expressed in heart. J Biol Chem, Vol. 271, pp. 3460-3468.  
Ye, Y.; Liu, E.; Shin, V.; Wu, W.; Luo, J. & Cho, C. (2004). Nicotine promoted colon cancer 
growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated 





Coronary Artery Aneurysms: An Update 
Karina M. Mata, Cleverson R. Fernandes,  
Elaine M. Floriano, Antonio P. Martins, 
Marcos A. Rossi and Simone G. Ramos 
Department of Pathology, Faculty of Medicine of Ribeirão Preto,  
Ribeirão Preto, University of São Paulo, 
Brazil 
1. Introduction 
Coronary artery aneurysm (CAA) is a neglected topic in the pathology literature; most 
descriptions of CAAs have been limited to reports of single cases and some reviews. 
Because CAAs are usually found incidentally during cardiac examinations, most of the 
reported cases have been diagnosed by coronary angiography, intravascular ultrasound 
and, on rare occasions, during autopsy (Ramos et al., 2008). Although they are rare, CAAs 
can be potentially fatal if they are not managed in a judicious and timely manner.  
The first description of a CAA has been attributed to Morgagni, an Italian 
anatomopathologist of the mid-18th century. However, the first CAA in a living patient was 
diagnosed by coronary angiography (Munkner et al., 1958). Since then, many studies have 
been conducted on the pathology of abnormal dilatations of the coronary arteries; however, 
attempts at defining and classifying these abnormalities still create problems for researchers 
and physicians who work in this area. The major problem is differentiating between 
aneurysms and ectasias. Currently, CAA is defined as a localized, irreversible dilatation of 
the blood vessel lumen that exceeds the diameter of the adjacent normal segment by more 
than 1.5-fold (Falsett & Carrol, 1978; Swaye et al. 1983; Syed & Lesch, 1997). In contrast, 
ectasia is used to describe a diffuse dilatation of coronary arteries that involves 50% or more 
of the length of the artery; this classification is made according to the appearance and 
number of vessels involved (Markis et al, 1976). Ectasia has been subcategorized based on 
the topographical extent in the major epicardial coronary arteries into the following 4 types: 
type I, diffuse ectasia of two or three arteries; type II, diffuse ectasia in one artery and 
localized in another; type III, diffuse ectasia of one artery only; and type IV, localized and 
segmental ecstatic lesions (Markis et al., 1976). The existence of the last type causes 
confusion in separating aneurysms from ectasias; therefore, additional efforts to define 
specific anatomic substrates will help to standardize the reporting of this disease and 
minimize discrepancies in the literature regarding management. 
On rare occasions, a CAA grows large enough to be called a giant CAA, for which a precise 
definition is still lacking. Some authors consider coronary aneurysms to be giants when the 
CAA is greater than 2 cm (Mora et al., 2011), whereas the Committee of the American Heart 
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Association has defined giant aneurysms as those greater than 8 mm. In the literature, most 
of the reported maximum diameters of giant CAAs in adults have varied from 5 to 16 cm. 
Recently, cases of right giant CAAs have been recorded in MEDLINE and selected English-
language articles describing CAAs with diameters exceeding 5 cm over a 10–year period 
(1998-2008; Ramos et al., 2008). A male predilection (63%) and a mean age of 58 years were 
observed. The most frequent cause was atherosclerosis (37%), especially in older patients. 
The symptoms of the CAAs varied, and only four patients were asymptomatic. Surgical 
resection was the treatment of choice (74%), and most patients underwent coronary artery 
bypass grafting (59%) or coronary artery reconstruction (7%). The majority of the patients 
had an uneventful recovery. Only 7% (2/27) of the patients died from cardiac causes related 
to the CAA (Ramos et al., 2008).  
2. Incidence and anatomic distribution  
A wide variation exists in the incidence of CAA. This variation can be attributed to the 
conceptual differences in the definition of coronary aneurysms and ectasia. In the 
literature, the incidence of coronary artery disease has been predominantly in men with 
an average age of 63.5 years (Befeler et al., 1977; Daoud et al., 1983). In the order of 
frequency, the following are the most affected coronaries: right coronary artery (RCA; 
40.4%), left anterior descending artery (32.3%), left circumflex artery (23.4%), and rarely, 
left main coronary artery (3.5%); (Syed & Lesh, 1997). Atherosclerotic or inflammatory 
coronary aneurysms are usually multiple and involve more than one coronary artery. In 
contrast, congenital, traumatic, or dissecting aneurysms are usually single. Although 
coronary aneurysms are seen at any age, those related to atherosclerosis usually appear 
later in life than those associated with a congenital or inflammatory nature (Daoud et al., 
1983).  
3. Classification 
CAAs have been classified in different ways based on the composition of the vessel wall 
and the morphological structure (Table 1). Aneurysms are often classified by macroscopic 
shape and size, according to the transversal and longitudinal size. Saccular aneurysms are 
spherical and show a transverse diameter greater than the longitudinal diameter, whereas 
fusiform aneurysms are characterized by a gradual and progressive dilatation that 
involves the complete circumference of the artery and have a transverse diameter that is 
smaller than the longitudinal diameter (Williams & Stewart et al., 1994). Moreover, CAAs 
may be true or false (pseudoaneurysms) depending on the composition of the aneurysmal 
wall. True aneurysms contain all normal vascular layers, and the blood remains within 
the confines of the circulatory system. False, or pseudoaneurysms, are extravascular 
hematomas that communicate with the intravascular space. Normal vascular integrity is 
usually lost, resulting in the formation of thin-walled structures that lack normal arterial 
wall layers. Pseudoaneurysms typically occur after disruption of the external elastic 
membrane and frequently result from blunt chest trauma or catheter-based coronary 
interventions (Aqel et al., 2004). Furthermore, pseudoaneurysms usually affect only a 
portion of the artery wall and are more vulnerable to thrombosis and rupture (Williams & 
Stewart, 1994). 
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Classification of CAAs 
Characteristics  Categories  Luminal diameter of the aneurysm 
Shape  Saccular Fusiform  
Maximum transverse diameter > longitudinal 
dimension 






All vascular layers present 








Diffuse dilatation of two or three vessels 
Diffuse dilatation in one vessel and localized in 
another 
Diffuse dilatation of one vessel only 
Localized or segmental dilatation 
Modified from Antoniadis et al., 2008; Díaz-Zamudio et al., 2009. 
Table 1. Morphologic and topographical classification of aneurysms and ectasias observed 
in coronary arteries. 
4. Epidemiology  
The prevalence of coronary artery disease in angiographic series has been documented to 
vary between 0.2 and 10%, but these studies have included both aneurysmal coronary 
disease and ectasias (Antoniadis et al., 2008). Because each angiographic diagnosis is 
operator-dependent, inter-observer variability may be responsible for the prevalence of 
discrepancies in different cohorts. Therefore, the documented frequencies may not represent 
the actual prevalence of coronary aneurysms in the general population. Moreover, one 
should not forget that a selection bias exists in patients referred for diagnostic coronary 
angiography. Table 2 shows exclusively the CAA prevalence in the most recent 
epidemiologic studies. 
Undoubtedly, important genetic and environmental influences affect incidence, and the 
CAA incidence has been shown to be lower in Asia than in North America and Europe. In 
contrast, a study of 302 patients with Kawasaki disease showed an incidence of coronary 
aneurysms of 10.3% in patients of Asian ethnicity compared with 6.9% in those of Caucasian 
ethnicity and 1.2% in those of African ethnicity (Porcella et al., 2005).   
Source  Diagnosis  Population  Prevalence (%) 
Falsetti & Carrol, 1976  Angiography  742  1.5 
Daoud et al., 1983  Autopsy  694  1.4 
Tunick et al.,1990  Angiography  8,422  0.2 
Wang et al., 1999  Angiography  10,120  0.1 
Harikrishnan et al., 2000  Angiography  3,200  0.7 
Groenke et al., 2005  Angiography  7,101  1.4 
Rozenberg & 
Nepomnyashchikh, 2005  Autopsy  
1,000 
  1.5 
Table 2. Prevalence of coronary artery aneurysms in angiographic and autopsy studies. 
 




Coronary atherosclerosis and Kawasaki disease are the principal causes of CAAs. 
Atherosclerosis is the most common etiology in the U.S., and Kawasaki disease is the most 
common etiology in the Far East (Cohen & Ogara, 2008). Atherosclerosis is responsible for 
more than 50% of CAAs in adults in the Western world, whereas Kawasaki disease, which is 
characterized by an acute, self-limited vasculitis occurring in childhood, may lead to the 
development of CAAs in 15 to 25% of untreated children (Falsetti & Carrol, 1976; Pahlavan 
& Niroomand, 2006). Other causes of CAAs include inflammatory arterial diseases 
(polyarteritis nodosa, syphilis, Takayasu arteritis, Behçet´s disease), connective tissue 
disorders (systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, 
scleroderma), hereditary collagen defects (Marfan syndrome, Ehlers-Danlos syndrome), 
coronary artery revascularization procedures (balloon angioplasty and laser atherectomy), 
candidiasis, chest traumas, and primary hyperaldosteronism (Alford et al., 1976; Antoniadis 
et al., 2008). CAA have also been noted in conjunction with infection, drug use, trauma, and 
percutaneous coronary intervention (Pahlavan & Niroomand, 2006). Therefore, many 
inflammatory disorders and infectious etiologies have been associated with CAAs. The 
etiologies usually vary according to the geographic location and age of the patient (Díaz-





Arteritis (polyarteriritis nodosa, syphilis, systemic lupus erythematous, Takayasu arteritis 





Connective tissue disorders (SLE, rheumatoid arthritis, ankylosing spondylitis, 
scleroderma) 
Hereditary collagen defects (Marfan and Ehlers-Danlos syndromes) 
Metastatic tumor 
Coronary angioplasty (balloon, laser atherectomy, stent implantation, directional coronary 
atherectomy, pulsed laser coronary angioplasty and brachytherapy)* 
Modified from Syed & Lesch, 1997. SLE: systemic lupus erythematosus. *Mostly pseudoaneurysms. 
 
Table 3. Etiology of Coronary Artery Aneurysms. 
The following sections describe the primary causes of CAA. 
5.1 Atherosclerosis 
Atherosclerosis is the most common cause of morbidity and mortality worldwide. This 
disease is characterized by chronic inflammatory and intimal lesions, called atheromas or 
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fibrofatty plaques, which protrude into the lumen, weaken the underlying media and 
undergo a series of complications affecting primarily elastic arteries and larger and 
medium sized muscular arteries, such as coronary arteries (Libby, 2002). Dauod et al. 
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Figure 1. 
 





Fig. 1. (A) Anterior view of the heart. Note a giant CAA (6x6.2x7.5 cm) starting after a 10-
mm-long segment of normal-sized RCA giving off the aorta and pushing back the right 
atrium. (B) Posterior view of the heart. The coronary aneurysm finishes as a 5-cm-long 
ecstasic arterial segment of the RCA along the atrioventricular groove to give off the 
posterior descending artery in the interventricular groove. In (A) and (B), the epicardium 
was removed to better show the diffuse atherosclerotic coronary artery disease (*). (C) 
Coronal section of the heart. The coronary aneurysm was empty and the wall was thickened 
with lipid deposits. Bar = 5cm. Microscopic section of the CAA wall. Note the dense 
fibrocollagenous thickening, extracellular lipids, mononuclear cells, and lymphocytic 
inflammatory infiltrates in the aneurysmal wall (D; Hematoxylin–eosin) and (E; Masson´s 
trichrome). Bar = 1mm. Ao: Aorta; CAA: coronary artery aneurysm; LA: left atrium; LV: left 
ventricle; PT: pulmonary trunk; RA: right atrium; RCA: right coronary artery, and RV: right 
ventricle. 
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5.2 Coronary vasculitis 
Systemic vasculitis represents a large group of diseases that are defined as inflammatory 
lesions of blood vessels (Lightfoot et al., 1990). Inflammatory thickening of the coronary 
arteries may lead to their occlusion, weakness of the wall, and in some cases, the 
development of aneurysms.  
5.2.1 Kawasaki Disease (KD) 
KD or mucocutaneous lymph node syndrome, is the most common cause of CAA in 
children and the second most common in adults. KD is a multisystem inflammatory illness 
that predominately affects children 6 months to 5 years of age, although younger infants 
and older children can also develop the illness (Amano et al., 1979). KD can result in acute 
vasculitis, most strikingly of the coronary arteries (Newburger et al., 1986). Important 
complications include coronary artery dilation and aneurysm formation, which occurs in 
10–15% of patients during the acute stage. The incidence of KD is at least ten times higher in 
Japan than in Western populations (Nakamura et al., 2008). Siblings of children with KD 
have a tenfold higher risk of developing the illness than the general population, and 
children whose parents had KD have a twofold increased incidence (Uehara et al., 2003).  
The etiology of KD remains a major pediatric enigma, despite efforts to identify the cause 
over the last four decades. Many proposed etiologies of KD have been suggested since Dr. 
Tomisaku Kawasaki’s initial description of the illness in Japan in the 1960s (Kawasaki, 1967). 
The most widely proposed theories have fallen under the categories of environmental toxin 
exposure, autoimmune pathogenesis, and infectious diseases. Because the clinical and 
epidemiologic features of KD support an infectious cause, one speculation is that the 
infectious agent travels from its portal of entry through the bloodstream and infects many 
organs and tissues; the immune response then targets these sites of infection. The theory of 
KD etiology that best fits the available data is that a ubiquitous infectious agent results in 
asymptomatic infection in most individuals but causes KD in a subset of genetically 
predisposed individuals (Rowley et al., 2008). Up to 25% of untreated children will develop 
persistent abnormalities in the coronary arteries; however, therapy with intravenous 
gammaglobulin and aspirin within the first ten days of fever onset reduces the prevalence of 
coronary artery abnormalities to approximately 5% (Newburger et al., 1986). 
Inflamed tissues in acute KD show inflammatory cell infiltration of the arterial wall 
(mononuclear cells, lymphocytes, and macrophages), destruction of the internal elastic lamina, 
necrosis of smooth muscle cells, myointimal proliferation and subsequent occurrence of 
dilations or aneurysms (Burgner et al., 2009). Histopathological findings have indicated 
destruction of coronary artery walls with diffuse vasculitis, raising the possibility that MMPs 
are also involved in coronary arterial wall destruction and the formation of CAAs (Amano et 
al., 1979). Among patients with KD, those with coronary artery lesions have higher plasma 
levels of both MMP 3 and MMP 9. Within the arterial wall, the production of MMPs and other 
enzymes by macrophages results in the destruction of collagen and elastin fibers. The wall can 
lose its structural integrity and dilate or balloon, forming an aneurysm. The immune response 
is ultimately successful in controlling the pathogen, but damage to the coronary arteries may 
have already occurred (Yilmazet al., 2007). 
The diagnosis of KD is clinical and is based on the major clinical features of the acute phase. 
Undoubtedly, many asymptomatic adult patients with coronary arterial lesions caused by 
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KD remain undiagnosed, forming a hidden cohort with this disease (Tsuda et al., 2007). 
Even once acute KD was recognized, the diagnosis of complicating coronary artery lesions 
was more difficult in the sixties and seventies. Symptoms are rare in this population until 
the onset of acute coronary syndrome; consequently, the presence of coronary artery disease 
is unsuspected in most patients. Only recently have technical developments allowed the 
detailed examination of coronary artery morphology. 
Although the precise etiology and pathogenesis of KD are not completely understood, the 
current management of acute KD is based upon prospective, controlled, multicenter treatment 
trials that have clearly demonstrated the efficacy of intravenous immunoglobulin (IVIG) and 
high-dose aspirin to halt inflammation and reduce the likelihood of the development of 
coronary abnormalities when administered by the tenth day of illness (Newburger et al., 1991). 
Whether or not to continue antithrombotic therapy in patients with regressed giant aneurysms 
is an important problem to resolve in the future (Tsuda et al., 2010). 
5.2.2 Polyarteritis nodosa (PAN) 
For decades, most forms of vasculitis were termed periarteritis nodosa. Newly recognized 
types of this disease were characterized and classified according to features that were 
similar to or distinct from those of PAN (Klinger, 1931; Churg & Strauss, 1951). In the early 
1900s, Ferrari (1903) and Dickson (1908) proposed the name polyarteritis nodosa, partly to 
distinguish the disorder described by Kussmaul & Maier (1866) from the vascular lesion of 
tertiary syphilis. Furthermore, the term polyarteritis nodosa emphasizes the panarteritic 
nature of this disease and underscores the fact that multiple arteries are affected by the 
process (Arkin, 1930). PAN is one of a spectrum of diseases that belong to the pathologic 
category of necrotizing vasculitis. The classic form of PAN was described by Kussmaul & 
Maier in 1866 as consisting of focal panmural, necrotizing inflammatory lesions in small- 
and medium-sized arteries and characterized by fibrinoid necrosis and infiltration of 
predominantly polymorphonuclear leukocytes. PAN is a multiple organ disorder with 
characteristic involvement of the renal and other visceral arteries. Coronary artery 
involvement (76%) ranks second in frequency behind the renal arteries (85%) (Lypsky et al., 
1994). Thrombosis, aneurysms, and arteritis of the coronary vessels are known 
complications of the disease. PAN affects 2 to 6 people per 100,000 per year and can be seen 
in all ethnic groups. Any age group can be affected, but the disease occurs more commonly 
in men than in women (2:1) and is seen in people between the ages of 40 and 60 years. The 
cause of PAN is unknown for most patients. For years, an infectious etiology for PAN has 
been considered. Early observers considered streptococci or Staphylococcus aureus to be likely 
candidates (David et al., 1993). Hepatitis B surface antigenemia (with immune complex 
formation) has been reported to be associated with approximately 20% of patients with PAN 
(Trepo et al., 1974). The incidence is higher in areas where hepatitis B is endemic. In studies 
from France, the percentage of cases of PAN attributed to hepatitis B viral infection 
decreased from 36% to 7% during the past decade after the development of vaccines against 
viral hepatitis (Guillevin et al., 1996).  
Aneurysms often form at the branching points of small- and medium-sized arteries and 
occur in 9% of patients with PAN (Kastner et al., 2000). The rupture of aneurysms may 
result in spontaneous hemorrhage in approximately 6% of cases (Zizic et al., 1982). Acute 
lesions in PAN swiftly evolve into a panarteritis with degeneration of the arterial wall, 
destruction of the external and internal elastic lamina, and fibrinoid necrosis. The cellular 
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infiltrate is pleomorphic, with both polymorphonuclear cells and lymphocytes present to 
various degrees at different stages. Degranulation of neutrophils within and around the 
arterial wall leads to leukocytoclasis. In time, this inflammation leads to transmural necrosis 
and a homogeneous, eosinophilic appearance of the blood vessel wall (fibrinoid necrosis). 
The vascular wall inflammation in PAN may be strikingly segmental, affecting only part of 
the circumference of a given artery. Segmental necrosis, in turn, leads to aneurysm 
formation. During later stages, complete occlusion may occur secondary to endothelial 
proliferation and thrombosis. Throughout involved tissues, the coexistence of acute and 
healed lesions is typical. Features of granulomatous vasculitis are absent. Acute PAN 
evolves into a sclerotic process with fibrosis of the damaged arterial wall and mesenchymal 
organization. In some cases, there is also recanalization of thrombi. Chronic arterial 
narrowing may result (Stone, 2002). 
The identification of PAN can be a clinical challenge given its varied spectrum of organ 
involvement, wide range of clinical symptoms, and variations in severity. The clinical course 
can last from months to years, and relapse occurs in 40% of treated patients with a median 
interval of 33 months (Gordon et al., 1993). If untreated, the disease may have a fulminant 
course; the 5-year survival is less than 15%. However, survival increases to 80% with steroid 
treatment, with or without cytotoxic drugs (Guillevin et al., 1996). Symptoms, such as fever, 
malaise, and weight loss, are common, and up to 70% of patients have abdominal pain, 
nausea, vomiting, and infarction are uncommon, occurring in 1% of cases (Zizic et al., 1982). 
A combination of corticosteroids and immunosuppressants is a highly effective therapy for 
progressive PAN. Therefore, early diagnosis, which is usually based on clinical signs and 
symptoms and laboratory and angiographic findings, is crucial for the prognosis of the 
patient (Parangui et al., 1991). Arterial angiography is still an important measure in cases 
suggestive of PAN when other noninvasive tests do not allow diagnosis. The diagnosis of 
PAN is strongly indicated by the finding of aneurysms within the vasculature during 
angiography (Holzknecht et al., 1997). Early diagnosis and treatment of PAN are necessary 
to prevent serious organ damage and should be suspected in patients with febrile disease, 
weight loss, and evidence of multiple organ involvement. The diagnostic criteria have been 
classified by the American College of Rheumatology (Ewald et al., 1987). Three of 10 criteria 
must be present for the diagnosis of PAN, and positive angiography is one of the criteria. In 
symptomatic patients (with primarily abdominal complaints, nephropathy, hypertension, or 
generalized malaise), angiography is a valuable diagnostic tool that can lead to the diagnosis 
in occult cases. Angiographic findings, including aneurysms, ectasia, or occlusive disease, 
are present in approximately 40%–90% of patients at the time clinical symptoms appear 
(Hekali et al., 1991).  
Some case reports of coronary angiograms performed in patients with PAN have been 
published. Przybojewski (1981) has described a 29-year-old man for whom the coronary 
angiography revealed a diffusely aneurysmal RCA with severe obstructive lesions in the left 
circumflex and left anterior descending arteries. PAN was subsequently diagnosed by a 
skeletal muscle biopsy. The biopsy showed fibrinoid necrosis affecting connective tissue and 
blood vessels in the muscle epimysium and adjacent fascia, which are features that are 
characteristic of a collagen vascular disease such as PAN. Pick et al. (1982) have reported a 
26-year-old woman who, during cardiac catheterization, revealed numerous aneurysms 
involving all three coronary vessels that were particularly worse in the distal RCA. Cassling 
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et al. (1985) have described a 30-year-old female smoker who presented with intermittent 
chest pain and a strongly positive stress test. Coronary angiography revealed severe luminal 
narrowing of several coronary arteries without aneurysm formation. The clinical diagnosis 
was occlusive atherosclerotic coronary artery disease. The patient died intraoperatively after 
the anastomosis of coronary artery bypass grafts. Subsequent autopsy revealed an 
unexpected coronary adventitial thickening and a polymorphous lymphocytic infiltrate 
consistent with PAN. An autopsy case of PAN is shown in the Figure 2. 
For cases of idiopathic PAN, corticosteroids and cytotoxic agents remain the cornerstones of 
treatment (Guillevin et al., 1996). Approximately half of patients with PAN achieve remissions 
or cures with high doses of corticosteroids alone (Lam et al., 1981). Fortunately, the availability 
of effective antiviral agents has revolutionized the treatment of hepatitis B virus (HBV) 
infection-associated cases in recent years (Guillevin et al., 1996). Prophylactic treatment of 
large aneurysms by means of catheter embolization should be considered in anticipation of the 
risk of rupture. Aortography may not adequately substitute for selective injections of the 
viscera, but the retroperitoneal branches are depicted, and they can also be involved with 
aneurysms that may rupture in rare cases. In a small percentage of patients with PAN, 
aneurysm rupture in an organ or retroperitoneal branch may be the first clinical evidence of 
the disease. Embolization therapy is often the treatment of choice (Hachulla et al., 1993). The 
presence of aneurysms may relate to the phase of the disease or its severity. Arterial segments 
of ectasia may be either a precursor to a fully expanded aneurysm or a phase in the healing 
process. Aneurysms of PAN may resolve over time as remission occurs (Guillevin et al., 1996). 
 
Fig. 2. (A) Right posterolateral view of the heart of a 56-year-old woman with systemic PAN. 
Note the multiple aneurysms in coronary arterial tree. (B) Detail of aneurysmal nodules in 
the right marginal artery (arrows). Histopathology of the coronary artery (C), showing an 
important luminal occlusion by intimal proliferation, partial disruption of the internal 
elastic laminae and tunica media, intense inflammatory infiltrate and remarkable adventitial 
fibrotic thickening (C; Hematoxylin–eosin and D; Masson´s trichrome). Bar = 1mm. PAN: 
Polyarteritis Nodosa. 
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5.2.3 Takayasu arteritis 
Takayasu arteritis (TA) was first described in 1908 by the Japanese ophthalmologist Takayasu, 
who reported ocular changes, such as aneurysms and arteriovenous anastomoses, in patients 
with this disease. This primary systemic vasculitis is a group of autoimmune syndromes 
characterized by stenosis, occlusion, or aneurysmal dilation that involves the large cardiac 
vessels, chiefly the aorta and its main branches. Epidemiological data have demonstrated that 
TA is more common in Asian countries than in other parts of the world. The incidence of 
aneurysms in patients with TA has been reported to be approximately 18% and 24%, and 
approximately 150 new cases per year have been estimated in Japan. However, the disease 
may be found worldwide, including occidental countries (Subramanyan et al., 1989). TA 
primarily affects females, and the female to male ratio can reach up to 8:1 in adulthood (age 
≤40 yr); in childhood, the ratio is significantly lower at 2:1 (Sharma et al., 1996; Mesquita et al., 
1998). The etiology of TA remains unknown, although autoimmune mechanisms and 
infections are factors that have been reported to be associated with the disease. Genetic aspects 
also appear to contribute to the pathogenesis of TA (Buzaid et al., 1995).  
The clinical progression of TA can be divided into acute and chronic phases. The acute phase 
comprises signs and symptoms of a systemic inflammatory process, such as fever, weight loss, 
anorexia, fainting, dizziness, nocturnal sweating, myalgia, arthralgia/arthritis, exanthema, 
abdominal pain, vomiting and anemia. The chronic phase is characterized by symptomatology 
of vascular occlusion with the appearance of hypertension and changes in peripheral pulses 
(Morales et al., 1991). However, these phases are not always distinct and may occur 
simultaneously (Kerr, 1995). Most of the lesions cause luminal narrowing, which can lead to 
occlusion; however, coronary aneurysms are extremely rare. CAA can develop as vascular 
walls weaken because of arterial hypertension and the extensive destruction of elastic fibers in 
the media. CAA often cause stasis of blood flow and result in mural thrombus (Lie, 1998). The 
histological changes are characterized by marked thickening of the adventitia, media, and 
intima (Subramanyan et al., 1989). The inflammatory process involves the coronary arteries in 
less than 10% of patients, mostly in the form of stenotic lesions (Sharma et al., 1995), and can be 
divided into 3 distinct morphologic types: stenosis or occlusion of the coronary ostia, diffuse or 
focal coronary arteritis, and coronary aneurysm formation (Panja et al., 1998). Rarely, the 
inflamed aorta of TA can be a source of dissection, but the various symptoms and signs more 
commonly mimic an aortic dissection (Reichman & Weber, 2004). 
Diagnosis is difficult because the initial stage of the disease may be asymptomatic or may be 
characterized by the presence of signs and symptoms of the acute phase. The latter may lead to 
an erroneous diagnosis, such as rheumatic fever, juvenile rheumatoid arthritis or systemic 
lupus erythematosus (Kerr, 1995). Angiography and clinical examination remain the 
cornerstones for the diagnosis of TA. While arteriographic studies of the aortic and pulmonary 
territories are necessary to obtain a complete sense of the extent of the disease, these invasive 
techniques cannot be frequently repeated (Hata et al., 1996). Echocardiography has become a 
valuable noninvasive diagnostic technique for the detection of cardiovascular complications in 
patients with TA (Soto et al., 1996).The use of drug-eluting stents for the effective treatment of 
coronary lesions associated with TA (Kang et al., 2006). However, surgical treatment of TA 
poses many difficulties related to the timing of the operation, the techniques and materials 
used, and postoperative management. Even though TA is considered a severe disease, it rarely 
causes death (Kerr, 1995). Nevertheless, the outcome depends on the medical and surgical 
 
Novel Strategies in Ischemic Heart Disease 
 
392 
treatment and on the cardiac involvement, severity, type of arterial hypertension and 
distribution of the vascular lesions (Mesquita et al., 1998). Currently, all treatment remains 
symptomatic because the etiology and pathogenesis of the disease are as yet unknown (Buzaid 
et al., 1985). Corticosteroids are the most widely employed drugs for the treatment of TA, and 
because they suppress the inflammatory manifestations and are helpful in the reversal of 
arterial stenosis, they are administered at high doses during the initial stage of the disease. 
Other drugs, such as cyclophosphamide, methotrexate and cyclosporin have been indicated 
for patients who do not respond to corticotherapy (Mesquita et al., 1998). An autopsy case is 
demonstrated in the Figure 3. 
 
Fig. 3. (A) Anterior and (B) posterior view of the heart, aorta and the major thoracic 
branches of a 17-year-old female diagnosed with Takayasu arteritis. Bar = 2.5cm. (C) Detail 
of the important luminal occlusion of the major thoracic arteries. (D) Histopathological view 
of the right carotid showing intimal thickening and partially recanalized thrombus. 
Hematoxylin-eosin; Bar = 1 mm. (E) RCA transversely sectioned to show the stenotic lumen. 
(F)  Histopathological view of the RCA showing intimal thickening, partially recanalized 
thrombus and prominent adventitial involvement. Hematoxylin-eosin; Bar = 1 mm. 
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In addition to those described above, some other diseases are also involved in the formation 
of CAA. Connective tissue diseases, such as Marfan syndrome, can cause aneurysms 
without atherosclerosis. Marfan syndrome is associated with mutations in the gene for 
fibrillin that is homologous to the family of latent TGF-β binding proteins, which hold TGF-
β in an inactive complex (Gelb, 2006). Cystic medial degeneration is a common feature of the 
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the development of aneurysms related to cocaine abuse. These include (a) direct endothelial 
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damage caused by severe episodic hypertension and vasoconstriction and (b) underlying 
atherosclerosis (Satran et al., 2005). 
6. Pathogenesis 
The pathogenesis of CAA is not completely understood but is likely to involve the 
destruction of the arterial media, thinning of the arterial wall, increased wall stress, and 
progressive dilatation of the coronary artery segment (Hirsch et al., 2000). Inflammation 
spilling over into the tunica media from the tunica intima has been hypothesized to link 
atherosclerosis to aneurysm formation in susceptible individuals. One could hypothesize 
that the giant cells that are sometimes present in CAA are merely reacting to cholesterol 
from atheroma and erythrocyte breakdown in the adjacent tunica intima. The 
lymphohistiocytic inflammation is merely spillover from the atherosclerosis in the adjacent 
tunica media. The cystic medial degeneration and aneurysm formation may be merely side 
effects of this spillover inflammation. Alternatively, one could hypothesize that the 
inflammation is sometimes due to autoimmune vasculitis coexisting with the atherosclerosis 
(Nichols et al., 2008).  
Aneurysm development can be a systemic or local disorder characterized by the 
overexpression of pro-inflammatory cytokines and enzymes that are capable of degrading 
elastin and other components of the vascular wall. The pathophysiology is focal 
destruction of the internal elastic lamina with early neutrophil infiltration followed by 
macrophages and cytotoxic T lymphocytes (Takahashi et al., 2005). Increased proteolysis 
of extracellular matrix proteins is probably a mechanism of CAA formation (Mata et al., 
2011). MMPs (1, 2, 3, 9 and 12) are capable of degrading essentially all components of the 
arterial wall matrix (elastin, collagen, proteoglycans, laminin, fibronectin, etc.) and are 
present at elevated concentrations in aneurysms, while decreased levels of tissue 
inhibitors of MMPs are present. The MMP-3, 5A allele is associated with higher promoter 
activity for transcription of the gene, and this allele is more common in patients with CAA 
plus atherosclerosis than patients with only coronary atherosclerosis (Lamblin et al., 
2005). CAAs have destruction of the tunica media, which is thinned, sometimes markedly, 
sometimes to the point of no longer being identifiable between the tunica intima and 
tunica adventitia. The normal smooth muscle cells and elastic fibers are replaced by 
hyalinized connective tissue. Destruction of the internal elastic lamina sometimes 
obscures the border between diseased tunica media and tunica intima diseased with 
atherosclerosis. Lipid deposits, foam cells, cholesterol clefts, eosinophilic debris, 
calcifications, neovascularization, inflammatory reactions, and sometimes hemorrhages 
can be seen and are sometimes limited to the tunica intima with atherosclerosis, 
sometimes extend into the tunica media and sometimes spread into the indistinct border 
zone. The inflammatory reaction chiefly consists of lymphocytes but can also include 
macrophages and sometimes foreign body giant cell formation around cholesterol clefts. 
Neutrophils, eosinophils, and plasma cells can be part of the inflammation. This 
inflammatory reaction is sometimes present in multiple arterial tunica and is sometimes 
transmural, involving all 3 layers of the artery. Thrombus formation is invariably present 
on the luminal surface of coronary aneurysms (Daoud et al., 1963). 
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Cause  Age  Description  Pathogenetic Mechanism 
Atherosclerosis  Adults   
Most common cause of 
CAA, clinical importance 
depends on association 
with significant coronary 
artery stenosis 
 
Local mechanical stress from 
stenosis, atherosclerotic 
pathologic findings extending 





 Childhood  
Most common cause of 
CAA in childhood in 
Japan, spontaneous 
resolution occurs in 50% 
 Autoimmune, vasculitis 
Takayasu  Young adults  
Common cause of CAA in 
young Asian females in 
Japan 
 Cellular immunity associated with chronic infection 
Polyateritis Nodosa  Young adults  
Necrotizing inflammatory 
lesions in small- and 
medium-sized arteries 
 
Characterized by fibrinoid 









Marfan syndrome, cystic 
medial necrosis 
 
IL-6, TGF-β, C-reactive 
protein, 
MMP-2, MMP-9 
Mycotic  Any age  
Infection with 
Staphylococcus 
aureus or Pseudomonas 
aeruginosa, 
syphilis, Lyme disease 
 
Microembolization to vasa 
vasorum, direct pathogen 
invasion of arterial wall, 




 Adults  
Clinical history helps 
establish diagnosis healing 
because of 
antiproliferative treatment 




Trauma from oversized 
balloon or high inflation 
pressures, coronary 
dissection, interventions in 
the setting of acute 
myocardial infarction, 
inadequate 
Modified from Diaz-Zamudio et al., 2009. 
Table 4. Cause, Age, Summary Description and Principal Pathogenetic Mechanisms of 
Coronary Artery Aneurysms 
7. Clinical manifestations and complications 
In most cases, CAAs are asymptomatic; then when symptomatic, the clinical manifestations 
depend on the underlying cause. Although CAA can be seen at any age, those that were 
related to atherosclerosis usually appear later in life than those of a congenital or 
inflammatory nature. 
No clinical feature characteristics exist for atherosclerotic CAAs. The clinical manifestations 
are similar to those seen in coronary artery disease (Tunick et al., 1990), and the patients 
may have angina pectoris, dyspnea, edema, myocardial infarction and sudden death (Pappy 
et al., 2011). Occasionally, a systolic murmur is heard over the precordium. An association 
with an abdominal aortic aneurysm and hypertension can occur. Large aneurysms, 
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particularly those that are partially or completely filled with mural thrombi, may create 
diagnostic challenges by masquerading as cardiac masses (Ramos et al., 2008). The main 
differential diagnoses include pericardial cysts and primary and metastatic tumors (Tunick 
et al., 1990). Transesophageal echocardiography and magnetic resonance imaging can add 
valuable diagnostic information; however, in many cases, diagnosis is not achieved until 
open-heart surgery. 
Factors that can contribute to development of complications are: distal embolization with 
myocardial ischemia, rupture with associated fistula, cardiac tamponade or 
hemopericardium, thrombosis, dissection, vasospasm and vessel compression (Syed & 
Lesch, 1997; Díaz-Zamudio et al., 2009). 
8. Diagnosis 
CAA may be detected by non-invasive tools, including echocardiography, computed 
tomography, and magnetic resonance imaging, but coronary angiography remains the best 
method for the assessment of coronary anatomy and pathology (Pahlavan & Niroomand, 
2006). Coronary angiography provides additional information regarding the size, shape, 
location and the number of existing anomalies and show an image of the coronary artery 
status (Gziut & Gil, 2008), determining the extent and severity of the coronary lumen 
obstruction in coronary artery disease (Scanlon et al., 1999). Multidetector row computed 
tomography (MDCT) technology, have led to widespread enthusiasm for the use of 
noninvasive coronary angiography (Hendel et al., 2006). The three dimensional evaluation 
helps to provide an easy understanding of complex anatomic structures and allows the 
analysis of the lumen and the vessel wall and the identification of thrombi and associated 
plaque formation. Other non-invasive methods can be also helpful in the diagnosis of 
aneurysms, including bidimensional transthoracic echocardiography, transesophageal 
echocardiography (Gziut & Gil, 2008) and electrocardiographic-gated scans, which is a dose 
modulation technique. These methods are recommended to minimize radiation dose and 
represent promising tools for the evaluation of children (Goz & Cakir, 2007), particularly 
children with Kawasaki disease (Beiser et al., 1998). Magnetic resonance (MR) angiography 
is an alternative for patients for whom exposure to repetitive radiation from multidetector 
CT is not wanted and for whom other noninvasive modalities are not suitable (Mavrogeni et 
al., 2004). However, these methods allow the investigation of only the proximal segments of 
the coronary arteries. Other modalities (such as intravascular ultrasound, Doppler flow 
wire, and pressure with for calculation of fractional flow reserve) can be incorporated into 
the invasive evaluation (e.g., angiography), and the pathology can often be treated during 
the same procedure. Multidetector-row computed tomography (MDCT), a technology that 
allows good noninvasive imaging of the coronary arteries, has been used despite of its 
indications and a still-to-be-defined role in the management of patients with cardiovascular 
symptoms (Zimmet & Miller., 2006). 
Undoubtedly, invasive coronary angiography remains the “gold standard” for the 
evaluation of CAA for a number of reasons. Only blood flow within the lumen can be 
evaluated, and conventional invasive coronary angiography provides no information about 
the vessel wall. Thus, with conventional coronary angiography, the true size of the 
aneurysm may be underestimated or the aneurysm may not even be seen when it is 
occluded or contains substantial thrombi or plaque (LaMotte & Mathur, 2000). 
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CAA treatment consists of medical management, surgical resection, and stent placement; 
however, the appropriate treatment for CAAs is controversial and depends on the particular 
clinical situation. The recently available results have been based primarily on case reports 
and not on controlled studies, which continue to cause a therapeutic dilemma. The 
medically conservative therapy generally consists of attempts to prevent thromboembolic 
complications in patients with aneurysmal arteries who are at increased thrombotic risk 
through administration of antiplatelet and anticoagulant medication (Demopoulos et al., 
1997). The use of anticoagulants is based on the observations of thrombus formation in 
association with CAA and its distal embolization. Surgical management is appropriate in 
symptomatic patients who have obstructive coronary artery disease or evidence of 
embolization leading to myocardial ischemia and in patients with CAAs with a risk of 
rupture (LaMotte & Mathur, 2000). Recently, percutaneous application of 
polytetrafluoroethylene (PTFE)-covered stents has gained popularity due their ability to 
effectively limit the expansion of CAAs by reducing blood flow within the aneurysm, 
thereby preventing their rupture. Some authors have suggested that PTFE-covered stents 
should be limited to patients whose aneurysms are < 10 mm in diameter (Cohen & O’Gara, 
2008). Percutaneous strategies also include coil embolization, autologous saphenous vein-
covered stent grafting, and one case report of DES implantation superimposed on a PTFE-
covered stent graft (Ghanta et al., 2007). 
Surgical strategies that have been described include aneurysm ligation, resection, 
marsupialization with interposition graft, and coronary artery bypass surgery. The majority 
of the experience regarding the aforementioned strategies stem from atherosclerosis-
induced CAAs (Antelmi et al., 1993). Some surgeons believe that surgical repair is 
mandatory when a coronary aneurysm is 3 times larger than the original vessel diameter. A 
complete surgical resection or stent placement may be performed, depending on the 
presence or absence of coexisting obstructive coronary artery disease. Another surgical 
option that is frequently used is coronary artery bypass graft (CABG) followed by the 
ligation or resection of the aneurysm. This approach is indicated in patients who have larger 
aneurysms that are at higher risk of rupture (Myler et al., 1991).   
However, special consideration must be taken when an immunoinflammatory condition is 
involved. Treatment strategies to improve outcomes in vasculitis-induced CAA involve the 
use of immunosuppressive therapy to abate the underlying inflammatory process. The role 
of catheter-based intervention needs to be further explored in this particular patient 
population. It must be emphasized that there is no consensus regarding how coronary 
lesions related to systemic inflammatory diseases should be treated (Pappy et al., 2011). 
Currently, no treatment of CAAs has been universally accepted due to their low incidence 
and the lack of controlled clinical trials. 
10. Conclusion 
CAA is an uncommon and often accidental finding. CAAs are usually associated with 
atherosclerosis in adults in Western countries, while Kawasaki disease is the most common 
cause of CAA in Japan and in children or young adults. Nevertheless, the exact mechanisms 
leading to CAA formation are still unclear. Unfortunately, the lack of specific prodromal 
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symptoms or factors predisposing to the formation of CAAs significantly limits the 
diagnostic possibilities, and consequently, the therapeutic modalities. One way to improve 
the understanding of the pathogenesis of aneurysms can be through the development of 
experimental models, such as those that are used for studying abdominal aortic aneurysms 
(Mata et al., 2011). Thus, this review aimed to provide an update on the pathogenesis and 
treatment of CAAs to highlight for physicians and thoracic surgeons the practical 
management of patients with this disease and to help avoid major complications, such as 
death. 
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1. Introduction  
Multiple organ dysfunction syndrome (MODS) has been the difficulty in clinical treatment 
of severe burns. In the 1990s, the incidence rate of MODS was 28.1% in severe burn patients, 
while the mortality rate was as high as 78%-98% (Huang et al., 1998). MODS was caused by 
two “attacks": the first attack was the early plasma leakage and the effective circulating 
blood volume reduction, as resulted in the systemic hypoxic-ischemic damage; the second 
attack was the invasion of consequent systemic inflammatory response and sepsis on the 
organs (Sheng, 2002). With enhancement of the clinical treatment of burns, the present point 
of view argues that the key to prevention of MODS is against the first "attack", ie, to control 
the burn shock, which can effectively prevent or mitigate the second "attack" to reduce the 
incidence of MODS (Sheng, 2002).  
Previously, only hypovolemia was concerned in the patients with burn shock. However, it is 
found that simple increase of the blood volume can not effectively curb the incidence of burn 
shock in a large number of clinical treatments of severely burned patients. These group of 
patients are often accompanied by hypodynamic blood circulation, thus too much or fast fluid 
perfusion may easily induce heart failure. Therefore, we have shifted our attention to the heart, 
a motivator organ for blood circulation. We further found that the heart is not the sole organ 
injured early by serious burn, and this damage and reduced pump function occurred before 
the vascular permeability change and the blood volume decrease (Huang, Li, & Yang, 2003; 
Huang et al., 1999b). The immediate early myocardial damage and weakened pump function 
of the heart can not only cause heart failure, but also induce or aggravate shock and hence 
become one of the generators leading to severe burn shock and systematic hypoxic-ischemic 
damage. Based on above, we proposed the hypothesis of "shock heart" involving systematic 
hypoxic-ischemic damage early after burn injury (Huang, Zheng, Fan, & Zhang, 2007; Huang, 
2009; Xiao et al., 2008b). In order to confirm this hypothesis, we have conducted a large 
number of animal experiments and clinical trials. On the one hand, we explored the effects of 
the early emergence of myocardial damage and cardiac dysfunction on the systemic organ 
perfusion and hypoxic-ischemic injury; on the other hand, an in depth study has been done on 
its development mechanism so as to find effective therapeutic targets for clinical use.  
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2. Early changes of cardiac function after severe burns 
In the early 1960s, Fozzard observed myocardial damage and cardiac output decrease in the 
burn patients and further found that this kind of heart failure was not due to pre-injury 
heart disease or excessive fluid infusion (Fozzard, 1961). Some scholars attributed the 
cardiac dysfunction to the vascular leakage of plasma into the injured area, causing 
decreased venous return and cardiac preload reduction (Evans, Purnell, Robinett, Batchelor, 
& Martin, 1952). Nonetheless, the subsequent experimental results differed from this view. 
The researchers found that before obvious extravasation of plasma, the cardiac output was 
significantly reduced and even a large volume of fluid resuscitation could not improve the 
cardiac output . (Moyer, Coller, Iob, Vaughan, & Marty, 1944) Therefore, it was considered 
that the microcirculatory disturbances, abnormal coagulation system (Brooks, Dragstedt, 
Warner, & Knisely, 1950) and peripheral vasoconstriction (Salzberg & Evans, 1950; Wolfe & 
Miller, 1976) after severe burn were key causes to the combined cardiac dysfunction. In 
1984, Adams et al established a guinea pig burn model to study the systolic and diastolic 
function changes of the the left ventricle after the injury. They found that when the burn 
injury exceeded 47% of the total body surface area (TBSA), the ventricular compliance was 
reduced and the cardiac isovolumic relaxation period extended, accompanied by significant 
myocardial contractile dysfunction, based on which they viewed that inherent myocardial 
damage led to the decrease of the adverse cardiac filling and ejection fraction of the left 
ventricle (Adams, Baxter, & Izenberg, 1984). 
Cardiac dysfunction after severe burns has been confirmed in many experimental studies. 
However, the myocardial systolic/diastolic dysfunction occurred in different time post-burn 
in different species animal models including mice, rats, hamsters, guinea pigs, rabbits, dogs, 
pigs and sheep (Adams, Baxter, & Parker, 1982; Baxter, Cook, & Shires, 1966; Elgjo et al., 
1998; Ferrara et al., 1998; Fozzard, 1961; Horton, Garcia, White, & Keffer, 1995; Horton, 
Maass, White, Sanders, & Murphy, 2004; Horton, White, Maass, & Sanders, 1998; White, 
Maass, Giroir, & Horton, 2001). Horton et al studied time course of heart function of the 
rabbit and rat after burn by dissecting the heart for in vitro perfusion at each time point. The 
results showed a transient decrease of the cardiac function after burn, which first appeared 
at 2 hours, decreased continually within 24-30 hours and gradually recovered at 48-72 hours 
after burn injury (Horton et al., 1995; Maass, Hybki, White, & Horton, 2002; Sheeran et al., 
1998). This short-term decreased heart function may be less risk for the otherwise healthy 
young adults with burn but may be so risky for the young, the elderly and the 
immunocompromised patients that they had to receive unaffordable fluid resuscitation. 
Recent studies also showed that the cardiac dysfunction after burn is an index for predicting 
the proneness to secondary infection, ie, it is closely related with morbidity and mortality of 
MODS in severely burned patients and can predict the long-term infection complications.  
Over the past 10 years, our laboratory have carried out a series of burn research on the pig, 
dog, rabbit, rat and other animal models and particularly established a mature rat model 
with 30% TBSA 3rd degree burn. When the rats were under anesthesia, the cardiac function 
was detected by inserting the catheter from the carotid artery to the left ventricle, when the 
other end of the catheter was connected with pressure transducer and multi-channel 
physiological recorder. Number of myocardial mechanical indicators were recorded early 
after burn injury (24 hours) at several preset time points, which could help deeper 
understand the course of the cardiac function change in the early time after burns (Xiao, Lei, 
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Dang, & Huang, 2011). As shown in Figure 1, in rats with 30% TBSA 3rd degree scald injury, 
the maximal rate of the rise/drop of left ventricular pressure (± dp/dt max) was 
significantly reduced 1 hour post-burn, while the mean arterial pressure (MAP) was 
declined until 3 hours after injury, indicating that the cardiovascular system itself has a 
certain compensatory ability and a stable blood pressure can be maintained temporarily by 
increasing the peripheral resistance. Our results showed that the heart function reached a 
valley at 12 hours after burn injury, then recovered for some extent but still remained at a 
low level at 24 hours after injury, which differed from the aforementioned time course 
results (the valley emerged at 24-30 hours after injury) reported by Horton et al. This 
difference may be due to different cardiac function test methods, ie, in vitro heart perfusion 
and in vivo intubation. However, our results undoubtedly confirm that the cardiac function 
was weakened rapidly after burn (1-2 hours after injury), when there was no obvious 
plasma extravasation or reduction of effective circulating blood volume (Carvajal, Linares, & 
Brouhard, 1979; Salzberg & Evans, 1950). Therefore, we can be sure that the cardiac 
dysfunction soon after severe burns was caused by myocardial cell damage and myocardial 
systolic/diastolic dysfunction of the heart itself rather than the burn shock, as is worthy of 
further study and exploration on these endogenous mechanism. 
 
Fig. 1. Time course of heart function after 30%TBSA 3rd degree burns in rats in vivo. All 
values are mean ± SEM. MAP, mean arterial pressure; LVSP, left ventricular systolic 
pressure; LVEDP, left ventricular end-diastolic pressure; ± dp/dt max, maximal rate of the 
rise/drop of left ventricular pressure. * p<0.05 vs sham. 
3. Organ perfusion at early stage following severe burns  
Severe burns induce a strong stress response and high excitement of the sympathetic-
adrenal medulla system. The catecholamines secreted by the sympathetic-adrenal medulla 
system can adjust the heart excitement, the peripheral vascular resistance and the 
capacitance vessels so that the blood supply to tissues and organs at the shock stage 
becomes more adequate and reasonable. However, the anatomy, physiology and tolerance 
to ischemia and compensatory ability differs in various organs, which leads to different 
blood supply of the main organs including heart, brain, liver, kidney and intestine after 
severe burns.  
 




The traditional pathophysiological view was that under severe stress conditions, especially 
reduction of the effective circulating blood volume, the body reduced the blood supply of 
most abdominal organs and gave priority to ensuring the blood supply of the heart, brain 
and other vital organs. However, a lot of experiments conducted in our laboratory 
confirmed no effective protection of the myocardial blood supply after severe burns. Early 
in 1996, Yang et al (Yang, Yang, & Chen, 1996) used radioactive tracer 86Rb uptake to detect 
the myocardial nutritional blood flow (NBF) changes of rats with 30% TBSA 3rd degree burn 
(Figure 2). The results showed that the myocardial nutritional blood flow was reduced by 
about 24% 1 hour after burn, then continued to decrease up to the valley at 12 hours and 
recovered mildly at 24 hours (but still lower than the sham group), which was similar to the 
trend of cardiac function change. Moreover, the earliest time point for determination of the 
myocardial blood flow was at 1 hour after injury, which was the same time that the cardiac 
function began to decline. Nonetheless, we are not sure about whether the myocardial 
ischemia damage resulted in decreased heart function or the reduced cardiac output led to 
the coronary flow decrease. Therefore, the myocardial blood flow was detected in the rats 
with 30% TBSA 3rd degree burns by using the fluorescent microspheres method at 10 min, 30 
min, 1 hour, 3 hours and 6 hours post-burn (Figure 3). The results showed that the regional  
myocardial blood flow was decreased significantly at 10 minutes, recovered mildly at 30 
minutes and 1 hour, and then continued to decline after burn (Yin, Huang, & Li, 2010). The 
myocardial blood flow was rapidly reduced 10 minutes after burn, which may be related to 
the contraction of the coronary caused by myocardial renin-angiotensin system (RAS) that 
was activated immediately after burn (Mackins et al., 2006). We used the enzyme linked 
immunosorbent assay (ELISA) method to detect the Ang II in the myocardial (Figure 4) and 
the results showed that the myocardial Ang II was increased from 10 minutes after injury. 
This is a very good explanation of the transient reduction of the myocardial blood flow at 10 
minutes after burn. The subsequent rebound increase of the blood perfusion may be due to 
accumulation of hypoxic metabolites that offset or exceeded the vascular contraction effect 
of Ang II and finally caused vasodilation. 
 
Fig. 2. Myocardial nutrition blood flow of the rats following 30%TBSA 3rd degree burns. All 
values are mean ± SEM. * p<0.05 vs sham. 
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Fig. 3. Myocardial blood perfusion of the rats following 30%TBSA 3rd degree burns. All 
values are mean ± SEM. * p<0.05 vs sham. 
In fact, under continuous increase of the Ang II, the compensatory mechanism of the heart 
itself was difficult to maintain too long and turned into decompensation about 3 hours post-
burn, with continual decrease of the myocardial blood flow. Thus, the myocardial blood flow 
was reduced before cardiac dysfunction after severe burns, indicating that the myocardial 
ischemia and hypoxia was the main cause for the cardiac dysfunction (Huang et al., 2003).  
 
Fig. 4. Content of cardiac local angiotensin II in the rats following 30%TBSA 3rd degree 
burns. All values are mean ± SEM. * p<0.05 vs sham. 
3.2 Brain 
Currently, there has seldom reported the cerebral blood flow perfusion at early stage after 
severe burns. But the cerebral edema was often complicated clinically after burn, the 
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pathological factors for which was different from brain trauma or brain damage simply 
caused by brain trauma or hypoxia. The complicated cerebral edema after burn is due to 
destructed microcirculation and blood-brain barrier function as well as increased 
permeability resulted from a variety of factors including ischemia and hypoxia, cell 
medium, endotoxin, electrolyte imbalance, acidosis and uncontrolled inflammation, which 
ultimately caused diffuse tissue edema. The vascular endothelial cells played a key role in 
the pathogenesis of brain edema after burn. On the one hand, the vascular endothelial cells 
had clear morphological changes, even formation of cracks and endothelial cell loss leading 
to the semi-permeable membrane barrier dysfunction and vascular permeability increase. 
On the other hand, the vascular endothelial cells could release a variety of media to further 
promote the microcirculation disorder, aggravate tissue ischemia and hypoxia and promote 
development of the tissue edema (Domres, Heller, & von Kothen, 1981; Li et al., 2001). 
 
Fig. 5. Cerebullar blood perfusion of the rats following 30%TBSA 3rd degree burns. All 
values are mean ± SEM. 
We have used the same fluorescent microspheres method to detect the brain blood flow in 
rats with 30% TBSA 3rd degree burns (Figure 5), which showed insignificant statistical 
difference upon the cerebral blood flow at all time points, indicating that the brain tissues 
still had a strong compensatory ability even after burn injury. Because the brain tissue has 
the minimum tolerance to the hypoxia out of all organs, the brain blood supply can still 
remain stable unless under a serious shortage of blood volume.  
3.3 Reduced perfusion and hypoxic-ischemic injury of the liver, kidney and intestine 
Catecholamines in the blood at early stage after burn was increased tens even hundreds 
times more than that in the normal time. The small blood vessels in the abdominal organs 
and kidney had rich sympathetic vasoconstrictor innervation, with dominant α-adrenergic 
receptors. With sympathetic excitement and catecholamine increase, the microvascular 
contraction of these organs significantly increased precapillary resistance and sharply 
decreased the microcirculation perfusion. While the β-adrenergic receptor stimulation 
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opened the arterial-venous anastomosis, which resulted in increase of the microcirculation 
non-nutritive blood flow, decrease of the nutritional blood flow and severe tissue ischemia 
and hypoxia. In addition, a great deal of Ang II produced by the activated circulatory 
system RAS was also involved in the vasoconstriction (Dolecek, Zavada, Adamkova, & 
Leikep, 1973).  
The laser Doppler flowmetry was employed to detect the blood flow of liver, kidney, and 
intestines of the rats with 30% 3rd degree burns, which showed that the hepatic, renal, and 
intestinal perfusion was significantly declined 1 hour post-burn and recovered for some 
extent at 24 hours (Figure 6). The blood flow changes differed significantly in different 
organs, ie, the blood flow was reduced the most significantly in the kidney, followed by the 
intestine and the liver the least. Despite obvious decrease, the hepatic blood flow remained 
stable overall. Judging from the recovery, the liver restored the blood flow better at 24 hours 
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concentration of the intracellular xanthine oxidase was increased, which prompted the 
substrate transforming to the xanthine oxidase via proteolysis or histamine. During the 
course of reperfusion, a large number of free radicals were produced with the improvement 
of hypoxia and finally induced reperfusion injury (Horton, 2003). Toklu et al detected 
malondialdehyde (MDA), reduced glutathione (GSH) level and myeloperoxidase (MPO) 
activity of skin, lung, liver, ileum and kidneys in rats at 6 and 48 hours after burns and 
found significant increase of MDA level and MPO activity but decrease of antioxidant GSH 
content; hence they viewed that the oxygen free radicals and lipid peroxidation plays an 
important role in organ damage after burn injury (Toklu et al., 2006). Sakarcan et al carried 
out similar experiments to confirm the protective effect of antioxidant Ginkgo biloba extract 
(Egb) on the rat organs after burn injury and the results showed increase of MDA level and 
MPO activity but decrease of GSH in the liver and kidney, together with increase of AST, 
ALT, BUN, Cr and LDH, as suggested liver and kidney dysfunction (Sakarcan et al., 2005). 
Zhou et al observed a series of liver changes 1 hour after burn in rats, mainly swelling, 
degeneration and necrosis of the hepatocytes, fatty degeneration or eosinophils detected by 
the light microscope, which resulted in point-like or small focal hepatocyte necrosis. In the 
meantime, the electron microscopy manifested different degrees of ultrastructure change of 
the hepatocytes and extensive damage to the nucleus and organelles. Their study also 
showed that ALT was increased at 1 hour and reached the peak at 12 hours after burn and 
that AST began to increase at 6 hours and continued to 48 hours after burn. The increase of 
blood AST and ALT was the inevitable result of serious liver parenchyma damage, 
indicating that burns can cause liver damage and progressive aggravation in a relatively 
short period of time. Especially the degeneration and necrosis of the hepatocytes, 
mitochondria degeneration and endoplasmic reticulum will undoubtedly and directly affect 
the normal function of the hepatocytes and weaken the detoxification function of the burn 
injury liver, when acute liver failure may occur in a few burn patients (Zhou, Huang, & 
Chen, 2002).  
In the normal adult, the kidney is body organ with the largest blood flow, with 1000-
1250ml/min, accounting for 20%-25% of cardiac output. The renal damage at burn shock 
stage is primarily due to sharp decline of the blood volume, reduction of the cardiac output 
and decrease of the renal blood flow. The heart failure induced by severe burns would 
directly result in of the effective circulating blood volume decrease, the sympathetic 
excitement and the redistribution of systemic blood, which affected the renal blood flow the 
most, with reduction of glomerular blood flow and filtration to 30%-50% or less of the 
normal (Figure 6). When the arterial pressure fell below 60 mmHg, the glomerular filtration 
would even stop and lead to anuria or oliguria. Sener et al found significant decrease of 
renal tissue GSH, increase of MDA, protein oxidation (PO) level and MPO activity and renal 
dysfunction (increase of BUN and local LDH) in rats at 6 hours post-burn and they argued 
that the kidney damage was mainly caused by lipid peroxidation and oxygen free radical 
damage and that the antioxidants Mesna exerted a protective effect on the kidneys (Sener et 
al., 2004). For oxygen free radical damage, Sener et al conducted a similar experiment in an 
attempt to prove the role of melatonin in preventing early kidney injury after burns (Sener, 
Sehirli, Satiroglu, Keyer-Uysal, & Yegen, 2002).  
The nerve-humoral regulation early after burns induced redistribution of the blood and the 
gastrointestinal hypoperfusion lasted for the longest. The blood flow of intestinal mucosa 
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and villi accounted for 80% and 60% of total gastrointestinal tract blood flow. A 10% 
decrease of systemic blood volume may lead to 40% decrease of the whole gastrointestinal 
tract blood flow. The vascular loop of the intestinal villi was with an extremely bent ring 
structure, which contributed to a short circuit exchange of the central villus arterioles with 
the venules and capillaries. Under shock and low perfusion state, the short circuit exchange 
increased to further reduce the oxygen supply of the villus top. The intestinal tissue had 
high metabolic rate and demanded great deal of the oxygen, indicating that the intestinal 
tissue was sensitive to ischemia and hypoxia and easy to be damaged, with slow recovery. 
Under stress state, the mucosal partial pressure of oxygen was decreased but the lactic acid 
levels significantly increased, the latter of which, during the ischemia-reperfusion process, 
released large amounts of oxygen free radicals that were the initiating factor for 
inflammatory mediators and cytokines cascade (Gianotti, Alexander, Pyles, James, & 
Babcock, 1993). 
The burn resulted in up-regulation of a variety of proteins regulating the stress response, 
reduction of self-repair ability of the intestinal mucosa by free radical damage, energy 
metabolism disorder of the intestines, increase of cell apoptosis (Zhang et al., 2002), 
cytoskeletal damage of the intestinal smooth muscle and gastrointestinal motility disorders 
(Tong, Wang, & Guo, 2006). Reduction of the synthesis of secretory IgA and apoptosis of the 
intestinal lymph node cells destructed the intestinal immune barrier (Fan, Xie, Zhou, Chen, 
& Deng, 2006), which may cause damage to the intestinal bacterial translocation and even 
endotoxemia. The intestinal ischemia-reperfusion injury caused "waterfall-like" cascade of 
inflammatory mediators by the way of p38/mitogen activated protein kinase (MAPK) (Gan, 
Pasricha, & Chen, 2007), as made the intestines as the "source" of systemic inflammatory 
response syndrome (SIRS). The uncontrolled development of SIRS would inevitably lead to 
MODS or multiple organ failure (MOF), so Hassoun et al considered the intestines was the 
initiating organ for post-traumatic MOF (Hassoun et al., 2001). Extensive burns, shock and 
other factors induced potential intestinal hypotension, intestinal hypoperfusion or recessive 
intestinal shock that may cause intestinal mucos ischemia and hypoxia, intestinal barrier 
dysfunction, and intestinal SIRS and MODS, as was called "shock bowel" by some scholars 
(Tu & Xiao, 2002).  
3.4 Effect of cardiac dysfunction on hepatic, renal, and intestinal blood flow 
The heart is the power organ of the circulatory system. It still remains unclear whether the 
perfusion changes of the liver, kidney, intestines and other organs is induced by the 
weakened heart function after burn injury. In order to verify the effect of cardiac function on 
the liver, kidney and intestine perfusion after severe burns, we established the rat model 
with 30% 3rd degree burns and then the cardiac function of the rats was intervened with 
cedilanid, low-dose angiotensin-converting enzyme inhibitor (ACEI) enalaprilat and high-
dose β-blocker propranolol. The cardiac function and the blood flow of liver, kidney and 
intestines were observed at 6 hours post-burn, which showed that cedilanid and low-dose 
enalaprilat could effectively enhance the heart function; ACEI action on the cardiac function 
indicated local RAS activation early after burn; Ang II increased the harmful effects of 
casoconstrictor on the myocardial (Figure 7A); and high-dose β-blocker propranolol could 
obviously inhibit the cardiac function. It was found that the liver, kidney and intestinal 
blood flow was significantly increased accordingly with cardiac function improvement and 
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decreased with further suppression of the cardiac function (Figure 7B). With aim to clarify 
the effect of cardiac function changes on perfusion of various organs after burn, an analysis 
was done on the correlation between the mechanical index ± dp/dt max and the liver, 
kidney and intestinal blood flow, which showed a positive correlation of liver, kidney and 
intestinal perfusion with the cardiac function after burn (Table 1). The results indicated that 
immediate early cardiac dysfunction may be an important initiating factor for secondary 
ischemia and hypoxia damage of multiple organs after severe burn.  
 
Fig. 7. Cardiac function and blood flow to liver, kidney, and intestine in the 30%TBSA 3rd 
degree burn rats treated with cedilanid, enalaprilat, and propranolol. All values are mean ± 
SEM. * p<0.05 vs simple burn. 
 +dp/dt max -dp/dt max 
Parameter tested †PCC P value  (2-tailed) PCC 
P value (2-
tailed) 
Hepatic blood flow 0.956* 0.001 0.976* 0.000 
Renal blood flow 0.985* 0.000 0.946* 0.001 
Intestinal blood flow 0.964* 0.000 0.918* 0.003 
Table 1. Summary table of correlation analysis between the maximal left ventricular 
pressure increase/decrease rate and organ blood flow in rats after a 3rd degree burn. Organ 
blood perfusion was significantly and positively correlated with heart systolic/diastolic 
function in rats after the burn (30% of body area) (* P < 0.01). †Pearson correlation 
coefficient. 
4. Mechanism for cardiac damage / heart function depression at early post-
burn stage  
Undoubtedly, myocardial cell damage is the immediate cause of heart function depression 
in the early burn period. Back in 1961, Fozzard claimed that myocardial damage may be the 
reason of cardiac output decrease not matching the change  of blood volume (Fozzard, 
1961). In the 1990s, serum troponin I (cTnI) was proposed as a highly specific and sensitive 
indicator in detecting cardiomyocyte injury (Horton et al., 1995). Murphy et al (Murphy, 
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Horton, Purdue, & Hunt, 1998) randomly examined the level of serum cTnI in a large 
number of burn patients. They found the serum cTnI was negative in patients with less than 
10% TBSA burns, while it continually rose in patients with more than 20% TBSA burns 
within 12 hours post-burn. It provided solid evidence for post-burn myocardial damage. By 
testing the serum cTnI in mature rat models of 30% TBSA 3rd degree burns at different time 
points, we found their serum cTnI levels increased at post-burn 30 minutes, reached the 
peak at 12 hours, but dropped at 24 hours. Nevertheless, their serum cTnI levels were still 
lower than the sham (non-burned) group (Xiao et al., 2008a). Bivariate correlation analysis 
indicated that serum cTnI levels were closely related with the post-burn change in heart 
function parameters (Xiao et al., 2008a). Other parameters of myocardial damage like 
myosin light chain 1 (CMLC1) and troponin T (cTnT) also increased evidently after burn 
(Huang et al., 2003; Huang et al., 1999b). Pathological observation found cloudy swelling of 
myocardial cells, interstitial vascular dilatation, congestion, edema, hemorrhage and 
inflammatory cell infiltration at 3 hours post-burn in scalded rats with 30% TBSA 3rd degree 
burns. At 12h hours post-burn, an irregular arrangement of cardiac muscle fibers (in the 
wavy-pattern) and sarcoplasm condensation were observed (Zhang et al., 2007a). All these 
facts implied that cardiac damage already existed in early severe burns, accompanied by 
decreased heart functions. Then what caused these cardiac damages? 
Since the evidence of “burn toxin” presented (Allgower et al., 1968), Baxter and his 
colleagues  attempted to seek myocardial depressant factors (MDF) in the plasma of burn 
patients. They infused the plasma of burn patients into the free hearts of normal guinea pigs 
and proved that such plasma was myocardial depressant (Baxter et al., 1966). To avoid 
species differences and immune reactions, Horton et al  collected the serum of 40%TBSA 
burned rats to infuse the isolated hearts of homogeneous rats. The serum was also proved to 
be myocardial depressant (Horton et al., 2004). Ferrara et al found that lymph fluid from the 
posterior limbs of burned animals could reduce the regional myocardial blood flow, 
resulting in decreased coronary systolic and diastolic activity (Ferrara et al., 1998). Sambol et 
al found that pre-burn mesenteric lymph duct ligation could greatly improve the impaired 
cardiac contractile function, which suggested the existence of myocardial depressant factors 
in burned animals (Sambol, White, Horton, & Deitch, 2002). All these researches implied 
that burn injuries indeed stimulated the activation and release of certain protein factors 
which had a negative regulatory or damaging role on cardiac muscles.  
Tumor necrosis factor (TNF-α) serum level were initially believed to be associated with the 
progression of infection (Marano et al., 1990; Marano et al., 1988). Some researchers also 
thought that the increase of TNF-α in post-burn plasma could be used as a measurement of 
the body’s immune response, which indicated increased risks of secondary sepsis and death 
(Cannon et al., 1992; Yamada et al., 2000). Subsequent researchers assayed the post-burn 
TNF-α, IL-1β, IL-6 and other factors and suggested that taking multiple factors into 
consideration, rather than a single inflammatory factor TNF-α, could better predict the onset 
of sepsis (Drost et al., 1993a; Drost, Burleson, Cioffi, Mason, & Pruitt, 1993b; Zhang et al., 
1998). However, Giroir and Beutler believed that the heart was an important source of TNF-
α, although this inflammatory factor could be produced by many other cells and organs 
(Giroir, Johnson, Brown, Allen, & Beutler, 1992). Then Giroir and Horton studied the role of 
TNF-α in postburn myocardial dysfunction and found enhanced synthesis of TNF-α by 
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myocardial cells with a more than 40% TBSA burns. The Anti-TNF-α strategy could prevent 
myocardial contractile dysfunction and elevate cardiac output (Giroir, Horton, White, 
McIntyre, & Lin, 1994). Substantial evidence has proved TNF-α to be one of the initial 
mediators in the “waterfall-like” inflammatory cascade response. In the animal models, 
intravenous injection of recombinated TNF-α could induce myocardial depression 
(Eichenholz et al., 1992; Pagani et al., 1992; Tracey et al., 1986). The administration of TNF-α 
to left ventricular myocardial cells cultured in vitro would produce a concentration-
dependent negative inotropic effect (Heard, Perkins, & Fink, 1992; Horton, Maass, White, & 
Sanders, 2001a; Maass, White, & Horton, 2005; Yokoyama et al., 1993). Meanwhile, the fact 
that transgenic mice with myocardial overexpression of TNF-α all died of dilated 
cardiomyopathy and congestive cardiac failure demonstrated its negative effect on 
myocardial contraction (Bryant et al., 1998). It was also reported that the serum TNF-α 
increase in the burn patients was not accompanied by signs of infection (Cannon et al., 
1992). The level of TNF-α produced by myocardial cells which were isolated from burned 
rats was 15 times that of the normal control rats (Williams, Bankey, Minei, McIntyre, & 
Turbeville, 1994). All these facts showed that TNF-α was a significant initiation factor in the 
postburn uncontrolled inflammatory cascade, as well as an important inflammatory factor 
in myocardial damage, playing an important role in MODS after sever burns. 
In the case of severe burn, tissue ischemia and hypoxic metabolism still continues under 
large-volume fluid resuscitation (Demling, Ikegami, & Lalonde, 1995). When ischemia is 
improved in the tissues, re-exposure to molecular oxygen will generate a large number of 
oxygen free radicals, leading to tissue damage (Horton, 2003). Metabolism of xanthine 
oxidase (XO) is the major source of oxygen free radicals produced after burns. Allopurinol is 
a competitive antagonist of XO. Allopurinol-pretreatment can prevent oxyradical-induced 
myocardial damage and cardiac function depression in rats (Horton & White, 1993). The rise 
of myocardial lactic acid levels after burns suggests the existence of hypoxic metabolism. 
Rapid large-volume fluid replacement will remove lactic acid accumulation and improve 
the myocardial creatine phosphorylation level. The addition of allopurinol to the 
replacement fluid will remove depolarization in cardiac cell membrane and enhance 
myocardial contractile function (Horton & White, 1995). Other studies suggested that 
neutrophil adhesion and activation was another source of oxygen free radicals after burns. 
Neutrophils release a large number of oxygen free radicals explosively and strengthen the 
effect of xanthine oxidase, causing damage to tissues and organs (Horton, Mileski, White, & 
Lipsky, 1996). In addition, burns also destroy the body's antioxidant defense mechanism, so 
that the tissues are more vulnerable to oxygen free radicals. Further researches found that 
the rise of MDA in plasma and myocardial tissues led to increase in local concentrations of 
peroxidized lipid peroxide and conjugated diene. These experiment results all demonstrated 
the role of oxygen free radicals in postburn organ damage and dysfunction (Cetinkale et al., 
1997; Cynober et al., 1985; Demling & LaLonde, 1990a, b; Takeda et al., 1984; Ward, Till, 
Hatherill, Annesley, & Kunkel, 1985).  
Multiple cellular and molecular signal transduction pathways have been verified to cause 
myocardial damage and mechanical dysfunction. The p38/MAPK pathway, for instance, 
regulates the synthesis and secretion of cytokines and plays a significant role in many heart 
diseases like myocardial hypertrophy, ischemia/reperfusion injury, and myocardial cell 
apoptosis (Sugden & Clerk, 1998; Wang et al., 1998; Zhang et al., 2008b). Myocardial 
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p38/MAPK activity was evidently elevated in cases of over 40% TBSA burns. This enhanced 
activity in the early postburn period (at 1 hour, 2 hours, and 4 hours post-burn) could be 
inhibited by its specific antagonist SB203580. Nevertheless, the activity of JNK was not 
interfered. The inhabitation of p38/MAPK activity decreased the production of myocardial 
TNF-α, improved postburn myocardial contractile function, as well as enhanced tolerance of 
vitro cultured myocardial cells to hypoxia and burn serum (Ballard-Croft, White, Maass, 
Hybki, & Horton, 2001; Zhang, Ying, Chen, Yang, & Huang, 2008a). Zhang et al also found 
that p38/MAPK involved in burn-induced degradation of myocardial cell membrane 
phospholipids, and revealed that it achieved such effects by adjusting cytosolic 
phospholipase A2 (cPLA2) (Zhang et al., 2007b). Moreover, hypoxia was recently found to 
cause myocardial cell microtubule depolymerization through activation of p38/MAPK and 
change of phosphorylation level of microtubule associated protein 4 (MAP4) and 
oncoprotein 18/stathmin (Op18) (Hu et al., 2009). Additionally, through F-actin 
cytoskeleton rearrangement and phosphorylation of L-caldesmon, p38/MAPK conducted 
an important role in endothelial barrier dysfunction induced by burn serum (Chu et al., 
2010).  
The Rho-kinase pathway has been proved by other researches to perform a critical role in 
the reconstruction of cardiac muscle fibers after burn injuries (Hoshijima, Sah, Wang, Chien, 
& Brown, 1998; Kobayashi et al., 2002). The activation and up-regulation of α-1-adrenergic 
pathway (Ballard-Croft, Maass, Sikes, White, & Horton, 2002) led to activation of 
RhoA/Rho-kinase (Suematsu et al., 2001). Evidence showed that the myocardial Rho-kinase 
expression was considerably enhanced at 1 hour, 2 hours, and 8 hours post-burn, and 
engaged in regulating the synthesis and release of inflammatory factors like TNF-α、IL-1β 
and IL-6 by myocardial cells in rats with over 40% TBSA burns (Horton, Maass, & Ballard-
Croft, 2005). 
Protein kinase C (PKC) was also found by some researchers to engage in regulating 
myocardial inflammatory reaction and cardiac dysfunction. PKCε, a major PKC isoform in 
adult cardiomyocytes, presented up-regulated expression and increased activity after burn 
injury. The expression of PKCα was also up-regulated at early post-burn stage, while the 
PKCδ expression increased later (at 24 hours post-burn). Even though the impacts of each 
PKC isoform after burn injuries remain unclear, it has been confirmed that PKC pathway 
involved in the regulation of myocardial cytokine synthesis. The inhibitor of PKC, either 
calphostin or chelerythine, could significatly reduce inflammatory cytokines secretion by 
myocardial cells and improve the damaged myocardial contractile function (Horton, White, 
& Maass, 1998). 
The transcription factor NF-κB, downstream of the PKC/p38/MAPK/JNK/Rho-kinase 
pathway, regulates a variety of genes of inflammatory cytokine, such as TNF-α and IL-1β, 
which are detrimental to cardiac function (Baeuerle & Baltimore, 1996). The level of 
myocardial NF-κB, according to Carlson et al’s finding, continuously increased from 1 hour 
to 24 hours post-burn. The NF-κB activation started earlier than secretion of TNF-α and IL-
1β by myocardial cells, which was again earlier than the occurrence of heart function 
impairment (Carlson et al., 2003). In further experiments, the NF-κB activity was inhibited 
by molecular or pharmacological approaches to explore its effect on myocardial 
inflammatory reaction and cardiac dysfunction. The NF-κB activity was elevated from 2 
hours to 24 hours post-burn in wild-type mice. NF-κB nuclear translocation was not 
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detected in burned mice with over-expression of IκB. In contrast with wild-type burned 
mice, burn mice overexpressing IκB presented decreased secretion of TNF-α and IL-1β and 
less heart function impairment. ALLN, the specific NF-κB antagonist agent, can also prevent 
NF-κB nuclear translocation, inhibit the secretion of TNF-α and IL-1β, and improve cardiac 
functions (Carlson et al., 2003). These facts imply that activation of NF-κB was upstream of 
signal transduction pathway, which performs a critical part in the pathological progression 
of burn-induced myocardial damage and cardiac dysfunction. 
Reports from our laboratory showed that both energy dysmetabolism (Liang, Tang, Yang, & 
Huang, 2002) and apoptosis (Zhang et al., 2008c) of myocardial cells induced by 
mitochondrial Ca2+ disorder after burns directly led to myocardial damage. Activation of 
tumor necrosis factor receptor-associated protein (TRAP1) and adenosine A1 receptor, 
however, inhibited the mitochondrial permeability transition pores (MPTP) to open, so as to 
prevent apoptosis provoked by MPTP opening and to achieve myocardial protection (Xiang, 
Huang, Shi, & Zhang, 2010a; Xiang et al., 2010b). We examined the RAS active ingredients 
and endothelin in serum and myocardial tissues at 10 minutes, 30 minutes, 1 hour, 3 hours, 
and 6 hours post-burn and found that concentrations of myocardial Ang II and its 
convertase ACE rose significantly since 10 minutes, while serum Ang II concentration 
increased notably since 30 minutes postburn, a little later. It demonstrated that the rapid 
activation of local cardiac RAS occurred earlier than the activation of circulatory RAS. 
Myocardial endothelin levels also increased 10 minutes after burns, and then maintained at 
a relatively higher level all the time. Serum endothelin levels, however, did not change 
much. Simultaneous myocardial blood flow measured by fluorescent microspheres also 
dropped at the same time point, suggesting these two strong vaso-excitor materials both 
involved in coronary vasoconstriction, resulting in cardiac insufficiency. Either ACEI or 
endothelin receptor blocking pharmacon could greatly improve myocardial perfusion, 
indicating the two substances’ crucial roles in myocardial impairment. The rapid activation 
of local cardiac RAS after burns increased the Ang II level in myocardial tissues within a 
short period. Vasoconstriction it induced then resulted in myocardial ischemia and damage, 
which might be the most immediate cause of myocardial impairment at the early post-burn 
stage (Yang, Yang, & Chen, 1999). 
Although the mechanism of myocardial damage and cardiac function depression in the 
early post-burn period has been explored and analyzed from various perspectives in 
multiple researches, it cannot be accurately explained only from a single aspect. The exact 
mechanism of myocardial damage may be the combined effects of multiple factors, or 
perhaps there are more convincing causes, which await our further investigation.  
5. Prevention and therapy strategies of the burn-related myocardial 
damage/cardiac dysfunction  
Based on the above-mentioned confirmed mechanisms of myocardial injury/decreased 
heart function, many scholars put forward the corresponding prevention and therapy 
strategies. 
For the damage of inflammatory mediators to the myocardial function after burn injury, 
many studies have focused on limiting the adhesion and activation of the neutrophils. The 
monoclonal antibody specific for the intracellular adhesion molecule 1 and 2 (ICAM-1 and 
ICAM-2), P, L, E-selectin has been proved to be with hemodynamic and myocardial 
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protection effect during the treatment of the burns (Flynn, Buda, Jeffords, & Lefer, 1996; 
Horton et al., 1996; Mileski, Winn, Harlan, & Rice, 1991). Some scholars even selected the 
ICAM-1 and P-selectin knockout mice to explore the role of the adhesion molecules and 
neutrophil activation in treatment of the organ damage, particularly the myocardial 
damage/decreased cardiac function after burn injury  
The most widely recognized clinical prevention and therapy means is to curb the oxygen 
free radicals damaging the organs, including clinical use of a large dose of the anti-oxidants. 
After burn injury, vitamin C and N-acetylcysteine can effectively improve the tissue energy 
load, improve the level of vitamin C and E in the tissues, enhance the elastase activity, 
enhance the microvascular function and inhibit production of the free radicals. The 
enhanced antioxidant capacity is helpful for maintenance of the high-energy phosphate 
level in the tissues, improvement local micro-circulation and effective prevention of the 
burn edema (LaLonde, Nayak, Hennigan, & Demling, 1997; Lalonde, Picard, Campbell, & 
Demling, 1994; Matsuda et al., 1992; Matsuda et al., 1991). Antioxidant therapy can protect 
the mitochondrial membrane integrity and thereby prevent cardiac dysfunction after burns 
(Zang, Maass, White, & Horton, 2007). Matsuda et al even found that the antioxidant 
vitamin therapy could reduce the planned amount of resuscitation fluid with an adequate 
cardiac output (Matsuda et al., 1993). Other experiments showed that the left ventricular 
systolic dysfunction, the continual increase of the preload and the coronary blood flow 
decrease in the rats with lack of vitamin antioxidant therapy, which, however, could be 
improve with the antioxidant treatment (Horton, 2003). 
Ulinastatin (UTI), the refined protease inhibitors extracted from the human urine, can not 
only inhibit the activities of many hydrolytic enzymes including trypsin, phospholipase A2, 
hyaluronidase and elastase, but also prevent the MDF production and ameliorate the 
circulatory state of shock. The experimental and clinical studies have proved that UTI 
exerted a significant effect on prevention and treatment of the myocardial damage, for it 
could regulate the inflammatory response balance, remove the oxygen free radicals, reduce 
the lipid peroxidation and inhibit the myocardial apoptosis (Huang, Xie, Zhang, Dang, & 
Qiong, 2008).  
For the patients with total burn area over 35% TBSA (of which 3rd degree burn over 20% 
TBSA), surgical removal of the entire eschar early after burn can reduce SIRS and 
endothelial system damage and hence effectively prevent the MODS (Huang, Yang, Chen, 
Crowther, & Li, 1999a). The mitochondrial damage is a key factor to myocardial apoptosis, 
which can be alleviated by using the mitochondrial stabilizers ruthenium red after burns 
(Wan-Yi, Hui, Zong-Cheng, & Yue-Sheng, 2002). The other measures such as antisense c-jun 
and p38 gene transfection (Huang & Hu, 2004; Huang et al., 2007) and hypertonic saline 
dextran (Horton, Maass, White, & Sanders, 2001b) also have certain curative effect.  
6. Conclusion  
In brief, the cardiac local RAS which is activated immediately after severe burns causing 
vasoconstriction results in ischemic and hypoxic injury in myocardiums, which contributes 
mostly and initially to the post-burn myocardial damage and heart dysfunction. The 
uncontrolled cascade response of the inflammatory factors, cytoskeleton and mitochondria 
destruction in cardiomyocytes, apoptosis and necrosis following ischemia and hypoxia are 
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directly responsible for the post-burn myocardial damage and cardiac dysfunction. And the 
cardaic pumping deficit with reduced output offers insufficient blood flow to the organs 
such as liver, kidney, and intestines, which induces and further aggravates the burn shock. 
In the pathophysiological course of severe burns, the myocardial damage/cardiac 
dysfunction and the burn shock (microcirculation disturbance and inadequate tissue and 
organ perfusion) are the two crossed main lines, the vicious circulation of which may lead 
the patients to MODS and even death. Can the originating factor for the myocardial damage 
be effectively blocked, the survival rate of the patients with extensive burns will be greatly 
improved. Thus, it is worthy of looking forward to a breakthrough in more in depth and 
effective endogenous protection mechanism of the myocardial damage.  
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1. Introduction 
Globally, the proportion of elderly people is growing faster than any other age group. In 
2000, one in ten, or about 600 million, people were 60 years or older. By 2025, it is expected 
to reach 1.2 billion people, and in 2050 around 1.9 billion (Hutton, 2008). Aging is a multi-
factorial process and has been defined as a time-dependent general decline in physiological 
function of an organism associated with a progressively increasing risk of morbidity and 
mortality. It is apparent that during aging different organs are losing their functional reserve 
and plasticity and become less able to fulfill their physiological function, especially under 
conditions of stress (Beneke & Bürkle, 2007).  
Coronary heart disease is the leading cause of death worldwide, and 3.8 million men and 3.4 
million women die of the disease each year (Yellon & Hausenloy, 2007). Heart aging is 
accompanied by changes that are progressive, pervasive, potentially deleterious, and, as far 
as is known, irreversible (Juhaszova et al., 2005). The incidence of heart disease begins to 
increase in men after the age of forty-five and in women after the age of fifty-five, and the 
rate for women tends to equal that of men after the age of seventy (MacDonald, 2002). 
Regardless of age, the heart’s well-being is critically dependent on its blood supply, and 
vascular disease places this in jeopardy. With increasing age, narrowing may develop in the 
coronary arteries, which lead to the heart. Reduced blood supply causes ischemia 
(insufficient blood supply for the heart's work) and may produce chest pain or angina. If 
ischemia is prolonged, irreversible damage resulting in widespread cell death appears, 
leading to loss of contractility and impairment of cardiac pump function.  
Several studies have identified age as a strong predictor of adverse events after acute 
coronary syndromes; as a result, elderly persons are a high-risk subgroup. Mortality due to 
ischemic cardiovascular diseases is significantly higher in the elderly than in young adults. 
The average age for a first MI is 66 years in men and 70 years in women, nearly 50% of 
hospital admissions for acute MI and 80% who die are age 65 years and over (Jugdutt et al., 
2008, as cited in Ertl &Frantz, 2005; Cheitlin & Zipes, 2001; Thom et al., 2006). After an acute 
myocardial infarction, early and successful myocardial reperfusion with the use of 
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thrombolytic therapy or primary percutaneous coronary intervention (PCI) is the most 
effective strategy for reducing the size of a myocardial infarct and improving the clinical 
outcome. The process of restoring blood flow to the ischemic myocardium, however, can 
induce injury. This phenomenon is termed myocardial ischemia/reperfusion (MI/R) injury. 
This form of myocardial injury, which by itself can induce cardiomyocyte death and 
increase infarct size, may in part explain why, despite optimal myocardial reperfusion, the 
rate of death after an acute myocardial infarction approaches 10% and the incidence of 
cardiac failure after an acute myocardial infarction is almost 25% (Yellon & Hausenloy, 2007, 
as cited in Keeley, 2003).  
Cell death is a primary factor in the pathogenesis of infarction after I/R and, because 
survival is strongly correlated to the cardiac myocytes mass lost after I/R injury, can be 
induced by two different pathways, necrosis and apoptosis which coexist during I/R. 
Apoptosis is more prevalent than necrosis in senescent animals and humans and increased 
more significantly in old rats than in young adult ones after renal ischemia reperfusion. 
Different from necrosis, which is induced by injurious agents, apoptosis is an active 
programmed cell death characterized by a series of stereotypic morphological and 
biochemical features. Therefore, it is easier to inhibit apoptosis than to prohibit necrosis for 
the aging heart. Inhibition of apoptosis may confer protection. So, apoptosis would be one of 
the efficient targets to ameliorate more serious MI/R injury in aging. In this chapter we 
focus on aging-induced cardiac myocyte apoptosis and its potential mechanisms after I/R 
injury. The chapter is divided into 4 sections: (1)High sensitivity to ischemic heart disease in 
elderly people; (2) Aging increases myocardial apoptosis under basal and stressed 
conditions; (3) RNS signaling induced apoptosis contributes to increased susceptibility of 
aging hearts to myocardial ischemic injury; (4) A mitochondrial pro-apoptotic protein, 
HtrA2/Omi, is another reason for enhanced MI/R injury in the aging heart. 
2. High sensitivity to ischemic heart disease in the elderly 
2.1 Risk factors for ischemic heart disease 
Ischemic heart disease (IHD), defined as the earliest manifestation of myocardial infarction, 
stable or unstable angina pectoris or sudden death, is a vital problem in our society and 
remains to be a major cause of morbidity and mortality in the elderly. Consequently, the 
identification of factors related to IHD and quantification of levels of risk is increasingly 
popular. There are many risk factors contributing to IHD, ranging from blood pressure, both 
systolic blood pressure (SBP) and diastolic blood pressure (DBP), to living habits like 
smoking and excessive fat in take. These are undoubtedly the predictors of long term 
coronary heart disease. IHD, or myocardial ischemic injury, results from severe impairment 
of the coronary blood supply usually produced by thrombosis or other acute alterations of 
coronary atherosclerotic plaques resulting from these risk factors.  
Curiously, however, the question was raised if these risk factors for IHD found at a young 
age are still predictive at older ages because IHD may develop in men at a young, middle, or 
older age. Via long-term studies concerning changing effects of risk factors with age, it has 
been confirmed (Mathewson et al.,1960; Robert et al.,1998) that blood pressure up to age 65 
years manifested itself as a significant factor for IHD—for one thing, the benefit of 10mmHg 
lower blood pressure was smaller in older compared to younger men; smoking relevance is 
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higher for younger men than for older men; more interesting, the role of either BMI (Body 
Mass Index) or DM (Diabetes Mellitus) does not vary significantly with age, even though 
BMI has the largest relative risk in younger men. In 2003, Lakatta and his colleagues 
ascertained that the aging artery was a “set-up” for vascular diseases (Lakatta & Levy, 2003). 
In consideration of studies, both in aging animal models of IHD and censuses on clinical 
symptoms, it is now well acknowledged that age is a major independent risk factor for IHD 
although the mechanisms responsible for this age-related pathologic change remain implicit.  
2.2 Aging and IHD 
Aging, characterized by a progressive deterioration of organs and cells, play an imperative 
role in the manifestation of IHD. The incidence and prevalence of ischemic heart disease 
increases steeply with advancing age. Considerable evidence from animal studies and 
clinical observations indicates that aged hearts are more susceptible to I/R injury, suffer 
from greater infarct expansion, and exhibit poorer outcomes. It is also disappointing that 
therapies such as thrombolysis and preconditioning confer less benefit in the aged with 
myocardial infarction than in younger adults. With the “graying of the population,” the 
morbidity and mortality attributable to cardiovascular diseases will likely continue to 
increase, resulting in a significant increase in the already huge economic health care burden. 
These factors call for a multitude of our efforts in uncovering the mechanisms responsible 
for MI/R in aging patients.  
2.3 Possible mechanisms of high sensitivity to IHD in the elderly 
Aging is a complex phenomenon associated with changed DNA transcription and RNA 
translation together with protein expression. Ischemic heart disease results from severe 
impairment of the coronary blood supply usually produced by thrombosis or other acute 
alterations of coronary atherosclerotic plaques. A crucial early step of atherosclerosis is the 
binding to endothelial cells and subsequent subendothelial migration of circulating 
monocytes and their transformation into foam cells by the uptake of lipids. Intercellular 
adhesion molecule-1(ICAM-1) and vascular cell adhesion molecule-1(VCAM-1) in 
endothelial cells, mediating the adhesion of leukocytes, are suspected of playing an 
important role in the formulation of early atherosclerotic lesions. Nobuhiro Morisaki 
(Morisaki et al., 1997) found, through determining the two molecules soluble in serum, that 
sICAM-1 was correlated only to the presence of IHD but not to age; yet sVCAM-1, not 
sICAM-1, was positively correlated to age. In other words, age was the most powerful 
independent predictor of the level of sVCAM-1 and increased susceptibility to ischemia in 
some sense.  
What’s more, aging is considered as an energy deficit implicated in myocardial weakness 
and reduced functions in humans’ hearts. The deficit has been demonstrated to be related to 
the dysfunctional mitochondria that is responsible for the maximum output of ATP, 
working as a primary site of generation of Reactive Oxygen Species (ROS) and participating 
in the regulation of apoptosis. With growing age, in the cell and particularly in 
mitochondria, the defense capacities against ROS become insufficient. Excessive ROS attacks 
mRNA, DNA, and long-term proteins, which is especially obvious with aging.  
A decrease in the total number of myocytes is associated with heart damage and an 
accelerated decline in cardiac functional capacity observed in aging hearts (Zhang et al., 
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2003). It was commonly believed that cardiac myocytes had little ability to regenerate.  
Therefore, the cardiac function mainly relies on the survival of cardiomyocytes.  Two of the 
most common forms of cell death are programmed cell death and accidental cell death. 
Programmed cell death is characterized by a series of stereotypic morphological and 
biochemical features, which is easier to manipulate. It is reported that compared with 
necrosis, apoptosis is one of the major factors contributing to cardiomyocyte loss. An 
abundance of evidences certify that cytosolic cytochrome c content is sharply elevated in 
aging rats (Sharon et al., 2002). Furthermore, Bcl-2, an antiapoptotic protein shows a strong 
tendency to decrease with age, while Bax, a proapoptotic protein, remains unchanged, so do 
apoptotic protease-activating factor 1 levels and caspase-3 activities, regarded as executor 
caspases following caspase-8 or caspase-9 activation. Additionally, chronic oxidative stress 
with age induces the increase of manganese superoxide dismutase, glutathione peroxidase 
activity and lipid peroxidation in aging heart mitochondria, which may contribute to IHD. 
Therefore, age was a major independent risk factor for IHD, and cardiomyocyte death with 
age may be the last and main event of high sensitivity to IHD.  
3. Aging increases myocardial apoptosis under basal and stressed 
conditions  
Nowadays, our population is aging at an unprecedented rate, and during 2000-2030, the 
worldwide population aged >65 years is projected to increase by approximately 550 million 
to 973 million (U.S. Census Bureau), increasing from 6.9% to 12.0% worldwide (Kinsella & 
Velkoff, 2001). Data from numerous animal researches and clinical studies support that 
aging is a major independent risk factor in the markedly enhanced risk of cardiovascular 
diseases in the elderly. There are marked changes related to age in myocardial structure and 
function in both animals and humans. Previous studies have demonstrated that both 
diastolic and systolic functions were aggravated in senescent hearts. As the basis of cardiac 
function, cardiac structure has incurred numerous changes, such as enlarged cardiac 
myocyte size and reduced myocyte numbers in elderly hearts.  
3.1 Aging and myocardial apoptosis  
Numerous studies have demonstrated that there was a significant loss of cardiac myocytes 
constituting an important determinant of the aging process, possibly mediating the 
aggravation of cardiac function. In animal research models, there was around a 32.5% 
reduction of myocytes in the left ventricles of rats during a period of 4 to 29 months 
(Anversa et al., 1990). The study carried out on aging human hearts by G. Olivetti displayed 
that there was around 35% aggregate loss of myocytes in both ventricles for 70 year-old 
healthy men compared to 25 year-old healthy young adults (Olivetti et al., 1991). The factors 
responsible for the abnormal loss of the cells in the ventricles remain unclear, and it will 
possibly open a new field to prevent or even reverse the disappearance of cardiac myocytes 
of aged hearts to reveal the potential mechanism for the aging associated cell loss. 
Cell death may occur through active mechanisms like cellular suicide or active or 
programmed cell death, often referred to as apoptosis. Inactive mechanisms normally 
induced in acute situations by infarct, severe toxic chemicals and extreme thermal damage, 
normally conferred as necrosis. Many studies suggest that both apoptosis and necrosis are 
involved in the aging process (Ohshima, 2006). Apoptosis is more prevalent than necrosis in 
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senescent animals and humans and increased more significantly in old rats than in young 
adult ones after myocardial ischemia reperfusion (Liu et al., 2002). Different from necrosis, 
which is induced by injurious agents, apoptosis is an active programmed cell death 
characterized by a series of stereotypic morphological and biochemical features. Therefore, 
it is easier to inhibit apoptosis than to prohibit necrosis for the aging heart. 
3.2 Apoptosis with age and IHD 
Accumulating studies indicate that aging is associated with an increase in myocardial 
susceptibility to ischemia and a decrease in postischemic recovery of cardiac function. 
Zhang et al. reported that in aging rats, myocardial ischemia and reperfusion-induced 
cardiac injury was enhanced in aging mice as evidenced by enlarged infarct size (38.5±2.7% 
vs 52.0±1.8%) (Zhang et al, 2007). 
As stated above, myocardial apoptosis, a gene-regulated programmed cell death, markedly 
increases with aging. It has been determined that compared to young mice, myocardial 
ischemia and reperfusion in aging mice induced an increased apoptosis. Zhang investigated 
the detailed apoptotic cell death by TUNEL staining and caspase 3 activity assay, and found 
that TUNEL positive cells increased from 5.0±1.8% in young hearts to 8.8±0.9% in old ones, 
and that the caspase 3 activity increased from 18.0±0.9 nmol/h/mg protein to 27.4±1.9 
nmol/h/mg protein (Zhang et al, 2007). However, the molecular mechanisms and signaling 
transduction pathways that are responsible for increased susceptibility of cardiomyocytes to 
apoptosis with aging remain largely unidentified.  
3.3 Signal transduction pathways of apoptosis 
Accumulating evidence indicates that apoptosis is an active, gene-directed process. One of 
the most widely recognized biochemical features of apoptosis is the activation of a class of 
cysteine proteases known as caspases. Cells possess multiple caspases that may work in a 
cascade fashion. The redundancy may serve to amplify and accelerate the response, as well 
as provide multiple mechanisms for success. Three pathways that activate caspases have 
been identified: the first one is activated through a cell surface signal leading to caspase 8 
(and/or 10 in some cell types) activation; the second, more complicated pathway involves 
the mitochondria and results in caspase 9 activation; the third is activated via the 
endoplasmic reticulum and induces caspase 12 activation.  
A variety of cellular stresses have been found to cause the disruption and collapse of the 
inner mitochondrial transmembrane potential, thus opening  mitochondrial pores (termed 
“mitochondrial permeability transition" or MPT) and resulting in the release of cytochrome 
c. Cytochrome c released from the mitochondria activates caspase 9 in the presence of Apaf-
1 (apoptosis protease activating factor-1) and ATP. In some cell types, activation of caspase 8 
(and/or caspase 2) by the cell surface death receptor also increases mitochondrial 
cytochrome c release and subsequent caspase 9 activation by facilitating the translocation of 
full-length or truncated Bid (p15 Bid) from the cytosol to the mitochondrial membrane. As 
well known,  caspase 9 can also be activated by caspase 12 released from the endoplasmic 
reticulum (ER) under stress. The activation of caspases 8 and 9 (initiator) followed by 
caspase 3 (executor)(6, and 7 in some cell types) with subsequent  degradation of a variety of 
proteins results in irreversible damage of the cells (apoptotic cell death). Recent studies have 
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demonstrated that formation of MPT also results in mitochondrial release of AIF (apoptosis-
inducing factor), a molecule that directly results in apoptosis. 
Under physiologic conditions, apoptosis is regulated by the balance of a variety of pro- and 
anti-apoptotic molecules. The disturbance of these balances contributes to well-known 
pathologies, such as neurodegenerative diseases, ischemia/reperfusion injury and cancer. 
Specifically, the formation of MPT and subsequent release of cytochrome c and AIF are 
controlled by the balance between anti-apoptotic (e.g., Bcl-2, Bcl-xl, Bcl-w, Bag-1 and BI-1) 
and pro-apoptotic (e.g., Bax, Bak, Bad, Bid and Bim) Bcl-2 family members, which 
themselves are regulated by the balance of upstream regulators, such as extracellular signal-
regulated kinase 1/2 (ERK1/2) and Akt (anti-apoptotic), p38 mitogen-activated protein 
kinase (MAPK) and JNK (c-Jun N-terminal Kinase) (pro-apoptotic) at both transcriptional 
and post-transcriptional levels. In a recent study, Jiang and colleagues reported that 
activation of caspase 9 is positively regulated by tumor suppressor putative HLA-DR-
associated proteins (PHAP) but inhibited by oncoprotein prothymosin- (ProT)(Jiang et al, 
2003). Finally, the activation of caspase 3 is inhibited by IAP (inhibitor of apoptosis protein) 
and B-Crystallin, and promoted by Smac/DIABLO and Omi/HtrA2 (proteins that are also 
released from mitochondria under stress) by interaction with IAP. Given the extreme 
complexity of the apoptosis signal transduction and the exponentially-increasing number of 
pro- and anti-apoptotic molecules, it is highly unlikely that a specific cell type, i.e., 
cardiomyocytes, under specific stress, i.e., aging, will involve all of these apoptotic 
molecules and disturb every pro- and anti-apoptotic balance. Identifying the specific anti-
/pro-apoptotic balance(s) that is (are) disturbed by aging, and uncovering the mechanisms 
responsible for the deregulation of apoptotic cell death in the aging heart will be the critical 
first step toward prevention and treatment of apoptotic cell death in patients with any heart 
disease. In the next section we will identify the reactive nitrogen species (RNS) signal and 
HtrA2/Omi related mitochondrial apoptotic pathway disturbed in the aging heart. 
4. RNS signaling induced apoptosis contributes to increased susceptibility of 
aging hearts to myocardial ischemic Injury.  
4.1 An overview of reactive nitrogen species and pathway 
Considerable evidence suggests that reactive oxygen species (ROS) play critical roles in the 
aging process and post-ischemic myocardial apoptosis. However, the outcome of clinical 
trials with antioxidant treatment during MI/R has been rather disappointing, suggesting 
that other factors in addition to ROS exist. Most recent data have identified nitric oxide 
derived reactive nitrogen species (RNS) intermediates as critical contributors and cell injury.  
RNS are produced by the reaction of NO with superoxide (Carr et al., 2000) and include NO 
and its derivatives (Wu et al., 2007). NO, as the most important mediator of RNS, has been 
identified as having three categories of signaling pathways in controlling cell death: (1) 
Classical signaling involves the selective activation of soluble guanylate cyclase (sGC) 
(cGMP-dependent protein kinases) (2) Less classical signaling: NO binds to cytochrome c 
oxidase (CcO) in the mitochondria and its functional consequences (3) Nonclassical 
signaling alludes to the formation of NO-induced posttranslational modifications (PTMs), 
especially S-nitrosylation, S-glutathionylation, and tyrosine nitration(Antonio et al., 2011).   
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4.1.1 Nitric oxide signaling pathway - Classical signaling pathways and apoptosis 
In classical signaling pathways, NO induces the rupture of the His–Fe(II) bond within the 
heme of sGC, which catalyzes in the conversion of GTP to cGMP (Antonio et al., 2011). 
Effects of cGMP occur through three main groups of cellular targets: cGMP-dependent 
protein kinases (PKGs), cGMP-gated cation channels, and PDEs. cGMP binding activates 
PKG, which phosphorylates serines and threonines on many cellular proteins, frequently 
resulting in changes in activity or function, subcellular localization, or regulatory features 
(Francis et al., 2010). Accumulating data have showed NO could regulate apoptosis in 
classical signal pathways.  
4.1.1.1 cGMP-Dependent inhibition of apoptotic signal transduction 
Research has shown that NO protects against PC12 cell death by inhibiting the activation of 
caspase proteases through cGMP production and activation of protein kinase G (Kim et al., 
1999). Another work further proves that the NO/cGMP pathway suppresses 6-OHDA-
induced PC12 cell apoptosis by suppressing the mitochondrial apoptosis signal 
viaPKG/PI3K/Akt-dependent Bad phosphorylation (HA et al., 2003).  NO has also been 
shown to inhibit TNF-a-induced TRADD recruitment and caspase 8 activity in a cGMP-
dependent way (De Nadai et al., 2000). More direct data shows that over production of 
endogenous NO or supplementation with exogenous NO protects SK-N-BE human 
neuroblastoma againstapoptosis induced by serum deprivation by using cGMP as an 
intermediate effector (Ciani et al., 2002). The anti-apoptotic role of NO through cGMP is also 
revealed in hepatocytes (Calafell et al., 2009). In vivo data reveal that enhancing the 
NO/cGMP pathway reduces hypoxia-induced neuron apoptosis by upregulating the bcl-
2/Bax ratio (Caretti et al., 2008). NO has also been shown to antagonize estrogen induced 
apoptosis in breast epithelial cells (Kastrati et al., 2010). 
4.1.1.2 cGMP-Dependent induction of apoptotic signal transduction 
Despite evidence that NO is anti-apoptotic, data also show that NO can induce apoptosis in 
a cGMP dependent manner in isolated adult cardiomyocytes. Induction of apoptosis by 
SNAP in cardiomyocytes was blocked by inhibitors of caspase-3, soluble guanylyl cyclase 
(sGC) or of cGMP dependent protein kinase (PKG) (Taimor et al., 2000). In vascular cells NO 
is shown to induce apoptosis through cGMP-dependent Protein Kinase (PKG) (Chiche et al., 
1998). 
4.1.2 Nitric oxide signaling pathway - Less classical signaling pathways and 
apoptosis 
The critical mediator of NO regulating apoptosis in less classical signalling pathways is 
cytochrome c oxidase (CcO), which is located on the inner membrane of the mitochondrion 
and catalyzes the oxidation of cytochrome c and the reduction of oxygen to water (Taylor & 
Moncada, 2010). The enzyme belongs to the superfamily of heme-copper oxidases and 
contains a highly conserved bimetallic active site composed of the heme iron of cytochrome 
a3 and a copper ion, CuB. The binuclear center, in its reduced form, is the binding site of the 
physiological substrate, O2. NO closely resembles O2 and therefore can also bind to this site 
(Martinez-Ruiz et al., 2011). NO at low concentrations inhibits mitochondrial CcO, resulting 
in an increase in H2O2 in the mitochondria, and this excess of H2O2 activates the death 
signaling pathways (Yuyama et al., 2003). CcO potentially generates impairment of 
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mitochondrial function, which in turn may potentiate apoptotic commitment. The NO 
toxicity can be indicated by the decrease of cytochrome c oxidase activity, which is 
paralleled the extent of apoptosis (Ciriolo et al., 2000). 
4.1.3 Nitric oxide signaling pathway-nonclassical signaling pathways and apoptosis 
Nitric oxide could exert part of its effects not only in a cGMP independent manner, but also 
without the need of binding to other metal centers, through covalent posttranslational 
modification (PTM) of target proteins. This mode of action is defined as denominate 
nonclassical signaling and affects mainly cysteine and tyrosine residues in proteins. The 
three best known NO-induced posttranslational modifications are S-nitrosylation, S-
glutathionylation, and tyrosine nitration.  
4.1.3.1 S-nitrosylation and apoptosis 
S-nitrosylation is an important biological reaction of nitric oxide; it refers to the conversion 
of thiol groups, including cysteine residues in proteins, to form S-nitrosothiols. S-
Nitrosylation is a mechanism for dynamic, post-translational regulation of most classes of 
protein. NO has been shown to regulate apoptosis through S-nitrosylation of protein.  
Research hasrevealed that S-nitrosylation mainly antangonizes apoptosis by targeting many 
elements in both extrinsic and intrinsic pathways (Iyer et al., 2008). Fas, as a cell surface 
receptor, is a member of the tumor necrosis receptor superfamily that induces apoptosis 
when cross-linked by Fas ligand or by Fas agonist antibody (Park et al., 2006; Lavrik et al., 
2005; Mannick & Schonhoff, 2004). Regulation of cell signaling by protein nitrosylation is 
well exemplified in the Fas signalling pathway (Mannick & Schonhoff, 2004). Consistent 
with receptor-mediated apoptosis, two main pathways of Fas-mediated apoptosis have been 
identified (Park et al., 2006). In type1 cells caspase-8 directly cleaves caspase-3, which starts 
the death cascade. In type2 cells the quantity of caspase-8 is insufficient to directly activate 
the executioner caspase-3. Instead, it involves (activates) tBid- mediated cytochrome c (Cyto-
C) release from mitochondria followed by apoptosome formation (Park et al., 2006; Lavrik et 
al., 2005). In resting cells caspase-3 zymogens in mitochondria are kept inactive via S-
nitrosylation of their catalytic site cysteine. Caspase-3 may be S-nitrosylated in mitochondria 
due to an association between S-nitrosylated caspase-3 and NOS. Moreover, S-nitrosylated 
but not denitrosylated caspase-3 associates with acid sphingomyelinase (ASM) in 
mitochondria. The association of S-nitrosylated caspase-3 with ASM provides another level 
of apoptosis regulation by inhibiting capase-3 cleavage and activation by initiator caspases. 
When cells are stimulated by Fas ligand, caspase-3 becomes denitrosylated. Denitrosylation 
stimulates caspase-3 activity by two mechanisms. First, denitrosylation allows the catalytic 
site of caspase-3 to function. In addition, denitrosylated caspase-3 presumably dissociates 
from ASM, allowing initiator caspases to cleave caspase-3 to its fully active form. Thus S-
nitrosylation/denitrosylation serves as an off/on switch for caspase-3 function during 
apoptosis. Cyto-C activity is also regulated by nitrosylation during Fas-induced apoptosis. 
However, in contrast to caspase-3, Cyto-C is not nitrosylated in resting cells. Instead, when 
cells receive an apoptotic stimulus, Cyto-C is nitrosylated on its heme iron in mitochondria 
and then is rapidly released into the cytoplasm. In the cytoplasm, hemenitrosylated Cyto-C 
stimulates caspase-3 cleavage by the apoptosome. Thus, coordinated denitrosylation of 
caspase- 3 and hemenitrosylation of Cyto-C serves to enhance caspase activation and Fas-
induced apoptosis. It remains to be determined if denitrosylation of caspase-3 is directly 
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linked to nitrosylation of Cyto-C in mitochondria via a direct transfer of a NO+ group from 
the catalytic site cysteine of caspase-3 to the heme iron of Cyto-C (Mannick et al., 1997; 
Mannick & Schonhoff, 2004; Schonhoff et al., 2003; Stamler et al., 2001(Mannick et al., 1997; 
Mannick & Schonhoff, 2004; Schonhoff et al., 2003; Stamler et al., 2001). NO can also inhibit 
apoptosis by direct nitrosylation of caspase-9 ( Török et al., 2002). 
In intrinsic apoptosis pathways, Cyto-C is released from mitochondria into cytoplasm 
initiates the apoptotic signals (Brüne, 2003; Schonhoff et al., 2003) and has been suggested as 
the commitment step for apoptosis (Gaston et al., 2003). Previous studies suggest that 
nitrosylation of Cyto-C is a novel mechanism of apoptosis regulation in cells and a very 
early event in apoptotic signalling (Schonhoff et al., 2003). However, the critical commitment 
step in the mitochondrial pathway of apoptosis has not been firmly established. Several 
recent findings  suggest that caspase-9 activation is essential for, and likely represents, the 
commitment step for the mitochondrial pathway of apoptosis. Nitrosylation of caspase-9 by 
induced (i) NOS generated NO inhibits apoptosis downstream of Cyto-C release and would 
appear to be another mechanism negatively regulating this pathway of apoptosis (Török et 
al., 2002). Besides nitrosylation of caspases, another mechanism underlying the anti-
apoptotic effects of NO via S-nitrosylation includes stimulation of the anti-apoptotic activity 
(function) of thioredoxin (Trx), which depends on S-nitrosylation at Cys69 (Haendeler et al., 
2002). S-nitrosylation and inhibition of Apoptosis signal regulating kinase (ASK1) (in L929 
cells) at Cys869 also lead to anti-apoptosis (Park et al., 2004).   
Although most of the reports have proven that S-nitrosylation mainly inhibits apoptosis, 
there are also data showing that S-nitrosylation could induce apoptosis as well. The 
mechanisms underlying the pro-apoptotic effects of NO via S-nitrosylation include 
inhibition of the anti-apoptotic transcription factor NF-B through a variety of mechanisms, 
including S-nitrosylation of NF-B (in A549 cells) or nitrosylation of the target cysteine in 
the IB kinase complex (IKK) (in Jurkat cells) leading to decreased NF-B–mediated 
transcription and decreased Bcl-2 expression (Marshall & Stamler, 2002; Schonhoff et al., 
2006). p21ras, JNK kinase, and the p50 monomer (of p50-p65) have been identified as sites of 
S-nitrosylation that mediate the stimulation or inhibition of NF-B by NO (Marshall and 
Stamler, 2002).  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is S-nitrosylated by 
NO, which initiates an interaction with the E3 ligase Siah1, leading to nuclear translocation 
and ubiquitin-mediated degradation of nuclear target proteins (Benhar & Stamler, 2005). 
Hara et al. has demonstrated that deprenyl and TCH346 are neuroprotective by preventing 
the S-nitrosylation of GAPDH and inhibiting GAPDH/Siah cell death cascade (Hara et al., 
2006). NO can also enhance apoptosis by NO-induced persistent inhibition and nitrosylation 
of mitochondrial Cyto-C oxidase in lung endothelial cells (Zhang et al., 2005). The work 
done by Gu et al. has illustrated that S-Nitrosylation activated Matrix metalloproteinase-9 in 
vitro was implicated in the pathogenesis of neurodegenerative diseases, stroke, and induced 
neuronal apoptosis (Gu et al., 2002). 
4.1.3.2 S-Glutathionylation and apoptosis 
S-thiolation refers to the incorporation of a low-molecular-mass (LMM) thiol to a protein via 
formation of a mixed disulfide bridge between a cysteine residue and the LMM thiol. In the 
intracellular environment in which GSH is the major thiol present, its incorporation results 
in a PTM named S-glutathionylation or S-glutathiolation, or more commonly S-thiolation 
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(Martinez-Ruiz et al., 2011). Protein S-glutathiolation, the reversible covalent addition of 
glutathione to cysteine residues on target proteins, is emerging as a candidate mechanism 
by which both changes in the intracellular redox state and the generation of reactive oxygen 
and nitrogen species may be transduced into a functional response (Klatt & Lamas, 2000). S-
glutathionylation is a redox signaling mechanism that can be produced without the 
concourse of NO. However, evidence for S-glutathionylation induced by NO and/or RNS 
has accumulated, linking this modification with NO signalling (Giustarini et al., 2004). At 
least two mechanisms explain the link between RNS production and S-glutathionylation. 
One is the observed glutathionylation induced by peroxynitrite. The other is a nitrosylated 
protein cysteine may react with GSH, or S-nitrosoglutathione can be formed and react with 
the cysteine thiol, both leading to S-glutathionylation (Martinez-Ruiz et al., 2011).  
Vikas Anathy et al. demonstrated that stimulation with Fas ligand (FasL) induces S-
glutathionylation of Fas at cysteine 294 independently of nicotinamide adenine dinucleotide 
phosphate reduced oxidase – induced ROS. Instead, Fas is S-glutathionylated after caspase-
dependent degradation of Grx1, increasing subsequent caspase activation and apoptosis 
(Anathy et al., 2009). Suparna Qanungo et al. indicated S-glutathionylation of p65-NFκB as a 
major mechanism underlying the inhibition of the NF_B survival pathway and promotion of 
apoptosis after GSH supplementation in hypoxic pancreatic cancer cells (Qanungo et al., 
2007). Therefore, RNS could regulate apoptosis through S-glutathionylation of protein 
4.1.3.3 Tyrosine nitration and apoptosis  
RNS-mediated nitration modifications include nitration of tyrosine, tryptophan, amine, 
carboxylic acid, and phenylalanine groups. However, nitration of tyrosine residues to 
produce nitrotyrosine has recently received much attention. Protein tyrosine nitration is a 
covalent protein modification resulting from the addition of a nitro (-NO2) group onto one 
of the two equivalent ortho carbons of the aromatic ring of tyrosine residues (Gow et al., 
2004). Biological nitration of tyrosine depends largely on free radical chemistry. There are 
two main key nitration pathways that operate in vivo and involve peroxynitrite and 
hemoperoxidase-catalyzed nitration (Peluffo & Radi, 2007). Tyrosine nitration is a two-step 
process where the initial reaction is the oxidation of the aromatic ring of tyrosine to yield 
tyrosyl radical (Tyr•) (oxidation step), which in turn adds •NO2 (addition step) to yield 3-
NO2-Tyr (Peluffo & Radi, 2007). 
4.1.3.3.1 RNS-mediated Tyrosine nitration induction of Apoptotic Signal Transduction 
Work by Hortelano et al. indicates that nitric oxide-dependent apoptosis in macrophages 
occurs in the presence of a sustained increase of the mitochondrial transmembrane potential, 
and that the chemical modification and release of cytochrome c from the mitochondria 
precedes the changes of the mitochondrial transmembrane potential. NO-dependent 
apoptosis in macrophages involves a chemical modification of cytochrome c that alters its 
structure and facilitates release from the mitochondria, regardless of the changes of the 
mitochondrial transmembrane potential (Hortelano et al., 1999). Cassina et al. has shown 
that Tyr-67 is a preferential site of nitration among the four conserved tyrosine residues in 
cytochrome c. Cytochrome c3+ was more extensively nitrated than cytochrome c2+ by 
mitochondrial but also cytosolic or extracellular derived ONOO- diffusing to the 
intermembrane space (Cassina et al., 2000). Tao et al. proved that nitrative inactivation of 
Trx plays a proapoptotic role in postischemic myocardium (Tao et al., 2006). Studies 
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conducted by Li et al. demonstrated that there exists a TNF-α-initiated, cardiomyocyte 
iNOS/NADPH oxidase-dependent, peroxynitrite-mediated signaling pathway that 
contributes to posttraumatic myocardial apoptosis. In this paper nitrotyrosine content acted 
as a footprint of in vivo peroxynitrite formation (Li et al., 2007). 
4.1.3.3.2 RNS-Mediated tyrosine nitration inhibition of apoptotic signal transduction 
Although many studies have shown that RNS-mediated tyrosine nitration mainly induce 
apoptosis. Some research indicated that it also can inhibit apoptosis. Work by Sonsoles 
Reinehr et al. indicates that CD95 nitration as a novel mechanism for apoptosis inhibition by 
NO, which competes with pro-apoptotic CD95-tyrosine phosphorylation(Reinehr et al,2004). 
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Gao et al’s results showed that the protective effects of adenosine on myocardial I/R injury 
are markedly diminished in aged animals and that the loss in NO release in response to 
adenosine may be at least partially responsible for this age-related alteration (Gao et al., 
2000). Studies also show that increased susceptibility of the type 2 diabetic GK rat heart to 
ischemic injury is not associated with impaired energy metabolism. Reduced coronary flow, 
upregulation of eNOS expression, and increased total NOx levels confirm NO pathway 
modifications in this model, presumably related to increased oxidative stress. Modifications 
in the NO pathway may play a major role in I/R injury of the type 2 diabetic GK rat heart 
(Desrois et al., 2010). Our results show that aging induces phenotypic upregulation of iNOS 
in the heart, in which β-AR stimulation interacts with ischemia and triggers a markedly 
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increased NO production, which creates a nitrative stress, generates toxic peroxynitrite, 
activates apoptosis, and eventually causes cardiac dysfunction and myocardial injury. An 
iNOS inhibitor-1400W can markedly attenuate these adverse effects in the aging heart  
(Li, 2006). 
4.3 Thioredoxin and aging-related myocardial apoptosis 
Thioredoxin (Trx) is a 12-kDa protein ubiquitously expressed in all living cells that fulfils a 
variety of biological functions related to cell proliferation and apoptosis. It is involved not 
only in cytoprotective functions against oxidative stress but also in the regulation of cellular 
proliferation and the aging process. Clinical and experimental results have demonstrated 
that inhibition of Trx promotes apoptosis (Lincoln et al, 2003). Recent in vitro studies 
demonstrate that Trx interacts directly with, and inhibits, the activity of apoptosis-
regulating kinase-1 (ASK1), a mitogen-activated protein (MAP) kinase that activates two 
proapoptotic kinases, p38 MAP kinase (MAPK) and c-Jun N-terminal kinase (JNK) (Liu & 
Min, 2002). In aged mouse livers, the ratio of ASK1/Trx–ASK1 (free ASK1/Trx-binding 
ASK1) increases and this correlates with the increased basal activity of the p38 MAPK 
pathway. These results suggest that Trx may play critical roles in cell proliferation and cell 
death in aging, and Trx activity/expression might be reduced in the aging heart, thus tilting 
the death/survival balance toward cell death and promoting ischemia/reperfusion injury.  
Under physiologic conditions, ASK1 activity is inhibited by several cellular factors, 
including Trx, glutaredoxin, and phosphoserine-binding protein 14-3-3 (Bishopric & 
Webster, 2002). Previous studies have demonstrated that many cellular stresses and 
apoptotic stimuli activate mitochondrial-dependent apoptotic pathways by facilitating 
dissociation of ASK1 with its inhibitory protein. Trx is physically associated with ASK1 in 
cardiac tissues from young animals. However, Trx–ASK1 binding was reduced in cardiac 
tissue from aging animals. Therefore, it is likely that increased posttranslational Trx 
modification in aging hearts results in disassociation of Trx from ASK1, thus increasing 
postischemic myocardial apoptosis by increasing p38 MAPK activity.  
Lots of studies have demonstrated that, in addition to upregulation or downregulation of 
Trx expression at the gene level, Trx activity is regulated by posttranslational modification. 
Three forms of posttranslational modification of Trx have been previously identified. These 
include oxidation, glutathionylation, and S-nitrosylation. Interestingly, all three forms of 
modification occur at cysteine residues but affect Trx function differently. Oxidation of the 
thiol groups of Cys-32 and-35 forms a disulfide bond which results in Trx inactivation. 
However, previous studies have demonstrated that administration of oxidized Trx-1 exerts 
significant antioxidant and cytoprotective effects unless intracellular Trx reductase is 
inhibited, indicating that oxidative Trx inhibition is reversible and this form of 
posttranslational modification may not be the major mechanism responsible for Trx 
inactivation in vivo (Andoh et al, 2003). Glutathionylation occurs at Cys-73, and this 
posttranslational modification significantly inhibits Trx activity (Casagrande et al, 2002). 
However, whether Trx glutathionylation may occur in vivo in diseased tissues remains 
completely unknown and the role of this form of posttranslational modification in 
regulating Trx function in vivo remains to be determined. S-nitrosylation has been reported 
to occur at either Cys-69 or Cys-73. In contrast to oxidation and glutathionylation, S-
nitrosylation increases Trx activity and further enhances its antiapoptotic effect (Haendeler 
et al., 2004; Mitchell & Marletta, 2005).  
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In a recent study, it has been demonstrated that, in addition to three previously reported 
posttranslational Trx modifications which all occur at the cysteine residue, Trx can also be 
modified at the tyrosine residue (protein nitration) in a peroxynitrite-dependent fashion 
(Tao et al., 2006). More interestingly, in contrast to the reversible (by Trx reductase) 
oxidative Trx inactivation, nitrative modification of Trx results in an irreversible 
inactivation. Therefore, nitric oxide and its secondary reaction products, particularly 
peroxynitrite, exert opposite effects on Trx activity. Specifically, nitric oxide itself induces 
Trx S-nitrosylation and enhances its activity. In contrast, peroxynitrite results in Trx 
nitration and causes an irreversible inactivation. In Zhang et al.’s study, Trx activity was 
determined by using the insulin disulfide reduction assay. Compared with young animals, 
cardiac Trx activity is decreased in the aging heart before myocardial ischemia and 
reperfusion, and this difference can be further amplified after myocardial ischemia and 
reperfusion. However, Trx expression is slightly increased, rather than decreased, in aging 
hearts. These results indicate that it is posttranslational Trx modification rather than 
reduced protein expression that reduces Trx activity in the aging heart (Zhang et al., 2007).  
5. A Mitochondrial pro-apoptotic protein, HtrA2/Omi, is another reason of 
enhanced MI/R injury in the aging heart  
It is well known that apoptotic cell death is orchestrated by a family of caspases. X-
chromosome linked inhibitor of apoptosis protein (XIAP), as a member of IAPs, was the 
most potent endogenous inhibitor of caspases in human beings. XIAP has three baculovirus 
IAP repeat (BIR1, BIR2, BIR3) domains and a really interesting new gene (RING) domain. 
Biochemical studies suggested BIR2 inhibits caspase-3 and caspase-7, whereas BIR3 inhibits 
caspase-9 (Deveraux et al., 1999). The RING domain is an E3 ligase that presumably directs 
targets to the ubiquitin-proteasome degradation system, such as caspase-3 (Salvesen & 
Duckett, 2002; Martin, 2002). The anti-apoptotic activity of XIAP is regulated by a group of 
proteins that bind to the BIR domains via N-terminal conserved 4-residue IAP-binding motif 
(Shi, 2002). Recently it has been shown that overexpression of XIAP via in vivo delivery in 
an adenovirus could reduce both myocardial apoptosis and infarction following I/R (Kim et 
al., 2011). Wang et al. the protein and mRNA content of XIAP in the heart after MI/R was 
decreased, while the protein content of XIAP showed positive correlation with cardiac 
function in 42 rats after MI/R(Wang et al., 2010). These findings suggested a link between 
myocardial apoptosis, and anti-apoptotic therapy was effective in reducing I/R injury. 
Meanwhile we found the degradation of XIAP in aging myocardium after MI/R was more 
than that in young myocardium after MI/R, which are consistent with previous results in 
which myocardial apoptosis was exaggerated with aging after MI/R. Additionally, the 
expression of XIAP was also significantly decreased than that in the young adult heart 
without the intervention of MI/R, which suggested that the decline of XIAP expression may 
be a major factor responsible for the increased susceptibility of the aging heart. 
XIAP is regulated by two cellular proteins, Smac/DIABLO and HtrA2/Omi, which are 
nuclear-encoded mitochondrial proteins. The cleavage of their mitochondrial-targeting 
sequences inside mitochondria generates processed active Smac /DIABLO and HtrA2/Omi 
with new apoptotic N termini, named the IAP-binding motif (IBM) (Srinivasula et al., 2003). 
Stimulated by apoptotic triggers, Smac/DIABLO and HtrA2/Omi release into the cytosol 
and competitively bind to the BIR domains of IAPs via IBM, so that the BIR-bound caspases 
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are released and reactivated, resulting in cell apoptosis (Wu et al., 2000, Suzuki et al., 2001). 
Unlike Smac/DIABLO, the pro-apoptotic activity of HtrA2/Omi involves not only IAP 
binding but also serine protease activity. Although Omi/HtrA2 and Smac/DIABLO both 
seem to target XIAP once released into the cytosol, increasing evidence suggests that 
Omi/HtrA2 may play a unique role in apoptosis. Several different Smac/DIABLO-deficient 
cells respond normally to various apoptotic stimuli, suggesting the existence of a redundant 
molecule or molecules compensating for a loss of Smac/DIABLO function (Okada et al., 
2002). In contrast, Omi/HtrA2-knockdown cells have shown to be more resistant to 
apoptotic stimuli (Martins et al., 2002). 
In addition, Liu et al. first provided direct evidence that a normal level of endogenously 
expressed HtrA2/Omi contributes to apoptosis after MI/R in vivo (Liu et al., 2005). Althaus 
et al. have also suggested that HtrA2/Omi plays a decisive role in apoptosis after MI/R in 
young rats (Althaus et al., 2007). Then Wang et al showed that the release of HtrA2/Omi 
from mitochondria to cytosol was significantly increased in the old MI/R rat heart 
compared with that in the young MI/R rats (Wang et al, 2006). Meanwhile, cytosol was 
markedly increased in the old sham group compared with that in the young sham group. 
Taken together, these results reveal that HtrA2/Omi plays a causative role in increased 
post-ischemic cardiomyocyte apoptosis in the aging heart (Okada et al., 2002). In order to 
investigate whether increased HtrA2/Omi plays an important role in aged myocardial 
apoptosis resulting in myocardial dysfunction and increased susceptibility to MI/R injury, 
Wang et al observed the effect of ucf-101, a highly selective Omi/HtrA2 inhibitor, on MI/R 
injury. They have provided direct evidence in the current study that treatment with ucf-101 
in aging MI/R animals reduced the caspase-3 activity and improved the cardiac functions. 
Their results demonstrated that translocation of Omi/HtrA2 from the mitochondria to the 
cytosol enhanced MI/R injury in aging heart via promoting myocardial apoptosis. These 
studies may provide some therapies to prevent the over-release of HtrA2/Omi from 
mitochondria with aging and reduce the risk for MI/R in the elderly. This could help to 
explain the loss of ventricular function with age and may lead to discoveries of specific 
therapeutic interventions that can attenuate this type of cell loss (Wang et al., 2010). 
6. Prospect 
Aging has become a major health issue and socioeconomic burden worldwide. Coronary 
heart disease is the leading cause of death worldwide, for patients presented with an acute 
myocardial infarction, early and successful myocardial reperfusion is the most effective 
interventional strategy for reducing infarct size and improving clinical outcomes. The 
process of myocardial reperfusion itself, however, can induce injury to the myocardium, 
thereby reducing the beneficial effects of myocardial reperfusion. Aging renders the heart 
more susceptible to cell death from ischemia/reperfusion. In order to develop strategies 
aimed to limit reversible and irreversible myocardial damage in older patients, there is a 
need to better understand how aging increases myocardial apoptosis in myocardial 
ischaemia/reperfusion.  
This chapter introduced that RNS signaling induced apoptosis contributes to increased 
susceptibility of aging hearts to myocardial ischemic injury, and the age-associated 
alterations in translocation of HtrA2/Omi from mitochondria to cytosol are implicated in 
the markedly increased risk for MI/R injury in old persons. 
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As mentioned above, three RNS signaling pathways have been recognized .On the one 
hand, many studies show that RNS can be pro-apoptotic; on the other hand, many studies 
show that RNS exert anti-apoptotic effects through the same signaling pathway. Further 
studies should continue to elucidate the many factors that determine how RNS promotes or 
inhibits apoptosis. 
Wang et al. results provide strong evidence that HtrA2/Omi plays a causative role in 
increased post-ischemic cardiomyocyte apoptosis in the aging heart, but the mechanisms of 
age-associated alterations in translocation of HtrA2/Omi from mitochondria to cytosol need 
elucidation. 
There is an urgent need for more research of myocardial ischemia/reperfusion conducted 
on senescent animals. Some researches about RNS signaling induced apoptosis contributes 
to increased susceptibility of aging hearts to myocardial ischemic injury have been 
performed in rats or mice. However, biological signaling pathways, proteolytic portfolios, 
and the overall response to myocardial injury can be quite different in these small rodents 
when compared to larger mammals. While these murine studies have provided invaluable 
insight and provoked new hypotheses, they must be carried forward using large animals 
that more closely recapitulate the clinically-relevant context and for carefully designed 
clinical trials involving aged human subjects. There also needs to be better coordinated 
efforts between basic science investigators, clinical trial managers and physicians. (Spinale, 
2010, as cited in Bujak et al., 2008; Singh et al., 2010; Lindsey, 2005; Juhaszova et al. ,2005 as 
cited in Bolli et al., 2004).  
Otherwise, most studies have been conducted on healthy aging animals. Ischemic heart 
disease develops as a consequence of a number of etiological risk factors and always coexists 
with other disease states. These include systemic arterial hypertension and related left 
ventricular hypertrophy, hyperlipidemia, and atherosclerosis, diabetes and insulin 
resistance, as well as heart failure. These systemic diseases with aging as a modifying 
condition exert multiple biochemical effects on the heart that can potentially affect the 
development of I/R injury and interfere with responses to cardioprotective interventions. 
Therefore, the development of rational therapeutic approaches to protect the ischemic heart 
requires preclinical studies that examine cardioprotection specifically in relation to 
complicating disease states and risk factors. Surprisingly, relatively little effort has been 
made to uncover the cellular mechanisms by which risk factors and systemic diseases such 
as hypertension, hyperlipidemia and atherosclerosis, diabetes, insulin resistance, and heart 
failure interfere with cardioprotective mechanisms of aging (Ferdinandy et al., 2007). 
Although, as mentioned above, RNS and HtrA2/Omi may be critical contributors in 
controlling apoptosis which determine the susceptibility of aging hearts to myocardial 
ischemic injury. 
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